background
allogen
hematopoiet
stem
cell
transplant
routin
offer
patient
highrisk
advanc
hope
improv
outcom
use
truli
nonmyeloabl
nma
condit
reduc
toxic
context
outcom
data
patient
nma
transplant
lack
report
outcom
patient
transplant
use
nma
condit
without
cell
deplet
method
first
transplant
patient
octob
june
review
consecut
patient
consid
unfit
fmc
condit
per
ukal
protocol
patient
condit
fludarabin
day
day
cyclophosphamid
day
day
short
cours
mtx
ciclosporin
use
gvhd
prophylaxi
standard
support
care
employ
thirtyon
patient
median
age
met
criteria
case
review
ball
philadelphia
chromosom
posit
patient
high
risk
diseas
standard
diagnost
criteria
first
complet
remiss
match
sibl
donor
use
instanc
remain
fulli
match
unrel
donor
patient
hctci
score
score
patient
score
higher
median
dose
x
kg
median
dose
x
kg
result
trm
low
year
year
respect
factor
includ
univari
analysi
includ
age
diagnosi
diseas
statu
hctci
donor
type
cmv
risk
cell
dose
significantli
impact
trm
incid
classic
acut
gvhd
grade
day
day
late
onset
agvhd
includ
elig
patient
develop
chronic
gvhd
stage
relaps
incid
low
year
patient
patient
impact
pretranspl
factor
includ
posit
mrd
post
phase
induct
present
patient
notabl
univari
analysi
relaps
significantli
lower
patient
develop
chronic
gvhd
background
allogen
stem
cell
transplant
allosct
treatment
choic
mani
patient
pt
suffer
acut
myeloid
leukemia
aml
graft
vs
leukemia
effect
gvl
appli
immunocompet
cell
donor
origin
import
effector
mechan
erad
leukemia
present
leukem
allospecif
antigen
malign
blast
regard
crucial
trigger
effect
allogen
immun
respons
convers
insuffici
stimulatori
capac
leukem
blast
thought
relev
escap
mechan
cellular
immunotherapi
allosct
donorlymphocyt
infus
dli
purpos
test
whether
abil
malign
blast
differenti
vitro
toward
dendrit
cell
leukem
origin
dc
leu
associ
respons
allosct
outcom
immunotherapi
second
allosct
dli
posttranspl
relaps
aml
method
leukem
blast
isol
peripher
blood
pb
bone
marrow
bm
sampl
aml
patient
allosct
relaps
allosct
panel
differ
assay
use
gener
dc
leu
vitro
contain
gmcsf
final
vitro
result
correl
clinic
characterist
outcom
patient
treat
donor
lymphocyt
infus
andor
allosct
result
dc
leu
could
gener
vitro
sampl
correl
proport
dcsubtyp
gener
ex
vivo
clinic
data
significantli
higher
mean
proport
dc
leu
dcfraction
found
respond
vs
nonrespond
immunotherapi
vs
vice
versa
chanc
respons
immunotherapi
significantli
higher
dc
leu
dc
ratio
could
reach
vivo
patientswer
character
longer
time
relaps
higher
probabl
leukemiafre
surviv
similarli
gener
higher
amount
dc
leu
mncfraction
gener
matur
dc
use
best
gmcsf
contain
assay
associ
longer
time
relaps
respect
patient
moreov
overal
surviv
improv
dc
leu
dc
could
gener
best
gmcsf
contain
assay
conclus
vitro
gener
dcdc
leu
leukem
blast
obtain
activ
stage
aml
allosct
relaps
post
transplant
associ
clinic
outcom
observ
support
role
antigen
present
leukem
cell
allogen
immun
respons
aml
disclosur
noth
declar
background
role
autolog
hematopoet
cell
transplant
hct
treatment
aml
clear
trial
past
shown
autolog
hct
consolid
lower
risk
relaps
howev
magnitud
effect
limit
autolog
hct
advoc
patient
aml
lower
genet
risk
patient
eventu
relaps
undergo
reinduct
follow
allogen
hct
method
aim
studi
analyz
outcom
allogen
hct
perform
compar
patient
prior
consolid
autolog
hct
vs
patient
chemotherapi
consolid
primari
outcom
non
relaps
mortal
nrm
allogen
hct
patient
without
prior
autolog
hct
secondari
outcom
includ
leukemia
free
surviv
lf
relaps
rate
ri
graft
versu
host
diseas
free
relaps
free
surviv
grf
overal
surviv
os
treatment
relat
toxic
result
adult
patient
reigster
alwp
ebmt
de
novo
aml
includ
receiv
first
allogen
hct
without
prior
autolog
hct
patient
transplant
characterist
shown
tabl
patient
group
entir
compar
patient
prior
autolog
hct
younger
less
often
favor
cytogenet
profil
commonli
donor
match
sibl
often
receiv
reduc
intens
condit
ric
compar
mac
condit
univari
outcom
shown
tabl
slightli
higher
nrm
risk
patient
prior
autolog
hct
consolid
multivari
analysi
nrm
risk
patient
prior
autolog
hct
adjust
patient
age
cytogenet
risk
categori
year
transplant
donor
type
condit
intens
sex
match
time
diagnosi
relaps
time
relaps
allogen
hct
compar
patient
chemotherapi
consolid
similarli
risk
event
lf
grf
higher
prior
autolog
hct
p
respect
risk
death
also
higher
statist
signific
conclus
may
conclud
advantag
potenti
higher
antileukem
activ
high
dose
chemotherapi
autolog
hct
given
patient
aml
shown
random
trial
vellenga
e
et
al
lower
relaps
higher
lf
approxim
signific
differ
overal
surviv
may
lost
higher
toxic
allogen
hct
case
subsequ
relaps
background
although
relaps
major
caus
mortal
patient
receiv
allogen
hematopoiet
cell
transplant
hct
acut
leukemia
limit
conflict
data
exist
extramedullari
relaps
emr
aim
describ
incid
risk
factor
outcom
prognosi
relaps
hct
recipi
method
retrospect
review
chart
consecut
allogen
hct
recipi
transplant
center
indic
acut
leukemia
record
age
gender
diseas
previou
extramedullari
involv
phase
transplant
type
transplant
donor
condit
graftversushostdiseas
gvhd
infect
treatmentrel
mortal
relaps
mortal
patient
extramedullari
relaps
addit
data
clinic
manifest
imag
cerebrospin
fluid
test
histopatholog
manag
addit
document
incid
isol
emr
iemr
bone
marrow
relaps
bmr
calcul
use
cumul
incid
ci
analysi
treatmentrel
mortal
consid
compet
risk
result
among
allohct
recipi
follow
year
patient
present
emr
major
emr
involv
central
nervou
system
cn
isol
emr
observ
patient
month
cumul
incid
ci
iemr
associ
pretranspl
advanc
diseas
phase
p
bmr
observ
patient
month
ci
multivari
analysi
bmr
ci
independ
associ
fungal
infect
p
pretranspl
diseas
phase
p
line
treatment
trm
whole
cohort
major
iemr
bmr
respect
patient
receiv
system
treatment
combin
local
radiat
iemr
donor
lymphocyt
infus
dli
respect
feasibl
extens
chronic
gvhd
record
iemr
bmr
patient
outcom
poor
iemr
overal
surviv
os
favor
os
iemr
associ
sibl
donor
factor
treatment
dli
presenc
chronic
gvhd
similarli
poor
outcom
os
observ
bmr
favor
os
independ
associ
diagnosi
aml
absenc
bacteri
infect
whole
cohort
iemr
bmr
independ
unfavor
predictor
os
p
along
extens
chronic
gvhd
conclus
larg
popul
longterm
followup
incid
iemr
rel
high
develop
late
posttranspl
period
associ
diseas
phase
transplant
furthermor
iemr
bmr
confer
similarli
poor
outcom
despit
system
treatment
extens
chronic
gvhd
independ
predictor
surviv
highlight
unmet
clinic
need
novel
approach
either
mainten
treatment
reduc
extramedullari
system
relaps
post
allohct
acut
leukemia
disclosur
compet
financi
interest
impact
tcell
deplet
outcom
patient
undergo
allogen
hematopoiet
stem
cell
transplant
acut
myeloid
leukemia
background
diagnosi
acut
myeloid
leukemia
aml
major
patient
pt
achiev
complet
remiss
cr
eventu
relaps
approxim
pt
maintain
cr
year
longer
late
relaps
year
cr
occur
rare
pt
receiv
hsct
late
effect
follow
routin
surveil
well
prevent
measur
purpos
studi
investig
longterm
outcom
pt
diagnosi
aml
undergo
hsct
institut
method
standard
followup
hsctsurvivor
appli
center
analyz
adult
pt
aml
consecut
transplant
januari
decemb
institut
written
consent
given
use
medic
record
research
landmark
analysi
adopt
patient
cr
hsct
ltcr
longterm
cr
result
ltcr
achiev
hsct
patient
male
femal
transplant
median
followup
year
median
age
transplant
year
r
select
donor
famili
haploident
rel
case
hla
ident
rel
match
unrel
donor
cordblood
cohort
ltcr
overal
surviv
ci
cumul
incid
relapseevalu
compet
risk
transplant
relat
mortal
trm
trm
evalu
compet
risk
relaps
respect
ci
cohort
eventfreesurviv
ef
ci
caus
death
relaps
pt
second
cancer
pt
sepsi
pt
incid
dyslipidemia
defin
cholesterol
mgdl
andor
ldl
mgdl
andor
triglycerid
mgdl
need
specif
treatment
incid
osteopenia
osteoporosisdefin
tscore
lower
greater
tscore
lower
respect
incid
second
cancer
nonmelanoma
skin
cancer
lung
carcinoma
cervic
intraepitheli
neoplasm
thyroid
cancer
gastric
cancer
colon
cancer
incid
chronic
moderatesever
gvhd
ci
latest
diagnosi
perform
day
note
pt
still
activ
treatment
last
followup
conclus
relaps
incid
low
patient
reach
ltcr
patient
transplant
obtain
excel
os
ef
reach
target
ltcr
proactiv
longterm
followup
strategi
counsel
essenti
keep
best
qualiti
surviv
advantag
offer
hsct
patient
aml
disclosur
chiara
bonini
research
contract
intellia
therapeut
author
declar
conflict
interest
background
relaps
graftversushost
diseas
gvhd
gvhdassoci
mortal
major
obstacl
success
transplant
unrel
mud
donor
children
acut
leukemia
al
neg
deplet
cell
b
lymphocyt
conserv
matur
donorderiv
natur
killer
cell
cell
graft
may
improv
gvhd
control
immun
reconstitut
prevent
relaps
present
retrospect
analys
cohort
pt
al
cr
transplant
mud
deplet
method
total
children
acut
leukemia
aml
femal
male
median
age
underw
allo
hsct
match
unrel
donor
june
juli
pt
complet
remiss
cr
pt
except
one
receiv
treosulfanbas
condit
either
melphalan
thiophosphamid
etoposid
ad
second
agent
fludarabin
use
pt
two
type
gvhd
prophylaxi
use
type
hatg
mgkg
posthsct
tacromtx
without
prophylaxi
type
thymoglobulin
ratg
rituximab
either
bortezomib
day
tacro
mtx
cell
deplet
clinimac
use
case
median
dose
cell
kg
cell
kg
median
time
followup
survivor
year
rang
result
primari
engraft
achiev
pt
median
time
neutrophil
platelet
recoveri
day
respect
evalu
pt
achiev
sustain
complet
donor
chimer
day
earli
day
mortal
bacteri
sepsi
adv
fulmin
hepat
overal
ptrm
year
six
late
trm
event
due
viral
infect
pt
bacteri
sepsi
pt
pt
bacteri
viral
infect
late
death
associ
cgvhd
prolong
corticosteroid
therapi
ci
acut
gvhd
grade
iiiv
ci
acut
gvhd
grade
iiiiv
ci
ci
cgvhd
regimen
effect
prevent
agvhd
iiiv
comparison
regimen
ci
vs
respect
event
acut
gvhd
grade
iiiiv
pt
regimen
ratg
also
effect
prevent
cgvhd
ci
year
hsct
vs
respect
cumul
incid
relaps
ci
without
differ
ratg
hatg
eventfre
surviv
ef
eventdeath
relaps
year
ci
overal
surviv
differ
age
diagnosi
conclus
confirm
deplet
lymphocyt
graft
ensur
high
engraft
rate
transplantrel
mortal
caus
infect
mostli
associ
case
chronic
gvhd
gvhd
prophylaxi
includ
ratgrituximab
bortezomib
improv
gvhd
control
recipi
graft
comparison
hatg
tacromtx
appar
without
loss
antileukem
activ
disclosur
result
baselin
rr
emd
lbl
diagnos
ino
patient
sc
patient
median
rang
age
ino
sc
patient
year
male
respect
rate
crcri
significantli
higher
ino
group
confid
interv
ci
compar
sc
ci
tabl
allogen
hematopoiet
stem
cell
transplant
carri
ino
sc
patient
prior
poststudi
induct
therapi
pf
hazard
ratio
hr
ci
median
pf
ci
month
among
ino
ci
month
sc
patient
os
hr
ci
median
os
ci
month
ino
versu
ci
month
sc
patient
figur
patient
advers
event
ae
seriou
ae
occur
ino
sc
patient
ino
sc
patient
grade
ae
one
patient
ino
group
die
veno
occlus
diseas
conclus
among
rr
patient
emd
lbl
improv
remiss
rate
transplant
rate
progress
free
surviv
shown
ino
group
versu
sc
group
although
patient
number
small
limit
abil
robust
comparison
result
support
use
ino
patient
difficult
treat
popul
rr
emd
lbl
background
bcrabltarget
tyrosin
kinas
inhibitor
tki
revolution
outcom
patient
inflict
ph
ball
moreov
addit
tki
may
relev
strategi
phlike
patient
method
hypothes
overcom
bm
microenvironmentmedi
protect
cell
tkimedi
apoptosi
may
enhanc
respons
tki
therapi
result
vitro
treatment
bcrablposit
cell
line
dasatinib
result
signific
dosedepend
cell
growth
inhibit
nm
p
furthermor
dasatinib
exhibit
signific
growth
suppress
bcrabl
neg
cell
reh
nm
nm
respect
howev
cocultur
bone
marrow
stromal
cell
bmsc
dasatinibmedi
effect
abrog
phand
ph
cell
furthermor
dasatinib
treatment
promot
signific
upregul
chemokin
receptor
mrna
cell
surfac
level
elev
express
accompani
increas
respons
cell
stimul
result
strong
sustain
phosphoryl
akt
increas
adhes
capac
bmsc
therefor
dasatinibinduc
upregul
promot
stromamedi
surviv
advantag
cell
upon
tki
therapi
next
order
overcom
stromal
protect
choos
combin
dasatinib
histon
deacetylas
inhibitor
panobinostat
known
abil
deplet
aml
cell
singleag
treatment
panobinostat
demonstr
signific
inhibit
phand
ph
cell
growth
low
nanomolar
concentr
p
importantli
combin
panobinostat
dasatinib
synerg
ci
effect
overcom
protect
provid
bmsc
induc
apoptosi
phand
ph
cell
demonstr
phosphatidylserin
extern
mitochondri
depolar
dna
fragment
furthermor
combin
panobinostat
dasatinib
significantli
reduc
surfac
level
phand
ph
cell
accordingli
respons
includ
akt
activ
adhes
bmsc
significantli
reduc
upon
combin
panobinostatdasatinib
treatment
data
indic
panobinostat
effect
suppress
basal
dasatinibinduc
express
function
cell
overcom
stromamedi
resist
dasatinib
determin
molecular
mechan
perform
gene
protein
express
analysi
panobinostat
alon
combin
dasatinib
significantli
downregul
protein
level
calcineurin
serinethreonin
protein
phosphatas
previous
implic
tall
ball
pathogenesi
well
critic
effector
calcineurin
signal
cascad
target
gene
previous
found
calcineurin
signal
posit
regul
express
lymphocyt
addit
cyclosporin
csa
decreas
basal
dasatinibinduc
surfac
level
cell
overcom
protect
bmsc
result
potenti
cytotox
effect
dasatininb
panobinostat
combin
csa
panobinostat
result
deeper
suppress
target
gene
thu
link
effect
panobinostat
calcineurindepend
downregul
block
abil
leukem
cell
respond
stromal
support
conclus
taken
togeth
result
identifi
calcineurin
signal
pathway
novel
target
panobinostat
cell
indic
hdac
inhibit
panobinostat
may
effect
strategi
facilit
antileukem
activ
tki
therapi
disclosur
noth
disclos
background
treatment
relapsedrefractori
acut
lymphoblast
leukemia
rrall
remain
clinic
challeng
gener
dismal
prognosi
allosct
use
sequenti
condit
flamsa
like
regimen
shown
promis
result
relapsedrefractori
aml
littl
known
efficaci
procedur
rrall
method
identifi
adult
patient
femal
median
age
rang
primari
refractori
phase
relaps
allograft
match
sibl
match
unrel
haploident
donor
ebmt
particip
center
almost
half
patient
tall
posit
philadelphia
chromosom
six
patient
underw
previou
autotranspl
karnofski
score
patient
condit
myeloabl
mac
high
dose
tbi
patient
reduc
intens
ric
includ
low
dose
tbi
chemotherapi
alon
vivo
cell
deplet
perform
case
patient
half
donor
cmv
posit
patient
male
receiv
graft
femal
donor
median
followup
rang
month
result
overal
patient
fail
engraft
die
within
day
allosct
without
relaps
could
achiev
complet
remiss
day
cumul
incid
grade
iiiv
grade
iiiiv
acut
gvhd
respect
cumul
incid
chronic
extens
chronic
gvhd
respect
relaps
incid
ri
nonrelaps
mortal
nrm
respect
leukemia
free
surviv
lf
overal
surviv
os
gvhd
relapsefre
surviv
grf
respect
multivari
cox
analysi
karnofoski
score
neg
affect
ri
lf
os
grf
also
condit
chemotherapi
alon
compar
tbibas
condit
neg
affect
relaps
rate
lf
os
conclus
allosct
use
sequenti
condit
regimen
propos
differ
team
rrall
could
option
especi
consid
tbibas
regimen
howev
overal
lf
suggest
patient
still
face
extrem
dismal
outcom
highlight
therapi
eg
bite
antibodi
inotuzumab
car
cell
need
combin
prior
andor
allosct
order
improv
outcom
disclosur
conflict
interest
fund
receiv
chemotherapi
cours
pt
treat
pt
worsen
gener
statu
invas
fungal
infect
result
fortythre
pt
complet
remiss
cr
neg
minim
residu
diseas
mrd
time
hsct
pt
activ
diseas
show
morpholog
cr
posit
mrd
develop
chronic
graft
versushost
diseas
cgvhd
follow
mild
moder
sever
grade
respect
patient
develop
cgvhd
dli
overal
leukemia
free
surviv
lf
time
month
absenc
cgvhd
hazard
ratio
hr
p
prehsct
diseas
statu
hr
p
import
factor
lf
pt
treat
chemobas
regimen
die
due
progress
infect
complic
patient
azadli
group
still
aliv
extramedullari
relaps
pt
treat
bldli
cr
os
better
dli
group
compar
chemotherapi
group
vs
month
respect
p
conclus
dli
allohsct
exhibit
definit
antileukem
effect
posttranspl
patient
bl
aza
report
increas
dli
graft
vsleukemia
gvl
effect
although
cgvhd
could
import
protect
factor
relaps
remain
main
caus
morbid
maximis
gvl
effect
without
put
patient
risk
gvhd
still
repres
unmet
need
data
show
combin
either
bl
aza
dli
infus
safe
might
repres
improv
diseas
control
earli
phase
relaps
disclosur
noth
declar
increas
detect
leukemiaspecif
adapt
innat
immunereact
cell
treatment
amldiseas
rat
one
therapyrefractori
amlpati
blastmodul
clinic
approv
respons
modifi
kitk
kitm
patent
convert
myeloid
blast
dendrit
cell
leukem
origin
dc
leu
stimul
dc
leu
antileukem
tcell
gener
ex
vivo
compound
approv
clinic
use
therefor
attract
tool
immunotherapi
myeloid
leukemia
method
dcdcleucultur
ratspati
wholeblood
wb
kit
mix
lymphocyt
cultur
mlc
tcell
kittreat
blood
function
blastcytotox
leukemiaspecif
assay
csaelispotdegranulationintracellular
cytokineassay
addit
flowcytometr
evalu
cellular
leukemiaspecif
lymphocyt
composit
perform
ratspt
blood
cours
diseas
result
amldiseas
rat
treat
k
untreat
control
signific
increas
dcleu
could
detect
spleenpb
kit
esp
treat
compar
untreat
anim
without
induct
blast
prolifer
signific
reduct
blast
seen
spleenpb
k
success
treatment
correl
increas
like
repres
tmemcel
reduct
therapyrefractori
amlpati
cours
decitabineldaractreat
kitm
shown
ex
vivo
gener
dcleu
activ
immunereact
cell
mediat
leukemiaspecificantileukem
respons
activ
leukemiaspecif
lymphocyt
monitor
low
proport
activ
stage
diseas
well
two
patient
cours
persist
diseas
one
patient
yo
male
offer
individu
system
salvagetreat
kitm
appli
continu
infus
refractori
leukemia
approv
local
ethic
commite
extens
inform
patient
experiment
natur
treatment
obtain
written
inform
consent
clinic
treatment
well
toler
patient
improv
clinic
neutrophil
wbc
increas
thrombocyt
reach
gl
day
week
treatment
patient
discharg
good
clinic
condit
day
later
progress
aml
seen
high
blast
count
pb
bm
patient
develop
sever
sepsi
die
day
later
immun
monitor
show
treatment
patient
without
kitmtreat
continu
increas
prolifer
tcell
nk
cikand
nkt
cell
bmemcel
dc
pb
product
produc
cik
nktcell
demonstr
suggest
vivo
productionactiv
potenti
leukemiaspecif
cell
immun
stimulatori
effect
decreas
discontinu
therapi
conclus
treatment
wb
well
leukem
diseas
organ
blastmodul
kit
especi
gmcsf
well
toler
induc
clinic
immunolog
improv
adapt
innat
immun
system
wherea
low
count
leukemiaspecif
activ
immunereact
cell
found
nonkittr
organ
disclosur
noth
declar
longterm
outcom
allogen
hematopoiet
stem
cell
transplant
acut
myeloid
leukemia
nonmyeloabl
myeloabl
condit
singlecent
cohort
studi
consecut
patient
klingen
gjaerd
niel
smedegaard
andersen
lone
smidstrup
frii
brian
thoma
kornblit
lykk
petersen
ida
henrik
rigshospitalet
copenhagen
denmark
background
sinc
institut
use
nonmyeloabl
nma
condit
regimen
older
year
significantli
comorbid
younger
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
acut
myeloid
leukemia
aml
aim
compar
longterm
outcom
nma
condit
patient
myeloabl
condit
patient
method
studi
nma
condit
adult
year
consecut
patient
receiv
first
allohsct
aml
rigshospitalet
nma
condit
consist
mainli
gy
total
bodi
irradi
tbi
fludarabin
mgm
case
condit
consist
mainli
cyclophosphamid
mg
kg
either
gy
tbi
case
busulfan
mg
kg
case
fludarabin
mgm
treosulfan
mgm
case
five
percent
nma
condit
patient
respect
receiv
antithymocyt
globulin
patient
follow
death
endoffollowup
octob
st
cumul
incid
confid
interv
ci
acut
graftversushost
diseas
agvhd
grade
iiiv
chronic
graftversushost
diseas
cgvhd
relaps
nonrelaps
mortal
nrm
calcul
compar
nma
condit
patient
use
gray
test
death
compet
risk
relaps
compar
nrm
overal
surviv
os
estim
kaplanmei
method
result
nma
condit
patient
compar
regard
sex
femal
respect
donor
match
relat
donor
respect
differ
expect
indic
regard
age
median
versu
year
respect
karnofski
score
respect
nma
condit
patient
gener
lower
aml
stage
transplant
st
complet
remiss
versu
condit
patient
lower
aml
cytogenet
risk
advers
risk
versu
condit
patient
patient
follow
total
personyear
median
followup
surviv
patient
year
agvhd
grade
iiiv
occur
less
frequent
nma
condit
patient
ci
versu
ci
condit
patient
p
cgvhd
occur
similar
rate
ci
nma
condit
patient
ci
condit
patient
p
trend
toward
higher
relaps
rate
nma
condit
patient
ci
versu
ci
condit
patient
p
nma
condit
patient
howev
statist
signific
lower
nrm
ci
versu
condit
patient
p
os
figur
compar
os
rate
ci
nma
condit
patient
ci
condit
patient
conclus
patient
aml
undergo
allohsct
nma
condit
institut
older
frailer
condit
patient
overal
surviv
transplant
compar
might
explain
gener
lower
aml
stage
cytogenet
risk
transplant
nma
condit
patient
jedlickova
saskia
rosa
toeng
julian
steinmann
han
martin
hubert
serv
gesin
bug
background
allogen
hsct
urgent
indic
patient
aml
first
complet
hematolog
remiss
chr
intens
chemotherapi
increas
recurr
minim
residu
diseas
mrd
patient
high
risk
hematolog
relaps
hr
prepar
transplant
hsct
activ
aml
found
associ
poor
outcom
azacitidin
recent
shown
substanti
delay
even
prevent
hr
patient
trial
platzbeck
et
al
lancet
oncolog
present
outcom
small
cohort
consecut
patient
mrdposit
aml
receiv
low
dose
cytarabin
ldarac
bridg
therapi
prior
hsct
method
mrd
assess
quantit
polymeras
chain
reaction
qpcr
use
mutat
mrd
neg
defin
ratio
oncogen
control
gene
increas
recurr
mrd
requir
ratio
shayegi
et
al
blood
primari
endpoint
retrospect
analysi
progress
hr
bone
marrow
blast
extramedullari
diseas
secondari
endpoint
achiev
molecular
remiss
prior
hsct
neutropenia
accord
ctcae
thrombocytopenia
anemia
admiss
hospit
os
rf
os
rf
calcul
first
dose
ldarac
ldarac
selfadminist
subcutan
patient
home
flat
dose
bid
day
repeat
week
necessari
result
nine
patient
median
age
rang
year
low
intermedi
highrisk
cytogenet
accord
eln
criteria
treat
continu
chr
increas
recurr
mrd
start
median
rang
day
last
consolid
therapi
ie
durat
chr
month
pt
patient
receiv
one
two
three
cycl
ldarac
prior
hsct
three
patient
neutropenia
occur
one
patient
need
platelet
transfus
patient
manag
outpati
set
eight
nine
patient
hr
success
prevent
patient
even
becam
mrd
neg
prior
hsct
one
patient
posit
aml
progress
hr
one
cycl
ldarac
receiv
salvag
therapi
highdos
arac
mitoxantron
ham
prior
hsct
patient
proceed
hsct
match
relat
unrel
haploident
donor
still
aliv
median
followup
day
condit
regimen
includ
fludarabin
flu
melphalan
mel
tbi
flumel
flutbi
flubusulfan
bu
hsct
ldaracrefractori
patient
relaps
result
probabl
rf
year
conclus
data
suggest
bridg
therapi
three
cycl
ldarac
prior
hsct
feasibl
associ
favor
outcom
patient
core
bind
factor
aml
molecular
relaps
month
achiev
first
chr
treatment
low
cost
administ
outpati
basi
well
toler
clinic
background
allogen
hematopoiet
stem
cell
transplant
hsct
cur
treatment
patient
aml
high
risk
diseas
qualifi
upfront
hsct
irrespect
presenc
match
sibl
donor
msd
absenc
msd
haploident
stem
cell
transplant
easier
option
success
rate
high
msd
high
volum
transplant
centr
present
experi
singl
centr
method
analyz
retrospect
data
aml
patient
undergon
hsct
centr
msd
transplant
use
fludarabin
busulfan
fludarabin
melphalan
condit
regimen
match
unrel
donor
transplant
mud
regim
use
fludarabin
busulfan
atg
follow
john
hopkin
protocol
haploident
hsct
cyclosporin
methotrex
use
gvhd
prophylaxi
msd
unrel
donor
group
cyclophosphamid
tacrolimu
mycophenol
use
haploident
posttranspl
day
surviv
overal
surviv
os
incid
gvhd
cmv
reactiv
comput
result
total
aml
patient
underw
hsct
studi
period
basic
clinic
characterist
studi
patient
present
tabl
condit
regim
signific
impact
os
surviv
day
os
function
relaps
free
surviv
rf
function
significantli
differ
msd
haploident
transplant
vs
vs
graph
diseas
statu
latest
follow
show
remiss
relaps
overal
one
year
surviv
five
year
surviv
entir
cohort
respect
averag
cost
msd
transplant
centr
inr
haploident
transplant
inr
mud
transplant
inr
stem
cell
procur
conclus
studi
show
compar
outcom
msd
haploident
transplant
respect
surviv
os
rate
gvhd
develop
countri
like
india
patient
cover
state
health
insur
addit
cost
procur
stem
cell
mud
transplant
would
add
financi
burden
patient
haploident
transplant
feasibl
option
case
nonavail
msd
due
eas
donor
avail
strong
motiv
famili
donor
donat
stem
cell
background
allogen
stem
cell
transplant
allohsct
indic
consolid
first
complet
remiss
favorablerisk
acut
myeloid
leukemia
aml
bear
mutat
nucleophosmin
absenc
intern
tandem
duplic
nevertheless
substanti
proport
patient
eventu
proceed
allohsct
beyond
chemoresist
minim
residu
diseas
mrd
might
compromis
transplant
outcom
studi
aim
examin
characterist
result
allohsct
aml
case
mutat
wildtyp
special
focu
molecular
monitor
mrd
follow
transplant
method
patient
womenmen
underw
allohsct
aml
transplant
median
age
patient
year
rang
diseas
phase
primari
refractori
among
patient
transplant
cr
avail
molecular
mrd
assess
detect
mutant
transcript
realtim
quantit
pcr
rqrcr
also
patient
fulfil
criteria
molecular
relaps
increas
level
transcript
two
success
bone
marrow
sampl
mutant
load
abl
transcript
condit
regimen
myeloabl
major
case
reducedintens
type
donor
vari
name
hlaident
sibl
match
unrel
haploident
rel
doubl
umbil
cord
blood
result
engraft
achiev
case
median
time
absolut
neutrophil
count
day
rang
among
patient
posttranspl
monitor
mrd
rqpcr
exhibit
stabl
molecular
remiss
wherea
rise
level
transcript
observ
case
due
either
hematolog
molecular
relaps
diseas
cumul
incid
cin
hematolog
relaps
nonrelaps
mortal
nrm
month
respect
event
relaps
nrm
encount
beyond
month
allohsct
patient
hematolog
relaps
post
transplant
die
diseas
wherea
one
achiev
stabl
complet
remiss
withdraw
immunosuppress
median
followup
time
month
rang
patient
continu
aliv
cr
estim
diseasefre
background
advanc
liposom
encapsul
cytarabinedaunorubicin
synergist
molar
ratio
approv
us
fda
ema
treatment
adult
newli
diagnos
therapyrel
aml
aml
myelodysplasiarel
chang
method
safeti
data
pool
studi
adult
age
year
newli
diagnos
relapsedrefractori
aml
induct
consist
unitsm
cytarabin
mgm
daunorubicin
mgm
day
second
induct
day
consolid
consist
unitsm
vari
studi
day
evalu
standardofcar
control
result
baselin
characterist
gener
balanc
control
major
patient
age
year
secondari
aml
control
includ
salvag
therapi
mitoxantroneetoposid
cytarabin
idarubicincytarabin
cytarabinebas
chemotherapi
mitoxantron
etoposid
treatmentemerg
advers
event
teae
profil
unitsm
compar
induct
control
associ
greater
proport
patient
teae
grade
teae
seriou
teae
consolid
tabl
therefor
consolid
dose
reduc
unitsm
latter
studi
dose
demonstr
improv
teae
profil
similar
consolid
control
frequent
system
organ
class
gastrointestin
disord
control
lower
incid
report
versu
control
differ
driven
lower
incid
diarrhea
versu
control
frequent
report
grade
teae
febril
neutropenia
control
pneumonia
hypoxia
bacteremia
earli
mortal
rate
overal
treatment
period
appear
lower
versu
control
day
day
tabl
major
earli
death
attribut
teae
conclus
across
studi
compris
clinic
develop
program
demonstr
safeti
profil
compar
convent
chemotherapi
adult
newli
diagnos
relapsedrefractori
aml
background
haploident
hematopoiet
stem
cell
transplant
hsct
posttransplant
cyclophosphamid
pgci
mark
improv
clinic
outcom
recent
studi
compar
allogen
hsct
use
unrel
donor
versu
haplo
donor
patient
acut
leukemia
suggest
equival
outcom
deplet
tcell
pgci
subsequ
appli
unrel
hsct
set
patient
unrel
donor
method
perform
retrospect
studi
patient
acut
leukemia
order
compar
outcom
hla
haploident
unrel
hsct
pgci
main
characterist
patient
similar
group
baselin
diseas
aml
haplo
group
aml
unrel
group
diseas
state
time
haplo
unrelatedhsct
follow
patient
non
aml
recipi
mainli
receiv
thiotepa
busulfan
fludarabin
recipi
receiv
tbi
etoposid
condit
patient
receiv
pbsc
graft
treat
rabbit
antithymocyt
globulin
atg
day
result
time
analysi
os
df
differ
haplo
unrel
group
vs
vs
incid
sever
grade
acut
gvhd
two
group
versu
recipi
haplohsct
transplant
statist
signific
less
like
experi
diseas
relaps
vs
chronic
gvhd
vs
howev
gvhd
free
relaps
free
surviv
grf
rate
slightli
higher
haplohsct
vs
addit
cumul
incid
trm
rate
higher
haplohsct
vs
haplo
unrel
group
underw
hsct
os
versu
non
aml
os
two
group
haplo
versu
unrel
howev
patient
os
higher
haplo
group
compar
unrel
group
versu
impact
pretranspl
diseas
state
powerful
effect
surviv
haplohsct
set
aml
versu
non
versu
non
viral
reactiv
signific
concern
group
conclus
retrospect
analysi
suggest
largerli
similar
os
df
haplo
versu
unrel
transplant
pgci
acut
leukemia
data
indic
haplohsct
result
lower
incid
relaps
chronic
gvhd
higher
grf
compar
unrel
hsct
addtion
pretranspl
diseas
state
import
effect
outcom
group
allopbsc
atg
use
safe
effect
graft
sourc
haplohsct
accept
posttranspl
outcom
replac
bm
set
statist
data
transplant
relat
characterist
provid
presentationw
emphas
use
pgci
gvhd
prophylaxi
type
allogen
transplant
base
result
recommend
haplohsct
pgci
unrel
transplant
patient
acut
leukemia
disclosur
disclosur
conflict
interest
none
excel
efficaci
toler
inotuzumab
ozogamicin
bcell
relaps
allohsct
background
donor
lymphocyt
infus
dli
could
use
prophylact
reduc
relaps
allogen
hematopoiet
stem
cell
transplant
highrisk
leukemialymphoma
without
effect
target
therapi
compar
safeti
efficaci
prophylact
dli
prevent
relaps
allogen
peripher
blood
stem
cell
transplant
haploident
donor
hidsct
matcheds
donor
msdsct
patient
highrisk
acut
myeloid
leukemia
aml
perform
retrospect
observ
cohort
studi
enrol
hidsct
msdsct
recipi
method
highrisk
featur
defin
nonremiss
nr
state
prior
transplant
includ
primari
induct
failur
relaps
untreat
refractori
reinduct
chemotherapi
untreat
aml
evolut
md
ii
achiev
complet
remiss
cycl
induct
chemotherapi
iii
carri
gene
mutat
schedul
time
prophylact
dli
day
transplant
msdsct
recipi
day
hidsct
recipi
gcsfmobil
peripher
blood
stem
cell
infus
recipi
dose
cellskg
csa
given
mgkg
bid
day
day
hidsct
day
msdsct
taper
per
month
discontinu
day
hidsct
day
msdsct
unless
graftversushost
diseas
gvhd
develop
patient
receiv
dli
day
hidsct
day
msdsct
csa
given
week
dli
hid
group
week
msd
group
though
concentr
ngml
dliassoci
gvhd
prophylaxi
taper
discontinu
within
week
unless
gvhd
develop
gvhd
occur
schedul
time
prophylact
dli
would
delay
week
gvhd
well
control
result
prophylact
dli
administ
median
day
hidsct
recipi
day
msdsct
recipi
group
display
similar
baselin
characterist
except
donor
gender
distribut
tabl
grade
acut
graftversushost
diseas
gvhd
postdli
higher
hidsct
group
msdsct
group
vs
grade
acut
gvhd
vs
chronic
gvhd
vs
sever
chronic
gvhd
vs
similar
two
group
p
oneyear
nonrelaps
mortal
higher
hidsct
group
msdsct
group
margin
signific
vs
oneyear
relaps
rate
similar
hidsct
group
msdsct
group
vs
p
estim
overal
surviv
os
vs
relapsefre
surviv
rf
vs
rate
similar
hidsct
group
msdsct
group
p
multivari
analys
nonremiss
statu
prior
transplant
poorrisk
gene
mutat
donor
age
year
predict
higher
risk
relaps
dli
nonremiss
statu
prior
transplant
predict
inferior
os
rf
patient
age
year
also
predict
inferior
os
conclus
prophylact
dli
hidsct
demonstr
similar
toler
efficaci
reduc
relaps
compar
msdsct
highrisk
aml
disclosur
author
declar
conflict
interest
prognost
impact
pretranspl
level
transplant
outcom
acut
leukemia
patient
background
cell
immunoglobulin
mucin
domaincontain
neg
regul
cell
express
varieti
tumor
includ
hematolog
malign
like
acut
myeloid
leukemia
aml
lymphoma
type
shown
associ
advers
prognosi
aim
studi
identifi
prognost
impact
pretranspl
level
earli
late
transplant
relat
complic
well
posttranspl
relaps
surviv
method
total
hematopoiet
stem
cell
transplant
hsct
recipi
initi
diagnosi
acut
leukemia
median
age
year
male
femal
includ
studi
aml
initi
diagnosi
patient
acut
lymphoblast
leukemia
patient
mix
phenotyp
acut
leukemia
patient
blastic
plasmacytoid
dendrit
cell
neoplasm
patient
solubl
level
pretranspl
serum
sampl
measur
enzym
link
immunosorb
assay
elisa
result
median
pretranspl
level
pgml
whole
cohort
pretranspl
level
significantli
higher
aml
patient
compar
vs
level
significantli
lower
patient
abnorm
cytogenet
compar
normal
karyotyp
cytogenet
abnorm
includ
mainli
complex
karyotyp
chromosom
abnorm
frequent
patient
low
level
pretranspl
level
significantli
higher
patient
develop
posttranspl
viral
hemorrhag
cystiti
posit
correl
demonstr
level
acut
graft
versu
host
diseas
gvhd
grade
median
followup
month
overal
surviv
os
found
better
group
compar
group
without
statist
signific
vs
p
figur
probabl
os
rel
better
aml
vs
p
patient
vs
p
repres
low
pretranspl
level
subgroup
analysi
conclus
studi
elev
level
pretranspl
level
aml
patient
compat
previou
report
underlin
increas
express
aml
stem
cell
possibl
associ
express
cytogenet
featur
confirm
studi
adequ
data
except
relationship
mutat
statu
also
express
exhaust
cell
patient
viral
infect
includ
human
immunodefici
viru
hepat
b
hepat
c
viru
play
essenti
role
regul
antivir
antitumor
immun
respons
may
explan
increas
frequenc
hemorrhag
cystiti
patient
higher
level
advers
prognost
impact
gvhd
os
confirm
without
statist
signific
may
relat
small
sampl
size
wide
spectrum
action
tumor
microenviron
includ
stimulatori
inhibitori
activ
clue
requir
defin
exact
role
molecul
clinic
cours
allogen
hsct
order
develop
target
therapeut
strategi
clinic
trial
registri
na
disclosur
noth
declar
homozyg
associ
increas
risk
relaps
hlamatch
transplant
recipi
acut
lymphoid
leukemia
japanes
nation
registri
studi
background
hematopoiet
stem
cell
transplant
hsct
role
natur
killer
nk
cell
express
killercel
immunoglobulinlik
receptor
kir
recogn
hlaclass
ligand
import
recogn
hlac
hlac
polymorph
base
th
amino
acid
transmembran
domain
low
frequenc
high
frequenc
strong
characterist
observ
japanes
use
larg
transplant
databas
report
homozyg
recipi
display
lower
relaps
rate
recipi
hlamatch
hsct
acut
myeloid
leukemia
aml
hr
p
chronic
myeloid
leukemia
cml
hr
p
effect
seem
independ
acut
graftversushost
diseas
agvhd
cytomegaloviru
reactiv
occurr
arima
n
et
al
bbmt
method
relaps
rate
japanes
recipi
first
underw
hlamatch
hsct
treatment
acut
lymphoid
leukemia
compar
pair
pair
use
data
japanes
data
center
hematopoiet
cell
transplant
adjust
transplant
characterist
cord
blood
transplant
exclud
multivari
compet
risk
regress
analys
perform
evalu
relaps
relapsefre
surviv
rf
estim
use
kaplanmei
method
result
recipi
achiev
remiss
experienc
graft
failur
recipi
notexpress
exclud
rest
recipi
age
year
median
year
analyz
median
followup
period
survivor
year
recipi
express
recipi
express
respect
hlamatch
hsct
recipi
higher
relaps
rate
recipi
hr
p
result
wors
rf
among
recipi
hr
p
frequent
relaps
recipi
notic
among
recipi
agvhd
hr
p
without
cytomegaloviru
reactiv
hr
p
phneg
hr
p
conclus
nk
cell
may
promot
graftversusleukemia
gvl
recipi
aml
cml
suppress
gvl
recipi
one
interpret
transplantactiv
nk
cell
impair
antigenpres
cell
depriv
cytotox
tlymphocyt
gvl
effect
cell
hypothesi
may
explain
fact
agvhd
necessari
recess
relaps
recipi
furthermor
phposit
cell
sometim
mimic
aml
cell
term
frequent
myeloid
antigen
express
might
directli
target
nk
cell
would
necessari
clarifi
vitro
charact
nk
cellaffect
transplant
immun
residu
leukemia
cell
disclosur
author
noth
declar
hematopoiet
stem
cell
transplant
sequenti
condit
children
relapsedrefractori
acut
leukemia
nao
yoshida
kazuki
matsumoto
daiki
yamashita
yiqe
zhu
daichi
sajiki
ryo
maemura
hirotoshi
sakaguchi
asahito
hama
children
medic
center
japanes
red
cross
nagoya
first
hospit
nagoya
japan
background
patient
acut
leukemia
fail
achiev
complet
remiss
show
dismal
prognosi
even
allogen
hematopoiet
stem
cell
transplant
hsct
studi
evalu
whether
sequenti
condit
approach
cytoreduct
chemotherapi
appli
shortli
prior
main
condit
follow
hsct
improv
prognosi
highrisk
patient
method
retrospect
analyz
outcom
children
median
rang
year
old
primari
refractori
n
refractori
relaps
n
acut
leukemia
aml
n
n
receiv
hsct
depart
stem
cell
sourc
relat
peripher
blood
pb
patient
relat
bone
marrow
unrel
bone
marrow
unrel
cord
blood
graft
hla
serolog
match
n
mismatch
n
recipi
total
patient
receiv
sequenti
condit
approach
cytoreduct
chemotherapi
fludarabinecytarabineidarubicingcsf
flagida
use
patient
mitoxantron
daunorubicincytarabin
regimen
combin
gemtuzumab
ozogamicin
without
wait
hematolog
recoveri
patient
promptli
underw
hsct
therefor
median
interv
cytoreduct
chemotherapi
main
condit
day
main
condit
regimen
total
bodi
irradiationbas
myeloabl
n
busulfanbas
myeloabl
n
reduc
intens
n
result
children
relapsedrefractori
acut
leukemia
overal
surviv
os
leukemiafre
surviv
lf
cumul
incid
relaps
ri
transplantationrel
mortal
trm
respect
multivari
analysi
use
sequenti
condit
identifi
favor
factor
lf
hazard
ratio
hr
p
although
differ
outcom
accord
type
cytoreduct
chemotherapi
main
condit
regimen
hlamatch
donor
hr
p
pb
blastsneg
begin
condit
hr
p
also
independ
associ
better
lf
sequenti
condit
leukemia
burden
prior
hsct
significantli
reduc
pb
blast
becam
undetect
begin
condit
patient
given
approach
patient
without
approach
p
notabl
outcom
patient
without
pb
blast
begin
condit
receiv
sequenti
condit
promis
os
lf
reach
ri
trm
respect
conclus
studi
reveal
hsct
sequenti
condit
effect
toler
treatment
option
children
relapsedrefractori
acut
leukemia
treatment
strategi
focu
reduct
leukemia
burden
immedi
prior
hsct
may
contribut
induct
longterm
remiss
patient
highrisk
acut
leukemia
disclosur
research
fund
japanes
red
cross
nagoya
hospit
research
grant
use
blinatumomab
achiev
remiss
consolid
haploident
transplant
cyclophosphamid
post
treatment
children
refractori
acut
lymphoblast
leukemia
background
patient
relaps
refractori
convent
treatment
possibl
achiev
long
term
remiss
report
refer
therapeut
efficaci
advers
event
blinatumomab
achiev
molecular
remiss
patient
preb
lead
haploident
cyclophosphamid
post
transplant
consolid
method
pilot
studi
conduct
children
refractori
strategi
achiev
remiss
blinatumomab
use
dose
contin
infus
hour
increas
dose
day
patient
mrd
log
cycl
receiv
haploident
bone
marrow
transplant
consolid
condit
regimen
total
bodi
irradi
scheme
day
cyclophosphamid
etoposid
receiv
prophylaxi
gvhd
cyclophosphamid
result
total
patient
includ
seven
achiev
complet
remiss
cycl
blinatumomab
one
partial
remiss
tabl
seven
patient
six
receiv
haploident
transplant
achiev
graft
transplant
patient
one
patient
bone
marrow
relaps
first
month
followup
patient
free
diseas
followup
month
figur
acut
complic
patient
present
cytokin
releas
syndrom
infus
blinatumumab
patient
present
tachycardia
tabl
patient
present
agvhd
hsct
grade
iii
grade
iv
conclus
allogen
bone
marrow
transplant
constitut
treatment
option
patient
relaps
becom
refractori
treatment
one
major
problem
basic
identifi
hlaident
donor
altern
haploident
donor
import
factor
get
result
diseas
statu
transplant
use
blinatumomab
proven
effect
achiev
remiss
relaps
acut
linfoblast
leukemia
preb
cd
refractori
treatment
characterist
male
median
age
diagnosi
rang
year
statu
diseas
relaps
refractori
primari
salvag
therapi
complet
remiss
blinatumomab
partial
remiss
blinatumomab
activ
diseas
tabl
tabl
demograph
characterist
patient
undergo
blinatumomab
disclosur
olayavarga
r
riveraluna
melchorvid
h
salazarrosal
g
lopezhernandez
n
ramirezurib
wish
confirm
known
conflict
interest
associ
abstact
financi
support
provid
mexican
associ
help
children
wiht
cancer
patient
sequenti
highdos
chemotherapi
reinduct
follow
myeloabl
allogen
transplant
activ
acut
myeloid
leukemia
method
center
relapsedrefractori
aml
patient
transplant
chemoinduc
neutropenia
highdos
salvag
chemotherapi
median
age
transplant
year
rang
patient
suffer
de
novo
n
secondari
aml
genet
risk
stratif
report
use
stardard
group
propos
european
leukemia
net
eln
favor
intermedi
ii
advers
risk
categori
diagnosi
observ
patient
respect
patient
activ
diseas
time
sequenti
therapi
median
marrow
blast
count
rang
patient
receiv
highdos
cytarabin
base
mec
regimen
salvag
therapi
donor
haploident
rel
patient
ident
sibl
matchedunrel
patient
respect
myeloabl
condit
use
implement
antileukem
effect
condit
thiotepabusulfanfludarabin
patient
start
median
day
rang
last
day
chemotherapi
bone
marrow
peripher
blood
stem
cell
use
graft
sourc
patient
graftversushost
diseas
gvhd
prophylaxi
support
care
administ
accordingli
hsct
platform
result
patient
engraft
median
day
neutrophil
recoveri
day
rang
median
followup
survivor
month
rang
non
relaps
mortal
relaps
incid
nrm
ri
year
year
respect
overal
cumul
incid
acut
chronic
gvhd
day
one
year
overal
surviv
os
year
eventfre
surviv
ef
signific
better
os
ef
observ
patient
favorableintermedi
iii
versu
advers
risk
score
year
os
vs
year
ef
vs
advers
risk
signific
impact
os
hr
ef
hr
univari
analysi
ri
sdhr
fine
gray
test
conclus
though
small
patient
cohort
find
suggest
sequenti
therapi
myeloabl
hsct
feasibl
treat
relapsedrefractori
aml
transplantrel
toxic
low
relaps
major
treatmentfailur
howev
even
approach
patient
advers
cytogenet
featur
dismal
prognosi
patient
use
new
drug
hsct
andor
mainten
therapi
transplant
highli
encourag
improv
outcom
disclosur
alessandro
busca
honoraria
gilead
scienc
merck
pfizer
pharmaceut
jazz
background
spite
satisfactori
result
overal
surviv
os
allohsct
st
nd
cr
aml
relaps
free
surviv
rf
graftversushostdiseas
freerelaps
free
surviv
grf
requir
improv
detect
mrd
one
factor
influenc
outcom
allohsct
aml
unclear
identif
import
improv
riskadapt
relaps
prophylact
treatment
allohsct
aim
evalu
outcom
allohcst
st
nd
cr
pediatr
aml
depend
level
mrd
statu
myeloabl
mac
reduc
intens
condit
regimen
ric
method
data
children
aml
st
nd
cr
underw
allohsct
analyz
median
age
moment
allohcst
year
old
mrd
neg
statu
patient
mrd
posit
flow
cytometri
mac
base
busulfan
mgbw
receiv
patient
treosulfan
patient
ric
base
melphalan
receiv
patient
base
busulfan
mgbw
patient
patient
receiv
prophylaxi
agvhd
atg
ptci
patient
plu
csa
tacrolimu
sirolimu
patient
depend
sourc
transplant
relat
unrel
haplo
donor
result
median
follow
year
cohort
mrd
posit
patient
os
vs
mrd
neg
p
rf
vs
accordingli
graftversushostdiseas
freerelaps
free
surviv
grf
mrd
posit
patient
vs
mrd
neg
p
os
rf
grf
mrd
posit
patient
mac
vs
ric
accordingli
p
os
rf
grf
mrd
neg
patient
mac
vs
ric
accordingli
p
os
rf
mrd
neg
patient
withwithout
ptci
vs
p
grf
vs
accordingli
os
rf
grf
mrd
posit
patient
withwithout
ptci
vs
p
conclus
mrd
statu
statist
signific
affect
os
relat
differ
approach
treatment
relaps
allohsct
mrd
posit
statu
statist
signific
decreas
rf
underlin
necess
posttranspl
therapi
improv
ric
vs
mac
patient
first
second
remiss
show
statist
signific
impact
os
rf
grf
ptci
significantli
improv
grf
mrd
neg
patient
disclosur
none
author
anyth
disclos
background
increas
overallsurviv
os
lymphoma
patient
higher
incid
therapyrel
clonal
bone
marrow
diseas
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
occur
gener
outcom
consid
poor
allogen
hematopoiet
stem
cell
transplant
allo
hsct
often
remain
potenti
cur
treatment
option
nonetheless
littl
data
avail
concern
patient
group
method
retrospect
collect
data
patient
therapyrel
aml
taml
md
tmd
treatment
hodgkin
lymphoma
hl
nonhodgkin
lymphoma
nhl
receiv
allo
hsct
median
followup
surviv
patient
year
rang
year
background
prognosi
relapsedrefractori
acut
leukemia
rr
al
poor
treatment
challeng
set
allogen
stem
cell
transplant
allosct
constitut
cur
option
although
high
relaps
rate
nonrelaps
mortal
nrm
sequenti
condit
regimen
follow
allosct
use
persist
diseas
aim
improv
diseas
control
intensifi
chemotherapi
thu
conced
time
presum
graftversusleukemia
effect
occur
method
clinic
outcom
rr
al
sequenti
condit
regimen
combin
chemotherapi
rescu
follow
ric
allosct
center
describ
patient
underw
sequenti
allosct
includ
primari
endpoint
progress
free
surviv
pf
overal
surviv
os
estim
kaplanmei
method
secondari
endpoint
nonrelaps
mortal
nrm
background
recommend
european
leukemia
net
eln
favorablerisk
genet
frg
acut
myeloid
leukemia
aml
favor
consolid
transplant
although
review
suggest
advantag
autolog
stem
cell
transplant
asct
event
free
surviv
object
compar
progress
free
surviv
pf
overal
surviv
os
normal
karyotyp
mutat
without
itd
allel
ratio
aml
patient
treat
consolid
chemotherapi
alon
cc
asct
allogen
stem
cell
transplant
allosct
method
retrospect
review
frgaml
patient
treat
one
institut
follow
induct
regimen
cytarabin
arac
daunorubicin
ade
mitoxantron
mice
consolid
regimen
arac
daunorubicin
acd
idarubicin
arac
miniic
highdos
arac
hidac
asct
condit
regimen
buci
bvac
allosct
buci
flubu
pf
os
calcul
start
last
consolid
stem
cell
infus
result
total
patient
evalu
median
age
year
femal
ecog
perform
statu
ps
ageadjust
charlson
comorbid
index
aacii
diagnosi
patient
treat
cc
asct
allosct
case
differ
group
age
aacii
ps
leucocyt
diagnosi
extramedullari
diseas
frequent
allosct
group
cc
asct
induct
ade
use
mice
patient
complet
remiss
cr
rate
differ
group
induct
regimen
cr
cc
group
consolid
regimen
cycl
cycl
acd
cycl
miniic
asct
patient
receiv
consolid
cycl
acd
cycl
miniic
allosct
patient
receiv
cycl
acd
cycl
hidac
consolid
imag
figur
pf
cc
asct
allosct
group
median
followup
month
pf
os
pf
asct
group
superior
cc
allosct
group
respect
figur
although
statist
signific
os
statist
similar
group
although
inferior
allosct
compar
cc
asct
respect
conclus
histor
cohort
review
although
advantag
os
asct
frg
aml
data
suggest
might
pf
improv
asct
cc
need
address
prospect
studi
disclosur
noth
declar
background
acut
myeloid
leukemia
hematolog
malign
diseas
motiv
persist
struggl
scientif
world
provid
effect
cure
establish
accept
surviv
rate
group
patient
autolog
stem
cell
transplant
myeloabl
condit
still
power
weapon
use
entiti
method
evalu
retrospect
patient
aml
autolog
stem
cell
transplant
perform
period
till
group
consist
patient
male
patient
femal
patient
median
age
diagnosi
year
averag
period
time
diagnosi
autolog
sct
month
result
major
group
use
myeloabl
condit
regimen
busulphancyclophosphamid
patient
patient
ad
melphalan
buci
condit
patient
use
beam
condit
rest
patient
use
bam
condit
regimen
auto
graft
use
peripher
blood
stem
cell
pbsc
patient
patient
use
bone
marrow
main
mobilis
regimen
pbsc
gcsf
etoposid
perform
patient
remain
patient
mobilis
pbsc
perform
gcsf
mean
number
od
apheresi
procedur
done
group
mean
number
collect
mononuclear
cell
kg
tt
mean
time
engraft
day
transplant
relat
mortal
trm
year
overal
surviv
patient
patient
main
reason
death
relaps
primari
diseas
patient
treat
salvag
chemotherapi
regimen
flagida
standard
induct
regimen
absenc
adequ
therapeut
respons
predominantli
complet
remiss
achiev
patient
transplant
complet
remiss
conclus
autolog
stem
cell
transplant
could
accept
therapeut
solut
patient
aml
consolid
therapi
neither
suitabl
compat
donor
avail
allogen
stem
cell
transplant
could
perform
variou
reason
depend
bone
marrow
transplant
unit
disclosur
noth
declar
prophylaxi
dli
alon
may
prevent
relaps
posit
aml
allogen
hct
background
one
potent
prognost
factor
affect
outcom
aml
presenc
cytogenet
molecular
marker
guid
select
postremiss
therapi
recent
favor
outcom
wt
neg
noncebpa
dm
group
allogen
hematopoiet
cell
transplant
allohct
report
similar
favor
risk
eln
risk
classif
howev
role
allohct
compar
consolid
chemotherapi
yet
elucid
method
data
patient
diagnos
aml
receiv
intens
induct
therapi
march
juli
includ
current
studi
address
time
depend
allohct
simon
makuch
method
use
graphic
represent
mantelbyar
test
andersen
gill
method
identifi
risk
factor
longterm
surviv
result
median
age
patient
year
rang
patient
male
mutat
detect
patient
none
low
high
ratio
patient
respect
eln
risk
classif
divid
patient
favor
intermedi
advers
risk
group
patient
respect
neg
group
includ
patient
allohct
perform
patient
overal
complet
respons
cr
induct
therapi
achiev
patient
patient
primari
refractori
diseas
cr
rate
differ
wt
neg
group
intermedi
risk
group
median
followup
durat
month
rang
month
oneyear
os
rate
favor
intermedi
advers
risk
group
p
among
intermedi
risk
group
os
rate
wt
neg
group
similar
intermedi
risk
allohct
perform
patient
wt
neg
group
oneyear
os
rate
differ
wt
neg
allogen
hematopoiet
stem
cell
transplant
allohsct
strategi
prolong
surviv
method
data
aml
pt
year
underw
ric
allohsct
institut
septemb
septemb
retrospect
collect
clinic
file
evalu
overal
surviv
os
novemb
calcul
os
use
kaplanmey
curv
result
identifi
pt
median
age
yo
median
htci
score
median
followup
month
one
patient
pt
cml
blast
crisi
first
major
molecular
remiss
remain
aml
pt
st
complet
remiss
cr
nd
cr
progress
diseas
pd
pt
could
classifi
md
accord
diagnost
criteria
donor
match
unrel
mud
mismatch
unrel
mmud
match
sibl
haploident
thirteen
pt
infus
peripher
blood
hsc
bone
marrow
condit
flubcnumel
unrel
donor
ud
pt
sibl
flumel
ud
pt
sibl
flubu
ud
pt
flutbi
sibl
haploident
graft
versu
host
diseas
gvhd
prophylaxi
tacrolimu
tac
mmf
ud
pt
sibl
tac
mtx
ud
pt
cyclosporin
cya
mmf
ud
pt
sibl
mmud
pt
atg
ptci
done
haploident
set
tac
mmf
median
time
neutrophil
platelet
engraft
whole
cohort
day
respect
one
pt
secondari
engraft
failur
requir
reinfus
select
cell
ten
pt
present
mild
acut
skin
gvhd
eleven
pt
chronic
gvhd
classifi
sever
requir
system
therapi
beyond
year
median
time
immunosuppress
day
year
os
death
diseaserel
relaps
month
pd
infect
complic
septic
shock
secondari
neoplasia
relev
complic
hypoxem
pneumonia
pt
urinari
sepsi
cmv
ebv
reactiv
respect
pt
pulmonari
renal
toxic
either
pt
end
followup
pt
remiss
without
neg
measur
residu
diseas
mrd
mrd
neg
pt
die
septic
shock
sever
intestin
gvhd
conclus
small
cohort
chronic
gvhd
infecti
complic
major
caus
morbid
treatment
relat
death
pt
maintain
achiev
mrd
neg
transplant
better
surviv
although
pt
result
suggest
allohsct
feasibl
consolid
strategi
select
aml
pt
year
imag
overal
surviv
disclosur
noth
declar
background
hematopoiet
stem
cell
transplant
hsct
cur
option
fanconi
anaemia
fa
inherit
disord
character
congenit
anomali
progress
bone
marrow
failur
bmf
predisposit
develop
malign
method
retrospect
analys
data
consecut
patient
underw
hsct
centr
till
june
data
analys
variabl
affect
outcom
term
overal
surviv
os
result
median
age
diagnosi
year
year
median
age
transplant
year
yr
patient
transplant
aplast
phase
male
femal
ratio
twentyfour
patient
congenit
anomali
along
bmf
phenotyp
normal
twentythre
patient
hla
match
sibl
parent
cousin
eleven
patient
gender
mismatch
transplant
three
patient
major
minor
abo
mismatch
background
paroxysm
nocturn
hemoglobinuria
pnh
rare
clonal
nonneoplast
hematopoiet
stem
cell
diseas
whose
incid
casesmillion
individu
worldwid
diseas
characterist
natur
histori
mostli
analyz
multicent
retrospect
studi
limit
heterogen
approach
herein
report
incid
sever
complic
outcom
real
life
set
scenario
pnh
patient
consecut
diagnos
manag
pnh
referr
center
januari
june
method
patient
receiv
homogen
diagnost
treatment
approach
accord
period
observ
avail
diagnost
test
eculizumab
patient
treat
eculizumab
receiv
vaccin
conjug
antimeningococcu
acwyserotyp
sinc
conjug
antimeningococcu
bserotyp
event
complic
patient
could
refer
dedic
hematolog
emerg
room
er
hour
daili
occurr
renal
failur
pulmonari
hypertens
specif
evalu
renal
function
studi
accord
cockcroftgault
formula
lung
function
prospect
monitor
daytimeon
exert
nocturn
pulsoximetr
profil
complet
spirometr
test
dlco
measur
result
pnh
patient
median
age
year
rang
analyz
diagnosi
patient
classic
pnh
aplast
pnh
intermedi
form
cumul
incid
ci
thrombosi
clonal
hematolog
neoplasm
respect
ci
pancytopenia
patient
classic
pnh
one
patient
show
spontan
disappear
pnh
clone
sinc
eculizumab
administ
patient
eculizumab
treatment
patient
reach
hemoglobin
level
dl
without
transfus
respect
nonrespons
eculizumab
treatment
thrombot
event
observ
two
sever
infecti
episod
respiratori
tract
urinari
tract
infect
observ
one
patient
extravascular
hemolysi
demonstr
patient
patient
show
signific
reduct
renal
functionout
patient
prospect
monitor
lung
function
patholog
alter
diurnal
nocturn
pulseoximetr
test
observ
patient
show
obstruct
restrict
ventilatori
defici
reduc
dlco
valu
overal
surviv
os
patient
die
nonpnh
relat
reason
censor
last
followup
better
os
even
statist
signific
associ
absenc
thrombot
event
period
diagnosi
conclus
studi
report
better
os
lower
rate
sever
complic
pnh
compar
previou
experi
although
renal
failur
lung
hypertens
report
group
observ
complic
along
prolong
followup
assum
avail
dedic
er
servic
enabl
earli
diagnosi
prompt
treatment
case
hemoglobinuria
crise
reduc
risk
organ
damag
complic
use
eculizumab
togeth
improv
support
approach
presum
account
trend
toward
better
surviv
wit
last
decad
manag
pnh
patient
disclosur
noth
declar
haploident
unrel
allogen
stem
cell
transplant
aplast
anemia
singl
center
experi
zafer
gulba
elif
birta
atesoglu
meral
sengez
dora
cigdem
eren
suat
celik
demet
cekdemir
background
aplast
anemia
syndrom
bone
marrow
failur
character
peripher
pancytopenia
marrow
hypoplasia
allogen
stem
cell
transplant
hlamatch
sibl
perform
firstlin
set
young
aplast
anemia
patient
elderli
patient
refractori
immunosuppress
treatment
patient
hlamatch
sibl
allogen
stem
cell
transplant
perform
unrel
haploident
donor
studi
analyza
compar
result
aplast
anemia
patient
undergon
allogen
stem
cell
transplant
either
match
unrel
haploident
donor
method
collect
analyz
data
aplast
anemia
patient
undergon
allogen
stem
cell
transplant
match
unrel
haploident
donor
result
patient
receiv
allogen
stem
cell
transplant
unrel
donor
patient
undergon
haploident
transplant
patient
undergon
haploident
transplant
engraft
failur
occur
transplant
differ
haploident
donor
fort
second
time
total
unrel
haploident
transplant
perform
median
age
patient
undergon
unrel
transplant
median
age
patient
undergon
unrel
transplant
result
haploident
unrel
transplant
shown
tabl
neutrophil
platelet
engraft
time
significantli
longer
haploident
transplant
respect
howev
vod
gvhd
day
mortal
rate
differ
group
similarli
overal
surviv
os
patient
undergon
haploident
unrel
transplant
significantli
differ
figur
conclus
although
number
patient
low
studi
conclud
urel
haploident
transplant
aplast
anemia
compar
toxic
efficaci
background
autolog
stem
cell
transplant
ahsct
effect
treatment
aggress
autoimmun
diseas
multipl
sclerosi
ms
howev
toxic
remain
major
concern
wide
applic
approach
post
transplant
viral
reactiv
may
induc
sever
complic
rigor
monitor
peripher
blood
viral
load
prompt
effect
therapi
requir
higher
rate
ebv
cmv
reactiv
observ
patient
affect
ms
condit
beam
plu
atg
compar
control
group
lymphoma
patient
without
atg
condit
regimen
report
polici
center
monitor
treatment
side
effect
method
seri
consecut
patient
ms
transplant
includ
analysi
patient
mobil
cyclophosphamid
gcsf
condit
beam
plu
rabbit
atg
monitor
cmvebv
dna
whole
blood
quantit
pcr
perform
engraft
weekli
least
one
month
longer
interv
preemptiv
treatment
valgancyclovir
start
case
cmv
viral
load
copiesml
case
ebv
assay
copiesml
determin
perform
rituximabbas
treatment
start
viral
copi
exceed
copi
patient
receiv
treatment
case
symptomat
diseas
valu
pcr
virus
ebv
titer
copiesml
result
detect
dna
cmv
observ
patient
median
time
transplant
day
rang
requir
preemptiv
treatment
patient
promptli
respond
treatment
within
week
ebv
viral
load
detect
patient
median
time
day
rang
one
patient
start
treatment
first
determin
high
viral
load
nine
present
ebv
viral
load
copiesml
three
treat
thereaft
persist
increas
viral
load
ml
six
patient
spontan
recov
ebv
reactiv
previou
treatment
predict
higher
risk
viral
reactiv
impact
engraft
relat
reactiv
observ
conclus
polici
show
despit
high
rate
cmv
ebv
reactiv
grade
iiiiv
advers
event
observ
suggest
key
role
viral
monitor
patient
efficaci
preemptiv
treatment
ebv
reactiv
low
titer
monitor
identifi
case
could
achiev
spontan
resolut
avoid
induct
immunosuppress
rituximab
data
confirm
patient
diagnos
ad
undergo
autolog
hsct
need
intens
pattern
care
hematolog
patient
background
autoimmun
diseas
chronic
seriou
condit
often
refractori
standard
therapi
sinc
autolog
haematopoiet
stem
cell
transplant
hsct
promis
altern
shown
satisfactori
longterm
result
aim
studi
evalu
immun
reconstitut
mortal
follow
hsct
patient
autoimmun
diseas
method
retrospect
studi
conduct
patient
diagnosi
autoimmun
diseas
underw
autolog
hsct
juli
januari
tertiari
referr
center
colombia
south
america
descript
statist
use
analyz
patient
demograph
clinic
characterist
result
seven
patient
includ
mean
age
year
rang
five
patient
femal
indic
hsct
system
sclerosi
multipl
sclerosi
myasthenia
gravi
condit
regimen
administ
patient
system
sclerosi
cyclophosphamid
human
antit
lymphocyt
immunoglobulin
beam
carmustin
etoposid
cytarabin
arac
melphalan
human
antit
lymphocyt
immunoglobulin
patient
multipl
sclerosi
cyclophosphamid
human
antit
lymphocyt
immunoglobulin
myasthenia
gravi
median
time
myeloid
engraft
neutrophil
day
posttransplant
platelet
engraft
defin
plateletsmm
untransfus
day
posthsct
median
time
hospit
day
rang
longer
inpati
manag
due
infecti
complic
infecti
complic
includ
bacteremia
caus
e
coli
pneumocysti
pneumonia
result
septic
shock
acut
respiratori
failur
respect
evalu
tcell
immun
reconstitut
none
patient
reach
normal
cell
valu
one
year
hsct
followup
four
patient
reach
normal
cell
valu
month
posthsct
regard
bcell
immun
reconstitut
patient
reach
igg
iga
normal
level
onemonth
posthsct
four
patient
achiev
normal
igm
background
multipl
sclerosi
ms
inflammatori
diseas
caus
autoimmun
reactiv
cell
myelin
accumul
evid
efficaci
highdos
chemotherapi
follow
autolog
haematopoiet
stem
cell
transplant
ahsct
ms
patient
fail
respons
standard
immunotherapi
despit
variabl
elig
criteria
condit
regimen
outcom
method
retrospect
review
ms
patient
submit
ahsct
centr
patient
elig
criteria
activ
relaps
remit
rrm
secondaryprogress
ms
spm
prior
failur
treatment
diseasemodifi
therapi
evid
diseas
activ
clinic
relaps
new
activ
lesion
magnet
reson
mr
mobil
peripher
blood
perform
granulocyt
colonystimul
factor
gcsf
condit
regimen
accord
beam
protocol
sever
ms
disabl
classifi
accord
expand
disabilitystatu
scale
edss
ahsct
toxic
evalu
result
seven
ms
patient
undergon
ahsct
male
median
age
ahsct
year
median
age
ms
diagnosi
year
median
time
diagnosi
ahsct
year
four
patient
spm
rrm
mr
activ
lesion
preahsct
relaps
rate
per
year
median
baselin
edss
median
number
previou
dmt
patient
treat
corticosteroid
copaxon
receiv
rituximab
natalizumab
alemtuzumab
fampridin
fingolimod
patient
collect
enough
cell
singl
apheresi
session
median
number
cell
infus
mean
dmso
volum
ml
median
inpati
stay
ahsct
day
patient
develop
febril
neutropenia
one
admit
intens
care
unit
due
sepsi
one
patient
develop
anaphylact
reaction
transfus
anoth
selflimit
encephalopathi
two
patient
oral
mucos
gastrointestin
toxic
grade
median
time
neutrophil
day
platelet
day
engraft
day
patient
transfus
median
unit
erythrocyt
platelet
treatmentrel
mortal
long
term
side
effect
observ
far
median
postahsct
followup
month
patient
develop
new
lesion
mr
experienc
symptom
consist
clinic
relaps
median
time
month
effect
rescu
corticosteroid
absenc
evid
diseas
activ
although
variat
concern
edss
punctuat
patient
selfreport
signific
benefit
especi
concern
limb
strength
sphincter
contin
improv
conclus
real
life
result
claim
stabil
effect
ms
patient
highli
activeprogress
diseas
ahsct
signific
toxic
failur
report
benefit
edss
punctuat
probabl
due
small
sampl
size
short
followup
studi
need
establish
best
patient
select
criteria
defin
ideal
time
includ
patient
transplant
program
well
evalu
long
term
outcom
disclosur
noth
declar
elena
poponina
elena
butina
anna
yovdiy
galina
zaytseva
natalia
minaeva
igor
paramonov
background
reactiv
epsteinbarr
viru
ebv
repres
potenti
lifethreaten
condit
approxim
patient
allogen
stem
cell
transplant
specif
treatment
avail
method
previous
develop
manufactur
protocol
expans
cytomegaloviru
cmv
ebvspecif
cell
stimul
gcsfmobil
stem
cell
graft
defin
peptid
pool
gari
advanc
therapeut
medicin
product
current
investig
ongo
phase
iiia
trial
eudract
number
howev
expans
virusspecif
cell
reli
preexist
virusspecif
memori
compart
stem
cell
donor
virusseroneg
donor
expans
achiev
therefor
aim
identifi
ebv
peptidespecif
cell
receptor
tcr
translat
offtheshelf
cell
product
treatment
prophylaxi
ebv
infect
ebvassoci
malign
leftov
cell
five
allogen
stem
cell
graft
expand
vitro
presenc
peptid
hpvgeadyfey
eplpqgqltay
associ
latent
lytic
ebv
infect
expans
singl
ebvspecif
cell
fac
sort
use
peptidemhc
pmhc
tetram
individu
tcr
pair
determin
singl
cell
sequenc
han
penter
confirm
peptid
specif
domin
tcr
pair
transfect
murin
hybridoma
cell
line
nfatdriven
gfp
express
siewert
function
candid
transduc
human
peripher
background
lymphoid
myeloid
acut
leukemia
frequent
caus
cancer
relat
death
children
interact
receptor
express
cytotox
immun
cell
ligand
upregul
mani
type
tumor
cell
includ
leukem
blast
import
antitumor
immun
surveil
nevertheless
tumor
cell
may
develop
immun
scape
strategi
like
ligand
shed
reduc
express
may
caus
receptor
downregul
engin
lymphocyt
car
may
overcom
immun
evas
becom
effect
therapeut
strategi
method
cell
obtain
deplet
nonmobil
apheresi
magnet
bead
use
clinimac
cell
gener
lentivir
transduct
cell
express
ligand
analyz
peripher
blood
bone
marrow
sampl
total
leukemia
patient
differ
statu
diseas
diagnosi
remiss
relapserefractori
differ
leukemia
cell
line
qpcr
flow
cytometri
cytotox
cell
leukemia
cell
evalu
perform
hour
europiumtda
assay
solubl
concentr
measur
sera
leukemia
patient
elisa
evalu
effect
cell
cultur
presenc
absenc
differ
concentr
day
one
week
later
cell
prolifer
car
downregul
measur
flow
cytometri
use
cell
trace
violet
label
respect
product
ifng
tnfa
measur
supernat
elisa
effect
cytotox
evalu
hoursdegranul
assay
cocultur
pretreat
cell
cell
line
result
ligand
express
leukemia
cell
line
leukem
blast
express
chang
diseas
statu
trend
decreas
diagnosi
relapserefractori
compar
remiss
cell
cytotox
leukemia
cell
line
percentag
specif
lysi
myeloid
tall
cell
line
suscept
cell
specif
lysi
rang
compar
ball
cell
line
physiolog
concentr
caus
increas
express
howev
supraphysiolog
level
decreas
express
time
increas
cell
prolifer
time
subpopul
affect
downregul
prolifer
impact
subset
effect
dosedepend
attenu
conclus
cell
cytotox
leukemia
cell
special
aml
tall
thu
could
novel
therapeut
approach
nonb
leukemia
ball
relaps
undetect
treatment
express
may
downregul
supraphysiolog
level
although
antitumor
activ
affect
soften
neg
effect
induc
express
cell
prolifer
cytokin
product
chang
observ
surfac
express
differ
stage
diseas
could
relat
ligand
releas
immun
escap
disclosur
noth
declar
denisclaud
roy
ine
adassi
leboeuf
vibhuti
p
dave
maisonneuverosemont
research
center
canada
univers
canada
background
patient
highrisk
leukaemia
allogen
haematopoiet
stem
cell
transplant
cur
treatment
presenc
alloreact
cell
donor
graft
howev
lead
high
probabl
develop
graftversushost
diseas
gvhd
tcell
deplet
minimis
presenc
gvhdcaus
alloreact
cell
often
result
increas
incid
infect
diseas
relaps
photodeplet
treatment
pdt
specif
deplet
activ
alloreact
cell
conserv
rest
cell
pdttreat
cell
utilis
tcelldeplet
haploident
transplant
help
reduc
infect
relaps
efficaci
safeti
pdttreat
cell
current
clinic
investig
phase
iii
trial
hatci
kiadi
pharma
reactiv
pdttreat
donor
cell
assess
toward
tumourassoci
viral
antigen
peptid
deriv
wilm
tumour
protein
preferenti
express
antigen
melanoma
pramep
cytomegaloviru
epsteinbarr
viru
cmv
ebvp
method
healthi
donor
hlaa
peripher
blood
mononuclear
cell
pbmc
cocultur
irradi
pbmc
anoth
mismatch
donor
mix
lymphocyt
reaction
photoact
rhodamin
deriv
ad
cell
expos
visibl
light
deplet
activ
alloreact
cell
elimin
alloreact
cell
postpdt
assess
use
hladr
activ
marker
ex
vivo
expans
protocol
exploit
evalu
impact
pdt
reactiv
tumour
viral
antigen
peptid
postpdt
cell
cocultur
irradi
autolog
monocytederiv
dendrit
cell
puls
pramep
cmvebvp
antigenspecif
cell
restimul
day
prameppuls
autolog
pbmc
cmvebvp
ad
directli
cultur
mhctetram
stain
perform
day
elispot
conduct
day
imag
function
viralspecif
cell
expand
postpdt
result
pdt
result
drastic
decreas
hladr
activ
markerexpress
cell
pdttreat
cell
show
signific
increas
background
acut
lymphoblast
leukemia
common
childhood
cancer
relaps
refractori
still
difficult
treat
engin
cell
equip
synthet
chimer
antigen
receptor
car
target
demonstr
remark
efficaci
treat
howev
natur
killer
nk
cell
known
targetindepend
cytotox
potenti
without
induct
cytokin
releas
syndrom
cr
graftversushostdiseas
gvhd
carnk
cell
overcom
persist
problem
therapi
car
cell
use
viral
vector
gener
car
nk
cell
limit
their
genotox
cost
regulatori
demand
develop
innov
protocol
use
nonvir
sleep
beauti
sb
transposit
third
parti
nk
cell
sourc
produc
shelf
carengin
cell
product
method
nk
cell
isol
peripher
blood
mononuclear
cell
pbmc
use
select
kit
success
expand
ex
vivo
cytokin
stimul
feedercel
free
condit
day
expans
nk
cell
electropor
use
pmaxgfp
transfect
effici
percent
live
cell
electropor
analyz
flow
cytometri
transposit
base
nucleofect
use
mrna
minicircl
mc
dna
vector
perform
differ
time
point
nk
cell
isol
transient
mcvenu
longtim
expans
viabil
base
nucleofect
measur
two
week
furthermor
transduct
nk
cell
differ
viral
amount
moi
conduct
cytotox
engin
cell
positiv
cell
line
address
result
transduct
maxim
nk
cell
could
show
transduct
effici
modifi
nk
cell
high
kill
activ
positiv
cell
e
ration
compar
negativ
cell
line
e
ration
nontransduc
nk
cell
e
ratio
first
experi
pmaxgfp
vector
base
nucleofect
could
show
increas
effici
post
electropor
slightli
decrea
live
cell
compar
nonelectropor
nk
cell
viabil
use
mrna
mcvenu
dna
electrotransfect
nk
cell
few
day
cultiv
reach
transfect
nk
cell
post
electropor
transient
express
mcvenu
posit
nk
cell
effici
increas
rate
live
cell
day
electropor
conclus
sleep
beauti
base
nucleofect
nk
cell
promis
nonvir
method
gener
easi
safer
higher
amount
genet
modifi
third
parti
nk
cell
therapi
also
broad
rang
clinic
applic
disclosur
winfri
wel
inventor
patent
describ
chimer
antigen
receptor
optim
hing
region
axel
schambach
inventor
patent
describ
alpharetrovir
sin
vector
michael
hudecek
zoltan
ivic
inventor
patent
relat
sleep
beaut
gene
transfer
technolog
remain
author
noth
disclos
background
matur
immun
cell
stem
cell
graft
essenti
graftversustumor
gvt
effect
elimin
residu
malign
cell
hematopoiet
stem
cell
transplant
hsct
donor
cell
also
involv
complic
graftversushost
diseas
gvhd
method
perform
prospect
studi
detail
graft
composit
recipi
peripher
blood
stem
cell
pbsc
bone
marrow
bm
order
identifi
correl
clinic
outcom
tabl
graft
character
concentr
cell
nk
cell
togeth
multicolor
flow
cytometri
panel
stain
hladr
detail
immun
phenotyp
cell
content
stem
cell
graft
analyz
fraction
posit
lymphocyt
absolut
concentr
convert
transplant
cell
kg
fraction
evalu
patient
receiv
bm
pbsc
concentr
cellskg
analyz
patient
transplant
pbsc
tabl
tabl
imag
figur
result
found
patient
transplant
graft
nk
cell
dose
median
kg
fraction
nk
cell
lymphocyt
median
significantli
increas
relapsefreesurviv
compar
patient
transplant
graft
contain
nk
cell
dose
valu
figur
result
stay
signific
multivari
analys
relaps
incid
significantli
lower
uniand
multivari
analys
patient
receiv
graft
high
nk
cell
fraction
compar
low
fraction
relaps
rate
versu
patient
transplant
high
versu
low
fraction
nk
cell
peripher
blood
concentr
nk
cell
obtain
sampl
pbsc
donor
gcsf
mobil
significantli
correl
graft
concentrationsand
fraction
nk
cell
analys
graft
content
nkt
cell
show
incid
grade
iiiv
acut
gvhd
significantli
lower
patient
background
extracorpor
photopheresi
ecp
immunomodulatori
treatment
shown
efficaci
steroid
refractori
acut
gvhd
mechan
action
partial
understood
clear
relationship
ecptreat
mononuclear
cell
mnc
lymphocyt
number
respons
ecp
object
studi
analys
relationship
infus
subpopul
cellular
respons
method
patient
differ
center
total
ecp
procedur
retrospect
anal
ecp
procedur
perform
ecp
procedur
perform
offlin
system
respons
defin
respond
complet
partial
respons
nonrespond
infus
cell
number
lymphocyt
monocyt
mononuclear
cell
lymmon
mnc
calcul
analyt
purpos
median
number
cell
infus
per
procedur
respons
median
number
procedur
respons
nonrespond
patient
cumul
number
cell
infus
respons
median
nonrespond
calcul
subgroup
procedur
perform
number
cell
infus
day
ecp
final
respons
surviv
impact
infus
number
cell
median
differ
tertil
assess
median
number
procedur
need
achiev
respons
imag
result
median
number
procedur
respons
observ
trend
toward
higher
median
number
monocyt
per
procedur
cumul
infus
monocyt
respond
patient
median
number
infus
vs
kg
cumul
infus
median
number
vs
kg
lost
day
treatment
also
trend
toward
higher
median
infus
mnc
respons
respond
vs
kg
observ
differ
number
lymphocyt
infus
patient
receiv
number
lymphocyt
per
procedur
first
tertil
kg
present
higher
respons
rate
vs
none
analys
paramet
show
signific
impact
overal
surviv
conclus
patient
acut
gvhd
respond
ecp
receiv
higher
number
monocyt
mnc
earli
phase
treatment
median
first
process
also
patient
receiv
higher
number
lymphocyt
first
procedur
achiev
higher
respons
rate
find
suggest
possibl
higher
number
treat
infus
cell
could
influenc
respons
ecp
specif
design
prospect
studi
need
ass
possibl
disclosur
noth
declar
background
field
kidney
transplant
made
enorm
progress
last
decad
toward
standard
treatment
patient
endstag
renal
diseas
howev
administr
immunosuppress
drug
still
one
major
limit
longterm
allograft
surviv
therefor
strategi
induct
donorspecif
toler
highli
desir
aim
clinic
phase
studi
donorderiv
modul
immun
cell
mic
conduct
method
donorderiv
mic
manufactur
gmp
condit
potenc
mic
test
differ
vitro
bioassay
mic
administ
patient
escal
x
micskg
day
group
x
micskg
day
group
b
day
group
c
kidney
transplant
accompani
standard
immunosuppress
medic
posttransplant
frequenc
advers
event
ae
assess
day
day
posttranspl
dynam
chang
variou
lymphocyt
subset
patient
mic
therapi
detect
multicolor
flow
cytometri
donorspecif
immunosuppress
assess
measur
antidonor
antibodi
mix
lymphocyt
reaction
mlr
donor
thirdparti
cell
result
kidney
transplant
recipi
observ
median
serum
creatinin
mgdl
day
remain
stabl
day
median
creatinin
mg
dl
without
signific
proteinuria
none
patient
experienc
reject
episod
ae
observ
three
ae
sever
importantli
none
associ
mic
transfus
besid
two
infecti
complic
posttranspl
posit
cross
match
result
donor
titer
de
novo
donorspecif
antibodi
record
notabl
immunosuppress
therapi
could
reduc
without
sign
reject
group
c
infus
observ
dramat
increas
b
cell
median
day
follow
reduct
day
group
c
notabl
regulatori
b
cell
significantli
increas
median
day
day
parallel
plasma
ratio
increas
median
cell
therapi
day
mic
cell
therapi
recipi
lymphocyt
show
minim
reactiv
irradi
donor
pbmc
vitro
reactiv
rd
partydonor
pbmc
impair
moreov
vitro
mic
product
demonstr
immunomodulatori
potenc
induc
tolerogen
dendrit
cell
tdc
character
low
express
costimulatori
matur
well
high
express
inhibitori
marker
function
tdc
could
inhibit
releas
also
prolifer
cmv
specif
cell
moreov
micinduc
tdc
show
capac
inhibit
donorspecif
alloreact
cell
prolifer
conclus
mic
cell
therapi
modul
immun
system
kidney
transplant
recipi
increas
ratio
regulatori
b
cell
facilit
reduct
convent
immunosuppress
therapi
without
allograft
injuri
reject
episod
therefor
mic
cell
therapi
repres
promis
strategi
transplant
medicin
current
prepar
phase
ii
trial
mic
cell
therapi
disclosur
noth
declar
genom
edit
graftderiv
cell
post
background
immunotherapi
use
car
cell
shown
promis
result
fight
cancer
howev
cart
cell
product
requir
special
infrastructur
oper
impli
high
cost
central
product
autom
product
cart
cell
clinimac
prodigi
devic
allow
clinicalgrad
manufactur
car
cell
method
million
cell
healthi
donor
cultur
texmac
supplement
iuml
day
cell
activ
cell
transact
day
one
activ
cell
transduc
lentivir
vector
moi
cell
expand
day
cell
product
next
harvest
count
analyz
viabil
express
antitumor
cytotox
differ
qualiti
test
includ
steril
vector
copi
number
genet
stabil
quantif
viral
particl
supernat
myctert
express
endotoxin
detect
perform
spare
cell
cryopreserv
either
autolog
plasma
dmso
albumin
dmso
hypothermosol
month
cryopreserv
cell
product
analyz
viabil
express
cytotox
result
memori
cell
expand
million
express
viabil
harvest
car
cell
show
specif
lysi
jurkat
cell
osteosarcoma
cell
line
microbiolog
contamin
observ
final
car
cell
product
vector
copi
number
valid
except
one
cgh
karyotyp
show
genet
alter
free
viral
particl
undetect
supernat
overexpress
myctert
found
except
one
valid
endotoxin
cryopreserv
cell
product
kept
express
one
year
freez
howev
viabil
cytotox
best
preserv
use
autolog
plasma
dmso
conclus
autom
product
largescal
clinicalgrad
cell
use
clinimac
prodigi
feasibl
reproduc
allow
decentr
protocol
gener
car
cell
clinic
use
background
immun
reconstitut
ir
essenti
control
sever
infect
hematopoiet
stem
cell
transplant
hsct
reconstitut
adapt
immun
may
take
year
recov
tlymphocyt
lt
delay
earli
lt
recoveri
increas
risk
relaps
viral
infect
transplant
relat
mortal
adopt
transfer
select
cell
subset
low
alloreact
potenti
emerg
strategi
improv
ir
method
deplet
naiv
cell
preserv
memori
cell
could
provid
function
lymphocyt
protect
infect
leukemia
relaps
low
risk
graft
versu
host
diseas
gvhd
present
experi
highdos
donor
memori
cell
donor
lymphocyt
infus
dli
assess
safeti
outcom
total
dli
hsct
perform
case
cmvebv
reactiv
mix
chimer
persist
lymphopenia
graft
reject
relaps
boost
ir
dli
product
obtain
perform
deplet
donor
leukapheresi
product
use
devic
result
twentytwo
pediatr
patient
median
age
year
rang
malign
nonmalign
diseas
receiv
tcr
alphabeta
deplet
graft
haploident
deplet
graft
match
unrel
match
relat
donor
median
day
rang
transplant
patient
receiv
total
dli
cell
median
rang
contain
median
kg
rang
kg
kg
rang
kg
cell
kg
rang
kg
infus
welltoler
develop
worsen
gvhd
total
episod
cmvebv
viral
reactiv
decreas
viral
load
clear
viral
load
show
clinic
improv
total
patient
persist
lymphopenia
slightli
increas
total
lymphocyt
count
normal
level
prophylact
dli
boost
ir
increas
lymphocyt
count
case
none
dli
administ
case
mix
chimer
graft
failur
relaps
effect
revert
situat
conclus
preliminari
data
suggest
infus
high
dose
memori
cell
safe
adopt
immunotherapi
strategi
efficaci
observ
patient
lymphopenia
cmvebv
reactiv
posit
result
patient
mix
chimer
graft
failur
relaps
howev
determin
real
efficaci
strategi
prospect
studi
requir
disclosur
noth
declar
background
increas
clinic
trial
confirm
chimer
antigen
receptor
cell
cart
target
antigen
promis
effect
approach
treatment
relapsedrefractori
rr
bcell
lineag
malign
consid
frequent
express
larg
part
acut
myeloid
leukemia
aml
cell
suppos
may
use
approach
rescu
rr
aml
patient
method
patient
receiv
lymphodeplet
chemotherapi
decitabin
fludarabin
cyclophosphamid
dac
fc
two
day
chemotherapi
autologousallogen
cell
provid
unicartherapi
biomedicin
technolog
co
shanghai
china
total
dose
cell
per
kilogram
kg
infus
dose
escal
within
day
research
protocol
approv
institut
review
board
first
affili
hospit
soochow
univers
patient
gave
written
inform
consent
result
case
respond
well
transient
revers
toxic
case
present
grade
cytokin
releas
syndrom
cr
manifest
intermitt
fever
chill
day
infus
half
month
associ
neutropenia
cart
cell
expans
observ
blood
without
obviou
increas
cytokin
infus
case
achiev
maintain
molecular
complet
remiss
cr
month
case
present
grade
cr
manifest
continu
high
fever
hypotens
grade
liver
disfunct
day
cell
infus
week
obviou
cytokin
releas
peak
serum
concentr
pgml
peak
crp
serum
concentr
detect
associ
cell
expans
blood
sever
offtumor
effect
observ
infus
case
achiev
hematolog
cr
cytogenet
cr
got
month
diseas
free
surviv
conclus
report
implic
safe
promis
approach
manag
rr
aml
express
may
provid
salvag
treatment
approach
aml
patient
express
benefit
certain
popul
aml
besid
blinag
malign
clinic
trial
registri
na
disclosur
noth
declar
work
support
research
grant
nation
key
r
program
china
nation
natur
scienc
foundat
china
background
chimer
antigen
receptor
engin
cart
cell
emerg
power
cellular
therapi
treat
malign
diseas
current
revolution
field
cancer
immunotherapi
cryopreserv
step
postmanufactur
logist
necess
larg
scale
cell
manufactur
process
also
mandatori
request
regulatori
author
case
relaps
st
cart
cell
transplant
second
applic
mayb
higher
dose
constitut
therapeut
option
howev
data
concern
clinic
grade
cart
cell
stabil
function
month
cryopreserv
releas
compani
far
investig
effect
cryopreserv
cart
cell
perform
studi
method
differ
batch
cart
cell
manufactur
accord
gmp
requir
institut
final
cart
product
frozen
concentr
x
cellsml
high
batch
x
cellsml
low
batch
control
freez
process
biofreez
devic
store
liquid
nitrogen
tank
releas
qualiti
control
test
steril
endotoxin
mycoplasma
perform
batch
accord
european
pharmacopoeia
unit
state
pharmacopoeia
guidelin
stabil
cart
cell
term
viabil
recoveri
transduct
effici
function
capac
determin
microscopi
multiparametr
flow
cytometri
well
releas
test
follow
sop
result
result
qualiti
control
fulli
met
requir
regulatori
author
stabil
result
highli
robust
reproduc
time
gmp
cart
batch
durat
cryopreserv
day
neg
influenc
cell
viabil
recoveri
viabl
cart
cell
transduct
effici
howev
cell
concentr
cryopreserv
signific
impact
postthaw
viabil
low
batch
vs
high
batch
vs
p
recoveri
low
batch
vs
high
batch
vs
p
cryopreserv
cart
cell
transduct
effici
moreov
observ
four
transient
sideeffect
cryopreserv
amount
cytokin
releas
cart
cell
cytokin
releas
percel
basi
multifunction
cart
cell
kill
capac
note
function
capac
cryopreserv
cart
cell
overnight
rest
compar
even
enhanc
releas
cart
cell
compar
fresh
cart
cell
multifunction
cart
cell
could
preserv
furthermor
kill
capac
cryopreserv
cart
cell
overnight
rest
could
reach
level
noncryopreservedfresh
cart
cell
conclus
cryopreserv
day
harm
effect
transduct
effici
function
cart
cell
howev
cell
number
per
millilit
freez
medium
matter
dose
x
cellsml
avoid
conduct
vitro
bioassay
determin
function
cart
cell
overnight
rest
process
could
mimic
situat
clinic
applic
elimin
transient
sideeffect
cryopreserv
fulli
regain
function
potenc
cart
cell
disclosur
noth
declar
background
dc
specif
tcell
import
mediat
ctlrespons
could
alreadi
show
allogen
donoror
autolog
tcell
obtain
amlpati
stimul
dc
leu
result
effici
lysi
naiv
blast
method
chemokinereleas
analys
cytometr
bead
array
serum
amlmdspt
well
supernat
differ
dcgeneratingmethod
correl
pt
clinic
cours
dcand
tcellinteract
well
specif
tcellreact
lytic
activ
dcleublast
stimul
tcell
mlc
naiv
blast
quantifi
cytotox
assay
result
minim
differ
median
chemokinelevel
pt
serum
subdivid
subtyp
seen
higher
releas
lower
releas
tendenti
correl
favour
subtyp
year
age
blast
pb
persist
diseas
higher
serumreleas
relaps
significantli
higher
found
compar
first
diagnosi
point
chang
diseas
activ
chemokin
level
wherea
chemokinelevel
dccultur
supernat
compar
serum
variabl
clear
correl
lateron
stimul
tcell
dcleu
mlc
improv
antileukem
tcell
activ
seen
higher
valu
chemokin
dccultur
supernat
alway
correl
improv
tcell
antileukem
activ
compar
stimul
blastcontain
mnc
control
wherea
respect
correspond
serum
valu
higher
releas
lower
valu
correl
higher
probabl
improv
antileukem
activ
dcleustimul
vs
blaststimul
tcell
predict
signific
cutoffvalu
could
evalu
separ
group
compar
moreov
correl
lateron
achiev
respons
immunotherapi
occurr
gvhd
seen
higher
serum
valu
lower
valu
correl
achiev
respons
immunotherapi
predict
cutoffvalu
could
evalu
separ
group
compar
respond
nonrespond
higher
level
lower
level
correl
occurr
gvhd
conclus
conclud
amlpt
serum
higher
valu
lower
valu
part
correl
favor
subtyp
improv
antitumorreact
function
sinc
dccultur
supernat
higher
valu
chemokin
correl
improv
antileukem
tcell
reactiv
conclud
chang
function
inflammatori
tumorpromot
antitumorreact
function
knowledg
contribut
develop
immunemodifi
strategi
promot
antileukem
adapt
immunerespons
disclosur
noth
declar
background
allogen
hematopoiet
cell
transplant
allohct
cur
treatment
option
patient
suffer
hematolog
malign
infus
donor
lymphocyt
dli
induc
sustain
remiss
case
minim
residu
diseas
relaps
potent
graftversusleukemia
gvl
effect
although
graftversushost
diseas
gvhd
repres
common
doselimit
toxic
invari
natur
killer
inkt
cell
known
prevent
gvhd
promot
benefici
antitumor
effect
investig
role
inkt
cell
success
dli
method
analyz
dli
sampl
flow
cytometri
inkt
cell
identifi
stain
tetram
cultureexpand
purifi
dliinkt
test
tumor
cell
line
primari
leukemia
cell
ex
vivo
tumor
control
model
tumor
cell
viabil
coincub
dliinkt
measur
flow
cytometri
use
result
inkt
cell
repres
rang
donor
lymphocyt
expand
follow
twoweek
protocol
preferenti
expans
inkt
cell
tumor
cell
line
jurkat
effici
lyse
coincub
dliinkt
marker
degranul
significantli
upregul
dliinkt
stimul
jurkat
addit
increas
concentr
sfasl
perforin
measur
coincub
dliinkt
jurkat
observ
tumor
cell
lysi
correl
express
mhcilik
molecul
consequ
ad
antibodi
cocultur
abrog
dliinktmedi
kill
tumor
cell
dliinkt
also
effici
lyse
primari
leukemia
cell
aml
blast
express
aml
blast
significantli
correl
dliinktmedi
tumor
cell
lysi
r
conclus
ex
vivo
expans
dliinkt
subsequ
dli
enrich
immunotherapeut
approach
could
improv
leukemia
control
thu
prevent
relaps
allohct
without
exacerb
gvhd
disclosur
noth
declar
gener
antigenspecif
cytotox
lymphocyt
target
use
activ
b
cell
sun
ok
yun
kyung
baek
hee
young
shin
hyoung
jin
kang
seoul
nation
univers
seoul
korea
republ
background
wilm
tumor
antigen
highli
express
mani
malign
includ
leukemia
target
tumor
associ
antigen
taa
cancer
immunotherapi
attract
studi
gener
cytotox
lymphocyt
confirm
activ
b
cell
act
cancer
antigen
present
cell
induc
ctl
method
induct
ctl
activ
b
cell
use
antigen
present
cell
b
cell
isol
pbmc
normal
healthi
donor
activ
nucleofect
plasmid
dna
activ
b
cell
cultur
pbmc
vitro
harvest
assay
result
cell
expand
time
day
cultur
examin
characterist
ctl
surfac
marker
ctl
marker
ratio
also
examin
nkt
cell
marker
see
nkt
cell
activ
cytokin
use
induct
ctl
portion
nkt
cell
ctl
show
decreas
cell
increas
effector
memori
central
memori
compar
nonstimul
pbmc
subsequ
elispot
enzymelink
immunospot
assay
perform
confirm
respons
induc
ctl
antigen
ctl
encount
target
antigen
produc
encount
target
cell
load
antigen
respond
secret
kill
assay
also
perform
determin
immunogen
induc
ctl
induc
ctl
found
kill
e
ratio
autolog
pbmc
met
target
pepmix
addit
found
ctl
kill
activ
encount
leukemia
cell
line
express
match
hlaa
conclus
studi
induc
antigenspecif
ctl
specif
react
use
activ
b
cell
antigenpres
cell
observ
confirm
b
cell
activ
act
taa
present
cell
induc
taa
specif
ctl
viral
antigen
consequ
ctl
could
induc
moreov
ctl
induc
activ
b
cell
abil
recogn
kill
target
cell
express
correctli
result
demonstr
vitro
expand
ctl
use
activ
b
cell
promis
candid
adopt
immunotherapi
cancer
disclosur
noth
declar
judith
michael
schumm
christian
braun
marina
schmidt
patrick
schlegel
christian
seitz
murat
akta
georg
rauser
sandra
karitzki
peter
lang
rupert
handgreting
univers
children
hospit
germani
miltenyi
biotec
gmbh
bergisch
gladbach
germani
background
cell
chimer
antigen
receptor
car
surfac
facilit
target
specif
surfac
express
antigen
research
clinic
trial
cell
show
impress
remiss
induct
rate
increas
surviv
heavili
pretreat
patient
therefor
car
cell
introduc
new
potent
cellular
therapeut
clinic
routin
order
establish
manufactur
cell
valid
run
fulli
autom
clinimac
prodigi
cell
transduct
process
perform
use
miltenyi
lentivir
vector
method
unmobil
leukapheres
donor
x
healthi
x
use
clinimac
prodigi
cell
transduct
process
leukocyt
undergo
cell
enrich
via
magnet
bead
follow
stimul
mac
gmp
cell
transduct
lentivir
vector
expans
final
formul
cellular
product
manufactur
fac
analys
perform
well
cytotox
assay
cell
product
result
total
volum
leukapheres
ml
x
total
mononuclear
cell
enrich
cell
transduc
lentivir
vector
expand
cell
harvest
day
final
cell
count
cellular
product
x
mononuclear
cell
two
healthi
volunt
allpati
respect
transduct
effici
cell
among
viabl
cell
final
count
car
cell
therefor
x
cell
final
product
exert
excel
cytolyt
activ
bcpall
cell
line
importantli
cell
gener
patient
demonstr
complet
erad
autolog
blast
e
ratio
hour
incub
conclus
clinimac
prodigi
cell
transduct
process
shown
run
fullyautom
manufactur
process
day
without
deviat
clean
room
environ
singl
devic
user
interact
reduc
activ
day
set
system
provid
fresh
medium
reagent
transduct
process
yield
high
number
cell
high
frequenc
transduc
cell
result
compar
unmobil
leukapheres
healthi
donor
show
expect
slightli
lower
result
patient
final
result
demonstr
clinimac
prodigi
cell
transduct
process
well
suit
provid
clinic
rr
bcm
studi
appropri
investig
medic
product
disclosur
background
allogen
hematopoiet
stem
cell
transplant
allohct
effect
strategi
long
term
control
sever
hematolog
diseas
howev
patient
could
experi
complic
graft
versu
host
diseas
gvhd
diseas
relaps
recent
introduct
posttranspl
cyclophosphamid
ptci
allow
significantli
reduc
gvhd
diseas
relaps
remain
import
issu
donorlymphocyt
infus
dli
establish
adopt
cell
therapi
diseas
relaps
allohsct
order
effici
safe
patient
immunosuppress
treatment
gvdhfree
report
data
efficaci
safeti
dli
infus
treatment
diseas
relaps
patient
receiv
peripher
blood
stem
cell
transplant
allopbsct
hlamatch
unrelatedrel
plu
ptci
gvdh
prophylaxi
clinic
trial
nct
method
collect
data
patient
treat
ptci
mgkgdie
day
mofetil
mycophenol
mmf
tacrolimu
gvhd
prophylaxi
allopbsct
receiv
dli
infus
treat
januari
octob
report
data
overal
respons
rate
orr
diseas
control
rate
dcr
dlirel
mortal
morbid
diagnosi
follow
multipl
myeloma
acut
myeloid
leukemia
acut
lymphoblast
leukemia
lymphoma
patient
one
chimer
loss
receiv
dli
diseas
relaps
result
median
time
transplant
dli
rang
month
median
number
dli
infus
rang
patient
receiv
cyclophosphamid
prepar
regimen
day
cryopreserv
dli
infus
case
dli
associ
lenalidomid
ponatinib
overal
respons
rate
orr
diseas
control
rate
dcr
achiev
patient
receiv
dli
loss
chimer
convert
full
donor
infus
dli
treatment
incid
acut
gvhd
grade
iiii
grade
iiiii
patient
start
short
cours
system
immunosuppress
treatment
none
patient
die
dli
advers
event
estim
overal
surviv
limit
followup
length
month
conclus
infus
nonmanipul
lymphocyt
allogen
donor
valuabl
safe
strategi
treatment
patient
relaps
allopbsct
ptci
ptci
show
high
efficaci
gvhd
prevent
allow
earli
discontinu
immunosuppress
drug
reach
goal
transform
transplant
platform
could
add
earli
dli
infus
new
strategi
diseas
control
clinic
trial
registri
nct
disclosur
noth
declar
extracorpor
photopheresi
treatment
refractori
chronic
gvhd
analysi
mononuclear
cell
infus
gillen
oarbeascoa
maria
luisa
lozano
luisa
maria
guerra
cristina
amunarriz
nuria
revilla
pastora
iniesta
cynthia
acosta
fleita
jose
lui
arroyo
eva
martinez
revuelta
andrea
galego
dolor
hernandezmarav
mi
kwon
aurora
viejo
jose
maria
garcia
gala
concepcion
andon
saavedra
jose
lui
diezmartin
background
extracorpor
photopheresi
ecp
immunomodulatori
treatment
shown
efficaci
steroid
refractori
chronic
gvhd
mechan
action
partial
understood
studi
correl
suggest
treat
mononuclear
cell
mnc
lymphocyt
respons
ecp
object
studi
analyz
relationship
infus
cellular
respons
chronic
gvhd
method
patient
differ
center
total
ecp
procedur
retrospect
analyz
ecp
procedur
perform
ecp
procedur
perform
offlin
system
respons
defin
respond
complet
partial
respons
nonrespond
infus
cell
number
lymphocyt
monocyt
mononuclear
cell
lymmon
mnc
calcul
analyt
purpos
median
number
cell
infus
per
procedur
respons
median
number
procedur
respons
nonrespond
patient
cumul
number
cell
infus
respons
median
nonrespond
calcul
subgroup
procedur
perform
number
cell
infus
day
ecp
final
respons
surviv
impact
infus
number
cell
median
differ
tertil
assess
median
number
procedur
need
achiev
respons
result
median
number
procedur
respons
observ
differ
median
number
lymphocyt
monocyt
mnc
infus
respons
day
respond
nonrespond
patient
differ
respons
patient
receiv
lymphocyt
monocyt
median
number
nevertheless
patient
receiv
total
absolut
number
mnc
median
cell
show
trend
toward
higher
respons
rate
vs
patient
receiv
cumul
number
lymphocyt
first
ecp
procedur
median
show
improv
overal
surviv
os
os
vs
patient
receiv
number
monocyt
median
show
trend
toward
better
surviv
signific
number
monocyt
infus
surpass
first
tertil
os
final
patient
receiv
cumul
number
mnc
first
tertil
also
show
improv
surviv
os
conclus
differ
infus
cellular
respond
nonrespond
patient
chronic
gvhd
time
found
except
trend
toward
better
respons
higher
mnc
infus
relationship
lymphocyt
monocyt
respons
rate
previou
studi
suggest
howev
even
relationship
respons
rate
patient
receiv
highest
number
lymphocyt
monocyt
mnc
cohort
show
improv
surviv
suggest
larger
quantiti
cell
could
exhibit
protect
effect
nevertheless
prospect
studi
address
relationship
need
disclosur
noth
declar
compar
analysi
cytotox
potenti
cytokineinduc
killer
natur
killer
cell
neuroblastoma
therapi
annekathrin
heinz
beatric
grebe
eva
mudri
jochen
bushra
rai
claudia
cappel
sabin
eva
retting
thoma
klingebiel
peter
bader
evelyn
ullrich
univers
hospit
frankfurt
frankfurt
germani
german
cancer
consortium
dktk
partner
site
frankfurt
germani
background
neuroblastoma
nb
common
solid
extracrani
tumor
childhood
despit
therapeut
progress
prognosi
highrisk
nb
poor
innov
therapi
medic
need
therefor
investig
cytotox
potenti
interleukin
il
activ
natur
killer
nk
cell
compar
activ
cytokineinduc
killer
cik
cell
differ
human
nb
cell
line
vitro
method
nk
cell
isol
peripher
blood
mononuclear
cell
pbmc
use
enrich
deplet
kit
success
expand
ex
vivo
differ
cytokin
combin
andor
feedercel
free
condit
contrast
cik
cell
gener
pbmc
ex
vivo
stimul
compar
analysi
expans
rate
puriti
phenotyp
cytotox
activ
differ
nb
cell
line
follow
differ
cultur
protocol
perform
result
enrich
nk
cell
show
median
expans
rate
day
cultur
final
frequenc
nk
cell
median
frequenc
cell
contrast
start
cell
product
deplet
consist
median
frequenc
nk
cell
expand
significantli
faster
also
reach
puriti
without
relev
cell
contamin
cik
cell
expand
median
rate
contain
nk
nklike
cell
interestingli
nk
cell
particularli
show
significantli
higher
median
cytotox
capac
nb
cell
deplet
enrich
deplet
compar
cik
cell
induc
kill
nb
cell
e
ratio
hour
coincub
assay
interestingli
prolong
ex
vivo
stimul
deplet
day
enhanc
median
expans
rate
slightli
reduc
cytotox
potenti
day
ex
vivo
expans
day
ex
vivo
expans
comparison
donor
addit
prior
harvest
increas
expans
rate
median
compar
donor
improv
cytotox
compar
fortun
nk
cell
product
show
high
viabil
relev
b
cell
contamin
median
interestingli
optim
cultur
procedur
use
anoth
cell
cultur
medium
led
improv
median
compar
nk
cell
expans
rate
day
also
result
compar
cytotox
conclus
nk
cik
cell
product
may
offer
innov
immun
therapeut
option
patient
highrisk
nb
allogen
stem
cell
transplant
studi
reveal
nk
cell
significantli
higher
cytotox
potenti
combat
nb
interestingli
use
expand
activ
nk
cell
develop
deplet
apheresi
product
highli
promis
addit
immunotherapi
combin
haploident
stem
cell
transplant
children
nb
disclosur
noth
declar
quantit
determin
donor
alloreact
tcell
haploident
donorrecipi
pair
enzymelink
immunospot
elispot
mix
lymphocyt
cultur
mlc
assay
background
tcell
alloreact
respons
graft
versu
host
diseas
morbid
associ
hematopoiet
stem
cell
transplant
hsct
also
graftversusleukemia
gvl
activ
regard
monitor
quantit
alloreact
tcell
allot
may
potenti
provid
valuabl
inform
individu
clinic
manag
transplant
recipi
aim
studi
optim
detect
comparison
elispot
mlc
assay
method
allot
determin
haploident
donorrecipi
pair
hsct
donor
mononuclear
cell
mnc
serv
effector
cell
ec
patient
mnc
use
stimulatori
cell
sc
ratio
ec
sc
frequenc
allot
donor
peripher
blood
test
elispot
assay
mlc
elispot
provid
detect
quantit
activ
tcell
basi
cytokin
secret
cell
coincub
time
h
ifngamma
h
detect
mcl
assay
donor
mnc
label
cfse
allot
prolifer
respons
stimul
alloantigen
determin
flow
cytometri
day
result
median
number
ifngamma
produc
allot
per
donor
mnc
ec
sc
ratio
ec
sc
ratio
median
frequenc
allot
ec
sc
ratio
ec
sc
ratio
among
lymphocyt
allot
less
frequent
donor
mnc
comparison
ifngammaproduc
allot
median
number
per
mnc
ec
sc
ratio
ec
sc
ratio
median
frequenc
ec
sc
ratio
ec
sc
ratio
among
lymphocyt
ec
sc
ratio
enough
stimul
produc
mnc
elispot
assay
optim
stimul
ifngamma
produc
cell
ec
sc
ratio
prefer
suggest
allot
predominantli
ifngamma
produc
cell
alloreact
prolifer
tclone
detect
mlc
donorrecipi
pair
day
cocultiv
median
percentag
prolifer
tclone
ec
sc
ratio
ec
sc
ratio
among
lymphocyt
howev
mlc
assay
permit
qualit
analysi
confirm
presenc
alloreact
tclone
give
inform
frequenc
within
cultur
result
elispot
mcl
assay
directli
correl
conclus
allot
detect
assay
haploident
donorrecipi
pair
elispot
mlc
differ
detect
due
fact
elispot
allow
detect
singl
cytokin
secret
cell
wherea
mlc
reveal
prolifer
clone
analysi
allot
haploident
donorrecipi
pair
may
provid
rational
manipul
alloimmun
respons
exploit
power
abil
allot
control
hematolog
malign
disclosur
noth
declar
allogen
mesenchym
stromal
cell
rescu
therapi
infant
lifethreaten
respiratori
syndrom
due
filamin
mutat
background
cellbas
therapi
gain
attent
respiratori
system
diseas
encourag
result
report
follow
mesenchym
stromal
cell
msc
administr
due
capac
produc
secret
varieti
paracrin
factor
bioactiv
macromolecul
msc
becam
key
player
lung
tissu
injuri
function
reduc
fibrosi
promot
normal
develop
alveoli
pulmonari
vessel
first
time
use
msc
infus
rescu
therapi
pediatr
patient
flna
gene
mutat
lifethreaten
respiratori
syndrom
method
child
new
pathogen
variant
flna
gene
age
month
due
seriou
irrevers
chronic
respiratori
failur
dismal
prognosi
treat
intraven
infus
allogen
bone
marrow
bm
msc
dose
mscskg
bodi
weight
bmmsc
produc
cell
factori
fondazion
ircc
policlinico
matteo
pavia
isol
expand
ex
vivo
healthi
donor
bm
follow
previous
report
protocol
premed
antistamin
drug
min
everi
infus
avoid
potenti
reaction
perform
evolut
respiratori
condit
detect
peripher
blood
collect
msc
treatment
treg
monitor
treg
defin
cell
express
forkhead
box
transcript
factor
defin
cell
express
intracellular
evalu
perform
flow
cytometri
facscanto
bd
bioscienc
san
diego
ca
previous
report
follow
standard
procedur
result
acut
advers
event
relat
msc
infus
record
followup
patient
maintain
good
gener
condit
show
regular
growth
system
respiratori
infect
occur
second
infus
child
experienc
progress
improv
clinic
respiratori
condit
good
adapt
mechan
ventil
absenc
episod
respiratori
exacerb
babi
maintain
adequ
volum
exchang
substanti
reduct
inspiratori
support
reduct
trigger
sensit
also
obtain
thorax
ct
scan
show
recoveri
basal
parenchyma
bilater
improv
anatomicalfunct
align
aerial
penetr
first
msc
administr
enrich
treg
percentag
peripher
blood
observ
second
msc
infus
signific
increas
ratio
note
conclus
report
suggest
msc
serial
infus
promis
therapi
aid
respiratori
failur
even
pediatr
patient
flna
mutat
intraven
administr
allogen
msc
feasibl
safe
without
toxic
result
suggest
mitig
lung
injuri
msc
may
act
regul
treg
balanc
investig
upcom
establish
use
therapeut
propos
interstiti
lung
diseas
children
disclosur
nothig
declar
feasibl
stimul
donor
nk
cell
manufactur
earli
infus
patient
high
risk
acut
myeloid
leukemia
undergo
haploident
transplant
background
nk
cell
provid
potent
antitumor
effect
set
manipul
haploident
hematopoiet
stem
cell
transplant
haplohsct
propos
novel
strategi
enhanc
antitumor
effect
allogen
transplant
infus
nk
cell
stimul
exvivo
adult
highrisk
acut
myeloid
leukemia
aml
patient
undergo
unmanipul
haplohsct
object
studi
provid
effici
product
data
obtain
manufactur
cellular
product
infus
method
select
criteria
includ
patient
highrisk
aml
undergo
unmanipul
haplohsct
lymphoapheresi
haploident
donor
perform
use
spectra
optia
bct
day
transplant
obtain
product
doubl
immunomagnet
cellular
select
clinimac
system
miltenyi
perform
two
step
deplet
follow
posit
select
obtain
enrich
cellular
product
nk
cell
incub
ngml
hour
gmp
condit
qualiti
microbiolog
control
perform
end
manufactur
step
dxh
cellular
counter
beckman
multiparametr
flow
cytometri
use
lymphocyt
subpopul
viabil
analysi
navio
cytomet
beckman
conjug
monoclon
antibodi
miltenyi
final
product
infus
intraven
patient
day
manufactur
condit
met
rang
nkkg
puriti
cellskg
discard
nk
cell
activ
product
measur
express
result
novemb
april
patient
includ
ongo
trial
two
product
manufactur
patient
one
first
patient
due
transplant
complic
first
second
infus
one
product
meet
minimum
viabil
criteria
discard
infus
final
product
mean
sem
nk
cell
puriti
recoveri
viabil
respect
log
deplet
rang
median
infus
dose
nk
cell
cell
per
kg
complet
manufactur
data
procedur
shown
tabl
background
cytokineinduc
killer
cik
cell
promis
immunotherapeut
approach
combat
relaps
follow
allogen
hematopoiet
stem
cell
transplant
hsct
acut
leukemia
myelodysplast
syndrom
show
safeti
efficaci
multicent
clinic
studi
pediatr
adult
patient
includ
eight
cik
cell
applic
escal
dose
ongo
method
favor
singl
larg
scale
cik
cell
gener
aim
appli
fresh
cik
cell
cryopreserv
readyforus
dose
accord
studi
protocol
contrast
recurr
manufactur
therefor
cryopreserv
cik
cell
test
freshli
gener
cik
cell
approv
equival
furthermor
altern
medium
supplement
cik
cell
cultur
investig
avoid
suppli
bottleneck
abserum
result
fresh
frozen
plasma
ffp
platelet
lysat
pl
abserum
cik
cell
cultur
show
median
expans
rate
wherea
cultiv
without
medium
addit
result
significantli
lower
prolifer
p
cik
cell
composit
includ
cell
nk
like
cell
minor
part
nk
cell
significantli
influenc
chang
medium
addit
moreov
neither
cytotox
cell
express
nk
like
cell
significantli
influenc
differ
medium
addit
cik
cell
gener
either
ficol
peripher
blood
pb
unstimul
leukapheresi
lp
product
util
regard
repeat
manufactur
within
clinic
studi
also
cryopreserv
lp
pbsc
start
materi
came
focu
interest
compar
cik
cell
expans
rate
signific
differ
entir
cik
cell
subgroup
cell
detect
four
start
materi
cryopreserv
cik
cell
signific
effect
cik
cell
composit
cytotox
express
nk
like
cell
small
albeit
signific
effect
cryopreserv
viabil
detect
freez
thaw
conclus
challeng
effici
time
personaland
cost
save
product
cik
cell
within
clinic
studi
introduc
ffp
enabl
cik
cell
manufactur
increas
patient
cohort
avoid
suppli
bottleneck
abserum
furthermor
cryopreserv
allow
storag
readyforus
cik
cell
dose
fulfil
demand
clinic
studi
clinic
trial
registri
eudract
number
disclosur
noth
declar
autom
gener
deplet
donor
lymphocyt
infus
dli
clinimac
system
method
current
clinimac
system
develop
graft
engin
magnet
label
cell
leukapheresi
product
deplet
white
blood
cell
wbc
develop
new
clinimac
process
order
eas
procedur
routineus
reduc
specif
accord
report
cell
number
dli
applic
enabl
use
peripher
blood
product
high
amount
red
blood
cell
rbc
new
system
test
perform
run
new
fluoresc
flow
analysi
protocol
develop
result
result
clinimac
prodigi
system
autom
procedur
integr
label
wash
step
new
applic
softwar
deplet
enabl
deplet
cell
total
wbc
peripher
blood
product
major
differ
process
rbc
remov
option
base
integr
camera
cell
pellet
detect
final
cell
product
provid
physiolog
salin
verif
run
peripher
blood
product
total
whole
blood
leukapheresi
product
result
mean
deplet
log
rang
cell
deplet
product
viabil
target
product
alway
mean
wbc
recoveri
mean
process
time
rang
without
includ
manual
step
ie
tube
set
instal
downstream
analysi
blood
product
flow
cytometri
data
line
preced
evalu
run
result
obtain
cooper
extern
beta
test
site
perform
result
furthermor
line
result
obtain
clinimac
plu
instrument
run
qualiti
control
deplet
product
develop
flow
cytometr
analysi
strategi
fast
accur
conveni
analysi
even
rare
count
remain
unwant
cell
allow
determin
cell
two
differ
level
subset
stain
minimum
requir
flow
cytometr
analysi
includ
color
defin
viabl
cell
evalu
cell
subset
addit
color
use
defin
viabl
cell
conclus
autom
clinimac
prodigi
system
process
capabl
deplet
cell
effici
peripher
blood
product
within
hour
new
process
fast
conveni
regulatori
compliant
method
prepar
readytous
cell
product
clinic
applic
submiss
european
notifi
bodi
ce
certif
import
next
step
myeloabl
condit
regimen
prefer
patient
gvhd
prophylaxi
regimen
csa
mtx
csammf
csa
atg
given
patient
despit
given
gvhd
prophylaxi
patient
transplant
patient
gvhd
featur
patient
experienc
steroid
resist
gvhd
transplant
includ
grade
grade
ecp
treatment
start
mean
day
diagnosi
steroid
resist
gvhd
patient
complet
respons
patient
partial
patient
respons
ecp
treatment
day
sixteen
patient
also
receiv
mesenchym
stem
cell
therapi
salvag
therapi
one
patient
experienc
hypocalcem
tetani
complic
ecp
procedur
thirteen
patient
die
directli
relat
steroid
resist
gvhd
condit
like
relaps
primari
diseas
pre
syndrom
also
play
role
death
conclus
extracorpor
photopheresi
reliabl
effect
second
line
treatment
modal
steroid
resist
gvhd
start
ecp
session
soon
gvhd
symptom
occur
increas
effect
mesenchym
stem
cell
administr
ecp
patient
limit
studi
reach
conclus
efficaci
ecp
need
hemodialysi
cathet
prolong
session
adequ
flow
possibl
cathet
relat
infect
lmitat
feasibl
ecp
disclosur
noth
declar
donor
lymphocyt
infus
administr
allogen
stem
cell
transplant
pediatr
singl
center
experi
background
loss
chimer
one
major
problem
allogen
stem
cell
transplant
sct
donorlymphocyt
infus
dli
use
treatment
taper
stop
immunosuppress
studi
dli
experi
patient
loss
chimer
sct
due
variou
benign
malign
hematolog
diseas
present
method
juli
twenti
patient
detect
chimer
loss
receiv
dli
sct
evalu
retrospect
patient
receiv
myeloabl
reduc
intens
condit
atg
cyclosporin
methotrex
gvhd
prophylaxi
chimer
analys
perform
short
tandem
repeat
str
method
peripher
blood
result
consid
mix
chimer
nonchimer
patient
consid
mix
chimer
immunosuppress
therapi
ceas
immedi
treat
dli
donor
lymphocyt
infus
perform
twoweek
interv
chimer
followup
student
mann
whitney
u
ki
kare
test
kaplanmei
analysi
use
result
age
median
femal
male
patient
evalu
initi
diagnos
thalassemia
major
aplast
anemia
aml
dli
initi
time
day
sct
total
number
dli
administr
dose
dli
kg
mean
kg
nine
patient
chimer
fell
first
month
transplant
patient
nonchimer
complet
chimer
mix
chimer
eleven
month
sct
patient
nonchimer
mix
chimer
earli
mix
chimer
found
relev
graft
reject
patient
follow
day
eight
patient
chimer
increas
dli
infus
continu
decreas
patient
dli
acut
gvhd
seen
groupth
group
decreas
chimer
dli
dose
mean
kg
group
increas
chimer
dli
dose
mean
kg
although
differ
statist
signific
numer
valu
reveal
significantli
differ
patient
mix
chimer
patient
complet
chimer
none
thalassem
patient
patient
thalassemiatrait
donor
mix
chimer
patient
whose
donor
normal
complet
chimer
one
nonchimericth
differ
signific
infus
dose
reveal
mean
kg
mix
chimer
patient
kg
complet
chimer
patient
kg
patient
loss
chimer
amount
seen
high
numer
valu
complet
chimer
statist
signific
found
overal
surviv
diseasefre
surviv
conclus
evalu
efficaci
dl
patient
mix
chimer
patient
group
conclud
chimer
loss
patient
earli
decreas
chimer
similar
literatur
spite
dli
practic
dose
applic
frequenc
greater
patient
increas
chimer
small
number
heterogen
patient
limit
studi
regard
studi
larger
seri
homogen
group
acquir
disclosur
noth
declar
phase
clinic
trial
repeat
administr
bonemarrow
deriv
mesenchym
stem
cell
steroidrefractori
chronic
graftversushost
diseas
patient
nayoun
kim
youngwoo
jeon
jaedeog
jang
keonil
im
nakgyun
chung
youngsun
nam
yunejin
song
junseok
lee
seokgoo
cho
cghvd
common
longterm
complic
allogen
hematopoiet
stem
cell
transplant
associ
poor
qualiti
life
increas
risk
morbid
mortal
current
standard
treatment
avail
patient
respond
steroid
altern
immunosuppress
drug
mesenchym
stem
cell
msc
use
treat
prevent
steroidrefractori
acut
gvhd
patient
studi
report
also
provid
basi
use
msc
steroid
refractori
cgvhd
patient
method
evalu
safeti
efficaci
repeatedinfus
msc
enrol
ten
sever
steroidrefractori
cgvhd
patient
steroid
refractori
defin
either
respons
steroid
last
least
week
progress
diseas
treatment
taper
last
least
week
patient
intraven
administ
msc
produc
thirdparti
bone
marrow
donor
interv
total
four
dose
dose
contain
cell
per
kg
bodi
weight
four
dose
consist
msc
donor
passag
result
enrol
ten
patient
femal
male
median
age
rang
median
cgvhd
affect
organ
rang
includ
skin
eye
oral
caviti
lung
liver
joint
ten
patient
receiv
plan
four
dose
msc
administ
total
infus
median
time
initi
cgvhd
diagnosi
first
msc
treatment
day
rang
msc
infus
well
toler
immedi
delay
toxic
week
first
msc
infus
ten
patient
show
partial
respons
show
allevi
clinic
symptom
increas
qualiti
life
organ
respons
seen
skin
eye
oral
caviti
liver
joint
howev
one
patient
die
progress
gvhd
one
patient
relaps
primari
diseas
conclus
repeat
infus
msc
feasibl
safe
may
effect
salvag
therapi
patient
steroidrefractori
cgvhd
largescal
clinic
studi
longterm
follow
need
futur
determin
role
msc
cgvhd
background
major
pregnant
polish
women
heard
cord
blood
bank
howev
doctor
suffici
knowledg
possibl
use
cord
blood
order
respond
potenti
concern
healthcar
profession
awar
cord
blood
could
use
treat
haematolog
diseas
order
make
doctor
awar
issu
provid
patient
inform
expect
would
like
present
data
use
cord
blood
store
blood
bank
haematolog
nonhaematolog
therapi
method
tabl
present
creat
use
data
gener
databas
polish
stem
cell
bank
warsaw
poland
data
regard
umbil
cord
blood
data
exclud
patient
plan
assess
day
day
discharg
day
transplant
year
transplant
case
patient
lost
followup
due
persist
lack
report
transplant
centr
result
case
therapeut
use
cb
transplant
replac
patient
tissu
case
administr
infus
without
destruct
patient
tissu
thirtythre
administ
standard
therapi
experiment
therapi
conclus
survey
studi
cite
indic
low
awar
cord
blood
use
among
healthcar
profession
hand
one
studi
indic
expect
place
cord
blood
bank
may
unreason
privat
cord
blood
bank
support
recommend
underlin
import
patient
educ
poland
cord
blood
approv
standard
therapi
approx
diseas
rare
polish
law
allow
use
cord
blood
sibl
parent
grandpar
donor
addit
activ
plan
clinic
trial
throughout
world
evalu
therapeut
efficaci
cord
blood
area
haematolog
neurolog
cardiolog
diabetolog
congenit
paediatr
disord
ophthalmolog
dermatolog
gastroenterolog
hiv
infect
qualiti
life
age
therefor
indic
may
expect
futur
background
cytokin
releas
syndrom
cr
identifi
clinic
signific
target
tumour
side
effect
chimer
antigen
receptor
car
tcell
therapi
clinic
increas
interkeukin
elev
cytokin
lactat
dehydrogenas
ldh
creactiv
protein
crp
ferritin
side
effect
includ
fever
fatigu
headach
encephalopathi
hypertens
tachycardia
coagulopathi
nausea
capillari
leak
multi
organ
dysfunct
cr
symptom
appear
earli
one
day
infus
resolv
quickli
last
week
sever
relat
diseas
burden
prior
car
tcell
therapi
method
bristol
oncolog
haematolog
centr
provid
car
tcell
therapi
patient
earli
collat
lead
consult
ward
fellow
nurs
team
member
appar
effect
way
manag
patient
post
car
tcell
therapi
side
effect
provid
educ
inform
poster
depict
flow
chart
aid
practition
recognis
effect
treatmanag
patient
cr
symptom
result
none
yet
prospect
tool
readi
first
patient
earli
conclus
continu
read
studi
day
prior
ward
receiv
first
car
tcell
patient
increasingli
import
entir
multi
disciplinari
team
recognis
cr
understand
import
earli
detect
care
monitor
earli
intervent
background
allogen
stem
cell
transplant
allosct
cur
procedur
primari
secondari
myelofibrosi
pmf
smf
elderli
peopl
mainli
affect
limit
feasibl
intens
myeloabl
chemotherapi
regimen
introduct
reducedintens
condit
ric
made
allosct
feasibl
effect
old
patient
nevertheless
incid
pmf
smf
neglig
young
patient
theoret
abl
toler
also
highintens
therapi
data
avail
efficaci
ricallosct
particular
set
youngag
mf
patient
method
studi
includ
myelofibrosi
young
patient
age
receiv
allosct
univers
hospit
hamburggermani
four
patient
previous
splenectom
patient
mostli
fall
intermedi
risk
group
accord
dipss
four
patient
belong
highrisk
tripleneg
categori
test
patient
po
graft
sourc
pbsc
patient
receiv
bmsc
patient
hlamatch
sibl
other
transplant
fullymatch
partiallymatch
unrel
donor
transplant
condit
accord
ebmt
protocol
busulfan
mgkg
po
mgkg
iv
fludarabin
atlg
neovii
germani
administ
day
dose
mgkg
die
mud
mgkg
die
mrd
transplant
follow
cylosporina
mycophenol
first
day
result
engraft
rate
median
neutrophil
engraft
time
day
platelet
engraft
reach
patient
median
day
four
patient
develop
poor
graft
function
success
treat
select
pbscboost
median
follow
year
estim
os
respect
dipssrisk
donor
hlamatch
result
signific
impact
factor
os
neither
cytogenet
molecular
abnorm
significantli
relat
os
twentyf
patient
experienc
agvhd
grade
cgvhd
observ
patient
mostli
begin
first
day
transplant
cumul
incid
trm
year
plateau
first
year
trm
trm
observ
patient
maxim
grade
marrow
fibrosi
furthermor
trm
never
occur
previous
splenectom
patient
signific
impact
splenectomi
os
observ
transplant
patient
relaps
die
without
treatment
infect
receiv
dli
durabl
cr
patient
dli
underw
second
allosct
longterm
surviv
case
conclus
ric
follow
allogen
sct
cur
treatment
approach
younger
patient
myelofibrosi
low
nrm
import
outcomedetermin
factor
donor
hlamatch
interestingli
marrow
high
grade
fibrosi
show
significantli
impact
trm
biolog
marker
mutat
cytogenet
larg
known
highli
predict
poor
prognosi
diseas
natur
cours
show
impact
surviv
suggest
patient
harbor
abnorm
could
get
greatest
benefit
allosct
data
collect
prospect
random
trial
need
confirm
conclus
disclosur
noth
declar
abstract
alreadi
publish
splenectomi
risk
factor
relaps
allogen
hematopoiet
stem
cell
transplant
patient
myelofibrosi
retrospect
cohort
studi
background
splenectomi
common
procedur
patient
pt
myelofibrosi
mf
perform
achiev
improv
blood
cell
count
reduc
bsymptom
howev
also
shown
splenectomi
may
advers
predispos
leukem
transform
set
aim
evalu
singlecent
retrospect
analysi
longterm
impact
preor
posttranspl
splenectomi
transplant
outcom
regard
overal
surviv
relaps
risk
method
retrospect
analysi
compris
data
pt
male
femal
primari
secondari
mf
allohsct
hlamatch
sibl
unrel
donor
center
median
age
year
rang
year
myeloabl
condit
regimen
perform
pt
pt
treat
reduc
intens
condit
peripher
blood
stem
cell
bone
marrow
median
x
cellskg
bodyweight
bw
rang
transplant
splenectomi
perform
pt
pt
splenectom
prior
pt
allohsct
relaps
diagnos
pt
median
durat
relaps
transplant
month
rang
month
result
median
durat
followup
cohort
month
rang
month
overal
surviv
os
pt
die
includ
pt
relaps
pt
die
treatment
relat
caus
observ
probabl
relaps
significantli
higher
splenectom
pt
nonsplenectom
pt
versu
rel
risk
rr
ci
year
os
nonsplenectomis
splenectomis
pt
relaps
rate
splenectomis
pt
independ
pre
pt
posttranspl
pt
treatment
rr
ci
conclus
basi
cohort
could
assert
preand
postallohsct
splenectomi
equal
significantli
associ
increas
relaps
ratio
patient
mf
also
tend
neg
affect
overal
surviv
imag
figur
overal
surviv
allohsct
patient
myelofibrosi
background
bcell
prolymphocyt
leukemia
bpll
rare
lymphoprolif
disord
although
allogen
stem
cell
transplant
allosct
could
cur
option
patient
often
qualifi
consolid
treatment
due
aggress
cours
diseas
case
studi
report
three
patient
fail
ibrutinib
therapi
achiev
complet
remiss
even
mrd
neg
treatment
chimer
rituximab
enabl
undergo
allosct
method
clinic
data
followup
data
collect
chart
review
result
three
patient
pt
male
year
pt
femal
year
pt
femal
year
refer
bpll
harbor
highli
complex
aberr
karyotyp
includ
abnorm
pt
pt
mutat
could
detect
pt
pt
three
patient
symptomat
diseas
rapidli
increas
hyperleukocytosi
massiv
splenomegali
two
treatmentna
one
relaps
chemoimmunotherapi
patient
put
ibrutinib
despit
initi
respons
treatment
two
patient
develop
progress
diseas
pt
month
pt
ibrutinib
wherea
pt
remain
partial
remiss
persist
leukocytosi
preclud
consolid
allosct
origin
intend
pt
ibrutinib
replac
venetoclax
without
respons
order
control
rapid
lymphoprolifer
rituximab
ad
venetoclax
grade
infus
reaction
tumor
lysi
syndrom
tl
fever
tachycardia
hypotonia
requir
intraven
vasopressor
follow
rituximab
administr
despit
fraction
rituximab
small
dose
howev
continu
rituximab
led
complet
durabl
clearanc
hyperleukocytosi
mrd
neg
despit
venetoclax
cessat
similar
pattern
observ
pt
receiv
rituximab
show
rapidli
increas
leukocytosi
upon
ibrutinib
complet
clearanc
bpll
cell
peripher
blood
mrd
neg
occur
initi
grade
tl
despit
modest
express
tumor
cell
patient
also
pt
achiev
profound
bpll
cell
deplet
mrd
rate
upon
addit
rituximab
ibrutinib
without
tl
case
subsequ
three
patient
abl
undergo
allosct
condit
fludarabin
total
bodi
irradi
gy
pt
receiv
stem
cell
hlaident
sibl
donor
wherea
pt
pt
unrel
donor
hlaident
hlamatch
respect
followup
time
month
posttranspl
pt
pt
current
ongo
mrdneg
remiss
pt
develop
acut
graftversushost
diseas
gvhd
liver
grade
nevertheless
clinic
cours
well
control
immunosuppress
pt
chronic
gvhd
skin
occur
pt
achiev
mrd
neg
allosct
develop
acut
chronic
steroidrefractori
gvhd
skin
gastrointestin
tract
nine
month
posttranspl
gvhd
deterior
complic
patient
die
pneumonia
month
posttranspl
conclus
supplementari
treatment
rituximab
induc
deep
remiss
patient
ibrutinibresist
genet
poorrisk
bpll
therebi
enabl
undergo
success
consolid
allosct
high
risk
lifethreaten
infus
reaction
tl
associ
addit
rituximab
taken
account
background
littl
experi
use
newer
target
therapi
cll
patient
relaps
allogen
stem
cell
transplant
allosct
background
evalu
safeti
efficaci
bcr
inhibitor
bcri
ibrutinib
idelalisib
administ
allosct
purpos
treat
cll
relaps
method
data
cll
pt
relaps
sct
subsequ
treat
ibrutinib
idelalisib
retrospect
collect
collabor
spanish
group
cll
gellc
spanish
group
stem
cell
transplant
geth
result
transplant
characterist
summar
tabl
eight
patient
receiv
bcri
first
salvag
treatment
sct
relaps
wherea
patient
receiv
prior
line
treatment
time
onset
bcri
patient
rai
stage
patient
lymph
node
size
cm
present
patient
complex
karyotyp
patient
respect
gene
mutat
detect
patient
median
time
sct
bcri
therapi
month
shorter
patient
treat
ibrutinib
median
month
treat
idealisib
median
month
median
time
ibrutinib
idelalisib
month
month
respect
best
overal
respons
rate
orr
obtain
ibrutinib
cr
pr
prl
wherea
patient
receiv
idelalisib
cr
prl
among
patient
treat
ibrutinib
present
advers
event
ae
diarrhea
asthenia
infect
frequent
hypertens
seen
patient
none
patient
develop
atrial
fibril
five
patient
stop
ibrutinib
treatment
due
toxic
progress
ibrutinib
discontinu
patient
newli
treat
idelalisib
venetoclax
patient
treat
idelalisib
develop
least
one
ae
diarrhea
pneumon
neutropenia
common
four
patient
discontinu
idelalisib
progress
toxic
venetoclax
given
idelalisib
patient
although
acut
andor
chronic
gvhd
bcri
document
patient
respect
one
patient
treat
idelalisib
reactiv
mild
chronic
gvhd
none
patient
receiv
infus
lymphocyt
donor
bcri
one
patient
underw
second
sct
median
followup
month
onset
bcri
treatment
patient
die
due
cll
progress
transform
wherea
patient
remain
respons
cr
pr
overal
surviv
probabl
whole
seri
month
conclus
studi
ibrutinib
idelalisib
administ
cll
patient
relaps
sct
increas
risk
gvhd
reactiv
show
high
incid
advers
event
nevertheless
bcri
offer
possibl
diseas
control
patient
poor
prognosi
studi
need
confirm
data
background
prior
introduct
tyrosin
kinas
inhibitor
tki
median
surviv
chronic
phase
chronic
myeloid
leukemia
cpcml
patient
approxim
month
standard
treatment
interferonalpha
result
complet
cytogenet
respons
patient
autolog
stem
cell
transplant
autosct
first
attempt
patient
transform
order
restor
second
cp
introduc
secondarili
cp
tri
prolong
respons
main
ration
autograft
cp
resid
reduct
tumor
burden
number
leukem
cell
risk
develop
blastic
transform
nevertheless
autosct
alon
abl
maintain
longterm
remiss
nowaday
tki
repres
stateoftheart
therapi
cml
concept
autosct
littl
interest
longterm
followup
outcom
set
current
unknown
aim
studi
evalu
first
time
longterm
outcom
cml
patient
receiv
autosct
chronic
phase
evalu
second
time
subgroup
analysi
outcom
receiv
tki
autotranspl
mainli
diseas
progressionloss
respons
andor
enhanc
diseas
respons
method
found
total
patient
receiv
autosct
cpcml
europ
year
male
median
age
autosct
year
rang
median
time
diagnosi
autosct
month
stem
cell
sourc
peripher
blood
patient
frequent
condit
regimen
busulfan
day
day
melphalan
one
day
prior
cell
reinfus
inform
receiv
tki
post
autosct
avail
patient
first
tki
imatinib
patient
dasatinib
nilotinib
ponatinib
one
patient
result
median
followup
year
rang
time
autosct
whole
popul
probabl
overal
surviv
os
year
ci
patient
relaps
median
time
month
autosct
total
patient
transplant
tki
era
surviv
avail
tki
perform
landmark
analysi
evalu
outcom
patient
receiv
autosct
surviv
tki
era
receiv
tki
year
os
probabl
patient
tki
treatment
ci
addit
data
request
sent
center
queri
prognosi
molecular
respons
treatment
diseas
detail
conclus
demonstr
preliminari
result
introduct
tki
improv
surviv
cml
patient
addit
patient
receiv
autosct
surviv
tki
era
also
receiv
tki
encourag
rate
longterm
surviv
extens
analysi
perform
addit
data
avail
studi
updat
result
disclosur
noth
declar
year
singl
center
transplant
experi
chronic
myeloid
leukemia
background
allogen
hematopoiet
stem
cell
transplant
hsct
consid
decad
cur
approach
patient
chronic
myeloid
leukemia
cml
tyrosin
kinas
inhibitor
tki
era
hsct
cml
reserv
patient
achiev
cytogenet
remiss
show
progress
diseas
multipl
tki
treatment
line
howev
progress
improv
longterm
surviv
obtain
overal
hsct
popul
present
studi
aim
evalu
whether
cml
patient
transplant
center
long
time
period
outcom
improv
time
method
consecut
patient
underw
transplant
compar
patient
receiv
transplant
overal
surviv
os
leukemiafre
surviv
lf
graftleukemiafre
surviv
glf
estim
use
kaplanmei
method
logrank
test
use
compar
risk
factor
categori
result
patient
median
age
year
st
nd
chronic
phase
acceler
phase
six
blast
crisi
match
relat
donor
altern
donor
match
unrel
donor
cord
blood
mismatch
relat
donor
use
case
respect
stem
cell
sourc
bone
marrow
use
patient
peripher
blood
umbil
cord
blood
tbibas
condit
regimen
use
patient
case
irradiationfre
condit
regimen
use
univari
multivari
analysi
irradiationfre
condit
regimen
hr
ci
transplant
perform
st
chronic
phase
acceler
phase
hr
ci
nd
chronic
phase
hr
ci
blast
crisi
hr
ci
p
associ
better
os
patient
transplant
wors
os
hr
ci
p
df
hr
ci
trend
wors
glf
observ
univari
analysi
hr
ci
first
period
observ
conclus
singl
center
experi
confirm
higher
os
df
glf
observ
cml
patient
allograft
recent
year
improv
condit
regimen
use
tbifre
condit
regimen
support
therapi
presum
contribut
result
togeth
recent
strategi
close
monitor
minim
residu
diseas
prompt
use
tki
donor
lymphocyt
infus
case
relaps
hsct
nowaday
safer
therapeut
procedur
cml
patient
consid
time
tkiresist
patient
avoid
progress
advanc
diseas
phase
disclosur
author
declar
conflict
interest
reducedintens
transplant
rit
patient
highrisk
advanc
chronic
lymphocyt
leukemia
last
year
improv
transplant
outcomessingl
centr
experi
hctci
pt
sourc
stem
cell
peripher
blood
bone
marrow
pt
median
infus
cd
cell
kg
condit
regimen
consist
fludarabin
melphalan
atg
unrel
donor
gvhd
prophylaxi
cyclosporin
methotrex
result
pt
engraft
none
pt
cr
rit
progress
day
rit
among
pt
beyond
cr
rit
achiev
least
pr
day
rit
pt
develop
acut
gvhd
pt
grade
iiiiv
among
evalu
pt
develop
chronic
gvhd
mild
moder
sever
median
followup
month
rang
month
pt
aliv
cr
pt
relaps
progress
month
rit
die
last
relaps
patient
achiev
next
cr
ibrutinib
pt
die
due
nrm
nrm
till
day
rit
estim
probabl
cgrf
pf
os
conclus
spite
rel
small
number
evalu
pt
retrospect
type
analysi
data
show
rit
pt
highrisk
advanc
cll
achiev
promis
result
pf
os
resp
recent
year
result
better
outcom
histor
patient
cohort
period
pf
resp
os
ebmt
publish
data
pt
transplant
cll
period
pf
resp
os
current
result
transplant
taken
account
futur
decisionmak
process
indic
transplant
pt
highrisk
cll
cours
also
context
new
updat
result
target
cll
treatment
complic
disclosur
method
retrospect
data
treatment
outcom
collect
singapor
childhood
cancer
registri
sccr
children
cancer
singapor
receiv
therapi
one
two
public
paediatr
cancer
center
kkh
nuh
total
thirti
two
case
diagnos
cml
receiv
treatment
either
center
twenti
year
period
result
age
diagnosi
thirti
two
children
rang
year
median
six
patient
pretki
era
treat
upfront
hsct
remaind
twenti
six
patient
initi
start
tki
hsct
median
period
month
diagnosi
rang
month
reason
hsct
ten
twelv
children
due
high
risk
featur
ie
acceleratedblast
phase
ccrno
cmr
remain
two
patient
hsct
due
parent
patient
prefer
attempt
upfront
cure
rather
use
lifelong
expens
tki
therapi
noncompli
tki
therapi
major
find
teenag
cohort
eleven
eighteen
transplant
use
match
sibl
donor
three
patient
cord
blood
stem
cell
sourc
one
patient
singl
antigen
mismatch
relat
donor
three
patient
mismatch
unrel
donor
hsct
patient
except
one
myeloabl
condit
busulfan
cyclophosphamid
atg
ad
accord
physician
prefer
one
patient
cytbi
condit
pretranspl
lymphoid
blast
crisi
anti
gvhd
medic
includ
cyclosporin
methotrex
tacrolimu
methylprednisolon
cord
transplant
patient
six
eighteen
patient
hsct
die
four
die
due
treatment
relat
mortal
infect
acut
gvhd
pulmonari
fibrosi
one
patient
die
due
earli
relaps
one
late
relaps
relat
mortal
pretki
era
hsct
relat
year
os
respect
posttki
era
year
os
entir
cohort
year
os
conclus
posttki
era
transplant
outcom
two
center
compar
lead
center
world
outcom
patient
mismatch
unrel
donor
poor
cohort
recommend
haploident
relat
donor
transplant
unrel
cord
blood
stem
cell
sourc
patient
match
sibl
unrel
donor
avail
clinic
trial
registri
na
disclosur
noth
disclos
fludarabin
busulfan
thiotepa
may
promis
condit
regimen
myelofibrosi
patient
undergo
allogen
stem
cell
transplant
background
allogen
stemcel
transplant
sct
cur
therapi
patient
myelofibrosi
howev
recurr
diseas
nonrelaps
mortal
nrm
frequent
caus
treatment
failur
optim
condit
regimen
sct
diseas
defin
method
retrospect
analyz
transplant
outcom
adult
patient
given
sct
myelofibrosi
singl
larg
academ
medic
center
patient
treat
sever
condit
regimen
group
accord
condit
intens
myeloabl
condit
mac
includ
busulfan
mgkg
cyclophosphamid
mgkg
buci
fludarabin
busulfan
mgkg
flu
fludarabin
treosulfan
gm
flu
treo
reducedintens
condit
includ
fludarabin
busulfan
mgkg
recent
adopt
tbf
regimen
includ
fludarabin
busulfan
mgkg
thiotepa
mg
patient
also
given
antithymocyt
globulin
condit
irrespect
donor
sourc
result
median
age
year
interquartil
rang
iqr
major
patient
document
splenomegali
previous
expos
ruxolitinib
donor
type
hlamatch
sibl
match
unrel
donor
dipp
score
distribut
high
median
followup
year
sinc
success
tyrosin
kinas
inhibitor
tki
transplantrel
mortal
consid
high
justifi
allogen
hematopoiet
stem
cell
transplant
allohsct
firstlin
treatment
chronic
myeloid
leukemia
cml
patient
chronic
phase
cp
allohsct
current
consid
patient
fail
least
tki
diseas
advanc
phase
nevertheless
optim
time
transplant
referr
still
well
defin
method
perform
retrospect
analysi
consecut
patient
cml
cp
receiv
first
transplant
hlaident
sibl
donor
partial
tcell
deplet
graft
center
partial
tcell
deplet
ptd
consist
vitro
alemtuzumab
incub
part
graft
infus
day
rest
contain
cellskg
given
tcell
addback
day
donor
lymphocyt
infus
dli
provid
absenc
gvhd
case
diseas
relaps
mix
chimer
molecular
monitor
perform
rtqpcr
test
peripher
blood
least
period
hsct
thereaft
test
schedul
maintain
possibl
follow
one
kaplanmei
method
employ
determin
probabl
overal
surviv
os
leukemia
free
surviv
lf
sinc
allohsct
result
median
age
hsct
year
rang
patient
first
cp
one
second
cp
twelv
patient
hsct
hsct
patient
present
suboptim
respons
intoler
imatinib
period
last
seven
patient
present
suboptim
respons
intoler
imatinib
dasatinib
nilotinib
period
time
interv
diagnosi
transplant
month
patient
patient
ebmt
risk
score
patient
condit
regimen
myeloabl
one
patient
stem
cell
sourc
pbsc
patient
bone
marrow
one
patient
engraft
patient
present
molecular
relaps
one
patient
hematolog
relaps
median
interv
transplant
relaps
month
rang
patient
receiv
dli
relaps
mix
chimer
patient
relaps
also
receiv
tki
without
prior
administr
dli
patient
present
grade
ii
agvhd
patient
moder
cgvhd
dli
agvhd
occur
cgvhd
patient
one
patient
die
diseas
progress
year
hsct
one
myocardi
infarct
year
hsct
median
followup
year
rang
os
lf
time
analysi
patient
aliv
major
molecular
respons
conclus
result
excel
longterm
surviv
transplantrel
mortal
suggest
ptcd
improv
outcom
cpcml
patient
transplant
ident
sibl
donor
use
decid
riskadapt
strategi
believ
ptcd
could
allow
earlier
transplant
referr
patient
fail
tki
ident
sibl
donor
disclosur
noth
declar
singl
tertiari
centr
experi
allogen
haematopoiet
stem
cell
transplant
allohsct
primari
secondari
myelofibrosi
mf
cur
option
fit
patient
allohsct
novel
therapi
emerg
current
recommend
elig
patient
life
expect
less
year
consid
allograft
method
retrospect
look
clinic
featur
outcom
allohsct
mf
perform
centr
sinc
result
patient
male
femal
age
year
old
median
age
highrisk
mf
per
intern
prognost
score
system
ipss
dynam
ipp
dipp
transplant
centr
sinc
diagnos
pmf
remain
secondari
mf
postet
postpv
mf
patient
group
receiv
sibl
allograft
match
unrel
donor
allograft
receiv
human
leukocyt
antigen
hla
match
transplant
hlamatch
hlamatch
graft
patient
receiv
reduc
intens
condit
ric
patient
fludarabin
melphalan
campath
fmc
fludarabin
busulphan
atg
fbatg
fludarabin
arac
campath
flag
campath
receiv
peripher
blood
sourc
hsc
engraft
occur
day
median
one
late
graft
reject
occur
patient
aliv
patient
current
aliv
overal
surviv
os
transplant
relat
mortal
trm
year
year
patient
die
graft
versu
host
diseas
gvhd
patient
septicaemia
lead
multiorgan
failur
acut
gvhd
grade
ii
skin
occur
patient
grade
iii
patient
patient
limit
chronic
gvhd
patient
receiv
donor
lymphocyt
infus
dli
mix
chimer
one
graft
failur
patient
develop
acut
grade
gvhd
die
respons
rate
aliv
patient
ie
exhibit
fibrosi
trephin
biopsi
aliv
patient
residu
fibrosi
donor
chimer
aliv
patient
residu
fibrosi
mix
donor
chimer
patient
nonassess
conclus
allohsct
remain
potenti
curabl
option
myelofibrosi
centr
serv
million
popul
new
case
per
year
patient
transplant
sinc
data
suggest
close
collabor
mpntreat
haematologist
transplant
physician
requir
suitabl
patient
transplant
assess
earli
diseas
cours
novel
molecular
prognost
system
like
identifi
best
place
benefit
futur
seri
current
support
allohsct
surviv
cure
rang
dynam
intern
prognost
score
system
dipss
score
time
hct
high
risk
patient
patient
molecular
evalu
avail
mutat
detect
patient
patient
carl
patient
patient
tripl
neg
driver
mutat
cytogenet
inform
avail
among
patient
complex
karyotyp
trisomi
trisomi
patient
underw
splenectomi
hct
ruxolitinib
administ
patient
hct
patient
receiv
stem
cell
hla
ident
sibl
match
unrel
donor
haploident
sibl
graft
sourc
bone
marrow
patient
peripher
blood
condit
myeloabl
patient
reduc
intens
patient
engraft
acut
graft
versu
host
diseas
absent
patient
grade
iii
grade
iiiiv
evalu
patient
chronic
graft
versu
host
diseas
limit
extens
absent
transplantrel
mortal
day
main
caus
death
acut
gvhd
patient
chronic
gvhd
pancreat
pulmonari
aspergillosi
relaps
occur
patient
main
caus
death
notabl
patient
experienc
late
relaps
year
hct
live
receiv
ruxolitinib
therapi
median
follow
day
rang
patient
aliv
diseasefre
live
kaplanmey
overal
surviv
diseasefre
surviv
year
respect
conclus
experi
confirm
hct
valid
option
achiev
cure
one
third
mf
patient
two
patient
experienc
late
year
recurr
mf
rariti
condit
limit
amount
data
case
avail
evalu
studi
lifelong
followup
mf
transplant
patient
warrant
better
understand
rare
event
disclosur
noth
declar
method
old
femal
diagnos
pmf
ipss
low
risk
dipssplu
intermedi
risk
subacut
buddchiari
syndrom
portal
vein
thrombosi
four
year
allohsct
reduc
splenomegali
constitut
symptom
perform
pretranspl
ruxolitinib
therapi
mg
daili
three
month
therapi
patient
achiev
clinic
improv
eln
criteria
contrastenhanc
comput
tomographi
magnet
reson
imag
show
enlarg
intrahepat
collater
vessel
sign
portal
vein
thrombosi
cavern
transform
multipl
dilat
collater
vein
gastroscopi
document
enlarg
esophag
vein
allogen
stem
cell
transplant
perform
hla
match
unrel
donor
peripher
stem
cell
x
cellskg
condit
regimen
consist
fludarabin
mg
busulfan
mgkg
po
posttranspl
cyclophosphamid
administ
mgkg
day
ruxolitinib
mg
use
till
graft
versu
host
diseas
prophylaxi
result
start
patient
experienc
eight
episod
ebv
sever
blood
loss
treat
bleed
episod
blackmor
tube
place
six
time
temporari
effect
place
blackmor
tube
patient
two
time
intub
requir
mechan
ventil
leukocyt
neutrophil
engraft
full
donor
chimer
molecular
remiss
achiev
platelet
engraft
document
poor
graft
function
present
due
cytomegaloviru
reactiv
parvoviru
reactiv
evb
stop
two
esophag
vein
ligat
two
procedur
gastric
vein
sclerotherapi
soon
patient
achiev
complet
platelet
recoveri
l
becam
red
blood
cell
transfus
independ
day
complet
remiss
confirm
splenomegali
resolut
regress
bone
marrow
fibrosi
full
donor
chimer
molecular
statu
cbc
show
hb
gl
platelet
l
leucocyt
l
ultrasound
examin
transplant
document
portal
vein
thrombosi
recan
day
develop
mild
nih
chronic
graft
versu
host
diseas
eye
mouth
involv
manag
topic
steroid
transplant
patient
aliv
complet
remiss
recurr
bleed
conclus
splanchnic
vein
thrombosi
significantli
complic
cours
allohsct
pmf
easi
access
surgic
intens
care
unit
endoscop
team
requir
make
allohsct
feasibl
group
patient
disclosur
patient
receiv
treosulfanbas
mac
regimen
treosulfan
total
dose
given
combin
differ
condit
drug
commonli
use
regimen
treosulfan
fludarabin
thiotepa
refer
ftt
use
serotherapi
given
patient
either
alemtuzumab
antithymocyt
globulin
respect
posttranspl
graftversushost
diseas
gvhd
prophylaxi
given
patient
base
mostli
ciclosporin
patient
receiv
transplant
identicalrel
donor
patient
receiv
transplant
matchedunrel
donor
two
patient
haploident
transplant
patient
fulli
hlamatch
stem
cell
sourc
use
bone
marrow
peripher
blood
stem
cell
umbil
cord
blood
treosulfanbas
condit
given
st
transplant
nd
transplant
failur
first
procedur
two
patient
receiv
treosulfanbas
condit
transplant
twice
result
neutrophil
engraft
platelet
engraft
occur
median
day
day
respect
chimer
full
donor
high
donor
mix
donor
gvhd
develop
patient
acut
gvhd
grade
iii
grade
iiiiv
develop
respect
chronic
gvhd
grade
iii
grade
iiiiv
develop
respect
chronic
gvhd
mild
limit
nonextens
resolv
complet
none
patient
persist
gvhd
necessit
longterm
system
immunosuppress
mild
vod
occur
sever
vod
occur
one
die
believ
relat
underli
diseas
wolman
syndrom
viral
reactiv
occur
patient
cmv
ebv
adenoviru
reactiv
found
respect
five
patient
invas
adenoviraemia
contribut
death
two
primari
graft
failur
happen
two
patient
due
adenoviraemia
seven
patient
secondari
graft
failur
autolog
reconstitut
graft
failur
significantli
lower
ftt
group
condit
group
median
followup
month
rang
month
eleven
patient
die
overal
surviv
eventfre
surviv
five
patient
die
due
complic
relat
origin
diseas
six
patient
die
due
transplantrel
caus
transplantrel
mortal
immun
reconstitut
aliv
patient
achiev
median
eight
month
time
significantli
longer
ftt
group
conclus
studi
demonstr
treosulfan
safe
effect
condit
drug
achiev
engraft
low
rate
graft
failur
transplantrel
mortal
morbid
even
use
twice
patient
disclosur
noth
declar
background
highdos
chemotherapi
hdc
follow
autolog
stem
cell
transplant
asct
treatment
choic
patient
relaps
high
risk
nhl
although
highdos
condit
regimen
commonli
use
patient
nonhodgkin
lymphoma
nhl
beam
bcnu
etoposid
cytarabin
melphalan
beac
bcnu
etoposid
cytarabin
cyclophosphamid
surviv
patient
nhl
receiv
highdos
chemotherapi
follow
asct
still
unsatisfactori
method
prospect
evalu
efficaci
toxic
busulfan
etoposid
cytarabin
melphalan
bueam
includ
iv
busulfan
instead
bcnu
standard
beam
condit
asct
patient
nhl
highdos
chemotherapi
consist
bu
mgkg
iv
qd
day
day
e
mgm
iv
bid
day
day
gm
iv
qd
day
day
mgm
iv
qd
day
center
korea
result
two
hundr
five
patient
enrol
onto
studi
main
subgroup
diffus
larg
b
cell
lymphoma
cell
lymphoma
nkt
cell
lymphoma
upfront
asct
perform
patient
salvag
asct
patient
diseas
statu
patient
hdtasct
consist
patient
complet
respons
patient
partial
respons
treatment
relat
toxic
includ
nausea
patient
diarrhea
patient
anorexia
patient
stomat
patient
grade
ii
major
case
common
grade
iii
toxic
stomat
diarrhea
anorexia
vod
transplantrel
mortal
occur
patient
due
infect
one
hundr
fifti
three
patient
achiev
complet
respons
patient
asct
patient
show
progress
diseas
median
followup
durat
month
estim
overal
surviv
progress
free
surviv
patient
respect
conclus
condit
regimen
bueam
asct
well
toler
seem
effect
patient
relaps
high
risk
nhl
disclosur
none
declar
background
allogen
hematopoiet
cell
transplant
hct
potenti
cur
high
risk
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
howev
gvhd
diseas
relaps
remain
major
challeng
recent
introduc
combin
posttranspl
cyclophosphamid
ptci
atg
mgkg
graftversushost
diseas
gvhd
prophylaxi
purpos
studi
compar
outcom
ptci
atg
gvhd
prophylaxi
regimen
high
risk
aml
md
method
retrospect
investig
outcom
patient
underw
allogen
hct
januari
juli
high
risk
aml
md
gvhd
prophylaxi
regimen
compar
overal
surviv
os
cumul
incid
relaps
cir
nonrelaps
mortal
nrm
univari
multivari
analysi
high
risk
aml
defin
secondari
aml
therapi
relat
aml
high
risk
cytogenet
eln
criteria
good
intermedi
cytogenet
risk
aml
primari
induct
failur
high
risk
md
defin
highveri
high
risk
wpss
score
result
median
age
patient
year
rang
year
donor
match
relat
patient
match
unrel
patient
haploident
patient
graft
sourc
peripher
blood
stem
cell
patient
myeloabl
condit
use
patient
reduc
intens
regimen
patient
ptci
combin
atg
use
patient
gvhd
prophylaxi
regimen
use
patient
donor
recipi
cmv
neg
patient
median
followup
survivor
month
rang
month
univari
analysi
demonstr
os
entir
cohort
year
ci
cir
year
ci
nrm
year
ci
concern
gvhd
prophylaxi
regimen
os
ptcyatg
versu
other
ci
versu
ci
figur
cir
ptcyatg
versu
ci
versu
ci
nrm
ptci
versu
ci
versu
ci
grade
iiiv
acut
gvhd
seen
ptcyatg
patient
versu
use
regimen
p
chronic
gvhd
observ
ptcyatg
patient
versu
use
regimen
multivari
analysi
os
confirm
gvhd
prophylaxi
regimen
influenc
predomin
predictor
surviv
age
hct
hr
ci
cir
ptcyatg
combin
influenc
compar
gvhd
prophylaxi
regimen
ric
condit
predomin
predictor
relaps
hr
ric
nrm
atg
ptci
combin
demonstr
signific
differ
age
hct
predomin
predictor
ci
conclus
ptcyatg
combin
gvhd
prophylaxi
demonstr
multivari
analysi
similar
os
cir
nrm
previous
use
regimen
center
decreas
atg
dose
may
potenti
decreas
relaps
rate
retain
advantag
decreas
gvhd
background
combin
fludarabin
myeloabl
dose
busulfan
repres
standard
care
condit
regimen
allogen
transplant
patient
myeloid
malign
giralt
lancet
oncolog
potent
antileukem
activ
associ
low
transplantrel
mortal
acut
gvhd
howev
earli
transplant
day
proport
patient
may
convert
full
donor
haemopoiet
chimer
particularli
antit
lymphocyt
globulin
atg
use
gvhd
prophylaxi
rambaldi
et
al
lancet
oncolog
method
retrospect
analyz
patient
underw
allogen
stem
cell
transplant
condit
regimen
hospit
novemb
august
median
age
year
rang
diagnos
aml
md
cml
mfi
diseas
statu
transplant
activ
diseas
patient
stem
cell
sourc
repres
pbsc
case
antit
lymphocyt
globulin
atg
part
condit
regimen
case
dose
mgkg
donor
hla
ident
sibl
match
unrel
mismatch
one
allel
one
antigen
mismatch
unrel
hematopoiet
chimer
molecularli
evalu
variabl
number
tandem
repeat
vntr
bone
marrow
bm
mononuclear
cell
peripher
blood
pb
lymphocyt
purifi
immunomagnet
posit
select
miltenyi
biotec
analysi
perform
day
transplant
result
day
transplant
proport
patient
full
bm
chimer
respect
time
point
pb
cell
chimer
day
patient
requir
infus
dli
treat
pend
overt
hematolog
relaps
patient
convert
lymphoid
chimer
mix
median
rang
complet
success
case
day
addit
patient
requir
dli
treat
diseas
relaps
progress
patient
improv
chimer
statu
immun
reconstitut
year
overal
surviv
relaps
nonrelaps
mortal
respect
figur
uni
multivari
analysi
aml
diagnosi
mix
bm
chimer
day
associ
relaps
overal
surviv
age
factor
significantli
associ
nrm
mix
pb
tlymphoid
chimer
day
advers
impact
nonrelaps
mortal
cumul
incid
relaps
leukemiafre
overal
surviv
conclus
atg
progress
increas
pb
lymphoid
donor
chimer
develop
gradual
transplant
case
without
need
dli
earli
mix
lymphoid
chimer
compromis
main
longterm
clinic
outcom
may
least
partial
explain
low
nonrelaps
mortal
incomplet
bm
chimer
within
first
month
strongli
correl
earli
diseas
progress
relaps
background
busulfan
bu
wide
use
compon
myeloabl
condit
regimen
hematopoiet
stem
cell
transplant
hsct
children
bu
narrow
cumul
exposur
window
relat
bu
exposur
toxic
well
establish
link
exposur
ef
clear
due
conflict
report
especi
pediatr
patient
obtain
ratio
bu
metabolit
ie
metabol
ratio
mr
may
serv
indic
bu
gsh
conjug
capac
individu
thu
cumul
exposur
bu
particular
day
could
use
along
auc
marker
predict
ef
present
investig
aim
evalu
util
bu
mr
predict
ef
children
undergo
allogen
hsct
method
two
differ
cohort
children
receiv
bu
four
time
daili
qid
daili
dose
qd
st
justin
hospit
montreal
studi
bu
su
level
measur
day
condit
regimen
end
infus
dose
qid
dose
qd
dose
ef
defin
time
transplant
death
relaps
reject
whichev
occur
first
receiveroper
characterist
curv
roc
bu
mr
measur
plot
show
tradeoff
sensit
vs
rate
ef
cutoff
test
shift
low
high
cutoff
valu
defin
base
j
statist
ie
result
twentytwo
male
femal
age
year
bu
qid
cohort
mean
mr
sd
cut
valu
mr
chosen
roc
analysi
cohort
better
sensit
specif
ef
predict
auc
ci
qd
cohort
nine
femal
four
male
age
year
mean
mr
sd
roc
analysi
cut
valu
chosen
better
sensit
specif
ef
predict
conclus
background
treosulfan
alkyl
agent
increasingli
use
prior
hematopoiet
stem
cell
transplant
hsct
main
object
studi
develop
popul
pharmacokinet
model
treosulfan
pediatr
hsct
recipi
explor
effect
differ
covari
treosulfan
pharmacokinet
pk
also
limit
sampl
model
lsm
develop
method
multicentr
studi
patient
receiv
dose
gm
treosulfan
day
administ
consecut
day
enrol
popul
pharmacokinet
model
develop
use
nonlinear
mix
effect
model
nonmem
version
use
psn
toolkit
version
model
environ
demograph
factor
well
laboratori
paramet
includ
covari
result
treosulfan
pk
best
describ
twocompart
model
bodyweightbas
allometr
model
improv
model
model
incorpor
bodi
surfac
area
bsa
clearanc
cl
intercompartment
clearanc
paramet
ci
lh
ci
typic
volum
distribut
central
peripher
compart
ci
l
ci
modelbas
dose
tabl
base
bodyweight
creat
achiev
target
exposur
mg
hrl
tabl
median
exposur
popul
estim
glomerular
filtrat
rate
egfr
shown
paramet
significantli
reduc
interpati
variabl
cl
limit
sampl
model
sampl
taken
hour
start
infus
accur
estim
pharmacokinet
paramet
treosulfan
conclus
best
knowledg
largest
cohort
pediatr
patient
treat
treosulfan
use
popul
pharmacokinet
studi
develop
twocompart
model
weight
egfr
covari
influenc
treosulfan
pk
recent
show
relationship
treosulfan
exposur
earli
toxic
patient
exposur
mg
hrl
increas
risk
develop
grade
higher
mucos
skin
toxic
anoth
studi
pediatr
patient
thalassemia
major
report
associ
treosulfan
clearanc
lhm
poor
overal
surviv
model
togeth
limit
sampl
strategi
use
adjust
dose
prior
treosulfan
administr
ongo
studi
conduct
differ
diseas
set
determin
treosulfan
exposur
influenc
patient
outcom
subsequ
optim
target
exposur
establish
background
autolog
stem
cell
transplant
asct
effect
treatment
method
nonhodgkin
lymphoma
nhl
recent
carmustin
etoposid
cytarabin
melphalan
beam
commonli
use
condit
regimen
despit
accept
efficaci
beam
carmustin
associ
major
pulmonari
toxic
reason
aim
studi
investig
safeti
efficaci
beb
condit
regimen
asct
nhl
method
conduct
prospect
multicent
phase
ii
studi
beb
condit
regimen
asct
nhl
patient
total
patient
enrol
center
underw
asct
beb
condit
regimen
busulfan
etoposid
bendamustin
imag
two
year
progressionfre
surviv
overal
surviv
result
median
age
year
rang
patient
men
common
type
diffus
larg
b
cell
lymphoma
half
patient
classifi
ipi
score
eight
patient
histori
relaps
patient
receiv
line
chemotherapi
asct
patient
complet
remiss
cr
state
asct
median
number
kg
cell
infus
rang
patient
engraft
median
time
day
rang
twelv
patient
experienc
neutropen
fever
patient
grade
toxic
asct
howev
one
document
infect
venoocclus
diseas
treatmentrel
death
three
month
cr
rate
median
followup
period
month
patient
exhibit
relaps
progress
patient
die
diseas
estim
pf
os
rate
respect
figur
conclus
beb
condit
regimen
asct
feasibl
toler
toxic
patient
nhl
disclosur
noth
declar
longterm
report
total
marrow
total
lymphoid
imrt
advanc
leukemia
myeloma
lymphoma
background
last
three
decad
total
bodi
irradi
tbi
continu
play
import
role
condit
regimen
patient
undergo
stemcel
transplant
sct
wide
varieti
advanc
hematolog
malign
howev
tbi
show
boundari
dose
limit
toxic
allogen
moreov
autolog
stem
cell
transplant
current
choic
condit
regimen
base
use
leasttox
regimen
achiev
optim
therapeut
result
report
aim
assess
feasibl
condit
strategi
base
high
dose
chemotherapi
wholebodi
radiotherapi
focus
select
extens
tumor
burden
irradi
allogen
autolog
stem
cell
transplant
method
sinc
decemb
sixtytwo
patient
pt
irradi
helic
tomotherapi
ht
extens
target
allogen
autolog
transplant
select
total
marrow
irradi
tmi
schedul
plan
treat
patient
high
risk
acut
leukemia
aml
multipl
myeloma
mm
part
condit
regimen
total
lymphoid
irradi
tli
plan
patient
refractori
relaps
rr
hodgkin
hd
nonhodgkin
lymphoma
nhl
result
tmi
tli
allow
deliv
therapeut
dose
extens
select
target
wide
reduct
toxic
organ
risk
oar
higher
radiat
dose
rate
oar
reduc
allogen
condit
regimen
tli
x
fludarabin
endoxan
patient
hd
pt
tmi
x
fludarabin
melphalan
patient
mm
pt
tmi
x
fx
thiotepa
fludarabin
busulfan
advanc
lam
patient
pt
tmi
boost
convent
tbi
gy
bifraction
dose
cyclophosphamid
pt
autolog
prepar
sct
consist
tli
follow
highdos
bendamustin
melphalan
patient
older
year
convent
feam
fotemustin
etoposid
cytarabin
melphalan
younger
patient
hd
e
nhl
pt
tmi
x
fx
plu
melphalan
deliv
autolog
sct
mm
lam
pt
unexpect
acut
toxic
found
allogen
set
patient
engraft
achiev
patient
acut
graft
versu
host
diseas
increas
detect
within
autolog
set
develop
grade
mucos
none
experienc
grade
extrahematolog
toxic
outcom
specif
diseas
report
conclus
current
report
describ
clinic
feasibl
use
ht
deliv
tmi
tli
set
autolog
transplant
allogen
stem
cell
condit
regimen
allow
patient
old
fragil
high
tumor
burden
achiev
abl
regimen
sct
knowledg
singl
institut
experi
describ
data
one
largest
cohort
patient
treat
europ
sinc
develop
irradi
techniqu
disclosur
induct
therapi
group
patient
base
polychemotherapi
without
use
new
drug
case
match
perform
accord
age
clinic
stage
diagnosi
respons
induct
therapi
condit
regimen
consist
iv
bu
dose
mg
kg
day
day
follow
mel
dose
mgm
day
bumel
group
versu
control
group
mainten
therapi
transplant
consist
interferon
steroid
major
patient
result
cutoff
date
updat
june
median
followup
month
bumel
group
respect
patient
relaps
bumel
group
patient
control
group
median
pf
ci
month
bumel
ci
month
group
p
figur
updat
patient
bumel
group
maintain
respons
continu
cr
two
neg
statu
minim
residu
diseas
year
transplant
tenyear
os
significantli
differ
group
ci
month
bumel
ci
month
control
grouptransplantrel
mortal
similar
group
patient
bumel
group
regard
toxic
bumel
associ
higher
incid
mucos
liver
toxic
melphalanonli
approach
patient
seri
develop
sinusoid
occlus
syndrom
hepat
toxic
observ
grade
iii
final
longterm
side
effect
report
among
bumel
recipi
conclus
longterm
followup
analysi
confirm
therapeut
strategi
includ
bumel
condit
regimen
beforeasct
patient
newli
diagnos
mm
highli
activ
safe
patient
imag
figur
progress
free
surviv
bumel
control
group
frequenc
acut
gvhd
grade
iiiiv
cc
ct
tt
transplantrel
mortal
higher
ttcarrier
cc
ct
vs
tt
tatma
cmv
infectionreactiv
cgvhd
also
differ
accord
donor
genotyp
fungal
infect
occur
frequent
caus
death
carrier
cc
vs
ct
vs
tt
conclus
result
suggest
donor
may
exert
advers
influenc
outcom
myeloabl
condit
find
might
explain
combin
therapi
calcineurin
mtor
inhibit
gvhd
prophylaxi
myeloabl
condit
disclosur
noth
declar
treosulfanbas
reduc
intens
condit
hlahaploident
transplant
use
ptci
gvhd
prophylaxi
highrisk
md
aml
elderli
background
standard
condit
regimen
prior
allogen
hematopoiet
stem
cell
transplant
allohsct
often
associ
consider
risk
sever
advers
event
especi
elderli
patient
suffer
highrisk
hr
mdsaml
previou
clinic
studi
demonstr
feasibl
treosulfanbas
reducedintens
condit
ric
stabl
engraft
low
nonrelaps
mortal
nrm
favor
surviv
elderli
patient
undergo
hlamatch
relat
unrel
allohsct
beelen
et
al
ash
howev
data
treosulfanbas
condit
tcellreplet
hlahaploident
haplohsct
set
highrisk
amlmd
patient
rare
report
outcom
eleven
patient
treat
treosulfanbas
condit
undergo
haplohsct
use
exclus
posttransplant
cyclophosphamid
ptci
gvhd
prophylaxi
method
eleven
patient
highrisk
hr
aml
md
underw
haplohsct
use
treosulfan
reduc
intens
condit
ric
ptci
gvhd
prophylaxi
retrospect
analyz
respect
outcom
toxic
patient
year
old
transplant
januari
februari
institut
major
patient
suffer
activ
diseas
time
treatment
initi
two
patient
present
cr
one
receiv
sequenti
condit
cytoreduct
chemotherapi
use
flamsa
appli
shortli
prior
treosulfanbas
ric
day
bone
marrow
graft
use
patient
postgraft
immunosuppress
consist
cyclophosphamid
tacrolimu
mmf
nation
cancer
institut
common
terminolog
criteria
advers
event
version
use
nonhematolog
toxic
assess
start
sequenti
therapi
initi
condit
day
result
median
age
entir
cohort
year
rang
hctci
eight
pt
median
rang
graft
reject
occur
neutrophil
platelet
engraft
achiev
patient
median
day
respect
acut
gvhd
grade
iiiv
occur
patient
exclus
involv
skin
one
develop
sever
acut
gvhd
patient
die
prior
haplohsct
sever
nonhematolog
regimenrel
toxic
occur
patient
predomin
affect
gastrointestin
tract
patient
suffer
patient
develop
fever
treatment
cours
four
posit
blood
cultur
cmv
reactiv
patient
risk
ebv
reactiv
ptld
occur
six
patient
clinic
radiolog
sign
pneumonia
probabl
invas
aspergillosi
without
detect
aspergillusantigen
bronchoalveolar
lavag
ci
nrm
day
four
patient
relaps
within
first
year
haplohsct
two
die
due
relaps
last
followup
dec
patient
aliv
median
followup
month
estim
os
df
respect
conclus
treosulfanbas
unmanipul
hlahaploident
allograft
use
ptci
gvhd
prophylaxi
hr
md
aml
patient
age
year
safe
well
toler
result
stabl
engraft
favor
toxic
profil
preliminari
data
show
promis
outcom
low
nrm
sever
acut
gvhd
favor
surviv
offer
attract
altern
ric
haplohsct
elderli
disclosur
noth
declar
comparison
outcom
total
bodi
irradi
tbi
vs
nontbi
condit
regimen
acut
lymphoblast
leukemia
allogen
transplant
background
adult
patient
diagnos
acut
lymphoblast
leukemia
longterm
result
poor
intens
chemotherapi
allogen
stem
stem
cell
transplant
potenti
treatment
provid
cure
patient
myeloabl
prepar
regimen
includ
total
bodi
irradi
cyclophosphamid
cy
busulfan
cyclophosphamidein
adult
patient
wbici
wide
use
toxic
rate
higher
aim
studi
compar
result
effect
tbici
busulf
regimen
allogen
bone
marrow
transplant
patient
method
patient
underw
transplant
use
myeloabl
prepar
regimen
without
addit
tbi
adult
bone
marrow
transplant
unit
medipol
medic
faculti
istanbul
univers
istanbul
medic
faculti
sisli
florenc
nightingal
hospit
atak
hospit
adult
bone
marrow
unit
analyz
overal
surviv
os
progress
free
surviv
pf
veno
occlus
diseas
acut
chronic
graft
versu
diseas
develop
rate
patient
result
demograph
characterist
patient
summar
tabl
signific
differ
group
donor
age
gender
stem
cell
sourc
observ
relaps
rate
statist
signific
groupther
statist
signific
differ
patient
underw
myeloabl
regimen
myeloabl
regimen
tbi
relap
death
os
pf
imag
figur
term
transplant
complic
also
respect
differ
develop
vod
acut
chronic
graft
versu
diseas
vod
common
group
use
tbi
p
conclus
although
contradictori
data
literatur
multicentr
studi
reveal
addit
tbi
myeloabl
prepar
regimen
compar
myeloabl
prepar
regimen
alon
posit
neg
effect
overal
survivalw
think
prepar
good
vod
prophylaxi
approch
give
tbi
futur
disclosur
gvhd
prophylaxi
cyclosporin
given
either
alon
mmf
methotrex
graft
sourc
bone
marrow
bm
case
pbsc
seven
case
match
sibl
cord
bm
two
case
one
match
relat
cord
twentyf
donor
famili
donor
ten
unrel
twentynin
donor
hla
match
six
mismatch
one
haploident
four
patient
engraft
failur
requir
second
transplant
two
retranspl
cyclophosphamid
tbi
one
fludarabin
busulfan
campath
one
condit
thirti
patient
aliv
four
patient
die
transplant
complic
one
die
metastat
squamou
cell
carcinoma
eight
survivor
mix
chimera
donor
well
none
develop
gvhd
nine
patient
develop
acut
gvhd
four
grade
seven
patient
later
develop
chronic
gvhd
two
extens
diseas
conclus
result
show
high
surviv
rate
low
rate
engraft
failur
reason
rate
gvhd
one
patient
die
late
effect
hsct
fa
mix
chimer
seem
present
problem
conclud
reduc
intens
fludarabin
base
condit
regimen
good
treatment
option
patient
fanconi
anemia
undergo
hsct
disclosur
noth
declar
total
marrow
irradi
bendamustin
reducedtox
myeloabl
condit
prior
allohsct
younger
patient
multipl
myeloma
background
prognosi
patient
multipl
myeloma
mm
improv
markedli
last
two
decad
despit
allohsct
remain
treatment
option
cur
potenti
howev
use
limit
due
high
incid
nonrelaps
mortal
nrm
myeloabl
condit
insuffici
efficaci
reducedintens
regimen
develop
new
protocol
character
reduc
toxic
preserv
myeloabl
potenti
base
use
total
marrow
irradi
tmi
combin
bendamustin
aim
studi
evalu
safeti
efficaci
singlecent
experi
method
year
mm
patient
year
old
offer
tandem
autoallohsct
part
firstlin
therapi
decis
base
individu
patient
prefer
detail
descript
potenti
risk
autohsct
preced
melphalan
mgm
iv
condit
prior
allohsct
consist
tmi
perform
use
helic
tomotherapi
dose
gyd
day
total
gy
bendamustin
iv
day
total
immunosuppress
therapi
consist
cyclosporin
methotrex
atg
peripher
blood
use
sourc
stem
cell
result
analysi
includ
patient
women
men
median
followup
month
median
age
allohsct
year
diseas
stage
allohsct
follow
patient
treat
hsct
either
hlamatch
sibl
unrel
donor
interv
autohsct
allohsct
month
patient
engraft
allohsct
median
time
neutrophil
platelet
recoveri
day
respect
one
patient
experienc
grade
acut
gvhd
case
grade
acut
gvhd
incid
mild
moder
sever
chronic
gvhd
respect
rate
grade
nonhematolog
toxic
one
patient
die
late
bacteri
infect
incid
trm
grade
advers
event
report
diseas
statu
month
allohsct
probabl
os
pf
month
respect
incid
progress
trm
respect
conclus
allohsct
use
tmi
bendamustin
condit
protocol
character
good
toler
low
risk
gvhd
may
use
younger
patient
mm
part
tandem
autoallohsct
strategi
encourag
result
report
studi
confirm
prospect
clinic
trial
disclosur
noth
declar
comparison
two
reduc
intens
condit
regimen
patient
myeloid
malign
singl
center
experi
compar
flumel
background
hematopoiet
stem
cell
transplant
hsct
remain
cur
option
highrisk
myeloid
neoplasm
optim
reducedintens
condit
ric
still
debat
method
singlecent
retrospect
analysi
conduct
institut
compar
two
differ
ric
regimen
adult
patient
transplant
myeloid
malign
total
patient
analys
treat
busulfanbas
fludarabin
mgm
busulfan
mgkg
melphalanbas
condit
regimen
fludarabin
mgm
melphalan
mgm
flumel
antithymocyt
globulin
atg
administ
patient
one
receiv
tbi
partial
vitro
tcell
deplet
perform
use
alemtuzumab
low
risk
patient
result
two
group
well
balanc
median
age
year
flumel
group
respect
median
follow
month
frequent
indic
transplant
group
aml
group
flumel
group
respect
stem
cell
sourc
peripher
blood
patient
patient
first
group
near
signific
worst
karnosfki
statu
transplant
compar
second
vs
patient
receiv
tpartial
deplet
graft
vs
p
neutrophil
engraft
significantli
shorter
flumel
vs
day
p
overal
surviv
os
diseasefre
surviv
df
respect
flumel
respect
significantli
differ
os
df
karnofski
factor
significantli
associ
univari
analysi
better
os
df
cumul
incid
ci
grade
acut
graftversushost
diseas
agvhd
flumel
p
associ
multivari
analysi
deplet
ric
type
p
respect
ci
chronic
gvhd
year
flumel
group
ci
nonrelaps
mortal
year
flumel
ci
relaps
year
first
second
group
p
associ
condit
regimen
multivari
analysi
differ
gvhdfree
relapsefre
surviv
grf
observ
two
group
flumel
conclus
compar
two
ric
regimen
myeloid
neoplasm
observ
higher
incid
agvhd
flumel
wherea
statist
differ
note
cgvhd
occurr
toxic
appear
higher
flumel
result
counterbalanc
higher
proport
relaps
account
differ
os
df
grf
two
group
find
could
partial
explain
larger
proport
patient
receiv
partial
tdeplet
ric
larger
trial
need
clarifi
issu
disclosur
noth
declar
oncedaili
vs
daili
intraven
busilvex
condit
regimen
allogen
stem
cell
transplant
patient
myeloid
malign
safeti
efficaci
background
busilvex
bu
part
standard
condit
regimen
allogen
stem
cell
transplant
asct
patient
myeloid
malign
usual
administ
intraven
iv
infus
daili
studi
aim
compar
saftey
efficaci
schedul
oncedaili
iv
bu
conduct
retrospect
studi
adult
patient
year
myeloid
malign
receiv
asct
hlaident
sibl
donor
januari
june
follow
iv
bubas
prepar
regimen
graftversu
host
diseas
gvhd
prophylaxi
consit
cyclosporin
short
cours
methotrex
intraven
bu
administ
daili
mgkg
everi
hour
dose
oncedaili
infus
mgkg
x
day
sinc
june
result
nintynin
patient
enrol
men
women
median
age
year
rang
median
time
diagnosi
asct
month
rang
year
diagnosi
acut
myeloid
leukemia
chronic
myeloid
leukemia
myelodysplas
syndrom
primit
myelofibrosi
chronic
myelomonocyt
leukemia
thirtyseven
patient
ebmtscor
sixtyf
patient
transplant
beyond
activ
diseas
condit
regimen
consist
bucyclophosphamid
patient
bufludarabin
patient
fourtim
daili
bu
given
patient
oncedaili
bu
patient
group
stem
cell
sourc
bm
patient
pbsc
patient
global
patient
characterist
well
balanc
two
group
rate
sever
complic
similar
two
group
statist
signific
differ
except
oral
mucos
nonrelaps
mortal
nrm
compar
two
group
group
respect
relaps
rate
respect
median
followup
year
rang
os
significantli
differ
group
vs
howev
rf
significantli
better
group
vs
conclus
oncedaili
iv
bu
regimen
seem
effici
safe
altern
daili
protocol
howev
result
interpret
caution
histor
comparison
lack
bu
pharmacokinet
studi
disclosur
background
standard
therapi
patient
juvenil
myelomonocyt
leukemia
jmml
allogen
hematopoiet
stem
cell
transplant
ahsct
choic
optim
condit
regimen
patient
jmml
crucial
well
longterm
observ
aim
estim
longterm
followup
surviv
rate
patient
jmml
ahsct
help
busulfan
treosulfanbas
condit
regimen
method
thirti
eight
patient
jmml
underw
ahsct
compar
equal
group
patient
receiv
busulfan
treosulfanbas
condit
regimen
median
age
hsct
donor
type
hlarel
hlarel
hlaunrel
hlaunrel
haploident
stem
cell
sourc
bm
pbsc
ucb
ucbbm
diseas
statu
hsct
cr
refractori
result
median
followup
month
month
estim
overal
surviv
os
probabl
patient
receiv
busulfanbas
condit
comparison
patient
treosulfanbas
regimen
eventfre
surviv
ef
group
busulfanbas
regimen
patient
treosulfanbas
condit
background
posttranspl
relaps
remain
lead
caus
treatment
failur
high
risk
hr
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
myeloprolif
neoplasia
mpn
receiv
allogen
hematopoiet
cell
transplant
allohct
especi
patient
relaps
refractori
aml
recent
sequenti
transplant
approach
develop
munich
group
compris
intens
cytoreduct
chemotherapi
flamsa
fludarabineamsacrinecytarabin
decreas
leukemia
cell
burden
shortli
prior
condit
regimen
success
use
highrisk
hr
amlmd
promis
result
method
studi
patient
median
age
year
rang
hr
aml
defin
refractori
relaps
diseas
secondari
leukemia
high
risk
diseas
risk
index
risk
hr
md
accord
ipssr
undergo
allohct
use
sequenti
transplant
approach
institut
januari
octob
sequenti
transplant
approach
combin
cytoreduct
chemotherapi
consist
either
flamsa
flag
ida
fludarabinecytarabinegranulocyt
coloni
stimul
factor
idarubicin
cloarac
clofarabinecytarabin
follow
reduc
ric
myeloabl
mac
condit
regimen
patient
receiv
peripher
blood
stem
cell
match
relat
donor
match
unrel
donor
mismatch
unrel
donor
postgraft
immunosuppress
consist
calcineurin
inhibitor
mycophenol
mofetil
patient
thymoglobulin
ad
gvhd
prophylaxi
unrel
donor
transplant
result
median
time
neutrophil
day
rang
median
followup
month
rang
month
kaplanmei
estim
leukemiafre
lf
overal
surviv
os
year
ci
ci
respect
patient
receiv
flag
cloarac
base
sequenti
regimen
show
trend
toward
favour
overal
surviv
os
compar
patient
given
flamsa
year
os
vs
year
cumul
incid
relaps
nonrelaps
mortal
nrm
ci
ci
respect
multivari
analysi
type
sequenti
condit
regimen
show
signific
impact
lf
os
nrm
relaps
conclus
sequenti
transplant
condit
flamsa
flag
cloarac
follow
allohct
effect
strategi
overcom
dismal
prognosi
hr
aml
md
enabl
longterm
diseas
free
surviv
studi
effect
strategi
posttranspl
mainten
therapi
prophylact
donor
lymphocyt
infus
need
elimin
risk
relaps
without
increas
risk
treatment
relat
toxic
disclosur
noth
declar
optim
blood
sampl
procedur
busulfan
therapeut
drug
monitor
tdm
optim
sampl
scheme
minut
hour
end
infus
reduc
number
blood
sampl
collect
reduc
nurs
laboratori
staff
time
increas
patient
conveni
studi
aim
show
perform
simplifi
sampl
protocol
includ
first
sampl
origin
protocol
method
individu
pk
paramet
retrospect
estim
use
sampl
simplifi
protocol
compar
obtain
sampl
origin
protocol
individu
pk
paramet
valu
one
compart
model
estim
use
maximum
likelihood
estim
model
algorithm
adapt
statist
analysi
result
perform
statgraph
centurion
xv
result
base
approv
dosag
recommend
mean
sd
initi
dose
mg
tdm
mean
sd
calcul
dose
day
remain
day
achiev
defin
target
cumul
auc
mg
obtain
origin
protocol
accord
simplifi
protocol
result
would
mg
median
mean
variat
calcul
dose
protocol
strong
relationship
cl
day
obtain
origin
protocol
simplifi
protocol
observ
r
high
correl
also
observ
patient
busulfan
r
popul
reduct
sampl
could
problemat
anova
test
log
cl
factor
patient
day
busulfan
type
sampl
protocol
perform
sampl
protocol
determin
nonstatist
signific
p
conclus
result
suggest
protocol
equival
concern
busulfan
cl
estim
calcul
auc
variat
protocol
regard
calcul
dose
day
remain
day
achiev
defin
target
cumul
auc
consid
accept
verifi
strong
relationship
busulfan
cl
obtain
protocol
sampl
protocol
nt
influenc
cl
statist
reduc
sampl
collect
determin
h
end
infus
shown
suffici
tdm
busulfan
implement
centr
line
publish
data
disclosur
noth
declar
impact
antithymocyt
globulin
dose
unrel
hematopoiet
stem
cell
transplant
patient
myeloid
neoplasm
background
antithymocyt
globulin
atg
wide
use
prophylaxi
graftversushost
diseas
gvhd
hematopoiet
stem
cell
transplant
hsct
howev
still
controversi
regard
optim
dose
atg
therefor
analyz
impact
atg
dose
unrel
hsct
patient
myeloid
neoplasm
method
retrospect
multicent
studi
assess
impact
atg
dose
clinic
outcom
patient
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
undergo
unrel
hsct
patient
receiv
peripher
blood
stem
cell
pbsc
transplant
condit
regimen
contain
iv
busulfan
bu
fludarabin
rabbit
atg
includ
studi
result
total
patent
median
age
year
aml
md
includ
analys
patient
receiv
myeloabl
regimen
iv
bu
mgkg
highatg
atg
mgkg
intermediateatg
atg
mgkg
lowatg
atg
mgkg
given
patient
respect
median
followup
month
cumul
incid
extens
chronic
gvhd
highatg
group
intermediateatg
group
lowatg
group
conclus
studi
show
incid
extens
chronic
gvhd
similar
regardless
dose
atg
transplant
pbsc
unrel
donor
patient
aml
md
howev
rate
relapsefre
surviv
rate
composit
end
point
chronic
gvhdfree
relapsefre
surviv
significantli
higher
intermedi
dose
method
retrospect
retriev
data
electron
medic
record
consecut
patient
age
older
underw
asct
lymphoma
last
year
institut
result
forti
four
patient
year
old
underw
asct
aug
aug
twenti
eight
receiv
reduceddos
condit
median
rang
dose
reduct
dose
reduc
patient
year
old
patient
age
outcom
follow
three
group
patient
compar
age
without
dose
reduct
b
age
dose
reduct
c
age
dose
reduct
tabl
one
patient
age
receiv
fulldos
condit
signific
differ
group
number
previou
chemotherapi
cycl
median
rang
howev
significantli
patient
age
complet
remiss
cr
pretranspl
full
reduceddos
condit
group
b
signific
intergroup
differ
observ
occurr
complic
mucos
infect
day
transplantrel
mortal
trm
engraft
day
similarli
signific
differ
found
either
progressionfre
surviv
pf
nonrelaps
mortal
nrm
respect
group
b
c
overal
surviv
os
tend
higher
group
b
compar
group
c
conclus
beambeac
condit
dose
reduct
found
advers
affect
pf
os
rate
despit
fact
patient
age
group
underw
asct
partial
remiss
dose
reduct
theier
achiev
trm
pf
os
rate
similar
patient
age
beambeac
condit
dose
may
suitabl
option
patient
seventh
decad
requir
asct
strategi
evalu
prospect
clinic
trial
background
transplant
relat
mortal
autolog
transplant
lymphoma
multipl
myeloma
report
worldwid
rang
trm
center
two
diseas
approxim
introduc
chang
mobil
schedul
condit
regimen
drug
dosag
determin
whether
chang
affect
transplant
relat
mortal
overal
surviv
method
april
use
beam
bcnu
mgm
day
etoposid
mg
day
cytarabin
mgm
day
melphalan
day
condit
chemotherapi
patient
admit
transplant
unit
autolog
transplant
hodgkin
nonhodgkin
lymphoma
patient
multipl
myeloma
high
dose
melphalan
use
mobil
protocol
consist
cyclophosphamid
follow
gcsf
twice
daili
till
stem
cell
collect
complet
januari
chang
beam
protocol
bendaeam
dose
modif
includ
bendamustin
day
cytarabin
day
etoposid
day
melphalan
day
multipl
myeloma
melphalan
reduc
use
gcsf
mobil
stem
cell
continu
till
stem
cell
harvest
complet
respons
treatment
evalu
compar
trm
overal
surviv
two
time
period
till
date
result
april
till
decemb
autolog
transplant
perform
male
femal
ratio
fifti
seven
patient
underw
transplant
lymphoma
multipl
myeloma
diagnosi
median
age
year
mean
mnc
engraft
achiev
patient
transplant
relat
mortal
overal
surviv
follow
month
sinc
januari
till
march
perform
autolog
transplant
male
fifteen
transplant
perform
lymphoma
multipl
myeloma
median
age
year
mean
mononuclear
cell
count
x
kg
mean
count
x
kg
engraft
achiev
patient
transplant
relat
mortal
overal
surviv
follow
month
conclus
abl
reduc
autolog
transplant
relat
mortal
decreas
dosag
condit
chemotherapi
chang
mobil
protocol
long
followup
need
determin
late
mortal
late
relaps
comparison
standard
chemotherapi
dosag
disclosur
noth
declar
risk
benefit
thiotepa
base
condit
follow
autolog
stem
cell
transplant
high
risk
lymphoma
year
stage
annarbor
diagnosi
hddlbclpcnsl
stage
ie
stage
ii
stage
iii
stage
iv
median
time
diagnosi
asct
hddlbclpcnsl
month
induct
treatment
hd
patient
abvd
dlbcl
patient
rchop
pcnsl
patient
high
dose
methotrex
cytosin
arabinosid
tumor
statu
asct
hddlbclpcnsl
complet
metabol
remiss
cmr
pcnsl
patient
first
complet
remiss
type
stem
cell
graft
periferi
blood
stem
cell
case
condit
thiotepa
day
busulphan
day
cyclophosphamid
day
plu
rituximab
day
dlbcl
pcnsl
median
follow
asct
day
tumor
stage
asct
defin
comput
tomographi
positron
emiss
tomographi
petct
result
median
time
engraft
day
thiotepa
caus
toxicoderma
appear
patient
cytomegaloviru
cmv
reactiv
seen
case
low
dna
content
copiesml
respond
complet
oral
valgancyclovir
therapi
transplant
relat
mortal
hddlbclpcnsl
n
case
bacteri
sepsi
one
system
mycos
one
pulmonari
fibrosi
incid
longlast
grade
iiiiv
thrombocytopenia
anaemia
median
time
durat
transplant
day
day
background
studi
evalu
efficaci
toxic
intraven
busulfan
thiotepa
condit
regimen
autolog
stem
cell
transplant
asct
patient
multipl
myeloma
mm
method
retrospect
analyz
data
patient
mm
receiv
intraven
busulfan
thiotepa
condit
asct
novemb
april
korea
result
median
time
transplant
month
patient
underw
asct
within
month
diagnosi
overal
respons
rate
asct
includ
complet
respons
good
partial
respons
partial
respons
common
sever
nonhematolog
toxic
grade
infect
three
patient
develop
venousocclus
diseas
one
patient
die
due
sever
pneumonia
asct
median
followup
month
median
progressionfre
surviv
pf
overal
surviv
os
reach
conclus
conclus
condit
regimen
intraven
busulfan
thiotepa
effect
toler
clinic
trial
registri
applic
disclosur
author
declar
conflict
interest
myeloabl
haploident
bone
marrow
transplant
posttranspl
cyclophosphamid
paediatr
patient
haematolog
malign
santanu
sen
sameer
tulpul
background
haploident
transplant
shown
safe
effect
treat
haematolog
malign
paediatr
popul
previous
report
experi
use
reduc
intens
condit
post
transplant
cyclophosphamid
haploident
patient
herein
report
experi
use
tbi
base
myeloabl
condit
treat
first
patient
haematolog
malign
method
patient
enrol
studi
relaps
acut
lymphoblast
leukemia
relapsedresist
acut
myeloid
leukemia
aml
aml
patient
genet
marker
high
risk
diseas
patient
earli
relaps
either
therapi
within
month
stop
therapi
patient
condit
ident
protocol
use
tbibas
myeloabl
prepar
regimen
fludarabin
mgm
tbi
cgi
bid
total
dose
cgi
follow
infus
unmanipul
peripher
blood
stem
cell
haploident
famili
donor
postgraft
immunosuppress
consist
cyclophosphamid
mgkgday
day
mycophenol
mofetil
day
tacrolimu
day
result
median
time
neutrophil
platelet
engraft
day
respect
patient
achiev
sustain
complet
donor
chimer
day
acut
gvhd
grade
iiiv
iiiiv
seen
respect
diseas
progress
occur
patient
month
transplant
one
death
due
sever
fungal
infect
estim
twoyear
surviv
relaps
respect
patient
sever
bk
viremia
cmv
reactiv
occur
patient
patient
success
manag
appropri
support
antivir
therapi
conclus
report
good
outcom
myeloabl
condit
haploident
transplant
excel
engraft
hope
longer
life
expect
small
number
patient
difficult
state
whether
use
myeloabl
condit
would
lead
better
long
term
outcom
cohort
patient
haematolog
malign
certainli
show
possibl
achiev
excel
earli
result
disclosur
noth
declar
fludarabin
combin
melphalan
atg
best
condit
hematopoiet
stem
cell
transplant
children
hemophagocyt
lymphohistiocytosi
method
prospect
studi
analyz
outcom
two
pediatr
patient
hlh
receiv
hsct
use
reducedintens
condit
ric
regimen
receiv
ric
regimen
base
use
fludarabin
mgm
day
day
combin
melphalan
mgm
day
day
hors
antithymocyt
globulin
atg
mgkgd
day
cyclosporin
methotrex
use
graftvshost
diseas
gvhd
prophylaxi
result
month
boy
primari
hlh
transplant
mother
year
girl
secondari
hlh
transplant
brother
donor
hla
match
recipi
receiv
x
kg
x
kg
cell
harvest
peripher
blood
stem
cell
respect
achiev
full
neutrophil
platelet
recoveri
time
neutrophil
recoveri
day
respect
full
chimer
achiev
addit
develop
grade
acut
gvhd
respect
gvhd
complet
control
prednisolon
aliv
complet
remiss
without
signific
complic
month
respect
conclus
appear
fludarabin
combin
melphalan
atg
may
best
condit
regimen
hematopoiet
stem
cell
transplant
children
hlh
due
number
case
studi
studi
suffici
sampl
size
requir
disclosur
background
hematopoiet
cell
transplant
hct
recipi
often
report
depress
impair
qualiti
life
qol
transplant
mix
evid
suggest
depress
may
risk
factor
greater
mortal
wors
qol
inconsist
find
may
due
fact
previou
studi
evalu
antidepress
use
aim
studi
compar
pretranspl
patientreport
physic
function
posttranspl
overal
surviv
os
four
group
hct
recipi
nondepressedtak
antidepress
treat
depress
depressedtak
antidepress
undertr
depress
depressednot
take
antidepress
untreat
depress
depressednot
take
antidepress
control
hypothes
physic
function
os
would
wors
among
patient
untreat
undertr
depress
rel
treat
depress
control
method
retrospect
casecontrol
studi
includ
patient
complet
depress
qualiti
life
questionnair
pretranspl
analys
conduct
separ
allogen
autolog
recipi
result
particip
men
mean
age
year
allogen
recipi
regard
depress
antidepress
use
allogen
patient
character
treat
depress
untreat
depress
undertr
depress
control
hierarch
linear
regress
model
indic
adjust
signific
univari
factor
perform
statu
diseas
statu
regimen
intens
allogen
patient
treat
depress
report
better
physic
function
patient
undertr
depress
untreat
depress
wors
physic
function
control
p
valu
cox
regress
model
indic
depressionantidepress
usag
associ
os
among
allogen
patient
p
valu
among
autolog
patient
character
treat
depress
untreat
depress
undertr
depress
control
hierarch
linear
regress
model
indic
control
signific
univari
factor
gender
perform
statu
diagnosi
diseas
statu
autolog
patient
treat
depress
report
better
physic
function
patient
undertr
depress
untreat
depress
wors
physic
function
control
p
valu
cox
regress
model
show
depressionantidepress
usag
associ
os
p
valu
patient
treat
depress
demonstr
significantli
wors
os
group
associ
longer
signific
multivari
analys
control
diagnosi
diseas
statu
conclus
patient
untreat
undertr
depress
pretranspl
may
benefit
depress
screen
treatment
improv
physic
function
disclosur
hslj
consult
redhil
biopharma
janssen
scientif
affair
eltrombopag
epag
induc
high
percentag
respons
patient
post
allohsct
poor
graft
function
pgf
activ
gvhd
lourd
aguirr
aitzib
lizardi
pilar
bachil
brigida
esteban
carmen
nagor
argoitia
araiz
aranzazu
aguirr
carlo
vallejo
background
persist
cytopenia
lifethr
complic
hsct
sever
caus
lead
situat
virus
gvhd
drug
etc
specif
entiti
one
call
poor
graft
function
pgf
diagnos
pt
cytopenia
day
presenc
donor
chimer
absenc
gvhd
relaps
pgf
frequent
altern
allohsct
haploident
mismatch
ucb
sever
therapeut
approach
pgf
poor
result
test
recent
epag
shown
improv
platelet
count
postallohsct
set
studi
analys
efficaci
epag
pt
posttranspl
persist
cytopenia
method
popul
analyz
includ
pt
underw
allohsct
june
may
unit
median
age
year
male
femal
baselin
diseas
aml
lpd
md
mpd
mm
bmf
donor
unrel
famili
includ
haploident
condit
ric
intens
sc
sourc
pb
bm
median
followup
month
epag
initi
point
first
posthsct
period
pt
seri
due
thrombocytopenia
plu
least
one
cytopenia
patient
characterist
shown
tabl
epag
start
mgday
escal
week
mgday
platelet
count
global
respons
consid
epag
patient
need
transfus
reach
three
follow
platelet
hgb
gdl
anc
epag
taper
respond
discontinu
respons
reach
week
result
epag
initi
pt
thrombocytopenia
anemia
hgb
gdl
neutropenia
anc
count
pre
post
respons
epag
shown
tabl
among
respond
one
relaps
thrombocytopenia
die
bleed
aliv
analysi
close
among
nonrespond
three
pt
gvhdassoci
cytopenia
final
die
infecti
complic
patient
relaps
aml
reach
new
cr
treatment
aliv
well
month
afterward
epag
taper
discontinu
pt
respond
respond
still
epag
epag
discontinu
pt
respond
rest
treatment
detail
shown
tabl
conclus
epag
work
strike
well
subject
pgf
otherwis
lifethreaten
situat
patient
epag
induc
impress
respons
platelet
strong
bilinear
trilinear
respons
also
seen
epag
improv
gvhdassoci
cytopenia
confirm
innov
transcend
result
initi
multicent
prospect
studi
role
epag
treatment
posthsct
pgf
five
six
urdt
mismatch
donor
woman
six
case
three
sister
three
daughter
background
hepat
vodso
multiorgan
dysfunct
mod
typic
renal
pulmonari
may
associ
mortal
defibrotid
approv
treat
sever
hepat
vodso
posthsct
patient
age
month
eu
hepat
vodso
renal
pulmonari
dysfunct
posthsct
us
analysi
provid
overview
safeti
result
studi
patient
vodso
without
mod
receiv
defibrotid
mgkgday
method
safeti
data
pool
patient
vodso
posthsct
treat
defibrotid
phase
trial
phase
random
dosefind
trial
receiv
mgkgday
safeti
data
histor
control
hc
phase
studi
also
provid
report
separ
due
differ
patient
popul
data
monitor
protocol
ae
expandedaccess
program
tind
patient
vod
so
without
mod
posthsct
vod
so
diagnos
baltimor
criteriabiopsi
phase
studi
diagnosi
baltimor
modifi
seattl
criteria
permit
tind
result
median
patient
age
hsct
phase
studi
year
year
hc
year
tind
phase
studi
defibrotidetr
group
experienc
ae
common
hypotens
diarrhea
multiorgan
failur
treatmentrel
ae
least
possibl
relat
defibrotid
tabl
hemorrhag
ae
special
interest
occur
patient
commonli
epistaxi
gastrointestin
pulmonari
alveolar
hemorrhag
hematuria
conjunctiv
hemorrhag
hc
experienc
ae
common
hypotens
tachycardia
diarrhea
nausea
pyrexia
agit
petechia
hemorrhag
occur
patient
common
petechia
hematuria
epistaxi
pulmonari
alveolar
hemorrhag
lip
hemorrhag
tind
patient
mod
patient
without
mod
ae
vodso
mod
commonli
either
subgroup
hypotens
respect
trae
occur
patient
tabl
treatmentemerg
hemorrhag
occur
patient
mod
patient
without
mod
commonli
either
subgroup
pulmonari
hemorrhag
respect
gastrointestin
hemorrhag
respect
conclus
incid
type
ae
expect
critic
ill
patient
pool
patient
ae
hemorrhag
hc
ae
hemorrhag
tind
patient
mod
higher
rate
ae
support
jazz
pharmaceut
event
n
phase
studi
disclosur
paul
g
richardson
serv
advisori
committe
consult
receiv
research
fund
jazz
pharmaceut
angela
r
smith
lesli
lehmann
noth
disclos
nanci
kernan
receiv
grant
gentium
conduct
studi
research
support
nation
cancer
institut
nation
institut
health
award
number
content
sole
respons
author
necessarili
repres
offici
view
nation
institut
health
research
grant
jazz
pharmaceut
robert
ryan
william
tapp
employe
jazz
pharmaceut
hold
stock
andor
stock
option
jazz
pharmaceut
plc
stephan
grupp
serv
steer
committe
consult
jazz
pharmaceut
defibrotid
treatment
adult
hepat
vod
so
without
multiorgan
failur
hematopoiet
cell
transplant
result
systemat
reviewmetaanalysi
background
although
hematopoiet
cell
transplant
hct
autolog
allogen
potenti
curabl
variou
hematolog
malign
procedur
associ
seriou
potenti
lifethreaten
complic
among
venoocclus
diseasesinusoid
obstruct
syndrom
vodso
liver
sever
studi
prospect
retrospect
report
outcom
defibrotid
use
prophylaxi
treatment
mix
popul
adult
pediatr
patient
systemat
reviewmetaanalysi
analyz
outcom
defibrotid
specif
use
treatment
adult
patient
hepat
vodso
without
multiorgan
failur
method
comprehens
search
larg
databas
medlinepubm
cochran
embas
novemb
identifi
public
analysi
restrict
adult
patient
defin
median
age
older
year
receiv
defibrotid
treatment
vodso
report
prospect
retrospect
includ
patient
studi
publish
full
manuscript
form
limit
base
languag
data
extract
relat
benefit
complet
remiss
cr
rate
overal
surviv
os
harm
hemorrhag
site
organspecif
total
studi
patient
met
inclus
criteria
result
median
year
public
prospect
studi
retrospect
one
prescrib
start
dose
defibrotid
vari
among
studi
rang
mgkgday
mgkgday
mostli
cours
pool
cr
rate
prospect
retrospect
studi
pool
day
os
rate
prospect
retrospect
studi
respect
pool
rate
hemorrhag
site
prospect
retrospect
studi
analyz
organspecif
hemorrhag
prospect
studi
patient
report
pool
rate
pulmonari
alveolar
pa
hemorrhag
gastrointestin
gi
hemorrhag
one
retrospect
studi
patient
report
incid
pa
hemorrhag
differ
studi
patient
report
incid
gi
hemorrhag
none
studi
report
cerebr
hemorrhag
complic
defibrotid
therapi
conclus
systemat
reviewmetaanalysi
confirm
efficaci
defibrotid
treatment
vodso
without
multiorgan
failur
yield
cr
rate
day
os
rate
purportedli
higher
pool
cr
os
rate
observ
retrospect
vs
prospect
studi
like
due
assignmentbia
inher
observ
studi
moreov
although
pool
hemorrhag
site
rate
consid
proport
signific
pool
rate
pa
gi
hemorrhag
prospect
studi
clinic
trial
registri
applic
disclosur
makd
consult
pharmacycl
mm
receiv
lectur
honoraria
research
support
jazz
pharma
efficaci
safeti
defibrotid
treatment
hepat
venoocclus
diseasesinusoid
obstruct
syndrom
follow
hematopoiet
stem
cell
transplant
interim
result
defifr
studi
background
hepat
venoocclus
diseasesinusoid
obstruct
syndrom
vodso
potenti
lifethreaten
complic
condit
hematopoiet
stem
cell
transplant
hsct
may
occur
nontranspl
chemotherapi
alon
vodso
multiorgan
dysfunct
mod
may
associ
mortal
support
care
alon
diagnosi
vodso
tradit
base
baltimor
modifi
seattl
criteria
howev
ebmt
recent
publish
separ
diagnost
criteria
adult
children
defibrotid
approv
treat
sever
hepat
vodso
posthsct
patient
age
month
eu
hepat
vodso
renal
pulmonari
dysfunct
posthsct
usa
goal
defifr
studi
request
french
health
author
collect
realworld
data
safeti
efficaci
broader
patient
popul
franc
includ
indic
first
interim
analysi
largest
current
evalu
defibrotid
treatment
vodso
europ
method
defifr
observ
multicent
postmarket
studi
includ
patient
treat
defibrotid
hsct
center
franc
interim
analysi
base
patient
treat
defibrotid
includ
sever
sever
posthsct
vodso
vodso
diagnos
use
tradit
criteria
surviv
complet
remiss
cr
total
serum
bilirubin
mgdl
resolut
mod
safeti
profil
report
result
total
patient
treat
defibrotid
includ
retrospect
prospect
juli
octob
tabl
disclosur
mohamad
mohti
receiv
honoraria
research
fund
jazz
pharmaceut
delphin
lebon
noth
disclos
ann
berceanu
none
charlott
jubert
receiv
fund
jazz
pharmaceut
ibrahim
yakoubagha
receiv
honoraria
jazz
pharmaceut
girault
none
mari
detrait
receiv
research
fund
jazz
pharmaceut
pochon
none
fanni
rialland
none
virgini
gandem
none
jeanhugu
dall
receiv
honoraria
jazz
pharmaceut
peffault
de
latour
receiv
research
grant
honoraria
board
pfizer
novarti
alexion
research
grant
amgen
honoraria
jazz
pharmaceut
david
michonneau
receiv
honoraria
jazz
pharmaceut
myriam
labopin
receiv
honoraria
jazz
pharmaceut
florian
delav
employe
jazz
pharmaceut
hold
stock
andor
stock
option
jazz
pharmaceut
plc
gerard
michel
none
ann
sirvent
none
laurenc
clement
none
annelis
menard
none
ann
huynh
receiv
honoraria
jazz
pharmaceut
virgini
bouvati
employe
jazz
pharmaceut
hold
stock
andor
stock
option
jazz
pharmaceut
plc
raj
hanvesakul
employe
jazz
pharmaceut
hold
stock
stock
option
jazz
pharmaceut
plc
zakaria
medeghri
employe
jazz
pharmaceut
hold
stock
andor
stock
option
jazz
pharmaceut
plc
incid
predictor
sever
cardiotox
patient
sever
aplast
anemia
haploident
hematopoiet
stem
cell
transplant
zhengli
xu
lanp
xu
yuanyuan
zhang
yifei
cheng
xiaodong
mo
fengrong
wang
yuhong
chen
wei
han
chenhua
yan
yuqian
sun
tingt
han
yu
wang
xiaohui
zhang
xiaojun
huang
peke
univers
institut
hematolog
peke
univers
peopl
hospit
beij
china
background
sever
cardiotox
hematopoiet
stem
cell
transplant
hsct
rare
fatal
complic
aim
studi
evalu
frequenc
sever
cardiac
complic
assess
abil
variou
factor
predict
complic
patient
aplast
anemia
haploident
transplant
first
studi
evalu
valu
clinic
imag
factor
predict
sever
cardiotox
among
saa
patient
haploident
transplant
method
retrospect
studi
conduct
consecut
aplast
anemia
patient
receiv
haploident
transplant
patient
receiv
unifi
regimen
includ
busulfan
cyclophosphamid
ctx
antithymocyt
globulin
singl
center
result
total
patient
develop
grade
iii
iv
cardiac
toxic
patient
cardiotox
significantli
poorer
overal
surviv
os
without
cardiotox
vs
p
multivari
model
identifi
four
independ
advers
predictor
sever
cardiotox
includ
pretranspl
ecog
score
abnorm
stt
wave
electrocardiogram
ecg
hyperlipemia
recalcul
ctx
dose
predict
risk
model
refin
low
risk
factor
intermedi
risk
factor
high
risk
factor
respect
incid
sever
cardiotox
high
intermediateand
lowrisk
group
p
correspond
os
rate
three
group
p
last
followup
conclus
patient
high
risk
score
poorest
outcom
monitor
close
reduc
intens
condit
might
recommend
patient
disclosur
conflict
interest
declar
background
allogen
stemcel
transplant
allosct
associ
signific
transplantrel
mortal
trm
acut
renal
failur
arf
frequent
complic
usual
present
earli
procedur
compromis
feasibl
aim
studi
analys
incid
arf
risk
factor
potenti
impact
trm
allosct
method
patient
includ
male
median
age
year
rang
treat
allosct
consecut
januari
april
singl
institut
patient
characterist
detail
tabl
median
followup
year
rang
renal
function
evalu
use
creatinin
data
collect
pretranspl
baselin
point
arf
develop
allosct
arf
evalu
use
akin
criteria
increas
baselin
increas
increas
chronic
renal
diseas
evalu
one
year
date
arf
use
kdigo
criteria
result
cumul
incid
arf
year
multivari
analysi
arf
associ
nonus
antithymocyt
globulin
condit
chemotherapi
hr
develop
sever
agvhd
hr
patient
arf
import
variabl
multivari
analysi
use
methotrex
mtx
plu
cyclosporin
vs
mycophenol
mofetil
plu
cyclosporin
gvhd
prophylaxi
myeloabl
condit
vs
reduc
intens
use
total
irradi
therapi
condit
trm
year
increas
significantli
accord
akin
akin
akin
overal
surviv
year
accord
akin
akin
akin
akin
figur
incid
chronic
renal
diseas
year
allosct
accord
arf
arf
conclus
arf
frequent
complic
first
year
allosct
associ
sever
factor
arf
associ
intens
strategi
receiv
condit
meanwhil
relat
develop
gvhd
associ
arf
develop
chronic
renal
diseas
background
introduct
cellular
therapi
cart
modal
gvhdprophylaxi
posttransplantcyclophosphamid
ptci
increas
number
admiss
day
boost
pressur
avail
bed
bmunit
sens
centr
start
athom
allogen
stem
cell
transplant
allosct
program
follow
aplasia
independ
ambulatori
patient
evalu
feasibl
safeti
allosct
compar
two
group
allohsctathom
ahgroup
vs
allohsctinpati
ipgroup
method
includ
patient
receiv
allosct
januari
singl
centr
patient
ahgroup
ipgroup
patient
receiv
condit
hospit
gvhdprophylaxi
consist
tacrolimu
tk
plu
mycophenol
mpm
methotrex
ptci
plu
tk
patient
receiv
prophylaxi
levofloxacin
fluconazol
acyclovir
besid
ahgroup
patient
receiv
prophylaxi
ceftriaxon
iv
ertapenem
iv
aspergillusprophylaxi
inhal
liposom
amphotericinb
posaconazol
neutropenia
patient
ahgroup
sinc
ptcyprophylaxi
receiv
nurs
visit
athom
daili
visit
physician
perform
hospit
complic
event
firstlin
therapi
neutropen
fever
meropenem
group
use
portabl
infus
pump
ahgroup
group
absenc
focal
infect
sign
sever
sepsi
allow
return
home
initi
antibiot
platelet
support
perform
athom
red
blood
support
hospit
result
median
rang
age
year
seri
median
followup
seri
achiev
sourc
sct
peripher
blood
case
nt
find
statist
differ
two
group
ah
vs
ip
term
age
diagnosi
type
donor
intens
condit
gvhdprophylaxi
toxic
mucos
acut
renal
injuri
neutropenia
thrombocytopenia
agvhd
aspergilosi
trm
interestingli
signific
reduct
neutropen
fever
observ
result
lower
use
meropenem
ahgroup
ipgroup
admiss
median
day
similar
group
repres
day
reduct
total
econom
cost
ahgroup
whole
analysi
result
detail
tabl
inpati
group
conclus
experi
home
allosct
includ
ptcygvhd
prophylaxi
feasibl
safe
procedur
reflect
similar
trm
aspergillosi
incid
athom
allosct
associ
signific
lower
risk
neutropen
fever
inpati
group
well
low
readmiss
rate
disclosur
gonzalo
honoraria
gilead
grant
jazz
pharmaceut
janssen
laura
honoraria
takeda
janssen
amgen
celgen
other
author
disclosur
declar
background
renal
complic
sickl
cell
diseas
scd
includ
episod
acut
kidney
injuri
aki
progress
chronic
kidney
diseas
ckd
hyperfiltr
defin
abnorm
high
glomerular
filtrat
rate
gfr
hematopoiet
stem
cell
transplant
hsct
hla
ident
sibl
donor
wellestablish
cur
treatment
scd
tradit
myeloabl
condit
mac
regimen
pose
risk
kidney
injuri
due
intens
use
chemotherapeut
agent
infecti
risk
use
calcineurin
inhibitor
cni
aki
subsequ
fluid
overload
fo
common
pediatr
hsct
report
aki
incid
kyungnam
koh
et
al
report
renal
outcom
pediatr
patient
scd
receiv
hsct
follow
nonmyeloabl
condit
nma
regimen
without
cni
exposur
method
retrospect
chart
review
describ
renal
outcom
pediatr
patient
year
age
younger
scd
hbss
underw
nma
hsct
alberta
canada
juli
februari
nma
regimen
illustr
figur
report
renal
outcom
measur
gfr
dtpa
prehsct
aki
kdigo
definit
posthsct
review
serum
creatinin
level
prehsct
one
month
posthsct
fo
calcul
max
post
hsct
weight
baselin
weight
baselin
weight
x
two
first
week
posthsct
estim
gfr
egfr
use
pediatr
schwartz
formula
last
followup
posthsct
ckd
defin
egfr
mildli
reduc
gfr
hyperfiltr
gfr
ml
imag
result
eighteen
patient
male
year
old
transplant
includ
common
premorbid
event
vasoocclus
crisi
acut
chest
syndrom
splenic
sequestr
cholelithiasi
median
followup
time
month
rang
month
patient
engraft
success
acut
chronic
gvhd
baselin
measur
gfr
rang
mildli
reduc
gfr
hyperfiltr
seen
one
patient
respect
baselin
prehsct
aki
event
one
transplant
relat
aki
secondari
delay
hemolyt
reaction
exchang
transfus
prepar
transplant
posthsct
aki
event
addit
substanti
fo
posthsct
observ
averag
fo
week
one
posthsct
rang
week
two
posthsct
rang
posthsct
egfr
remain
last
followup
patient
hyperfiltr
present
patient
conclus
first
studi
describ
stabl
kidney
function
children
scd
present
nma
hsct
regimen
cgi
total
bodi
irradi
tbi
prolong
posthsct
sirolimu
episod
aki
signific
fluid
overload
observ
first
month
posthsct
patient
develop
ckd
followup
prospect
studi
need
confirm
find
determin
stabl
renal
function
persist
longerterm
followup
disclosur
noth
declar
lung
microbiota
patient
idiopath
pneumonia
syndrom
ip
hct
background
idiopath
pneumonia
syndrom
ip
noninfecti
pulmonari
complic
hematopoiet
cell
transplant
hct
etiolog
remain
unknown
recent
studi
report
variou
diseas
associ
chang
microbiota
aim
studi
evalu
lung
microbiota
hct
recipi
ip
identifi
microorgan
potenti
associ
ip
method
frozen
bronchoalveolar
lavag
bal
sampl
hct
recipi
ip
research
bal
sampl
asymptomat
hct
recipi
control
retrospect
analyz
sampl
neg
common
virus
quantit
pcr
sequenc
librari
made
input
dna
per
sampl
nextera
xt
illumina
sampl
pool
sequenc
hiseq
obtain
pair
end
data
sequenc
data
analysi
read
classif
perform
sunbeam
qualiti
control
read
classif
perform
use
komplex
kraken
classifi
bacteri
archeal
viral
genom
use
sequenc
data
bronchoscop
prewash
separ
cohort
control
environment
sourc
braycurtiss
dissimilar
among
sampl
calcul
use
vegan
r
packag
permanova
twosid
wilcoxon
rank
sum
test
use
compar
studi
group
result
bal
sampl
start
median
raw
read
pair
per
sampl
reduc
read
assign
microbi
taxa
follow
qualiti
control
bacteri
phyla
proteobacteria
firmicut
abund
follow
bacteroidet
actinobacteria
bal
bronchoscop
prewash
sampl
separ
bal
prewash
microbiota
use
braycurtiss
dissimilar
plot
show
bal
sampl
distinguish
sequenc
assign
staphylococcu
acidovorax
bradyrhizobium
speci
prewash
sampl
distinguish
mostli
pseudomona
elizabethkingia
speci
consist
environment
sourc
figur
within
bal
sampl
staphylococcu
speci
main
driver
separ
ip
case
control
permanova
figur
consist
linear
discrimin
analysi
identifi
taxa
best
distinguish
case
control
identifi
staphylococcu
especi
epidermidi
ip
case
lactobacillu
streptococcu
speci
control
compar
rel
abund
epidermidi
studi
group
ip
case
sampl
significantli
enrich
epidermidi
compar
control
p
twosid
wilcoxon
rank
sum
test
prewash
sampl
p
virus
classifi
categori
human
pathogen
nonhuman
pathogen
bacteriophag
torqu
teno
virus
ttv
commonli
detect
viru
among
virus
replic
human
cell
trend
toward
higher
abund
ip
case
sampl
control
conclus
lung
microbi
sequenc
hct
recipi
predominantli
consist
proteobacteria
firmicut
consider
overlap
environment
background
patient
ip
significantli
staphylococcu
sequenc
detect
asymptomat
hct
patient
result
suggest
patient
acut
lung
injuri
posthct
show
distinct
pattern
lung
microbiota
although
heterogen
sampl
collect
process
exclud
singular
organ
uniqu
associ
ip
prospect
studi
requir
confirm
find
defin
clinic
signific
differ
abund
pattern
disclosur
noth
declar
abstract
withdrawn
romiplostim
treatment
thrombocytopenia
allogen
stem
cell
transplant
background
thrombocytopenia
common
complic
allogen
stem
cell
transplant
allohct
variabl
possibl
caus
drug
side
effect
infect
poor
graft
function
graft
vs
host
diseas
gvhd
immun
mediat
purpos
studi
evalu
efficaci
romiplostim
thrombopoietin
receptor
agonist
patient
prolong
thrombocytopenia
obviou
caus
allogen
transplant
method
retrospect
analysi
allohct
patient
receiv
romiplostim
singl
bmt
unit
novemb
novemb
romiplostim
given
prolong
week
thrombocytopenia
could
nt
explain
obviou
caus
administr
drug
antibioticsantivir
infect
gvhd
patient
complet
remiss
complet
chimer
respons
romiplostim
treatment
consid
transfus
independ
plt
result
total
patient
median
year
receiv
romiplostim
patient
male
femal
aml
pt
md
hodgkin
receiv
myelobl
busiphexbas
ric
condit
transplant
sibl
vud
haploident
donor
pbsc
bm
patient
reveal
primari
neutrophil
median
day
rang
platelet
day
engraft
romiplostim
start
median
day
rang
median
dose
median
platelet
count
commenc
treatment
romiplostim
rang
transfusiondepend
total
patient
respond
romiplostim
treatment
eight
transfus
depend
patient
respond
administr
romiplostim
six
patient
transfus
independ
romiplostin
initi
plt
median
rang
respond
median
durat
treatment
day
median
follow
commenc
romiplostim
day
three
patient
experienc
relaps
thrombocytopenia
discontinu
romiplostim
reiniti
romiplostim
commenc
respond
nt
administr
romiplostim
done
extern
basi
well
toler
patient
two
patient
experienc
gvhd
romiplostim
treatment
patient
transplant
unrel
donor
day
initi
treatment
romiplostim
patient
interrupt
romiplostim
due
diseas
relaps
patient
receiv
romiplostim
aliv
complet
remiss
die
due
relaps
due
trm
conclus
present
high
respons
rate
romiplostim
patient
prolong
thrombocytopenia
allogen
transplant
retrospect
studi
side
effect
administr
romiplostim
howev
administr
romiplostim
allohct
control
prospect
trial
disclosur
report
singlecent
analysi
adult
patient
median
age
year
rang
mf
receiv
tpo
agonist
isol
sever
thrombocytopenia
spgf
allohsct
primari
diagnos
aml
md
pmf
mdsmpn
saa
cml
nhl
sever
pgf
defin
cytopenia
lineag
platelet
l
anc
l
hemoglobin
gl
time
sustain
engraft
full
stabl
mix
donor
chimer
sign
relaps
median
dose
romiplostim
rang
mcgkg
weekli
eltrombopag
rang
mgday
overal
respons
includ
cr
platelet
l
anc
l
hemoglobin
gl
pr
platelet
l
anc
l
hemoglobin
gl
result
median
time
pgf
diagnosi
treatment
tpo
agonist
day
median
treatment
durat
week
tpo
agonist
well
toler
case
grade
iiiiv
toxic
tpo
agonist
combin
rituximab
rituximab
dli
hsc
boost
patient
total
patient
met
criteria
respons
cr
pr
combin
therapi
show
differ
compar
tpo
agonist
alon
depend
tpo
agonist
use
time
therapi
initi
median
increas
anc
respond
l
platelet
count
l
total
patient
die
due
relaps
gvhd
iiiiv
grade
infect
twoyear
os
start
tpo
agonist
therapi
ci
signific
differ
respond
nonrespond
ci
vs
ci
conclus
studi
show
promis
result
tpo
agonist
manag
spgf
studi
warrant
specifi
optim
time
dose
regimen
predictor
respons
imag
twoyear
os
respond
nonrespond
tpo
agonist
therapi
disclosur
conflict
interest
disclos
cytomegaloviru
reactiv
kinet
peak
titer
novel
predictor
surviv
relaps
allogen
cell
transplant
hematolog
malign
saskia
leser
evren
bayraktar
nikolao
michael
koldehoff
lara
kasperidu
esteban
arrietabolano
mirko
trill
katharina
fleischhauer
dietrich
w
beelen
amin
turki
univers
hospit
essen
essen
germani
background
allogen
hematopoiet
cell
transplant
hct
human
cytomegaloviru
cmv
reactiv
associ
nonrelaps
mortal
nrm
also
reduc
relaps
patient
leukemia
shown
numer
studi
evalu
cmv
reactiv
qualit
yesno
paramet
first
month
posttranspl
hypothes
longitudin
quantit
assess
cmv
reactiv
kinet
viru
load
might
improv
patientspecif
clinic
outcom
associ
method
retrospect
studi
includ
patient
hct
hematolog
malign
treat
univers
hospit
essen
germani
cmv
titer
monitor
weekli
quantit
pcr
qpcr
cmv
reactiv
defin
cutoff
genom
copi
per
ml
patient
includ
analysi
least
measur
avail
first
day
hct
total
sampl
analyz
subgroup
analys
perform
accord
time
cmv
reactiv
beforeaft
cmv
viremia
titer
copiesml
result
cmv
reactiv
detect
median
age
year
rang
year
patient
baselin
characterist
age
gender
underli
diseas
transplant
patient
without
cmv
reactiv
compar
cmv
reactiv
kinet
follow
gaussian
normal
distribut
median
first
reactiv
peak
titer
except
patient
reactiv
overal
surviv
os
cmv
reactiv
group
whole
significantli
differ
nonreactiv
group
vs
month
howev
subgroup
analys
os
significantli
reduc
patient
earli
compar
later
reactiv
vs
month
moreov
importantli
os
significantli
reduc
patient
cmv
reactiv
high
titer
copiesml
compar
lower
titer
vs
month
p
cox
regress
analys
confirm
significantli
reduc
os
patient
cmv
reactiv
copiesml
day
compar
cohort
hr
ci
p
hr
ci
respect
nrm
consist
higher
hr
ci
p
patient
cmv
copi
risk
hematolog
relaps
exclus
reduc
patient
peak
cmv
viremia
copiesml
hr
ci
compar
patient
without
cmv
reactiv
level
cmv
reactiv
effect
observ
conclus
data
show
cmv
reactiv
high
titer
copiesml
associ
significantli
reduc
os
cmv
reactiv
intermedi
titer
copiesml
posit
impact
relaps
incid
find
underlin
complex
cmv
reactiv
hct
outcom
support
longitudin
evalu
cmv
titer
individu
quantit
kinet
model
risk
assess
hct
distinguish
advantag
detriment
aspect
cmv
reactiv
disclosur
att
receiv
lectur
fee
jazz
pharmaceut
travel
subsidi
neovii
biotech
outsid
submit
work
author
declar
compet
financi
interest
within
submit
work
associ
serum
ferritin
level
start
condit
mortal
allosct
prospect
nonintervent
studi
ebmt
transplant
complic
work
parti
background
elev
serum
ferritin
level
occur
due
iron
overload
inflamm
macrophag
activ
correl
high
serum
ferritin
level
increas
mortal
allosct
suggest
sever
retrospect
analys
well
two
smaller
prospect
studi
method
intern
multicentr
studi
aim
studi
associ
ferritin
serum
level
start
condit
allosct
outcom
patient
acut
leukemia
lymphoma
md
receiv
match
sibl
allosct
first
time
consid
inclus
regardless
condit
data
prospect
collect
comparison
outcom
patient
high
low
ferritin
level
perform
use
univari
analysi
multivari
analysi
use
causespecif
cox
model
variabl
includ
multivari
analys
age
sex
mismatch
diagnosi
diseas
statu
karnofski
score
number
cell
given
intens
condit
type
gvhd
prophylaxi
atg
use
time
diagnosi
transplant
year
transplant
cmv
statu
result
twenti
center
european
countri
report
data
allosct
recipi
patient
characterist
given
tabl
ferritin
cut
point
determin
median
measur
ferritin
level
overal
surviv
allosct
recipi
ferritin
level
cut
measur
start
condit
significantli
shorter
figur
univari
multivari
progressionfre
surviv
also
shorter
figur
univari
multivari
p
excess
mortal
high
ferritin
group
due
higher
relaps
incid
univari
multivari
increas
nonrelaps
mortal
univari
multivari
nonrelaps
mortal
driven
significantli
higher
infectionrel
mortal
high
ferritin
group
univari
p
multivari
hr
ci
p
acut
chronic
gvhd
incid
sever
associ
serum
ferritin
level
conclus
ferritin
level
start
condit
serv
routin
laboratori
biomark
predict
mortal
allosct
disclosur
author
declar
confict
interest
relat
studi
predict
reduc
lung
function
acut
gvhd
surfact
protein
allogen
stem
cell
transplant
transplant
hsct
may
progress
bronchiol
obliteran
high
mortal
rate
surfact
protein
spd
innat
defens
molecul
involv
immun
regul
epitheli
surfac
particularli
lung
elev
level
associ
exacerb
chronic
obstruct
pulmonari
diseas
copd
aim
studi
investig
whether
spd
plasma
level
variant
gene
encod
spd
may
predict
develop
reduc
lung
function
allogen
hsct
method
perform
populationbas
singlecent
studi
children
age
year
treat
allogen
hsct
studi
consist
prospect
studi
serial
plasma
spd
level
genotyp
patient
first
month
hsct
retrospect
studi
genotyp
within
spd
gene
patient
transplant
pulmonari
function
test
perform
regularli
part
clinic
monitor
result
day
graft
infus
day
spd
level
reduc
compar
level
start
treatment
condit
chemotherapi
defin
baselin
ngml
quartil
day
vs
ngml
baselin
p
day
spd
level
increas
remain
increas
whole
studi
period
ngml
baselin
vs
ngml
month
p
acut
gvhd
agvhd
occur
patient
patient
grade
high
spd
level
day
associ
develop
agvhd
ngml
vs
ngml
p
fig
cc
genotyp
associ
gener
low
spd
level
low
time
interv
compar
genotyp
significantli
month
posthsct
overal
correl
spd
level
lung
function
stratifi
genotyp
high
baselin
spd
level
predict
reduc
month
cc
tt
homozyg
individu
conclus
patient
genotyp
caus
low
capac
spd
product
increas
risk
develop
pulmonari
impair
hsct
addit
data
lend
support
studi
indic
spd
product
may
increas
inflammatori
pulmonari
diseas
act
reactiv
protect
mechan
research
warrant
defin
role
spd
level
genotyp
prognost
tool
lung
function
agvhd
imag
background
allogen
hematopoiet
cell
transplant
allohct
mean
long
period
restrict
mobil
rang
therapi
relat
side
effect
muscl
function
context
patient
demonstr
huge
declin
physic
capac
muscl
mass
particular
accompani
decreas
qualiti
life
qol
resist
train
could
maintain
muscl
mass
limit
patientsb
lood
valu
plateletcount
wellb
whole
bodi
vibrat
wbv
shown
maintain
muscl
mass
bed
rest
less
impact
blood
pressur
convent
resist
exercis
furthermor
also
shown
feasibl
patient
high
dose
chemotherapi
therefor
aim
studi
examin
effect
wbv
allohct
patient
physic
function
perform
well
qol
method
patient
receiv
allohct
randomli
alloc
either
wbv
exercis
group
ig
activ
control
group
cg
stretch
mobil
group
exercis
whole
time
hospit
time
per
week
underw
pre
postand
followupassess
physic
capac
determin
maximum
oxygen
consumpt
vo
maximum
power
p
max
cardiorespiratori
exercis
test
maximum
strength
knee
extensor
flexor
ex
max
flex
max
isokinet
strength
test
function
perform
assess
jump
height
counter
movement
jump
cmj
time
chair
rise
test
crt
well
power
output
test
qol
assess
questionnair
eortc
result
allohsct
vo
p
max
decreas
group
till
followup
increas
seen
ig
day
vo
group
differ
seen
ex
max
flex
max
reduc
cg
hospit
jump
height
power
output
decreas
cg
hospit
differ
group
seen
chang
jump
height
preto
followupassess
increas
ig
decreas
cg
ig
show
decreas
time
baselin
followup
crt
increas
power
output
qol
decreas
cg
hospit
followup
qol
increas
group
ig
cg
cg
physic
function
decreas
intervent
wherea
increas
seen
ig
preto
followupassess
bodi
imag
signific
wors
cg
compar
ig
hospit
discharg
well
followup
measur
got
wors
time
conclus
wbv
shown
maintain
maximum
strength
jump
perform
qol
allohct
although
cardiorespiratori
fit
could
maintain
wbv
hospit
seem
follow
period
till
day
recoveri
cardiorespiratori
system
enhanc
wbv
carri
allohst
nevertheless
reason
chang
recoveri
analyz
studi
well
treatment
effect
wbv
compar
convent
resist
train
disclosur
support
grant
faculti
medicin
comprehens
cancer
center
freiburg
respiratori
viru
infect
within
year
allosct
signific
risk
factor
obstruct
ventilatori
disturb
kosei
kageyama
michiho
ebihara
mitsuhiro
yuasa
daisuk
kaji
aya
nishida
shinsuk
takagi
hisashi
yamamoto
go
yamamoto
yuki
asanomori
naoyuki
uchida
atsushi
wake
akiko
yoneyama
shigeyoshi
makino
shuichi
taniguchi
toranomon
hospit
hematolog
tokyo
japan
background
obstruct
ventilatori
disturb
ovd
one
major
lifethread
complic
chronic
phase
allogen
stem
cell
transplant
allosct
bronchiol
obliteran
establish
etiolog
part
chronic
graftversushost
diseas
major
caus
late
nonrelaps
mortal
allosct
etiolog
impact
respiratori
function
allosct
risk
factor
ovd
well
understood
method
address
issu
retrospect
review
medic
record
consecut
patient
first
allosct
toranomon
hospit
detect
ovd
forc
expiratori
volum
second
show
less
predict
spirometri
test
defin
posit
recipi
show
less
pretranspl
test
reduct
regard
posit
nasopharyng
swab
upper
respiratori
tract
symptom
test
presenc
respiratori
viral
antigen
adv
piv
rsv
patient
ecog
perform
statu
activ
infect
transplant
exclud
analysi
case
earli
death
relaps
day
posttranspl
case
graft
failur
also
exclud
result
median
age
year
rang
underli
diseas
aml
mdsmpd
cml
atl
hl
nhl
other
five
hundr
twentynin
remiss
time
transplant
five
hundr
eightythre
patient
condit
myeloabl
regimen
wherea
patient
receiv
reducedintens
regimen
donor
sourc
consist
relat
peripher
blood
bone
marrow
bm
unrel
bm
fortysix
develop
ovd
median
day
posttranspl
cumul
incid
ovd
total
popul
recipi
could
spirometri
overal
surviv
year
patient
develop
ovd
compar
develop
univari
analysi
diseas
statu
craa
noncr
recipi
age
age
prior
autolog
stem
cell
transplant
ye
intens
condit
regimen
mac
ric
tbi
dose
gy
gy
busulfan
dose
donor
sourc
cord
blood
noncord
impact
incid
ovd
patient
develop
respiratori
viru
infect
show
significantli
higher
incid
ovd
compar
develop
vs
p
multivari
analysi
respiratori
viru
infect
signific
risk
factor
develop
ovd
ci
p
conclus
respiratori
viru
infect
within
year
allosct
signific
risk
factor
ovd
disclosur
noth
declar
background
metabol
syndrom
met
relat
increas
risk
cardiovascular
diseas
diabet
usual
seen
overweight
individu
gener
popul
investig
met
clinic
risk
factor
two
decad
hsct
method
male
survivor
treat
myeloabl
allohsct
childhood
year
denmark
invit
followup
studi
met
defin
presenc
least
three
ncep
atp
iii
criteria
fast
plasma
triglycerid
tg
mmoll
high
densiti
lipoprotein
hdl
mmoll
medic
treatment
hyperlipidemia
fast
plasma
glucos
fpg
mmoll
abdomin
circumfer
ac
cm
bp
mmhg
systol
mmhg
diastol
medic
treatment
hypertens
patient
overt
includ
met
group
furthermor
patient
examin
chronic
graftversushost
diseas
cgvhd
nihcriteria
time
followup
high
sensit
creactiv
protein
hscrp
measur
preval
met
compar
nordic
refer
group
hildrum
et
al
result
includ
elig
male
particip
rate
age
year
median
year
median
rang
followup
year
male
malign
diagnosi
treat
tbibas
condit
donor
match
sibl
match
rel
match
unrel
donor
met
preval
young
adult
survivor
compar
preval
report
nordic
refer
instead
preval
compar
report
compon
met
elev
tg
hypertens
decreas
hdl
frequent
fpg
elev
importantli
met
increas
ac
mean
bmi
kgm
hsct
survivor
within
normal
rang
contrast
featur
met
observ
background
popul
met
significantli
associ
tbi
rr
ci
follow
singl
compon
met
mean
tbi
group
vs
mean
nontbi
group
elev
tg
mmoll
vs
mmol
l
p
lower
hdl
mmoll
vs
mmoll
higher
diastol
bp
mmhg
vs
mmhg
met
demonstr
one
patient
receiv
nontbi
base
condit
sixteen
patient
cgvhd
nine
moder
sever
case
cgvhd
associ
met
howev
lowgrad
inflamm
measur
hscrp
relat
increas
ac
tg
conclus
result
indic
male
longterm
survivor
allohsct
childhood
high
risk
met
earlier
age
gener
popul
presenc
met
despit
normal
bmi
sever
patient
suggest
unconvent
etiolog
like
effect
tbi
lowgrad
inflamm
disclosur
noth
declar
result
survey
complet
transplant
director
transplant
consult
nonconsult
grade
physician
hsct
clinic
nurs
specialist
cn
centr
countri
centr
adultonli
paediatriconli
treat
adult
paediatr
patient
mix
centr
locat
higher
degre
latitud
northern
countri
lower
latitud
southern
countri
time
survey
member
european
union
eu
measur
serum
vd
routin
perform
centr
prior
allogen
hsct
main
clinic
indic
known
osteopaeniaosteoporosi
previou
fractur
treatment
steroid
prematur
menopaus
establish
menopaus
monitor
occur
everi
month
everi
month
year
timepoint
regard
season
taken
account
major
centr
local
nationalintern
guidelin
nice
follow
centr
respect
common
cutoff
valu
serum
vd
commenc
replac
nmoll
northern
countri
tend
use
valu
nmoll
wherea
southern
countri
nmoll
use
cutoff
valu
follow
hsct
centr
prescrib
vd
supplement
maintain
calcium
metabol
bone
health
enhanc
immun
reconstitut
posthsct
gvhd
prevent
enhanc
immunesuppress
treat
gvhd
treat
depressionfatigu
reduc
relaps
risk
load
dose
administr
adult
mix
paediatr
mean
durat
week
median
daili
load
dose
iu
median
mainten
daili
dose
iu
remark
differ
adult
paediatr
centr
northern
southern
countri
vd
replac
prescrib
transplant
physician
famili
physician
endocrinologist
cn
other
centr
patient
advis
buy
overthecount
vd
prescrib
combin
calcium
carbon
alon
centr
eventu
discontinu
centr
therapeut
level
vd
reach
dexa
scan
return
normal
symptomat
improv
conclus
survey
demonstr
discrep
monitor
replac
vd
across
ebmt
allogen
hsct
programm
although
awar
arisen
last
decad
still
lack
evid
optim
level
vd
requir
immunemodul
posthsct
survey
emphasis
need
specif
guidelin
harmonis
current
manag
vd
defici
adult
paediatr
hsct
set
disclosur
background
use
unmanipul
haploident
sct
haplosct
posttranspl
cyclophosphamid
ptci
gvhd
prophylaxi
wide
extend
primari
secondari
graft
failur
rel
uncommon
complic
howev
poor
graft
function
pgf
haplosct
ptci
describ
thoroughli
object
studi
describ
characterist
treatment
outcom
patient
pgf
haplosct
ptci
method
retrospect
analyz
haplosct
ptci
consecut
perform
centr
pgf
defin
either
occur
initi
engraft
persist
neutropenia
anc
need
least
dose
gcsf
andor
thrombocytopenia
platelet
platelet
transfus
depend
complet
donor
chimer
without
concurr
sever
gvhd
diseas
relaps
result
nineteen
patient
exclud
analysi
due
earli
mortal
death
day
primari
graft
failur
absenc
neutrophil
engraft
day
mix
chimer
secondari
graft
failur
develop
sever
cytopenia
mix
chimer
initi
achiev
neutrophil
engraft
thirti
one
patient
diagnos
pgf
main
characterist
patient
summar
tabl
twenti
six
patient
present
neutropenia
treat
gcsf
patient
develop
sever
thrombocytopenia
without
neutropenia
treat
platelet
transfus
twenti
four
patient
least
cmv
reactiv
patient
cmv
reactiv
patient
receiv
valganciclovir
cmv
reactiv
treatment
although
patient
achiev
adequ
peripher
blood
count
pbc
initi
salvag
therapi
patient
persist
cytopenia
spite
gcsf
platelet
transfus
cmv
reactiv
resolut
myelotox
drug
withdraw
four
treat
boost
select
peripher
blood
donor
cell
median
day
median
cell
infus
kg
patient
achiev
adequ
pbc
salvag
therapi
two
develop
gvhd
patient
treat
increas
dose
thrombopoietin
tpo
receptor
agonist
tra
eltrombopag
one
patient
start
treatment
day
hsct
daili
increas
dose
daili
complet
recoveri
pbc
month
initi
tra
second
patient
start
treatment
day
hsct
daili
increas
dose
daili
complet
recoveri
pbc
month
initi
tra
twenti
one
patient
pgf
diagnosi
long
term
surviv
conclus
poor
graft
function
frequent
complic
haplosct
cypost
cmv
reactiv
myelotox
drug
could
relev
factor
associ
develop
entiti
although
patient
recov
pbc
without
specif
therapi
beyond
gcsf
platelet
transfus
small
group
patient
persist
cytopenia
boost
select
cell
effect
revert
condit
gvhd
main
complic
procedur
use
tra
seem
interest
option
patient
although
experi
need
draw
definit
conclus
disclosur
noth
declar
also
frequent
observ
high
risk
patient
anxieti
hadsa
score
depress
hadsd
score
found
respect
patient
high
distress
statu
nccn
dt
score
found
younger
age
year
significantli
associ
poor
qualiti
life
score
factbmt
high
risk
fatigu
anxieti
hadsa
depress
hadsd
femal
sex
significantli
relat
lower
physic
wellb
score
higher
distress
score
p
respect
acut
lymphoblast
leukemia
survivor
allohct
show
significantli
wors
qualiti
life
score
factbmt
higher
depress
score
hadsd
compar
diseas
chronic
graft
versu
host
diseas
gvhd
continu
immunosuppress
usag
also
signific
advers
impact
lower
factbmt
score
respect
higher
hadsd
score
respect
signific
differ
fact
bmt
hadsa
hadsd
nccn
dt
accord
donor
type
condit
intens
antithymocyt
globulin
use
acut
gvhd
smoke
alcohol
drink
continu
allohct
survivor
survivor
exercis
regularli
regular
health
screen
test
done
patient
conclus
allohct
survivor
year
follow
allohct
still
mani
physic
psycholog
symptom
younger
patient
year
femal
chronic
gvhd
sustain
use
immunosuppress
signific
risk
factor
poor
qualiti
life
anxieti
need
build
activ
survivorship
care
plan
allohct
especi
patient
disclosur
author
noth
declar
evalu
new
ebmt
criteria
diagnosi
vodso
consecut
transplant
patient
use
electron
patient
record
analysi
system
asha
aggarw
nicola
gray
oliv
loma
katalin
balassa
nadjoua
maouch
robert
danbi
andi
peniket
grant
vallanc
background
venoocclus
diseas
vod
sinusoid
obstruct
syndrom
so
recognis
complic
haematopoiet
stem
cell
transplant
hepat
vasculatur
endotheli
cell
damag
condit
chemotherapi
lead
venou
occlus
centrilobar
necrosi
ebmt
criteria
diagnosi
vod
bilirubin
two
pain
hepatomegali
weight
gain
ascit
vod
often
underdiagnos
result
treatment
may
delay
integr
electron
patient
record
epr
system
wide
use
provid
opportun
retrospect
audit
practic
identifi
patient
vod
may
undiagnos
treatment
delay
addit
system
potenti
alert
clinician
potenti
diagnosi
vod
method
develop
softwar
analys
data
download
epr
identifi
patient
vod
possibl
diagnosi
accord
new
ebmt
criteria
order
identifi
patient
may
vod
first
screen
patient
bilirubin
mmoll
absolut
requir
clinic
diagnosi
vod
within
first
day
transplant
epr
data
use
assess
whether
patient
weight
gain
radiolog
report
review
patient
bilirubin
mmoll
ascertain
reveal
ascit
pain
hepatomegali
result
patient
underw
transplant
procedur
januari
juli
transplant
patient
found
bilirubin
mmoll
autograft
patient
allograft
patient
elev
bilirubin
level
patient
assess
evid
weight
gain
case
patient
autograft
patient
allograft
patient
seven
patient
autograft
allograft
radiolog
evid
ascit
two
patient
record
pain
hepatomegali
post
allograft
overal
analysi
identifi
patient
overal
fulfil
ebmt
diagnost
criteria
classic
earli
vod
receiv
defibrotid
patient
receiv
allogen
transplant
fail
identifi
case
late
onset
vod
undiagnos
patient
period
conclus
analysi
enabl
us
effici
perform
complet
audit
practic
identifi
patient
vod
would
recommend
use
electron
patient
record
retrospect
audit
practic
way
tool
creat
analysi
made
freeli
avail
public
use
detail
present
ebmt
meet
plan
extend
function
epr
system
provid
alert
clinician
vod
possibl
diagnosi
may
lead
rapid
treatment
patient
data
suggest
elev
bilirubin
weight
gain
frequent
occur
criteria
base
alert
disclosur
gvallanc
perform
consult
work
jazz
pharmaceut
endotheli
activ
stress
index
predict
outcom
allogen
stem
cell
transplantationa
retrospect
cohort
analysi
zinaida
peric
tomislav
taborsak
nadira
durakov
lana
desnica
alen
ostoj
ranka
serventiseiwerth
radovan
vrhovac
univers
hospit
centr
zagreb
zagreb
croatia
background
endotheli
dysfunct
common
pathophysiolog
major
complic
allosct
graftversushost
diseas
venoocclus
diseas
thrombot
microangiopathi
sepsi
endotheli
activ
stress
index
easix
simpl
score
compris
standard
laboratori
paramet
creatinin
ldh
thrombocyt
develop
potenti
tool
predict
allosct
mortal
luft
colleagu
recent
valid
easix
includ
three
retrospect
cohort
show
easix
taken
start
condit
use
independ
predictor
surviv
allosct
method
aim
studi
retrospect
evalu
pretranspl
easix
cohort
consecut
patient
underw
allosct
univers
hospit
centr
zagreb
use
cutoff
use
valid
cohort
compar
two
group
patient
overal
surviv
os
transplantrel
mortal
trm
group
comparison
done
use
logrank
test
gray
test
compet
risk
outcom
multivari
analysi
evalu
associ
os
relev
variabl
use
cox
proportionalhazard
regress
model
result
studi
group
includ
patient
compris
male
femal
median
age
year
rang
year
time
transplant
frequent
malign
popul
acut
leukemia
patient
myelodysplasticmyeloprolif
neoplasm
patient
donor
ident
sibl
patient
match
unrel
donor
patient
haploident
patient
patient
receiv
myeloabl
condit
regimen
patient
receiv
reducedintens
condit
regimen
median
followup
month
rang
whole
studi
group
os
month
ci
group
patient
low
easix
score
ci
group
patient
high
easix
score
differ
mainli
attribut
higher
trm
group
high
easix
score
ci
month
compar
group
low
easix
score
ci
month
multivari
analysi
includ
easix
patient
age
intens
condit
diagnosi
lymphoid
vs
myeloid
statu
diseas
transplant
type
donor
wors
os
independ
associ
older
age
patient
hr
ci
high
easix
score
hr
ci
conclus
retrospect
data
support
previou
data
suggest
easix
could
potenti
serv
valid
tool
predict
allosct
outcom
simpl
biomark
panel
easix
could
easili
implement
clinic
decis
make
field
allosct
retrospect
data
need
valid
prospect
studi
current
conduct
clinic
background
venoocclus
diseas
vod
potenti
devast
complic
occur
hematopoiet
stem
cell
transplant
hsct
sever
case
lead
multiorgan
failur
mohti
defibrotid
proven
effect
prevent
treat
vod
critic
clinician
awar
diagnos
treat
seriou
complic
hsct
studi
conduct
determin
onlin
simulationbas
continu
medic
educ
cme
intervent
could
improv
perform
hematologistsoncologist
hem
onc
advanc
practic
provid
nurs
practition
physician
assist
app
diagnosi
treatment
patient
vod
method
cme
certifi
virtual
patient
simul
vp
made
avail
via
websit
dedic
continu
profession
develop
vp
consist
case
present
platform
allow
clinician
assess
patient
make
diagnost
therapeut
decis
support
extens
databas
diagnost
treatment
possibl
match
scope
depth
actual
practic
clinic
decis
analyz
use
sophist
decis
engin
tailor
clinic
guidanc
cg
employ
uptod
evidencebas
faculti
recommend
provid
decis
one
case
vod
case
acut
myeloid
leukemia
aml
decis
collect
postcg
compar
user
baselin
precg
decis
use
pair
ttest
determin
pvalu
p
indic
signific
data
collect
result
time
assess
hemonc
app
fulfil
particip
criteria
complet
vod
case
simul
conclus
studi
demonstr
vp
immers
engag
clinician
authent
practic
learn
experi
improv
evidencebas
clinic
decis
relat
manag
vod
vp
increas
percentag
clinician
util
standard
criteria
diagnos
vod
order
defibrotid
iv
fluid
vod
manag
howev
educ
need
increas
compet
perform
clinician
particularli
app
area
order
posit
impact
patient
disclosur
noth
declar
nationwid
retrospect
studi
hematopoiet
stem
cell
transplant
solid
organ
transplant
recipi
behalf
jshct
transplant
complic
work
group
background
outcom
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
remain
unclear
address
issu
conduct
retrospect
survey
japan
societi
hematopoiet
stem
cell
transplant
center
method
address
issu
conduct
nationwid
retrospect
survey
japan
societi
hematopoiet
stem
cell
transplant
jshct
center
first
questionnair
email
jshct
center
request
inform
case
hsct
sot
recipi
patient
data
sot
collect
send
second
questionnair
center
patient
base
report
patient
data
hsct
identifi
japan
transplant
outcom
registri
databas
transplant
registri
unifi
manag
program
trump
confirm
result
jshct
center
respond
survey
respond
center
report
total
patient
undergon
sot
live
donor
subsequ
hsct
consist
three
autolog
hsct
autohsct
allogen
hsct
allohsct
autohsct
patient
receiv
liver
transplant
hapatoblastoma
achiev
neutrophil
engraft
day
hsct
two
three
patient
aliv
one
year
hsct
allohsct
seven
patient
receiv
liver
transplant
nine
patient
receiv
kidney
transplant
five
patient
receiv
hsct
unrel
donor
patient
receiv
hsct
relat
donor
two
donor
ident
sot
stem
cell
sourc
seven
peripher
blood
stem
cell
six
bone
marrow
three
cord
blood
one
patient
achiev
neutrophil
engraft
day
hsct
fiveyear
overal
surviv
patient
bone
marrow
failur
patient
malign
diseas
one
patient
malign
diseas
receiv
allohsct
nonremiss
seven
nine
kidneytranspl
recipi
experienc
dialysi
three
patient
experienc
renal
reject
hsct
contrari
livertranspl
recipi
experienc
hepat
reject
conclus
sot
recipi
outcom
allohsct
malign
diseas
poor
partli
due
diseas
statu
allohsct
sever
renal
complic
common
kidneytranspl
recipi
suggest
renal
care
caution
allohsct
disclosur
work
support
part
practic
research
project
allerg
diseas
immunolog
research
technolog
medic
transplant
japan
agenc
medic
research
develop
ame
high
incid
low
mortal
ebv
relat
ptld
tcell
replet
alloperipher
blood
hct
aggress
monitor
without
preemptiv
rituximab
background
aim
studi
report
incid
outcom
posttranspl
lymphoprolif
disord
ptld
set
allogen
peripher
blood
hematopoiet
stem
cell
transplant
allohsct
combin
posttranspl
cyclophosphamid
ptci
antithymocyt
globulin
atg
graft
versu
host
diseas
gvhd
prophylaxi
method
octob
may
adult
patient
diagnos
hematolog
malign
underw
first
tcell
replet
allohsct
center
patient
receiv
reduc
intens
condit
regimen
fludarabin
busulfan
total
bodi
irradi
combin
rabbitatg
ptci
cyclosporin
csa
ebv
titr
monitor
weekli
quantit
pcr
plasma
sampl
cutoff
valu
test
posit
copi
ebv
dnaml
plasma
last
follow
novemb
median
follow
patient
known
aliv
month
rang
result
patient
inform
summar
tabl
ebv
reactiv
document
patient
median
time
ebv
reactiv
diagnosi
presumedproven
pp
ptld
day
day
month
respect
median
time
first
ebv
reactiv
ppptld
day
seventeen
patient
develop
ppptld
median
age
year
two
receiv
mrd
mud
mud
haploident
donor
graft
twelv
therapeut
cyclosporin
diagnosi
preemptiv
therapi
given
case
probabl
proven
ptld
given
rituximab
treatment
base
reduct
immunosuppress
patient
addit
weekli
rituximab
mg
case
fifteen
achiev
complet
clinic
respons
pcr
neg
two
patient
die
secondari
ptld
conclus
atg
base
condit
associ
increas
viral
reactiv
frequent
ebv
monitor
preemptiv
treatment
may
lead
rapid
diseas
control
research
requir
optim
monitor
manag
strategi
allohsct
recipi
disclosur
noth
declar
acoust
enrich
extracellular
vesicl
potenti
marker
allogen
hematopoiet
stem
cell
transplant
complic
hooich
lim
robert
palmason
stig
lenhoff
thoma
laurel
stefan
schede
background
extracellular
vesicl
ev
contain
number
conditionspecif
protein
dna
rna
type
might
therefor
use
earli
detect
posttranspl
complic
howev
tradit
ev
isol
ultracentrifug
time
consum
requir
larg
sampl
volum
thu
make
difficult
perform
longitudin
studi
larger
patient
cohort
therefor
investig
whether
recentlydevelop
acoust
trap
could
appli
isol
ev
patient
plasma
biomark
develop
method
plasma
sampl
collect
consecut
patient
month
allogen
hematopoiet
stem
cell
transplant
patient
age
year
highrisk
refractoryrelaps
diseas
transplant
mobil
pbsc
relat
unrel
donor
standard
condit
gvhd
prophylaxi
cyclosporin
methotrex
plasma
sampl
frozen
thaw
ev
enrich
use
novel
acoustofluidicbas
technolog
acoust
trap
acoust
trap
use
ultrasound
local
acoust
stand
wave
produc
piezoelectr
transduc
capillari
first
polystyren
bead
captur
serv
seed
particl
wash
target
particl
ev
captur
trap
acoust
field
semiautomat
trap
devic
acoutrap
use
isol
ev
dilut
plasma
pb
number
ev
size
distribut
analyz
nanoparticl
track
analysi
mirna
analysi
perform
qpcrev
enrich
duplic
dilut
plasma
nanoparticl
track
analysi
qpcr
analysi
respect
result
ev
success
isol
plasma
sampl
total
plasma
sampl
process
number
trap
ev
rang
condit
per
dilut
plasma
transplant
maximum
chang
ev
number
individu
patient
compar
pretransplant
valu
rang
patient
show
slight
increas
ev
size
transplant
eight
patient
show
sign
infect
receiv
iv
antibiot
increas
level
ev
record
three
patient
episod
furthermor
increas
ev
number
observ
patient
requir
iv
antivir
therapi
cmv
reactiv
acut
grade
gvhd
observ
five
patient
two
increas
ev
number
one
patient
develop
grade
iv
gvhd
accompani
increas
ev
number
interestingli
progress
increas
ev
number
preced
detect
earli
relaps
preb
patient
three
week
rna
isol
trap
ev
yield
suffici
materi
mirna
profil
first
mirna
profil
data
demonstr
mirna
detect
ev
sampl
acoust
enrich
ev
affect
hemolysi
contrast
correspond
whole
plasma
sampl
dcq
conclus
acoust
trap
allow
effici
rapid
enrich
ev
small
volum
plasma
sampl
trap
ev
sampl
contain
suffici
amount
mirna
downstream
analysi
thu
promis
candid
biomark
develop
transplant
disclosur
laurel
schede
founder
board
member
acousort
ab
lundbas
biotech
sme
develop
particl
cell
sort
method
base
ultrasound
incid
risk
factor
outcom
primari
poor
graft
function
allogen
hematopoiet
stem
cell
transplant
fei
gao
jimin
shi
yi
luo
yamin
tan
xiaoyu
lai
jian
yu
huang
yanmin
zhao
background
allogen
hematopoiet
stem
cell
transplant
allohsct
cur
therapi
hematolog
malign
mani
blood
diseas
primari
poor
graft
function
pgf
still
sever
complic
follow
hsct
lead
poor
prognosi
incid
risk
factor
pgf
total
reveal
method
januari
decemb
total
patient
receiv
allohsct
center
analyz
retrospect
male
femal
median
age
year
year
pgf
defin
persist
neutropenia
l
thrombocytopenia
l
gl
engraft
hypocellular
bone
marrow
full
donor
chimer
without
concurr
graftversushost
diseas
diseas
relaps
incid
calcul
patient
total
patient
nineteen
develop
primari
pgf
ratio
nest
case
control
studi
use
good
graft
function
ggf
subject
transplant
year
sex
age
year
carri
result
data
analyz
univari
multivari
logist
regress
univari
analysi
identifi
diseas
speci
time
diagnosi
transplant
diseas
state
myelofibrosi
splenomegali
serum
ferritin
sf
level
cmv
infect
mononuclear
cell
graft
potenti
risk
factor
p
pgf
multivari
analysi
identifi
element
independ
risk
factor
p
includ
cell
background
transplant
survivor
affect
cgvhd
usual
take
one
immunosuppress
well
prophylact
antimicrobi
use
multipl
medic
class
concurr
pose
risk
drugdrug
interact
amplifi
sideeffect
use
medic
cgvhddirect
immunosuppress
therapi
wellcharacter
studi
aim
evalu
pattern
opioid
analges
use
cohort
patient
sever
affect
cgvhd
method
patient
cgvhd
consecut
enrol
crosssect
natur
histori
studi
nih
particip
underw
comprehens
evalu
includ
detail
histori
physic
examin
includ
current
medic
multidisciplinari
evalu
laboratori
diagnost
test
analysi
respond
classifi
receiv
receiv
opioid
analges
follow
initi
screen
univari
method
multivari
logist
regress
analysi
mlr
use
identifi
set
factor
could
jointli
impact
opioid
use
mlr
data
divid
train
patient
valid
set
result
studi
age
year
femal
sever
cgvhd
per
nih
score
criteria
current
receiv
high
moder
level
system
immunosuppress
approxim
one
third
take
opioid
analges
oa
base
univari
screen
result
p
set
paramet
evalu
univari
logist
regress
train
set
follow
paramet
retain
signific
includ
mlr
model
nih
averag
score
per
organ
total
lss
patient
impress
sever
nih
cgvhd
sever
presenc
skin
erythema
karnofski
perform
score
kp
clinician
therapeut
intent
nih
joint
score
presenc
sever
cgvhd
symptom
includ
rash
mouth
sore
avoid
food
vomit
weight
loss
joint
muscl
ach
joint
limit
energi
loss
need
nap
fever
anxieti
multivari
logist
regress
identifi
kp
predict
oa
use
ci
train
set
pt
use
opioid
correctli
identifi
take
opioid
identifi
overal
fraction
correctli
identifi
pt
ci
test
set
use
opioid
correctli
identifi
take
opioid
correctli
identifi
overal
ci
classif
accuraci
conclus
studi
show
burden
oa
cgvhd
cohort
lower
kp
significantli
associ
oa
use
well
selfreport
symptom
sever
cgvhd
diseas
could
interest
develop
nonpharmaceut
intervent
patient
popul
addit
prospect
studi
need
explor
indic
effect
oa
popul
survivor
disclosur
conflict
interest
declar
rct
test
internetbas
program
patientcent
survivorship
care
plan
hct
survivor
patient
caregiv
input
essenti
inform
design
featur
mobil
app
platform
usabl
engag
target
method
use
qualit
research
design
conduct
telephon
focu
group
adult
patient
caregiv
unit
state
adult
age
year
time
studi
entri
hct
recipi
least
oneyear
posthct
particip
particip
abl
commun
english
could
receiv
hct
diagnosi
donor
sourc
stem
cell
type
multipl
transplant
includ
particip
ask
review
print
onlin
visual
present
mobil
app
focu
group
prepar
discuss
respons
materi
call
focu
group
conduct
satur
new
qualit
content
offer
result
three
focu
group
conduct
total
particip
patient
two
caregiverspati
advoc
patient
receiv
allogen
hct
averag
time
sinc
hct
year
rang
year
major
particip
femal
particip
differ
perspect
use
app
track
followup
appoint
lab
valu
health
care
plan
high
interest
app
tailor
meet
specif
need
patient
includ
track
inform
time
eg
test
result
medic
health
inform
avail
specif
need
minim
duplic
inform
data
entri
particip
recommend
sync
app
calendar
onlin
patient
portal
alreadi
use
reason
provid
use
app
includ
percept
materi
repeat
inform
alreadi
receiv
side
effect
graftversushost
diseas
restrict
vision
motor
skill
lack
comfort
app
older
particip
conclus
mani
health
technolog
mobil
app
creat
improv
patient
health
survivorship
care
studi
hct
survivor
caregiv
identifi
varieti
featur
would
want
app
websit
particular
featur
tailor
individu
need
health
technolog
provid
opportun
improv
survivorship
care
patient
caregiv
engag
process
develop
tool
assur
technolog
fit
need
use
given
effort
requir
maintain
technolog
requir
test
health
benefit
rigor
clinic
trial
clinic
background
thank
allogen
stem
cell
transplant
allohsct
patient
suffer
hematolog
malign
seen
increas
life
durat
expect
mani
side
effet
includ
decreas
physic
perform
qualiti
life
intens
physic
perform
decreas
variabl
patient
today
know
aim
studi
first
character
physic
perform
subject
less
year
follow
allohsct
use
cardiopulmonari
exercis
test
cpet
determin
predict
factor
exercis
perform
method
retrospect
analysi
patient
allohsct
hematolog
depart
toulouseoncopol
cpet
cpet
perform
use
cycl
ergomet
analyz
breath
breath
masterscreen
cpx
carefus
san
diego
usa
continu
electrocardiogram
blood
pressur
monitor
protocol
includ
rest
period
warmup
pedal
follow
increment
phase
exhaust
activ
recoveri
pedal
passiv
recoveri
three
exercis
marker
analys
peak
oxygen
uptak
peak
vo
vevco
slope
first
ventilatori
threshold
vt
data
rel
condit
regimen
shortterm
complic
impair
cpet
day
physic
activ
sinc
allohsct
gather
result
allohsct
nearli
patient
report
fatigu
half
report
dyspnea
report
pain
muscular
neurolog
psycholog
impair
patient
suffer
moder
sever
physic
intoler
particularli
myeloabl
condit
regimen
use
patient
follow
rehabilit
session
supervis
physiotherapist
nonsupervis
physic
activ
perform
patient
despit
normal
lung
function
test
echocardiographi
find
patient
exercis
intoler
ei
exercis
decondit
abnorm
ventilatori
effici
patient
moder
sever
impair
exercis
capac
significantli
younger
diagnosi
allohsct
patient
sever
decondit
conclus
base
retrospect
studi
report
first
time
complet
result
cpet
detail
clinic
evalu
concern
defici
disabl
follow
first
year
allohsct
result
confirm
exercis
impair
frequent
half
patient
suffer
alter
one
three
perform
marker
despit
activ
disclosur
noth
declar
demyelin
disord
paradigm
immun
disord
hematopoiet
stem
cell
transplant
background
neurolog
complic
major
problem
patient
undergon
hematopoiet
stem
cell
transplant
hsct
given
higher
surviv
transplant
patient
burden
neurolog
complic
increas
last
year
signific
reduct
overal
surviv
demonstr
patient
develop
neurolog
complic
hsct
irrespect
hematopoiet
stem
cell
hsc
sourc
neurolog
disord
transplant
set
compris
wide
varieti
ethiolog
includ
demyelin
diseas
caus
immun
nonimmun
mechan
analyz
clinic
present
underli
ethiolog
patient
develop
hsctrelat
demyelin
disord
order
give
diagnost
prognost
clue
use
manag
sever
treatabl
complic
transplant
set
method
total
patient
depart
develop
neurolog
complic
hsct
consecut
collect
name
diagnosi
demyelin
disord
group
describ
accord
ethiolog
neurolog
disord
result
patient
immunemedi
process
found
diagnos
infect
etiolog
suppos
demyelin
disord
caus
toxic
exposit
definit
etiolog
diagnosi
formul
remain
patient
patient
develop
immunemedi
demyelin
disord
compar
clear
immun
pathogen
mechan
detect
higher
incid
acut
graftversushost
diseas
agvhd
detect
former
latter
vs
moreov
comparison
two
group
reveal
evid
immunemedi
process
slight
higher
preval
tcell
deplet
hsct
thanthos
immunemedi
demyelin
disord
vs
final
lymphoprolif
disord
preexist
hsct
detect
patient
immunemedi
demyelin
disord
without
evid
immunemedi
process
conclus
demyelin
disord
may
respons
near
neurolog
complic
posttranspl
set
among
immunemedi
process
like
involv
case
result
suggest
immun
mechan
underliesth
agvhd
may
also
involv
develop
demyelin
diseas
transplant
patient
also
may
possibl
lymphoprolif
disord
preexist
hsct
risk
factor
abl
increas
risk
develop
immunemedi
demyelin
disord
posttranspl
set
use
tcell
deplet
hsct
increas
risk
immunemedi
disord
least
small
fraction
transplant
patient
despit
result
valid
larger
cohort
patient
specul
possibl
connect
wide
rang
complex
still
poorli
defin
immun
disord
influenc
prognosi
cours
transplant
patient
disclosur
background
injuri
mucos
barrier
subsequ
develop
oral
mucos
om
among
common
toxic
allogen
stem
cell
transplant
sct
despit
high
preval
om
debilit
natur
prospect
studi
evalu
determin
om
scarc
therefor
prospect
evalu
occurr
om
follow
sct
risk
factor
om
implic
short
longterm
outcom
assess
method
om
prospect
evalu
weekli
basi
patient
undergo
allogen
hsct
grade
om
determin
base
nation
cancer
institut
common
toxic
criteria
advers
event
ctcae
scale
v
sever
om
defin
grade
ii
iv
condit
regimen
evalu
individu
accord
intens
myeloabl
mac
reduc
intens
ric
reduc
toxic
rtc
latter
categori
includ
patient
receiv
fludarabin
treosulfan
dose
flutreo
risk
factor
develop
sever
om
initi
identifi
univari
analysi
analyz
multivari
logist
regress
model
associ
om
peritranspl
infecti
complic
iv
morphin
consumpt
hospit
length
neutrophil
engraft
acut
chronic
graftversushost
diseas
gvhd
nonrelaps
mortal
nrm
overal
surviv
assess
univari
analysi
compet
event
consid
analyz
engraft
gvhd
nrm
result
patient
underw
allogen
sct
includ
median
followup
day
lead
indic
transplant
acut
myeloid
leukemia
lymphoma
myelodysplast
syndrom
major
patient
receiv
allograft
match
sibl
unrel
donor
methotrex
gvhd
prophylaxi
median
time
om
onset
interquartil
rang
iqr
day
preval
grade
iiiv
om
median
durat
om
day
iv
morphin
administr
median
day
patient
grade
iiiiv
om
univari
analysi
younger
age
lower
bmi
recent
smoke
histori
recent
antibiot
exposur
mac
p
use
methotrex
associ
increas
risk
grade
iiiv
om
multivari
model
risk
grade
iiiv
om
lower
rtc
ie
flutreo
vs
mac
odd
ratio
p
rtc
vs
ric
mycophenol
mofetil
vs
methotrex
recent
smoke
compar
lower
grade
grade
iiiv
om
associ
longer
hospit
durat
median
day
vs
day
delay
neutrophil
engraft
median
vs
day
gastrointestin
relat
infect
vs
grade
iiiv
om
associ
increas
risk
bloodstream
infect
acut
chronic
gvhd
nonrelaps
mortal
increas
mortal
conclus
oral
mucos
preval
among
allogeneicsct
recipi
importantli
fludarabinetreosulfan
consid
myeloabl
associ
markedli
reduc
risk
om
consequ
om
includ
prolong
hospit
delay
neutrophil
engraft
tendenc
gastrointestin
infect
increas
risk
gvhd
mortal
disclosur
noth
declar
background
advent
recent
diagnost
techniqu
assess
iron
overload
mri
systemat
use
screen
tool
set
secondari
hemochromatosi
led
increas
awar
focal
nodular
hyperplasia
fnh
repres
possibl
incident
find
hematopoiet
stem
cell
transplant
hsct
method
clinic
radiolog
featur
patient
undergo
hsct
singl
pediatr
institut
retrospect
review
fnh
order
provid
estim
preval
fnh
hsct
analys
mri
scan
perform
last
year
centr
record
number
patient
fnh
group
addit
data
patient
incident
diagnos
fnh
abdomin
imag
perform
differ
clinic
indic
collect
group
b
result
eight
transplant
patient
underw
least
one
mri
scan
septemb
septemb
incident
diagnos
fnh
group
b
includ
subject
fnh
incident
found
ultrasound
mri
scan
perform
overal
transplant
patient
male
transplant
al
case
bone
marrow
failur
case
median
age
year
diagnos
fnh
year
hsct
name
year
group
year
group
b
variabl
degre
iron
overload
demonstr
patient
lic
microgg
baselin
serum
ferritin
ngml
potenti
risk
factor
fnh
report
tabl
patient
radiolog
find
pathognomon
diagnosi
fnh
confirm
histolog
subject
label
fnhlike
although
potenti
diagnosi
hepat
adenoma
could
rule
patient
fnh
present
isol
lesion
hepat
nodul
diagnosi
size
nodul
diagnosi
rang
mm
unenhanc
mri
scan
lesion
predominantli
hyperintens
sequenc
dynam
studi
contrast
medium
lesion
strongli
enhanc
arteri
phase
variabl
degre
washout
late
venou
scan
hepat
function
test
normal
enrol
patient
diagnosi
fnh
among
patient
least
followup
scan
avail
present
complet
regress
reduct
increas
size
andor
number
lesion
patient
nodul
remain
substanti
unchang
mean
radiolog
followup
year
malign
transform
observ
conclus
fnh
repres
rel
frequent
incident
find
hsct
although
malign
transform
rare
given
demonstr
variabl
evolut
hepat
nodul
radiolog
followup
highli
recommend
disclosur
noth
disclos
incid
risk
factor
hepat
sinusoid
obstruct
syndrom
allogen
transplant
retrospect
multicent
studi
turkish
hematolog
research
educ
group
threg
updat
data
method
ten
center
turkey
enrol
studi
retrospect
evalu
medic
record
patient
treat
allosct
januari
decemb
baltimor
criterion
use
assess
hso
four
hundr
twenti
six
patient
treat
prophylaxi
defibrotid
alon
one
nacetylcystein
diuret
heparin
use
defibrotid
mgkgday
result
studi
includ
patient
male
femal
median
age
year
demograph
clinic
characterist
patient
summar
tabl
seventythre
patient
hso
treat
defibrotid
diagnosi
median
time
start
defibrotid
patient
day
thirtyseven
patient
hso
recov
complet
fortynin
die
result
multi
organ
failur
incid
hsosrel
mortal
allohsct
cohort
found
univari
analysi
statist
signific
associ
found
hso
incid
agesex
recipi
type
condit
regimen
stem
cell
sourc
type
gvhd
prophylaxi
hand
donor
type
engraft
statu
prophylaxi
hso
significantli
associ
hso
develop
hso
prophylaxi
significantli
decreas
hsosassoci
mortal
conclus
hso
still
remain
seriou
lifethreaten
complic
allosct
although
incid
low
hso
associ
increas
nonrelaps
mortal
hso
prophylaxi
especi
defibrotid
seem
reduc
hso
associ
mortal
high
risk
patient
disclosur
noth
declar
prophylaxi
defibrotid
adult
high
risk
venoocclus
diseas
result
patient
background
hepat
sinusoid
obstruct
syndrom
venoocclus
diseas
sosvod
life
threaten
complic
occur
hematopoiet
stem
cell
transplant
hsct
sever
sosvod
rapidli
evolv
multipl
organ
dysfunct
syndrom
mod
associ
mortal
rate
exced
precoc
defibrotid
df
treatment
lead
factor
efficaci
prophylact
use
df
recommend
children
valu
valid
adult
popul
although
factor
individu
risk
assess
vod
debat
present
realworld
experi
df
prophylaxi
adult
patient
high
risk
sosvod
receiv
allogen
hsct
method
treat
prophylact
defibrotid
ursodeoxychol
acid
udca
patient
median
age
year
rang
nine
patient
receiv
allogen
hsct
acut
lymphoblast
leukemia
ball
tall
one
patient
sever
aplast
anemia
one
patient
primari
myelofibrosi
high
risk
sosvod
previou
hepatotox
patient
previou
hsct
patient
doubl
alkyl
agent
patient
previou
treatment
inotuzomab
ozogamicin
io
patient
patient
treat
io
receiv
cycl
io
receiv
cycl
last
io
dose
administ
median
day
hsct
rang
defibrotid
administ
daili
dose
total
dose
mg
kg
per
day
udca
dose
mg
twice
per
day
start
day
prior
transplant
patient
receiv
treosulfanfludarabin
base
condit
patient
thiotepa
ad
condit
patient
low
dose
tbi
gvhd
prophylaxi
includ
posttranspl
cyclophosphamid
rapamycin
mycophenol
patient
except
one
patient
aplast
anemia
receiv
atg
rapamycin
mycophenol
donor
sourc
pbsc
case
seven
patient
receiv
famili
haploident
mmrd
transplant
patient
mrd
transplant
patient
mud
transplant
result
median
durat
defibrotid
therapi
day
rang
day
document
nonsever
gastrointestin
bleed
occur
patient
requir
defibrotid
temporarili
discontinu
signific
bleed
experienc
four
patient
develop
grade
iiiv
acut
gvhd
transplantassoci
thrombot
microangiopathi
diagnos
overal
sosvod
occur
case
within
day
hsct
day
lateonset
sosvod
diagnos
sosvod
sever
caus
mod
death
case
patient
character
common
pattern
high
risk
factor
sosvod
prior
hsct
salvag
treatment
ball
cycl
io
close
hsct
furthermor
receiv
fulli
myeloabl
condit
regimen
treosulfan
thiotepa
mmrd
transplant
conclus
defibrotid
prophylaxi
safe
well
toler
sever
relat
complic
sosvod
occur
despit
continu
df
prophylaxi
patient
treat
inotuzomab
ozogamicin
close
undergo
nd
transplant
reduc
incid
sever
vod
pre
allohsct
treatment
inotuzomab
ozogamicin
prompt
avoid
cumul
risk
factor
vod
use
doubl
alkyl
agent
disclosur
background
busulfan
backbon
mani
prepar
regimen
administ
children
undergo
allogen
autolog
hematopoiet
stem
cell
transplant
hsct
among
mani
longterm
advers
effect
busulfan
caus
variou
degre
pulmonari
injuri
although
well
describ
adult
larg
seri
explor
pulmonari
toxic
busulfan
children
describ
longterm
pulmonari
followup
larg
group
children
treat
singl
center
receiv
highdos
busulfan
examin
relationship
system
drug
exposur
lung
function
time
method
surviv
children
receiv
highdos
busulfan
context
hsct
schneider
medic
center
refer
serial
pulmonari
function
monitor
includ
spirometri
plethysmographi
diffus
capac
carbon
monoxid
dlco
pretranspl
test
avail
children
old
enough
perform
procedur
spirometri
result
adjust
accord
revis
global
lung
initi
formula
age
gender
height
pulmonari
injuri
defin
z
score
spirometri
predict
paramet
busulfan
level
monitor
follow
second
drug
dose
patient
receiv
busulfan
four
daili
dose
area
curv
auc
calcul
perform
bayesian
calcul
result
patient
age
year
diagnos
malign
nonmalign
diseas
treat
highdos
busulfan
shortterm
survivor
least
one
posttranspl
pulmonari
function
evalu
mean
age
treatment
busulfan
year
rang
year
children
children
undergon
autolog
transplant
children
allogen
transplant
patient
eventu
relaps
die
children
one
pulmonari
risk
factor
hsct
chest
upper
abdomen
radiat
chest
wall
tumor
lung
metastasi
chest
surgeri
prior
administr
pulmonarytox
drug
asthma
followup
year
median
year
fvc
spirometri
test
decreas
significantli
respect
decreas
dlco
statist
signific
patient
abnorm
pulmonari
function
test
seven
children
symptomat
diseas
two
may
manifest
gvhd
interestingli
correl
found
busulfan
auc
busulfan
peak
level
number
busulfan
dose
administ
type
transplant
autolog
vs
allogen
primari
diseas
pulmonari
injuri
even
censor
children
pretranspl
pulmonari
risk
factor
note
decreas
fvc
conclus
adult
pulmonari
injuri
observ
children
treat
highdos
busulfan
prior
hsct
correl
observ
busulfan
auc
pulmonari
injuri
followup
children
receiv
drug
includ
regular
pulmonari
monitor
referr
pulmonologist
subclin
pulmonari
compromis
found
counsel
regard
measur
might
prevent
amelior
pulmonari
damag
continu
followup
cohort
patient
inform
pretranspl
patient
inform
session
futur
use
busulfan
children
disclosur
noth
declar
background
transplantassoci
thrombot
microangiopathi
tatma
specif
complic
allogen
hematopoiet
stem
cell
transplant
hsct
posthsct
tma
attribut
vascular
endotheli
damag
caus
highdos
chemotherapi
calcineurin
inhibitor
cni
graftversushost
diseas
gvhd
infect
littl
evid
publish
regard
efficaci
factor
influenc
outcom
withdraw
cni
method
analysi
compris
total
patient
diagnos
hematolog
malign
aml
md
hodgkin
lymphoma
cml
neuroblastoma
receiv
allosct
match
relat
unrel
haploident
donor
patient
diagnos
tatma
base
cho
criteria
median
age
patient
adult
children
gvhd
prophylaxi
perform
tacrolimu
tac
cyclosporin
csa
combin
tacrolimussirolimu
sir
patient
receiv
atg
ptci
withdraw
cni
accompani
administr
system
steroid
patient
substitut
sir
reach
level
csa
ngml
tac
ngml
target
concentr
sir
ngml
pediatr
patient
receiv
combin
tacsir
tac
discontinu
one
step
sir
continu
median
time
develop
tma
day
allosct
rang
median
followup
surviv
patient
day
primari
outcom
overal
surviv
os
year
develop
tatma
result
follow
signific
predictor
os
identifi
tac
replac
sir
p
ptci
prophylaxi
p
acut
gvhd
agvhd
grade
previou
sepsi
level
ldh
debut
combin
sirtac
prophylaxi
major
sever
cn
symptom
p
signific
differ
os
accord
patient
age
sex
salvag
diseas
statu
transplant
previou
vod
viral
hhv
cmv
ebv
reactiv
count
cell
transfus
ldh
level
shizocyt
creatinin
debut
tatma
multivari
analysi
replac
cni
sir
hr
ci
baselin
ldh
level
hr
hr
associ
surviv
differ
cut
ldh
agvhd
grade
hr
use
ptci
hr
signific
multivari
analysi
figur
tatma
case
ptci
significantli
less
frequent
associ
clinic
signific
agvhd
vs
p
surviv
higher
ptci
vs
signific
due
sampl
size
tatma
factor
lead
caus
death
gvhd
progress
bacteri
infect
tma
conclus
replac
tac
sir
effect
therapeut
strategi
group
patient
debut
tatma
least
ptci
less
like
associ
agvhd
signific
overlap
popul
ptci
prophylaxi
substitut
sir
thu
studi
power
provid
guidanc
patient
convent
prophylaxi
tatma
imag
disclosur
none
author
anyth
disclos
donorrecipi
mismatch
effect
allogen
hematopoiet
stem
cell
transplant
outcom
singlecent
retrospect
studi
background
transmiss
major
histocompat
complex
blood
group
system
gene
independ
approxim
allogen
hematopoiet
stem
cell
transplant
allohsct
realiz
crosswis
group
boundari
howev
due
widespread
express
antigen
varieti
human
tissu
erythrocyt
incompat
may
impact
outcom
allogen
hsct
goe
beyond
wellknown
immunehematolog
complic
immedi
hemolysi
due
presenc
isoagglutinin
delay
hemolysi
due
passeng
b
lymphocyt
aim
assess
donorrecipi
mismatch
effect
allohsct
outcom
compris
nonrelaps
mortal
nrm
overal
relapsefre
surviv
posttranspl
prc
transfus
requir
well
relaps
rate
incid
graftfailur
acut
gvhd
method
clinic
laboratori
data
consecut
patient
undergo
allogen
hsct
fondazion
ircc
ca
granda
maggior
policlinico
hospit
milan
itali
retrospect
collect
kaplan
meier
estim
use
analysi
surviv
outcom
nrm
relaps
acut
gvhd
cumul
incid
investig
compet
risk
analysi
result
patient
seri
includ
major
minor
bidirect
transplant
indic
allohsct
mainli
amlmd
pt
pt
tnhlctcl
pt
mean
overal
surviv
group
patient
undergo
major
mismatch
minor
mismatch
hsct
month
ci
month
ci
month
ci
respect
nrm
three
group
significantli
differ
point
estim
year
respect
wherea
signific
differ
observ
relaps
rate
graft
failur
incid
although
statist
differ
incid
acut
grade
iiiiv
gvhd
twice
high
patient
transplant
minor
donor
ident
group
vs
follow
transplant
prc
transfus
requir
significantli
higher
major
mismatch
transplant
patient
median
vs
margin
posit
correl
antidonor
ab
igg
titer
measur
prior
hsct
total
number
prc
transfus
first
year
follow
transplant
observ
one
case
prca
occur
woman
transplant
male
hlaident
sibl
use
peripher
blood
stem
cell
sourc
follow
myeloabl
condit
aml
first
complet
remiss
antia
igg
isoagglutinin
titer
prior
transplant
first
year
post
transplant
patient
requir
total
prc
transfus
gradual
resolut
occur
introduct
danazol
treatment
conclus
patient
cohort
major
minor
mismatch
associ
significantli
higher
nrm
major
mismatch
associ
higher
prc
transfus
requir
frequent
occur
sever
acut
gvhd
also
suggest
minor
transplant
altogeth
result
suggest
allohsct
outcom
may
significantli
affect
blood
group
mismatch
disclosur
noth
declar
background
attma
sever
endotheli
injuri
complic
may
involv
intestin
vasculatur
intestin
tma
could
fatal
missdiagnos
clinic
patholog
criteria
differenti
intestin
gvhd
need
aim
studi
analyz
incid
histolog
characterist
intestin
tma
patient
diagnos
system
tma
method
analyz
incid
tma
patient
underw
allohsct
institut
januari
tma
diagnosi
base
ho
criteria
patholog
review
biopsi
patient
endoscopi
perform
day
day
diagnosi
tma
suspici
gvhd
review
perform
pathologist
expert
gvhd
examin
biopsi
search
hystopatholog
featur
gvhd
tma
viral
infect
diagnosi
gastrointestin
gvhd
stablish
accord
mcdonald
sale
criteria
intestin
tma
diagnosi
stablish
warren
et
al
criteria
result
patient
diagnos
tma
transplant
characterist
tma
data
patient
system
tma
shown
imag
patient
tma
diagnos
prior
simultan
acut
gvhd
grade
iiiiv
gastrointestin
gvhd
intestin
tma
report
patient
diagnosi
wherea
review
base
warren
criteria
perform
patient
pathologist
found
least
criteria
endotheli
damag
patient
warren
criteria
found
frequent
featur
endotheli
cell
swell
perivascular
mucos
hemorrhag
review
hystolog
featur
biopsi
shown
tabl
imag
regard
gvhd
found
patient
diagnosi
patholog
review
median
followup
month
patient
system
tma
dead
death
relat
tma
tma
tma
gvhd
tmainfect
patient
warren
criteria
patholog
review
poor
outcom
compar
patient
less
criteria
aliv
vs
month
conclus
intestin
tma
lifethreaten
underdiagnos
entiti
patient
patient
diagnos
intestin
tma
found
patient
endotheli
damag
gastrointestin
biopsi
patholog
review
gvhd
histolog
criteria
present
patient
mainli
histolog
grade
iii
prognosi
patient
poor
pathologist
efford
diagnos
entiti
guarrant
disclosur
noth
disclosur
strategi
reduc
neutropen
fever
hospit
readmiss
multipl
myeloma
patient
manag
home
autolog
stem
cell
transplant
background
neutropen
fever
nf
frequent
caus
readmiss
outpati
autolog
stem
cell
transplant
asct
program
home
model
multipl
myeloma
patient
ad
primari
prophylaxi
ceftriaxon
decreas
incid
fever
aplasia
phase
aim
studi
analyz
addit
two
strategi
reduc
noninfecti
nf
withdraw
gcsf
addit
primari
prophylaxi
engraft
syndrom
corticosteroid
asct
method
januari
august
myeloma
patient
manag
athom
sinc
day
asct
condit
patient
receiv
prophylaxi
quinolon
fluconazol
aerol
pentamidin
lowdos
acyclovir
hv
ceftriaxon
sinc
day
patient
classifi
group
group
gcsf
sinc
day
without
corticosteroid
group
b
gcsf
corticosteroid
group
c
gcsf
prednison
mgkgday
sinc
day
granulocyt
recoveri
firstlin
therapi
home
nf
piperacillintazobactam
iv
use
portabl
intermitt
infus
pump
fever
indic
immedi
medic
consult
patient
present
sign
focal
infect
sever
sepsi
admit
indic
readmiss
willing
patient
caregiv
uncontrol
nausea
vomit
diarrhoea
mucos
requir
total
parenter
nutrit
iv
morphic
result
main
characterist
patient
outcom
shown
tabl
differ
group
regard
age
gender
immunolog
subtyp
respons
asct
hctci
cell
dose
infus
patient
advanc
diseas
iss
iii
group
c
compar
group
vs
durat
neutropenia
longer
group
receiv
gcsf
day
b
day
c
day
p
compar
group
group
c
observ
incid
nf
readmiss
rate
lower
group
c
nf
vs
rel
risk
reduct
number
need
treat
readmiss
vs
respect
cumul
incid
nf
group
group
b
group
c
nonadministr
gcsf
addit
prophylact
corticosteroid
modifi
incid
grade
mucos
first
day
durat
fever
number
bacteri
infect
document
multivari
analysi
combin
gcsf
corticosteroid
maintain
protect
effect
develop
nf
hospit
readmiss
respect
conclus
nonus
gcsf
addit
prophylact
corticosteroid
mm
patient
manag
home
asct
minim
incid
noninfecti
fever
optim
hospit
resourc
reduc
hospit
readmiss
disclosur
noth
declar
background
antibodi
titer
vaccineprevent
diseas
declin
year
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
revaccin
therefor
consid
best
practic
tri
offer
hsct
recipi
level
protect
vaccin
prevent
diseas
gener
popul
data
literatur
avail
concern
vaccinerel
problem
hsct
recipi
perform
farmacovigil
evalu
cohort
allotranspl
patient
follow
clinic
year
period
method
octob
novemb
administ
list
recommend
vaccin
hsct
recipi
attend
routin
patient
clinic
fulfil
follow
criteria
cell
b
cell
antibodi
infus
month
ivig
therapi
month
activ
sever
graftversushostdiseas
gvhd
chemotherapi
biolog
therapeut
agent
go
vaccin
suggest
influenza
pneumococc
conjug
polio
inactiv
polio
vaccin
diphteria
tetanu
acellular
pertussi
hepat
b
hepat
haemophilu
influenza
type
b
meningococc
quadrival
human
papillomaviru
meningococc
b
measlesmumpsrubella
mmr
varicella
live
vaccin
mmr
varicella
recommend
year
hsct
patient
chronic
gvhd
patient
ask
take
list
local
health
facil
order
vaccin
inject
vaccin
tabl
arrang
dose
alreadi
receiv
receiv
check
vaccin
tabl
visit
monitor
potenti
side
effect
gvhd
statu
month
first
vaccin
inject
result
twentynin
patient
evalu
tabl
without
gvhd
chronic
gvhd
mild
moder
sever
median
time
hsct
month
median
number
vaccin
receiv
regard
patient
without
chronic
gvhd
experienc
fever
vaccin
inject
develop
transient
mild
reduct
platelet
count
patient
report
headach
otalgia
vaccin
inject
anoth
one
transient
joint
pain
patient
present
sign
mouth
chronic
gvhd
score
nih
transaminas
increas
grade
accord
world
health
organ
toxic
scale
month
first
vaccin
dose
cyclosporin
dose
augment
regard
patient
chronic
gvhd
experienc
fever
vaccin
inject
patient
mild
chronic
gvhd
mouth
present
hepat
flare
two
three
month
first
vaccin
dose
respect
case
new
increas
cyclosporin
methylprednisolon
dose
determin
progress
normal
liver
enzym
conclus
data
show
vaccin
global
well
toler
hsct
recipi
even
suffer
chronic
gvhd
howev
close
monitor
warrant
order
better
evalu
possibl
vaccin
side
effect
set
patient
background
allogen
hsct
improv
surviv
aml
patient
age
year
age
compar
chemotherapi
alon
haematopoiet
stem
cell
transplant
comorbid
index
hctci
ebmt
score
predict
nonrelaps
mortal
overal
surviv
yet
littl
known
whether
qol
preserv
patient
group
whether
hctci
perform
score
prebmt
correl
qol
post
allohsct
method
conduct
retrospect
analysi
patient
year
older
underw
ric
allohsct
univers
hospit
wale
cardiff
septemb
decemb
hctci
karnofski
perform
score
kp
ebmt
score
calcul
prior
transplant
qol
measur
use
fact
bmt
version
questionnair
complet
month
post
transplant
patient
group
time
point
differ
perform
indic
allow
group
comparison
compound
sub
score
use
mannwhitney
u
test
result
patient
includ
studi
median
age
year
rang
patient
characterist
includ
condit
donor
type
pretranspl
hctci
kp
score
summaris
tabl
year
year
overal
surviv
os
patient
cohort
respect
hctci
vs
significantli
associ
poorer
bmtrelat
qol
domain
month
gener
qol
domain
month
posttranspl
ebmt
score
show
correl
qol
paramet
patient
kp
vs
show
signific
differ
gener
bmtrelat
qol
month
qol
domain
month
symptomrel
qol
gener
qol
bmtrelat
qol
importantli
neither
hctci
kp
pretranspl
predict
qol
month
post
transplant
conclus
patient
select
key
ensur
maximum
benefit
allohsct
term
overal
surviv
also
regard
qol
survivorship
note
patient
hctci
kp
significantli
poorer
qol
month
post
allohsct
qol
recov
month
post
transplant
signific
differ
longer
seen
data
show
select
aml
patient
age
year
good
perform
statu
low
comorbid
index
favour
outcom
achiev
good
qol
maintain
throughout
post
transplant
period
background
advanc
allosct
technolog
support
care
use
reduc
intens
condit
regimen
older
patient
led
signific
improv
longterm
surviv
transplant
survivor
elev
probabl
late
morbid
mortal
includ
abnorm
phosphocalc
metabol
bone
diseas
rapid
progress
bone
loss
occur
within
first
month
transplant
follow
slow
process
recoveri
bone
loss
persist
month
bone
fractur
worsen
qualiti
life
allosct
survivor
real
burden
diseas
unknown
object
studi
ascertain
preval
bone
patholog
vertebr
fractur
earli
transplant
center
method
retrospect
observ
studi
fortynin
patient
femal
median
age
rang
underw
allosct
includ
studi
period
month
transplant
may
preand
posttranspl
risk
factor
associ
bone
diseas
record
age
year
femal
sex
menopaus
hormon
replac
therapi
previou
treatment
steroid
previou
fractur
weight
kg
bmi
low
physic
activ
low
calcium
intak
smoke
alcohol
intak
histori
femor
fractur
parent
patient
laboratori
data
includ
serum
calcium
pth
lumbar
femor
bmd
dxa
spinal
xray
also
evalu
vertebr
fractur
defin
reduct
anterior
middl
posterior
high
vertebr
bodi
result
identifi
vertebr
fractur
patient
five
patient
fractur
prior
transplant
patient
present
de
novo
vertebr
fractur
follow
transplant
therefor
preval
de
novo
postranspl
fractur
fractur
asymptomat
time
diagnosi
patient
vertebr
fractur
presct
risk
factor
median
risk
factor
presct
rang
frequent
low
calcium
intak
steroid
exposur
presenc
previou
fractur
menopaus
patient
fractur
less
risk
factor
pretph
ad
new
risk
factor
transplant
mainli
steroid
treatment
fortyfour
patient
vitamin
insuffici
osteopenia
osteoporosi
vitamin
insuffici
bone
diseas
frequent
women
men
vs
vitamin
vs
osteopenia
vs
osteoporosi
vs
vertebr
fractur
respect
conclus
preval
posttranspl
bone
diseas
vertebr
fractur
seri
high
fractur
appear
de
novo
allosct
asymptomat
diagnos
xray
patient
present
vertebr
fractur
frequent
risk
factor
identifi
presct
patient
undergo
allosct
bone
health
assess
earli
treatment
indic
start
prevent
therapi
avoid
bone
loss
fractur
measur
physic
exercis
vitamin
calcium
supplement
dxa
spinal
xray
baselin
follow
transplant
also
highli
recommend
disclosur
receiv
grant
dkmsspain
foundat
author
noth
declar
use
gcsf
select
patient
autolog
stem
cell
transplant
associ
low
incid
engraft
syndrom
background
use
gcsf
autolog
stem
cell
transplant
asct
acceler
neutrophil
recoveri
howev
relat
increas
risk
engraft
syndrom
es
develop
studi
reason
routin
prescrib
gcsf
asct
use
patient
signific
complic
enterocol
sever
sepsi
atrial
fibril
stem
cell
infus
main
object
studi
evalu
incid
es
patient
receiv
asct
monoclon
gammopathi
mg
nonhodgkin
lymphoma
nhl
hodgkin
lymphoma
hl
receiv
gcsf
need
secondari
object
evalu
differ
engraft
day
well
length
inpati
stay
method
retrospect
analyz
patient
mg
lymphoma
underw
asct
condit
high
dose
melphalan
mgm
beam
respect
center
specif
clinic
featur
es
accord
spitzer
maiolino
criteria
evalu
day
day
engraft
statist
analysi
perform
spss
v
result
thirtyon
patient
mg
patient
lymphoma
analyz
median
age
transplant
year
patient
male
median
prior
line
treatment
patient
gm
lymphoma
respect
tabl
show
mobil
gcsf
plerixafor
perform
patient
chemotherapi
gcsf
plerixafor
patient
median
x
kg
cell
infus
eleven
patient
receiv
gcsf
due
infect
enterocol
listeriosi
acut
hepat
septic
shock
atrial
fibril
fibrilloflutt
median
time
sct
first
day
gcsf
day
median
time
gcsf
treatment
day
patient
receiv
gcsf
show
short
time
neutrophil
engraft
l
day
vs
day
p
longer
durat
hospit
day
vs
day
p
nonrelaps
mortal
day
es
diagnos
patient
amyloidosi
multipl
myeloma
plasmablast
lymphoma
statist
differ
incid
es
patient
receiv
gcsf
patient
analyz
diseas
es
appear
patient
receiv
gcsf
lymphoma
group
none
patient
mg
receiv
gcsf
develop
find
statist
differ
patient
develop
es
age
year
vs
year
length
hospit
day
vs
day
number
x
kg
cell
infus
vs
conclus
use
gcsf
select
patient
associ
low
incid
es
studi
confirm
use
gcsf
acceler
neutrophil
recoveri
unclear
increas
incid
es
especi
patient
lymphoma
imag
background
graft
failur
one
problem
allohsct
gvhd
relaps
problem
graft
failur
becom
signific
due
increas
number
allohsct
ric
condit
regimen
haploident
hlamismatch
unrel
donor
role
cell
graft
failur
well
known
report
impact
tmemori
cell
subset
count
antithymocyt
globulin
atg
administr
primari
graft
failur
allohsct
method
sixteen
patient
acut
leukemia
transplant
nation
research
center
hematolog
includ
prospect
studi
patient
receiv
hors
atg
dose
mgkgday
day
allohsct
gvhd
prophylaxi
balanc
factor
could
affect
engraft
detail
patient
characterist
list
tabl
peripher
blood
sampl
collect
day
allohsct
atg
inject
edtatub
flow
cytometri
analysi
perform
bd
fac
canto
ii
becton
dickinson
usa
defin
tmemori
subset
tnaiv
tstem
cell
memori
tnvscm
tcentral
memori
tcm
ttransit
memori
ttm
teffector
memori
tem
ttermin
effector
tte
among
tcell
sysmex
use
calcul
absolut
count
differ
tcell
subset
mannwhitney
u
test
use
nonparametr
data
analysi
two
group
fisher
exact
test
use
tabl
pvalu
less
consid
statist
signific
result
influenc
tmemori
cell
subset
count
atg
administr
primari
graft
failur
shown
figur
accord
data
high
absolut
number
associ
primari
graft
failur
conclus
base
find
high
absolut
number
could
one
prognost
factor
primari
graft
failur
allohsct
optim
atg
dose
due
recipi
absolut
tmemori
cell
subset
count
atg
administ
may
prevent
graft
failur
improv
posttranspl
result
background
upper
gastrointestin
graftversushost
diseas
gi
gvhd
increasingli
recognis
entiti
follow
allogen
stem
cell
transplant
sct
budesonid
wide
use
inflammatori
bowel
condit
also
found
benefici
gi
gvhd
major
benefit
budesonid
attribut
poor
absorpt
extens
firstpass
metabol
via
cytochrom
cyp
translat
less
system
steroidrel
effect
howev
transplant
patient
often
expos
multipl
drug
among
agent
act
inhibitor
therefor
increas
budesonid
bioavail
might
lead
system
toxic
azol
antifung
drug
probabl
common
concomitantli
use
inhibitor
transplant
recipi
method
review
allogen
sct
record
patient
treat
oral
budesonid
gi
gvhd
transplant
centr
retrospect
aim
work
assess
develop
adren
suppress
without
clinic
featur
iatrogen
cush
syndrom
standard
dose
budesonid
mg
three
time
day
patient
receiv
prednisolon
glucocorticosteroid
avail
serum
cortisol
level
measur
exclud
result
analys
identifi
four
allogen
sct
patient
adren
suppress
diagnos
undetect
serum
cortisol
level
oral
budesonid
treatment
patient
two
develop
iatrogen
cush
syndrom
patient
treat
inhibitor
concomitantli
clarithromycin
fluconazol
clarithomycin
voriconazol
develop
rapid
within
week
symptom
includ
morpholog
featur
moon
face
high
blood
pressur
weight
gain
peripher
oedema
proxim
myopathi
symptom
resolv
gradual
follow
cessat
azol
antifung
agent
gradual
wean
budesonid
conclus
although
singl
agent
budesonid
treatment
given
gi
gvhd
rare
associ
system
side
effect
patient
azol
antifung
drug
macrolid
antibiot
higher
risk
system
toxic
due
drug
interact
patient
allerg
penicillin
receiv
macrolidebas
prophylaxi
especi
vulner
knowledg
number
case
report
literatur
system
effect
oral
budesonid
transplant
recipi
less
observ
support
previou
report
potenti
oral
budesonid
induc
system
effect
therefor
advis
care
monitor
patient
treat
budesonid
combin
inhibitor
includ
antimicrobi
agent
routin
use
sct
disclosur
none
implement
strategi
overcom
barrier
establish
consolid
hematopoiet
stem
cell
transplant
program
develop
countri
background
nation
institut
medic
scienc
nutrit
salvador
zubiran
nation
health
institut
locat
mexico
citi
although
mexico
consid
uppermiddl
incom
countri
popul
live
poverti
without
health
care
coverag
patient
within
social
stratum
refer
institut
first
hematopoiet
stem
cell
transplant
hsct
mexico
perform
institut
year
hsct
sporad
perform
show
poor
overal
surviv
os
high
nonrelaps
mortal
nrm
outcom
result
unstructur
hsct
program
limitedresourc
patient
low
socioeconom
statu
pauciti
populationadapt
procedur
accord
result
decis
establish
hsct
program
made
therefor
order
set
success
hsct
program
implement
financi
medic
strategi
necessari
object
studi
describ
barrier
implement
strategi
establish
hsct
program
mexico
along
outcom
patient
undergo
procedur
throughout
reorgan
program
method
studi
health
servic
research
barrier
detect
base
result
hsct
program
shown
tabl
show
financi
medic
research
strategi
implement
barrier
result
novemb
novemb
hsct
perform
patient
institut
hsct
autolog
forti
one
patient
underw
hsct
patient
male
median
age
year
rang
frequent
underli
diseas
autohsct
lymphoma
nonseminomat
germ
cell
tumor
multipl
myeloma
acut
leukemia
aplast
anemia
myelodysplast
syndrom
frequent
diagnosi
patient
undergo
allohsct
acut
leukemia
frequent
diagnosi
patient
undergo
haploident
hsct
acut
chronic
gvhd
present
grade
iii
limit
respect
allohsct
nrm
respect
nrm
autohsct
os
auto
allohsct
respect
conclus
futur
perspect
hsct
program
includ
acquisit
fund
unrel
donor
improv
outcom
patient
undergo
haploident
hsct
increas
number
inpati
room
conclud
despit
pauciti
resourc
limit
implement
financi
medic
research
strategi
shown
barrier
effect
overcom
develop
countri
order
establish
consolid
nation
renown
hsct
program
provid
good
outcom
patient
disclosur
none
author
conflict
interest
disclos
effect
protect
buffer
daili
stress
relationship
qualiti
dyad
follow
hematopoiet
stem
cell
transplant
result
daili
process
methodolog
malgorzata
sobczykkruszelnicka
aleksandra
kroemek
zuzanna
kwissagajewska
sebastian
giebel
background
cancerrel
support
commun
eg
protect
buffer
may
impact
risk
psycholog
relationship
distress
patient
follow
hematopoiet
stem
cell
transplant
hsct
caregiv
previou
studi
reveal
protect
buffer
ie
hide
one
concern
deni
one
worri
mix
effect
benefici
protect
person
costli
especi
person
use
unrel
dyadic
wellb
howev
littl
evid
link
dyadic
protect
buffer
distress
use
daili
process
methodolog
assess
relationship
daili
protect
buffer
sameand
nextday
stress
relationship
qualiti
patientcaregiv
dyad
follow
hsct
whether
similar
complementar
protect
buffer
dyad
adapt
method
two
hundr
patient
first
autolog
allogen
hsct
caregiv
spous
anoth
rel
independ
complet
measur
daili
protect
buffer
daili
relationship
qualiti
daili
stress
consecut
even
discharg
actorpartnerinterdepend
model
ie
partner
caregiv
report
regard
support
commun
distress
studi
use
test
studi
hypothes
result
patient
caregiv
multilevel
structur
equat
model
show
signific
posit
relationship
daili
protect
buffer
sameday
relationship
qualiti
associ
protect
buffer
sameday
stress
level
neg
nextday
analys
patientreport
protect
buffer
relat
patient
higher
relationship
qualiti
wherea
caregiverreport
protect
buffer
increas
patient
daili
stress
complementar
protect
buffer
relat
higher
immedi
sameday
relationship
qualiti
patient
caregiv
benefit
similar
delay
effect
although
patient
conclus
contrari
previou
studi
protect
buffer
rather
benefici
effect
dyad
follow
hsct
protect
partner
relationship
reveal
neg
emot
powerless
relat
cost
parti
find
suggest
effect
daili
protect
buffer
dyad
follow
hsct
depend
support
time
sameor
nextday
effect
differ
parti
patient
seem
benefit
similar
protect
buffer
caregiv
complementar
fit
patient
caregiv
support
commun
ought
taken
consider
practic
approach
disclosur
noth
declar
viru
reactiv
low
dose
cell
associati
secondari
poor
graft
function
within
first
day
allogen
stem
cell
transplant
yuqian
sun
xiaojun
huang
background
secondari
poof
graft
function
spgf
defin
secondari
cytopenia
initi
engraft
hsct
shown
associ
poor
prognosi
howev
report
incid
risk
factor
outcom
spgf
method
patient
receiv
transplant
peke
univers
peopl
hospiti
januari
decemb
retrospect
review
fulfil
follow
condit
diagnos
acut
leukemia
myelodysplast
syndrom
receiv
allosct
either
match
sibl
donor
msd
haploident
relat
donor
hid
pgf
defin
persist
neutropenia
l
thrombocytopenia
platelet
l
andor
hemoglobin
gl
least
consecut
day
transfusiondepend
associ
hypoplasticaplast
bone
marrow
bm
complet
donor
chimer
without
concurr
graftversushost
diseas
gvhd
diseas
relaps
primari
pgf
defin
failur
achiev
initi
engraft
day
transplant
secondari
pgf
defin
fulfil
criteria
initi
engraft
hsct
result
januari
decemb
patient
receiv
transplant
peke
univers
peopl
hospiti
retrospect
review
among
patient
achiev
initi
engraft
patient
develop
spgf
cumul
incid
spgf
day
median
time
secondari
pgf
day
transplant
low
median
cell
dose
hr
ci
ebv
reactiv
hr
ci
cmv
reactiv
hr
ci
identifi
independ
risk
factor
spgf
signific
differ
pgf
incid
msd
group
hid
patient
overal
surviv
patient
spgf
year
transplant
significantli
poor
patient
ggf
versu
p
conclus
conclus
spgf
develop
patient
allosct
especi
patient
cmv
ebv
reactiv
infus
low
dose
cell
prognosi
spgf
still
poor
due
lack
standard
treatment
disclosur
conflict
interet
thiotepa
treosulfan
busulfan
base
condit
significantli
gonadotox
treosulfan
previou
studi
suggest
busulfan
result
longterm
gonad
toxic
previou
studi
compar
gonad
toxic
outcom
treatment
busulfan
treosulfan
newer
agent
similar
marrow
toxic
busulfan
reduc
nonmarrow
toxcitiy
aim
determin
whether
differ
pubert
fertil
outcom
paediatr
patient
treat
treosulfan
compar
busulfan
method
inclus
criteria
patient
receiv
either
busulfan
treosulfan
treosulfan
thiotepa
one
hct
age
year
august
elig
patient
review
clinic
part
routin
followup
thu
research
ethic
approv
requir
follic
stimul
hormon
luteinis
hormon
oestradiol
pubert
histori
note
ovarian
reserv
estim
femal
patient
measur
serum
antimullerian
hormon
amh
male
patient
serum
testosteron
measur
also
offer
semen
analysi
result
thirtyf
patient
met
inclus
criteria
twentyf
want
review
seventeen
femal
eight
male
mean
age
hct
year
mean
age
review
year
mean
year
sinc
hct
year
femal
patient
treat
busulfan
treosulfan
thiotepa
minim
amh
none
patient
regular
period
femal
treat
treosulfan
normal
amh
regular
period
without
need
hormon
replac
four
male
patient
opt
semen
analysi
significantli
reduc
sperm
count
conclus
result
suggest
femal
treat
treosulfan
minim
reduct
ovarian
reserv
compar
condit
regimen
casu
signific
compromis
although
small
studi
thu
suitabl
statist
analysi
clinic
find
mark
futur
studi
investig
optim
dose
treosulfan
could
use
achiev
bone
marrow
engraft
limit
longterm
effect
fertil
disclosur
background
autolog
allogen
hematopoiet
stem
cell
transplant
hsct
potenti
cur
treatment
hematolog
malign
patient
relat
complic
may
need
admiss
intens
care
unit
icu
specif
therapi
organ
support
mortal
risk
factor
support
care
princip
caus
admiss
icu
describ
cohort
patient
pt
method
retrospect
studi
pt
male
median
age
year
rang
underw
allohsct
center
juli
octob
two
hundr
twentyseven
pt
receiv
autolog
hsct
autohct
allogen
hsct
allohsct
unrel
donor
ident
sibl
remaind
mismatch
relat
donor
twentythre
pt
admit
icu
transplant
procedur
admiss
result
fifteen
pt
male
median
age
year
rang
patient
baselin
diseas
multipl
myeloma
lymphoma
lymphoma
acut
lymphoblast
leukemia
myelodisplas
syndrom
solid
tumor
acut
myeloblast
leukemia
fifteen
pt
receiv
autohsct
allohsct
unrel
donor
allohsct
ident
sibl
remaind
haploident
hsct
autohsct
pt
allohsct
admit
icu
median
stay
icu
day
rang
reason
admiss
respiratori
insuffici
septic
shock
renal
insuffici
multiorgan
failur
twentyon
pt
requir
respiratori
support
nasal
cannula
oxygen
mask
cm
noninvas
mechan
ventil
nimv
invas
mechan
ventil
imv
fourteen
pt
need
inotrop
agent
shock
treatment
final
pt
requir
substitut
renal
therapi
hemodialysi
haemofiltr
hdhf
eleven
pt
die
male
median
age
year
rang
ten
need
imv
treat
inotrop
agent
patient
requir
hdhf
die
imv
treatment
inotrop
agent
associ
icu
mortal
respect
conclus
seri
pt
need
admiss
icu
present
mortal
rate
approxim
differ
preval
icu
admiss
regard
hsct
donor
main
reason
admiss
respiratori
failur
imv
requir
pt
imv
treatment
inotrop
agent
associ
icu
mortal
earli
identif
pt
risk
icu
admiss
could
benefici
impact
surviv
improv
disclosur
noth
declar
associ
thrombot
risk
factor
venooclus
diseas
childhood
allogen
hematopoiet
stem
cell
transplant
background
venooclus
diseas
vod
major
complic
hematopoiet
stem
cell
transplant
hsct
studi
level
fibrinolyt
factor
especi
plasminogen
activ
level
found
associ
vod
howev
littl
known
relationship
thrombophilia
risk
factor
vod
studi
aim
investig
associ
major
thrombophil
gene
mutat
vod
pediatr
hsct
patient
method
review
retrospect
patient
vod
underw
hsct
ankara
pediatr
pediatr
hematologyoncolog
train
educ
hospit
bone
marrow
transplant
unit
turkey
fiftyon
patient
develop
vod
transplant
studi
period
accept
control
group
evalu
plasma
homocystein
lipoprotein
level
protein
c
activ
antigen
level
factor
v
mutat
prothrombin
mutat
methylenetetrahydrofolatereductas
mthfr
mutat
plasminogen
activ
polymorph
hsct
also
evalu
patient
hospit
file
note
demograph
valu
complic
hsct
statist
investig
done
spss
statist
window
p
accept
signific
result
differ
control
vod
group
regard
age
sex
diagnosi
donor
type
condit
regimen
hsc
sourc
hla
type
differ
group
accord
homocystein
lipoprotein
protein
c
activ
antigen
level
find
relat
genet
variat
thrombophilia
vod
tabl
vod
group
patient
acut
graft
versu
host
diseas
agvhd
control
group
patient
agvhd
febril
episod
frequent
vod
group
compar
control
respect
vs
overal
surviv
vod
group
control
group
diseas
free
surviv
also
differ
vod
control
group
respect
vs
conclus
literatur
recent
studi
show
higher
level
patient
vod
howev
studi
find
relationship
congenit
thrombophilia
factor
vod
new
studi
larger
sampl
group
necessari
better
evalu
associ
congenit
thrombophilia
factor
vod
disclosur
noth
declar
differ
strategi
chemotherapyinduc
nausea
vomit
cinv
prevent
hematolog
patient
receiv
autolog
hematopoiet
stem
cell
transplant
singl
center
experi
ilaria
cutini
riccardo
boncompagni
chiara
nozzoli
antonella
gozzini
stefano
guidi
chiara
innocenti
massimo
di
gioia
lorenzo
tofani
riccardo
saccardi
background
despit
improv
pharmacolog
control
cinv
still
repres
major
problem
patient
undergo
hematopoiet
stem
cell
transplant
hsct
present
comparison
two
pharmacolog
strategi
prevent
cinv
multipl
myeloma
mm
hodgkin
hl
nonhodgkin
lymphoma
nhl
patient
receiv
autolog
hsct
institut
method
januari
juli
retrospect
analyz
consecut
patient
median
age
year
diagnos
mm
hl
nhl
underw
autolog
hsct
follow
melphalan
mgsqm
beamfeam
condit
regimen
respect
first
patient
receiv
cinv
prophylaxi
palonosetron
iv
dexamethason
mg
die
regimen
whilst
follow
administ
fosaprepit
iv
ondansetron
iv
dexamethason
mg
die
regimen
b
cinv
prophylaxi
administ
day
melphalan
infus
day
form
transplant
emesi
breakthrough
treat
alizaprid
metoclopramid
nausea
vomit
assess
ctcae
score
system
categor
variabl
compar
pearson
chisquar
test
result
overal
incid
nausea
grade
grade
grade
respect
regimen
shown
grade
grade
respect
regimen
b
grade
grade
grade
respect
pearson
chisquar
test
show
differ
group
overal
observ
vomit
grade
grade
grade
regimen
grade
grade
grade
regimen
b
grade
grade
condit
regimen
nt
signific
impact
either
nausea
vomit
patientsyoung
median
yr
report
higher
incid
nausea
relat
cinv
treatment
vomit
vs
multivari
analysi
overal
incid
nausea
relat
age
younger
patient
higher
probabl
develop
nausea
p
whilst
higher
incid
vomit
relat
regimen
p
previous
report
nausea
p
smoke
habit
conclus
regimen
equal
effect
nausea
control
howev
regimen
b
evidenc
better
vomit
control
find
particularli
relev
center
polici
includ
earli
discharg
program
therefor
improv
patient
qualiti
life
procedur
costeffect
clinic
background
patient
underw
allogen
hematopoiet
cell
transplant
hct
challeng
medic
psycholog
social
complic
support
group
might
help
hctsurvivor
cope
challeng
howev
exist
literatur
posthct
support
group
scarc
moreov
data
professionallyfacilit
support
group
exist
aim
project
establish
professionallyfacilit
support
group
assess
discuss
topic
method
patient
receiv
allogen
hct
adult
stem
cell
transplant
program
univers
clinic
mannheim
invit
particip
professionallyfacilit
support
group
addit
spous
life
partner
invit
theologian
also
physician
serv
facilit
function
within
transplant
team
format
group
unstructur
without
rule
regard
regular
attend
facilit
provid
topic
curriculum
first
year
group
met
everi
day
follow
monthli
schedul
fifth
meet
attend
discuss
topic
minut
facilit
content
minut
analys
combin
induct
deduct
approach
particip
provid
inform
consent
studi
result
altogeth
patient
femal
male
spouseslif
partner
femal
male
particip
patient
spous
attend
one
meet
among
particip
meet
median
time
particip
month
median
count
particip
eight
particip
attend
meet
longer
one
year
longer
three
year
sex
differ
respect
frequenc
durat
particip
howev
frequenc
particip
decreas
significantli
longer
particip
attend
meet
group
meet
facilit
record
themat
differ
contribut
discuss
divid
distinct
topic
topic
group
main
categori
medic
topic
b
privat
life
environ
c
human
relationship
physic
mental
condit
e
support
group
eight
categori
complianc
econom
issu
religion
sexual
death
die
support
cope
object
need
otherwis
specifi
issu
could
group
one
main
categori
frequent
issu
medic
topic
human
relationship
physic
mental
condit
privat
life
environ
financi
issu
support
group
support
cope
object
need
noteworthi
death
die
rare
topic
sexual
never
mention
conclus
knowledg
first
prospect
systemat
analysi
professionallyfacilit
support
group
hctsurvivor
data
might
help
establish
support
group
identifi
psychosoci
need
patient
target
specif
support
disclosur
noth
declar
background
endotheli
damag
associ
inflammatori
complic
appear
earli
hsct
sinusoid
obstruct
syndrom
acut
gvhd
engraft
syndrom
es
inflammatori
condit
diagnos
maiolino
clinic
score
potenti
es
exhibit
high
morbid
mortal
especi
autologoushsct
multipl
myeloma
mm
patient
sinc
introduct
new
drug
proteasom
inhibitor
immunomodulatori
drug
imid
object
present
studi
evalu
es
associ
endotheli
dysfunct
patient
mm
underw
autohsct
method
includ
six
patient
mm
receiv
induct
treatment
includ
new
drug
consolid
respons
autologoushsct
analys
compar
effect
incub
endotheli
cell
vitro
serum
sampl
patient
es
vs
es
serum
sampl
collect
pre
day
transplant
addit
sampl
collect
es
onset
discharg
day
es
group
endotheli
cell
hmec
cultur
expos
media
contain
serum
patient
cell
growth
control
morpholog
express
adhes
receptor
cell
surfac
analys
immunofluoresc
activ
inflamm
relat
mapk
signal
pathway
evalu
sdspage
western
blot
result
exposur
hmec
monolay
sera
patient
develop
es
onset
day
result
increas
express
cell
surfac
higher
observ
sera
patient
develop
es
discharg
day
label
area
vs
respect
addit
experi
sera
patient
develop
es
express
cell
expos
sera
day
reduc
respect
observ
sera
day
probabl
due
corticosteroid
use
prophylaxi
centr
reduct
observ
es
patient
regard
phosphoryl
significantli
higher
cell
expos
sera
es
patient
respons
sera
patient
develop
es
conclus
increas
express
adhes
receptor
surfac
intracellular
activ
endotheli
cell
expos
sera
patient
develop
es
indic
exist
endotheli
activ
associ
es
interestingli
prophylaxi
es
corticosteroid
seem
less
effect
patient
develop
es
patient
develop
complic
result
need
valid
higher
number
patient
modif
addit
marker
endotheli
dysfunct
investig
disclosur
gonzalo
honoraria
gilead
grant
jazz
pharmaceut
author
disclosur
comment
associ
uric
acid
level
allogen
haematopoet
stem
cell
transplant
transplant
outcom
singl
centr
experi
background
uric
acid
ua
known
endogen
danger
signal
activ
nodlik
receptor
protein
nlrp
inflasomeua
releas
injur
cell
condit
allogen
stem
cell
transplant
hsct
preclin
studi
demonstr
inflasomemedi
product
regul
graftversushost
diseas
gvhd
ua
role
inflamm
gvhd
unclear
discord
report
literatur
potenti
protect
role
ua
gvhd
hsct
method
perform
retrospect
studi
assess
associ
serum
ua
level
preand
post
tabl
tabl
result
characterist
patient
shown
tabl
median
age
year
rang
patient
male
twentyseven
patient
receiv
low
dose
atg
part
gvhd
prophylaxi
allopurinol
day
start
condit
therapi
day
median
level
ua
mg
dl
condit
mgdl
day
mgdl
day
mgdl
day
impact
ua
level
os
time
hsct
ua
level
day
associ
higher
ci
relaps
year
ci
ua
level
mgdl
ci
ua
level
mgdl
p
trend
higher
ci
grade
iiiv
agvhd
subgroup
patient
treat
atg
ua
mgdl
vs
p
day
higher
nrm
ua
day
vs
conclus
studi
ua
level
show
impact
os
tendenc
ci
grade
iiiv
agvhd
grade
iiiv
nrm
subgroup
patient
treat
atg
surprisingli
high
level
ua
day
hsct
associ
signific
higher
incid
relaps
disclosur
dkm
foundat
instituto
carlo
iii
grc
generalitat
de
catalunya
background
venoocclus
diseas
vod
earli
uncommon
seriou
complic
stem
cell
transplant
sct
associ
high
morbid
mortal
defibrotid
licens
treatment
vod
time
start
treatment
tst
affect
outcom
minor
differ
exist
seattl
baltimor
classic
ebmt
criteria
may
trigger
differ
start
point
treatment
late
onset
vod
day
less
recognis
hypothes
may
wors
outcom
longer
time
diagnosi
limit
treatment
option
across
differ
healthcar
system
method
electron
patient
record
bmt
centr
pharmaci
databas
review
timepoint
clinic
biochem
manifest
vod
diagnosi
tst
surviv
longterm
outcom
analys
result
patient
underw
allogen
sct
develop
vod
includ
paediatr
case
none
autolog
sct
patient
develop
vod
paediatr
autolog
sct
patient
analys
adult
patient
develop
vod
median
age
year
rang
develop
day
patient
lateonset
vod
per
ebmt
criteria
rang
day
case
class
sever
moder
vod
patient
receiv
defibrotid
diagnosi
patient
within
day
patient
day
patient
receiv
treatment
day
overal
mortal
cohort
patient
earli
onset
vod
patient
lateonset
vod
die
death
die
liver
failur
patient
vod
like
contribut
factor
death
patient
die
subarachnoid
haemorrhag
relaps
diseas
patient
receiv
defibrotid
day
patient
die
compar
treatment
day
treatment
within
day
lone
surviv
patient
receiv
treatment
day
sever
chronic
liver
diseas
complic
patient
fit
seattl
criteria
earlyonset
vod
fit
baltimor
ebmt
criteria
classic
vod
patient
met
baltimor
criteria
later
seattl
criteria
met
rang
day
conclus
vod
carri
high
morbid
mortal
beyond
known
risk
factor
caveat
limit
number
studi
strongli
suspect
increas
time
definit
treatment
defibrotid
delay
particularli
beyond
day
nearli
quarter
case
vod
lateonset
per
classic
ebmt
criteria
howev
contrari
hypothesi
overal
outcom
mortal
appear
wors
time
treatment
emerg
strong
predict
factor
condit
treatment
relat
factor
play
stronger
role
endotheli
dysfunct
hepatoport
circul
may
much
play
perhap
lateonset
diseas
uniform
use
diagnost
criteria
high
degre
vigil
even
beyond
day
lead
earli
treatment
may
improv
outcom
vod
disclosur
noth
declar
background
hsctassoci
thrombot
microangiopathi
tatma
affect
patient
receiv
allogen
sct
high
mortal
sever
case
endotheli
injuri
mediat
complement
activ
atribuit
major
role
pathogenesi
blockad
eculizumab
offer
promis
result
method
present
experi
pediatr
case
tatma
treat
eculizumab
diagnosi
tatma
stablish
attend
jodel
et
al
criteria
clinic
data
collect
retrospect
medic
record
result
case
diagnos
august
april
median
age
year
time
diagnosi
primari
diseas
acut
leukemia
case
aml
sever
aplast
anemia
primari
immunodefici
receiv
first
sct
case
mud
mmrd
deplet
haploident
graft
mac
regimen
case
ric
case
receiv
calcineurin
inhibitor
cyclosporin
gvhd
prophylaxi
patient
develop
agvhd
grade
higher
case
patient
present
viral
reactiv
hypertens
present
case
tma
diagnosi
requir
antihypertens
drug
patient
renal
injuri
consist
lessthannorm
glomerular
filtrat
rate
median
proteinuria
urin
proteintocreatinin
ratio
higher
tan
mgmg
case
data
avail
patient
serum
haptoglobin
decreas
case
diagnosi
schistocyt
detect
patient
cutaneo
sign
present
case
digest
symptom
neurolog
affect
notori
develop
polyseros
normal
case
higher
ngml
patient
lower
data
avail
case
patient
receiv
defibrotid
treatment
case
receiv
also
rituximab
associ
therapeut
plasma
exchang
receiv
eculizumab
first
line
case
median
day
diagnosi
eculizumab
start
treatment
correctli
monitor
level
case
avail
quick
enough
median
number
dose
need
induct
therapi
median
interv
dose
day
patient
requir
reduc
interv
higher
dose
maintain
supress
patient
respond
die
tma
patient
hematolog
respons
chronic
renal
injuri
resolut
acut
renal
failur
case
nevertheless
patient
respond
eculizumab
die
tma
relat
complic
invas
fungal
infect
patient
aliv
median
follow
month
treatment
start
conclus
experi
support
promis
result
eculizumab
base
treatment
tatma
highlight
import
earli
treatment
care
therapi
monitor
supress
prospect
studi
need
achiev
better
knowledg
patholog
treatment
disclosur
noth
declar
background
approxim
allogen
hematopoiet
stem
cell
transplant
allohsct
made
sort
abo
blood
group
system
incompat
hsct
abo
donorrecipi
incompat
impli
risk
complic
process
infus
acut
hemolyt
anemia
ah
delay
graft
later
complic
due
presenc
isohemaglutinin
pure
red
cell
aplasia
passeng
lymphocyt
syndrom
also
abo
incompat
could
impact
graft
versu
host
diseas
gvhd
incid
could
associ
relaps
mortal
nrm
overal
surviv
os
conclud
evid
abo
incompat
impact
aim
studi
identifi
complic
respons
associ
abo
incompat
patient
undergo
allogen
hematopoiet
stem
cell
transplant
method
retrospect
studi
perform
patient
receiv
allohsct
januari
august
two
group
perform
accord
presenc
abo
incompat
demograph
clinic
inform
collect
physic
electron
medic
record
inform
analyz
spss
result
sixtyeight
patient
enrol
studi
male
median
age
year
follow
diagnos
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
granulocyt
chronic
leukemia
myelodysplast
syndrom
dendrit
cell
neoplasm
aplast
anemia
ninetyon
percent
patient
receiv
transplant
ident
hla
donor
receiv
haploident
transplant
fiftytwo
patient
abocompat
patient
aboincompat
none
patient
aboincompat
receiv
haploident
transplant
contrast
group
nt
show
differ
fever
infect
bacteri
isol
presenc
degre
acut
chronic
gvhd
relaps
diseas
graft
failur
vs
intermedi
risk
cmv
serostatu
vs
relev
characterist
complic
describ
tabl
contrast
analysi
vs
show
within
whole
group
death
vs
respect
overal
surviv
vs
median
vs
month
respect
mortal
associ
relaps
vs
respect
mortal
relat
transplant
vs
respect
conclus
abo
incompat
show
associ
complic
relat
infus
higher
tendenc
graft
failur
abo
incompat
group
statist
signific
import
expand
studi
disclosur
none
declar
method
retrospect
data
nhl
patient
underw
asct
analys
patient
identifi
use
swbmt
databas
data
met
collect
use
paper
electron
hospit
record
fortyeight
patient
exclud
due
loss
followup
inaccessibleincomplet
record
death
caus
death
determin
ncepatpiii
definit
met
use
requir
criteria
met
bmi
use
replac
central
obes
impair
fast
glucos
respect
criteria
includ
triglycerid
tg
treatment
high
densiti
lipoprotein
cholesterol
hdlc
male
femal
treatment
blood
pressur
systol
diastol
treatment
result
preval
met
cohort
eightytwo
percent
patient
met
one
criterion
met
twentyseven
percent
fulfil
one
criterion
fulfil
two
criteria
three
criteria
four
criteria
five
criteria
greatest
preval
met
age
group
account
patient
met
overal
preval
decreas
declin
age
tabl
number
patient
age
year
small
make
judgement
risk
rais
triglycerid
criterion
frequent
met
patient
follow
hypertens
rais
bmi
low
hdlc
increas
conclus
preval
met
cohort
higher
estim
worldwid
preval
major
age
categori
keep
posttranspl
studi
show
increas
preval
met
transplant
moreov
overal
preval
met
greater
older
popul
could
associ
cumul
effect
age
declin
normal
metabol
homeostat
mechan
background
acut
renal
failur
arf
frequent
complic
earli
postallogen
hematopoiet
stem
cell
transplant
allohsct
period
either
myeloabl
nonmyeloabl
nma
condit
regimen
aim
studi
compar
incid
arf
type
hsct
evalu
impact
overal
surviv
os
nonrelaps
mortal
nrm
method
allosct
perform
one
center
includ
studi
allohsct
cord
blood
haploident
donor
exclud
renal
function
incid
main
complic
allosct
day
day
evalu
arf
defin
accord
kdigo
kidney
diseas
improv
global
outcom
classif
rel
increas
serum
creatinin
level
consid
marker
kidney
damag
result
seventyseven
patient
receiv
allohsct
nma
allohsct
recipi
nma
allohsct
higher
median
age
year
rang
vs
year
p
higher
frequenc
arteri
hypertens
vs
p
show
frequent
activ
diseas
allosct
vs
group
frequent
graftversushost
diseas
gvhd
prophylaxi
regimen
cyclosporin
methotrex
median
followup
time
year
nma
group
year
group
patient
group
higher
incid
grade
mucos
vs
p
acut
gvhd
grade
vs
patient
nma
allohsct
incid
arf
similar
group
nma
nma
group
arteri
hypertens
hr
obes
hr
p
prior
pneumonia
hr
predispos
factor
arf
multivari
analysi
wherea
factor
identifi
group
arf
impact
os
group
vs
nma
group
vs
group
howev
wors
os
observ
patient
grade
arf
nma
group
vs
patient
grade
arf
group
vs
turn
arf
influenc
nrm
group
associ
trend
higher
nrm
nma
group
vs
conclus
arf
frequent
complic
patient
receiv
allohsct
irrespect
intens
condit
regimen
moder
sever
arf
neg
impact
os
disclosur
support
grant
contra
el
aecc
instituto
carlo
iii
fi
grc
cerca
program
generalitat
de
catalunya
la
caixa
foundat
treatment
risk
factor
hepat
venoocclus
diseas
pediatr
hematopoiet
stem
cell
transplant
singlecent
experi
barbaro
sahin
ilgen
sasmaz
ali
antmen
background
defibrotid
emerg
promis
treatment
option
hepat
venoocclus
diseas
signific
caus
mortal
recipi
hsct
vod
diagnosi
quit
difficult
even
recent
introduc
ebmt
criteria
studi
report
treatment
outcom
respons
prophylaxi
requir
aim
evalu
efficaci
defibrotid
prophylaxi
hsct
recipi
center
method
total
transplant
patient
januari
juli
includ
studi
patient
factor
increas
risk
vod
receiv
mgkgday
prophylaxi
patient
coagul
renal
liver
function
test
monitor
daili
clinic
find
complaint
record
diagnos
made
via
ebmt
vod
criteria
patient
develop
vod
receiv
treatment
increas
df
dose
mgkgday
support
intervent
complet
remiss
vod
find
patient
return
prophylaxi
dose
close
followup
patient
perform
day
result
total
patient
develop
vod
none
case
sever
mild
moder
median
age
year
common
clinic
find
weight
increas
hepatomegali
right
upper
quadrant
pain
ascit
develop
vod
treatment
mgkgday
df
initi
averag
durat
treatment
dosag
day
advers
event
report
patient
conclus
find
consist
previou
studi
topic
believ
use
df
prophylact
agent
vod
benefici
pediatr
patient
risk
factor
disclosur
author
report
conflict
interest
work
background
sever
factor
might
influenc
outcom
allohsct
analysi
impact
donorreceptor
blood
groupincompat
perform
differ
seri
alway
show
result
consequ
clinic
impact
remain
controversi
minormismatch
character
abil
donor
b
lymphocyt
produc
antirecipi
antibodi
majormismatch
case
antibodi
donor
antigen
present
recipi
method
pt
underw
allohsct
may
august
center
median
age
year
rang
pt
male
femal
baselin
diseas
aml
lpd
md
mpd
mm
bmf
donor
unrel
relat
case
includ
haploident
donorrecipi
abo
compat
follow
majormismatch
includ
bidirect
nonmajormismatch
includ
minormismatch
match
donorrecipi
rh
compat
follow
majormismatch
nonmajormismatch
includ
minormismatch
match
impact
donorrecipi
abo
rh
compat
transfus
need
prbc
platelet
concentr
surviv
day
analyz
result
global
seri
median
number
transfus
day
prbc
platelet
concentr
day
overal
mortal
rhincompat
nonmajor
abo
incompat
case
show
differ
result
howev
major
abomismatch
case
need
prbc
transfus
median
rang
platelet
transfus
median
rang
higher
day
mortal
p
see
tabl
conclus
analysi
show
donorrecipi
rhincompat
well
minor
aboincompat
impact
prbc
platelet
concentr
transfus
need
mortal
contrarili
donorrecipi
major
aboincompat
signific
advers
impact
prbc
platelet
concentr
transfus
need
mortal
donorrecipi
rhincompat
minor
aboincompatibilitymight
consid
margin
import
time
choos
potenti
donor
donorrecipi
major
aboincompat
probabl
factor
consid
along
featur
choos
best
donor
background
survivor
haematopoiet
stem
cell
transplant
hsct
signific
risk
develop
treatmentrel
complic
includ
cardiovascular
risk
factor
arteri
hypertens
could
eventu
lead
cardiovascular
diseas
aim
studi
evalu
incid
risk
factor
hypertens
follow
hsct
colombian
popul
method
retrospect
cohort
studi
conduct
assess
incid
risk
factor
hypertens
consecut
adult
hsct
recipi
underw
transplant
tertiari
referr
center
colombia
south
america
blood
pressur
data
two
differ
measur
collect
time
point
day
mobil
autolog
hsct
day
infus
allogen
transplant
day
month
posttransplant
hypertens
defin
systol
blood
pressur
andor
diastol
blood
pressur
mmhg
patient
histori
arteri
hypertens
exclud
result
one
hundr
seventyf
patient
includ
mean
age
year
rang
ninetyon
patient
male
one
hundr
sixteen
patient
underw
autolog
hsct
allogen
hsct
common
indic
hsct
acut
leukemia
follow
nonhodgkin
lymphoma
multipl
myeloma
twelv
patient
medic
histori
type
diabet
mellitu
dm
dyslipidemia
alcohol
consumpt
tobacco
smoke
two
patient
histori
tobacco
smoke
activ
smoker
time
transplant
twentyfour
patient
develop
hypertens
end
first
year
posthsct
followup
two
patient
systol
diastol
systol
diastol
hypertens
one
patient
hypertens
two
time
point
incid
hypertens
time
point
day
posthsct
first
month
three
month
month
oneyear
posttransplant
allogen
hsct
p
therapi
calcineurin
inhibitor
p
prehsct
fast
glucos
level
p
acut
gvhd
p
chronic
gvhd
p
media
diastol
blood
pressur
p
significantli
associ
develop
arteri
hypertens
howev
age
histori
type
dm
histori
tobacco
consumpt
volum
infus
prophylact
treatment
gvhd
mycophenol
chronic
gvhd
serum
creatinin
level
day
hsct
overweight
obes
time
transplant
significantli
associ
develop
hypertens
conclus
arteri
hypertens
fairli
common
complic
hsct
recipi
similar
find
report
previou
studi
associ
allogen
stem
cell
transplant
therapi
calcineurin
inhibitor
acut
chronic
gvhd
posthsct
hypertens
found
present
cohort
studi
need
assess
link
hsct
develop
longterm
cardiovascular
complic
disclosur
noth
declar
tramadolbas
pain
manag
oral
esophag
mucos
pediatr
hsct
recipi
background
mucos
one
common
earli
hsct
complic
seen
transplant
recipi
patient
develop
gr
iiiiv
mucos
mucos
character
pain
gastrointestin
mucosa
lesion
impair
solid
liquid
food
intak
increas
risk
infect
bleed
intestin
paresi
thu
greatli
decreas
qualiti
life
transplant
recipi
accord
recommend
moder
pain
control
pediatr
patient
base
use
lowdos
morphin
howev
factor
genet
polymorph
caus
variabl
morphin
pharmacokinet
children
side
effect
social
factor
caregiv
gener
unwilling
use
narcot
analges
caus
need
altern
pain
relief
option
pediatr
practic
tramadol
opioid
nonopioid
mechan
action
may
feasibl
option
mild
moder
pain
may
deliv
via
patientcontrol
analgesia
pca
although
consensu
optim
paramet
pediatr
practic
method
total
pediatr
patient
median
age
rang
year
receiv
autolog
allogen
hsct
clinic
part
treatment
regimen
solid
tumor
leukemia
acquir
aplast
anemia
inherit
condit
includ
condit
regimen
myeloabl
mac
reducedintens
ric
patient
patient
oral
andor
esophag
mucos
accompani
moder
pain
pain
sever
assess
use
scale
correspond
patient
age
vari
point
pain
control
base
intraven
tramadol
administr
use
patientcontrol
analgesia
pca
approach
follow
pca
paramet
use
load
dose
mg
kg
exceed
mg
basal
infus
rate
mg
kg
exceed
mg
bolu
mg
kg
exceed
mg
lockout
interv
min
maxim
daili
dose
mgkgday
pain
control
consid
adequ
patient
satisfi
basic
breakthrough
pain
score
valu
higher
accordingli
case
inadequ
pain
control
nsaid
ad
nonrespond
switch
morphin
patient
divid
group
base
condit
regimen
intens
result
whole
patient
requir
pain
control
measur
escal
tramadol
pain
control
rate
slightli
higher
ric
compar
mac
recipi
case
inadequ
pain
control
due
progress
mucos
lesion
pca
regimen
use
character
complic
drowsi
observ
patient
case
patient
also
anemia
patient
sever
nausea
requir
switch
morphin
conclus
tramadol
effect
pain
control
option
transplant
recipi
mild
moder
pain
due
oral
esophag
mucos
without
progress
mucos
lesion
pca
allow
achiev
low
complic
rate
therefor
option
may
consid
mac
ric
recipi
disclosur
immun
reconstitut
lymphocyt
subset
allogen
stem
cell
transplant
sct
vaccin
background
infecti
diseas
major
caus
morbid
mortal
allogen
stem
cell
transplant
sct
vaccin
constitut
effect
strategi
prevent
infect
optim
time
start
vaccin
well
stablish
order
individu
earli
vaccin
schedul
studi
lymphocyt
subset
involv
gener
enough
respons
produc
protect
serolog
level
method
studi
retrospect
patient
undergon
allogen
sct
hospit
patient
distribut
age
rang
yearsold
diagnosi
acut
leukaemiamyelodysplast
syndrom
chronic
myeloid
leukemia
patient
lymphoma
patient
analyt
paramet
nk
total
b
function
b
lymphocyt
subset
memori
effector
immunoglobulin
level
igg
iga
igm
specif
igg
pneumococcu
tetanu
hbv
chickenpox
measl
rubella
mump
clinic
paramet
collect
medic
record
result
distribut
patient
two
group
base
time
lymphocyt
analys
less
month
sinc
sct
patient
patient
show
complet
immun
reconstitut
although
enough
function
b
lymphocyt
gener
respons
vaccin
patient
vaccin
pneumococcu
complet
gener
suffici
protect
antibodi
level
despit
immunosuppress
treatment
month
sinc
sct
patient
begin
vaccin
collect
specif
antibodi
patient
compar
serolog
statu
sct
observ
protect
tetanu
frequent
preserv
patient
hbv
least
frequent
patient
one
patient
treat
alemtuzumab
patient
group
minimum
absolut
count
cellsmicrol
cellsmicrol
nk
cellsmicrol
b
cell
cellsmicrol
also
observ
presenc
b
effector
b
memori
cell
predomin
memori
cell
immunoglobulin
level
within
normal
rang
group
regist
vaccin
patient
vaccin
flu
pneumococcu
hbv
rest
vaccin
administ
heterogen
type
time
patient
immunosuppress
treatment
time
vaccin
abl
gener
enough
specif
antibodi
pneumococcu
conclus
immun
reconstitut
complet
month
sct
although
minim
immunolog
reconstitut
observ
noswitch
memori
b
lymphocyt
last
one
reach
minimum
normal
valu
accord
patient
age
patient
maintain
serolog
protect
allogen
sct
immunoglobulin
level
normal
suggest
need
immunoglobulin
administr
prevent
infect
flu
pneumococcu
hbv
vaccin
frequent
administ
pneumococcu
vaccin
gener
much
larger
serolog
respons
hbv
seroconvers
occur
patient
immunosuppress
treatment
analysi
lymphocyt
nk
b
total
b
function
subset
could
use
program
earli
vaccin
schedul
sct
complet
vaccin
schedul
heterogen
despit
give
specif
indic
therefor
rigor
supervis
process
may
requir
background
signific
advanc
achiev
allogen
transplant
allohct
field
result
better
posttranspl
outcom
therefor
complic
graft
vs
host
diseas
gvhd
diseas
recurr
becom
increasingli
import
post
transplant
metabol
syndrom
ptm
caus
sever
factor
ie
immunosuppress
agent
chemoradiotherapi
antivir
biolog
therapi
well
known
post
transplant
complic
pediatr
allograft
longterm
survivor
howev
studi
evalu
preval
ptm
adult
retrospect
studi
sought
evalu
incid
risk
factor
impact
ptm
allosct
outcom
method
sinc
patient
male
femal
adequ
clinic
laboratori
data
minimum
followup
month
includ
studi
median
age
year
myeloabl
reduc
intens
regimen
receiv
either
mobil
peripher
blood
stem
cell
marrow
graft
origin
fullmatch
sibl
haploident
donor
calcineurin
inhibitor
plu
either
shortterm
methotrex
mycophenol
mofetil
given
gvhd
prophylaxi
diagnosi
ptm
base
ncepatpiii
criteria
patient
unknown
data
abdomin
circumfer
bodi
mass
index
bmi
consid
criterion
ptm
diagnosi
independ
ttest
logist
regress
analysi
logrank
test
use
statist
analysi
result
twenti
patient
male
femal
assess
ptm
within
first
month
follow
allograft
seventeen
diagnos
st
trimest
post
allosct
addit
patient
nd
trimest
sixteen
patient
elev
glucos
bmi
elev
triglycerid
level
low
hdl
level
hypertens
four
alreadi
known
histori
ms
allosct
patient
data
avail
ms
diagnosi
allosct
interestingli
patient
diagnos
ptm
either
st
nd
trimest
syndrom
revers
fulfil
criteria
ptm
beyond
month
post
allosct
patient
gender
age
bmi
type
condit
regimen
gvhd
coexist
evalu
potenti
predispos
factor
ptm
diagnosi
univari
multivari
analysi
bmi
age
year
detect
signific
risk
factor
p
ptm
affect
neg
surviv
nrm
incid
post
allosct
conclus
studi
agreement
public
demonstr
ptm
uncommon
complic
post
earli
post
transplant
period
howev
signific
number
patient
syndrom
revers
patient
high
risk
featur
bmi
age
year
known
histori
diabetesmellitu
dyslipidemia
hypertens
apart
close
monitor
specif
diet
encourag
adequ
exercis
might
help
reduc
incid
sever
ptm
nevertheless
prospect
well
design
trial
warrant
determin
accur
incid
sever
impact
ptm
allosct
outcom
disclosur
conflict
ofinterest
experi
singl
center
human
hospit
process
technolog
team
train
impact
qol
patient
famili
maria
claudia
moreira
marcia
rejan
marcia
garnica
andrea
ribeiro
paulo
cesar
dia
ilza
fellow
background
hematopoiet
stem
cell
transplant
hsct
one
aggress
therapeut
modal
intern
medicin
make
highli
stress
experi
patient
famili
durat
hospit
prolong
sever
intercurr
frequent
gener
anxieti
patient
caregiv
may
lead
confin
reactiv
depress
intervent
hospit
environ
addit
continu
train
multidisciplinari
team
posit
impact
process
improv
process
discharg
qualiti
life
patient
famili
method
object
research
evalu
impact
reformul
unit
complet
may
modifi
facil
avail
hermet
balconi
room
view
intern
garden
also
addit
screen
corridor
floor
imag
technolog
known
videoowal
interconnect
motion
sensor
kinect
allow
interact
patient
famili
besid
facilit
physiotherapi
physic
exercis
retrain
multidisciplinari
team
emphasi
practic
human
methodolog
consist
applic
questionnair
satisfact
patient
famili
period
hospit
bone
marrow
transplant
unit
third
quarter
item
evalu
rang
qualiti
inform
provid
medic
team
nurs
cordial
agil
patient
patient
treat
global
team
result
compar
similar
period
unit
previou
year
indic
collect
simultan
anoth
unit
hospit
cardiointens
result
overal
segment
satisfact
score
variou
item
survey
higher
compar
previou
period
unit
also
higher
obtain
high
complex
unit
hospit
compos
patient
submit
mental
psycholog
stress
similar
oncohematologicosa
report
free
speech
also
obtain
anonym
order
guarante
authent
free
express
subject
analyz
conclus
result
obtain
allow
valid
technic
profession
team
initi
bring
indic
allow
better
monitor
support
patient
rel
difficult
time
treatment
serv
initi
tool
continu
process
human
stimul
multidisciplinari
team
continu
improv
process
disclosur
background
pure
red
cell
anemia
prca
rare
complic
aboincopat
hematopoet
stem
cell
transplant
character
anemia
reticulocytopenia
absenc
erythroid
precursor
patient
bone
marrow
patient
prca
resolv
spontan
within
month
howev
small
number
patient
requir
continu
red
blood
cell
rbc
transfus
treatment
complic
difficult
standard
differ
approach
use
rituximab
donor
lymphocyt
plasma
exchang
differ
outcom
recent
remark
respons
treatment
bortezomib
describ
case
prca
method
review
patient
receiv
allogen
hematopoet
stem
cell
transplant
hct
januar
august
institut
sixti
eight
patient
receiv
major
abomismach
hct
prca
defin
complet
absenc
erythroid
precursor
day
bone
marrow
punctur
absenc
donor
red
cell
recipi
requir
rbc
transfus
result
one
patient
develop
prca
year
old
male
receiv
myeloabl
hlamatch
abomismatch
sibl
donor
transplant
brother
year
acut
myeloid
leukemia
aml
mrd
posit
donor
blood
type
rh
posit
patient
rh
posit
patient
complic
transplant
day
bone
marrow
punctur
shown
erythroid
precursor
day
punctur
biopsi
erythroid
precursor
transfus
depend
anemia
requir
rbc
transfus
everi
two
week
retukulocytopenia
parvo
viru
cytomegaloviru
neg
due
high
ferritin
level
increas
luiver
enzym
without
sign
gvhd
treatment
deferasirox
start
patient
achiv
mrd
neg
evid
complet
chimer
high
titer
antia
antib
issohemagglutinin
presentw
start
treatment
rituximab
weekli
week
howev
without
respons
pathogenesi
prca
thought
due
recipi
plasma
cell
bortezomib
proteasom
inhibitor
induc
apoptosi
plasma
cell
given
c
two
time
weekli
two
week
patient
respond
treatment
two
week
later
increas
hb
gdl
increas
retikulocyt
number
patient
continu
well
last
control
conclus
prca
aplasia
rare
seriou
complic
aboincompat
hct
bortezomib
effect
treatment
complic
mediat
residu
host
isohemeagglutinin
hct
recommend
standard
care
clinic
method
work
retrospect
observ
crosssect
analyt
includ
patient
receiv
hsct
stem
cell
transplant
unit
utmo
spanish
acronym
solcaguayaquil
year
use
kaplanmei
method
analyz
surviv
rate
autolog
allogen
transplant
inform
collect
studi
obtain
databas
solcay
institut
review
file
patient
includ
result
least
patient
undergo
hsct
year
accord
type
hsct
receiv
autolog
transplant
receiv
allogen
transplant
relat
donor
main
sourc
transplant
peripher
blood
follow
obtain
umbil
cord
blood
bone
marrow
aspir
frequent
report
patholog
acut
lymphoblast
leukemia
multipl
myeloma
mm
acut
myeloid
leukemia
aml
overal
surviv
ic
patient
undergo
autolog
transplant
surviv
meanwhil
patient
undergo
allogen
transplant
surviv
p
highest
death
rate
occur
first
year
hsct
decreas
consider
period
main
caus
mortal
relat
transplant
mrt
graftversushost
diseas
gvhd
howev
main
caus
mortal
studi
popul
relaps
patient
present
frequent
conclus
result
show
patient
undergo
hsct
surviv
high
rate
deceas
patient
studi
die
first
year
transplant
due
relaps
main
caus
deceas
studi
relat
hsct
relaps
patient
compar
gvhd
main
caus
mrt
consid
hsct
techniqu
still
develop
ecuador
despit
short
time
take
institut
medic
limit
present
health
field
present
excel
result
compar
studi
conduct
develop
countri
background
pigment
epithelioid
melanocytoma
pem
earli
known
type
melanoma
rare
tumor
unpredict
clinic
behavior
metastat
potenti
pem
gener
favor
prognosi
involv
region
lymph
node
rare
extranod
distant
nodal
metastas
extrem
rare
report
patient
fanconi
anemia
fa
pem
develop
distant
metastas
earli
term
allogen
hematopoiet
stem
cell
transplant
hsct
method
old
boy
fa
hospit
hsct
blueblack
painless
nodulu
mm
note
left
cheek
lesion
observ
earli
childhood
life
slightli
increas
size
distant
region
metastas
computer
tomographi
ct
scintigraphi
tc
nodulu
region
lymph
node
radic
remov
hsct
resect
margin
within
normal
tissu
microscop
derma
subcutan
fat
infiltr
epithelioid
spindl
cell
total
express
melana
express
level
histolog
structur
specif
pem
hsct
graft
deplet
match
unrel
donor
perform
condit
regimen
includ
total
lymphoid
irradi
fludarabin
mg
cyclophosphamid
mgkg
rabbit
atg
mgkg
rituximab
mgm
result
day
hsct
detect
tumor
left
cheek
parotid
region
histolog
structur
ident
primari
lesion
ct
segment
left
lung
detect
focu
mm
caviti
invas
aspergillosi
suspect
empir
antifung
treatment
start
day
lung
lesion
increas
size
mm
penetr
bronchu
bronchoscopi
biopsi
pem
metastasi
histolog
confirm
moreov
tumor
face
continu
grow
therapi
cobimetinib
vemurafenib
effect
patient
die
progress
pem
day
hsct
conclus
pem
earli
describ
indol
tumor
rare
distant
metastasi
favor
prognosi
suspect
pem
may
acquir
aggress
cours
absenc
immunolog
control
especi
high
immunocompromis
patient
hsct
disclosur
noth
declar
abstract
withdrawn
lidia
gartcheva
antoaneta
mihova
penka
ganeva
margarita
guenova
branimir
spassov
background
main
object
studi
assess
dynam
quantit
qualit
chang
paramet
b
cell
popul
product
immunoglobulin
patient
autolog
transplant
hematopoiet
stem
cell
cours
recoveri
immun
system
method
patient
hematolog
neoplasm
undergo
autolog
transplant
includ
studi
women
men
averag
age
year
patient
diagnos
lymphoma
n
multipl
myeloma
leukemia
n
solid
tumor
n
time
transplant
patient
complet
clinic
remiss
least
good
partial
respons
patient
partial
remiss
patient
progress
patient
evalu
nine
time
point
examin
clinicallaboratori
flow
cytometr
immunochem
method
result
percentag
b
cell
reach
minimum
valu
one
month
transplant
began
increas
second
month
reach
plateau
around
mean
valu
period
month
transplant
absolut
number
remain
low
entir
period
observ
amount
igg
igm
serum
immunoglobulin
gradual
increas
within
refer
rang
throughout
entir
period
iga
level
vari
around
lower
refer
rang
conclus
implement
adequ
humor
immun
respons
hamper
reduct
circul
b
cell
suppress
prolif
potenti
function
deficit
restor
bcell
function
occur
period
month
year
autolog
transplant
clinic
trial
registri
clinic
trial
disclosur
noth
declar
justyna
background
allogen
hematopoiet
stem
cell
transplant
allohsct
lifesav
well
establish
therapi
wide
rang
diseas
howev
still
uncommon
treatment
infant
less
month
age
data
indic
outcom
allohsct
youngest
group
patient
spars
primari
object
studi
assess
incid
indic
posthsct
complic
gener
outcom
allohsct
among
infant
older
month
latter
sequela
hsct
physic
cognit
develop
secondari
aim
studi
method
retrospect
analyz
data
patient
underw
allohsct
year
age
depart
pediatr
hematolog
oncolog
bone
marrow
transplant
year
clinic
epidemiolog
featur
well
indic
transplant
earli
late
complic
gener
outcom
assess
result
infant
underw
hsct
depart
compris
patient
undergo
hsct
analyz
period
time
thirtyon
patient
receiv
stem
cell
match
unrel
donor
mud
mismatch
haploident
relat
donor
mmrd
sibl
donor
msd
nonmalign
disord
indic
transplant
patient
malign
diseas
acut
graft
versu
host
diseas
agvhd
occur
infant
chronic
graft
versu
host
diseas
cgvhd
major
graft
reject
seen
infant
transplant
mmrd
wherea
rest
associ
mud
median
followup
studi
cohort
day
day
aliv
patient
rang
yr
day
deceas
rang
day
overal
surviv
os
studi
cohort
transplant
relat
mortal
trm
children
malign
patient
die
compar
patient
nonmalign
group
respect
main
caus
death
analyz
group
infant
infect
conclus
allohsct
rare
perform
children
less
month
age
major
patient
receiv
stem
cell
due
nonmalign
disord
among
youngest
hsct
recipi
haploident
transplant
common
gener
pediatr
transplant
popul
graft
reject
signific
problem
infant
transplant
mmrd
disclosur
noth
declar
unusu
noninfecti
lung
complic
allogen
haematopoiet
stem
cell
transplant
claudia
lucia
sossa
melo
manuel
rosal
francisco
fernando
naranjo
junoy
sara
lui
antonio
salazar
angela
manosalva
maria
claudia
marcela
chalela
manuel
jirovecii
infect
viral
infect
nocardia
describ
case
patient
acut
lymphoblast
leukemia
diagnosi
pap
associ
hsct
pulmonari
pneumocysti
method
colombian
femal
patient
diagnos
bprecursor
highrisk
januari
posit
philadelphia
chromosom
posit
bcr
abl
februari
infiltr
central
nervou
system
cn
lymphoblast
karyotyp
without
legibl
metaphas
refractori
induct
accord
pethema
protocol
vincristin
daunorubicin
prednison
lasparaginas
presenc
blast
end
induct
reinduct
perform
flagida
protocol
idarubicin
fludarabin
cytarabin
achiev
complet
remiss
obtain
minimum
residu
diseas
mrd
dasatinib
initi
bcr
abl
express
cn
involv
time
diagnosi
allogen
hsct
perform
male
brother
donor
low
intens
condit
tt
buflu
prophylaxi
graftversushost
diseas
gvhd
tacrolimu
sirolimu
patient
show
earli
posttranspl
complic
given
reactiv
cytomegaloviru
hemorrhag
cystiti
grade
due
adenoviru
late
complic
us
gvhd
cutan
level
subsequ
hepat
gastrointestin
involv
seen
immunosuppress
therapi
administ
high
dose
system
corticosteroid
result
patient
hospit
day
posttransplant
due
febril
neutropenia
respiratori
symptom
normal
chest
ct
ct
paranas
sinus
acut
pansinus
receiv
meropenem
intraven
everi
hour
plu
vancomycin
intraven
everi
hour
day
symptom
resolut
remain
hospit
cytopenia
normal
bone
marrow
chimer
day
posttranspl
present
fever
leukocytosi
acut
respiratori
failur
chest
ct
show
bilater
alveolar
occup
crazypav
pattern
frost
glass
see
imag
diagnost
fibrobronchoscopi
perform
report
postop
pneumocysti
jirovecii
receiv
day
trimethoprimsulfamethoxazol
torpid
evolut
requir
mechan
ventil
tracheostomi
persist
hypoxemia
report
cultur
fungi
mycobacteria
respiratori
panel
filmarray
neg
patholog
report
obtain
neutrophil
well
pa
stain
acellular
pink
materi
elev
serum
ldh
diagnosi
secondari
pap
patient
continu
poor
gener
condit
refractori
hypoxemia
high
ventilatori
paramet
hemodynam
instabl
due
abl
candid
treatment
total
pulmonari
lavag
lead
multiorgan
failur
later
death
imag
high
resolut
chest
ct
sampl
opacif
frost
glass
pattern
crazypav
b
conclus
import
consid
diagnosi
pap
noninfecti
pulmonari
complic
patient
allogen
hsct
despit
low
incid
recogn
disclosur
noth
declar
method
project
approv
clinic
trial
ethic
committe
pair
blood
sampl
drawn
picc
line
venepunctur
voluntari
allohsct
recipi
receiv
continu
infus
tacrolimu
februari
august
pt
insert
doublelumen
polyurethan
picc
tacrolimu
alway
administ
red
line
blood
draw
alway
perform
purpl
line
patient
sign
inform
consent
male
women
median
age
year
venepunctur
carri
arm
picc
set
contralater
arm
limit
group
nurs
perform
extract
sampl
result
shown
tabl
tacrolimu
trough
level
determin
blood
venepunctur
similar
blood
drawn
picc
median
vs
ngml
compar
one
one
individu
patient
differ
signific
chang
dose
prescript
case
conclus
experi
signific
differ
tacrolimu
level
draw
picc
line
compar
peripher
site
opinion
line
tacrolimu
infus
properli
identifi
one
use
sampl
draw
altern
one
venepunctur
obtain
sampl
peripher
site
justifi
tacrolimu
level
measur
background
patient
undergo
hsct
may
requir
icu
admiss
due
transplantrel
toxic
aim
studi
analys
singl
centr
experi
hsct
patient
requir
icu
admiss
factor
affect
outcom
method
includ
adult
patient
age
allogen
autolog
hsct
st
georg
hospit
data
retrospect
collect
patient
note
icu
outcom
surviv
analys
patient
admit
icu
outcom
analys
last
icu
admiss
result
allograft
patient
includ
male
median
age
year
rang
year
femal
median
age
year
rang
year
diagnosi
n
includ
aml
acml
cmml
hl
md
mdsmpn
fl
scd
sixteen
patient
receiv
first
transplant
receiv
second
transplant
eight
patient
sibl
donor
patient
unrel
donor
sixteen
patient
match
donor
patient
match
donor
patient
match
donor
nineteen
receiv
reduc
intens
condit
ric
one
receiv
myeloabl
condit
major
ric
allohsct
patient
condit
fludarabin
mephalan
campath
fmc
small
number
condit
busulfan
fludarabin
atg
allohsct
patient
condit
tbi
cyclophosphamid
gvhd
prophylaxi
ciclosporin
alon
start
day
target
level
ugl
ric
ciclosporin
methotrex
patient
two
allograft
patient
admit
icu
three
occas
patient
male
year
old
one
mmud
allograft
mdsmpn
nd
mud
allograft
relaps
aml
reason
icu
admiss
includ
sepsi
cardiac
arrest
respiratori
failur
median
durat
icu
admiss
day
rang
death
within
day
transplant
one
patient
die
day
second
icu
admiss
multi
organ
failur
mof
one
patient
die
icu
discharg
day
relaps
diseas
bronchopneumonia
dissemin
fungal
infect
icu
mortal
rate
mortal
rate
nineteen
autolog
patient
includ
median
age
rang
year
myeloma
patient
condit
melphalan
lymphoma
patient
condit
beam
icu
admiss
mortal
rate
conclus
centr
icu
admiss
rate
icu
mortal
rate
caus
icu
admiss
allohsct
patient
autolog
patient
compar
literatur
report
autolog
transplant
safe
death
icu
admiss
despit
older
age
mortal
rate
allohsct
patient
requir
icu
admiss
remain
high
patient
appropri
refer
icu
one
deni
icu
admiss
analysi
extend
preced
year
disclosur
noth
declar
liposom
doxorubicin
treatment
iatrogen
kaposi
sarcoma
follow
hematopoiet
stem
cell
transplant
background
iatrogen
kaposi
sarcoma
ik
repres
rare
complic
hematopoiet
stem
cell
transplant
hsct
relat
infect
hivneg
immunocompromis
patient
pt
method
describ
case
ik
occur
allogen
hsct
provid
review
literatur
use
pub
med
result
man
hivneg
receiv
full
hlamatch
relat
hsct
reduc
intens
condit
regimen
relaps
aml
gvhd
prophylaxi
base
atg
freseniu
mgkg
cyclosporin
cya
methotrex
sever
complic
occur
first
day
transplant
shortli
cya
withdraw
develop
grade
acut
gvhd
gvhd
resolv
restart
cya
fifth
month
transplant
patient
develop
sever
red
purpl
angiomat
plaqu
nodul
involv
skin
lower
limb
right
arm
nose
figur
skin
biopsi
reveal
multipl
local
ik
posit
viremia
detect
peripher
blood
viscer
involv
exclud
patient
treat
cya
taper
nine
cours
liposom
doxorubicin
everi
day
obtain
neg
viremia
partial
respons
skin
lesion
last
follow
month
transplant
patient
complet
remiss
cr
aml
cyafre
without
sign
gvhd
recurr
singl
stabl
residu
ik
lesion
left
limb
current
wait
local
radiotherapi
found
addit
ik
publish
case
hsct
posthsct
ik
secondari
allogeneichsct
occur
adult
male
pt
median
age
time
ik
diagnosi
year
rang
thirteen
pt
mediterranean
origin
frequent
underli
diseas
aml
gvhd
prophylaxi
primari
base
calcineurin
inhibitor
half
pt
develop
gvhd
treat
steroid
immun
suppress
drug
median
time
hsct
occurr
ik
month
rang
cutan
ik
preval
form
manifest
howev
viscer
involv
report
pt
four
case
associ
bm
failur
report
immun
suppress
drug
taper
chemotherapi
frequent
action
taken
diagnosi
ik
case
liposom
doxorubicin
use
chemotherapi
cr
rate
high
wherea
progress
diseas
occur
pt
viscer
involv
pt
ik
caus
death
conclus
withdrawn
immun
suppress
drug
anthracyclin
base
chemotherapi
repres
feasibl
treatment
option
pt
ik
hsct
clinic
background
acquir
haemophilia
aha
autoimmun
diseas
caus
spontan
product
neutral
immunoglobulin
g
igg
autoantibodi
inhibitor
target
endogen
fviii
treatment
inhibitor
present
addit
challeng
hematopoiet
stem
cell
transplant
hsct
recipi
preserv
graft
restor
normal
hematopoiesi
critic
describ
manag
case
aha
acut
myeloid
leukemia
patient
follow
hsct
method
clinic
laboratori
molecular
aspect
italian
male
develop
aha
allogen
bone
marrow
transplant
collect
present
order
show
diagnos
manag
sever
rare
complic
within
special
set
hsct
result
man
itd
neg
differenti
chromosom
normal
acut
myeloid
leukemia
aml
third
complet
remiss
cr
submit
hematopoiet
stem
cell
transplant
hsct
haploident
son
condit
regimen
consist
oncothiotepa
busulfan
fludarabin
follow
infus
tcell
deplet
bone
marrow
graft
gvhd
prophylaxi
consist
cyclosporin
csa
mycophenol
mophetyl
mmf
neutrophil
engraft
occur
day
recipi
autoimmun
neg
month
posttransplant
patient
receiv
antipneumococc
vaccin
fifteen
day
postvaccin
patient
admit
inpati
ward
due
gener
malais
diffus
muscl
joint
pain
cutan
bleed
oedema
hyperchrom
urin
constip
physic
examin
reveal
diffus
ecchymosi
swell
deep
muscl
progress
function
disabl
due
hematoma
hemorrhag
suffus
tongu
frenulum
antifactor
viii
inhibitor
buml
high
titer
buml
thu
diagnosi
acquir
autoimmun
haemophilia
made
treatment
feiba
combin
prednison
start
patient
clinic
condit
dramat
improv
refer
improv
movement
resolut
joint
muscl
pain
despit
persist
deep
hematoma
one
day
treatment
determin
increas
fviii
c
valu
improv
aptt
second
follow
medic
check
physic
examin
show
progress
disappear
deep
muscl
hematoma
normal
valu
fviii
c
conclus
aha
rare
sever
complic
follow
hsct
could
appear
year
afterengraft
prompt
diagnosi
earli
treatment
feiba
corticosteroid
necessari
avoid
lifethreaten
sequela
inclus
coagul
panel
laboratori
exam
perform
followup
advis
order
earli
detect
lifethreaten
complic
disclosur
noth
declar
background
splanchnic
thrombosi
uncommon
complic
myelofibrosi
controind
proceed
hematopoiet
stem
cell
transplant
hsct
due
risk
addit
vascular
endotheli
complic
present
patient
myelofibrosi
mf
proceed
hsct
unrel
donor
despit
splanchnic
thrombosi
unresolv
heparin
treatment
unabl
proceed
surgic
treatment
due
sever
thrombocytemia
method
woman
mf
secondari
essenti
thrombocythemia
score
accord
dynam
intern
prognost
stage
system
dipss
extrem
splenomegali
maximum
diamet
cm
refractori
ruxolitinib
show
extens
thrombosi
portal
splenic
vein
unresolv
heparin
therapi
time
avail
hla
abo
match
unrel
donor
receiv
condit
regimen
includ
fludarabin
thiotepa
gvhd
prophylaxi
atg
thymoglobulin
cyclosporin
methotrex
follow
reinfus
kg
pbsc
time
transplant
awar
high
risk
develop
so
basi
older
age
recipi
unrel
donor
advanc
stage
myelofibrosi
ferritin
serum
level
ngmg
result
day
hsct
so
complic
aplasia
phase
character
jaundic
ascit
weight
gain
progress
increas
creatinin
bilirubin
serum
level
ultrasound
abdomen
confirm
unchang
thrombosi
extens
develop
ascit
day
patient
categor
sever
so
stage
accord
ebmt
sever
criteria
doubl
bilirubin
serum
level
hour
increas
comparison
baselin
weight
therefor
defibrotid
promptli
start
associ
diuret
therapi
treatment
continu
week
allow
gradual
restor
water
balanc
normal
bilirubin
serum
level
last
followup
month
hsct
patient
show
persist
nontransfus
depend
anemia
platelet
palpabl
spleen
cm
rib
allogen
chimer
granulocyt
compart
lymphocyt
compart
splanchnic
thrombosi
partial
recan
replac
collater
circl
cavern
aspect
patient
treatment
fondaparinux
shown
neither
signific
infecti
episod
acut
chronic
gvhd
conclus
conclud
defibrotid
treatment
allow
perform
successful
allogen
transplant
patient
mf
associ
overt
pictur
splanchnic
thrombosi
background
hematopoiet
stem
cell
transplant
hsct
associ
increas
incid
secondari
malign
includ
skin
cancer
squamou
cell
carcinoma
scc
common
type
patient
receiv
immunosuppress
therapi
chronic
graftversushost
diseas
cgvhd
appear
import
risk
factor
develop
recent
studi
describ
voriconazol
exposur
independ
factor
may
contribut
increas
risk
well
best
knowledg
case
scc
report
pediatr
allogen
hsct
date
method
present
case
report
yearold
boy
develop
scc
highrisk
featur
six
year
undergo
hematopopoiet
stem
cell
transplant
result
yearold
boy
acut
lymphoblast
leukemia
underw
match
unrel
bone
marrow
transplant
year
ago
develop
grade
iv
agvhd
follow
extens
cgvhd
gener
scleroderma
requir
intens
continu
immunosuppress
therapi
prolong
antifung
prophylaxi
voriconazol
march
develop
scc
involv
left
tempor
region
complet
excis
two
month
later
lesion
scalp
nose
note
intrales
treatment
methotrex
start
howev
unfavor
evolut
note
put
system
treatment
includ
cisplatin
cetuximab
receiv
whole
scheme
januari
march
continu
cetuximab
ten
dose
total
may
unacept
sever
tubulopathi
requir
admiss
hospit
sever
ocass
achiev
good
partial
respons
progress
note
shortli
follow
point
non
cur
therapeut
option
found
put
intrales
methotrex
photodynam
theraphi
weekli
basi
palli
intent
unfortun
tumor
growth
fast
patient
pass
away
august
fifteen
month
squamou
cell
carcinoma
diagnosi
due
tumor
progress
conclus
scc
rare
nonprevi
describ
secondari
malign
children
undergo
hsct
highrisk
featur
scc
constitut
aggres
diseas
median
overal
surviv
year
cgvhd
appear
import
risk
factor
develop
voriconazol
inducedphotosensit
might
play
role
cisplatin
base
regimen
cetuximab
therapeut
option
dissemin
andor
high
risk
case
outcom
unsatisfactori
case
altern
therapeut
option
need
explor
disclosur
background
pregnanc
rare
event
allogen
stem
cell
transplant
sct
acut
leukemia
report
best
knowledg
first
time
success
pregnanc
treosulfanbas
condit
method
old
woman
diagnos
acut
myeloid
leukemia
aml
secondari
chronic
myelomonocyt
leukemia
juli
ovarian
preserv
perform
leuprolid
acet
depot
inject
prior
cytostat
chemotherapi
note
cryopreserv
oocyt
ovarian
tissu
conduct
receiv
two
cycl
chemotherapi
consist
idarubicin
day
cytarabin
bid
day
due
secondari
origin
aml
sct
perform
first
complet
remiss
aml
condit
treosulfan
day
fludarabin
day
receiv
cell
per
kilogram
bodi
weight
hlamatch
unrel
donor
result
followup
bone
marrow
aspir
show
continu
complet
remiss
aml
seven
month
sct
becam
pregnant
decid
induc
abort
januari
month
hsct
becam
pregnant
desir
child
medic
examin
perform
monthli
outpati
basi
stringent
cooper
matern
clinic
cours
pregnanc
unremark
although
hospit
due
prematur
labor
th
week
pregnanc
howev
gynecolog
examin
show
clinic
signific
find
section
plan
could
discharg
th
week
pregnanc
gave
birth
healthi
girl
cesarean
section
peripartum
develop
hypoethesia
left
bodi
half
neurolog
examin
show
abnorm
recov
immedi
postpartum
complic
breastfeed
establish
addit
food
necessari
suffici
nutrit
child
conclus
case
success
pregnanc
follow
sct
demonstr
fertil
recov
treosulfanbas
condit
howev
detail
studi
ovarian
function
fertil
necessari
gain
insight
risk
prematur
ovarian
failur
disclosur
noth
declar
experiment
stem
cell
transplant
therapi
allohsct
children
adolesc
patient
diagnos
rr
ball
background
ball
children
adolesc
describ
favour
prognosi
patient
diagnos
relaps
refractori
result
allohsct
children
adolesc
group
leukemia
center
analyz
order
understand
therapeut
effect
patient
method
retrospect
analysi
june
juli
children
adolesc
diagnos
relaps
refractori
ball
receiv
allohsct
total
case
patient
divid
two
group
depend
whether
accept
allohsct
accord
fcmmrd
level
allohsct
os
lf
cumul
recurr
rate
analyz
r
use
statist
analysi
softwar
result
conclus
rr
ball
children
adolesc
fcmmrd
pretranspl
nt
obviou
effect
outcom
allohsct
level
obviou
effect
come
neg
group
obvious
better
posit
group
obvious
improv
os
lf
mainli
make
patient
fusion
zero
rr
ball
children
adolesc
chemotherapi
ca
nt
make
fusion
zero
suggest
accept
therapi
make
fusion
zero
improv
outcom
os
lf
disclosur
background
current
hematopoiet
stem
cell
transplant
hsct
repres
cur
treatment
numer
hematopoiet
malign
like
leukemia
immun
defici
metabol
diseas
serv
qualiti
marker
stem
cell
graft
sole
express
stem
cell
also
varieti
progenitor
role
impact
subpopul
remain
unknown
made
use
genet
barcod
system
analyz
influenc
contribut
reconstitut
clonal
level
method
fluoresc
activ
cell
sort
fac
use
sort
hematopoiet
stem
progenitor
popul
name
hsc
mpp
cmp
clp
lentivir
transduc
previous
establish
barcod
system
mix
mark
cell
bone
marrow
support
lethal
irradi
recipi
anim
transplant
monitor
week
focus
bone
marrow
blood
spleen
thymu
chosen
endpoint
sampl
use
analyz
contribut
subpopul
reconstitut
process
base
fluoresc
protein
fp
express
investig
clonal
contribut
differ
organ
perform
next
gener
sequenc
ng
frequenc
uniqu
barcod
sampl
analyz
bioinformat
approach
result
maximum
cell
express
encod
fp
mostli
deriv
hsc
mpp
cmpderiv
cell
detect
week
transplant
myeloid
compart
cell
deriv
clp
detect
time
point
analyz
barcod
content
differ
mark
cell
nextgenerationsequenc
accord
fac
data
major
clone
week
observ
deriv
hsc
mpp
cmpderiv
clone
contribut
first
week
clpderiv
clone
bare
detect
observ
major
differ
regard
age
donor
recipi
despit
total
number
clone
higher
group
receiv
age
graft
independ
transduc
cell
popul
conclus
show
suitabl
highli
complex
multicolor
barcod
system
studi
clonal
contribut
hsc
three
progenitor
popul
hsct
result
contribut
better
understand
differ
popul
interact
support
establish
new
hematopoiet
system
emphas
variabl
data
graft
recipi
age
comprehens
analysi
give
rise
impress
necess
person
graft
composit
treatment
success
could
influenc
disclosur
noth
declar
surviv
fate
adipos
deriv
mesenchym
stem
cell
rat
brain
injuri
model
background
mesenchym
stem
cell
identifi
promis
candid
treatment
central
nervou
system
cn
injuri
neurotroph
support
immunomodul
adipos
tissu
attract
sourc
mesenchym
stromalstem
cell
asc
regen
therapeut
applic
harvest
autolog
donor
minim
invas
method
rapidli
expand
ex
vivo
show
low
immunogen
allogen
use
autolog
heterolog
set
present
studi
examin
fate
effect
intracerebroventricularli
icv
transplant
asc
traumat
brain
injuri
tbi
model
method
asc
isol
inguin
fat
pad
adult
wistar
rat
steril
condit
cultur
accord
standard
procedur
asc
passag
cell
seed
transfect
sleep
beauti
transposas
venusneo
r
plasmid
select
antibiot
result
gener
homogen
asc
popul
express
fluoresc
venu
protein
sever
passag
phenotyp
character
show
cell
doubl
posit
stem
cell
marker
verifi
mesenchym
origin
tbi
induc
stereotact
surgeri
deep
anaesthesia
subsequ
icv
transplant
venu
asc
perform
adult
wistar
rat
normal
ascstranspl
tbisalin
transplant
rat
use
control
prolifer
migrat
surviv
fate
transplant
asc
effect
injuri
restor
examin
six
week
post
transplant
pt
result
six
week
pt
asc
express
fluoresc
venu
protein
therefor
identifi
brain
parenchyma
presenc
brain
also
confirm
masson
trichrom
stain
reveal
collagen
deposit
asc
found
lesser
number
compar
transplant
exhibit
prolif
activ
asc
found
scatter
distribut
brain
individu
cell
aggreg
asc
mass
format
later
ventricl
extens
migrat
asc
mainli
perform
white
matter
track
corpu
callosum
fimbria
hippocampu
six
week
pt
asc
retain
characterist
mesenchym
cell
differenti
cell
neural
lineag
asc
exhibit
limit
longterm
surviv
restrict
perivascular
area
probabl
contribut
vascular
format
home
asc
periinjur
area
detect
half
anim
achiev
corpu
callosum
reveal
collagen
deposit
white
matter
track
transplant
asc
reduc
area
tbi
caviti
enhanc
astrogli
scar
periinjur
area
tbi
asc
transplant
anim
cortic
injuri
site
show
significantli
smaller
volum
lower
tissu
loss
compar
tbivehicl
anim
respect
versu
respect
conclus
consid
effect
asc
inflamm
regener
suggest
transplant
brain
injuri
may
promot
host
brain
repair
mechan
asc
transplant
may
benefici
tbi
howev
effect
need
care
indepth
evalu
disclosur
noth
declar
xiena
cao
yuan
kong
zhongshi
lyu
qi
wen
minmin
shi
qianyu
sun
yuhong
chen
yu
wang
lanp
xu
xiaohui
zhang
xiaojun
huang
background
poor
graft
function
pgf
remain
seriou
complic
allogen
hematopoiet
stem
cell
transplant
allohsct
previou
work
report
abnorm
bone
marrow
bm
endotheli
cell
ec
involv
pathogenesi
pgf
patient
allohsct
bmt
explicit
mechan
requir
clarif
autophagi
selfdegrad
process
respons
elimin
cytosol
compon
includ
protein
damag
organel
recent
find
demonstr
stimul
autophagi
could
reduc
oxid
statu
angiogen
potenti
ecsaft
highglucos
exposur
diabet
patientshowev
littl
known
regard
autophagi
bm
ec
pgf
patient
therefor
current
studi
perform
evalu
whether
autophagi
bm
ec
play
role
pathogenesi
pgf
moreov
investig
effect
autophag
regul
ec
therebi
regul
hematopoiet
stem
cell
hsc
method
prospect
casecontrol
studi
autophagi
level
compar
bm
ec
pgf
patient
match
good
graft
function
ggf
patientsth
express
level
autophagyrel
marker
intracellular
autophagosom
detect
immunohistochem
stain
flow
cytometri
western
blot
transmiss
electron
microscopi
subsequ
rapamycin
autophagi
activ
hydroxychloroquin
hcq
autophagi
inhibitor
administr
toth
cultiv
bm
ec
human
umbil
vein
endotheli
cell
huvec
respectivelyth
autophag
vacuoleswer
detect
monodansylcadaverin
mdc
stain
assay
bm
ecsand
huvec
evalu
cell
count
diiacldl
doubl
stain
migrat
cell
prolifer
level
reactiv
oxygen
speci
ro
explor
whether
autophagi
would
affect
abil
bm
ec
support
hsc
vitro
bm
cell
healthi
donor
cocultur
cultiv
bm
ec
huvec
colonyform
unit
cfu
apoptosi
cocultur
hsc
analyz
result
defect
autophagi
bm
ec
character
decreas
intracellular
autophagosom
autophag
vacuol
decreas
express
high
level
observ
pgf
patient
compar
ggf
patient
moreov
cocultur
bm
cell
bm
ec
show
signific
defici
cfu
plate
effici
increas
apoptosi
cell
pgf
patient
vitro
upregul
autophagi
rapamycin
quantit
function
improv
bm
ecsand
huvec
manifest
diiacldl
doubl
stain
cell
increas
capac
migrat
lower
level
ro
apoptosi
via
regul
pathway
wherea
inhibit
autophagi
hcq
aggrav
huvec
bm
ec
pgf
patient
furthermor
vitro
upregul
autophagi
rapamycin
signific
improv
cfu
plate
effici
decreas
apoptosi
bm
hsc
cocultur
huvec
bm
ec
pgf
patient
conclus
find
suggest
defect
autophagi
bm
ec
may
involv
pathogenesi
pgf
effect
rapamycin
pgfpatient
potenti
mediat
improv
dysfunct
bm
ecsto
support
hsc
therefor
would
valu
investig
whether
upregul
cytoprotect
autophagi
bm
ec
may
amelior
pgf
therebi
provid
novel
clinic
intervent
pgf
futur
clinic
background
heparanas
hpse
specif
cleav
saccarid
chain
heparan
sulphat
proteoglycan
hs
lead
loss
integr
extracellular
matrix
releas
hsbound
cytokin
chemokin
angiogen
growth
factor
hpse
gene
polymorph
includ
approxim
snp
combin
two
snp
involv
regul
hpse
express
invers
correl
mrna
express
protein
level
ggcc
ggct
ggtt
gacc
low
group
express
high
hpse
concentr
gact
gatt
median
group
express
intermedi
hpse
level
aatt
aact
express
low
hpse
concentr
high
group
studi
hpse
snp
allogen
stem
cell
transplant
hsct
set
evalu
possibl
associ
posthsct
outcom
method
enrol
patient
submit
hsct
depart
sinc
coupl
recipientdonor
snp
genotyp
use
restrict
fragment
lenght
polymorph
assay
wherea
snp
allelespecif
polimeras
chain
reaction
appli
hpse
genotyp
distribut
compar
differ
group
accord
posthsct
outcom
graftversushost
diseas
gvhd
transplantrel
mortal
trm
overal
surviv
os
infecti
complic
diseasefre
surviv
df
statist
analysi
perform
use
ncss
result
distribut
snp
follow
gg
ga
aa
among
recipi
among
donor
respect
hardyweinberg
equilibrium
hwe
respect
distribut
snp
follow
cc
ct
tt
among
recipi
among
donor
respect
snp
distribut
respect
hwe
associ
found
recipi
snp
cumul
incid
agvhd
among
patient
submit
reduc
intens
condit
ric
tt
genotyp
ct
cc
genotyp
hand
associ
identifi
donor
snp
combin
cumul
incid
agvhd
low
group
donor
median
group
donor
high
group
donor
convers
aa
genotyp
donor
result
independ
risk
factor
cgvhd
de
novo
develop
od
togeth
donorrecipi
sex
mismatch
femal
donor
male
recipi
vs
other
od
consid
cmv
reactiv
rate
hsct
associ
observ
accord
recipi
snp
cc
genotyp
ct
genotyp
tt
genotyp
multivari
analysi
confirm
recipi
snp
independ
risk
factor
cmv
reactiv
hsct
od
togeth
recipi
cmv
serostatu
transplant
posit
vs
neg
p
od
conclus
hpse
role
wide
studi
set
inflamm
autoimmun
diseas
hematolog
diseas
tumor
howev
still
remain
debat
induc
protect
activ
hpse
set
gvhd
obvious
result
need
confirm
valid
cohort
clinic
trial
registri
na
disclosur
noth
declar
novel
protocol
autolog
hsct
patient
high
risk
complic
ambulatori
chemomobil
transplant
fresh
hematopoiet
stem
cell
backup
storag
background
autolog
hematopoiet
stem
cell
transplant
ahsct
standard
treatment
mani
patient
high
risk
complic
dialys
patient
patient
heart
kidney
amyloidosi
patient
system
sclerosi
introduc
recent
novel
protocol
ahsct
combin
ambulatori
mobil
low
dose
arac
gcsf
connect
direct
ahsct
fresh
cell
protocol
allow
us
reduc
transplant
risk
variou
patient
group
tradit
connect
high
risk
complic
work
summar
experi
high
risk
patient
method
prospect
collect
databas
patient
ahsct
search
patient
underw
ahsct
chemomobil
arac
transplant
fresh
cell
fulfil
least
one
studi
inclus
criteria
depend
dialysi
b
amyloidosi
c
system
sclerosi
disqualif
transplant
centr
due
high
risk
complic
togeth
patient
select
analysi
amyloidosi
organ
involv
dialys
system
sclerosi
unfit
centr
databas
includ
prospect
record
seriou
advers
event
mobil
transplant
result
transplant
perform
group
patient
mortal
day
patient
underw
success
ambulatori
mobil
patient
receiv
mephalan
condit
singl
infus
median
dose
min
max
mean
engraft
day
white
blood
cell
day
plt
gl
rate
complic
low
case
neutropen
fewer
singl
bacteri
cultur
staphylococcu
epidermidi
without
clinic
sign
infect
median
mucos
grade
without
patient
parenter
nutrit
median
time
hospit
day
min
max
conclus
present
novel
protocol
transplant
combin
chemomobil
ahsct
fresh
cell
excel
safeti
profil
among
sever
ill
patient
allow
safe
effici
transplant
protocol
abl
overcom
multipl
risk
factor
perform
full
intens
transplant
fragil
patient
disclosur
noth
declar
singl
umbil
cord
blood
transplant
provid
durabl
diseas
remiss
advanc
hematolog
malign
elderli
patient
background
although
allogen
hematopoiet
stem
cell
transplant
allo
hsct
potenti
cur
therapi
varieti
hematolog
malign
littl
report
outcom
elderli
patient
remiss
transplant
point
recipi
age
alon
regard
contraind
allo
hsct
literatur
recent
support
suitabl
donor
condit
regimen
appropri
manag
complic
conduct
retrospect
studi
elderli
patient
advanc
hematolog
malign
elucid
outcom
singl
umbil
cord
blood
transplant
sucbt
toranomon
hospit
kajigaya
japan
method
retrospect
investig
outcom
patient
age
underw
first
ucbt
june
decemb
medic
center
result
diseas
includ
acut
myelogen
leukemia
myelodysplast
syndrom
adult
tcell
leukemialymphoma
myelofibrosi
chronic
lymphocyt
leukemia
median
age
transplant
year
rang
followup
survivor
post
transplant
day
rang
patient
complet
remiss
cr
time
transplant
reduc
intens
condit
ric
regimen
use
patient
patient
receiv
tacrolimu
mycophenol
mofetil
graftversushost
diseas
gvhd
prophylaxi
case
except
earli
death
achiev
neutrophil
recoveri
median
day
rang
year
overal
surviv
os
rate
diseas
free
surviv
df
confid
interv
ci
perform
univari
analysi
identifi
factor
influenc
os
year
statist
signific
demonstr
age
transplant
age
vs
ci
vs
ci
cumul
incid
nonrelaps
mortal
nrm
day
ci
relaps
year
ci
two
patient
develop
acut
gvhd
iiiv
one
develop
sever
gvhd
day
transplant
main
caus
death
infect
includ
sepsi
viral
enceph
follow
idiopath
pneumonia
syndrom
thrombot
microangiopathi
earli
phase
transplant
contrast
patient
die
recurr
conclus
although
report
consist
relaps
refractori
diseas
elderli
patient
time
sucbt
durabl
remiss
lower
incid
gvhd
could
noteworthi
compar
previou
report
strategi
reduc
rate
nrm
longer
durat
follow
would
warrant
disclosur
background
pearson
syndrom
kearnssayr
syndrom
metabol
disord
caus
denovo
delet
mitochondri
dna
mtdna
allogen
stem
cell
transplant
shown
improv
metabol
function
distal
organ
sever
metabol
disord
bear
signific
morbid
mortal
especi
patient
mitochondri
disord
novel
gene
therapi
may
correct
diseas
rise
genom
dna
mutat
target
mitochondri
dna
complex
mitochondria
abl
transfer
cell
cell
seen
preclin
model
mitochondri
metabol
disord
introduc
novel
concept
mitochondri
augment
therapi
mat
autolog
cell
children
mitochondri
delet
syndrom
method
patient
treat
compassionateus
program
approv
sheba
medic
center
irb
isra
ministri
health
briefli
mobil
perform
use
gcsf
alon
addit
plerixafor
cell
isol
via
miltenyi
clinimac
system
cocultur
matern
mitochondria
drawn
peripher
blood
confirm
nondelet
hour
reinfus
patient
without
condit
patient
follow
clinic
metabol
paramet
result
four
patient
present
differ
delet
mitochondri
dna
differ
baselin
characterist
treat
age
year
despit
normal
cbc
signific
bone
marrow
hypocellular
seen
evalu
patient
cellular
age
correl
low
coloni
form
unit
capac
patient
low
yield
mobil
leukapheresi
product
patient
receiv
averag
enrich
cellskg
rang
median
enrich
cell
rang
infus
reaction
occur
sever
advers
event
cellular
therapi
leukapheresisrel
anemia
hypokalemia
hypocalcemia
alkalosi
resolv
promptli
proper
supplement
followup
durat
variabl
rang
month
abl
show
improv
mitochondri
heteroplasmi
proport
delet
mtdna
total
mitochondri
dna
normal
mtdna
content
start
month
cell
therapi
correl
improv
atp
product
peripher
blood
deriv
mononuclear
cell
clinic
patient
show
improv
aerob
function
endur
measur
halfbruc
protocol
sittostand
test
walk
test
muscl
strength
handheld
dynamometri
qualiti
life
measur
intern
pediatr
metabol
disabl
scale
metabol
crise
occur
follow
cell
infus
conclus
patient
delet
mtdna
metabol
dysfunct
includ
poor
bone
marrow
cellular
function
hematopoiet
stem
cell
patient
mtdna
delet
enrich
normal
mitochondria
via
mat
first
shown
patient
novel
process
safe
result
increas
normal
mtdna
peripher
blood
patient
improv
metabol
clinic
function
clinic
trial
registri
clinicaltrialsgov
disclosur
moria
blumkin
noa
sher
natali
yivgi
ohana
minovia
therapeut
employ
high
cytotox
effici
alpharetrovir
engin
chimer
antigen
receptor
natur
killer
cell
treatment
acut
lymphoblast
leukemia
stephan
tobia
bext
annekathrin
heinz
franziska
schenk
axel
schambach
winfri
wel
ute
modlich
evelyn
ullrich
background
autolog
chimer
antigen
receptormodifi
car
cell
specif
show
potent
antitumor
efficaci
clinic
trial
regard
relaps
refractori
acut
lymphoblast
leukemia
natur
killer
nk
cell
cytotox
lymphocyt
capabl
kill
target
nonspecif
manner
addit
caus
gvhd
therefor
use
cell
exhibit
sever
advantag
safeti
clinic
use
possibl
allogen
set
potenti
also
attack
heterolog
leukemia
cell
lost
previou
approach
use
cell
prestimul
feeder
cell
bear
potenti
risk
thu
focus
optim
gener
cell
viral
transduct
feedercel
free
condit
method
human
nk
cell
isol
healthi
donor
peripher
blood
mononuclear
cell
via
neg
select
feedercel
free
expans
phase
interleukin
transduct
perform
egfp
encod
vector
differ
multipl
infect
moi
optim
gene
modif
differ
transduct
enhanc
retronectin
viral
vector
system
lentivir
alpharetrovir
compar
final
gener
cell
test
abil
kill
cell
line
result
nk
cell
transduc
lentivir
egfp
encod
vector
lentivir
vector
use
retronectin
show
similar
transduct
effici
transduct
enhanc
egfp
retronectin
moi
moi
retronectin
moi
moi
moi
moi
gener
cell
show
increas
cytotox
capac
cell
compar
nontransduc
nt
nk
cell
vs
effector
target
e
ratio
nk
cell
popul
equal
effici
kill
cell
vs
alpharetrovir
transduct
nk
cell
egfp
encod
vector
show
higher
transduct
rate
retronectin
retronectin
moi
moi
moi
moi
use
similar
transduct
effici
could
achiev
alpharetrovir
encod
vector
moi
moi
moi
outperform
effici
lentivir
gener
cell
experi
moi
moi
moi
addit
alpharetrovir
cell
show
higher
cell
kill
activ
cell
lentivir
cell
ntnk
cell
vs
vs
e
ratio
interestingli
similar
kill
activ
achiev
e
ratio
vs
vs
alpharetrovir
cell
remain
stabl
cytotox
level
lower
cell
concentr
e
ratio
three
nk
cell
popul
equal
effici
kill
cell
vs
vs
e
ratio
conclus
cell
success
gener
feedercel
free
condit
use
differ
transduct
enhanc
viral
vector
system
data
suggest
usag
combin
alpharetrovir
vector
genet
modifi
nk
cell
achiev
suffici
amount
transduc
cell
cell
mediat
high
cytotox
therefor
may
offer
new
therapeut
option
treatment
disclosur
axel
schambach
inventor
patent
describ
alpharetrovir
sin
vector
winfri
wel
inventor
patent
describ
chimer
antigen
receptor
optim
hing
region
remain
author
noth
disclos
graftversushost
diseaseclin
walter
bianca
huberkrassnitz
barbara
uhl
gregor
gorkiewicz
hildegard
greinix
christoph
peter
neumeist
background
steroidrefractori
acut
gastrointestin
gi
graftversushost
diseas
agvhd
sever
complic
allogen
hematopoiet
stem
cell
transplant
allohsct
associ
high
mortal
rate
loss
intestin
bacteri
divers
thought
associ
sever
giagvhd
impair
intestin
microbiota
reduc
divers
independ
predictor
mortal
method
fecal
microbiota
transplant
fmt
procedur
perform
accord
protocol
approv
local
ethic
committe
obtain
inform
consent
donor
healthi
adult
subject
screen
potenti
infect
serolog
microbiolog
test
accord
local
standard
donor
stool
dilut
salin
homogen
volum
ml
fecal
solut
instil
termin
ileum
caecum
via
colonoscop
microbiota
sequenc
analysi
rdna
perform
fmt
afterward
predefin
timepoint
result
report
outcom
nine
patient
refractori
line
immunosuppress
therapi
lower
gistag
iii
iv
agvhd
follow
repetit
fmt
singl
donor
patient
receiv
allohsct
md
aml
pmf
mm
follow
reduc
intens
mac
condit
regimen
use
pbsc
stem
cell
sourc
onset
lower
gi
agvhd
day
allohsct
nine
patient
refractori
sever
line
immunosuppress
therapi
receiv
fmt
patient
treat
fmt
patient
fmt
administ
twice
mostli
weekli
interv
five
patient
achiev
clinic
complet
respons
resolv
diarrhea
gastrointestin
complaint
four
could
discharg
without
gvhd
symptom
two
patient
pr
nc
discontinu
fmt
pr
nc
due
concomit
infect
metapneumovir
pneumonia
cmv
gastroenter
nonrespond
succumb
gvhdrelat
infecti
complic
establish
donor
microbiota
emerg
new
taxa
increas
bacteri
richnessdivers
disappear
enterococcu
signatur
associ
diseas
control
respons
fmt
except
possibl
transmiss
adenoviru
fmt
one
patient
immedi
procedurerel
infect
side
effect
observ
conclus
restor
dysbiosi
fmt
might
repres
promis
novel
therapeut
approach
subset
patient
refractori
lower
giagvhd
vigor
donor
screen
infecti
diseas
mandatori
clinic
background
migrat
alloactiv
donor
effector
tcell
lymphoid
tissu
target
organ
import
step
acut
graft
versu
host
diseas
gvhd
receptor
play
crucial
role
lymphocyt
traffick
data
anim
model
suggest
pharmacolog
modul
receptor
reduc
gvhd
improv
mortal
investig
mode
action
use
secondgener
modul
prophylaxi
gvhd
pilot
clinic
trial
patient
undergo
allogen
hsct
method
multicentr
phase
prospect
open
label
twopart
studi
conduct
evalu
safeti
toler
pharmacokinet
patient
undergo
allogen
hsct
hematolog
malign
primari
endpoint
safeti
initi
efficaci
explor
base
incid
gvhd
mortal
relaps
part
singl
arm
open
label
studi
investig
safeti
mgday
ad
standard
care
gvhd
prophylaxi
csamtx
patient
part
random
twoarm
open
label
studi
compar
safeti
efficaci
pk
mgday
combin
tacrolimusmtx
mgday
combin
csamtx
patient
part
treatment
initi
day
hsct
continu
addit
day
patient
follow
year
result
patient
includ
studi
patient
complet
treatment
assign
dose
median
durat
followup
day
rang
day
safe
well
toler
seriou
advers
event
sae
suspect
relat
observ
macular
edema
peripher
edema
relat
advers
event
occur
resolv
without
sequela
note
incid
macular
edema
hsct
recipi
unknown
neutrophil
engraft
confirm
patient
median
day
rang
day
patient
present
grade
iii
iv
acut
gvhd
day
gvhd
infect
relat
death
occur
first
day
surviv
death
occur
treatment
death
occur
studi
day
due
lymphoma
relaps
second
death
occur
studi
day
due
liver
gvhd
four
patient
die
followup
period
due
gastrointestin
gvhd
day
aspir
pneumonia
day
relaps
day
day
kaplanmei
estim
overal
surviv
year
compar
data
two
dose
group
mg
major
differ
safeti
engraft
gvhd
rate
mortal
observ
conclus
clinic
trial
first
test
modul
popul
data
suggest
neg
impact
engraft
overal
safe
well
toler
base
exploratori
data
compar
match
histor
mortal
data
may
favor
effect
overal
surviv
figur
background
uric
acid
danger
signal
contribut
inflamm
relev
allosct
demonstr
preclin
model
deplet
uric
acid
led
improv
surviv
reduc
gvhd
j
exp
med
sep
result
clinic
pilot
trial
suggest
peritranspl
uric
acid
deplet
reduc
acut
gvhd
incid
bbmt
may
method
intern
multicentr
studi
aim
studi
associ
uric
acid
serum
level
start
condit
allosct
outcom
patient
acut
leukemia
lymphoma
md
receiv
match
sibl
allosct
first
time
consid
inclus
regardless
condit
data
prospect
collect
comparison
outcom
patient
high
low
uric
acid
level
perform
use
univari
analysi
multivari
analysi
use
causespecif
cox
model
variabl
includ
multivari
analys
age
sex
mismatch
diagnosi
diseas
statu
karnofski
score
number
cell
given
intens
condit
type
gvhd
prophylaxi
atg
use
time
diagnosi
transplant
year
transplant
cmv
statu
result
twenti
center
european
countri
report
data
allosct
recipi
patient
characterist
given
tabl
uric
acid
cut
point
determin
median
measur
uric
acid
level
overal
surviv
os
progress
free
surviv
pf
allosct
recipi
uric
acid
level
cut
measur
start
condit
significantli
shorter
figur
os
univari
p
multivari
p
figur
pf
univari
multivari
nonrelaps
mortal
significantli
increas
allosct
recipi
high
uric
acid
level
prior
start
condit
univari
multivari
addit
nonsignific
trend
toward
higher
acut
gvhd
incid
gvhd
grade
iiiv
univari
multivari
allosct
recipi
uric
acid
level
cut
transplant
final
incid
relaps
allosct
moder
increas
cohort
higher
uric
acid
level
univari
multivari
conclus
high
uric
acid
level
start
condit
correl
high
mortal
allosct
result
serv
rational
clinic
trial
deplet
uric
acid
allosct
result
found
signific
correl
donor
g
polymorph
hsct
outcom
genotyp
aa
present
donor
ag
donor
donor
homozyg
g
allel
recipi
receiv
graft
g
allel
carrier
donor
show
significantli
increas
cumul
incid
relaps
month
aa
ag
gg
contrari
frequenc
acut
gvhd
grade
iiiiv
cytomegaloviru
cmv
reactivationdiseas
decreas
accord
presenc
g
allel
donor
genotyp
agvhd
aa
ag
gg
p
cmv
aa
ag
gg
p
cumul
incid
agvhd
also
markedli
decreas
among
patient
g
allel
carrier
donor
day
aa
ag
gg
donor
genotyp
similarli
influenc
hsct
outcom
mud
donor
mac
condit
subgroup
overal
surviv
os
differ
patient
subgroup
accord
donor
genotyp
os
month
aa
ag
gg
p
find
correl
recipi
g
polymorph
hsct
outcom
conclus
sever
snp
previous
describ
associ
relaps
rate
incid
agvhd
os
result
often
contradictori
public
studi
g
polymorph
hsct
donor
influenc
risk
relaps
agvhd
cmv
caus
death
overal
surviv
genotyp
g
polymorph
donor
may
help
risk
assess
process
choic
personalis
therapi
disclosur
noth
declar
background
although
steroid
remain
firstlin
therapi
treatment
acut
graft
versu
host
diseas
agvhd
respons
rate
patient
grade
iiiiv
diseas
poor
appar
improv
surviv
past
year
perform
prospect
multicent
trial
assess
efficaci
safeti
combin
ruxolitinib
etanercept
novel
approach
treat
grade
iiiiv
sragvhd
method
forti
malign
hematolog
diseas
patient
grade
iiiiv
sragvhd
allosct
three
center
east
china
enrol
januari
june
ruxolitinib
initi
dose
mg
bid
month
taper
gradual
anoth
one
month
etanercept
administr
biw
week
result
median
age
patient
rang
year
day
combin
treatment
overal
respons
rate
orr
includ
cr
pr
median
time
optim
respons
rang
day
incid
cr
per
organ
skin
liver
gut
respect
agvhd
relaps
rate
analyz
patient
achiev
cr
pr
surviv
beyond
day
relaps
agvhd
occur
respons
patient
patient
receiv
ruxolitinib
within
day
agvhd
onset
signific
higher
cr
rate
delay
ruxolitinib
therapi
vs
patient
without
gut
infect
signific
higher
cr
rate
infect
cohort
vs
logist
regress
analysi
time
agvhd
ruxolitinib
gut
infect
independ
predictor
incomplet
respons
thirteen
patient
suffer
least
infecti
episod
start
combin
therapi
pulmonari
infecti
diseas
frequent
complic
iiiiv
cytopenia
cmvreactiv
observ
patient
overal
surviv
os
initi
combin
therapi
nrm
relaps
incid
respect
patient
complet
respons
day
significantli
higher
os
probabl
noncr
patient
os
vs
compar
histor
cohort
basiliximab
etanercept
sragvhd
center
signific
differ
found
baselin
although
orr
patient
treat
ruxolitinib
etanercept
ident
histor
cohort
ruxolitinib
group
achiev
rapid
remiss
liver
agvhd
gut
agvhd
histor
cohort
gut
agvhd
day
vs
day
liver
agvhd
day
vs
day
thu
regard
hospit
stay
agvhd
onset
ruxolitinib
cohort
stay
shorter
median
day
vs
day
basiliximab
cohort
conclus
combin
treatment
ruxolitinib
etanercept
result
rapid
cr
viscer
agvhd
meanwhil
reserv
graft
antileukemia
gvl
effect
relaps
rate
primari
diseas
rel
lower
variou
infect
complic
associ
ruxolitinib
merit
attent
disclosur
noth
declar
background
graftversushost
diseas
gvhd
remain
one
main
lifethreaten
complic
allohsct
especi
patient
nonmalign
diseas
standard
gvhd
prophylaxi
strategi
mostli
base
use
calcineurin
inhibitor
alon
combin
immunosuppress
posttranspl
cyclophosphamid
ptci
effect
gvhd
prophylaxi
optiont
adult
patient
pt
limit
data
children
method
studi
aim
evalu
ptci
gvhd
prophylaxi
pediatr
pt
inherit
disord
undergo
allohsct
pt
pediatr
age
median
age
yo
rang
month
yo
differ
type
inherit
disord
bone
marrow
failur
syndrom
storag
diseas
primari
immunodeficiencydisord
inrol
retrospect
studi
donor
type
matchedmismatch
unrel
mudmmud
match
relat
donor
mrd
haploident
haplo
condit
regimen
myeloabl
mac
reduceintens
ric
graft
sours
bone
marrow
bm
peripher
blood
stem
cell
pbsc
combint
bm
pbscbmcord
blood
ptci
mgkg
day
base
gvhd
prophylaxi
reciv
pt
standart
gvhd
prophylaxi
base
calcineurin
inhibitor
pt
result
cumul
incid
ci
agvhd
grade
agvhd
respect
ptci
base
gvhd
prophylaxi
reduc
ci
agvhd
vs
anoth
reduc
ci
agvhd
factor
mac
vs
ric
pt
group
mrd
vs
haplo
group
vs
mudmmud
group
bm
transplant
sourc
vs
pbsc
group
multivari
analysi
mac
hr
ci
time
diagnosi
allohsct
less
month
hr
ci
predict
reduc
ci
agvhd
agvhd
st
signific
factor
increas
ci
femal
donor
univari
vs
multivari
analysi
hr
ci
year
overal
surviv
os
improv
os
factor
transplant
age
younger
yo
vs
time
diagnosi
allohsct
less
month
vs
engraft
vs
multivari
analysi
transplant
age
younger
yo
hr
ci
engraft
hr
ci
predict
os
conclus
ptcybas
gvhd
prophylaxi
effect
option
reduc
risk
acut
gvhd
use
unrel
donor
bone
marrow
transplant
sourc
mac
reduc
ci
gvhd
perform
allohscr
earlier
diagno
earlier
age
improv
os
patient
inherit
disord
background
diarrhea
frequent
complic
allosct
onset
often
difficult
differenti
gi
gvhd
caus
enterocol
recent
noninvas
test
fecal
calprotectin
fc
valid
marker
gut
inflamm
patient
inflammatori
bowel
diseas
studi
publish
regard
use
diagnost
marker
gi
gvhd
method
aim
studi
explor
level
fc
allosct
recipi
newonset
diarrhea
far
includ
allosct
recipi
develop
acut
diarrhea
stage
median
day
post
allosct
stool
sampl
analyz
soon
possibl
onset
diarrhea
fc
level
determin
addit
extens
microbiolog
panel
infecti
enterocol
includ
noroviru
pcr
c
difficil
associ
diarrhea
endoscopi
histolog
analysi
perform
accord
treat
physician
discret
result
patient
characterist
summar
tabl
median
followup
survivor
day
twentyeight
patient
diagnos
gigvhd
addit
caus
diarrhea
drugrel
enterotox
viral
enter
food
intoler
cjejunienter
nonspecif
caus
concentr
fc
higher
patient
gi
gvhd
vs
caus
diarrhea
vs
p
patient
develop
sever
enterocol
normal
slightli
rais
calprotectin
onset
diarrhea
case
includ
patient
enterotox
drugrel
diarrhea
among
patient
gigvhd
later
found
steroidresist
shown
figur
found
signific
associ
high
fc
severerefractori
gvhd
hr
note
high
valu
fc
also
found
patient
sever
infecti
enter
noroviru
adenoviru
cjejuni
infect
baselin
fc
respect
overal
surviv
month
hypoalbuminemia
thrombocytopenia
variabl
link
os
univari
analysi
regardless
caus
enterocol
conclus
absenc
standar
expens
biomark
panel
analyz
predict
gvhd
onset
outcom
fc
test
may
use
tool
allosct
set
initi
result
show
fc
help
predict
mild
caus
diarrhea
identifi
patient
high
probabl
develop
sever
potenti
steroidrefractori
gi
gvhd
although
high
level
also
found
sever
infecti
enter
background
urgent
need
effect
therapi
sever
acut
gvhd
result
gvhd
therapi
beyond
month
rare
report
report
median
followup
year
introduc
mesenchym
stromal
cell
therapi
sever
acut
gvhd
dramat
respons
patient
placenta
protect
fetu
mother
haploident
immun
system
pregnanc
found
matern
stromal
cell
fetal
membran
call
decidua
stromal
cell
dsc
immunosuppress
sourc
stromal
cell
method
treat
patient
median
year
age
rang
sever
acut
gvhd
biopsi
proven
gastrointestin
gvhd
steroid
progress
day
use
improv
protocol
dsc
thaw
infus
buffer
albumin
dsc
given
median
dose
x
cellskg
dose
given
one
week
apart
viabil
frozen
thaw
dsc
cell
passag
result
complet
resolut
gvhd
seen
patient
partial
respons
cumul
incid
chronic
gvhd
six
mild
moder
one
sever
nih
overal
gvhd
sever
score
nine
patient
die
relaps
acut
gvhd
septicemia
zygomycet
infect
liver
insuffici
cerebr
hemorrhag
failur
chronic
gvhd
obstruct
bronchiol
four
year
transplant
relat
mortalliy
overal
surviv
surviv
significantli
wors
patient
undergo
allogen
hematopoiet
cell
transplant
period
conclus
conclud
dsc
seem
promis
therapi
sever
acut
gvhd
random
trial
way
disclosur
noth
declar
antiapoptot
protein
upregul
graftversushost
diseas
stem
cell
transplant
allohsct
develop
either
acut
chronic
gvhd
recent
inhibitor
venetoclax
approv
treatment
chronic
lymphocyt
leukemia
induct
apoptosi
deplet
lymphocyt
subpopul
eg
follicular
bcell
tcell
led
explor
autoimmun
diseas
method
establish
express
level
gene
pathway
lowinput
rna
sequenc
perform
cell
isol
noninflam
skin
peripher
blood
hsct
recipi
differ
time
point
year
transplant
furthermor
analyz
blood
lung
gut
skin
sampl
patient
post
allohsct
without
previous
untreat
acut
chronic
gvhd
rtpcr
flow
cytometri
tissu
immunofluoresc
imag
upregul
b
lymphocyt
acut
chronic
gvhd
lesion
result
rnasequenc
reveal
cell
upregul
upon
condit
treatment
day
cell
patient
later
develop
gvhd
fail
downregul
transplant
protein
level
elev
overal
leukocyt
pathogen
cell
subset
includ
monocyt
lymphocyt
nkt
cell
show
significantli
higher
express
peripher
blood
gvhd
patient
compar
healthi
control
result
could
recapitul
tissu
sampl
diseasepromot
lymphocyt
b
nk
nkt
numer
expand
express
acut
chronic
gvhd
skin
lesion
notabl
nonpathogen
cell
type
keratinocyt
exhibit
increas
express
compar
control
sampl
hsct
recipi
healthi
donor
rna
express
depend
type
condit
mac
vs
ric
gvhd
grade
correl
diseas
sever
significantli
elev
biopsi
patient
steroidrefractori
gvhd
conclus
could
show
exclus
upregul
gvhdmediat
cell
type
peripher
blood
tissu
sampl
affect
gvhd
correl
gvhd
sever
respons
firstlin
therapi
thu
inhibit
may
present
novel
urgent
need
target
therapi
treatment
steroidrefractori
acut
chronic
gvhd
disclosur
support
docm
fellowship
od
austrain
academi
scienc
background
graftversushost
diseas
gvhd
repres
major
contributor
morbid
mortal
recipi
allogen
hematopoiet
cell
transplant
hct
sever
therapeut
strategi
exist
gvhd
prophylaxi
includ
posttranspl
cyclophosphamid
ptci
antithymocyt
globulin
atg
sever
group
describ
use
ptci
younger
patient
pauciti
data
efficaci
ptci
older
individu
particularli
combin
atg
investig
combin
effect
ptci
atg
transplant
outcom
older
patient
princess
margaret
cancer
centr
toronto
canada
method
retrospect
studi
includ
patient
age
underw
allogen
hct
indic
centr
decemb
juli
overal
surviv
os
calcul
use
kaplanmei
analysi
multivari
cox
proport
hazard
regress
cumul
incid
relaps
cir
nonrelaps
mortal
nrm
calcul
use
compet
risk
regress
fine
gray
method
incid
acut
agvhd
chronic
cgvhd
compar
use
fisher
exact
test
result
patient
male
median
age
rang
median
followup
among
survivor
month
rang
acut
myeloid
leukaemia
aml
common
indic
hct
patient
follow
myelodysplast
syndrom
patient
myelofibrosi
patient
eightyfour
patient
match
unrel
donor
match
relat
donor
haploident
donor
one
hundr
twentyf
patient
receiv
reduc
intens
condit
sixtytwo
patient
receiv
ptci
combin
atg
mgkg
receiv
form
gvhd
prophylaxi
os
year
confid
interv
ci
entir
cohort
patient
receiv
ptci
atg
superior
os
compar
gvhd
prophylaxi
regimen
figur
ci
vs
ci
respect
ci
nrm
entir
cohort
ci
patient
receiv
ptci
atg
lower
nrm
compar
figur
ci
vs
ci
respect
ci
cir
whole
group
ci
use
ptci
atg
associ
modest
increas
cir
two
year
figur
ci
vs
respect
ci
trend
toward
lower
incid
grade
iiiv
agvhd
among
patient
receiv
ptci
atg
compar
vs
incid
grade
iiiv
cgvhd
lower
individu
receiv
ptci
atg
compar
vs
conclus
older
hct
recipi
use
ptci
combin
atg
associ
improv
os
lower
nrm
decreas
risk
agvhd
cgvhd
modest
increas
relaps
risk
therefor
ptci
atg
combin
repres
effect
strategi
gvhd
prophylaxi
older
allogen
hct
recipi
disclosur
author
conflict
interest
declar
outcom
sever
graft
versu
host
diseas
pediatr
patient
nonmalign
diseas
allogen
bone
marrow
transplant
singl
center
experi
irina
zaidman
sigal
grisariu
batia
avni
ehud
evenor
bella
shadur
adeeb
nasereddin
polina
stepenski
background
hematopoiet
stem
cell
transplant
hsct
remain
cur
option
mani
nonmalign
diseas
pediatr
patient
surviv
hsct
improv
last
year
due
signific
advanc
human
leukocyt
antigen
hla
type
techniqu
less
toxic
condit
regimen
better
support
care
result
surviv
cure
non
malign
diseas
graftversushost
diseas
gvhd
remain
major
complic
hsct
lead
caus
morbid
mortal
prognosi
patient
high
grade
gvhd
dismal
surviv
rate
vari
pediatr
patient
method
retrospect
studi
includ
patient
non
malign
diseas
underw
allogen
hsct
hadassah
medic
center
collect
data
includ
clinic
data
transplant
characterist
studi
approv
institut
helsinki
committe
result
children
nonmalign
diseas
underw
allogen
bone
marrow
transplant
hadassah
univers
hospit
ten
year
period
fifti
seven
patient
develop
agvhd
grade
twenti
five
grade
median
age
rang
patient
male
male
femal
patient
underw
bmt
fulli
match
famili
member
children
transplant
match
unrel
donor
mismatch
donor
twenti
one
patient
sever
gvhd
surviv
four
patient
die
sever
gvhd
complic
immunosuppress
treatment
deceas
patient
transplant
mismatch
donor
case
age
donor
advanc
patient
develop
sever
gvhd
die
second
hsct
patient
refractori
differ
treatment
modal
three
patient
die
one
death
sever
gvhd
patient
transplant
develop
high
grade
gvhd
conclus
result
studi
show
high
surviv
rate
pediatr
patient
non
malign
diseas
sever
gvhd
signific
risk
factor
mortal
group
includ
mismatch
donor
advanc
age
donor
second
transplant
trend
better
surviv
observ
addit
multicentr
studi
analyz
outcom
agvhd
pediatr
patient
nonmalign
diseas
urgent
requir
background
chronic
graftversushost
diseas
cgvhd
seriou
late
complic
allogen
hematopoiet
stem
cell
transplant
allohsct
heterogen
present
still
poorli
understood
pathophysiolog
includ
inflamm
endotheli
dysfunct
factor
viii
fviii
von
willebrand
factor
vwf
coagul
factor
also
known
indic
endotheli
dysfunct
inflamm
differ
set
therefor
could
serv
interest
candid
biomark
cgvhd
method
sinc
patient
allohsct
assess
multidisciplinari
cgvhd
team
univers
hospit
center
zagreb
croatia
use
establish
nih
cgvhdrelat
measur
extens
histori
physic
laboratori
evalu
perform
includ
fviii
vwf
ag
vwf
ac
analysi
descript
statist
nonparametr
analys
perform
variabl
show
signific
univari
correl
use
multivari
logist
regress
mlr
identifi
predict
fviii
vwf
ag
vwf
ac
cgvhd
patient
result
cgvhd
patient
control
subject
allohsct
without
cgvhd
analys
median
age
cgvhd
patient
year
femal
underw
allohsct
hematolog
malign
myeloabl
condit
match
relat
donor
median
time
hsct
studi
day
cgvhd
diagnosi
studi
day
demograph
neither
transplant
relat
signific
differ
cgvhd
patient
control
besid
stem
cell
sourc
peripher
blood
vs
histori
acut
gvhd
vs
p
major
patient
moder
sever
nih
global
cgvhd
score
activ
cgvhd
impress
median
number
organ
involv
cgvhd
frequent
involv
organ
mouth
skin
eye
cgvhd
patient
compar
control
higher
fviii
level
median
vs
refer
rang
higher
vwf
ag
median
vs
refer
rang
vwf
ac
show
trend
toward
higher
level
among
patient
median
vs
refer
rang
patient
higher
ggt
lower
anticardiolipin
igg
igm
lower
albumin
control
without
differ
laboratori
paramet
univari
analysi
show
among
cgvhd
patient
higher
fviii
associ
wors
karnofski
score
ks
perform
score
ps
higher
leukocyt
cholesterol
triglycerid
ast
alt
ggt
ldh
lower
albumin
higher
vwf
ag
vwf
ac
cgvhd
patient
associ
wors
ks
ps
p
activ
cgvhd
p
wors
nih
cgvhd
liver
nih
cgvhd
mouth
higher
total
nih
score
higher
number
organ
involv
higher
esr
monocyt
ddimer
ast
alt
ggt
ldh
triglycerid
ferritin
total
protein
iga
lower
albumin
mlr
analysi
show
leukocyt
cholesterol
strongest
predictor
fviii
p
strongest
predictor
vwf
ac
number
organ
involv
cgvhd
conclus
result
studi
detect
high
fviii
vwf
level
cgvhd
patient
possibl
reflect
cgvhd
manifest
need
confirm
larger
longitudin
studi
disclosur
work
support
part
uniti
knowledg
fund
project
entitl
clinic
biolog
factor
determin
sever
activ
chronic
graftversushost
diseas
allogen
hematopoiet
stem
cell
transplant
also
part
croatian
scienc
foundat
project
entitl
new
biomark
chronic
graftversushost
diseas
antonela
samardz
work
financ
croatian
scienc
fondat
young
research
career
develop
project
train
doctor
student
background
thrombot
microangiopathi
tma
sever
complic
allogen
hematopoiet
cell
transplant
hct
multisystem
involv
recent
report
recogn
evid
tma
intestin
vasculatur
intestin
tmaitma
patient
graftversushost
diseas
gvhd
without
tma
aim
identifi
patient
itma
describ
histolog
clinic
prognost
featur
method
prospect
evalu
avail
endoscop
sampl
stomach
andor
colon
consecut
adult
hct
recipi
previous
describ
histopatholog
sign
itma
januari
system
tma
diagnos
accord
intern
work
group
criteria
compar
find
among
clinic
group
gvhdsystem
tma
gvhdno
system
tma
gvhdno
tma
result
studi
patient
classifi
gvhd
system
tma
gvhdno
system
tma
gvhdno
tma
baselin
transplant
characterist
age
donor
hla
match
condit
differ
significantli
among
group
histolog
featur
itma
includ
loss
gland
total
denud
mucosa
apoptosi
detach
endotheli
cell
intralumin
fibrin
intralumin
microthrombi
mucos
hemorrhag
found
patient
previous
describ
featur
intralumin
schistocyt
observ
patient
interestingli
loss
gland
total
denud
mucosa
apoptosi
detach
endotheli
cell
also
found
patient
gvhd
itma
suggest
featur
pathognomon
itma
among
itma
patient
two
patient
classifi
clinic
group
acut
gvhdsystem
tma
patient
clinic
histopatholog
featur
itma
sever
grade
iiiiv
steroidrefractori
acut
gvhd
patient
extens
chronic
gvhd
patient
evid
system
tma
major
patient
itma
occur
earli
posttranspl
period
month
clinic
featur
gastrointestin
bleed
diarrhea
pain
nausea
present
differ
patient
without
itma
prognosi
poor
patient
itma
suffer
significantli
higher
mortal
rate
compar
rest
patient
popul
median
followup
month
overal
surviv
probabl
os
itma
gvhd
system
tma
unfavor
predict
factor
os
itma
hla
mismatch
donor
gastrointestin
bleed
conclus
intestin
tma
emerg
novel
distinct
entiti
patient
gvhd
andor
system
tma
distinct
histolog
featur
may
use
differenti
diagnosi
sever
hct
complic
mortal
rate
higher
system
tma
highlight
need
proper
recognit
itma
need
studi
term
diagnost
therapeut
potenti
disclosur
eg
support
european
hematolog
associ
clinic
research
grant
remain
author
declar
compet
financi
interest
benefici
effect
thrombomodulin
gene
polymorph
hematopoiet
stem
cell
transplant
background
chronic
graftversushost
diseas
cgvhd
remain
major
caus
late
morbid
mortal
allogen
blood
marrow
transplant
treatment
option
cgvhd
particularli
sclerot
form
remain
limit
activ
hedgehog
hh
signal
shown
therapeut
target
mous
human
cgvhd
limit
efficaci
signific
toxic
describ
publish
clinic
trial
defilipp
method
adult
patient
steroid
refractori
sclerodermat
cgvhd
defin
requir
mgkgday
prednison
dose
equival
pde
need
secondor
thirdlin
therapi
beyond
corticosteroid
calcineurin
inhibitor
sirolimu
elig
open
label
studi
vismodegib
first
gener
hh
pathway
inhibitor
primari
endpoint
failur
free
surviv
defin
absenc
nonrelaps
mortal
recurr
malign
steroid
dose
month
mgkgday
pde
addit
new
system
treatment
vismodegib
administ
oral
month
dose
reduct
develop
toxic
peripher
blood
mononuclear
cell
isol
sampl
collect
treatment
initi
everi
three
month
thereaft
immun
profil
circul
b
cell
analyz
flow
cytometri
helper
polar
qrtpcr
sortpurifi
cell
result
time
interim
analysi
patient
evalu
patient
complet
month
treatment
five
patient
complet
month
treatment
therapi
discontinu
patient
prior
month
due
treatmentrel
unrel
side
effect
patient
experienc
grade
toxic
muscl
cramp
dysgeusia
singl
grade
toxic
weight
loss
patient
complet
month
therapi
demonstr
partial
respons
overal
primari
endpoint
reach
patient
patient
discontinu
vismodegib
cgvhd
worsen
acut
discontinu
correl
analysi
immun
cellular
subset
peripher
blood
pair
sampl
pretreat
month
therapi
document
modul
b
cell
subset
pathogen
cgvhd
pregermin
center
plasmablastlik
b
cell
diminish
helper
polar
cell
conclus
overal
use
vismodegib
associ
potenti
clinic
efficaci
sclerodermat
cgvhd
possibl
mechanist
evid
aris
correl
studi
side
effect
common
studi
hh
inhibit
cgvhd
warrant
futur
studi
employ
adjust
dose
regimen
along
support
care
intervent
offset
side
effect
test
novel
hh
inhibitor
enhanc
safeti
profil
clinic
background
graftversushost
diseas
gvhd
result
recognit
host
antigen
donor
cell
follow
allogen
hematopoiet
stem
cell
transplant
sct
test
hypothesi
somat
neomut
occur
sct
donor
andor
recipi
dna
may
trigger
gvhd
method
longitudin
analyz
constitut
somat
mutat
whole
exom
sequenc
we
patient
receiv
sct
sexmatch
hlaident
sibl
mutat
acut
myeloid
leukemia
pt
mutat
primari
myelofibrosi
pt
patient
initi
refractori
alloreact
ie
display
sign
gvhd
even
sever
donor
lymphocyt
infus
acut
gut
gvhd
final
occur
dli
preced
lymphodeplet
chemotherapi
pt
gvhd
correl
graftversustumor
effect
we
perform
dna
recipi
saliva
donor
pbmc
germlin
sampl
sequenti
postsct
pbmc
sampl
illumina
pairedend
read
mean
depth
coverag
germlin
somat
mutat
determin
use
inhous
bioinformat
pipelin
name
ewok
curi
institut
smaug
henri
mondor
hospit
use
briefli
gatk
variant
caller
germlin
sampl
combin
variant
caller
match
normaltumor
pair
adjust
paramet
detect
somat
mutat
minim
variant
allel
frequenc
vaf
compar
recipi
donor
germlin
variat
minim
coverag
germlin
tumor
sampl
result
we
allow
detect
somat
driver
mutat
explain
aml
pmf
patient
initi
timepoint
driver
mutat
disappear
follow
timepoint
expect
somat
variant
rate
higher
pt
aml
pt
pmf
timepoint
except
final
gvhd
timepoint
inde
final
point
somat
variant
rate
dramat
decreas
compar
previou
timepoint
subtract
variant
detect
preand
postsct
identifi
ultim
timepoint
gvhd
occurr
creat
set
variant
respect
patient
keep
variant
least
read
mutat
dna
variant
classifi
categori
slight
increas
time
gvhd
ie
compar
highest
previou
vaf
alpp
gene
ii
signific
increas
time
ie
compar
highest
previou
vaf
gene
none
variant
gene
involv
common
patient
ontolog
classif
mutat
gene
show
implic
cell
death
regul
map
kinas
activ
mrna
splice
immun
system
process
make
good
candid
studi
identif
variant
appear
pregvh
turn
time
gvhd
ongo
unveil
put
neoantigen
could
trigger
alloreact
respons
conclus
use
comprehens
preand
postsct
we
donorrecipi
pair
identifi
sever
neomut
donor
andor
recipi
dna
correl
gvhgvt
effect
develop
disclosur
result
total
patient
experienc
cgvhd
mild
moder
sever
cgvhd
observ
patient
respect
cumul
incid
total
cgvhd
ci
cumul
incid
moder
sever
sever
cgvhd
ci
ci
respect
patient
loci
mismatch
higher
cumul
incid
total
cgvhd
vs
moder
sever
cgvhd
vs
compar
patient
loci
mismatch
patient
matern
donor
higher
cumul
incid
moder
sever
cgvhd
vs
compar
patient
donor
patient
grade
iii
iv
acut
graftversushost
agvhd
higher
cumul
incid
total
cgvhd
vs
p
moder
sever
cgvhd
vs
p
compar
patient
without
agvhd
multivari
analysi
grade
iii
iv
agvhd
independ
risk
factor
total
cgvhd
ci
p
moder
sever
cgvhd
ci
p
model
exclud
agvhd
matern
donor
risk
factor
moder
sever
cgvhd
ci
conclus
observ
sever
agvhd
import
risk
factor
cgvhd
haplohsct
intervent
consid
patient
prevent
sever
cgvhd
disclosur
none
author
potenti
financi
conflict
interest
relat
manuscript
background
extracorpor
photopheresi
ecp
success
use
treatment
graftversushost
diseas
gvhd
ecp
therapi
might
restor
balanc
effector
regulatori
cell
sever
impair
gvhd
nk
cell
first
lymphocyt
subset
reconstitut
allogen
hematopoiet
stem
cell
transplant
allohsct
import
innat
immun
cell
popul
nk
cell
tempor
bridg
transient
period
tcell
defici
post
allohsct
protect
opportunist
infect
prevent
leukem
relaps
graftversusleukemia
gvl
effect
nk
cell
preserv
homeostasi
target
kill
alloreact
cell
therebi
control
gvhd
also
enhanc
inflamm
secret
therebi
promot
gvhd
therefor
investig
role
nk
cell
gvhd
patient
ecp
therapi
method
thirti
four
patient
steroidrefractori
resist
agvhd
moder
sever
cgvhd
receiv
ecp
therapi
perform
accord
guidelin
glucksberg
nih
criteria
use
clinic
stage
agvhd
cgvhd
ecp
therapi
respect
comprehens
phenotyp
analysi
nk
cell
evalu
multicolor
flow
cytometri
nk
activ
term
kill
function
cytokin
releas
capac
prolifer
function
monitor
releas
assay
intracellular
cytokin
stain
cfse
stain
respect
result
five
differ
nk
cell
subset
defin
base
express
bri
nk
cell
display
immatur
activ
profil
high
express
agvhd
patient
higher
frequenc
bri
nk
cell
compar
hd
cgvhd
patient
character
signific
increas
dim
nk
cell
subset
high
express
differenti
marker
note
bri
nk
cell
could
serv
novel
predict
biomark
respons
agvhd
patient
ecp
treatment
respond
agvhd
patient
increas
bri
nk
cell
observ
alreadi
earli
ecp
treatment
phase
suggest
immun
reconstitut
prime
progenitor
ecp
could
differenti
immatur
bri
nk
cell
matur
dim
nk
cell
reduct
bri
nk
cell
moreov
dim
nk
cell
could
matur
upregul
express
ecp
notabl
ecp
therapi
could
shift
nk
cell
cytotox
regulatori
phenotyp
within
bri
nk
cell
spite
immunomodulatori
effect
ecp
nk
cell
nk
activ
could
kept
intact
ecp
therapi
kill
activ
nk
cell
stabl
confirm
cr
releas
assay
ecp
therapi
neg
effect
quantiti
qualiti
cytokin
releas
nk
cell
upon
stimul
especi
polyfunction
nk
cell
alter
significantli
ecp
therapi
conclus
nk
cell
play
import
role
gvhd
could
serv
predict
cell
popul
clinic
respons
ecp
therapi
current
studi
ecp
influenc
differenti
matur
educ
nk
cell
amelior
gvhd
without
compris
antivir
immun
defens
gvl
effect
disclosur
author
declar
compet
financi
interest
except
follow
therako
mallinckrodt
gave
financi
support
ms
document
clinic
cours
analysi
immun
cell
patient
pw
honoraria
membership
advisori
board
sanofiaventi
abstract
withdrawn
cyclosporin
level
day
posttranspl
associ
significantli
reduc
acut
graftversushost
diseas
follow
allogen
hematopoiet
stem
cell
transplant
monica
bianchi
dominik
heim
claudia
lengerk
martina
kleber
dimitrio
tsakiri
jakob
passweg
alexandar
tzankov
michael
meding
background
acut
graftversushost
diseas
agvhd
remain
major
complic
allogen
hematopoiet
stem
cell
transplant
allohsct
affect
patient
especi
steroidrefractori
agvhd
poor
prognosi
prophylaxi
cyclosporin
csa
backbon
gvhd
prevent
condit
regimen
method
retrospect
analysi
patient
treat
allohsct
correl
csa
level
day
transplant
day
day
incid
acut
chronic
gvhd
postul
higher
target
csa
level
result
lower
incid
rate
especi
agvhd
allohsct
result
assess
patient
either
aml
lymphomamyeloma
mdsmpn
cll
cml
bone
marrow
failur
patient
clinic
relev
agvhd
grade
mean
csa
level
lower
day
day
respect
compar
patient
without
agvhd
respect
day
day
x
patient
csa
level
incid
agvhd
significantli
frequent
compar
patient
csa
level
versu
p
x
patient
cgvhd
signific
differ
csa
level
compar
csa
level
optim
csa
cutoff
level
prevent
ie
roughli
incid
reduct
agvhd
day
day
figur
compet
risk
analysi
time
agvhd
grade
use
death
caus
compet
risk
associ
csa
level
day
day
unrel
donor
myeloabl
condit
mac
diagnosi
lymphomamyeloma
conclus
data
support
close
monitor
activ
adjust
csa
dose
maintain
therapeut
csa
level
first
day
allohcst
reduc
agvhd
disclosur
note
declar
liposom
cyclosporin
inhal
lcsai
treat
bronchiol
obliteran
syndrom
novel
formul
therapeut
potenti
patient
bo
follow
allohsct
noreen
roth
henig
emili
hofstett
dominik
kappel
gerhard
boerner
background
bronchiol
obliteran
syndrom
bo
rapidli
progress
lung
diseas
caus
tcell
mediat
inflamm
lead
blockag
bronchiol
lead
respiratori
failur
death
shortli
diagnosi
approxim
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
develop
bo
develop
bo
respiratori
form
chronic
graftvshost
diseas
cgvhd
addit
sign
cgvhd
mean
time
bo
diagnosi
rang
day
posttranspl
histopatholog
bo
allohsct
lung
transplant
ident
earli
studi
lcsai
prevent
bo
lung
transplant
recipi
demonstr
therapeut
benefit
lcsai
novel
liposom
formul
cyclosporin
administ
via
pari
investig
eflow
nebul
deliv
potent
immunosuppress
site
diseas
pharmacokinet
toler
lcsai
present
method
retrospect
review
two
clinic
studi
lcsai
isoton
bo
associ
lung
transplant
studi
control
arm
result
report
patient
receiv
lcsai
subject
receiv
singl
lung
transplant
doubl
lung
transplant
bid
via
inhal
blood
sampl
pharmacokinet
analysi
cyclosporin
concentr
collect
inhal
immedi
inhal
thereaft
interv
min
hour
local
gener
toler
lcsai
investig
result
two
studi
subject
receiv
either
mg
bid
lcsai
pharmacokinet
model
predict
constant
drug
level
lung
maximum
serum
cyclosporin
concentr
inhal
ngml
trough
level
daili
administr
ngml
evid
accumul
follow
repeat
exposur
toler
data
assess
patientmonth
exposur
lcsai
report
symptom
pharyng
sore
cough
dyspnoea
wheez
subject
discontinu
due
intoler
inhal
time
averag
min
conclus
lcsai
provid
high
constant
concentr
airway
lung
site
bo
lcsai
well
toler
lung
transplant
patient
use
lcsai
instead
augment
system
csa
reduc
total
drug
exposur
multicentr
phase
safeti
exploratori
efficaci
trial
treatment
bo
allohsct
recipi
underway
disclosur
background
number
biomark
predict
nonrelaps
mortal
nrm
graftversushost
diseas
gvhd
relaps
incid
ri
convent
gvhd
prophylaxi
base
calcineurin
inhibitor
without
antithymocyt
globulin
current
limit
data
whether
convent
predict
biomark
work
posttransplant
cyclophosphamid
ptci
prophylaxi
method
prospect
singlecent
studi
enrol
adult
patient
acut
leukemia
cr
aml
receiv
match
relat
bone
marrow
bm
graft
singleag
ptci
receiv
unrel
peripher
blood
stem
cell
graft
pbsc
ptci
tacrolimu
mmf
graft
studi
flow
cytometri
fac
aria
ii
antibodi
miltenyi
biotec
follow
popul
analyz
nkt
inkt
treg
doubleposit
tcell
doubleneg
tcell
tcralphabeta
tcr
memori
cell
crypreserv
plasma
analys
elisa
commerci
kit
ebiosci
critic
diagnost
vegf
solubl
tnf
receptor
stnfr
solubl
receptor
stnfr
mention
biomark
test
logist
regress
roc
analysi
assay
auc
select
analysi
fynegray
regress
compet
risk
cut
level
determin
signific
paramet
result
median
followup
month
rang
whole
group
overal
surviv
os
eventfre
surviv
ef
grade
iiiv
acut
gvhd
moder
sever
chronic
gvhd
nrm
mortal
patient
gvhd
ri
differ
bmrelat
pbscunrel
graft
incid
gvhd
nrm
ri
p
signific
predictor
acut
gvhd
low
level
level
p
vs
cut
pgml
chronic
gvhd
predict
high
percentag
inkt
cell
graft
vs
cut
correl
level
number
nk
cell
graft
nrm
relat
infecti
complic
nonetheless
high
level
vegf
day
p
vs
cut
ngml
p
vs
cut
ngml
low
percentag
graft
vs
cut
identifi
biomark
nrm
associ
pretranspl
crp
ferritin
level
p
signific
paramet
ri
level
cell
graft
none
identifi
biomark
significantli
predict
overal
surviv
p
conclus
relat
unrel
graft
ptci
studi
biomark
low
clinic
util
due
low
gvhdrelat
mortal
howev
vegf
predict
infectionrel
mortal
also
studi
verifi
previou
observ
high
level
associ
reduc
gvhd
incid
ptci
identifi
import
nk
inkt
cell
induct
toler
ptci
refer
background
hematopoiet
cell
transplant
hct
cur
approach
mani
hematolog
malign
lifethreaten
toxic
graftversushost
diseas
gvhd
infect
still
limit
fullpotenti
impact
diseas
strategi
keep
allohsct
effect
safe
need
order
reduc
morbid
improv
immunolog
effect
control
diseas
relaps
posttranspl
cyclophosphamid
ptci
demonstr
improv
acut
gvhd
agvhd
chronic
gvhd
cgvhd
control
allogen
bonemarrow
hct
ident
haploident
donor
use
ptci
peripher
blood
stem
cell
transplant
allopbsct
hlamatch
unrelatedrel
donor
investig
group
clinic
trial
nct
preliminari
result
publish
last
year
report
updat
efficaci
safeti
data
expand
cohort
patient
treat
ptci
follow
tacrolimu
mycophenol
mofetil
tmmf
method
analys
data
consecut
patient
highrisk
hematolog
malign
receiv
allopbsct
hlamatch
unrelatedrel
donor
march
august
gvhd
prophylaxi
ptci
mgkg
day
tacrolimu
day
mmf
day
day
primari
object
cumul
incid
agvhd
cgvhd
secondari
object
eventfre
surviv
ef
cgvhdef
overal
surviv
os
nonrelaps
mortal
nrm
result
patient
median
age
transplant
rang
year
patient
transplant
first
complet
respons
cr
patient
secondthird
cr
other
diseas
control
median
dose
rang
x
infus
primari
graft
failur
observ
one
patient
patient
mmf
day
median
day
tacrolimu
discontinu
rang
eight
patient
develop
agvhd
grade
iiiii
median
day
onset
day
rang
grade
iv
observ
case
lateonset
agvhd
report
cumul
incid
cgvhd
median
day
onset
rang
system
treatment
requir
patient
abl
discontinu
immunosuppress
median
followup
rang
month
ef
cgvhdef
os
nonrelaps
mortal
nrm
patient
die
multidrug
resist
bacteria
septicemia
nowaday
patient
aliv
evid
diseas
continu
complet
reintegr
normal
daili
life
activ
conclus
updat
report
result
confirm
larger
cohort
patient
longer
followup
ptci
pbschct
highli
activ
agvhd
cgvhd
prevent
extrem
limit
nrm
strategi
allow
earlier
discontinu
immunosuppress
also
reduc
overal
time
exposur
patient
featur
might
contribut
futur
transform
hct
safe
immunolog
platform
may
combin
advanc
form
cellular
therapi
cartcel
aim
increas
safe
graftversustumor
effect
clinic
method
pediatr
patient
year
nmd
undergo
unrel
hct
elig
singl
center
phase
trial
follow
reduc
intens
condit
abatacept
mgkg
iv
day
ad
standard
gvhd
prophylaxi
cyclosporin
mycophenol
mofetil
mmf
patient
follow
year
standard
hct
outcom
imag
figur
result
sinc
june
patient
enrol
transplant
tabl
exclud
donor
sourc
bone
marrow
median
followup
year
patient
surviv
without
diseas
initi
engraft
success
median
day
neutrophil
platelet
respect
one
patient
secondari
graft
reject
set
viral
reactiv
cmvebv
success
engraft
follow
nd
unrel
hct
engraft
patient
myeloid
chimer
timepoint
tlymphoid
chimer
mix
reach
figur
one
patient
saa
primari
graft
reject
set
inadequ
tnc
dose
x
kg
die
marrow
aplasiainfect
despit
nd
hct
second
death
wilm
tumor
occur
month
post
success
hct
patient
dba
constitut
chromosom
abnorm
except
patient
patient
receiv
dose
abatacept
well
toler
sever
advers
event
expect
hct
popul
cmv
ebv
reactiv
occur
patient
resolut
use
standard
antivir
therapi
one
patient
diagnos
ebvdriven
posttranspl
lymphoprolif
diseas
respond
rituximab
immun
suppress
withdraw
patient
develop
sever
acut
grade
iiiiv
chronic
gvhd
tabl
patient
requir
system
immun
suppress
year
conclus
preliminari
data
suggest
abatacept
safe
ad
cyclosporin
mmf
gvhd
prophylaxi
pediatr
patient
bone
marrow
failur
undergo
unrel
donor
hct
encourag
rate
gvhd
despit
half
patient
mismatch
donor
given
higher
risk
graft
reject
nonmalign
cohort
reject
addit
gvhd
primari
focu
subsequ
multicent
phase
trial
clinic
trial
registri
clinicaltri
gvhd
may
separ
toxic
infecti
complic
earli
phase
allohsct
method
file
identifi
patient
upper
gastrointestin
tract
endoscopi
allohsct
biopsi
taken
esophagu
stomach
duodenum
simultan
patient
exclud
infect
reflux
diseas
drug
toxiti
remain
patient
includ
studi
evalu
routin
stain
esophag
biopsi
appli
grade
scheme
compar
histolog
find
within
stomach
duodenum
endoscop
find
clinic
cours
result
biopsi
sampl
esophagu
identifi
histolog
featur
acut
gvhd
rang
vacuolar
degener
grade
singlecel
apoptosi
grade
format
cleft
grade
mucosa
denud
advanc
case
grade
resembl
epitheli
lesion
acut
gvhd
skin
find
correl
gvhd
involv
stomach
duodenum
clinic
manifest
gvhd
organ
endoscop
patient
gvhd
reveal
sign
inflamm
rang
erythema
ulcer
advanc
case
sometim
reminisc
reflux
infect
clinic
patient
abdomin
discomfort
rang
inappet
nausea
accompani
emesi
diarrhea
weight
loss
conclus
shown
acut
esophag
gvhd
occur
allohsct
correl
acut
gvhd
stomach
duodenum
could
diagnos
grade
histolog
endoscop
find
sign
inflamm
result
may
help
establish
histolog
diagnosi
acut
gvhd
use
endoscop
biopsi
esophagu
explain
alter
observ
esophag
mucosa
patient
allohsct
background
intestin
acut
graft
versu
host
diseas
agvhd
major
thread
allogen
hematolog
stem
cell
transplant
allohsct
high
mortal
patient
refractori
steroid
treatment
particular
recent
paper
point
correl
histolog
grade
intestin
gvhd
prognosi
patient
allohsct
howev
comparison
clinic
score
perform
far
method
analysi
retrospect
data
patient
underw
endoscopi
due
clinic
sign
agvhd
day
allohsct
evalu
patient
least
biopsi
differ
site
colon
taken
simultan
biopsi
seri
maximum
histolog
grad
agvhd
accord
lerner
scheme
obtain
compar
glucksberg
stage
lower
gastro
intestin
tract
gslgi
overal
glucksberg
grade
ogg
three
grade
compar
nonrelap
relat
mortal
use
logrank
test
sensit
steroid
treatment
appli
receiv
oper
characterist
patient
receiv
steroid
treatment
patient
nonrelap
relat
mortal
respond
nonrespond
calcul
use
also
logrank
test
result
histolog
grade
strongli
correl
surviv
statist
signific
correl
also
found
gslgi
wherea
ogg
reveal
signific
correl
nonrelap
relat
mortal
mainli
relat
infect
sepsi
patient
die
eightyon
patient
receiv
steroid
therapi
sensit
steroid
therapi
correl
three
score
p
strongest
gslgi
area
curv
auc
compar
ogg
auc
histolog
score
auc
surviv
patient
sensit
steroid
treatment
significantli
better
steroid
refractori
patient
conclus
found
histolog
clinic
grade
patient
allohsct
intestin
gvhd
correl
surviv
respond
steroid
treatment
histolog
score
may
predict
surviv
precis
ogg
gslgi
add
substanti
inform
predict
treatment
respons
emerg
evid
suggest
regulatori
b
cell
breg
play
essenti
role
inflamm
autoimmun
diseas
tumor
data
exist
role
breg
contest
hematopoiet
allogen
stem
cell
transplant
hsct
author
observ
breg
patient
chronic
graftversushost
diseas
cgvhd
less
frequent
less
like
produc
breg
compar
healthi
donor
patient
without
cgvhd
find
suggest
breg
may
involv
cgvhd
pathogenesi
purpos
studi
evalu
possibl
role
b
cell
subset
gvhd
occurr
method
lymphocyt
subset
enumer
perform
aquio
cl
flow
cytomet
beckman
coulter
quantit
autom
analyz
perform
two
diagnost
panel
b
cell
subset
memori
matur
transit
b
cell
peripher
blood
sampl
analyz
aquio
design
softwar
tool
creation
userdefin
applic
specif
design
beckman
coulter
center
flow
cytometr
analysi
perform
follow
donor
patient
basal
level
graft
product
patient
day
hsct
statist
signific
assess
prism
softwar
graphpad
mann
withney
test
p
consid
statist
signific
result
actual
enrol
patient
submit
hsct
center
novemb
preliminari
statist
analysi
perform
patient
stem
cell
sourc
peripher
blood
pb
case
bone
marrow
bm
other
condit
regimen
myeloabl
patient
ric
patient
agvhd
diagnos
patient
associ
found
b
cell
subset
donor
patient
baselin
occurr
agvhd
howev
found
higher
median
percentag
transit
b
cell
graft
product
patient
without
agvhd
compar
patient
agvhd
fig
addit
patient
without
agvhd
show
lower
median
percentag
memori
b
cell
rang
graft
product
compar
patient
agvhd
rang
p
final
subgroup
patient
receiv
pb
stem
cell
sourc
observ
higher
percentag
lymphocyt
graft
product
patient
agvhd
rang
compar
patient
without
agvhd
rang
monitor
b
cell
reconstitut
observ
event
appear
day
hsct
b
transit
immatur
event
predominantli
conclus
data
suggest
possibl
protect
link
transit
b
cell
agvhd
develop
result
data
need
confirm
larger
cohort
patient
moreov
interest
evalu
relationship
transit
b
cell
day
occurr
cgvhd
clinic
background
agvhd
major
complic
allogen
hematopoiet
stem
cell
transplant
hsct
risk
factor
posthsct
mortal
object
analysi
describ
patient
agvhd
suboptim
respons
corticosteroid
method
patient
develop
ibmtr
sever
index
iiiv
agvhd
first
hsct
includ
ongo
chart
review
center
unit
state
patient
ever
particip
gvhd
prophylaxi
trial
use
jak
inhibitor
exclud
studi
suboptim
respons
corticosteroid
defin
use
addit
system
antigvhd
therapi
inabl
taper
highdos
steroid
mg
kg
taper
corticosteroid
mgday
result
analysi
includ
patient
suboptim
respons
corticosteroid
mean
age
year
male
median
time
transplant
agvhd
diagnosi
day
time
maximum
agvhd
grade
patient
grade
ii
grade
iiiiv
lower
gi
involv
organ
involv
time
diagnosi
maximum
agvhd
grade
patient
new
organ
involv
increas
agvhd
grade
median
time
diagnosi
maximum
grade
day
day
patient
lower
gi
involv
system
corticosteroid
initi
day
diagnosi
patient
averag
start
daili
dose
mg
mgkg
prednison
mg
mgkg
methylprednisolon
steroid
dose
increas
patient
followup
unabl
taper
mgday
among
patient
receiv
addit
system
antigvhd
therapi
increas
corticosteroid
dose
initi
addit
antigvhd
therapi
median
time
initi
corticosteroid
addit
therapi
day
frequent
use
therapi
mycophenyal
mofetil
atg
extracorpor
photophoresi
tocilizumab
etanercept
sirolimu
agvhd
recur
patient
manag
increas
corticosteroid
dose
patient
infect
within
first
day
posthsct
forti
patient
requir
hospit
readmiss
readmiss
within
day
posthsct
mean
inpati
lengthofstay
day
relaps
underli
malign
report
patient
twothird
patient
die
median
interquartil
rang
iqr
day
agvhd
diagnosi
higher
proport
patient
maximum
grade
iiiiv
agvhd
die
median
iqr
day
major
patient
lower
gi
agvhd
die
median
iqr
day
conclus
major
patient
agvhd
suboptim
respons
system
corticosteroid
sever
rapidli
progress
diseas
result
high
mortal
rate
progress
rapid
mortal
increas
patient
lower
gi
involv
patient
requir
readmiss
hospit
extend
lengthofstay
urgent
need
exist
effect
toler
therapi
quickli
resolv
lifethreaten
agvhd
earli
stage
diseas
disclosur
result
median
time
onset
bo
allohct
month
rang
previou
acut
gvhd
n
grade
iiiiv
n
n
cgvhd
exclus
lung
involv
patient
organ
affect
diagnosi
bo
n
immunosuppress
treatment
patient
bo
receiv
ecp
secondlin
treatment
median
durat
treatment
month
time
respons
month
median
session
evalu
respons
base
evolut
measur
n
complet
respons
n
partial
respons
n
stabl
diseas
one
patient
get
respons
anoth
evalu
patient
n
could
reduc
immunosuppress
one
case
complet
discontinu
trend
earli
separ
surviv
curv
favor
ecp
figur
one
patient
sepsi
secondari
central
venou
cathet
infect
complic
relat
ecp
conclus
ecp
emerg
promis
treatment
bo
allohct
experi
ecp
effect
stabil
improv
diseas
mani
patient
allow
taper
esteroid
minim
associ
complic
howev
prospect
studi
longer
followup
need
support
find
disclosur
noth
declar
background
key
role
signal
acut
graft
vs
host
diseas
agvhd
cytokin
releas
syndrom
cr
evok
grow
use
tocilizumab
receptor
antibodi
set
apart
regul
tand
bcell
differenti
immun
cell
migrat
inflammatori
site
tcell
recruit
complex
upregul
product
fibrinogen
fg
acut
phase
protein
includ
creactiv
protein
crp
method
retrospect
analyz
data
patient
treat
tocilizumab
due
steroidrefractori
sr
agvhd
patient
cr
median
age
year
respect
seven
patient
transplant
unrel
donor
mudmmud
sibl
donor
eight
patient
receiv
myeloabl
reduc
intens
condit
regimen
analyz
data
includ
concentr
fg
crp
incid
infect
tocilizumab
administr
week
follow
infus
result
stage
ii
agvhd
diagnos
patient
stage
iii
stage
iv
patient
involv
gastrointestin
tract
gi
observ
case
median
fg
concentr
tocilizumab
administr
gl
rang
crp
mgdl
rang
patient
activ
infect
infus
antibodi
observ
declin
fg
crp
level
median
level
fg
gl
rang
day
tocilizumab
infus
sever
bleed
complic
median
crp
valu
mgdl
rang
despit
confirm
infecti
complic
three
week
infus
tocilizumab
fg
rais
normal
rang
patient
fig
five
patient
sr
agvhd
achiev
complet
respons
partial
respons
tocilizumab
therapi
imag
fibrinogen
level
gvhd
patient
follow
tocilizumab
infus
group
treat
tocilizumab
due
cr
higher
initi
level
fg
gl
rang
crp
mg
dl
rang
administr
drug
reduc
fg
crp
level
baselin
valu
also
observ
group
howev
concentr
higher
gvhd
patient
fg
gl
rang
crp
mgdl
rang
patient
differenti
diagnosi
dissemin
intravascular
coagul
exclud
conclus
fibrinogen
declin
tocilizumab
therapi
due
cytokineregul
product
liver
coagul
monitor
perform
first
week
administr
antibodi
avoid
seriou
bleed
complic
crp
concentr
remain
low
despit
presenc
activ
infect
follow
infus
tocilizumab
crp
fail
marker
infect
week
follow
therapi
tocilizumab
effect
therapi
patient
agvhd
especi
gi
involv
disclosur
noth
declar
vanish
bile
duct
allogen
hsct
realli
gvhd
antonio
grasso
lorenzo
dantiga
aurelio
sonzogni
massimo
gregori
alessandra
maestro
roberto
simeon
natalia
maximova
background
evalu
liver
gvhd
histor
base
elev
bilirubin
level
reduct
degener
small
bile
duct
histolog
sampl
posttranspl
liver
biopsi
howev
lack
studi
compar
histolog
find
ductopenia
postautolog
hsct
postallogen
hsct
studi
sever
ductopenia
follow
allogen
hsct
aim
demonstr
lack
correl
ductopenia
clinic
sign
liver
gvhd
method
retrospect
collect
seri
allogen
hsct
perform
institut
burlo
garofolo
patient
undergo
percutan
liver
biopsi
case
three
month
one
year
three
year
hsct
indic
biopsi
alter
note
weekli
followup
assess
least
one
clinic
laboratori
marker
liver
impair
cholestasi
ductopenia
defin
number
portal
tract
interlobular
bile
duct
divid
total
number
sever
ratio
less
clinic
gvhd
defin
nih
consensu
criteria
result
popul
involv
male
femal
oncolog
nononcolog
underli
diseas
clinic
sign
liver
gvhd
present
patient
contextu
intestin
involv
cutan
intestin
involv
patient
underw
biopsi
mean
time
day
hsct
patient
underw
biopsi
month
hsct
patient
three
year
hsct
result
biopsi
show
tabl
differ
incid
ductopenia
found
liver
gvhd
group
gvhd
tabl
tabl
incid
ductopenia
month
month
year
hsct
total
popul
gvhd
group
nogvhd
group
group
receiv
chemotherapi
prior
hsct
overal
incid
ductopenia
sever
ductopenia
statist
signif
comparison
oncolog
underli
diseas
group
ductopenia
sever
ductopenia
furthermor
littl
subgroup
patient
extrapol
popul
receiv
liver
biopsi
hsct
diagnost
assess
oncolog
underli
diseas
alreadi
show
ductopenia
sign
ductopenia
found
other
nononcolog
diseas
conclus
correl
incid
gvhd
histolog
find
ductopenia
liver
biopsi
ductopenia
may
caus
first
place
chemotherapi
treatment
receiv
hsct
myeloabl
condit
hsct
relat
gvhd
hypothesi
strengthen
subgroup
analysi
prehsct
biopsi
background
second
third
line
therapi
steroid
refractori
acut
graft
versu
host
diseas
agvhd
allogen
stem
cell
transplant
asct
still
lack
ruxolitinib
select
januskinas
inhibitor
could
show
high
efficaci
agvhd
well
extracorpor
photopheresi
ecp
report
singl
center
experi
combin
therapeut
approach
sever
steroid
refractori
agvhd
addit
analysi
immun
statu
patient
elucid
direct
effect
treatment
immun
respons
method
june
februari
patient
male
femal
median
age
year
r
steroid
refractori
agvhd
lower
gitract
asct
treat
ruxolitinib
extracorpor
photopheresi
third
fourth
fifth
line
therapi
patient
show
addit
agvhd
skin
liver
upper
gitract
patient
overal
grade
iii
iv
agvhd
steroid
refractori
defin
improv
day
aggrav
day
steroid
treatmentmedian
start
ruxolitinib
ecp
day
asct
r
mediandur
ruxolitinib
therapi
day
r
median
start
dosag
mg
per
day
x
mg
r
mg
patient
start
ecp
treatment
per
week
individu
reduct
treatment
frequenc
median
number
ecp
treatment
r
median
frequenc
ecp
therapi
week
r
cytomegaloviru
cmv
statu
patient
immun
statu
ten
patient
lymphocyt
count
helper
lymphocyt
regulatori
cell
count
collect
previous
four
week
start
combin
treatment
four
week
stop
treatment
result
oneyear
estim
overal
surviv
os
patient
median
estim
os
day
patient
die
relaps
underli
diseas
one
sever
therapi
refractori
agvhd
lower
gi
tract
due
infect
complic
agvhd
refractori
set
overal
respons
complet
remiss
rate
partial
remiss
rate
patient
cytopenia
ctc
iiii
treatment
grade
iv
cytopenia
report
cmv
reactiv
ruxolitinib
occur
case
taper
steroid
could
perform
rapidli
medium
reduct
time
day
reduc
half
dosageremark
regulatori
cell
significantli
increas
combin
ruxolitinibecp
treatment
compar
regulatori
cell
count
treatment
stop
treatment
regulatori
cell
count
decreas
see
figur
signific
chang
whole
lymphocyt
count
helper
cell
count
observ
conclus
treatment
sever
steroid
refractori
agvhd
ruxolitinib
plu
ecp
could
show
high
complet
remiss
rate
one
year
os
detect
increas
regulatori
cell
count
treatment
underlin
direct
effect
immun
respons
encourag
pursu
promis
therapeut
approach
background
due
increas
immunosuppress
infect
remain
main
caus
death
follow
higher
risk
relaps
patient
treat
acut
graft
versu
host
diseas
agvhd
allogen
stem
cell
transplant
sct
report
singlecentr
experi
extracorpor
photopheresi
ecp
acut
gvhd
introduc
order
reduc
steroid
treatment
comparison
overal
surviv
os
patient
ecp
patient
receiv
standard
first
line
therapi
agvhd
perform
method
retrospect
analys
patient
acut
gvhd
grade
iiiv
treat
januari
octob
total
allogen
sct
period
patient
receiv
calcineurin
inhibitor
sirolimu
receiv
steroid
treatment
agvhd
twentyf
patient
receiv
ecp
steroid
lower
intent
defin
respons
reduct
steroid
dose
least
baselin
ad
anoth
immunosuppres
agent
repeat
second
steroid
treatment
ecp
start
lower
steroid
prevent
agvhd
flare
check
separ
patient
respons
refractorydepend
steroid
averag
patient
receiv
ecp
procedur
weekli
result
taper
immunosuppress
therapi
defin
success
patient
ecp
group
group
patient
without
ecp
patient
steroid
refractori
steroid
depend
agvhd
compar
patient
ecp
group
four
patient
steroid
refractori
depend
agvhd
show
improv
ecp
group
compar
one
non
ecp
group
twenti
patient
die
due
infecti
complic
due
relaps
non
ecp
cohort
ecp
cohort
patient
die
due
infect
due
relaps
median
os
month
non
ecp
group
r
compar
month
r
ecp
group
os
year
non
ecp
compar
ecp
cohort
observ
patient
agvhd
treat
ecp
faster
steroid
taper
longer
os
compar
patient
without
ecp
conclus
ecp
enabl
success
taper
withdraw
steroid
therapi
mani
patient
even
steroid
refractori
steroid
depend
reduct
immunosuppress
lead
reduc
incid
infect
relaps
translat
better
overal
surviv
background
cur
potenti
allogen
stem
cell
transplant
hamper
graftversushost
diseas
gvhd
preclin
studi
show
efficac
inhibitor
ruxolitinib
treatment
steroidrefractori
gvhd
method
report
monocentr
retrospect
studi
ruxolitinib
respons
follow
case
chronic
gvhd
cgvhd
improv
standard
immunosuppress
therapi
complet
organ
respons
cr
defin
resolut
clinic
manifest
cgvhd
specif
organ
good
respons
partial
vgpr
defin
improv
clinic
manifest
cgvhd
decreas
corticosteroid
partial
respons
pr
associ
less
decreas
corticosteroid
treatment
failur
defin
absenc
improv
cgvhd
deterior
cgvhd
organ
least
one
stage
develop
cgvhd
manifest
previous
unaffect
organ
use
addit
agent
control
diseas
result
median
age
transplant
year
rang
patient
present
acut
myeloid
leukemia
donor
type
sibl
unrel
haploident
two
patient
benefit
cord
blood
transplant
patient
receiv
either
myeloabl
reduc
intens
condit
regimen
stem
cell
sourc
peripher
blood
patient
patient
present
mild
moder
sever
cgvhd
accord
nih
score
median
number
regimen
prior
ruxolitinib
rang
among
corticosteroid
median
followup
ruxolitinib
month
rang
overal
respons
rate
orr
month
cr
vgpr
pr
figur
patient
fail
month
introduct
ruxolitinib
rate
cr
increas
time
month
month
month
vgpr
rate
rather
stabl
month
month
month
vs
month
among
patient
steroid
patient
discontinu
steroid
overal
surviv
os
diseasefre
surviv
df
ruxolitinib
ci
ci
respect
sever
cytopenia
grade
observ
patient
introduct
ruxolitinib
patient
present
bacteri
infect
patient
present
invas
pulmonari
aspergillosi
patient
develop
pneumocysti
cytomegaloviru
reactiv
requir
preemptiv
treatment
observ
patient
toxic
requir
withdraw
ruxolitinib
imag
figur
partial
respons
mesenchym
stem
cell
msc
secondlin
therapi
vari
acut
gvhd
patient
report
experi
use
msc
treat
refractori
agvhd
method
studi
retrospect
singl
center
studi
data
collect
patient
file
twenti
patient
enrol
age
rang
month
year
april
april
result
five
patient
receiv
reduc
intens
condit
patient
receiv
myeloabl
regimen
hsct
one
haploident
autolog
cord
blood
mud
msd
transplant
perform
patient
elig
develop
grade
iiiv
agvhd
patient
treat
standard
firstlin
treatment
corticosteroid
least
one
secondlin
therapi
definit
steroid
resist
agvhd
consid
either
respons
steroid
treatment
last
least
day
progress
treatment
least
one
grade
within
first
hour
prophylact
treatment
calcineurin
inhibitor
continu
therapeut
dose
level
total
dose
msc
infus
median
dose
msc
cell
per
kg
bodi
weight
median
durat
diagnosi
agvhd
initi
msc
therapi
day
rang
receiv
msc
dose
rang
one
seven
none
patient
sever
sideeffect
infus
msc
overal
complet
respons
ocr
obtain
patient
partial
respons
patient
respons
nr
document
patient
studi
group
complet
respons
rate
liver
gastrointestin
skin
agvhd
respect
four
patient
die
day
use
msc
complic
agvhd
eleven
patient
still
aliv
median
followup
day
day
first
msc
infus
one
year
estim
probabl
overal
surviv
patient
achiev
ocr
partial
remissionno
remiss
day
msc
respect
conclus
conclus
msc
appear
safe
effect
treatment
option
pediatr
patient
steroid
refractori
agvhd
disclosur
noth
declar
effect
extracorpor
photopheresi
product
serum
elafin
chronic
graft
versu
host
diseas
arun
alfr
charlott
burton
kathryn
goddard
nichloa
matthew
background
extracorpor
photopheresi
ecp
second
line
therapi
steroid
refractori
depend
intoler
chronic
gvhd
cgvhd
order
guid
ecp
unmet
need
predict
diagnost
biomark
elafin
serineproteas
inhibitor
primarili
produc
epitheli
cell
particularli
keratinocyt
inflammatori
skin
diseas
plasma
epiderm
elafin
identifi
biomark
skin
gvhd
sinc
skin
cgvhd
note
particularli
high
respons
rate
ecp
conduct
studi
investig
whether
ecp
affect
product
elafin
method
serum
sampl
collect
cgvhd
patient
male
femal
age
rang
agematch
healthi
control
male
femal
ecp
month
interv
year
patient
gvhd
affect
skin
mucos
membran
liver
joint
gut
eye
genit
respiratori
involv
serum
elafin
assess
elisa
r
system
data
analys
use
graphpad
prism
statist
test
perform
includ
mannwhitney
pearson
correl
test
anova
repeat
measur
appropri
result
chronic
gvhd
patient
present
ecp
significantli
elev
serum
level
elafin
median
iqr
compar
healthi
control
median
ngml
iqr
patient
skin
involv
elafin
level
iqr
healthi
control
diseas
score
avail
signific
correl
modifi
rodnan
nih
bsa
score
subanalysi
perform
group
cgvhd
patient
accord
quartil
serum
elafin
preecp
baselin
retrospect
analysi
patient
month
ecp
reveal
serum
elafin
level
upper
quartil
elafin
hi
preecp
minmax
show
signific
reduct
month
therapi
p
mean
sd
ngml
vs
respect
sustain
month
ecp
p
mean
sd
ng
ml
contrast
patient
elafin
level
upper
quartil
elafin
lo
show
signific
chang
mean
sd
vs
ngml
respect
note
preecp
patient
elafin
median
receiv
significantli
corticosteroid
cs
p
mean
sd
vs
respect
significantli
reduc
month
ecp
p
mgd
cs
dose
significantli
chang
elafin
hi
patient
month
p
mean
sd
vs
respect
conclus
consist
recent
data
found
serum
elafin
significantli
elev
subset
cgvhd
patient
compar
healthi
control
correl
skin
diseas
score
ecp
administr
associ
reduct
serum
elafin
elafin
hi
subset
elafin
lo
elafin
hi
patient
toler
differ
rate
ecpmedi
taper
cs
immunosuppress
suggest
preecp
elafin
measur
may
predict
valu
refer
background
allogen
hematopoiet
stem
cell
transplant
hsct
potenti
cur
treatment
mani
malign
malign
hematolog
diseas
primari
immunodefici
metabol
deposit
diseas
children
graft
versu
host
diseas
gvhd
major
caus
morbid
lead
caus
nonrelaps
mortal
corticosteroid
standard
firstlin
system
treatment
acut
chronic
gvhd
wherea
second
line
option
corticosteroidrefractori
patient
standardis
ruxolitinib
potent
inhibitor
jak
show
signific
respons
refractori
gvhd
patient
recent
report
method
present
two
centr
experi
ruxolitinib
gvhd
treatment
pediatr
patient
studi
conduct
two
spanish
pediatr
hsct
centr
hospit
vall
dhebron
barcelona
hospit
universitario
la
paz
madrid
patient
receiv
ruxolitinib
sinc
drug
avail
includ
retrospect
analysi
result
march
decemb
pediatr
patient
acut
chronic
gvhd
refractori
corticosteroid
treat
ruxolitinib
differ
episod
one
patient
receiv
differ
moment
one
patient
receiv
patient
sex
birth
femal
male
case
median
age
hsct
year
primari
diseas
malign
patient
non
malign
median
time
gvhd
diagnosi
day
gvhd
episod
treat
corticosteroid
first
line
maximum
dose
mgkgday
main
dose
use
mgkgday
episod
patient
receiv
median
number
previou
line
treatment
includ
steroid
start
ruxolinib
extracorpor
photopheresi
episod
sirolimu
mesenchym
cell
ruxolitinib
initi
indic
acut
gut
refractorysteroid
depend
gvhd
episod
chronic
multisystem
episod
indic
chronic
lung
episod
chronic
skin
acut
skin
gvhd
median
posthsct
time
ruxolitinib
start
day
dose
rang
depend
age
weight
toler
hematolog
liver
toxic
averag
durat
treatment
day
complet
respons
cr
rate
global
partial
respons
pr
respons
nr
progress
one
patient
recent
treatment
start
patient
mean
time
maximum
respons
week
treatment
stop
caus
cr
case
infect
liver
toxic
sever
side
effect
directli
relat
ruxolitinib
treatment
describ
conclus
ruxolitinib
recent
introduc
second
line
strategi
rescu
corticosteroidrefractori
gvhd
pediatr
patient
result
random
trial
lack
present
experi
two
centr
main
indic
start
treatment
acut
gut
chronic
multisystem
gvhd
patient
achiev
grade
respons
partial
complet
allow
stop
taper
corticosteroid
toxic
profil
appear
accept
disclosur
noth
declar
stabil
tacrolimu
concentr
earli
allogen
hematopoiet
stem
cell
transplant
reduc
risk
acut
gvhd
background
tacrolimu
use
immunosuppress
drug
allogen
hematopoiet
stem
cell
transplant
allohsct
well
known
earli
concentr
level
tacrolimu
correl
risk
acut
graft
versu
host
diseas
agvhd
howev
whether
rang
standard
deriv
sd
earli
tacrolimu
concentr
allohsct
also
affect
risk
agvhd
still
remain
unknown
investig
correl
rang
sd
earli
tacrolimu
concentr
donor
hematopoiet
cell
engraft
develop
agvhd
method
retrospect
assess
patient
underw
allohsct
hospit
patient
receiv
standard
gvhd
prophylaxi
continu
intraven
iv
tac
start
dose
mg
kgday
day
allohsct
day
iv
methotrex
day
dose
mgm
mgm
mgm
respect
tac
dosag
adjust
target
serum
concentr
ngml
least
day
taper
evalu
sd
weekli
tacrolimu
concentr
rang
sd
tacrolimu
concentr
calcul
differ
rang
sd
group
develop
develop
agvhd
compar
use
mannwhitney
u
test
multivari
analysi
perform
use
multipl
logist
regress
analysi
patient
given
written
consent
allow
use
medic
record
research
accord
declar
helsinki
institut
review
board
approv
studi
result
male
femal
median
age
year
rang
year
risk
diseas
lowstandard
high
pt
number
donor
hlaident
sibl
hlamismatch
relat
donor
hlamatch
unrel
donor
hlamismatch
unrel
donor
thirtyseven
patient
develop
agvhd
grade
iii
gradeiiiiv
patient
result
wide
rang
sd
significantli
increas
risk
agvhd
agvhdgroup
ngml
agvhd
group
ngml
multivari
analysi
demonstr
narrow
rang
sd
tacrolimu
concentr
reduc
risk
agvhd
ci
correl
gender
age
diseas
statu
hla
develop
agvhd
conclus
rang
sd
engraft
phase
donor
hematopoiet
cell
significantli
correl
develop
agvhd
fine
tune
earli
tacrolimu
concentr
narrow
rang
sd
reduc
risk
agvhd
result
improv
overal
surviv
allohsct
disclosur
noth
declair
ruxolitinib
treatment
steroidrefractori
graftversushost
diseas
hanseung
park
jehwan
lee
junghe
lee
eunji
choi
miee
seol
youngshin
lee
youngah
kang
mijin
jeon
kyoohyung
lee
background
steroidrefractori
graft
versushost
diseas
gvhd
one
lethal
complic
allogen
hematopoiet
cell
transplant
recent
studi
shown
ruxolitinib
janu
kinas
inhibitor
effect
patient
suffer
gvhd
report
retrospect
result
ruxolitinib
treatment
steroidrefractori
gvhd
method
patient
receiv
cyclosporin
short
cours
methotrex
gvhd
prophylaxi
antithymocyt
globulin
ad
unrel
mismatch
famili
donor
hct
ruxolitinib
mg
twice
daili
ad
immunosuppress
treatment
patient
steroidrefractori
gvhd
result
total
patient
gvhd
acut
includ
patient
donor
lymphocyt
infus
dli
relat
chronic
includ
analysi
patient
grade
acut
gvhd
sever
chronic
gvhd
time
ruxolitinib
treatment
six
patient
acut
gvhd
respond
ruxolitinib
includ
complet
respons
cr
median
time
respons
day
rang
nineteen
patient
receiv
ruxolitinib
sever
chronic
gvhd
median
involv
organ
rang
fourteen
patient
show
respons
ruxolitinib
includ
cr
median
time
respons
day
rang
five
respond
discontinu
ruxolitinib
patient
still
agent
median
followup
durat
month
die
relaps
diseas
infect
surviv
probabl
eleven
respond
discontinu
ruxolitinib
gvhd
relaps
patient
day
ruxolitinib
discontinu
thrombocytopenia
common
advers
event
ruxolitinib
treatment
grade
infecti
advers
event
occur
pneumonia
brain
abscess
liver
abscess
conclus
ruxolitinib
treatment
seem
effect
treatment
steroidrefractori
gvhd
includ
longstand
chronic
gvhd
agent
well
toler
rel
safe
disclosur
noth
declar
antibodi
tocilizumab
salvag
therapi
treatment
sever
chronic
gvhd
stem
cell
transplant
retrospect
analysi
background
sever
chronic
graftversushost
diseas
cgvhd
remain
relev
factor
affect
surviv
longterm
qualiti
life
allogen
hematopoiet
stem
cell
transplant
hct
besid
corticosteroid
establish
therapi
cgvhd
mani
use
immunosuppress
agent
may
lead
signific
toxic
incl
infecti
complic
tocilizumab
antibodi
shown
efficaci
acut
gvhd
cgvhd
retrospect
analyz
efficaci
safeti
patient
receiv
tocilizumab
treatment
advanc
cgvhd
center
year
method
patient
sever
steroid
refractori
cgvhd
median
age
year
rang
yr
receiv
least
two
prior
line
therapi
cgvhd
rang
regimen
treat
tocilizumab
least
one
cycl
dosag
mgkg
iv
maximum
mg
median
number
cycl
rang
nih
consensu
criteria
grade
cgvhd
immunosuppress
regimen
note
time
first
tocilizumab
administr
month
therapi
patient
receiv
addit
concomit
immunosuppress
agent
alreadi
given
least
week
without
respons
start
tocilizumab
new
immunosuppress
ad
parallel
tocilizumab
respons
assess
stop
start
addit
new
patient
receiv
peripher
stem
cell
allograft
gvhd
prophylaxi
consist
calcineurin
inhibitor
combin
methotrex
mycophenol
case
unrel
donor
atg
ad
patient
quiescent
onset
cgvhd
one
patient
develop
de
novo
cgvhd
median
number
day
hct
onset
cgvhd
median
number
day
hct
initi
tocilizumab
therapi
day
cgvhd
onset
patient
mild
cgvhd
patient
moder
cgvhd
thrombocyt
count
patient
organ
involv
initi
tocilizumab
therapi
skin
grade
eye
mouth
fascia
lung
genit
patient
still
receiv
tocilizumab
time
analysi
result
tocilizumab
given
fairli
recent
patient
followup
reach
patient
threemonth
followup
initi
tocilizumab
therapi
patient
show
partial
remiss
patient
stabl
diseas
patient
progress
diseas
cgvhd
maxim
respons
partial
remiss
stabl
diseas
progress
diseas
patient
requir
subsequ
new
immunosuppress
treatment
one
patient
yet
reach
followup
tocilizumab
therapi
none
patient
suffer
recurr
underli
malign
two
patient
develop
signific
respiratori
infect
one
patient
develop
soft
tissu
infect
requir
antibiot
treatment
paus
tocilizumab
administr
hospit
admiss
requir
os
rf
median
follow
month
rang
month
conclus
tocilizumab
appear
promis
treatment
option
advanc
cgvhd
evalu
within
phase
ii
trial
requir
disclosur
noth
declar
background
allogen
hematopoiet
stem
cell
transplant
hsct
mani
patient
suffer
aml
cur
treatment
option
one
major
complic
graft
versu
host
diseas
gvhd
caus
donor
immun
cell
attack
healthi
tissu
regulatori
cell
treg
get
huge
attent
past
year
import
role
maintain
immun
balanc
collect
peripher
blood
sampl
patient
differ
time
point
hsct
investig
immunereconstitut
treg
predict
marker
develop
gvhd
method
collect
blood
sampl
patient
cours
allogen
hsct
prospect
week
patient
receiv
condit
regimen
fludarabin
melphalan
combin
alemtuzumab
cell
deplet
patient
develop
acut
gvhd
later
cours
isol
pbmc
perform
fac
multicolor
stain
cell
nk
cell
treg
identifi
nk
cell
character
neg
divid
nk
cell
subpopul
due
express
dim
high
result
neg
cell
patient
develop
acut
gvhd
later
cours
show
signific
elev
level
neg
cell
especi
neg
treg
neg
treg
cell
one
patient
develop
acut
gvhd
show
lot
neg
treg
miss
effector
cell
recent
show
neg
effector
cell
impair
effector
function
data
suggest
neg
treg
relev
combin
function
effector
cell
develop
agvhd
cell
marker
patient
without
agvhd
show
elev
express
garp
treg
garp
significantli
higher
express
treg
indic
better
suppress
capac
treg
detect
throughout
tigit
show
heterogen
express
profil
without
signific
differ
two
group
nk
cell
detect
higher
ratio
dim
nkcell
popul
patient
without
could
also
show
tigit
mainli
express
dim
nk
cell
conclus
other
show
reconstitut
neg
cell
subset
alemtuzumab
mediat
cell
deplet
data
effector
cell
show
impair
effector
function
neg
cell
recent
present
data
impair
suppress
capac
neg
treg
associ
acut
gvhd
retrospect
ebmt
ash
provid
prospect
data
patient
use
alemtuzumab
context
hsct
preliminari
data
suggest
total
amount
negtreg
ratio
neg
treg
treg
allogen
hsct
could
predict
agvhd
data
may
basi
immun
monitor
patient
evalu
risk
agvhd
could
lead
use
prophylact
treg
dli
context
alemtuzumab
mediat
cell
deplet
disclosur
medac
travel
support
novarti
consult
fee
pfizer
consult
fee
shireconsult
fee
background
multipl
factor
diseas
activ
sever
therapi
andor
dietari
habit
caus
chang
nutrit
statu
independ
interact
presenc
malnutrit
signific
weight
loss
chronic
gvhd
cgvhd
patient
report
literatur
aim
crosssect
studi
identifi
factor
affect
nutrit
statu
cgvhd
patient
method
nutrit
statu
patient
cgvhd
treat
univers
hospit
center
zagreb
croatia
assess
anthropometr
measur
height
bodi
weight
bw
bodi
mass
index
bmi
clinic
valid
tool
patientgener
subject
global
assess
pgsga
patient
categor
wellnourish
pgsga
moder
malnourish
pgsga
b
sever
malnourish
pgsga
c
use
patient
evalu
accord
nih
criteria
cgvhd
diagnosi
descript
correl
analysi
preform
result
total
adult
cgvhd
patient
includ
studi
women
median
age
year
mild
cgvhd
moder
sever
patient
accord
pgsga
rate
patient
pgsga
pgsga
b
pgsga
c
give
total
malnutrit
risk
malnutrit
preval
mean
bmi
kgm
correl
pgsga
rate
malnutrit
accord
bmi
defin
bmi
kgm
found
patient
bw
chang
month
signific
patient
accord
pgsga
assess
tool
oral
symptom
report
patient
decreas
appetit
report
patient
associ
oral
cgvhd
nih
score
bw
bmi
gastrointestin
gi
symptom
assess
sga
gener
mild
correl
gi
cgvhd
nih
score
signific
associ
found
nutrit
statu
nih
cgvhd
score
corticosteroid
therapi
present
correl
pgsga
rate
bw
bmi
appetit
chang
patient
alter
pgsga
rate
bmi
appetit
bodi
weight
chang
dietari
counsel
oral
nutrit
supplement
initi
conclus
oral
symptom
decreas
appetit
corticosteroid
therapi
cgvhd
patient
associ
alter
nutrit
statu
accord
pgsga
bmi
therefor
pgsga
might
sensit
tool
assess
chang
nutrit
statu
detect
patient
risk
malnutrit
bmi
sinc
includ
differ
factor
like
physic
examin
presenc
gi
symptom
corticosteroid
therapi
score
system
nutrit
counsel
support
import
cgvhd
patient
especi
presenc
oral
symptom
disclosur
noth
declar
background
sclerot
skin
chang
common
featur
chronic
graft
versu
host
diseas
cgvhd
one
challeng
aspect
diagnosi
manag
sclerodermoid
cgvhd
scgvhd
differenti
revers
symptom
relat
activ
cgvhd
nonrevers
symptom
relat
residu
perman
damag
longstand
fibrosi
although
sever
candid
biomark
cgvhd
inflammatori
activ
propos
none
current
valid
therefor
need
develop
quantifi
reproduc
measur
tool
guid
clinic
decis
report
experi
evalu
use
highfrequ
ultrasonographi
hfu
plu
doppler
ultrasound
doppleru
serum
fibrosi
biomark
determin
inflammatori
activ
scgvhd
method
report
patient
scgvhd
hfu
plu
doppleru
perform
diagnosi
scgvhd
differ
timepoint
treatment
initi
serum
hyaluron
acid
procolageniii
measur
fibrosi
biomark
simultan
hfu
doppleru
nih
cgvhd
consensu
confer
diagnosi
criteria
score
system
respons
criteria
use
assess
global
organspecif
cgvhd
measur
overal
respons
therapi
abnorm
ultrasound
find
defin
presenc
follow
hypoechogen
dermi
dermoepiderm
junction
effac
hypoechogen
septa
andor
hyperechogen
lobul
hypodermi
hypoechogen
fascia
myositi
hfu
vessel
thicker
dermi
andor
hypodermi
systol
pressur
cmsec
index
vascular
resist
doppleru
inflammatori
activ
classifi
mild
moder
sever
accord
sever
doppleru
find
result
hfsu
show
abnorm
find
patient
diagnosi
chang
except
two
patient
along
treatment
followup
inflammatori
activ
doppleru
observ
patient
diagnosi
mild
moder
sever
four
patient
respond
treatment
complet
respons
cr
partial
respons
pr
one
present
clinic
improv
less
pr
one
progress
diseas
patient
clinic
respons
also
prom
improv
normal
patient
achiev
respons
show
normal
improv
doppleru
find
patient
clinic
improv
less
pr
patient
progress
diseas
show
persist
inflammatori
doppleru
find
patient
normal
light
increas
procollagen
level
diagnosi
signific
chang
observ
followup
level
hyaluron
acid
tend
high
patient
progress
scgvhd
patient
tend
decreas
normal
respond
therapi
patient
conclus
exploratori
studi
hfsu
reliabl
method
evalu
sclerot
skin
chang
scgvhd
doppleru
show
good
correl
diseas
activ
respons
treatment
serum
hyaluron
acid
level
might
biomark
diseas
activ
deserv
investig
hfsu
plu
doppleru
use
noninvas
repeat
devic
monitor
patient
suffer
scgvhd
accord
result
doppleru
may
sensit
paramet
hfsu
assess
inflammatori
activ
scgvhd
disclosur
receiv
grant
dkmsspain
foundat
author
noth
declar
posttranspl
cyclophosphamid
versu
antithymocyteglobulin
hlamatch
unrel
haploident
transplant
hematolog
malign
background
posttranspl
cyclophosphamid
ptci
antithymocyteglobulin
atg
commonli
use
regimen
prophylaxi
graftversu
host
diseas
gvhd
compar
two
regimen
hlamatch
unrel
mud
haploident
transplant
hematolog
malign
method
retrospect
analyz
consecut
adult
patient
hematolog
malign
receiv
mud
haploident
transplant
chungnam
nation
univers
hospit
januari
januari
patient
receiv
second
transplant
refractori
diseas
exclud
result
studi
includ
patient
median
age
rang
year
patient
receiv
mud
transplant
patient
ptci
atg
group
respect
patient
receiv
haploident
transplant
patient
ptci
atg
group
graft
sourc
peripher
blood
stem
cell
patient
median
followup
durat
month
rang
mud
transplant
estim
surviv
rate
ptci
vs
atg
relaps
rate
ptci
vs
atg
cumul
incid
grade
acut
gvhd
ptci
vs
atg
estim
extens
chronic
gvhd
rate
ptci
vs
atg
haploident
transplant
estim
surviv
rate
ptci
vs
atg
relaps
rate
ptci
vs
atg
cumul
incid
grade
acut
gvhd
rate
ptci
vs
atg
estim
month
extens
chronic
gvhd
rate
ptci
vs
atg
patient
receiv
ptci
significantli
longer
neutrophil
engraft
time
receiv
atg
haploident
transplant
median
rang
day
vs
day
conclus
ptci
might
good
option
prophylaxi
gvhd
hlamatch
unrel
transplant
well
haploident
transplant
disclosur
noth
declar
earli
fam
therapi
post
allohsct
bronchiol
obliteran
syndrom
background
bronchiol
obliteran
syndrom
bo
potenti
major
complic
allogen
hematopoiet
stem
cell
transplant
hsct
attribut
alloimmun
reaction
small
airway
bo
consid
pulmonari
manifest
chronic
gvhd
report
incid
bo
rang
bosattribut
mortal
high
year
ago
new
therapeut
approach
fluticason
azithromycin
montelukast
fam
describ
norman
bc
et
al
bmt
aim
analyz
outcom
pt
develop
bo
precoci
treat
fam
scheme
method
allohsct
perform
center
januari
juli
includ
analysi
baselin
diseas
aml
lpd
md
mpd
mm
bmf
day
day
overal
mortal
respect
rest
characterist
seri
shown
tabl
fam
therapi
systemat
start
patient
first
diagnos
bo
result
eleven
patient
diagnos
bo
diagnosi
bo
pt
exhibit
predict
median
rang
andor
declin
prehsct
day
pt
alreadi
syndrom
two
die
end
first
year
one
due
invas
zygomycosi
cn
plu
pulmonari
baselin
diseas
progress
day
pt
bo
two
pt
bo
die
month
posthsct
due
baselin
diseas
progress
close
analysi
pt
aliv
median
followup
month
rang
mortal
bosattribut
mortal
pt
complic
respect
conclus
bo
infrequ
sever
complic
allohsct
bo
seem
less
frequent
pt
prophylact
pretranspl
ratg
posttranspl
cyclophosphamid
well
pt
undergo
transplant
bm
compar
pbsc
earli
diagnosi
therapi
critic
minim
bosattribut
mortal
disclosur
background
donor
lymphocyt
infus
dli
establish
treatment
patient
hematolog
malign
relaps
allogen
hematopoiet
stem
cell
transplant
hsct
howev
associ
increas
risk
graftversushost
diseas
gvhd
modest
antitumor
activ
compar
infus
nonmobil
lymphocyt
granulocyt
colonystimul
factor
gcsf
prime
dli
might
induc
stronger
antitumor
effect
reduc
risk
infusioninduc
gvhd
due
limit
experi
gcsf
prime
dli
patient
relaps
haploident
hsct
conduct
retrospect
studi
patient
hospit
receiv
dli
relaps
hematolog
diseas
follow
relat
hlamatch
hlahaploident
hsct
method
institut
research
board
approv
studi
identifi
patient
hematolog
malign
receiv
dli
follow
relat
allohsct
nation
taiwan
univers
hospit
aug
infus
obtain
cryopreserv
specimen
collect
store
multipl
aliquot
time
initi
haploident
peripher
stem
cell
graft
patient
receiv
dli
either
hematolog
relaps
preemptiv
prophylact
treatment
univari
multivari
analysi
perform
use
cox
proport
hazard
regress
model
result
patient
follow
relat
hlamatch
patient
follow
hlahaploident
hsct
receiv
dose
dli
respect
comparison
median
cell
dosag
haplodli
significantli
lower
p
dli
sibl
donor
median
cell
dosag
kg
rang
kg
kg
rang
kg
respect
median
time
dli
initi
sibl
hsct
haplohsct
day
rang
day
day
rang
day
respect
overal
patient
follow
sibl
hsct
develop
grade
acut
gvhd
dli
wherea
patient
receiv
haplohsct
develop
grade
acut
gvhd
dli
importantli
patient
receiv
dli
cell
dosag
less
kg
differ
risk
develop
grade
acut
gvhd
patient
receiv
dli
sibl
haplo
donor
figur
interestingli
patient
receiv
dli
cell
dosag
equal
kg
patient
follow
haplohsct
develop
grade
acut
gvhd
dli
significantli
patient
follow
sibl
hsct
develop
grade
acut
gvhd
dli
figur
cumul
incid
grade
acut
gvhd
day
haplohsct
sibl
hsct
ci
ci
respect
figur
p
imag
conclus
studi
show
administr
gcsf
mobil
dli
feasibl
haploident
hsct
relaps
hematolog
malign
howev
dli
cell
dosag
equal
kg
patient
receiv
haplohsct
associ
significantli
higher
risk
develop
acut
gvhd
dli
sibl
donor
disclosur
author
declar
compet
financi
interest
background
freseniu
phelix
uva
irradi
devic
use
photoactiv
mnc
collect
amicu
system
close
util
special
mnc
kit
modifi
instrument
softwar
preliminari
result
phase
safeti
trial
involv
three
patient
treatment
chronic
graft
vs
host
diseas
present
method
reason
transplant
patient
age
year
acut
myelogen
leukemia
myelodysplast
syndrom
myelodysplast
syndrom
pnh
stem
cell
sourc
peripher
blood
match
develop
chronic
skin
gvhd
inclus
criteria
includ
wbc
plt
count
l
gfr
mlminbsa
ast
unitl
exclus
criteria
includ
activ
gi
bleed
nyha
cardiac
diseas
greater
grade
iii
presenc
lightsensit
diseas
amicu
softwar
phelix
softwar
use
set
includ
mlmin
max
draw
rate
ml
fix
cycl
volum
mgkgmin
citrat
infus
rate
acda
ratio
venou
access
peripher
subcutan
port
target
uva
dose
jcm
dose
ml
result
follow
mean
sd
procedur
result
obtain
ml
whole
blood
acda
drawn
ml
acda
use
ml
salin
use
minut
procedur
time
ml
total
blood
volum
minor
alarm
amicu
alarm
phelix
encount
aerob
anaerob
cultur
neg
mean
endotoxin
level
euml
mean
prepost
cbc
plasma
hemoglobin
level
wbc
neutrophil
basophil
eosinophil
lymphocyt
monocyt
platelet
x
l
hct
gdl
hgb
mgdl
plasma
hemoglobin
plasma
hemoglobin
delta
product
gram
subject
gram
collect
product
hct
mean
yield
tabl
advers
event
includ
one
acut
respiratori
failur
respiratori
failur
muscular
weak
musculoskelet
discomfort
peripher
swell
three
four
event
occur
one
patient
two
week
studi
procedur
none
advers
event
consid
relat
procedur
investig
product
patient
experienc
acut
respiratori
failur
remov
studi
death
due
pneumonia
felt
unrel
procedur
conclus
result
indic
new
close
photopheresi
system
capabl
collect
suffici
mnc
irradi
cell
produc
high
lymphocyt
apoptosi
minim
alarm
advers
reaction
patient
also
acut
gvhd
skin
liver
patient
could
treat
control
methylprednislon
monotherapi
patient
steroid
refractori
gvhd
patient
could
salvag
addit
drug
patient
refractori
acut
gut
gvhd
could
salvag
despit
three
line
therapi
time
report
patient
aliv
patient
die
due
transplant
relat
mortal
patient
develop
relaps
diseas
binari
logist
regress
analysi
baselin
clinic
treatment
relat
predictor
diseas
indic
diseas
statu
transplant
transplant
type
graft
sourc
type
condit
could
identifi
develop
acut
gvhd
gastrointestin
system
conclus
acut
gvhd
gastrointestin
system
signific
caus
morbid
allohct
patient
centr
studi
warrant
cohort
prospect
analysi
gut
microbiom
analysi
faecal
multidrug
resist
organ
surveil
condit
relat
toxic
antibiot
usag
ongo
clinic
trial
registri
applic
disclosur
author
declar
potenti
conflict
interest
benefit
precaut
ruxolitinib
steroidrefractori
acut
gvhd
background
corticosteroid
standard
firstlin
treatment
option
patient
acut
graftversu
host
diseas
gvhd
approxim
half
patient
becom
refractori
steroid
requir
secondlin
treatment
ruxolitinib
potenti
treat
gvhd
steroidrefractori
sr
patient
base
retrospect
clinic
data
ongo
prospect
trial
current
enrol
patient
evalu
therapeut
potenti
ruxolitinib
gvhd
method
analyz
retrospect
clinic
experi
ruxolitinib
patient
grade
steroidrefractori
acut
gvhd
patient
compar
control
group
receiv
ruxolitinib
addit
immun
statu
evalu
week
administr
ruxolitinib
use
flowcytometri
ruxolitinib
use
third
option
sr
gvhd
combin
previous
use
immunosuppress
drug
steroid
gradual
decreas
accord
symptom
discontinu
patient
receiv
ruxolitinib
mg
twice
daili
bid
increas
mg
bid
hematolog
paramet
stabl
treatmentrel
toxic
result
fifteen
patient
assess
respons
seven
patient
achiev
complet
respons
partial
respons
respons
week
first
ruxolitinib
dose
overal
respons
rate
three
treatment
failur
advers
effect
manag
except
infecti
complic
infecti
complic
occur
patient
n
result
two
death
common
caus
infecti
event
includ
cytomegaloviru
n
herpeszost
epsteinbarr
viru
fungal
infect
n
pneumocysti
jiroveci
n
bacteri
infect
n
pneumonia
unknown
origin
n
cell
count
tend
decreas
group
ruxolitinib
compar
control
group
especi
cell
count
conclus
ruxolitinib
effect
control
sr
gvhd
lead
clinic
benefit
howev
need
awar
infecti
complic
ruxolitinib
may
lead
increas
risk
opportunist
infect
reactiv
latent
infect
addit
common
infecti
complic
presum
involv
cell
dysfunct
clinic
background
graft
versu
host
diseas
gvhd
one
common
lifethreaten
complic
post
hsct
contribut
significantli
morbid
mortal
affect
gastrointestin
tract
gi
major
caus
death
earli
period
post
hsct
due
widespread
tissu
involv
patient
diagnos
gi
gvhd
surgic
treatment
rare
consid
method
among
allohsct
perform
depart
pediatr
hematolog
oncolog
bone
marrow
transplant
wroclaw
poland
year
case
diagnos
gi
gvhd
studi
present
case
refer
benefit
surgic
approach
result
male
year
old
underw
hsct
match
unrel
donor
mud
due
chronic
myelogen
leukemia
cml
subsequ
molecular
relaps
succes
treat
donor
lymphocyt
infus
follow
agvhd
skin
gut
involv
grade
iv
extens
immunosuppress
steroid
mycofenol
mofetil
atg
result
signific
resolut
agvhd
symptom
howev
aggrav
sever
abdomin
pain
lack
gut
movement
suggest
bowel
obstruct
due
presenc
acut
abdomen
patient
immedi
direct
laparotomi
resect
constrict
bowel
segment
follow
subsequ
laparotomi
secondari
obstruct
provid
complet
resolut
abdomin
symptom
year
followup
patient
aliv
well
eleven
year
old
male
diagnos
skin
gut
grade
iv
agvhd
day
post
mudhsct
perform
due
acut
myelogen
leukemia
aml
receiv
pronlong
immunosuppress
treatment
includ
steroid
antibodi
msc
ecp
led
resolv
skin
leasion
diarhoea
nevertheless
patient
suffer
sever
paroxysm
abdomin
pain
incident
vomit
ct
enterographi
show
partial
small
bowel
constrict
numer
surgic
consult
eventu
day
patient
underw
laparotomi
constrict
bowel
resect
histopatolog
examin
resect
tissu
reveal
moder
gvhd
immunosuppers
taper
low
dose
steroid
ecp
year
post
hsct
patient
aliv
rare
experienc
mild
abdomin
cramp
fourteen
year
old
femal
develop
sever
abdomin
pain
high
volum
diarhoea
day
post
mudhsct
perform
sever
anaplast
anemia
saa
despit
extens
immunosuppress
steroid
antitnf
antibodi
patient
condit
improv
consist
stomach
pain
suspect
subileu
confirm
ct
enterographi
laparotomi
perform
resect
inflam
obstruct
bowel
made
microscop
evalu
confirm
prior
gvhd
diagnosi
therefor
immunosuppress
includ
csa
taper
dose
steroid
continu
complet
resolut
abdomin
symptom
almost
immedi
achiev
postsurgeri
howev
month
recurr
abdomin
cramp
observ
well
control
pain
killer
conclus
commonli
gi
gvhd
diffus
inflammatori
process
howev
case
may
local
may
lead
partial
bowel
constrict
case
sever
prolong
stomach
pain
despit
partial
resolv
gvhd
symptom
ileu
consid
ct
enterographi
may
use
diagnosi
confirm
patient
surgic
intervent
may
improv
qualiti
life
even
salvag
approach
disclosur
noth
disclos
impact
uric
acid
level
preand
earli
postgraft
infus
period
gvhd
occur
allotranspl
outcom
year
underw
allogen
stem
cell
transplant
allosct
fullmatch
sibl
donor
acut
leukemia
sever
aplast
anemiapnh
lymphoma
myelodysplast
myeloprolif
syndrom
thirtytwo
patient
remiss
time
allosct
beyond
better
accur
assess
ua
level
agvhd
incid
unlik
publish
studi
evalu
ua
level
day
evalu
ua
level
differ
time
point
peritranspl
period
condit
regimen
initi
day
major
patient
develop
agvhd
within
day
posttranspl
incorpor
studi
ua
level
beyond
day
also
investig
effect
ua
surviv
nonrelaps
mortal
nrm
vast
major
patient
receiv
allopurinol
st
day
condit
regimen
till
day
independ
ttest
kaplanmeir
method
logrank
test
use
statist
analysi
result
median
ua
level
mgdl
day
respect
statist
analysi
purpos
group
patient
lowua
valu
mgdl
highua
mgdl
threshold
chosen
base
ua
valu
collect
sampl
final
patient
develop
agvhd
assess
gr
gr
iiiiv
incid
agvhd
gr
similar
rang
group
patient
lowua
highua
estim
time
point
day
notic
better
overal
surviv
patient
lowua
vs
howev
without
statist
signific
ten
patient
succumb
nrm
caus
death
attribut
gvhd
complic
nrm
assess
higher
highua
group
vs
also
differ
statist
signific
conclus
though
studi
bear
limit
small
number
patient
retrospect
origin
least
knowledg
first
evalu
impact
ua
level
differ
time
point
peritranspl
period
agvhd
incid
studi
ua
level
influenc
incid
sever
agvhd
higher
nrm
rate
patient
ua
mgdl
merit
evalu
definit
role
ua
allosct
outcom
clarifi
well
design
prospect
trial
disclosur
result
five
male
patient
genit
cgvhd
manifest
present
urethr
strictur
patient
phimosi
requir
surgic
treatment
one
patient
five
patient
simultan
cutan
oral
andor
ocular
cgvhd
manifest
first
patient
underw
urethroplasti
bulbomembran
part
urethra
terminotermin
anastomosi
urethroplasti
penil
part
urethra
buccal
mucosa
autograft
bmg
dorsal
onlay
result
signific
improv
symptom
normal
miction
afterward
biopsi
urethra
show
mononuclear
infiltr
lamina
propria
consist
cgvhd
biopsi
buccal
mucosa
done
prior
surgeri
neg
cgvhd
involv
second
patient
underw
urethrotomi
due
circular
strictur
symptom
reappear
candid
bmg
two
patient
urethr
dilat
done
fifth
patient
present
phimosi
requir
circumcis
result
signific
improv
symptom
conclus
male
genit
cgvhd
underrecogn
underreport
manifest
patient
allohsct
need
activ
ask
genit
symptom
sexual
function
especi
diagnos
mucocutan
ocular
cgvhd
multidisciplinari
approach
earli
recognit
frequent
followup
necessari
time
start
treatment
new
method
bmg
cgvhd
patient
urethr
strictur
seem
promis
investig
disclosur
noth
declar
abstract
withdrawn
heracl
phase
ii
singlearm
prospect
studi
assess
efficaci
fecal
microbiota
transfer
treatment
steroid
refractori
gastrointestin
agvhd
post
allohsct
background
steroidrefractori
acut
graftversushost
diseas
sragvhd
associ
mortal
rate
reduc
qualiti
life
qol
far
approv
standard
care
agvhd
secondlin
treatment
urgent
need
identifi
effect
therapi
sragvhd
improv
patient
outcom
fecal
microbiota
transfer
fmt
might
benefici
substanti
improv
prognosi
higher
gut
microbi
divers
strongli
associ
increas
surviv
gvhd
patient
recent
studi
report
promis
result
sragvhd
patient
treat
fmt
evalu
confirm
efficaci
safeti
fmt
agvhd
warrant
ongo
phase
studi
heracl
investig
efficaci
allogen
fmt
treatment
patient
sragvhd
heracl
launch
odysse
studi
show
promis
result
reconstruct
gut
microbiota
divers
induct
chemotherapi
fmt
acut
myeloid
leukemia
patient
expect
fmtbase
biotherapeut
drug
could
effect
treatment
contain
sragvhd
therebi
reduc
risk
lifethreaten
complic
allogen
hsct
method
heracl
singlearm
multicent
prospect
trial
european
countri
patient
age
yearsold
underw
allogen
hematopoiet
stem
cell
transplant
allohsct
develop
first
episod
stage
agvhd
gut
predomin
resist
firstlin
steroid
therapi
elig
inclus
main
exclus
criteria
compris
use
secondlin
gvhd
therapi
patient
grade
iv
hyperacut
gvhd
late
onset
agvhd
overlap
chronic
gvhd
agvhd
donor
lymphocyt
infus
patient
receiv
first
enema
within
day
sr
diagnosi
addit
one
week
apart
highlydivers
microbiomerich
enema
formul
obtain
pool
rigor
screen
faec
healthi
donor
manufactur
standard
process
use
signatur
maat
microbiom
restor
biotherapeut
mmrb
platform
inclus
dose
day
post
inclus
patient
faec
blood
collect
safeti
monitor
perform
correspond
blood
analys
exploratori
measur
faec
includ
character
gut
microbiota
composit
evolut
impact
metabol
gut
inflamm
immun
system
phenotyp
perform
flow
cytometri
peripher
blood
mononuclear
cell
elisa
assay
plasma
patient
qol
assess
use
standard
questionnair
primari
object
assess
efficaci
evalu
complet
respons
cr
accord
modifi
glucksberg
criteria
good
partial
respons
vgpr
defin
martin
et
al
bbmt
day
postinclus
primari
followup
secondari
object
includ
fmt
safeti
assess
evalu
fmt
impact
sever
endpoint
overal
relapsefre
gvhdfree
surviv
chronic
gvhd
evalu
well
multidrug
resist
bacteria
carriag
patient
followedup
year
inclus
overal
patient
plan
enrol
treat
assess
overal
respons
rate
safeti
profil
result
background
antiprogram
cell
death
protein
monoclon
antibodi
use
bridg
subsequ
allogen
hematopoiet
stem
cell
transplant
hsct
patient
relapsedrefractori
lymphoma
hl
strategi
report
effect
frequent
onset
steroidrefractori
graft
versu
host
diseas
gvhd
also
report
report
clinic
case
patient
affect
hl
undergo
allogen
hsct
treat
nivolumab
method
patient
year
respect
advanc
hl
relaps
previou
autolog
allogen
hsct
underw
rescu
therapi
nivolumab
cycl
respect
depend
time
partial
respons
achiev
avail
donor
two
patient
receiv
thiotepafludarabinecyclophosphamid
condit
atgbas
prophylaxi
pb
cell
unrel
donor
third
patient
receiv
bm
cell
haploident
donor
use
baltimora
nonmieloabl
platform
result
followup
month
hsct
respect
patient
achiev
maintain
complet
remiss
petct
scan
patient
develop
acut
gvhd
day
respect
patient
progress
grade
iv
acut
gvhd
hepat
intestin
involv
unrespons
first
line
mgkg
steroid
therapi
second
line
etanercept
plu
extracorpor
photopheresi
ecp
third
line
therapi
ruxolitinib
partial
control
gvhd
gvhd
onset
patient
preceed
prolong
fever
without
microbiolog
find
patient
develop
hepat
grade
ii
gvhd
high
transaminas
level
initi
respons
steroid
therapi
progress
gut
requir
second
line
therapi
etanercept
patient
progress
sever
chronic
gvhd
skin
involv
result
unrespons
steroid
ecp
partial
control
ruxolitinib
immun
reconstitut
delay
patient
month
post
transplant
level
level
respect
patient
underw
haploident
transplant
receiv
posttraspl
cyclophosphamid
ptci
immunosuppress
treatment
month
hsct
without
evid
gvhd
histori
infect
patient
receiv
pbsc
unrel
donor
atg
prophylaxi
patient
develop
dissemin
fusariosi
day
die
cn
fusarium
local
year
hsct
despit
target
antifung
therapi
patient
pulmonari
aspergillosi
sepsi
multidrug
resist
psuedomona
aeruginosa
otomastoid
month
hsct
ruxolitinib
treatment
skin
clinic
partial
respons
conclus
case
seri
confirm
nivolumab
bridg
transplant
effect
appropri
select
patient
howev
risk
acut
gvhd
delay
immun
reconstitut
may
requir
care
consider
moment
plan
transplant
possibl
advantag
ptci
gvhd
platform
haploident
donor
address
larger
studi
background
acut
graftversushost
diseas
agvhd
import
complic
allogen
hematopoiet
stem
cell
transplant
hsct
standard
secondlin
treatment
establish
corticosteroid
refractori
agvhd
agent
good
option
treatment
patient
especi
lower
gi
tract
involv
method
april
juli
review
outcom
patient
steroidrefractori
sr
agvhd
treat
etanercept
least
second
line
treatment
etanercept
dose
mg
twice
week
first
week
follow
weekli
dose
result
median
age
year
rang
year
patient
male
fourteen
patient
nonadvanc
diseas
statu
hstc
eleven
patient
receiv
myeloabl
condit
stem
cell
sourc
peripher
blood
patient
sixteen
patient
hla
match
characterist
patient
agvhd
stage
previou
rescu
treatment
etanercept
outcom
shown
tabl
seventeen
patient
classic
agvhd
lateonset
agvhd
etanercept
given
nd
rd
th
line
patient
respect
median
dose
etanercept
administ
rang
patient
complet
dose
plan
treatment
aliv
month
onset
rescu
treatment
complic
etanercept
treatment
infect
gram
neg
bacilli
grade
neutropenia
grade
thrombocytopenia
etanercept
indic
rescu
treatment
due
progress
day
agvhd
treatment
respons
day
treatment
complet
remiss
day
treatment
relaps
due
decreas
corticosteroid
dose
end
treatment
patient
achiev
complet
respons
patient
partial
respons
aliv
patient
receiv
etanercept
nd
line
treatment
lower
gi
agvhd
without
organ
significantli
involv
caus
death
agvhd
without
infect
patient
leukemia
relaps
patient
conclus
although
etanercept
option
treatment
sr
agvhd
patient
prognost
remain
poor
effect
altern
strategi
need
prompt
initi
etanercept
rescu
treatment
sr
agvhd
crucial
improv
prognosi
background
although
cyclosporin
csa
tacrolimu
calcineurin
inhibitor
csa
wide
use
pediatr
hematopoet
stem
cell
transplant
hsct
prophylact
drug
acut
graft
versu
host
diseas
agvhd
clinic
experi
data
clinic
efficaci
convers
tacrolimu
present
singl
center
data
arguabl
topic
method
studi
involv
data
pediatr
hsct
patient
medic
park
hospit
patient
prophylact
csa
therapi
variou
reason
csa
convert
tacrolimu
therapi
patient
convers
due
agvhd
steroid
first
line
therapi
agvhd
convers
tacrolimu
done
concurr
start
steroid
therapi
within
hour
start
steroid
also
patient
immunosupress
therapi
agvhd
exclud
respons
defin
resolut
symptom
within
day
convers
result
mean
age
studi
popul
month
month
malefemal
ratio
donor
type
mud
patient
mfd
patient
haplo
patient
mean
convers
time
day
day
rational
convers
agvhd
patient
unprop
csa
plasma
level
patient
allerg
reaction
patient
nephrotox
patient
hepatotox
patient
sever
headach
patient
high
arteri
blood
pressur
patient
one
refractori
vomit
autoimmun
thyroid
visual
disturb
subgroup
analysi
agvhd
patient
reveal
mean
convers
time
agvhd
day
day
respond
whose
agvhd
resolv
complet
convers
patient
proper
tacrolimu
level
convers
due
unprop
csa
level
also
patient
alleg
reaction
sever
headach
visiual
disturb
refractori
vomit
group
respond
convers
complet
one
patient
nephrotox
group
respond
also
patient
hepatox
group
respond
one
patient
suffer
autoimmun
thyroid
respond
convers
conclus
studi
obviou
respons
convers
specif
advers
effect
csa
tacrolimu
good
altern
patient
unprop
csa
level
convers
high
percentag
nonrespond
show
feasibl
make
convers
tacrolimu
acut
gvhd
disclosur
noth
declar
background
capillari
leak
syndrom
caus
dysfunct
vascular
endotheli
cell
character
weight
gain
gener
edema
unrespons
diuret
treatment
hypotensionit
usual
develop
first
day
post
hsctand
great
difficuti
distinguish
complic
occur
post
allohsct
diagnos
complic
earli
stage
difficulti
method
man
admit
ningbo
first
hospit
abnorm
peripher
blood
diagnos
classic
morpholog
immunophenotypecytogenet
evalu
show
normal
xy
patient
achiev
cr
induct
therapi
includ
idarubicin
cytarabin
etoposid
consolid
therapi
allohsct
hla
ident
relat
dornor
male
donorrecipi
match
high
resolut
hla
type
hlaa
b
c
match
performedth
recipi
receiv
condit
busulfan
mgkgday
inject
day
cyclophosphamid
mgkgday
inject
day
cytarabin
inject
day
semustin
oral
donor
peripher
blood
stem
cell
pbsc
mnc
mobil
pheres
administ
recipi
gvhd
prophylaxi
consist
tradit
cyclosporin
shortcours
methotrex
mg
day
day
cyclosporin
inject
qer
day
mot
reduc
until
hematopoiet
reconstitut
sucess
day
complet
donor
chimer
acheiev
csa
gradual
reduc
taperedon
day
patient
manifest
increas
time
volum
faec
diagnos
gut
standard
immunosuppress
drug
includ
methylprednisolon
cyclosporin
administr
immunosuppress
drug
gradual
reduc
gvhd
controlledon
patient
felt
distress
distress
relat
exercis
temperatur
normal
gain
weightther
edema
bodylaboratori
test
includ
routin
blood
test
creactiv
protein
procalcitonin
blood
ga
analysi
cmvdna
ebvdna
normal
ct
scan
show
pleural
fill
water
could
enlarg
pericardi
effus
bodypulmonari
function
test
show
reduc
function
ventil
diffus
fuctionth
laboratori
test
pleural
effus
normal
blast
cell
detect
pleural
effus
cell
count
dectabl
level
next
gener
sequenc
minim
residu
diseas
show
gene
mutat
thu
post
capillari
leak
syndrom
consid
sirolimu
adopt
taken
place
cyclosporin
immunoglobulin
adminstr
reduc
edema
result
take
togeth
comprehens
effus
pleural
cardiac
absorb
well
conclus
occur
capillari
leak
syndrom
rare
limit
data
capillari
leak
syndrom
comprehens
mechan
cl
total
identifiedand
standard
treatment
treat
complicationat
present
cl
patient
absorb
well
administr
sirolimu
close
followup
need
disclosur
noth
declar
graftversushost
diseasepreclin
anim
model
shortterm
posttranspl
cyclophosphamid
graftversushost
diseas
prophylaxi
emi
yokoyama
daigo
hashimoto
takahid
ara
eko
hayas
takanori
teshima
hokkaido
univers
faculti
medicin
hematolog
sapporo
japan
background
posttranspl
highdos
cyclophosphamid
ptci
combin
immunosuppress
calcineurininhibitor
ci
increasingli
use
gvhd
prophylaxi
hlahaploident
match
hematopoiet
stem
cell
transplant
hsct
howev
ci
could
hamper
reconstitut
regulatori
cell
treg
toler
induct
hsct
facilit
us
develop
novel
cifreeptcybas
gvhd
prophylaxi
current
studi
develop
novel
gvhd
prophylaxi
ptci
combin
shortterm
administr
select
agonist
receptor
type
use
murin
model
mhc
haploident
bone
marrow
transplant
bmt
method
bd
recipi
lethal
irradi
transplant
bone
marrow
cell
splenocyt
allogen
b
donor
cy
dose
mgkg
intraperiton
inject
recipi
day
krp
dose
mgkg
oral
administr
daili
day
day
bmt
donor
cell
target
organ
secondari
lymphoid
organ
evalu
flow
cytometr
analysi
plasma
level
determin
use
cytometr
bead
array
evalu
graftversusleukemia
gvl
effect
recipi
mice
intraven
inject
luciferasetransduc
cell
day
vivo
bioluminesc
imagingwa
conduct
weekli
bmt
result
sever
gvhd
develop
allogen
recipi
mice
die
day
bmtptci
alon
dose
mgkg
significantli
amelior
gvhd
ptcytreat
allogen
recipi
surviv
oral
administr
alon
enhanc
contract
donor
cell
lymph
node
also
amelior
gvhd
previous
shown
agonist
fingolimod
next
test
shortterm
day
ad
ptci
enhanc
antigvhd
effect
ptci
found
surviv
group
significantli
prolong
compar
ptcyalon
group
figur
plasma
level
tnfa
clinic
gvhd
score
figur
b
donor
tcell
infiltr
target
organ
gut
skin
also
significantli
reduc
ptci
group
compar
ptcyalon
group
figur
c
unlik
ci
addit
ptci
promot
treg
reconstitut
bmt
final
bioluminesc
imag
demonstr
prolifer
inject
day
significantli
delay
ptci
allogen
recipi
compar
control
mice
transplant
tcell
deplet
bone
marrow
cell
suggest
signific
gvl
effect
persist
recipi
conclus
combin
shortterm
ptci
promis
novel
calcineurinfre
gvhd
prophylaxi
mhchaploident
sct
recent
show
donor
inkt
cell
expand
ex
vivo
abl
prevent
activ
prolifer
alloreact
donor
cell
promot
effici
graftversusleukemia
effect
schmid
et
al
howev
underli
mechan
human
inkt
cell
induc
immun
toler
allogen
hct
fulli
understood
method
monocytederiv
dendrit
cell
dc
cultur
mix
lymphocyt
reaction
mhcmismatch
cell
cultureexpand
inkt
cell
tcell
activ
prolifer
analyz
multiparametr
flow
cytometri
releas
cytokin
measur
via
multiplex
analysi
transwel
assay
imag
flow
cytometri
perform
elucid
cellcel
interact
beadcontrol
flow
cytometrybas
cytotox
assay
use
evalu
dc
apoptosi
apoptot
dc
purifi
fluorescenceactiv
cell
sort
investig
tolerogen
potenti
prime
regulatori
cell
treg
result
addit
inkt
cell
mix
lymphocyt
reaction
result
significantli
reduc
activ
prolifer
mhcmismatch
cell
transwel
assay
imag
flow
cytometri
reveal
cell
contactdepend
mechan
inkt
cell
dc
lead
apoptosi
increas
dna
fragment
dc
time
interestingli
variou
fluorescenceactiv
singl
cell
sort
inktcel
subset
abl
induc
apoptosi
host
dc
multiplex
analysi
reveal
dc
trigger
inktcel
releas
cytotox
factor
like
perforin
granzym
b
granulysin
block
inktcel
receptor
engag
antibodi
prevent
inktcel
degranul
well
subsequ
induct
host
dc
apoptosi
inhibit
cytotox
factor
also
abrog
apoptosi
dc
turn
sort
apoptot
dc
induc
tolerogen
dc
character
high
express
mix
lymphocyt
reaction
tolerogen
dc
promot
expans
treg
prevent
activ
prolifer
mhcmismatch
cell
conclus
propos
novel
mechan
cultureexpand
human
inkt
cell
prevent
gvhd
allogen
hct
host
dc
apoptosi
donor
inkt
cell
induc
tolerogen
immunoenviron
character
high
dc
expand
donor
treg
inhibit
activ
expans
alloreact
donor
cell
find
pave
avenu
clinic
translat
adopt
transfer
cultureexpand
inkt
cell
human
disclosur
noth
declar
result
vipko
mice
transplant
allogen
tcd
bm
alon
increas
graft
reject
lower
level
donor
chimer
day
surviv
compar
surviv
wt
recipi
transplant
tcd
bm
plu
donor
cell
balbc
donor
vip
kio
mice
led
donor
chimer
significantli
increas
gvhdmortal
compar
wt
recipi
vs
surviv
model
p
vs
surviv
balbc
model
p
donorderiv
cell
vipko
recipi
significantli
higher
polar
higher
p
p
cell
higher
frequenc
p
p
p
cell
compar
wt
recipi
second
allogen
transplant
radiat
chimera
caus
lethal
gvhd
mortal
vipko
vipko
wt
vipko
mice
wt
wt
vipko
wt
mice
demonstr
protect
effect
vip
due
synthesi
nonhematopoiet
recipi
cell
immunofluoresc
imag
allobmt
recipi
show
mark
upregul
vip
lung
posttranspl
high
vip
product
within
neuron
innerv
lung
final
demonstr
shortterm
administr
vip
day
day
prevent
gvhdmortal
vipko
recipi
transplant
mhc
donor
bm
cell
conclus
absenc
vip
recipi
cell
led
increas
graft
reject
absenc
donor
cell
increas
lethal
gvhd
donor
cell
transplant
indic
vip
induc
posttranspl
regul
alloreact
host
graftreject
lymphocyt
donor
gvhdcaus
cell
protect
effect
parenter
vip
administr
suggest
vipmimet
repres
novel
approach
prevent
treat
gvhd
data
also
suggest
mechan
action
mitig
gvhd
antitrypsin
aat
wherebi
aat
inhibit
proteolyt
inactiv
endogen
vip
disclosur
dr
waller
report
person
fee
support
cambium
medic
technolog
grant
celldex
person
fee
kalytera
grant
person
fee
novarti
grant
nonfinanci
support
pharmacycl
equiti
ownership
ceru
corpor
chimerix
outsid
submit
work
addit
dr
waller
intellectu
properti
relat
vip
signal
licens
cambium
oncolog
hold
equiti
lowdens
neutrophil
expans
associ
acut
graft
versu
host
diseas
allogen
hematopoiet
stem
cell
transplant
patient
background
lowdens
neutrophil
ldn
distinguish
normaldens
neutrophil
ndn
anomal
sediment
within
mononuclear
cell
fraction
densiti
gradient
centrifug
peripher
blood
pb
analys
ldn
ndn
gcsfstimul
donor
lymphoma
patient
previous
demonstr
depend
physiopatholog
condit
immatur
ldn
promot
cell
surviv
product
matur
ldn
exert
immunosuppress
proprieti
aim
studi
establish
frequenc
ldn
pb
allogen
hematopoiet
stem
cell
transplant
hsct
patient
throughout
immun
reconstitut
verifi
potenti
correl
acut
graft
versu
host
diseas
agvhd
method
patient
undergo
hsct
institut
decemb
june
prospect
enrol
studi
upon
inform
consent
institut
board
approv
criteria
inclus
age
year
absenc
rheumatolog
viral
diseas
pb
sampl
collect
day
hsct
time
within
day
case
gvhd
firstlin
therapi
eight
healthi
donor
hd
enrol
control
mononuclear
polymorphonuclear
whole
blood
cell
analys
flow
cytometri
vioblu
pe
fitc
stain
ldn
express
percentag
pb
mononuclear
cell
pbmc
whole
blood
cell
character
base
express
ndn
express
percentag
whole
blood
cell
also
analys
stain
result
patient
mf
median
age
enrol
studi
patient
receiv
hsct
hlaident
haploident
relat
hlaident
unrel
donor
median
time
day
patient
develop
grade
iiiv
agvhd
patient
receiv
gcsf
agvhd
onset
schedul
assess
interrupt
agvhd
patient
begin
firstlin
treatment
patient
relaps
primari
malign
patient
develop
de
novo
lateacut
chronic
gvhd
start
day
frequenc
ldn
within
pbmc
higher
patient
compar
hd
patient
develop
agvhd
show
decreas
frequenc
ldn
progress
increas
ldn
day
interestingli
patient
agvhd
show
significantli
higher
frequenc
ldn
compar
patient
without
agvhd
throughout
time
laps
ie
day
vs
consist
patient
agvhd
significantli
lower
frequenc
ldn
vs
frequenc
matur
ndn
normal
patient
sinc
day
conclus
ldn
repres
hsct
patient
hd
signific
expans
parallel
decreas
subpopul
patient
agvhd
compar
without
agvhd
accord
previous
demonstr
cell
activ
function
ldn
tempt
specul
expans
subpopul
may
contribut
agvhd
develop
disclosur
noth
declar
background
acut
graftversushost
diseas
agvhd
major
complic
allogen
hematopoiet
stem
cell
transplant
allohsct
neg
impact
morbid
mortal
patient
accumul
evid
suggest
abnorm
regulatori
treg
cell
contribut
pathogenesi
gvhd
underli
molecular
mechan
still
remain
larg
unknown
method
studi
enrol
patient
treat
allogen
hsct
institut
hematolog
chines
academi
medic
scienc
well
agematch
healthi
adult
control
sampl
ratio
treg
pb
bm
healthi
control
hc
patient
without
agvhd
determin
flow
cytometri
transcript
profil
treg
patient
without
acut
gvhd
measur
pathway
enrich
analys
perform
kyoto
encyclopedia
gene
genom
kegg
pathway
databas
geneset
enrich
analysi
gsea
express
transcript
level
protein
level
measur
realtim
pcr
analyz
system
seri
function
assay
vitro
perform
assess
function
stabil
treg
patient
without
agvhdmeanwhil
assum
affect
gvhd
outcom
establish
murin
transplant
model
recipi
balbc
anim
transplant
amount
mixtur
made
bm
cell
yfp
treg
either
mice
result
studi
demonstr
bm
decreas
frequenc
treg
accompani
revers
lower
ratio
treg
frequenc
bm
pb
agvhd
patient
meanwhil
number
function
treg
bone
marrow
also
affect
hematopoiet
reconstitut
futhermor
elucid
mechan
regul
treg
homeostasi
examin
role
treg
patient
agvhd
agvhd
murin
model
studi
demonstr
treg
lost
express
weaken
suppressor
function
agvhd
transcript
profil
pathway
analysi
reveal
nfkb
signal
activ
impair
wide
spectrum
immunosuppress
gene
agvhd
treg
mice
experi
suggest
methyl
might
lead
instabl
treg
agvhd
group
transplant
marrow
graft
exacerb
gvhd
lethal
conclus
studi
indic
critic
homeostat
regul
treg
agvhd
target
therefor
repres
novel
therapeut
strategi
promot
immun
toler
mitig
sever
agvhd
disclosur
nation
program
key
basic
research
project
program
role
aryl
hydrocarbon
receptor
intestin
allogen
hsct
mice
wonsik
lee
soungmin
lee
sjkil
seo
inj
univers
busan
paik
hospit
hematooncolog
busan
korea
republ
background
aryl
hydrocarbon
receptor
ahr
ligandactiv
transcript
factor
activ
variou
small
molecul
diet
microorgan
host
metabol
xenobiot
toxic
chemic
function
ahr
demonstr
crucial
regul
intestin
homeostasi
investig
regulatori
role
ahr
intestin
recipi
allogen
hematopoiet
cell
transplant
mice
method
wildtyp
wt
b
ido
b
ahr
b
mice
lethal
irradi
transplant
x
tcdbm
plu
x
cell
balbc
donor
mice
ahr
activ
colon
tissu
recipi
determin
ahr
target
gene
express
use
realtim
pcr
recipi
mice
monitor
everi
day
surviv
clinic
score
histopatholog
pathogen
effector
cytokin
level
colon
tissu
analyz
evalu
ahr
function
result
observ
constitut
express
colon
tissu
recipi
mice
although
express
level
increas
tbi
condit
addit
upregul
level
donor
cell
alloreact
observ
contrast
express
markedli
induc
colon
tissu
donor
cell
alloreact
observ
express
significantli
decreas
colon
idorecipi
donor
cell
alloreact
chang
idoand
ahrrecipi
mice
show
higher
histopatholog
score
intestin
gvhd
increas
pathogen
cytokin
level
colon
compar
wt
mice
conclus
result
demonstr
ahrinduc
target
gene
profil
might
differ
induc
intestin
ligand
depend
manner
hsct
affect
intestin
gvhd
disclosur
noth
declar
abstract
alreadi
publish
abstract
withdrawn
vitro
platelet
activ
evalu
allogen
hematopoet
stem
cell
transplant
patient
respons
haemostat
stimul
cytomegaloviru
stimul
gvhd
complic
one
risk
factor
cmv
reactiv
result
inflammatori
platelet
respons
highrisk
period
gvhd
allogen
hsct
remain
unknown
studi
aim
character
spontan
platelet
activ
month
allogen
hsct
respons
haemostat
stimul
cmv
stimul
method
compar
group
healthi
volunt
group
allogen
hsct
patient
follow
th
th
day
hsct
platelet
activ
determin
platelet
surfac
express
use
flow
cytomet
stimul
haemostat
agent
thrombinreceptor
activ
peptid
trap
stimul
cmv
glycoprotein
b
inflammatori
respons
determin
detect
immun
mediat
rant
use
elisa
techniqu
stimul
platelet
supernat
result
platelet
activ
molecul
releas
observ
stimul
cmv
glycoprotein
b
group
rant
baselin
level
spontan
higher
allogen
hsc
patient
healthi
volunt
platelet
allogen
hsct
patient
activ
haemostat
stimul
releas
rant
situat
platelet
releas
rant
platelet
healthi
volunt
conclus
although
platelet
activ
detect
respons
cmv
glycoprotein
b
stimul
studi
reveal
chronic
platelet
activ
condit
month
allogen
hsct
haemostat
induc
hyperrespons
lead
releas
molecul
immunemodul
properti
involv
pathophysiolog
gvhd
move
away
hsct
phenomenon
seem
gradual
weaken
clinic
trial
registri
fipalloc
http
disclosur
noth
declar
effici
process
characterist
umbil
cordderiv
mesenchym
stromal
cell
feasibl
sourc
antiinflammatori
therapi
background
recent
umbil
cord
uc
becom
attract
sourc
mesenchym
stromal
cell
msc
abund
sourc
eas
collect
fetal
origin
without
invas
process
donor
low
immunogen
immunosuppress
abil
tissu
repair
potenc
object
studi
explor
effici
safe
product
evalu
antiinflammatori
potenc
ucmsc
applic
acut
graft
versu
host
diseas
gvhd
method
inform
consent
obtain
mother
plan
cesarean
section
uc
tissu
cut
cryopreserv
safeti
assess
includ
infect
babi
health
develop
done
month
birth
perform
smallscal
qualiti
test
frozen
uc
initi
isol
master
ucmsc
frozenthaw
uc
improv
explant
method
pass
qualiti
test
master
ucmsc
cryopreserv
thaw
expand
product
cell
cryopreserv
origin
serumfre
cryoprotect
dbad
solut
mix
lymphocyt
reaction
mlr
assay
cocultur
ucmsc
carri
use
respond
mononuclear
cell
mnc
stain
cfse
prolifer
cytokin
secret
analyz
flowcytometri
result
ucmsc
cultur
show
significantli
higher
prolifer
abil
compar
bone
marrowderiv
msc
posit
neg
hladr
neg
even
high
concentr
bmmsc
becam
posit
hladr
constitut
express
ucmsc
induc
addit
mlr
respond
cell
prolifer
trigger
allogen
dendrit
cell
inhibit
effici
parti
deriv
ucmsc
induc
ido
hgf
analyz
rtpcr
inhibit
supernat
cytokin
bead
array
ucmsc
migrat
toward
treat
mnc
increas
regulatori
cell
incid
peripher
mononuclear
cell
cocultur
conclus
result
demonstr
cryopreserv
uc
feasibl
effici
sourc
msc
frozenthaw
ucmsc
high
antiinflammatori
background
new
protocol
develop
amicu
separ
enabl
devic
perform
ecp
procedur
amicu
separ
use
photoactiv
devic
dispos
kit
provid
ecp
therapi
close
system
object
studi
evalu
safeti
perform
investig
amicu
ecp
system
healthi
human
subject
method
irbapprov
written
inform
consent
obtain
subject
male
femal
amicu
ecp
system
process
either
ml
whole
blood
n
per
arm
use
doubleneedl
access
acda
anticoagul
wb
ac
ratio
mnc
collect
complet
subject
disconnect
devic
ml
inject
directli
collect
mnc
product
salin
approxim
ml
total
photoactiv
jcm
uva
light
post
photoactiv
amicu
separ
reinfus
treat
mnc
transfer
pack
subject
laboratori
safeti
paramet
evalu
vitro
evalu
perform
subject
whole
blood
collect
mnc
treat
mnc
reinfus
cell
lymphocyt
monocyt
analysi
perform
sampl
purifi
use
densiti
gradient
separ
cultur
day
post
treatment
result
procedur
median
rang
wb
process
ml
use
ml
acda
procedur
time
minut
includ
photoactiv
advers
event
report
subject
vital
sign
hematolog
valu
unremark
within
expect
valu
wbc
count
collect
mnc
compris
lymphocyt
monocyt
granulocyt
platelet
count
background
transfus
white
blood
cell
wbc
caus
number
transfus
reaction
complic
exampl
transfusionassoci
graft
versu
host
diseas
tagvht
still
effect
treatment
fatal
complic
transfus
effect
method
prevent
tagvht
irradi
blood
compon
ioniz
radiat
xray
gamma
radiat
use
ioniz
radiat
sourc
number
technic
materi
difficulti
emerg
pathogen
reduct
technolog
prt
blood
compon
target
nucleic
acid
open
possibl
use
technolog
altern
irradi
blood
compon
sever
prt
demonstr
effect
inactiv
wbc
platelet
concentr
blood
plasma
determin
influenc
prt
base
combin
effect
riboflavin
rf
ultraviolet
uv
viabil
prolifer
potenti
lymphocyt
whole
blood
import
method
sampl
whole
blood
obtain
healthi
volunt
sampl
divid
three
unequ
part
untreat
control
gamma
irradi
treat
rf
uv
prt
mirasol
terumo
bct
inc
mononuclear
cell
mnc
cfse
stain
viabil
prolifer
activ
test
interv
hour
consecut
day
flow
cytometri
statist
analysi
perform
xlstat
level
signific
calcul
mannwhitney
test
express
pvalu
p
result
median
viabil
mnc
applic
method
treatment
day
decreas
day
median
percentag
viabl
mnc
control
group
gamma
irradi
rfuv
prt
median
spontan
prolif
activ
day
untreat
gamma
irradi
mnc
differ
respect
p
phytohemaglutenin
pha
induc
prolifer
day
gammairradi
sampl
significantli
lower
comparison
control
group
respect
p
sampl
treat
rfuv
spontan
stimul
prolifer
cell
detect
median
percentag
prolifer
mnc
less
use
prt
whole
blood
well
gamma
irradi
significantli
reduc
viabil
lymphocyt
storag
day
conclus
inactiv
wbc
use
rfuv
prt
use
necessari
bonu
number
reason
one
procedur
two
effect
achiev
infecti
immunolog
safeti
use
prt
whole
blood
give
potenti
obtain
pathogenreduc
immunolog
safeti
compon
blood
reduc
materi
cost
staff
load
use
rfuv
system
complex
secur
requir
difficulti
servic
use
sourc
ioniz
radiat
result
demonstr
promis
potenti
use
technolog
altern
irradi
disclosur
noth
declar
influenc
allogen
stem
cell
transplant
cell
prolifer
treg
function
background
acut
chronic
graft
versu
host
diseas
cgvhd
one
major
complic
allogen
hematopoiet
stem
cell
transplant
ahsct
applic
regulatori
cell
treg
immunosuppress
dli
prevent
treat
gvhd
investig
clinic
trial
ask
question
could
clinic
condit
eg
cytokin
drug
effect
limit
efficaci
approach
face
problem
test
influenc
cell
prolifer
treg
function
method
lymphocyt
healthi
donor
incub
cell
medium
aim
v
serum
contain
serum
healthi
donor
serum
deriv
patient
ahsct
without
gvhd
next
evalu
suppress
function
treg
perform
treg
suppress
assay
also
compar
serum
patient
suffer
gvhd
versu
serum
obtain
healthi
donor
prolifer
cfse
stain
cell
measur
day
test
effect
immunosuppress
drug
treg
perform
treg
suppress
assay
incub
treg
corticosteroid
tacrolimu
combin
drug
result
serum
patient
acut
chronic
gvhd
neg
effect
cell
prolifer
avoid
bia
test
perform
sampl
patient
without
low
level
immunosuppress
drug
incub
serum
patient
without
gvhd
serum
healthi
individu
show
differ
cell
prolifer
treg
healthi
donor
show
stronger
antiprolif
capac
incub
serum
deriv
patient
gvhd
treg
previous
incub
immunosuppress
drug
show
decreas
suppress
capac
conclus
compon
serum
gvhd
patient
seem
antiprolif
effect
lymphocyt
fact
might
influenc
clinic
cours
gvhd
limit
factor
therapeut
applic
treg
dli
even
system
treatment
immunosuppress
drug
eg
corticosteroid
calcineurininhibitor
diminish
treg
applic
next
step
analyz
serum
compon
respons
immunosuppress
effect
multi
cytokin
assay
proteom
analysi
aim
project
develop
new
strategi
avoid
gvhd
optim
clinic
set
treg
dli
disclosur
background
hypercalcaemia
sever
follow
stem
cell
transplant
sct
osteopetrosi
patient
denosumab
fulli
human
monoclon
antibodi
bind
cytokin
rankl
receptor
activ
ligand
essenti
factor
initi
bone
turnov
rankl
inhibit
block
osteoclast
matur
function
surviv
thu
reduc
bone
resorpt
describ
effect
manag
hypercalcaemia
patient
rank
mutat
osteopetrosi
receiv
haploident
sct
method
patient
diagnos
osteopetrosi
year
age
defect
gene
code
rank
receiv
matern
haploident
sct
age
year
patient
calcium
level
monitor
regularli
post
sct
denosumab
administ
hypercalcaemia
per
laboratori
report
clinic
symptom
drug
dilut
water
inject
make
solut
facilit
subcutan
administr
result
signific
hypercalcaemia
emerg
day
level
treat
hyperhydr
diuret
ineffect
reduc
hypercalcaemia
therefor
denosumab
initi
day
posttranspl
initi
dose
determin
use
avail
paediatr
case
report
mgkg
repeat
larger
dose
given
day
later
due
inadequ
respons
calcium
decreas
calcium
decreas
dose
four
week
later
third
dose
requir
calcium
level
increas
dose
increas
anoth
four
dose
increas
anoth
dose
repeat
everi
week
normalis
excess
drop
calcium
achiev
larger
dose
month
follow
posttranspl
three
admiss
last
less
hour
symptom
hypercalcaemia
manag
denosumab
administr
hyperhydr
remain
dose
given
outpati
set
conclus
denosumab
safe
use
first
line
agent
treat
post
stem
cell
transplant
hypercalcemia
patient
osteopetrosi
dose
requir
initi
start
dose
order
control
hypercalcemia
new
higher
dose
previous
suggest
origin
report
denosumab
effect
even
dilut
safe
given
children
weigh
less
disclosur
noth
declar
method
clinic
laboratori
molecular
aspect
italian
male
patient
develop
complic
collect
present
order
discuss
origin
clinic
outcom
manag
rare
posttranspl
event
result
man
affect
highrisk
chromosom
abnorm
mllprob
egil
bi
relaps
mainten
treatment
nonrespons
reinduct
chemotherapi
second
complet
remiss
ii
cr
blinatumumab
treatment
receiv
femal
cb
transplant
accord
sorror
ebmt
score
consid
highrisk
transplant
patient
cb
unit
sexmismatch
share
blood
group
cmvebv
receiv
tbf
condit
regimen
follow
infus
kg
cb
cell
gvhd
prophylaxi
consist
rabbit
atg
cyclosporin
csa
mycophenol
mophetyl
mmf
neutrophil
engraft
occur
day
wherea
platelet
never
day
cm
bulg
area
becam
appar
left
pariet
region
skull
echotomographi
show
lesion
adher
bone
without
infiltr
lack
blood
vessel
suggest
may
either
site
diseas
relaps
area
infect
time
bone
marrow
bm
aspir
show
morpholog
cr
confirm
immunephenotyp
studi
xy
fish
complet
chimera
sinc
patient
still
febril
biopsi
perform
day
axial
diamet
lesion
ct
scan
show
appear
reveal
previou
echotomographi
increas
cm
thu
lesion
surgic
remov
histolog
examin
show
cell
whose
phenotyp
suggest
granulocyt
sarcoma
rather
histiocyt
sarcoma
immunochemistri
confirm
suggest
show
nuclear
posit
fish
studi
demonstr
neoplast
cell
recipi
origin
novel
bm
aspir
show
cr
confirm
immunephenotyp
studi
fish
reveal
complet
chimera
sinc
patient
still
pancytopen
due
anticmv
treatment
radiotherapi
nine
fraction
given
lesion
complet
resolv
conclus
granulocyt
sarcoma
recipi
origin
occur
three
month
cb
transplant
rare
unusu
event
order
explain
complic
suggest
granulocyt
sarcoma
cell
dormant
alreadi
present
time
prob
diagnosi
surviv
initi
treatment
also
cb
transplant
condit
regimen
ca
nt
exclud
immunesuppress
treatment
given
earli
posttranspl
might
promot
outgrowth
neoplast
cell
popul
disclosur
noth
declar
haemoglobinopathi
inborn
error
metabol
abstract
alreadi
publish
addit
fludarabin
antithymocyt
globulin
busulfan
cyclophosphamid
condit
improv
outcom
lowrisk
matchedrel
bone
marrow
transplant
children
sever
thalassaemia
fluatgbuci
atg
dose
mgkg
patient
except
patient
splenomegali
cm
costal
margin
andor
sexmismatchedmatern
donor
atg
increas
mgkg
patient
younger
year
hepatomegali
liver
cm
costal
margin
bmt
result
actuari
overal
surviv
os
atgbuci
fluatgbuci
group
thalassemiafre
surviv
tf
gvhdfree
thalassaemiafre
surviv
gtf
median
follow
month
month
respect
significantli
improv
outcom
logrank
statist
fluatgbuci
group
signific
differ
group
pretranspl
characterist
posttranspl
complic
except
follow
median
cell
dose
nd
group
total
nucleat
cell
dose
vs
x
cellkg
p
csa
taper
start
later
new
protocol
day
vs
median
age
bmt
vs
year
number
prebmt
transfus
ferritin
bmt
vs
ngml
higher
second
group
day
chimer
also
significantli
higher
new
protocol
respect
trend
toward
increas
incid
venoocculs
diseas
vod
posterior
revers
encephalopathi
syndrom
pre
second
group
differ
reach
statist
signific
conclus
ad
fludarabin
target
dose
increas
atg
standard
buci
context
seem
significantli
improv
outcom
thalassaemia
transplant
without
contribut
excess
gvhd
infecti
complic
protocol
easili
administ
low
resourc
set
without
major
addit
cost
clinic
acquir
clonal
disord
hemopoiet
stem
cell
cur
treatment
allogen
hematopoiet
stem
cell
transplant
howev
still
report
outcom
allogen
hematopoiet
stem
cell
transplant
allohsct
patient
pnh
compar
paroxysm
nocturn
hemoglobinuriaaplast
anemia
pnhaa
syndrom
studi
aim
compar
outcom
allohsct
pnh
pnhaa
syndrom
method
clinic
data
pnh
patient
receiv
allohsct
pnh
pnhaa
center
juli
june
analyz
retrospect
compar
outcom
pnh
group
pnhaa
group
clinic
data
includ
male
patient
femal
patient
median
age
year
rang
patient
receiv
variou
treatment
transplant
steroid
androgen
cyclosporin
csa
antithymocyt
globulin
growth
factor
median
interv
pnh
diagnosi
hsct
month
rang
condit
regimen
modifi
bucybas
regimen
haploident
donor
unrel
donor
csa
mycophenol
mofetil
mmf
shortterm
methotrex
mtx
administ
graftversu
host
diseas
gvhd
prophylaxi
patient
match
sibl
donor
treat
flucybas
regimen
csa
administ
gvhd
prophylaxi
result
differ
baselin
group
p
except
gender
haploident
donor
median
valu
absolut
nucleat
cell
count
kg
pnh
group
kg
pnhaa
group
p
median
dose
cell
infus
kg
kg
p
respect
patient
attain
complet
engraft
patient
occur
graft
failur
median
time
myeloid
engraft
rang
day
pnh
group
rang
day
pnhaa
group
p
median
time
platelet
engraft
rang
day
rang
day
p
respect
median
followup
month
pnh
group
month
pnhaa
group
p
pnh
pnhaa
group
incid
grade
iiv
acut
graftversushost
diseas
agvhd
p
grade
iiiv
agvhd
p
chronic
gvhd
p
moderatesever
chronic
gvhd
p
haplohsct
msd
group
incid
infect
p
patient
occur
earli
death
relaps
estim
overal
surviv
os
pnh
pnhaa
group
p
gvhdfree
failurefre
surviv
gff
p
conclus
preliminari
result
indic
allohsct
feasibl
choic
pnh
favor
outcom
time
myeloid
platelet
engraft
pnh
group
faster
pnhaa
group
differ
os
gff
pnh
group
pnhaa
group
disclosur
disclosur
pattern
calcineurin
inhibitorassoci
neurotox
sickl
cell
diseas
patient
receiv
stem
cell
transplant
background
allogen
hsct
msd
repres
current
cur
option
sickl
cell
diseas
scd
limit
donor
avail
neurotox
nt
contribut
significantli
hsctassoci
morbid
mortal
calcineurininhibitor
cni
associ
nt
rang
sever
nt
elev
incid
nt
scd
around
might
trigger
system
vasculopathi
scd
brain
primari
target
although
cyclosporin
csa
tacrolimu
proinflammatori
effect
pronounc
csa
infus
modal
also
might
impact
bolu
inject
versu
continu
infus
method
pilot
studi
compar
tcell
deplet
haploident
hsct
thaplo
hsct
msd
hsct
patient
pt
advanc
stage
scd
use
almost
ident
condit
regimen
pt
year
yr
homozyg
scd
hb
treat
nine
pt
receiv
msd
bone
marrow
graft
pt
receiv
thaplohsct
second
thaplo
due
graft
reject
immunosuppress
consist
either
csa
msd
thaplo
msd
combin
mycophenol
mofetil
mmf
administ
continu
infus
csa
bolu
inject
target
level
adjust
csa
ngml
ng
ml
durat
immunosuppress
month
thaplosct
month
msd
depend
chimer
result
cnirel
nt
observ
sever
nt
pre
visual
disturb
aphasia
nt
preval
msd
thaplo
incid
nt
ident
csa
howev
major
sever
nt
pre
occur
csa
complet
recoveri
nt
achiev
pt
either
spontan
switch
withdraw
moreov
pt
nt
yr
yr
suggest
increas
risk
age
pt
preexist
cerebrovascular
diseas
experienc
posthsct
nt
note
pt
sever
nt
also
develop
mild
acut
gvhd
overal
os
diseasefre
surviv
df
median
followup
month
thaplohsct
month
msd
hsct
vs
respect
conclus
data
confirm
elev
nt
risk
scd
pt
follow
allohsct
importantli
incid
nt
seem
relat
age
pt
nt
yr
donor
sourc
msd
vs
thaplo
type
cni
inhibitor
almost
sever
nt
particularli
pre
observ
csa
continu
infus
vs
bolu
inject
csa
might
level
concentr
peak
nt
observ
csa
could
consequ
predominantli
csarel
vascular
toxic
inflict
predamag
vessel
scd
mechan
action
could
relat
system
endotheliopathi
vod
tam
agvhd
observ
pt
sever
nt
compar
overal
agvhd
rate
disclosur
noth
declar
background
matchedrel
bone
marrow
transplant
bmt
may
cure
lowriskchildren
sever
thalassemia
st
defin
thalassemia
syndrom
inabl
keep
spontan
hemoglobin
gdl
well
known
patient
statu
time
transplant
critic
predict
transplant
outcom
liver
size
cm
establish
advers
prognost
factor
term
transplantrel
mortal
experi
spleen
size
cm
costal
margini
associ
increas
reject
rate
blood
vol
suppl
optimis
liver
spleen
size
prior
transplant
like
improv
transplant
outcom
method
retrospect
review
effect
strategi
reduc
liver
spleen
size
pretranspl
use
hydroxyurea
supertransfus
intens
iron
chelat
consid
liver
size
cm
spleen
size
less
cm
costal
margin
good
risk
featur
liver
biopsi
perform
thu
pesaro
risk
classif
could
assign
transplant
candid
start
hydroxyurea
minimum
month
pretransfus
haemoglobin
maintain
gmdl
hydroxyurea
child
hepatospenomegali
enrollmentand
improv
liver
spleen
size
adequ
trial
hydroxyurea
minimum
month
treatment
achiev
maximum
dose
mgkg
day
toler
haematolog
toxic
ie
neutrophil
count
andor
platelet
count
patient
given
trial
supertransfus
maintain
haemoglobin
gdl
minimum
month
prior
declar
patient
fail
downstag
result
transplant
across
collabor
center
india
patient
hepatosplenomegali
enrol
henc
activ
downstag
twelv
patient
exclud
due
inadequ
inform
record
remain
patient
enlarg
liver
andor
spleen
downstag
lowrisk
featur
patient
receiv
adequ
hydroxyurea
trial
among
seven
patient
requir
super
transfus
addit
maxim
hydroxyurea
patient
success
downstag
strategi
proceed
transplant
lowrisk
patient
among
remain
patient
liver
cm
one
spleen
cm
signific
improv
liver
spleen
size
time
enrol
transplant
p
valu
respect
wilcoxon
test
pair
sampl
two
tail
median
durat
downstag
month
rang
month
signific
differ
overal
surviv
os
diseasefre
surviv
df
log
rank
test
downstag
group
hepatosplenomegali
enrol
p
valu
respect
conclus
major
children
thalassaemia
high
transplant
risk
featur
liver
spleen
size
reduc
pretranspl
use
hydroxyurea
supertransfus
therebi
decreas
transplant
risk
disclosur
noth
declar
abstract
alreadi
publish
abstract
withdrawn
longitudin
analysi
effect
hematopoiet
cell
transplant
ocular
diseas
children
mucopolysaccharidosi
show
ongo
diseas
progress
background
corneal
cloud
seen
nearli
patient
caus
visual
impair
hematopoiet
cell
transplant
hct
abl
stabil
diseas
mani
organ
includ
brain
howev
residu
diseas
peripher
tissu
often
describ
therefor
aim
studi
determin
longterm
effect
hct
ocular
diseas
patient
method
corneal
cloud
grade
visual
acuiti
decim
scale
prospect
collect
consecut
patient
treat
hct
umc
utrecht
primari
outcom
interest
effect
time
corneal
cloud
visual
acuiti
analyz
use
linear
mix
model
correl
corneal
cloud
visual
acuiti
analyz
pearson
rho
paramet
studi
clinic
phenotyp
age
time
transplant
hematolog
enzym
level
transplant
outcom
interest
analyz
includ
intraocular
pressur
refract
macula
len
abnorm
imag
result
success
engraft
patient
includ
chimer
normal
enzym
level
hct
corneal
cloud
stabil
first
year
hct
increas
rapidli
beyond
three
year
figur
predictor
increas
corneal
cloud
age
time
transplant
ci
clinic
phenotyp
ci
visual
acuiti
also
worsen
significantli
time
ci
corneal
cloud
strongli
neg
correl
visual
acuiti
p
conclus
initi
stabil
ongo
ocular
diseas
seen
patient
despit
success
hct
hallmark
shortcom
current
standard
therapi
new
therapi
overcom
weak
spot
current
therapi
necessari
improv
late
outcom
patient
clinic
trial
registri
na
disclosur
btavdb
support
research
grant
sylvia
toth
chariti
foundat
hagu
netherland
work
studi
sponsor
studi
public
nonprofit
organ
support
scienc
gener
role
gather
analyz
interpret
data
author
would
like
thank
parent
patient
particip
studi
author
state
competit
financi
interest
studi
background
paroxysm
nocturn
hemoglobinuria
pnh
acquir
clonal
disord
hemopoiet
stem
cell
cur
treatment
allogen
hematopoiet
stem
cell
transplant
haploident
donor
hematopoiet
stem
cell
transplant
haplohsct
increasingli
appli
cur
therapi
patient
hematolog
diseas
howev
still
report
use
haplohsct
treatment
pnh
studi
aim
compar
outcom
haplohsct
matcheds
donor
transplant
msdhsct
pnh
method
clinic
data
pnh
patient
receiv
hsct
haplohsct
msdhsct
center
juli
may
analyz
retrospect
compar
outcom
haplohsct
group
msdhsct
group
clinic
data
includ
male
patient
femal
patient
classic
pnh
pnhaa
syndrom
median
age
year
rang
patient
receiv
variou
treatment
transplant
steroid
androgen
cyclosporin
csa
antithymocyt
globulin
growth
factor
median
interv
pnh
diagnosi
sct
month
rang
condit
regimen
modifi
bucybas
regimen
haplohsct
group
csa
mycophenol
mofetil
mmf
shortterm
methotrex
mtx
administ
graftversu
host
diseas
gvhd
prophylaxi
patient
msdhsct
treat
flucybas
regimen
csa
administ
gvhd
prophylaxi
result
differ
gender
age
patient
pnhaa
median
time
diagnosi
transplant
group
median
valu
absolut
nucleat
cell
count
kg
haplohsct
group
kg
msdhsct
group
p
median
dose
cell
infus
kg
kg
p
respect
patient
attain
complet
engraft
patient
occur
graft
failur
median
time
myeloid
engraft
rang
day
haplohsct
group
rang
day
msdhsct
group
p
median
time
platelet
engraft
rang
day
rang
day
p
respect
median
followup
month
haplohsct
group
month
msdhsct
group
p
haplohsct
msdhsct
group
incid
grade
iiv
acut
graftversushost
diseas
agvhd
p
grade
iiiv
agvhd
p
chronic
gvhd
p
moderatesever
chronic
gvhd
p
haplohsct
msd
group
incid
infect
p
patient
occur
earli
death
relaps
estim
overal
surviv
os
haplohsct
msdhsct
group
p
gvhdfree
failurefre
surviv
gff
p
conclus
preliminari
result
indic
haplohsct
feasibl
choic
pnh
favor
outcom
haplohsct
msdhsct
similar
therapeut
efficaci
disclosur
disclosur
pre
bmt
thalassemia
major
india
lower
incid
limit
impact
background
posterior
revers
encephalopathi
syndrom
pre
rel
common
complic
seen
blood
marrow
transplant
bmt
hemoglobinopathi
report
frequenc
pre
also
associ
poorer
surviv
rate
sever
hemoglobinopathi
one
frequent
indic
bmt
develop
world
particularli
india
given
risk
reject
multipli
transfus
patient
need
minim
gvhd
risk
immunosuppress
postbmt
nonmalign
condit
particularli
intens
prolong
sought
measur
incid
impact
pre
develop
countri
method
analys
success
transplant
thalassemia
use
protocol
atgbucycsammf
csamtx
maintain
cyclosporin
csa
blood
level
ngml
patient
protocol
fluatgbucycsamtx
maintain
higher
csa
level
post
ie
ngml
patient
fulli
match
donor
gcsfprime
bone
marrow
patient
second
transplant
differ
match
relat
donor
pre
confirm
brain
ctmri
patient
result
recipi
pre
sibl
donor
male
femal
age
median
iqr
year
frequenc
pre
diseas
free
surviv
patient
pre
pre
resolv
complet
csa
switch
mmf
patient
receiv
mtx
csa
time
pre
occurr
csa
stop
mmf
continu
patient
take
csammf
combin
csa
continu
patient
three
patient
pre
grade
acut
gvhd
grade
gvhd
none
develop
chronic
gvhd
csa
level
time
pre
median
ngml
iqr
patient
ngml
three
patient
pre
thrombocytopen
hypertens
stage
observ
four
patient
stage
one
patient
one
patient
hypertens
one
patient
blood
pressur
valu
avail
two
patient
methylprednisolon
mgkgday
one
dexamethason
one
patient
start
csa
pre
episod
within
week
anoth
one
csa
level
ng
ml
methylprednisolon
mgkgday
ruxolitinib
gvhd
protocol
statist
signific
improv
diseas
free
surviv
p
probabl
occurr
pre
increas
p
see
figur
yet
benign
cours
patient
conclus
stop
immunosuppress
may
key
factor
could
explain
better
outcom
pre
report
intensifi
immunosuppress
prebmt
lead
pre
albeit
significantli
yet
quit
manag
even
addit
fludarabin
pre
incid
lower
previous
report
imag
background
sicklecel
diseas
scd
group
genet
hemoglobin
disord
mark
brain
vasculopathi
allogen
hematopoiet
stem
cell
transplant
hsct
cur
option
abl
stop
vascular
diseas
progress
diffusiontensor
imag
dti
magnet
reson
imag
mri
techniqu
sensit
brownian
motion
water
molecul
cellular
environ
microscop
quantit
techniqu
abl
detect
white
matter
wm
alter
convent
mri
aim
studi
use
dti
evalu
axon
damag
structur
connect
brain
patient
scd
submit
hlaident
sibl
allogen
hsct
method
sixteen
scd
patient
extens
vasculopathi
detect
convent
mri
male
age
rang
year
agematch
healthi
control
male
age
rang
year
particip
prospect
studi
mri
acquisit
perform
scanner
two
time
patient
year
hsct
singl
moment
control
dti
acquisit
fraction
anisotropi
fa
mean
md
radial
rd
axial
diffus
ad
calcul
wm
whole
brain
structur
connect
also
analyz
base
graph
theori
obtain
effici
length
path
cluster
coeffici
brain
network
anova
test
appli
analyz
fa
differ
among
control
patient
hsct
pair
twotail
ttest
use
determin
statist
signific
chang
fa
diffus
mean
valu
network
paramet
hsct
result
mean
fa
lower
patient
hsct
control
p
increas
hsct
statist
differ
compar
control
control
patient
hsct
patient
hsct
post
hoc
dunnett
test
error
anova
test
patient
compar
hsct
md
rd
decreas
hsct
p
respect
hand
fa
increas
p
hsct
effici
higher
p
path
length
index
lower
studi
entri
tabl
conclus
studi
indic
hsct
patient
scd
present
axon
damag
detect
convent
mri
compar
healthi
control
also
suggest
hsct
abl
promot
axon
recoveri
reorgan
partial
diffus
recoveri
could
associ
still
unidentifi
mechan
myelin
regener
futur
longer
follow
comparison
form
treatment
requir
background
bmt
wellestablish
treatment
modal
haemoglobinopathi
limit
avail
relat
donor
unrel
transplant
histor
shown
variabl
outcom
driven
gvhd
toxic
usual
restrict
match
impact
reduc
toxic
condit
regimen
yet
known
method
twentyf
consecut
unrel
bone
marrow
transplant
condit
fludarabin
mgm
treosulfan
gm
thiotepa
mg
kg
atg
thymoglobulin
mgkg
sourc
stem
cell
marrow
n
ptci
pbsc
n
endogen
haemopoiesi
suppress
pretransplant
minimum
week
gvhd
prophylaxi
provid
ciclosporinsirolimu
mmf
thirteen
patient
transplant
b
thalassaemia
major
one
thalassaemia
major
sickl
cell
diseas
median
age
year
ten
patient
match
thalassemia
sickl
patient
match
thalassaemia
sickl
median
cell
dose
x
tnckg
rang
x
rang
median
surviv
month
patient
thalassaemia
pesaro
class
ii
pesaro
class
iii
patient
intens
chelat
pretransplant
return
class
ii
patient
sickl
cell
diseas
transplant
stroke
recurr
vasooclus
crise
andor
acut
chest
syndrom
respond
hydroxycarbamid
result
patient
engraft
achiev
evid
donor
haemopoiesi
day
achiev
transfusionindepend
donor
haematolog
valu
subsequ
one
patient
thalassaemia
suffer
secondari
graft
failur
day
macrophag
activ
syndrom
median
neutrophil
engraft
day
rang
day
patient
respect
patient
sickl
cell
diseas
platelet
count
maintain
x
l
time
median
platelet
engraft
x
l
day
rang
day
rang
patient
respect
three
death
match
group
two
thalassaemia
day
due
idiopath
pneumonia
syndrom
day
due
ma
one
scd
day
due
ip
differ
trend
complic
seen
degre
match
segreg
otherwis
diseas
conclus
conclus
unrel
bmt
haemoglobinopathi
reduc
toxic
regimen
feasibl
whilst
gvhd
caus
signific
morbid
transplant
period
alloreactiveendotheli
complic
vod
macrophag
activ
syndrom
idiopath
pneumonia
syndrom
seen
transplant
diseasefre
surviv
depend
transplantrel
mortal
lack
longterm
toxic
includ
chronic
gvhd
determin
degre
match
match
transplant
excel
longterm
outcom
chronic
gvhd
month
consid
patient
without
relat
donor
wherea
transplant
signific
toxic
mortal
warrant
haploident
approach
disclosur
conflict
longterm
safeti
efficaci
lentiglobin
gene
therapi
patient
transfusiondepend
follow
complet
phase
northstar
studi
patient
transfusiondepend
tdt
may
benefit
gene
therapi
involv
gene
addit
hematopoiet
stem
cell
hsc
enabl
product
function
hemoglobin
hb
lentiglobin
gene
therapi
contain
autolog
hsc
transduc
ex
vivo
lentivir
vector
encod
substitut
transcript
control
encod
locu
control
region
safeti
efficaci
lentiglobin
evalu
adult
adolesc
tdt
phase
northstar
studi
method
patient
tdt
mlkgyear
red
blood
cell
rbc
rbc
transfusionsyear
receiv
gcsf
plerixafor
hsc
mobil
gener
drug
product
dp
hsc
transduc
lentivir
vector
patient
underw
singleag
myeloabl
busulfan
condit
infus
dp
follow
safeti
efficaci
result
eighteen
patient
treat
complet
northstar
studi
septemb
patient
median
followup
min
max
month
median
age
consent
min
max
year
includ
patient
year
old
patient
receiv
median
cell
dose
min
max
cell
kg
median
dp
vector
copi
number
vcn
min
max
vector
copi
diploid
genom
median
liver
iron
content
lic
baselin
min
max
mg
feg
dw
outcom
age
baselin
iron
statu
present
median
time
neutrophil
platelet
engraft
min
max
min
max
day
respect
four
patient
platelet
engraft
day
four
patient
platelet
count
l
month
none
patient
grade
bleed
event
postlentiglobin
infus
transfus
independ
ti
defin
weight
averag
hb
gdl
without
rbc
transfus
month
achiev
patient
genotyp
patient
genotyp
patient
achiev
ti
total
hb
last
visit
gdl
lic
increas
baselin
patient
achiev
ti
median
month
decreas
baselin
median
month
respect
nonhematolog
grade
advers
event
postinfus
patient
includ
stomat
febril
neutropenia
pharyng
inflamm
irregular
menstruat
transplantrel
mortal
vectormedi
replic
compet
lentiviru
clonal
domin
two
patient
experienc
grade
seriou
venoocclus
liver
diseas
tabl
event
resolv
follow
treatment
defibrotid
attribut
myeloabl
condit
conclus
northstar
studi
patient
tdt
genotyp
patient
genotyp
achiev
transfus
independ
safeti
profil
lentiglobin
remain
consist
myeloabl
busulfan
condit
longer
time
platelet
engraft
observ
patient
graft
failur
report
clinic
background
sickl
cell
diseas
scd
inherit
hemoglobin
disord
associ
high
morbid
mortal
current
allogen
hematopoiet
stem
cell
transplant
hsct
cur
therapi
scd
transplant
outcom
thiotepa
treosulfan
fludarabin
ttf
prepar
regimen
encourag
regimen
directli
compar
prepar
regimen
scd
therefor
plan
compar
event
free
probabl
death
reject
high
grade
acut
graft
versu
host
diseas
agvhd
ttf
busulfan
fludarabin
bf
regimen
method
retrospect
cohort
studi
includ
patient
scd
receiv
allogen
hsct
center
transplant
center
refer
follow
day
patient
transplant
juli
decemb
use
kaplanmei
curv
estim
event
free
probabl
death
reject
high
grade
agvhd
grade
cox
regress
use
assess
impact
prepar
regimen
outcom
result
total
patient
includ
median
age
year
interquartil
rang
iqr
median
hemoglobin
gdl
iqr
sixtytwo
percent
male
proport
patient
splenectomi
stroke
acut
chest
syndrom
respect
patient
receiv
peripher
collect
hematopoiet
stem
cell
match
sibl
donor
median
stem
cell
dose
x
kg
iqr
patient
receiv
cyclosporin
tacrolimu
base
agvhd
prophylaxi
patient
receiv
ttf
bf
prepar
regimen
patient
bf
group
receiv
atg
median
followup
time
month
rang
four
patient
die
followup
period
os
confid
interv
ci
year
os
differ
hr
p
ttf
bf
regimen
probabl
high
grade
agvhd
free
surviv
day
ci
patient
probabl
ttf
group
bf
group
differ
statist
signific
hr
p
reject
free
surviv
month
ci
patient
patient
ttf
group
reject
reject
free
surviv
month
bf
group
statist
signific
p
conclus
patient
scd
undergo
allogen
hsct
match
sibl
donor
ttf
prepar
regimen
associ
improv
os
reject
free
high
grade
free
agvhd
surviv
compar
bf
prepar
regimen
larger
studi
need
confirm
find
disclosur
noth
declar
novel
strategi
haploident
hematopoiet
stem
cell
transplant
sickl
cell
diseas
method
consecut
patient
suffer
scd
underw
hhsct
jan
till
date
enrol
studi
underw
autolog
backup
target
dose
kg
follow
pretranspl
immun
suppress
pti
cycl
weekli
interv
use
fludarabin
cyclophosphamid
dexamethason
day
along
hypertransfus
target
hb
hydroxyurea
azathioprin
day
graft
mobil
use
gcsf
plerixafor
c
hour
pbsch
condit
includ
thiotepa
two
divid
dose
fludarabin
cyclophosphamid
mgkg
tbi
thymic
shield
ratg
genzym
thymoglobulin
mgkg
gvhd
prophylaxi
includ
ptci
mgkgday
sirolimu
target
level
till
month
post
hsct
mmf
till
start
result
median
age
patient
year
rang
year
transplant
patient
repeat
episod
one
complic
warrant
transplant
nonrespons
hydroxyurea
six
matern
donor
patern
sibl
median
age
donor
year
rang
year
dsa
neg
cutoff
mfi
iu
patient
receiv
kg
cell
irrespect
harvest
dose
rang
kg
median
dose
kg
rang
kg
patient
engraft
median
time
neutrophil
engraft
day
rang
day
median
time
platelet
engraft
day
rang
day
median
durat
hospit
stay
day
rang
day
one
patient
cytokin
releas
syndrom
need
tocilizumab
five
engraft
syndrom
treat
short
cours
steroid
two
cmv
reactiv
need
treatment
ganciclovirvalganciclovir
acut
gvhd
grade
ii
seen
one
patient
till
date
analysi
none
featur
compat
chronic
gvhd
patient
aliv
without
sickl
cell
diseas
lanski
karnofski
score
median
follow
day
rang
probabl
surviv
scafre
surviv
transplantrel
mortal
transplant
respect
one
patient
die
due
mdr
klebsiella
sepsi
discharg
initi
receiv
iv
ganciclovir
day
care
basi
full
donor
chimer
none
patient
primari
secondari
graft
failur
conclus
pretranspl
immun
suppress
upfront
use
plerixafor
graft
mobil
decreas
risk
graft
failur
graft
versu
host
diseas
lead
overal
better
surviv
hhsct
sickl
cell
diseas
disclosur
none
combin
haematopoiet
stem
cell
transplant
enzym
replac
therapi
wolman
diseas
outcom
challeng
jane
kinsella
denis
bonney
helen
campbel
robert
wynn
simon
jone
background
infantil
lysosom
acid
lipas
deficiencymor
commonli
known
wolman
diseas
autosom
recess
lysosom
storag
diseas
characteris
storag
cholesterol
ester
liver
spleen
gastrointestin
tract
children
present
age
month
tradit
poor
prognosi
almost
dead
age
month
bone
marrow
transplant
use
correct
diseas
manifest
limit
high
procedurerel
mortal
signific
comorbid
surviv
chang
past
year
due
pharmacolog
enzym
replac
therapi
still
present
challeng
patient
clinician
children
haematopoiet
stem
cell
transplant
offer
bmt
enzym
replac
therapi
certain
specif
circumst
method
four
children
wolman
diseas
treat
enzym
replac
therapi
limit
alloantibodi
poor
venou
access
receiv
treosulfanbas
myeloabl
condit
serotherapi
follow
match
haematopoiet
stem
cell
transplant
two
famili
donor
one
sibl
donor
one
unrel
donor
result
three
four
children
surviv
transplant
continu
receiv
enzym
replac
therapi
reduc
dose
frequenc
improv
toler
continu
grow
develop
growth
gastrointestin
histolog
improv
children
receiv
transplant
compar
receiv
enzym
replac
alon
monitor
peripher
blood
chimer
shown
diseaseassoci
engraft
defect
mix
chimer
surviv
patient
conclus
haemopoiet
stem
cell
transplant
suitabl
treatment
option
children
wolman
diseas
receiv
enzym
replac
therapi
possibl
venou
access
sensitis
cost
reason
improv
toler
enzym
treatment
allow
reduct
enzym
dose
frequenc
howev
result
engraft
good
expect
transplant
myeloabl
condit
match
donor
engraft
defect
observ
lysosom
acid
lipas
defici
anim
model
understand
poor
engraft
children
wolman
diseas
requir
determin
whether
risk
transplant
benefici
patient
consider
futur
treatment
option
includ
gene
therapi
background
thalassemia
major
common
transfus
depend
hemolyt
anemia
world
absent
reduc
product
hemoglobin
caus
sever
ineffect
erythropoiesi
massiv
erythroid
hyperplasia
bone
marrow
extramedullari
hematopoesi
occur
patient
requir
regular
transfus
therapi
lifelong
current
proven
cur
treatment
thalassemia
allogen
stem
cell
transplant
sct
method
evalu
immun
reconstitut
result
patient
year
hematopoet
stem
cell
transplant
pediatr
bone
marrow
transplant
center
januari
decemb
patient
receiv
immunosuppress
treatment
least
month
normal
lymphocyt
count
immunoglobulin
level
transfus
independ
lymphocyt
subtyp
chimer
percentag
relationship
donor
type
evalu
year
transplant
result
age
transplant
rang
year
median
year
seven
male
match
unrel
donor
type
chosen
patient
other
patient
transplant
famili
match
donor
match
sibl
patient
match
famili
patient
patient
receiv
myeloabl
condit
regimen
contain
busulfantreosulfan
cyclophosphamid
thiotepa
fludarabin
follow
time
month
mean
month
patient
whole
bone
marrow
product
use
peripher
stem
cell
harvest
remain
patient
level
found
low
patient
normal
patient
mean
level
sever
low
patient
patient
level
increas
total
patient
compensatori
ratio
low
patient
rang
b
cell
low
patient
immunoglobulin
level
normal
chimer
valu
mean
donor
product
type
differ
lymphocyt
reconstitut
year
respect
patient
aliv
well
year
transplant
conclus
year
transplant
although
patient
well
condit
regard
infect
frequenc
transfuss
depend
seen
lymphocyt
subtyp
reconstitut
could
achiev
enough
normal
children
conclud
low
cell
level
expect
find
almost
patient
patient
may
tendenc
suffer
seriou
bacteri
viral
infect
close
follow
requir
term
infect
long
level
continu
low
immunoglobulin
replac
therapi
requir
even
patient
low
b
cell
level
disclosur
noth
declar
phase
intern
multicentr
trial
assess
haploident
tcell
deplet
stem
cell
transplant
patient
sickl
cell
diseas
avail
sibl
donor
background
sickl
cell
diseas
scd
inherit
disord
estim
affect
newborn
per
year
worldwid
allogen
hematopoiet
stem
cell
transplant
hsct
match
sibl
donor
msd
current
cur
standard
care
scd
patient
pt
howev
msd
avail
tcell
deplet
haploident
hsct
thaplohsct
rel
mostli
parent
expand
donor
avail
exhibit
low
gvhd
rate
thu
could
offer
cure
remain
scd
patient
pilot
studi
compar
thaplohsct
msd
hsct
advanc
stage
scd
use
almost
ident
transplant
regimen
overal
os
diseasefre
surviv
df
vs
respect
method
result
led
design
clinic
trial
assess
tcdhaplohsct
prospect
aim
demonstr
hsct
haploident
rel
inferior
msd
hsct
regard
major
outcom
paramet
phase
prospect
stratifi
openlabel
studi
target
enrol
patient
age
year
homozyg
hb
diseas
heterozyg
hbsc
hb
suffer
sever
moder
scd
relat
complic
inclus
criteria
clinic
signific
scd
relat
complic
stroke
silent
crisi
patholog
angiomri
transcrani
doppler
tcd
veloc
cm
episod
acut
chest
syndrom
ac
lifetim
chronic
transfus
depend
transfusionrefractori
alloimmun
other
pt
fulfil
inclus
criteria
stratifi
accord
donor
avail
pt
msd
receiv
bone
marrow
graft
pt
requir
altern
donor
transplant
deplet
graft
haploident
famili
donor
condit
regimen
group
ident
except
antithymoglobulin
atgneovii
given
upfront
thaplohsct
versu
day
msd
chemotherapi
consist
thiotepa
fludarabin
treosulfan
posttranspl
immunosuppress
consist
mofetil
mycophenol
tacrolimu
durat
month
thaplohsct
month
msd
depend
chimer
eudract
number
result
primari
efficaci
endpoint
event
free
surviv
ef
event
defin
incid
acut
gvhd
grade
iii
iv
chronic
gvhd
reject
graft
failur
death
reason
key
secondari
endpoint
os
df
graft
failur
hematolog
immunolog
reconstitut
qualiti
life
qol
assess
fertil
primari
null
hypothesi
ef
scd
patient
treat
thaplohsct
nonrelevantli
inferior
ef
msd
arm
conclus
result
help
determin
deplet
thaplohsct
consid
equival
msd
hsct
regard
df
advers
event
safeti
order
offer
form
cure
major
patient
scd
disclosur
noth
declar
hit
three
bird
one
stone
success
stem
cell
transplant
one
famili
donor
three
sibl
method
august
three
thalassem
sibl
admit
hospit
stem
cell
transplant
full
match
donor
year
old
sister
patient
gener
health
condit
specif
health
issu
due
thalassemia
check
extens
decid
perform
first
transplant
older
sister
diseas
transplant
complic
expect
intens
due
prolong
transfus
chelat
therapi
oldest
daughter
famili
healthi
plan
accompani
sister
transplant
unit
parent
take
care
other
organ
period
whole
famili
result
year
old
sibl
first
admit
bone
marrow
transplant
unit
juli
condit
regimen
busulfan
fludarabin
cyclophosphamid
thiotepa
antithymocyteglobulin
atg
defibrotid
prophylaxi
given
healthi
donor
admit
hospit
receiv
gcsf
continu
day
harvest
stem
cell
collect
peripher
day
viabl
cell
patient
receiv
stem
cell
cell
product
divid
part
accord
infus
problem
record
stem
cell
transfus
gvhd
prophylaxi
given
cyclosporin
methotrex
sever
sinusoid
obstruct
syndrom
observ
success
manag
support
therapi
neutrophil
engraft
day
platelet
day
full
blood
chimer
result
day
day
day
consecut
month
first
transplant
year
old
sister
admit
hospit
octob
condit
defibrotid
prophylaxi
gvhd
prophylaxi
given
peripher
deriv
previous
frost
stem
cell
infus
without
complic
mild
sinusoid
obstruct
syndrom
observ
manag
support
therapi
success
neutrophil
engraft
day
platelet
day
full
blood
chimer
result
day
day
day
consecut
third
transplant
perform
januari
condit
prophylaxi
regimen
although
defibrotid
use
mild
so
observ
treat
support
therapi
success
neutrophil
engraft
day
platelet
day
full
blood
chimer
result
day
day
day
consecut
conclus
patient
follow
year
first
transplat
neither
advers
gvhd
symptom
observ
present
case
uniqu
exampl
match
famili
donor
transplant
first
success
exampl
one
donor
three
recipi
disclosur
noth
declar
result
femal
patient
admit
anemia
rd
month
birth
transfus
everi
month
th
month
year
age
sinc
investig
direct
toward
hemoglobinopathi
membran
defect
like
hereditari
spherocytosi
unremark
transfus
year
age
hemoglobin
level
constant
gdl
bm
examin
show
erythroid
hyperplasia
featur
dyserythropoiesi
binucl
erythroblast
decid
followup
patient
diagnosi
cda
ii
age
need
transfus
start
everi
month
led
parent
patient
request
bone
marrow
transplant
howev
diagnosi
definit
insuffici
data
transplant
cda
ii
patient
decid
go
followup
nevertheless
year
frequenc
transfus
gradual
increas
everi
week
bone
marrow
transplant
brought
question
time
genet
examin
start
gene
analyz
direct
sequenc
hsct
decis
hla
match
brother
carri
mutat
heterozyg
state
taken
prepar
regimen
busulfan
bu
myeloabl
weight
adjust
dose
day
mgkg
cyclophosphamid
cy
day
mgkg
antithymocyt
globulin
atg
freseniu
use
graftversushost
diseas
gvhd
prophylaxi
cyclosporin
start
day
shortterm
methotrex
day
transplant
bm
dose
total
nucleat
kg
kg
neutrophil
platelet
engraft
achiev
respect
inde
grade
hemorrhag
cystiti
due
bk
viru
moder
venoocclus
diseas
prolong
platelet
transfus
day
conceal
exact
engraft
day
platelet
patient
discharg
day
need
transfus
follow
complet
chimer
type
gvhd
sinc
year
old
regular
surveil
transplant
centr
without
symptom
conclus
hsct
data
cda
ii
patient
still
insuffici
howev
base
data
tm
patient
similar
treatment
approach
td
cda
ii
patient
seen
hsct
reliabl
effect
disclosur
noth
declar
hematopoiet
stem
cell
background
prognosi
frontlin
therapi
ball
patient
improv
due
monoclon
antibodi
approxim
patient
achiev
complet
remiss
relaps
refractori
r
r
ball
also
mrd
outcom
rel
poor
diseasefre
surviv
df
cohort
cohort
allohsct
indic
complet
remiss
transplant
crucial
prognosi
convent
chemotherapi
associ
high
failur
rate
signific
toxic
immunotherapi
monoclon
antibodi
cart
promis
approach
aim
evalu
efficaci
frequenc
respons
os
df
toxic
especi
neurotox
cytokinereleas
syndrom
bispecif
monoclon
antibodi
blinatumomab
patient
children
adult
persist
minim
residu
diseas
mrd
rr
ball
bridg
allohsct
method
studi
includ
patient
high
risk
ball
blinatumomab
treat
among
pt
mll
pt
refractori
previou
chemotherapi
allohsct
defer
type
donor
median
age
yo
rang
children
yo
adult
yo
rr
pt
mrd
pt
median
day
follow
blinatumomab
appli
cycl
follow
offperiod
start
follow
cycl
major
pt
receiv
one
cycl
rr
group
dose
mcgd
first
day
afterward
patient
weight
less
kg
receiv
mcgm
accordingli
mrd
group
dose
mcgm
result
frequenc
respons
blinatumomab
higher
mrd
pt
comparison
rr
pt
vs
mrd
pt
cr
mrdwa
achiev
pt
pt
mrd
blinatumomab
twoyear
os
group
twenti
pt
receiv
allohsct
rr
pt
cr
mrdwa
achiev
pt
pt
mrd
blinatumomab
pt
hematolog
respons
twoyear
os
rr
fifteen
pt
receiv
allohsct
os
cr
mrdpatient
receiv
allohsct
significantli
differ
comparison
patient
receiv
blinatumomab
monotherapi
vs
signific
differ
df
observ
two
year
cr
mrdpt
depend
statu
diseas
therapymrd
vs
rr
vs
report
advers
event
febril
fever
common
neutropenia
thrombocytopenia
infect
neurotox
cytokinereleas
syndrom
complic
revers
conclus
blinatumomab
effect
option
patient
high
risk
ball
especi
group
mrd
persist
previou
chemotherapi
facilit
effect
bridg
hsct
blinatumomab
therapi
gener
well
toler
disclosur
address
transcript
regul
differenti
cell
human
embryon
stem
cell
esc
use
selfassembl
peptid
hydrogel
without
stromal
cell
compar
embryoid
bodi
eb
cultur
system
method
esc
differenti
induc
eb
cultur
system
threedimension
hydrogel
cultur
system
engraft
potenti
differenti
cell
evalu
flow
cytometri
cell
mobil
peripher
mononuclear
blood
cell
mpbmc
differenti
esc
differ
time
day
day
day
purifi
fluorescentactiv
cell
sort
sort
cell
captur
mediums
microfluid
chip
use
fluidigm
singl
cell
auto
prep
system
sequenc
perform
hiseq
x
ten
result
selfassembl
peptid
hydrogel
form
scaffold
cell
cultur
pore
diamet
rang
nm
compar
eb
cultur
system
esc
cultur
system
differenti
potent
differenti
cell
system
shortterm
engraft
nog
mice
myeloid
cell
b
cell
cell
could
detect
peripher
blood
transplant
howev
engraft
obtain
differenti
cell
eb
cultur
system
obtain
analyz
esc
cell
eb
cultur
system
cell
cultur
system
cell
mpbmc
cell
divid
cluter
figur
differenti
system
cell
day
heterogen
cell
day
day
figur
howev
cell
mpbmc
homogen
probabl
differenti
cell
contain
sever
cell
lineag
includ
hematopoiet
cell
endotheli
cell
mesenchym
cell
transcript
overlap
individu
cell
eb
cultur
system
howev
found
cluster
compos
mainli
cell
day
day
express
similar
level
sever
hematopoiet
regul
hsc
erg
figur
cluster
almost
cell
day
also
express
highest
among
cluster
differenti
cell
figur
conclus
studi
demonstr
hydrogel
cultur
system
facilit
hematopoiet
specif
esc
disclosur
noth
declar
higher
cell
dose
increas
overal
surviv
set
dual
tlymphocyt
suppress
atg
ptci
match
relat
unrel
donor
allosct
background
consensu
donor
cell
number
requir
optim
outcom
allogen
stem
cell
transplant
allosct
controversi
benefit
harm
higher
cell
dose
allosct
studi
aim
evalu
impact
cell
dose
allosct
patient
receiv
reduc
intens
condit
ric
combin
antithymoglobulin
atg
posttranspl
cyclophosphamid
ptci
use
relat
mrd
match
unrel
donor
mud
method
singlecentr
retrospect
analysi
adult
patient
receiv
allosct
hematolog
malign
octob
may
receiv
ric
use
fludarabin
day
day
busulfan
day
day
total
bodi
irradi
cgi
day
patient
also
receiv
rabbitatg
mgkg
day
ptci
day
cyclosporin
day
unmanipul
peripher
blood
stem
cell
infus
day
analys
done
use
threshold
arbitrari
cell
dose
kg
target
dose
cell
dose
accord
quartil
kg
result
median
cell
dose
kg
median
follow
month
rang
median
neutrophil
engraft
rang
day
platelet
engraft
rang
day
cell
dose
greater
kg
associ
increas
overal
surviv
os
year
ci
vs
ci
figur
higher
dose
also
associ
shorter
platelet
engraft
time
figur
signific
differ
neutrophil
engraft
nonrelaps
mortal
nrm
relaps
free
surviv
rf
grade
iiiv
acut
graft
versu
host
diseas
agvhd
moder
sever
chronic
graft
versu
host
diseas
cgvhd
tabl
analys
use
quartil
cell
dose
threshold
show
trend
toward
decreas
os
cell
dose
howev
statist
signific
figur
higher
cell
dose
associ
shorter
platelet
engraft
time
figur
signific
differ
neutrophil
engraft
nrm
rf
agvhd
cgvhd
tabl
conclus
cell
dose
greater
kg
significantli
increas
overal
surviv
set
ric
dual
tlymphocyt
suppress
atg
ptci
mrd
mud
allohsct
studi
larger
number
patient
longer
follow
recommend
valid
find
disclosur
method
fifti
two
adult
patient
includ
median
cell
request
infus
patient
receiv
ric
regimen
includ
fludarabin
day
busulfan
day
total
bodi
irradi
cgi
day
combin
rabbitatg
mgkg
day
ptci
day
cyclosporin
unmanipul
peripher
blood
stem
cell
infus
last
followup
novemb
median
followup
month
rang
median
cell
dose
count
infus
arbitrarili
divid
cohort
two
group
dose
cutoff
point
result
find
summar
infus
dose
signific
wors
impact
overal
surviv
os
relapsefre
surviv
rf
cumul
incid
acut
gvhd
chronic
gvhd
could
compar
two
cohort
due
differ
median
followup
conclus
infus
cell
dose
count
higher
cellskg
signific
advers
impact
overal
surviv
grade
iiiv
acut
gvhd
set
ric
dual
tlymphocyt
suppress
atg
ptci
haplohsct
disclosur
noth
declar
longterm
thymic
activ
immunereconstitut
haploident
allograft
posttranspl
cyclophosphamid
background
use
posttranspl
cyclophosphamid
ptci
expand
applic
replet
haploident
stem
cell
transplant
haplohsct
set
investig
thymu
role
longterm
clinic
outcom
evalu
immun
reconstitut
kinet
perform
method
twentynin
patient
median
age
enrol
blood
sampl
collect
condit
month
haplohsct
analys
tcell
subset
flowcytometri
correl
gener
linear
model
realtim
pcr
rtpcr
quantif
signal
joint
tcell
receptor
excis
dna
circl
sjtrec
specif
marker
naiv
tcell
thymopoiesi
naiv
b
central
c
memori
revert
tcell
defin
follow
b
c
respect
sjtrec
rtpcr
perform
genom
dna
ng
extract
sort
tcell
result
gradual
increas
absolut
number
cell
subset
sjtrec
copi
first
month
year
posttranspl
observ
figur
howev
year
tcell
level
sjtrec
level
lower
observ
healthi
donor
sjtrec
kinet
associ
increas
naiv
tcell
overal
p
correl
suggest
naiv
tcell
deriv
thymic
reeduc
donor
precursor
stem
cell
wherea
naiv
tcell
undergo
peripher
expans
thymic
product
furthermor
increas
revert
memori
tcell
also
significantli
correl
sjtrec
kinet
p
central
effector
memori
tcell
show
faster
thymicindepend
expans
tcell
interestingli
sjtrec
level
thymic
depend
immunereconstitut
higher
cohort
patient
undergo
hsct
hla
ident
donor
manuscript
prepar
clinic
outcom
thymic
function
correl
start
month
hsct
lower
thymic
output
significantli
associ
multivari
analysi
low
pretranspl
trec
valu
p
p
respect
moderatesever
chronic
graftversushost
diseas
gvhd
p
age
year
p
conclus
thymu
despit
agedepend
involut
substanti
contribut
tcell
reconstitut
haplohsct
chronic
gvhd
older
age
significantli
correl
reduc
thymic
function
overal
lower
product
sjtrec
haplohsct
compar
hla
ident
sibl
hsct
may
partli
due
higher
degre
mismatch
mhc
molecul
thymic
reeduc
imag
figur
background
use
allogen
hematopoiet
stem
cell
transplant
hsct
treatment
adolesc
young
adult
aya
philadelphia
neg
decreas
adopt
pediatr
inspir
protocol
treat
age
group
incorpor
minim
residu
diseas
assess
routin
care
patient
previous
use
defin
mainli
diseas
risk
featur
present
method
studi
aya
age
year
underw
allogen
hsct
institut
philadelphia
neg
februari
decemb
studi
patient
receiv
calgb
base
adult
chemotherapi
protocol
induct
underw
match
relat
donor
mrd
transplant
cytbi
condit
mtxcsa
gvhd
prophylaxi
patient
elig
allogen
hsct
mrd
plu
one
follow
risk
factor
age
year
high
present
wbc
count
ball
tall
high
risk
immunophenotyp
prob
prot
earli
matur
bulki
splenomegali
bulki
lymphadenopathi
high
risk
cytogenet
low
hypodiploidynear
triploidi
complex
cn
involv
relaps
refractori
diseas
induct
studi
investig
impact
differ
risk
factor
long
term
outcom
allogen
hsct
result
median
os
studi
patient
reach
year
median
df
year
figur
univari
analysi
relaps
refractori
diseas
prior
transplant
independ
risk
factor
os
df
pvalu
respect
figur
addit
patient
risk
factor
prior
transplant
significantli
lower
long
term
outcom
compar
patient
one
two
risk
factor
median
os
month
median
df
month
respect
figur
conclus
result
show
long
term
outcom
hsct
aya
philadelphia
neg
treat
adult
type
chemotherapi
regimen
significantli
better
patient
show
good
respons
initi
therapi
limit
poor
prognost
factor
present
worsen
df
number
poor
prognost
featur
increas
conclud
use
risk
score
help
predict
outcom
allogen
hsct
aya
philadelphia
neg
treat
adult
type
chemotherapi
protocol
disclosur
conflict
interest
prospect
singl
center
survey
donorspecif
antihla
antibodi
desensit
strategi
patient
undergo
allogen
stem
cell
transplant
background
set
hematopoiet
stem
cell
transplant
hsct
consid
risk
poor
engraft
graft
failur
gf
detect
antibodi
ab
direct
donor
specif
hla
loci
dsa
repres
contraind
proceed
donor
suggest
search
donor
mani
case
suffici
time
search
altern
donor
necessari
plan
immunosuppress
strategi
decreas
dsa
level
thu
reduc
risk
gf
date
consensu
desensit
standard
manag
dsa
hsct
aim
studi
determin
incid
antihla
ab
dsa
hematolog
patient
candid
allogen
hsct
efficaci
desensit
protocol
present
updat
result
obtain
strategi
method
august
septemb
prospect
screen
dsa
consecut
patient
candid
allogen
hsct
antihla
ab
research
carri
use
luminex
bead
assay
lifecod
screen
lsa
iiiimmucor
result
express
mean
fluoresc
intens
mfi
mfi
consid
posit
case
mismatch
relat
donor
flow
cytometr
crossmatch
test
fcxm
perform
patient
dsa
one
avail
donor
desensit
strategi
employ
schedul
rituximab
day
singlevolum
plasmapheresi
procedur
pp
usual
day
intraven
immunoglobulin
day
infus
hla
select
platelet
dsa
absorpt
case
persist
antibodi
direct
class
hla
antigen
aim
schedul
avoid
interfer
chemotherapi
antitcel
globulin
infus
condit
regimen
result
sinc
august
patient
prospect
screen
thirtythre
patient
show
antihla
ab
dsa
treat
desensit
strategi
appli
accord
mfi
score
fcxm
result
obtain
engraft
case
altern
donor
select
case
research
altern
donor
still
underway
dsa
detect
perform
everi
day
hsct
first
month
day
follow
hsct
neither
dsa
rebound
complic
observ
followup
conclus
prospect
analysi
underlin
high
frequenc
antihla
antibodi
detect
hematolog
patient
confirm
necess
routin
evalu
presenc
dsa
allogen
mismatch
hsct
desensit
schedul
base
combin
pp
rituximab
ivig
platelet
absorpt
prove
success
reduc
dsa
confirm
necess
prospect
multicent
collabor
better
defin
role
dsa
hla
locu
critic
mfi
cutoff
level
associ
higher
risk
gf
transplant
transfus
specialist
joint
defin
consensu
standard
desensit
strategi
disclosur
frequent
techniqu
use
counterbal
partial
incompat
hsct
select
associ
sustain
engraft
effect
reduct
cell
minim
gvhd
hand
approach
could
delay
immun
reconstitut
increas
risk
viral
fungal
infect
mud
set
use
pbsc
procedur
center
recent
adopt
impli
infus
relev
higher
number
cell
time
compar
bone
marrow
bm
sinc
centr
part
patient
primari
immunodefici
appli
procedur
minim
risk
sever
gvhd
infus
control
number
posit
cell
method
report
data
paediatr
patient
receiv
mud
hsct
patient
receiv
hsct
bmt
unit
children
hospit
brescia
patient
receiv
condit
accord
european
group
bone
marrow
transplant
ebmt
european
societi
immunodefici
esid
guidelin
select
realiz
milteni
column
ideal
addback
posit
cell
kg
stem
cell
sourc
bm
case
pbsc
case
result
median
patient
age
transplant
year
rang
year
mean
number
infus
cell
kg
kg
bm
product
kg
kg
pbsc
mean
time
engraft
day
posthsct
concern
acut
gvhd
overal
incid
children
present
complic
present
gvhd
grade
iii
none
gvhd
grade
iv
chronic
gvhd
present
limit
acut
gvhd
incid
sever
nt
significantli
differ
bm
recipi
pbsc
recipi
case
chronic
gvhd
preval
latter
major
infect
present
posttranspl
period
immunolog
reconstitut
cellular
humor
complet
month
overal
surviv
year
result
obtain
show
possibl
control
sever
gvhd
addback
control
number
lymphocyt
acut
gvhd
nt
sever
children
present
limit
chronic
gvhd
method
allow
graft
primari
immunodefici
patient
even
pbsc
without
infus
mani
cell
fact
especi
young
children
number
could
excess
riski
nevertheless
case
oncohaematolog
patient
gvl
effect
preserv
disclosur
background
dc
rare
genet
disord
result
defect
telomer
length
mainten
character
mucocutan
featur
bone
marrow
failur
bmf
high
predisposit
cancer
pulmonari
fibrosi
bmf
remain
major
caus
mortal
hsct
definit
treatment
restor
hematopoiesi
limit
high
incid
treatmentrel
mortal
method
retrospect
analysi
patient
pt
dc
underw
hsct
bone
marrow
transplant
unit
clinic
hospit
feder
univers
brazil
result
boy
girl
median
age
receiv
hsct
md
mud
mmrd
haploident
receiv
bone
marrow
bm
receiv
cord
blood
unit
cbu
median
tnc
infus
kg
rang
kg
cbu
kg
two
pt
receiv
myeloabl
preparatori
regimen
busulfan
bu
cyclophosphamid
cy
fludarabin
flu
antithymocyt
globulin
atg
remain
pt
receiv
ric
regimen
haplo
graft
versu
host
diseas
gvhd
prophylaxi
consist
cyclosporin
csa
methotrex
steroid
cbu
posttranspl
cy
csa
mycophenol
mofetil
haploident
transplant
evalu
pt
engraft
median
time
neutrophil
recoveri
day
day
one
patient
experienc
primari
graft
failur
haplo
second
graft
failur
occur
went
second
hsct
surviv
acut
gvhd
grade
iiiv
occur
pt
risk
moder
sever
chronic
gvhd
occur
pt
case
occur
pt
previous
present
acut
gvhd
overal
surviv
os
median
followup
os
slightli
better
msd
transplant
compar
other
x
caus
earli
death
includ
adenoviru
sepsi
toxic
preparatori
regimen
sepsi
primari
graft
failur
remain
aliv
hsct
median
fu
among
develop
organ
involv
underli
diseas
hepatopulmonari
syndrom
hp
die
due
pulmonari
fibrosi
liver
fibrosi
gi
bleed
hp
cgvhd
sepsi
infect
lost
fu
conclus
earli
mortal
bmf
reduc
hsct
late
outcom
remain
consequ
underli
diseas
long
term
fu
essenti
order
detect
late
complic
relat
hsct
procedur
underli
diseas
disclosur
noth
declar
singl
intrabon
cordblood
transplant
treosulfanbas
regimen
atgfre
sirolimusbas
gvhd
prophylaxi
fast
hematopoiet
engraft
immunereconstitut
patient
background
cord
blood
transplant
cbt
requir
less
stringent
hlamatch
compar
peripher
blood
stem
cell
bone
marrow
howev
cbt
associ
delay
engraft
immun
reconstitut
especi
vivo
tcell
deplet
antithymoglobulin
atg
use
method
patient
highrisk
diseas
receiv
intrabon
infus
unwash
singl
cb
unit
atgfre
gvhd
prophylaxi
activ
diseas
cbt
receiv
prior
allogen
stem
cell
transplant
median
age
rang
r
condit
regimen
myeloabl
treosulfan
fludarabin
intensifi
melphalan
tbi
hla
match
case
respect
gvhd
prophylaxi
includ
sirolimu
mycophenol
acid
mmf
result
thaw
median
cell
x
kg
r
median
cell
x
kg
r
median
cell
x
kg
r
evalu
patient
engraft
sustain
full
donor
chimer
day
median
time
neutrophil
anc
consecut
day
platelet
engraft
immunereconstitut
cbt
patient
tabl
compar
two
cohort
patient
transplant
center
adult
donor
without
patient
includ
posttranspl
cyclophosphamid
cohort
atg
associ
sirolimu
mmf
profil
immunereconstitut
day
show
better
recoveri
timepoint
cbt
noatg
versu
atg
cohort
statist
signific
differ
first
cohort
moreov
ratio
time
point
better
cbt
cohort
vs
noatg
cohort
b
cell
recoveri
faster
cbt
cohort
immunoglobulin
recoveri
superimpos
across
differ
platform
focus
late
event
day
cbt
pt
experienc
ebv
reactiv
median
time
day
treat
rituximab
experienc
late
cmv
reactiv
solv
last
visit
sirolimu
withdrawn
median
day
r
patient
develop
sever
chronic
gvhd
solv
last
visit
overal
median
followup
day
r
pt
aliv
well
conclus
data
confirm
intrabon
cbt
without
invivo
tcell
deplet
associ
fast
hematopoiet
engraft
immunereconstitut
low
rate
chronic
gvhd
late
infect
event
background
promis
improv
hematopoiet
stem
cell
transplant
hsct
may
lie
transplant
high
number
pluripot
stem
cell
minim
time
span
transplant
immunolog
reconstitut
henc
ex
vivo
platform
need
support
hsc
prolifer
applic
time
mainten
pluripot
diminish
hsc
differenti
lineagespecif
progenitor
cell
method
artifici
model
natur
hsc
nich
vitro
use
bone
marrow
bm
like
scaffold
made
polydimethylsiloxan
pdm
structur
base
human
long
bone
cross
section
repres
bm
human
cryoconserv
hsc
cultur
distinct
cultiv
system
day
differ
condit
cell
count
fac
analys
day
conduct
character
cultiv
hsc
use
antibodi
alon
combin
antibodi
result
optim
cultur
condit
human
hsc
commerci
avail
medium
supplement
panel
cytokin
valproic
acid
found
signific
increas
number
hsc
simultan
increas
vital
use
system
compar
convent
cultur
improv
achiev
introduc
silicon
oxidecov
pdm
structur
suggest
hydrophil
surfac
properti
offer
superior
attach
semiadher
hsc
precis
character
cultiv
hsc
introduc
panel
fac
marker
reflect
immatur
amplifi
hsc
surprisingli
increas
immatur
cultiv
hsc
noncov
pdm
reveal
best
suit
amplif
cell
number
vital
immatur
hsc
increas
cultiv
noncov
pdm
compar
silicon
oxidecov
pdm
system
conclus
establish
scaffold
accord
human
bm
found
platform
mimick
natur
nich
human
hsc
suitabl
amplifi
human
hsc
vitro
support
vital
pluripot
abil
selfrenew
imag
introduct
sion
cover
pdm
structur
mainten
hsc
could
improv
despit
better
conserv
hsc
use
silicon
oxidecov
pdm
found
immatur
human
hsc
obvious
prefer
hydrophob
condit
found
noncov
pdm
disclosur
noth
declar
abstract
alreadi
publish
improv
neutrophil
engraft
follow
chang
freez
method
background
set
autolog
haematopoiet
progenitor
cell
hpc
transplant
haematolog
disord
peripher
blood
stem
cell
routin
collect
via
apheresi
cryopreserv
leicest
royal
infirmari
use
control
rate
freezer
crf
cryopreserv
cellular
therapi
product
literatur
review
cryopreserv
techniqu
undertaken
sinc
crf
requir
replac
review
found
consist
evid
cryopreserv
use
minu
c
compar
crf
engraft
time
neg
affect
chang
simplifi
method
freez
would
also
cost
save
benefit
switch
crf
minu
c
freezer
method
result
two
minu
c
freezer
purchas
follow
accept
prepar
process
dosier
ppd
prepar
human
tissu
author
valid
carri
januari
stem
cell
laboratori
lri
switch
crf
method
minu
c
cryopreserv
cellular
therapi
product
briefli
cell
frozen
use
dmso
wakchemi
human
albumin
solut
grifol
cyrobag
origen
biomed
inc
cell
transfer
cold
pack
minu
c
freezer
cell
packag
stainless
steel
heattransf
plate
plate
place
within
bubbl
wrap
bag
place
rack
within
minu
c
freezer
allow
air
circul
freeli
around
bag
one
plate
elusbtc
thermocoupl
data
logger
thermosens
insert
bag
stainless
steel
plate
record
freez
profil
data
download
run
overnight
freez
minu
c
cell
subsequ
remov
bubbl
wrap
plate
transfer
minu
c
freezer
follow
morn
result
total
patient
autolog
stem
cell
frozen
use
method
far
year
addit
engraft
data
neutrophil
postfreez
trypan
blue
viabil
also
compar
previou
year
total
patient
cell
cryopreserv
underw
collect
post
freez
median
viabil
total
median
neutrophil
engraft
day
median
dose
infus
x
kg
far
patient
undergon
collect
median
viabil
subsequ
median
neutrophil
engraft
day
median
dose
infus
x
kg
conclus
ongo
save
approxim
per
annum
made
chang
procedur
benefit
chang
simplifi
method
freez
also
result
reduct
staff
work
overtim
importantli
simplifi
cryopreserv
method
result
improv
neutrophil
engraft
time
sinc
chang
cryopreserv
techniqu
previou
method
use
crf
mechan
freez
use
minu
c
freezer
disclosur
noth
declar
low
dose
granulocyt
apheresi
product
predict
better
outcom
autolog
hematopoiet
stem
cell
transplant
multipl
myeloma
patient
background
highdos
chemotherapi
autolog
stemcel
transplant
asct
remain
standard
consolid
therapi
multipl
myeloma
mm
peripher
blood
stem
cell
collect
may
contamin
larg
quantiti
granulocyt
consequ
outcom
asct
still
unclear
hand
effect
perform
apheresi
high
level
monoclon
compon
mc
outcom
unknown
object
studi
analyz
effect
total
nucleat
cell
tnc
granulocyt
count
consid
contamin
compon
apheresi
product
well
influenc
mc
apheresi
product
outcom
asct
mm
method
eightytwo
patient
diagnos
mm
mobil
filgrastim
plu
plerixafor
insuffici
mobil
cell
day
apheresi
collect
perform
cmnc
program
spectra
optia
cell
separ
count
carri
accord
ishag
protocol
target
kg
subsequ
cryopreserv
perform
accord
local
protocol
result
median
rang
collect
tnc
granulocyt
kg
kg
kg
respect
median
rang
infus
tnc
granulocyt
kg
kg
kg
respect
success
collect
first
line
therapi
perform
patient
treatment
mm
continu
carri
apheresi
patient
per
protocol
signific
reduct
mc
observ
prior
asct
indic
improv
respons
apheresi
optim
respons
cr
vgpr
time
apheresi
achiev
patient
suboptim
respons
partial
minim
respons
observ
remain
undergo
apheresi
optim
respons
result
lower
number
tnc
granulocyt
harvest
subtyp
mc
influenc
number
tnc
granulocyt
product
apheresi
differ
collect
tnc
granulocyt
observ
plerixafor
use
mobil
agent
type
chemotherapi
given
prior
apheresi
influenc
characterist
apheresi
product
signific
improv
overal
surviv
os
probabl
ci
observ
low
tnc
figur
lower
incid
relaps
figur
nonrelaps
mortal
observ
patient
receiv
low
granulocyt
count
graft
signific
correl
observ
time
engraft
number
tnc
granulocyt
infus
similarli
increas
frequenc
engraft
syndrom
observ
higher
number
tnc
granulocyt
infus
conclus
seri
low
dose
granulocyt
product
apheresi
predict
better
outcom
asct
mm
patient
amount
mc
time
apheresi
influenc
characterist
harvest
effort
avoid
contamin
graft
import
impact
outcom
asct
mm
patient
disclosur
dkm
foundat
instituto
carlo
iii
grc
generalitat
de
catalunya
background
initi
experi
year
hematopoiet
stem
cell
transplant
hsct
mud
graft
deplet
patient
cgd
show
high
rate
secondari
graft
dysfunct
incid
graft
reject
improv
outcom
hypothes
use
plerixafor
gcsf
addit
agent
condit
regimen
would
offer
advantag
better
outcom
trial
regist
wwwclinicaltrialsgov
method
april
septemb
patient
cgd
underw
allogen
hsct
mach
unrel
donor
graft
condit
regimen
includ
treosulfan
g
fludarabin
mg
thiotepa
mg
kg
gcsf
mcg
kg
plerixafor
mcg
kg
patient
receiv
rabbit
atg
genzym
europ
bv
netherland
mgkg
serotherapi
case
tcrab
graft
deplet
use
immunemagnet
method
miltenyi
biotec
bergisch
gladbach
germani
accord
manufactur
instruct
stem
cell
sourc
gcsf
mobil
peripher
blood
stem
cell
case
posttranspl
gvhd
prophylaxi
perform
minim
follow
day
hsct
result
neutrophil
platelet
engraft
occur
day
posthsct
patient
patient
full
donor
chimer
whole
blood
case
observ
predominantli
donor
mix
chimer
last
follow
patient
full
donor
chimer
compart
mix
chimer
lineag
stabl
without
sign
graft
dysfunct
acut
gvhd
verifi
case
limit
skin
grade
patient
aliv
period
month
posthsct
good
graft
function
without
sever
clinic
problem
conclus
present
first
experi
gcsf
plerixafor
addit
condit
regimen
hsct
graft
deplet
cgd
patient
suppos
preliminari
result
encourag
frequenc
primari
secondari
graft
dysfunct
patient
group
observ
today
signific
toxic
complic
well
clinic
sever
manifest
gvhd
current
recruit
patient
continu
estim
rate
immun
reconstitut
detail
analys
evalu
later
background
introduct
believ
aboincompat
minor
import
allogen
stem
cell
transplant
allosct
clinic
outcom
equival
abocompat
sct
therefor
perform
singl
center
retrospect
studi
character
impact
aboincompat
outcom
haploident
stem
cell
transplant
haplosct
method
analysi
includ
consecut
patient
underw
haplosct
variou
hematolog
malign
center
octob
may
use
institut
databas
evalu
detail
characterist
patient
transplant
outcom
result
demograph
featur
patient
donor
summar
tabl
patient
advanc
hematolog
diseas
high
risk
relaps
patient
acut
leukemia
patient
earli
transplantrel
mortal
seen
cohort
patient
remain
patient
follow
month
donor
type
abo
group
switch
observ
median
day
day
transplant
abl
show
statist
differ
term
blood
group
switch
minor
major
abo
incompat
transplant
median
red
blood
cell
rbc
transfus
first
day
abo
compat
incompat
transplant
median
unit
rang
median
unit
rang
statist
differ
also
encount
rbc
transfus
need
stem
cell
sourc
peripher
blood
vs
bone
marrow
total
patient
follow
reticulocyt
engraft
median
time
reticulocyt
engraft
day
rang
patient
reticulocyt
engraft
tend
faster
minor
abomismatch
group
major
abocompat
one
nineteen
patient
achiev
independ
rbc
support
median
time
day
rang
day
abocompat
patient
day
rang
day
minor
aboincompatibilityand
day
rang
day
major
aboincompatibilitygroup
respect
p
engraftman
kinet
due
major
minor
aboincompatibilitytranspl
present
tabl
pure
red
cell
aplasia
develop
cohort
conclus
present
singl
center
studi
provid
new
evid
import
abo
system
erythrocyt
recoveri
haploident
stem
cell
transplant
import
note
random
prospect
larger
studi
warrant
disclosur
noth
declar
low
dose
antit
lymphocyt
globulin
protect
sever
form
graft
versu
host
diseas
patient
undergo
allogen
stem
cell
transplant
background
graft
versu
host
diseas
gvhd
import
complic
allogen
stem
cell
transplant
allosct
optim
dose
differ
antitlymphocyt
globulin
atg
formul
set
establish
yet
aim
studi
analyz
impact
low
dose
atgfreseniu
atgf
allosct
outcom
method
analyz
adult
patient
receiv
allosct
hematolog
malign
octob
march
gvhd
prophylaxi
includ
total
dose
mgkg
mgkg
day
atgf
patient
receiv
graft
peripher
blood
unrel
donor
mismatch
andor
older
year
associ
calcineurin
inhibitor
mycophenol
mofetilshort
coursemethotrex
statist
analysi
perform
use
spss
r
softwar
result
median
age
year
patient
male
seventyfour
percent
patient
underw
myeloabl
condit
stem
cell
sourc
peripher
blood
patient
unrel
donor
mismatch
seventeen
patient
high
risk
cmv
statu
dr
see
imag
engraft
observ
patient
primari
graft
failur
occur
patient
myelofibrosi
aml
twenti
evalu
patient
develop
grade
acut
gvhd
cumul
incid
sever
agvhd
moderatesever
chronic
gvhd
ci
ci
patient
develop
sever
cgvhd
twentynin
patient
discontinu
immunosuppress
first
year
transplant
median
durat
immunosuppress
patient
moderatesever
cgvhd
day
year
nonrelaps
mortal
nrm
ci
thirtynin
patient
develop
relev
infecti
complic
two
patient
die
within
first
day
due
gram
neg
blood
stream
infect
eleven
least
two
episod
cytomegaloviru
cmv
reactiv
day
three
patient
develop
cmv
gastrointestin
diseas
probabl
invas
fungal
infect
posttranspl
lymphoprolif
disord
associ
epstein
barr
viru
median
follow
month
aliv
patient
gvhd
relaps
free
surviv
grf
one
year
overal
surviv
os
progress
free
surviv
pf
two
year
ci
ci
ci
respect
relaps
incid
two
year
ci
complet
remiss
transplant
associ
better
long
term
surviv
year
p
hla
dispar
affect
os
see
imag
conclus
use
low
dose
atgf
protect
sever
form
acut
chronic
gvhd
cohort
high
preval
unrel
donor
high
median
age
strategi
show
good
result
grf
os
pf
popul
high
risk
develop
gvhd
relaps
disclosur
noth
declar
perform
paramet
ngsproduct
chimer
monitor
applic
patient
hematopoiet
stem
cell
transplant
method
purpos
sampl
patient
mix
chimer
mc
increas
amount
recipi
dna
analyz
compar
use
realtim
pcr
insertionsdelet
indel
fragment
analysi
shorttandem
repeat
str
ng
indel
result
wherea
realtim
pcr
display
excel
sensit
mc
poor
precis
fragment
analysi
exhibit
good
precis
limit
sensit
contrast
ng
chimer
demonstr
good
sensit
limit
detect
lod
mc
precis
throughout
whole
spectrum
patientdonor
mix
chimer
ng
chimer
product
devys
chimer
exhibit
least
three
averag
eight
least
two
averag
inform
genet
marker
indel
suitabl
monitor
mix
chimer
patient
correspond
match
unrel
relat
donor
sampl
order
establish
perform
separ
techniqu
determin
mix
chimer
retrospect
patient
sampl
cohort
patient
monitor
sampl
week
posthsct
low
intermedi
high
mix
chimer
includ
analyz
dna
monitor
sampl
extract
sort
cell
fraction
result
show
although
evalu
techniqu
suitabl
monitor
patientdonor
chimer
allogen
hematopoiet
stem
cell
transplant
hsct
ng
chimer
product
exhibit
high
sensit
lod
broad
dynam
rang
detect
rang
good
precis
accuraci
throughout
whole
spectrum
mix
chimer
patientdonor
addit
ng
chimer
product
employ
nonpopul
depend
highli
inform
genet
marker
provid
stabl
resolut
power
thu
suitabl
monitor
mix
chimer
disclosur
dan
hauzenberg
medic
advis
devys
ab
sharehold
devys
hold
gender
distribut
male
femal
age
median
year
old
month
stem
cell
sourc
bone
marrow
peripher
blood
stem
cell
patient
receiv
match
unrel
donor
hematopoet
stem
cell
transplant
patient
match
unrel
donor
hematopoet
stem
cell
transplant
differ
antigen
blood
system
singl
group
minor
major
mix
age
donor
year
old
gender
differ
donorrecipi
malefemal
femalemal
one
sex
also
took
account
impact
gender
differ
cytomegaloviru
serostatu
donorrecipi
pair
result
group
estim
probabl
overal
surviv
group
surviv
increas
donor
age
year
reduc
surviv
howev
surviv
donor
year
old
found
differ
surviv
transplant
donor
compat
incompat
antigen
blood
system
cytomegaloviru
serostatu
gender
differ
donor
recipi
studi
donorrel
factor
found
neg
impact
human
leucincompat
incid
chronic
gvhd
p
combin
cytomegaloviru
posit
serostatu
donor
neg
statu
recipi
increas
risk
primari
graft
reject
comparison
other
p
conclus
studi
show
role
genet
match
hla
system
patient
unrel
donor
donor
age
valu
transplant
better
outcom
lower
incid
sever
gvhd
ch
gvhd
younger
donor
increas
surviv
signific
increas
surviv
donor
year
old
disclosur
noth
declar
allogen
stem
cell
transplant
chronic
myelomonocyt
leukemia
singl
center
experi
nine
patient
relaps
median
month
differ
strategi
point
case
modul
immunosuppress
case
uniqu
strategi
case
donor
lymphocyt
infus
dli
case
employ
hypometil
agent
hma
case
intens
chemotherapi
reach
cr
two
patient
one
dli
one
hma
consolid
second
asct
eleven
patient
die
relaps
main
caus
transplant
relat
mortal
trm
global
trm
last
followup
patient
still
aliv
cr
relaps
situat
median
followup
month
event
free
surviv
ef
month
overal
surviv
os
month
observ
advantag
term
os
patient
reach
cr
post
asct
develop
chronic
gvchd
respect
conclus
asct
still
cur
option
despit
high
relaps
rate
reach
cr
post
asct
develop
chronic
gvhd
seem
confer
advantag
term
os
import
know
molecular
profil
entiti
consid
asct
disclosur
studi
document
first
experi
cell
process
lab
seek
integr
process
autom
technolog
wash
volum
reduc
product
account
initi
materi
sourc
volum
variabl
product
characterist
number
bag
method
report
preclin
assess
lab
initi
work
lovo
cell
process
system
product
experi
day
machin
studi
use
product
intend
destruct
workflow
use
parallel
sequenti
process
schedul
waterbath
thaw
bag
sampl
weigh
determin
volum
subsequ
connect
lovo
pool
transfer
pack
connect
lovo
bag
dilut
mlmin
lovo
use
hydroxyethylstarch
voluven
freseniu
kabi
process
use
cycl
procedur
process
bag
weigh
volum
sampl
store
refriger
lovo
final
product
bag
sampl
assess
hour
result
viabil
absolut
count
determin
use
flow
cytometri
process
durat
solut
volum
consum
determin
lovo
sensor
confirm
oper
data
present
percentag
rel
postthaw
valu
note
valu
present
total
process
yield
result
focu
lovo
process
step
conclus
oper
easili
integr
softwar
drive
machin
machin
demonstr
flexibl
widerang
volum
cellinput
number
bag
lovo
produc
product
meet
specif
quick
reliabl
manner
work
platform
perform
valid
qualifi
system
product
use
properti
aim
studi
evalu
prospect
efficaci
fbm
protocol
prevent
om
patient
undergo
hsct
method
patient
consecut
underw
hsct
center
onward
receiv
five
weekli
fbm
session
bidiod
laser
lumix
prodent
itali
simultan
emit
power
energi
per
point
procedur
start
day
begin
condit
regimen
tenth
day
posttranspl
laser
appli
defocus
mode
mucos
surfac
area
session
morphin
dose
om
level
accord
scale
pain
numer
rate
scale
nr
record
result
consecut
patient
femal
submit
hsct
analyz
median
age
year
rang
eighteen
patient
acut
leukemia
myelodysplast
syndrom
lymphoprolif
diseas
median
number
treatment
line
hsct
rang
transplant
patient
advanc
diseas
myeloabl
condit
regimen
mac
thyotepa
busulphan
fludarabin
employ
patient
condit
reduc
dose
busulphan
ric
infus
patient
seven
patient
evid
om
incid
grade
iiiv
om
group
patient
receiv
mac
median
durat
day
rang
grade
om
observ
day
patient
ric
group
incid
om
median
durat
day
rang
patient
evid
grade
iv
om
whole
popul
maximum
nr
valu
morphin
administr
requir
patient
due
occurr
nonor
complic
conclus
experi
prophylaxi
fbm
prevent
reduc
om
safe
effect
compar
result
previou
experi
report
literatur
use
prevent
complic
neg
affect
qualiti
life
transplant
patient
studi
larg
seri
necessari
confirm
result
disclosur
noth
declar
background
cytogenet
abnorm
essenti
part
prognost
system
myeloid
malign
hematopoiet
stem
cell
transplant
hsct
howev
role
posttransplant
prognosi
unknown
aim
studi
assess
prognost
impact
genet
risk
stratif
aml
md
patient
posttransplant
cours
could
addit
tool
make
decis
regard
preemptiv
therapi
method
retrospect
analysi
cover
patient
treat
allohsct
cytogenet
studi
includ
karyotyp
cand
gband
fluoresc
situ
hybrid
fish
number
analyz
cell
exceed
european
cytogenet
associ
guidelin
fish
least
interphas
nuclei
analyz
cytogenet
risk
group
aml
assess
base
eln
criteria
patient
md
stratifi
three
group
favor
good
good
prognost
score
intermedi
advers
poor
poor
prognost
score
accord
ipssr
interestingli
poorest
surviv
patient
monosomi
chromosom
present
patient
succumb
refractori
diseas
patient
delet
long
arm
chromosom
del
aliv
time
write
report
median
followup
month
relaps
diagnos
patient
includ
advers
intermedi
favor
cytogenet
risk
among
patient
complex
karyotyp
andor
cytogenet
evolut
prior
hct
patient
relaps
includ
die
followup
cytogenet
studi
relaps
transplant
perform
patient
clonal
evolut
origin
karyotyp
addit
abnorm
die
new
aberr
cell
without
primari
chang
die
patient
unfavor
intermedi
group
cytogenet
relaps
diagnos
fish
analysi
treat
azacitidin
dli
achiev
cr
stabil
transient
respons
deceas
conclus
cytogenet
studi
patient
transplant
may
facilit
assess
mortal
karyotyp
may
undergo
cytogenet
evolut
allohsct
patient
monosomi
chromosom
seem
particularli
poor
prognosi
transplant
patient
vulner
new
cytogenet
alter
disclosur
noth
declar
method
primari
endpoint
rate
complet
respons
cr
defin
emesi
nausea
without
rescu
medic
acut
delay
cr
cinv
rate
posttranspl
complic
discharg
prospect
analyz
patient
undergo
autolog
allogen
stem
cell
transplant
receiv
cinv
prophylaxi
nepa
dexamethason
schedul
shown
seri
patient
femal
patient
median
age
year
frequent
diagnosi
myeloma
lymphoma
patient
diagnos
aml
md
myeloma
patient
receiv
one
day
hdct
melphalan
lymphoma
patient
condit
feam
ttfluedx
hdct
busulfanbas
mdsct
regimen
offer
amlmd
patient
result
incid
cr
observ
respect
grade
nausea
vomit
accord
report
patient
respect
femal
sex
associ
increas
risk
acut
hr
p
ci
delay
hr
p
ci
cinv
similar
rate
observ
oneday
hdct
compar
mdsct
group
pn
median
lenght
stay
day
case
cardiotox
exitu
observ
incid
febril
neutropenia
fuo
sepsi
pneumonia
one
patient
experienc
agvhd
day
neutrophil
platelet
recoveri
occur
median
day
day
respect
conclus
nepa
seem
safe
effect
prevent
acut
delay
cinv
patient
receiv
one
day
hdct
mdsct
condit
regimen
hsct
studi
need
defin
better
combin
better
schedul
transplant
set
disclosur
noth
declar
background
vod
tatma
repres
two
earli
endotheli
complic
occur
allogen
stem
cell
transplant
sct
share
mani
pretranspl
risk
factor
aim
studi
evalu
impact
donor
graft
composit
engraft
kinet
infect
develop
endotheli
complic
ec
method
retrospect
review
consecut
sct
recipi
institut
januari
june
median
age
year
rang
acut
leukemia
diagnos
patient
complet
remiss
document
patient
transplant
donor
sourc
hla
mismatch
donor
unrel
donor
patient
hbv
posit
patient
sampl
condit
regimen
busulfan
base
patient
ursodeoxychol
acid
unfraction
heparin
given
patient
vod
prophylaxi
cyclosporin
use
gvhd
prophylaxi
lymphocyt
subpopul
analysi
cell
count
donor
graft
perform
use
bd
fac
cantol
patient
routin
monitor
ebv
cmv
pcr
hemolysi
test
creatinin
electrolyt
panel
proteinuria
complet
blood
count
blood
pressur
schistocyt
direct
examin
day
fisher
exact
test
use
compar
categor
variabl
continu
variabl
analyz
anova
test
diagnosi
vod
tatma
carri
use
ebmt
cho
criteria
respect
result
incid
sever
vod
tma
respect
cmv
reactiv
viral
load
cv
ml
patient
without
ec
respect
p
hr
ci
median
day
neutrophil
ns
engraft
vs
vs
vodtma
group
vs
control
group
respect
rapid
neutrophil
engraft
ns
ns
within
day
relat
higher
risk
ec
hr
p
ci
p
ci
patient
ec
receiv
donor
graft
higher
median
number
p
lower
number
nk
cell
p
patient
receiv
cell
count
nk
cell
count
present
rel
risk
ec
p
ci
p
ci
respect
differ
respect
analyz
variabl
patient
develop
vodtma
compar
conclus
cmv
viremia
earli
neutrophil
engraft
donor
nk
cell
infus
associ
risk
vod
tma
studi
evalu
link
variabl
risk
develop
two
complic
could
interest
investig
relationship
larger
seri
clinic
trial
registri
applic
disclosur
noth
declar
last
hope
turn
good
best
haplosct
follow
tbf
condit
pt
cyclophosphamid
tacrolimu
gvhd
prophylaxi
background
hematopoiet
stem
cell
transplant
effect
therapi
varieti
sever
hematolog
diseas
last
decad
haploident
sct
haplosct
follow
ptci
gvhd
prophylaxi
report
valid
altern
patient
lack
hla
match
donor
therefor
analys
outcom
method
patient
without
hlamatch
donor
receiv
haplosct
thiotepa
mgkg
day
fludarabin
day
oral
busulfan
h
day
pkd
dose
adjust
use
condit
regiment
patient
year
busulfan
administr
limit
two
day
gvhd
prophylaxi
consist
cyclophosphamid
mgkg
day
tacrolimu
continu
iv
infus
day
patient
receiv
pbsc
stem
cell
sourc
outcom
analys
overal
surviv
os
progress
free
surviv
pf
cumul
incid
ci
gvhd
relaps
nonrelaps
mortal
nrm
result
median
age
rang
male
femal
diagnos
aml
md
hl
nhl
mm
n
transplant
earli
diseas
statu
case
advanc
statu
includ
secondthird
cr
n
one
aplasia
without
progress
diseas
n
activeprogress
diseas
n
stabl
diseas
four
case
second
alosct
thu
patient
high
high
rdri
intermedi
ebmt
score
patient
n
donor
son
daughter
sibl
patient
mother
median
time
neutrophil
platelet
recoveri
day
respect
gcsf
use
one
patient
primari
graft
failur
attribut
antihla
donor
specif
antibodi
median
follow
survivor
month
rang
overal
surviv
month
month
pf
respect
cumul
incid
relaps
respect
nrm
month
day
grade
acut
gvhd
mild
moder
sever
chronic
gvhd
respect
ebmt
first
alosct
variabl
clearli
impact
os
univari
analysi
combin
covari
ebmt
prior
alosct
vs
patient
show
month
os
vs
p
pf
vs
p
nrm
vs
p
without
impact
relaps
vs
p
conclus
haplosct
ageadapt
tbf
condit
regimen
pbsc
ptci
follow
tacrolimu
led
encourag
result
mainli
patient
low
ebmt
score
first
alosct
although
formerli
consid
last
alosct
strategi
agre
time
come
compar
strategi
hla
mud
even
elderli
sibl
donor
ongo
prospect
random
multin
trial
disclosur
noth
disclosur
background
autolog
hematopoiet
stem
cell
transplant
autosct
acut
myeloid
leukaemia
aml
increas
becom
viabl
option
increas
number
patient
due
limit
avail
match
sibl
unrel
donor
allogen
hematopoiet
stem
cell
transplant
allosct
examin
relev
longterm
outcom
local
patient
cohort
method
retrospect
review
data
autosct
done
aml
centr
period
st
januari
st
dec
electron
record
patient
acut
promyelocyt
leukaemia
apml
exclud
analysi
patient
stratifi
base
number
high
risk
featur
present
achiev
complet
remiss
cr
follow
induct
chemotherapi
high
present
total
white
cell
count
wbc
x
ml
advers
cytogenet
exampl
complex
cytogenet
advers
molecular
mutat
exampl
mll
gene
arrang
outcom
data
includ
mortal
overal
surviv
os
nonrelaps
mortal
nrm
morbid
leukaemia
free
surviv
lf
record
analys
result
total
patient
identifi
median
age
diagnosi
old
cohort
compris
male
femal
overal
median
os
median
lf
year
year
respect
nrm
differ
median
os
median
lf
patient
achiev
cr
follow
induct
chemotherapi
cr
follow
induct
chemotherapi
year
versu
year
logrank
year
versu
year
logrank
respect
median
os
statist
signific
patient
zero
versu
one
two
high
risk
featur
present
year
versu
year
versu
year
logrank
respect
howev
median
lf
statist
signific
three
patient
cohort
year
versu
year
versu
year
logrank
respect
conclus
patient
cohort
autosct
appear
feasibl
option
patent
aml
without
match
sibl
unrel
donor
avail
disclosur
none
declar
method
thalassem
patientsunderw
hisct
median
age
patient
year
male
preponder
across
gender
abo
mismatch
transplant
done
patient
stem
cell
sourc
bone
marrow
peripher
blood
patient
mean
stem
cell
dose
x
cell
kg
mean
volum
product
ml
prepar
regimen
includ
antithymocyt
globulin
busulfan
fludarabin
cyclophosphamidegraft
versu
host
diseas
gvhd
prophylaxi
compris
posttranspl
cyclophosphamid
day
follow
tacrolimu
mycophenol
mofetil
patient
observ
hematopoiet
recoveri
neutrophil
platelet
engraft
transplant
relat
mortal
includ
acut
chronic
gvhd
skin
gut
liverand
lung
primari
secondari
graft
failur
infecti
complic
result
nine
sixteenpati
engraft
full
donor
chimer
twelv
patient
belong
pesaro
class
toclass
ii
patient
median
time
neutrophil
plateletengraft
day
respect
averag
number
pack
red
cell
platelet
transfus
respectivelyprimari
graft
failur
observ
secondari
graft
failur
observ
patient
two
patient
receiv
second
dose
stem
cell
engraft
day
infus
patient
primari
graft
failur
die
one
sepsi
day
intracrani
bleed
day
acut
gvhdof
gut
skin
grade
iiiii
observ
patient
within
first
day
posttranspl
none
patient
grade
iv
gvhd
cytomegaloviru
reactiv
occur
patient
receiv
preemptiv
therapi
intraven
ganciclovir
none
develop
cmv
diseas
invas
fungal
infect
observ
patient
cultur
proven
bacterialinfect
document
patient
requir
intraven
antibiot
first
day
posttransplantoveral
surviv
relaps
free
surviv
median
followup
day
conclus
haploident
transplant
suitabl
modal
thalassem
patient
lack
full
match
donor
pakistan
view
result
suggest
thalassemia
patient
offer
hiscta
option
cure
clinic
background
gemtuzumab
ozogamicin
go
monoclon
antibodi
signific
activ
de
novo
relapsedrefractori
rr
acut
myeloid
leukemia
aml
relev
side
effect
consist
hepatotox
especi
sinusoid
obstruct
syndrom
so
object
studi
analyz
toler
go
induct
reinduct
therapi
patient
aml
possibl
impact
subsequ
hematopoiet
stem
cell
transplant
hsct
method
patient
receiv
go
three
hospit
collect
medic
record
retrospect
review
result
fourteen
patient
diagnos
de
novo
aml
receiv
go
day
combin
standard
chemotherapi
idarubicin
cytarabin
schedul
induct
therapi
hyperbilirubinemia
bilirubin
unl
detect
patient
increas
aspart
aminotransferas
ast
unl
twelv
patient
achiev
complet
remiss
cr
one
refractori
evalu
rr
set
patient
diagnos
aml
biphenotyp
acut
leukemia
acut
promyelocyt
leukemia
receiv
go
subsequ
rescu
therapi
either
monotherapi
combin
cytotox
chemotherapi
prior
hsct
perform
patient
autolog
allogen
rescu
therapi
indic
refractori
relaps
partial
respons
absenc
donor
four
patient
receiv
dose
go
mgm
patient
one
dose
hyperbilirubinemia
unl
observ
patient
increas
ast
unl
patient
seven
patient
achiev
cr
refractori
obtain
partial
respons
die
earli
induct
thirteen
patient
receiv
subsequ
hsct
autolog
allogen
go
therapi
de
novo
aml
rr
group
reason
perform
hsct
remain
patient
low
cytogenet
risk
activ
chronic
graft
versu
host
diseas
gvhd
previou
hsct
earli
death
treatment
relaps
sever
complic
rescu
treatment
unknown
condit
regimen
myeloabl
nonmyeloabl
sequenti
donor
match
sibl
unrel
cyclosporin
methotrex
thymoglobulin
administ
gvhd
prophylaxi
patient
cyclosporin
mycophenol
thymoglobulin
hyperbilirubinemia
observ
patient
belong
de
novo
aml
group
death
hsct
occur
patient
due
infect
relaps
gvhd
traffic
accid
three
patient
current
aliv
remiss
so
observ
patient
conclus
de
novo
rr
aml
administr
low
dose
go
feasibl
impact
subsequ
hsct
outcom
although
degre
hepatotox
observ
case
so
observ
either
hsct
disclosur
support
grant
contra
el
aecc
instituto
carlo
iii
fi
grc
cerca
program
generalitat
de
catalunya
la
caixa
foundat
outcom
allogen
hematopoiet
stem
cell
transplant
patient
benign
hematolog
disord
saqib
ansari
tahir
shamsi
uzma
zaidi
saima
siddiqui
tasneem
farzana
background
allogen
hematopoiet
stem
cell
transplant
potenti
cur
treatment
modal
hematolog
disord
evalu
outcom
patient
suffer
benign
hematolog
disord
includ
aplast
anemia
fanconi
anemia
thalassemia
match
relat
allogen
transplant
method
patient
hematolog
disord
includ
aplast
anemia
aa
beta
thalassemia
btm
fanconi
anemia
fa
sever
combin
immun
defici
disord
scid
hla
ident
relat
donor
underw
allogen
transplant
includ
donor
given
gcsf
dose
kgday
daili
four
day
prior
harvest
condit
regimen
thalassemia
includ
cyclophosphamid
cy
busulfan
bu
bu
cy
thiotepa
bu
cy
antithymocyt
globulin
atg
condit
regimen
aplast
anemia
includ
fludarabin
flu
cy
flu
atg
cy
cy
atg
patient
fanconi
anemia
flu
atg
flu
cy
atg
flu
cy
atg
flu
atg
cy
given
condit
regimen
offer
patient
scid
result
total
allogen
transplant
perform
benign
hematolog
disord
includ
aa
btm
fa
scid
juli
median
age
year
rang
across
gender
abo
blood
group
transplant
median
time
neutrophil
platelet
recoveri
day
rang
rang
primari
secondari
graft
failur
observ
overal
surviv
aplast
anemia
beta
thalassemia
fanconi
anemia
sever
combin
immun
defici
disord
eighti
four
patient
expir
among
patient
expir
within
day
post
transplant
main
caus
death
includ
sepsi
multi
organ
failur
gut
gvhd
conclus
develop
world
scenario
non
malign
disord
lead
caus
morbid
mortal
bone
marrow
transplant
success
implement
better
long
term
diseas
free
surviv
qualiti
life
clinic
background
hematopoiet
cell
transplant
hct
remain
cur
therapi
mani
diseas
yet
transplant
survivor
carri
unusu
high
burden
morbid
primarili
exposur
intens
chemotherapi
radiat
gvhd
studi
aim
evalu
burden
chronic
diseas
end
life
allogeneichct
identifi
disabilityadjust
life
year
dali
method
pubm
medlin
ovid
databas
queri
util
specif
mesh
terminolog
post
allo
stem
cell
hematopoiet
bone
marrow
transplant
collect
data
impact
hct
variabl
affect
survivor
health
aspect
rate
late
complic
compar
risk
gener
popul
unit
state
result
total
studi
fulfil
select
criteria
total
patient
tabl
median
os
mark
vari
wide
studi
major
patient
mark
found
new
comorbid
therebi
indic
huge
burden
late
effect
end
life
though
exact
dali
could
calcul
due
incomplet
data
hct
survivor
found
higher
risk
prematur
arteri
diseas
pad
compar
gener
popul
howev
gvhd
addit
tbi
condit
regimen
found
significantli
associ
pad
regard
risk
new
cancer
cumul
incid
develop
year
respect
increas
risk
compar
gener
popul
seen
solid
cancer
includ
cancer
lip
tonsil
oropharynx
p
bone
p
soft
tissu
p
vulva
respect
mental
health
depress
preval
survivor
still
antidepress
last
followup
cognit
impair
psychiatr
disord
found
survivor
respect
common
caus
nrm
first
year
gvhd
howev
year
lead
caus
death
condit
mac
regimen
secondari
cancer
ric
group
new
cancer
gvhd
contribut
equal
conclus
hct
survivor
remain
risk
signific
complic
lead
prematur
death
burden
comorbid
end
life
significantli
gener
popul
background
late
onset
hemorrhag
cystiti
hc
common
complic
hematopoiet
stem
cell
transplant
hsct
frequent
associ
reactiv
bk
viru
bkhc
consensu
best
therapi
bkhc
mani
differ
treatment
report
hyper
baric
oxygen
therapi
hbot
use
primari
adjuv
therapi
divers
clinic
situat
involv
hypox
injuri
tissu
explor
use
tool
treat
bk
hc
report
experi
hbot
combin
noninvas
support
care
children
adolesc
suffer
bkhc
follow
allogen
hsct
method
computer
databas
schneider
medic
center
israel
review
patient
age
year
underw
hsct
januari
june
develop
bkhc
hbot
therapi
consist
hour
session
atmospher
patient
breath
oxygen
mask
parent
accompani
patient
treatment
result
fourteen
patient
varieti
underli
diseas
receiv
hbot
treatment
bkhc
follow
hsct
initi
treatment
children
bkhc
center
prior
includ
continu
bladder
irrig
intravesicular
instil
variou
medic
begin
adopt
noninvas
strategi
includ
administr
oral
anticholinerg
oxybutinin
system
pain
manag
hyperhydr
administr
weekli
cidofovir
probenecid
hbot
administ
patient
fail
regimen
protocol
averag
time
start
hbot
drop
prior
day
median
onset
hc
day
post
hsct
patient
receiv
immunosuppress
treatment
onset
bkhc
patient
suffer
macrohematuria
blood
clot
grade
iii
cystiti
experienc
sever
dysuria
urgenc
bk
viruria
present
patient
concurr
bk
viremia
detect
test
patient
report
symptomat
improv
mean
day
follow
initi
hbot
patient
experienc
seriou
advers
effect
due
hbot
two
patient
requir
insert
tympan
ventil
tube
eleven
patient
experienc
complet
remiss
bkhc
follow
hbot
overal
respons
rate
patient
eight
patient
eventu
succumb
due
either
hsct
complic
diseas
relaps
conclus
hyperbar
oxygen
therapi
safe
effect
noninvas
well
toler
treatment
modal
bk
hc
consid
first
line
therapi
complic
hsct
clinic
background
everi
year
almost
one
thousand
case
hematolog
malign
pediatr
popul
report
peru
allogen
hematopoiet
stem
cell
transplant
allohsct
altern
strategi
mani
case
pediatr
popul
requir
hsct
compat
human
leukocyt
antigen
hla
donor
remain
access
intern
donor
registri
extend
await
time
condit
progress
diseas
allohsct
potenti
help
children
sever
hematolog
disord
noncompat
hla
donor
hla
genotyp
ident
sibl
donor
best
option
pursu
hsct
nevertheless
patient
altern
sourc
stem
cell
could
obtain
haploident
donor
like
one
parent
haploident
transplant
program
mac
implement
peru
reduc
risk
graftversushost
diseas
gvhd
support
immun
system
reconstitut
expand
pool
donor
allow
patient
access
treatment
effici
safe
shown
deplet
posit
b
cell
procedur
allohsct
method
mobil
leukapheresi
product
haploident
healthi
donor
wash
remov
platelet
prepar
perform
accord
miltenyi
manual
cell
deplet
analysi
initi
leukapheresi
product
deplet
graft
target
nontarget
product
perform
use
flow
cytomet
cell
analyz
fluorochromelabel
antibodi
miltenyi
biotec
use
novocyt
cytomet
result
obtain
ex
vivo
tcell
deplet
allohsct
procedur
show
overal
surviv
os
end
first
year
low
incid
gvhd
mac
cell
effect
logp
logp
respect
obtain
minimum
level
deplet
lymphocyt
within
clinic
establish
paramet
divers
patholog
addit
cell
deplet
significantli
affect
hematopoiet
stem
cell
popul
cell
cell
popul
tcr
cell
highli
recov
respect
contribut
better
engraft
allohsct
conclus
peruvian
result
oscil
within
european
rang
os
data
suggest
mac
method
effici
effect
safe
strategi
haploident
hsct
remark
costbenefit
ratio
make
viabl
countri
latin
american
region
peruvian
socioeconom
characterist
evalu
genoresist
viral
reactiv
treatment
implement
strategi
improv
os
better
result
achiev
patient
allohsct
valid
test
peru
preliminari
pharmacoeconom
evalu
allow
us
establish
magnet
activ
cell
sort
mac
promissori
strategi
compar
altern
haploident
hsct
necessari
increas
number
procedur
order
confirm
efficaci
safeti
mac
larger
popul
disclosur
author
conflict
interest
abstract
alreadi
publish
microcost
studi
hematopoiet
stem
cell
transplant
two
hospit
institut
southern
brazil
background
hematopoiet
stem
cell
transplant
hsct
potenti
cur
treatment
indic
patient
oncohematolog
hereditari
immunolog
diseas
consid
increas
patient
indic
hsct
lack
knowledg
cost
result
treatment
import
identifi
detail
resourc
consum
phase
hsct
provid
knowledg
public
health
brazilian
system
aim
measur
total
cost
relat
hsct
base
microcost
studi
patient
assist
two
hospit
south
region
brazil
method
hsct
cost
estim
use
timedriven
activ
base
cost
method
tdabc
measur
cost
servic
product
base
actual
consumpt
resourc
collect
data
medic
record
patient
submit
allogen
hsct
public
privat
philanthrop
hospit
interview
profession
involv
tcth
activ
perform
chronoanalysi
consult
financi
administr
system
report
hospit
order
compar
cost
accord
clinic
complic
observ
patient
group
two
rang
complex
low
medium
high
studi
divid
stage
hsct
process
map
cost
measur
analysi
result
final
cost
compar
activ
resourc
hospit
studi
financ
psiduh
agreement
sign
ministri
health
moinho
de
vento
hospit
adjust
term
number
approv
research
ethic
committe
result
hsct
process
map
follow
step
defin
hospit
ii
condit
iii
transplant
iv
period
aplasia
v
engraft
vi
observ
vii
preand
medic
discharg
seven
patient
classifi
low
medium
complex
level
hospit
median
time
day
median
cost
usd
wherea
five
patient
classifi
high
complex
present
median
time
day
median
cost
usd
hsct
cost
evalu
identifi
step
ii
iv
present
greatest
cost
high
complex
patient
lower
complex
patient
present
step
ii
iv
median
cost
usd
higher
complex
usd
addit
median
cost
materi
drug
usd
usd
lower
higher
complex
patient
conclus
tdabc
method
allow
identif
moment
patient
consum
resourc
hsct
stage
period
condit
aplasia
present
higher
cost
repres
total
hospit
valu
stage
higher
complex
patient
present
three
time
higher
median
cost
resourc
greatest
impact
medicin
medic
materi
cost
time
lower
complex
patient
conclus
studi
allow
detail
identif
hsct
cost
patient
differ
complex
rang
two
hospit
southern
brazil
therefor
identif
servic
demand
regard
clinic
complex
allow
gener
import
inform
manag
best
care
health
servic
disclosur
background
immunodefici
due
lrba
defici
character
hypogammaglobulinemia
autoimmun
hemolyt
anemia
lymphadenopathi
autoimmun
hepat
autoimmun
enteropathi
fundament
characterist
patient
togeth
histori
recurr
invas
infectionsth
therapi
includ
immunosuppress
endoven
immunoglobulin
bone
marrow
transplant
final
therapi
patient
especi
seriou
case
recent
year
also
light
increasingli
target
condit
regim
associ
ever
better
prognosi
method
present
case
caterina
patient
lrba
defici
diagnos
year
age
histori
hypogammaglobulinemia
recur
invas
bacteri
fungal
infect
pictur
autoimmun
repres
ahia
myeliti
autoimmun
hepat
enteropathi
treatment
abatacept
sirolimu
also
present
leptin
defici
lipodystrophysh
present
observ
ostemiel
multipl
outbreak
tibia
femur
left
knee
secondari
sepsi
mrsa
broad
spectrum
antibiot
therapi
curettag
surgeri
perform
hospitalizationaft
month
broadspectrum
antibiot
therapi
daptomycin
rifampicin
ceftarolin
cotrimoxazol
levofloxacin
dalbavancin
resolut
infectionsbecaus
serious
diseas
therefor
decid
subject
catherin
hematopoiet
stem
cell
transplant
result
therefor
perform
bone
marrow
transplant
mud
condit
reduc
intens
delay
day
treosulfan
fludarabin
thiotepa
prophylaxi
gvhd
perform
atg
kg
day
sirolimu
alreadi
practic
enteropathi
mmf
hepat
pictur
also
perform
prophylaxi
vod
defibrotid
day
transplant
perform
peripher
stem
cell
x
kg
x
kgthe
patient
alway
present
good
gener
condit
engraf
pmn
plt
chimer
donor
pmn
pbl
prophylaxi
gvhd
chang
replac
sirolimu
tacrolimu
appear
grade
cutan
gvhd
conclus
success
perform
bone
marrow
transplant
patient
lrba
defici
new
antibiot
molecul
use
induc
infecti
remiss
new
lowintens
regimen
prevent
fear
complic
vod
key
success
complic
case
high
number
cell
infus
control
number
key
rapid
engraft
minim
gvhd
readili
control
immunosuppress
disclosur
background
absenc
hlamatch
relat
donor
allogen
stem
cell
transplant
haploident
donor
potenti
altern
patient
hematolog
malign
indic
allogen
stem
cell
transplant
herein
retrospect
assess
outcom
haplosct
patient
refractori
hematolog
malign
method
analysi
includ
consecut
patient
underw
haplosct
variou
hematolog
malign
center
octob
may
use
institut
databas
evalu
detail
characterist
patient
transplant
outcom
result
demograph
featur
patient
donor
summar
tabl
patient
advanc
diseas
high
risk
relaps
major
patient
underw
haplosct
parent
patient
earli
transplantrel
mortal
seen
cohort
patient
four
patient
treat
second
haplosct
recov
hematopoiesi
second
transplant
remain
patient
follow
median
month
donor
type
abo
group
switch
observ
median
day
day
transplant
median
time
engraft
day
rang
patient
first
transplant
patient
develop
acut
gvhd
patient
grade
iiiii
acut
gvhd
five
chronic
gvhd
none
extens
manifest
prep
regimen
rel
well
toler
limit
regimenrel
toxic
cmv
reactiv
occur
patient
followup
studi
eight
patient
relaps
median
day
post
transplant
rang
day
cr
achiev
patient
haplosct
mean
estim
os
pf
respect
conclus
given
grow
data
similar
outcom
hlamatch
haploident
sct
studi
requir
determin
whether
factor
may
import
donor
select
hlamatch
clinic
trial
registri
disclosur
noth
declar
outcom
allogen
stem
cell
transplant
hodgkin
nonhodgkin
lymphoma
singl
center
experinc
turkey
uysal
hale
nur
akad
soyer
mahmut
tobu
murat
tombuloglu
guray
saydam
filiz
vural
background
allogen
sct
allosct
gener
option
treatment
choic
young
fit
patient
relapsedrefractori
lymphoma
heavili
pretreat
failur
autolog
stem
cell
transplant
asct
relaps
asct
associ
poor
prognosi
allosct
potenti
cur
therapi
lymphoma
relaps
asct
method
studi
evalu
patient
hl
nhl
treat
allohsct
novemb
decemb
ege
univers
adult
hematolog
transplant
unit
result
patient
diseas
transplant
characterist
illustr
tabl
histolog
subtyp
nhl
evalu
cell
lymphoma
mantl
cell
diffus
larg
bcell
lymphoma
bcell
lymphoma
unclassifi
featur
intermedi
dlbcl
classic
hodgkin
lymphoma
histolog
subtyp
hl
determin
nodular
scleros
median
number
prior
treatment
allohsct
rang
twelv
patient
refractori
diseas
patient
complet
remiss
patient
partial
remiss
allohsct
median
time
diagnosi
allosct
rang
month
peripher
stem
cell
use
stem
cell
sourc
total
bodi
irrit
plu
fludarabin
plu
cyclophosphamid
busulfan
plu
cyclophosphamid
prefer
frequent
condit
nonmyeloabl
myeloabl
respect
neutrophil
engraft
occur
median
rang
day
graft
versu
host
diseas
gvhd
prophylaxi
appli
cyclosporin
plu
methotrex
prefer
frequent
gvhd
occur
acut
gvhd
chronic
gvhd
venoocclus
diseas
vod
occur
patient
transplant
relat
death
observ
patient
overal
surviv
os
diseasefreesurviv
df
evalu
median
rang
rang
month
respect
analyz
os
df
illustr
figur
six
patient
aliv
without
diseas
rapid
taper
immunosuopress
therapi
underw
therapi
ponatinibat
dose
result
afther
month
therapi
observ
rapid
decreas
minim
residu
diseas
molecular
assess
mmr
non
detect
confirm
bone
marrow
revalu
day
salvag
therapi
patient
experienc
graftversushost
diseas
ponatinib
treatment
well
toler
consid
safe
easili
manag
side
conclus
mayb
era
tyrosin
kinas
inhibitor
tki
philadelphia
chromosom
posit
acut
lymphoblast
leukemia
ph
could
benefit
combin
treatment
transpalnt
tki
howev
studi
need
confirm
hypothes
disclosur
noth
declar
immunodefici
diseas
macrophag
background
although
number
patient
hiv
infect
hematolog
diseas
success
undergon
allogen
hsct
togeth
combin
antiretrovir
therapi
cart
short
longterm
outcom
remain
well
known
report
largest
spanish
experi
hivinfect
adult
patient
highrisk
hematolog
malign
allogen
hsct
method
retrospect
review
hivposit
patient
receiv
allogen
hsct
spanish
center
within
geth
grupo
de
trasplant
terapia
celular
result
baselin
transplant
characterist
patient
shown
tabl
median
age
year
patient
men
frequent
underli
malign
nonhodgkin
lymphoma
aml
half
patient
hlaident
sibl
donor
half
altern
donor
use
peripher
blood
use
graft
sourc
transplant
time
hsct
patient
receiv
suppress
cart
median
year
show
detect
plasma
hiv
rna
one
poor
adher
cart
togeth
accumul
multipl
resist
mutat
patient
detect
hiv
rna
low
level
copiesml
patient
receiv
cart
throughout
transplant
procedur
tempor
stop
two
patient
due
signific
mucos
median
followup
month
overal
surviv
os
eventfre
surviv
ef
nrm
month
relaps
month
grade
iiiv
agvhd
rate
moderatesever
cgvhd
rate
month
signific
proport
patient
show
infecti
complic
viral
infect
frequent
caus
two
patient
invas
aspergillosi
one
patient
present
dissemin
tuberculosi
caus
death
includ
infect
relaps
toxic
among
patient
die
due
infect
sever
chronic
gvhd
immunosuppress
therapi
two
patient
show
sever
toxic
relat
drug
interact
antiretrovir
therapi
survivor
except
one
show
undetect
hiv
load
last
followup
hsct
conclus
allogen
hsct
effect
therapi
highrisk
hematolog
malign
patient
hiv
infect
provid
longterm
diseas
free
surviv
togeth
longterm
hiv
suppress
cart
howev
drug
interact
antiretrovir
agent
occurr
gvhd
frequent
infecti
complic
account
complex
procedur
popul
select
hivinfect
patient
hematolog
malign
consid
allohsct
indic
experienc
center
multidisciplinari
care
disclosur
background
primari
immunodefici
pid
rare
diseas
often
associ
genet
defect
immun
system
predispos
individu
recurr
infect
increas
risk
allergi
autoimmun
malign
allogen
haematopoiet
stem
cell
transplant
hsct
success
use
cur
therapi
sever
form
pid
pid
genet
diseas
children
healthi
human
leukocyt
antigen
hla
match
sibl
donor
avail
umbil
cord
blood
graft
unrel
donor
suitabl
altern
cell
sourc
report
result
umbil
cord
blood
transplant
ucbt
perform
patient
pid
children
hospit
fudan
univers
china
method
patient
includ
chronic
granulomat
diseas
cgd
sever
combin
immunodefici
scid
receptora
defici
wiskottaldrich
syndrom
leukocyt
adhes
defici
lad
sever
congenit
neutropaenia
scn
immunodefici
patient
assess
clinic
immunologist
confirm
clinic
phenotyp
genet
diagnosi
median
age
patient
month
rang
month
median
bodi
weight
kg
rang
kg
patient
receiv
hla
allelesmismatch
cord
blood
unit
hla
fulli
match
match
match
match
median
nucleat
cell
cord
blood
kg
rang
kg
median
cell
kg
rang
kg
result
median
followup
time
month
rang
month
overal
surviv
rate
year
patient
cgd
scid
respect
patient
die
death
occur
day
transplant
main
caus
death
infect
patient
engraft
median
time
neutrophil
engraft
day
rang
median
time
platelet
engraft
day
rang
cumul
incid
grade
acut
gvhd
chronic
gvhd
conclus
unrel
ucbt
consid
pid
patient
without
hla
match
sibl
donor
effect
control
infect
transplant
import
improv
surviv
disclosur
background
dedic
cytokinesi
dock
defici
caus
combin
immun
defici
characteris
recurr
bacteri
infect
suscept
viral
infect
eczema
food
allergi
vascul
increas
risk
malign
due
high
morbid
mortal
diseas
hsct
increasingli
offer
patient
potenti
cur
therapi
method
retrospect
review
outcom
hsct
patient
dock
defici
great
north
children
hospit
newcastl
upon
tyne
publish
refer
result
ten
patient
dock
defici
treat
hsct
median
age
rang
median
durat
follow
rang
rang
donor
sourc
msd
mud
tcr
deplet
haploident
condit
regimen
treoflu
treofluthiotepa
serotherapi
alemtuzumab
atgrituximab
none
one
patient
receiv
tcr
alpha
deplet
haploident
transplant
receiv
add
back
tcell
caspacid
molecular
safeti
switch
bellicum
pharmaceut
skin
agvhd
occur
patient
stage
stage
patient
cgvhd
overal
surviv
surviv
compar
regardless
donor
sourc
death
occur
within
month
transplant
patient
die
signific
burden
diseas
pretranspl
patient
chronic
liver
failur
secondari
cryptosporidi
scleros
cirrhot
liver
secondari
cryptosporidium
cerebr
vascul
axillari
aneurysm
aortic
vascul
requir
graft
ascend
aortic
pn
depend
failur
thrive
histori
cryptosporidium
infect
candida
bal
pretranspl
caus
death
patient
respiratori
failur
progress
encephalopathi
multiorgan
failur
septic
shock
encephalopathi
multiorgan
failur
septic
shock
treatment
tma
two
patient
reactiv
cryptosporidium
prior
death
pretranspl
cryptosporidium
associ
mortal
graph
one
patient
surviv
suffer
stroke
pretranspl
one
suffer
basilar
arteri
aneurysm
year
posttranspl
time
latest
follow
donor
chimer
survivor
high
level
mix
conclus
singl
centr
studi
hsct
patient
consist
literatur
indic
hsct
potenti
cur
therapi
patient
dock
defici
increas
morbid
associ
cryptosporidi
infect
like
consequ
overal
diseas
burden
rather
infect
specif
effect
howev
highlight
improv
outcom
transplant
prior
develop
multipl
comorbid
suggest
hsct
consid
earli
unclear
whether
late
occurr
vascular
complic
transplant
caus
manifest
diseas
correct
transplant
result
vascular
injuri
sustain
pretranspl
refer
method
refer
infant
underw
test
immun
phenotyp
ab
gd
memori
cell
b
cell
nk
cell
number
function
activ
nk
cell
matern
engraft
adenosin
deaminas
ada
purin
nucleosid
phosphorylas
pnp
enzym
activ
genet
test
confirm
diagnosi
scid
underw
either
allogen
hematopoiet
stem
cell
transplant
hct
elig
gene
therapi
gt
infant
identifi
ada
defici
etiolog
scid
receiv
enzym
replac
therapi
prior
proceed
definit
therapi
result
twentythre
infant
confirm
scid
three
infant
famili
histori
scid
would
identifi
without
nb
addit
one
infant
born
prematur
week
diagnos
pnp
defici
develop
infect
infant
identifi
nb
repeat
test
week
gestat
normal
like
due
support
transient
cell
product
exogen
enzym
provid
red
cell
transfus
twelv
infant
confirm
low
trec
nonscid
diagnosi
transient
lymphopenia
infanc
normal
trec
immun
phenotyp
function
prenat
exposur
genet
confirm
digeorg
syndrom
prolong
lymphopenia
three
prolong
lymphopenia
two
recurr
infect
one
ultim
diagnos
ataxia
telangiectasia
one
absent
trec
near
normal
number
cell
normal
pha
specif
antigen
respons
absent
b
cell
undergo
transplant
near
futur
third
continu
absent
trec
short
telomer
low
number
ab
cell
presenc
gd
cell
vaccin
respons
freedom
infect
identifi
genet
etiolog
summari
patient
refer
msk
confirm
abnorm
nb
scid
nonscid
diagnosi
uniform
collect
data
infant
threshold
trigger
repeat
test
vari
state
state
incid
signific
nonscid
disord
identifi
also
like
vari
state
state
although
institut
specif
experi
bias
infant
confirm
low
number
trec
prior
referr
signific
number
disord
nonscid
cohort
emphas
import
full
evalu
followup
infant
disclosur
none
relat
work
present
susan
prockop
research
fund
mesoblast
atara
biotherapeut
nanci
kernan
research
fund
jaz
pharmaceut
richard
research
fund
royalti
atara
biotherapeut
kevin
curran
consult
juno
pharmaceut
novarti
jj
boelen
avrobio
magenta
chimerix
bluebird
bio
background
posttranspl
autoimmun
cytopenia
aic
challeng
associ
substanti
morbid
mortal
aim
studi
cumul
incid
ci
posthct
autoimmun
cytopenia
aic
predictor
cohort
children
primari
immunodefici
pid
method
retrospect
studi
includ
children
pid
underw
first
hsct
fludarabin
f
treosulfan
thio
great
north
children
hospit
main
outcom
interest
ci
aic
predictor
fineandgrey
regress
model
use
analys
predictor
aic
consid
death
compet
event
variabl
includ
age
transplant
year
vs
year
gender
diagnosi
scid
vs
immunedysregulatori
disord
vs
pid
pretranspl
aic
preand
posttranspl
respiratori
viru
donor
mfd
vs
mud
vs
mmfdmmud
vs
haploident
donor
abo
incompat
condit
ft
vs
ftthio
serotherapi
none
vs
alemtuzumab
vs
alemtuzumab
vs
atg
stem
cell
sourc
marrow
vs
pbsc
vs
cord
vs
exvivo
deplet
pbsc
infus
stem
cell
dose
tnc
agvhd
none
vs
agvhd
cgvhd
none
vs
cgvhd
viral
infect
cmvadenoviru
viraemia
chimer
full
vs
mix
chimer
wb
within
first
year
posthct
impact
thymopoiesi
use
cell
recoveri
studi
result
median
age
transplant
year
rang
year
primari
diagnos
scid
immunedysregulatori
disord
pid
donor
mfd
mud
mmfd
mmud
haploident
parent
stem
cell
sourc
marrow
unmanipul
pbsc
exvivo
tdeplet
pbsc
cb
receiv
addit
thiotepa
csammf
gvhd
prophylaxi
median
durat
followup
survivor
year
rang
year
os
entir
cohort
ci
aic
develop
aic
aiha
aiha
median
onset
aic
month
posthct
rang
month
patient
treat
median
treatment
modal
rang
one
steroid
steroidhighdoseivig
steroidhighdoseivigrituximab
steroid
highdoseivigsirolimu
steroid
highdoseivigrituximabsirolimu
median
time
resolut
achiev
remiss
first
aic
month
rang
month
one
relaps
two
relaps
die
develop
aic
aspergillu
pneumonia
multiorgan
failur
surviv
patient
aic
ongo
aiha
median
followup
year
posthct
rang
year
univari
completingrisk
analysi
age
transplant
pretranspl
aic
associ
higher
incid
aic
figur
ic
fineandgrey
model
age
transplant
hr
ci
independ
associ
aic
complet
immun
reconstitut
data
cell
month
posthct
associ
lower
incid
aic
hr
ci
figur
conclus
younger
age
thymopoiesi
associ
lower
incid
aic
children
pid
hct
clinic
background
human
defici
report
present
tetrad
anemia
nephriti
inflamm
asplenia
fatal
treat
autoinflammatori
disord
macrophag
monocyt
express
engag
recycl
red
cell
human
defici
result
intravascular
hemolysi
sever
damag
endotheli
system
kidney
organ
transplant
either
healthi
wild
type
macrophag
new
macrophag
produc
sct
healthi
donor
proven
cur
defici
mice
report
first
success
allogen
sct
human
defici
report
second
success
nonmyeloabl
msd
hsct
child
defici
method
present
complaint
fever
anemia
sever
hypertens
past
age
year
admit
high
fever
month
need
blood
transfus
first
time
sever
anemia
high
platelet
high
ferritin
treat
macrophag
activ
syndrom
prednisolon
alon
later
cyclosporin
ad
short
statur
abnorm
faci
normal
develop
hemoglobin
gdl
urin
haemoglobin
posit
platelet
ferritin
mcgl
urin
albumin
urin
rbc
ultrasound
ct
scan
abdomen
show
asplenia
diagnosi
defici
suspect
mutat
analysi
show
homozyg
missens
mutat
chromosom
would
result
absenc
function
protein
parent
carrier
mutat
manag
next
prednisolon
hydroxyurea
mycophenol
mofetil
mmf
howev
remain
steroid
depend
hlatyp
confirm
healthi
unaffect
brother
fulli
match
donor
age
year
taken
msd
sct
take
inform
consent
weigh
kg
condit
total
bodi
irradi
gray
infus
millionkg
peripher
blood
stem
cell
brother
graftvshost
diseas
gvhd
prophylaxi
consist
tacrolimu
mmf
result
toler
procedur
well
entir
hospit
stay
unev
lowest
platelet
count
record
neutrophil
engraft
day
discharg
urin
albumin
nil
gvhd
chimer
show
donor
cell
donor
postsct
well
evid
hemolysi
proteinuria
hypertens
fever
normal
ferritin
platelet
gain
cm
height
kg
weight
last
month
viral
reactiv
immun
recoveri
month
post
sct
good
conclus
nonmyeoabl
allogen
msd
sct
cur
treatment
option
human
defici
disclosur
nil
two
decad
excel
transplant
surviv
children
chronic
granulomat
diseas
report
supraregion
immunolog
transplant
centr
europ
background
haematopoiet
stem
cell
transplant
hsct
confer
lifelong
cur
therapi
chronic
granulomat
diseas
cgd
abil
donorderiv
neutrophil
replac
recipi
defect
neutrophil
make
hsct
superior
therapi
compar
convent
standard
care
use
antimicrobi
therapi
method
examin
outcom
children
cgd
receiv
first
hsct
great
north
children
hospit
outcom
includ
overal
surviv
os
eventfre
surviv
es
toxic
endpoint
autoimmun
diseas
longterm
surviv
graft
function
cox
proportionalhazard
model
use
analys
predictor
os
es
variabl
includ
predictor
analysi
age
transplant
donor
stem
cell
sourc
stem
cell
dose
condit
result
children
includ
analysi
median
age
transplant
year
rang
year
xlink
autosom
recess
cgd
twenti
match
famili
donor
unrel
donor
parent
haploident
donor
prior
variou
condit
regimen
use
patient
undergo
condit
pharmacokinet
guid
intraven
iv
busulfan
bu
iv
cyclophosphamid
without
serotherapi
condit
regimen
switch
flutreosulfanalemtuzumab
gvhd
prophylaxi
use
ciclosporin
csa
mycophenol
mofetil
mmf
famili
unrel
donor
flutreosulfanthiotepaatgrituximab
use
tcr
alphabeta
deplet
haploident
graft
ten
patient
grade
iiiv
acut
gvhd
grade
iiiiv
acut
gvhd
none
chronic
gvhd
os
entir
cohort
ci
figur
analysi
age
transplant
reveal
os
children
transplant
year
age
ci
children
year
age
p
figur
os
compar
match
famili
donor
ci
unrel
donor
transplant
figur
four
haploident
transplant
success
es
entir
cohort
ci
none
variabl
associ
es
seven
patient
slip
chimer
receiv
success
second
transplant
five
death
due
transplantrel
complic
multiorgan
failur
pulmonari
haemorrhag
graft
iv
acut
gvhd
posttranspl
lymphoprolif
diseas
median
age
transplant
deceas
patient
year
rang
year
cumul
incid
autoimmun
diseas
respect
three
immun
cytopenia
autoimmun
endocrinopathi
thyroid
dysfunct
type
diabet
mellitu
median
age
longterm
survivor
year
rang
year
median
durat
followup
year
rang
year
late
death
entir
cohort
median
donor
myeloid
chimer
rang
conclus
despit
limit
singl
centr
studi
find
confirm
hsct
safe
longlast
cur
therapi
children
cgd
disclosur
none
non
medic
challeng
diagnosi
transplant
patient
primari
immun
defici
experi
tertiari
care
center
india
sagar
bhattad
stalin
ramprakash
raghuram
cp
chetan
ginigeri
fulvio
porta
background
primari
immun
defici
pid
increasingli
recogn
sever
part
india
despit
diagnos
mani
patient
fail
receiv
optim
care
due
financi
social
constraint
method
case
record
patient
diagnos
treat
includ
hematopoiet
stem
cell
transplant
pid
diseas
feb
nov
aster
cmi
hospit
bangalor
india
analys
factor
lead
defer
suboptim
care
assess
detail
result
patient
variou
pid
diagnos
studi
period
detail
tabl
warrant
hematopoiet
stem
cell
transplant
hsct
definit
cur
treatment
total
children
receiv
hsct
die
aliv
well
children
sever
combin
immun
defici
die
hsct
could
carri
critic
ill
present
stabl
defer
treatment
cite
financi
social
constraint
children
need
transplant
continu
remain
followup
transplant
date
signific
financi
constraint
famili
convinc
need
transplant
prepar
transplant
tabl
scid
sever
combin
immun
defici
vodivenoocclus
diseas
immunodefici
cgd
chronic
granulomat
diseas
hlh
hemophagolymphohistiocytosi
wiskott
aldrich
syndrom
xlt
x
link
thrombocytopenia
ladleukocyt
adhes
defici
msmd
mendelian
suscept
mycobacteri
diseas
xla
x
link
agammaglobulinemia
cvid
common
variabl
immun
defici
apec
autoimmun
polyendocrinopathi
candidiasi
ectoderm
dystrophi
cmcc
chronic
mucocutan
candidiasi
ataxia
telangiectasia
conclus
present
experi
develop
countri
discuss
nonmed
factor
lead
suboptim
care
children
pid
children
warrant
hsct
could
transplant
cohort
among
hsct
potenti
cur
children
die
hsct
could
offer
transplant
develop
countri
pose
uniqu
challeng
due
absenc
govern
fund
andor
univers
insur
coverag
addit
delay
diagnosi
critic
state
patient
admiss
financi
social
factor
significantli
contribut
poor
outcom
disclosur
none
outcom
hematopoiet
stem
cell
transplant
hsct
pediatr
patient
hemophagocyt
lymphohistiocytosi
hlh
korea
method
korea
histiocytosi
work
parti
retrospect
collect
nationwid
data
patient
diagnos
hlh
underw
allogen
hsct
clinic
characterist
treatment
outcom
patient
analyz
result
total
patient
enrol
patient
fhl
infect
associ
hlh
secondari
hlh
unknown
caus
patient
treat
protocol
patient
achiev
complet
respons
cr
treatment
week
main
reason
receiv
transplant
fhl
reactiv
refractori
diseas
condit
regimen
busulfanbas
patient
fludarabinebas
treosulfanbas
busulfanfludarabinebas
stem
cell
sourc
use
hsct
peripher
blood
patient
cord
blood
bone
marrow
donor
type
hsct
unrel
donor
patient
relat
match
sibl
donor
haploident
donor
partial
match
donor
caus
death
patient
diseas
reactiv
progress
acut
gvhd
withwithout
vod
graft
failur
five
year
overal
surviv
rate
respect
diseas
statu
time
hsct
cr
patient
noncr
surviv
rate
patient
receiv
hsct
cr
patient
transplant
noncr
statu
patient
receiv
hsct
use
peripher
blood
stem
cell
better
surviv
rate
compar
patient
receiv
cord
blood
stem
cell
significantli
presenc
neurolog
symptom
diseas
statu
intial
week
therapi
condit
regimen
cd
posit
cell
count
statist
signific
impact
surviv
conclus
hsct
improv
surviv
patient
famili
relaps
refractori
hlh
korean
nationwid
hlh
registri
result
similar
report
literatur
diseas
statu
time
hsct
stem
cell
sourc
transplant
import
prognost
factor
affect
surviv
hlh
patient
underw
hsct
clinic
trial
registri
registri
number
disclosur
best
knowledg
name
author
conflict
interest
financi
otherwis
hematopoiet
cell
transplant
reduc
intens
condit
regimen
use
fludarabin
busulfan
fludarabinemelphalan
primari
immunodefici
diseas
background
primari
immunodefici
diseas
pid
congenit
disord
innat
acquir
immun
system
hematopoiet
cell
transplant
hct
treatment
option
pid
lifethreaten
infect
immun
dysregul
reduc
intens
condit
ric
increasingli
use
prevent
complic
hct
optim
regimen
establish
perform
hct
pid
ric
use
fludarabin
busulfan
flubu
melphalan
flumel
accord
guidelin
european
societi
immunodefici
esid
european
societi
blood
marrow
transplant
ebmt
assess
efficaci
safeti
ric
method
april
decemb
pid
patient
underw
richct
use
flubu
flumel
tmdu
analyz
retrospect
auc
bu
set
mg
hourl
sever
combin
immunodefici
diseas
scid
mg
hourl
nonscid
overal
surviv
os
analyz
result
median
age
hct
year
old
male
femal
patient
flubu
use
patient
scid
combin
immunodefici
diseas
cid
ectoderm
dysplasia
eda
sever
congenit
neutropenia
scn
flumel
use
patient
scid
cid
xiap
defici
eda
antithymocyt
globulin
use
patient
flubu
group
patient
flumel
group
cord
blood
bone
marrow
use
donor
sourc
match
donor
use
patient
flubu
flumel
group
respect
median
follow
period
year
two
yearso
patient
flubu
group
patient
flumel
group
patient
respect
neutrophil
engraft
patient
flubu
group
flumel
group
scid
patient
flubu
group
achiev
engraft
surviv
seven
flumel
group
achiev
engraft
patient
secondari
graft
failur
patient
die
nonscid
flubu
group
achiev
engraft
patient
secondari
graft
failur
nonscid
patient
flumel
group
engraft
surviv
two
patient
flubu
group
flumel
group
suffer
sever
acut
graftversushost
diseas
grade
iiiiv
ten
patient
hemophagocyt
lymphohistiocytosi
hlh
viral
reactiv
infect
observ
patient
resolv
one
patient
conclus
richct
use
flubu
flumel
advantag
neutrophil
engraft
flubu
scid
flumel
cid
immun
dysregul
may
effect
opinion
flubu
regimen
need
improv
secondari
graft
failur
nonscid
prevent
hlh
transplant
use
dexamethason
palmit
consid
disclosur
noth
declar
surviv
hematopoiet
stem
cell
transplant
graft
deplet
older
children
primari
immunodefici
background
deplet
graft
engin
method
prove
valuabl
increas
surviv
rate
hematopoiet
stem
cell
transplant
hsct
patient
primari
immunodefici
pid
decreas
surviv
rate
older
patient
pid
previous
report
transplant
nonmanipul
graft
method
patient
variou
pid
exclud
classic
scid
receiv
allogen
hsct
graft
deplet
septemb
center
analyz
median
age
hsct
year
rang
patient
divid
age
group
year
patient
year
year
patient
receiv
hsct
match
unrel
haploident
donor
sibl
condit
regimen
alkyl
agent
antithymocyt
globulin
use
patient
patient
receiv
short
cours
variou
posttranspl
immunosuppress
median
follow
hsct
year
rang
year
result
overal
surviv
os
patient
ci
observ
similar
os
younger
age
group
ci
year
ci
year
age
seven
patient
older
group
year
age
die
os
ci
patient
older
age
group
die
combin
pid
wiscottaldrich
syndrom
undefin
pid
defici
defici
nijmegen
breakag
syndrom
nb
kabuki
syndrom
icf
syndrom
median
time
death
hsct
year
rang
six
transplantrel
mortal
trm
five
patient
hsctassoci
viral
infect
cmv
pneumonia
adv
infect
fulmin
hepat
multiorgan
interestingli
prolong
histori
dissemin
viral
infect
adv
reduct
viral
load
blood
fluid
tissu
upon
treatment
one
patient
kabuki
syndrom
hsct
develop
associ
kaposi
sarcoma
success
treat
eventu
patient
reduct
viral
infect
sarcoma
symptom
develop
multiorgan
failur
clinic
laboratori
evid
endothelium
cell
damag
syndrom
one
patient
nb
die
high
grade
lymphoma
progress
conclus
hsct
deplet
demonstr
high
surviv
rate
patient
variou
pid
group
patient
age
older
year
predispos
decreas
posttranspl
surviv
patient
combin
pid
higher
risk
posttranspl
mortal
conclud
least
patient
prolong
histori
viral
infect
hsct
caus
death
could
multiorgan
failur
due
endothelium
cell
damag
syndrom
result
persist
inflamm
drug
toxic
effect
disclosur
background
chronic
granulomat
diseas
cgd
primari
immunodefici
pid
caus
mutat
subunit
nicotinamid
dinucleotid
phosphat
nadph
oxidas
lead
reduct
microbicid
activ
phagocyt
cell
start
earli
age
cgd
patient
suffer
sever
recurr
infect
well
inflammatori
event
allogen
hematopoiet
stem
cell
transplant
hsct
cur
option
cgd
patient
insuffici
benefit
support
care
prophylact
antibiot
report
seri
patient
cgd
underw
unrel
umbil
cord
blood
transplant
ucbt
center
method
retrospect
studi
observ
seri
consecut
ucbt
perform
center
children
cgd
age
transplant
month
rang
month
median
bodi
weight
kg
rang
kg
patient
receiv
myeloabl
condit
regimen
consist
busulfan
fludarabin
cytarabin
cyclophosphamid
gcsf
patient
receiv
anoth
myeloabl
condit
regimen
consist
busulfan
fludarabin
cyclophosphamid
atg
prophylaxi
graftversushost
diseas
gvhd
tacrolimu
result
engraft
occur
patient
patient
occur
graft
failur
receiv
myeloabl
condit
regimen
without
atg
median
time
neutrophil
platelet
engraft
rang
rang
day
patient
develop
acut
gvhd
episod
grade
iiiiv
agvhd
chronic
gvhd
occur
patient
median
followup
month
rang
month
overal
surviv
rate
eventfre
surviv
rate
conclus
unrel
ucbt
consid
potenti
cur
method
children
cgd
cgd
patient
use
myeloabl
condit
regimen
atg
show
better
graft
surviv
disclosur
noth
declar
background
invas
fungal
infect
ifi
remain
major
caus
treatmentrel
morbid
mortal
aml
patient
although
uncommon
present
unusu
sever
clinic
featur
might
indic
underli
immunodefici
caspaseassoci
recruit
domain
recogn
crucial
role
effect
antifung
respons
lead
differenti
initi
inflammatori
cytokin
cascad
particularli
interferongamma
ifng
increas
macrophag
activ
patient
homozyg
mutat
known
significantli
increas
suscept
lifethreaten
system
candidiasi
howev
sequenc
variant
may
lead
increas
ifisuscept
even
heterozygos
eg
immunosuppress
describ
addit
treatment
option
immun
stimul
effect
leukocyt
immun
respons
situat
immunolog
blind
method
report
case
old
male
aml
sever
system
candida
tropicali
infect
unrespons
tripleantimycot
regimen
lead
multiorgan
failur
discov
bear
heterozyg
mutat
immunotherapi
lead
complet
respons
dissemin
infect
result
patient
develop
septic
fever
immedi
first
chemotherapi
cycl
unexpectedli
candida
tropicali
confirm
blood
cultur
within
hour
liposom
amphotericin
b
ambisom
start
immedi
howev
candida
rapidli
dissemin
lung
liver
spleen
kidney
cn
despit
extend
antimycot
therapi
caspofungin
voriconazol
fluconazol
patient
splenectom
due
massiv
infiltr
figur
genet
test
mycosi
predisposit
reveal
heterozyg
mutat
gene
inherit
father
treatment
start
subcutan
time
per
week
lead
almost
complet
respons
dissemin
infect
due
sever
infect
chemotherapi
interrupt
one
cours
howev
bone
marrow
remain
complet
remiss
almost
one
year
patient
experienc
altogeth
two
relaps
requir
unrel
allogen
haploident
hsct
combin
ambisom
fluconazol
prophylaxi
mycosi
observ
despit
extens
prolong
immunosuppress
conclus
ifi
aml
patient
common
howev
unusu
present
presum
immun
compet
individu
rais
suspicion
immunodefici
case
unexpect
earli
candidasepsi
complet
unrespons
adequ
multiag
treatment
use
adult
immun
stimulatori
cytokin
littl
data
avail
children
knowledg
first
case
success
treatment
pediatr
aml
patient
dissemin
candida
sepsi
bear
mutat
given
elev
mortal
risk
ifi
appar
safe
welltoler
applic
adjuv
immunotherapi
might
consid
studi
need
defin
indic
durat
kind
adjunct
immunotherapi
moreov
consid
wide
heterogen
genet
mutat
involv
ifisuscept
genomewid
express
profil
might
use
pediatr
cancer
patient
identif
specif
immun
pathway
might
help
identifi
individu
ifisuscept
order
improv
outcom
highrisk
patient
imag
background
chronic
granulomat
diseas
cgd
curabl
allogen
hematopoet
stem
cell
transplant
hsct
recent
report
haploident
donor
hsct
post
transplant
cyclophosphamid
ptci
famili
donor
pediatr
primari
immun
defici
shown
encourag
result
howev
report
cgd
describ
success
haploident
hsct
child
cgd
myeloabl
condit
ptci
yearold
male
child
diagnos
cgd
show
oxid
activ
dihydrorhodamin
dhr
test
match
relat
unrel
donor
avail
underw
haploident
hsct
take
inform
consent
parent
may
donor
hla
match
healthi
elder
sister
oxid
activ
dhr
multipl
admiss
recurr
pneumonia
prior
hsct
condit
rituximab
iv
day
thiotepa
mg
kgdose
intraven
iv
day
busulfan
mgkgdose
daili
iv
day
day
fludarabin
daili
iv
day
day
rabbit
antithymoglubulin
thymoglobulin
mg
kgdose
daili
day
peripher
blood
stem
cell
millionkg
cell
harvest
sister
transfus
patient
day
graft
vs
host
diseas
gvhd
prophylaxi
ptci
mg
kg
intraven
cyclosporin
target
level
ngml
mmf
result
neutrophil
engraft
platelet
chimer
month
fulli
donor
develop
acut
chronic
gvhd
month
lymphocyt
count
show
viral
reactiv
diseas
free
gvhd
free
post
hsct
taper
dose
cyclosporin
dhr
test
show
oxid
activ
day
background
primari
immun
defici
pid
function
disord
inherit
immun
system
increas
predisposit
infecti
diseas
number
sever
incid
birth
live
immunolog
dysregul
may
increas
predisposit
autoimmun
diseas
malign
latter
frequent
present
cur
treatment
hematopoiet
stem
cell
transplant
hsct
method
describ
patient
transplant
primari
immun
defici
instituto
nacion
de
pediatria
condit
regimen
depend
type
donor
patholog
myeloabl
reduc
intens
non
myeloabl
without
modif
statist
significantli
overal
surviv
result
total
patient
includ
sever
combin
immunodefici
scid
patholog
frequent
transplant
figur
seventi
three
percent
molecular
diagnosi
case
famili
pid
use
sourc
umbil
cord
blood
ucb
peripher
blood
howev
trend
sourc
obtain
modifi
year
ago
figur
median
graft
day
ucb
day
bone
marrow
bm
day
peripher
blood
pb
figur
main
complic
infecti
bacteri
viral
noninfecti
pregraft
syndrom
conclus
overal
surviv
surviv
accord
patholog
chediak
higashi
syndrom
scid
griselli
syndrom
hyper
igm
syndrom
cgd
hemophagocyt
lymphohistiocytosi
disclosur
rosa
maria
nideshda
salazarrosal
olayavarga
alberto
gerardo
del
maria
de
lo
wish
confirm
known
conflict
interest
associ
abstact
financi
support
provid
mexican
associ
help
children
wiht
cancer
patient
longterm
outcom
follow
hematopoiet
stem
cell
transplant
wiskottaldrich
syndrom
singl
institut
mamoru
honda
yukayo
terashita
minako
sugiyama
yuko
cho
akihiro
iguchi
background
wiskottaldrich
syndrom
xlink
disord
hematopoiet
cell
character
thrombocytopenia
small
platelet
eczema
immunodefici
hematopoiet
stem
cell
transplant
hsct
cur
treatment
recommend
perform
soon
diagnos
myeloabl
condit
hsct
recommend
high
risk
develop
autoimmun
diseas
patient
mix
chimera
hsct
howev
report
late
complic
pubert
develop
erupt
teeth
patient
receiv
hsct
thu
evalu
late
complic
patient
receiv
hsct
hokkaido
univers
hospit
method
review
medic
record
male
patient
receiv
hsct
result
mean
age
hsct
rang
year
median
followup
time
hsct
rang
year
condit
regimen
patient
compris
busulfan
mgkg
day
cyclophosphamid
mgkg
day
mgkg
day
addit
antithymocyt
globulin
mgkgday
day
administ
patient
engraft
normal
platelet
count
complet
chimera
confirm
patient
patient
show
complic
sever
chronic
graftversushost
diseas
autoimmun
diseas
short
statur
sd
second
malign
howev
high
ige
level
observ
patient
pubert
develop
confirm
patient
lack
complet
erupt
perman
teeth
observ
patient
receiv
hsct
age
year
conclus
although
smallcohort
studi
singl
institut
complet
chimera
achiev
patient
receiv
hsct
busulfanbas
myeloabl
condit
howev
late
complic
male
infertil
incomplet
erupt
perman
teeth
remain
major
problem
disclosur
noth
declar
method
perform
unrel
umbil
cord
blood
transplant
ucbt
consecut
children
ladi
median
age
children
month
rang
month
median
bodi
weight
kg
rang
kg
patient
receiv
myeloabl
condit
regimen
consist
busulfan
fludarabin
cytarabin
prophylaxi
graftversushost
diseas
gvhd
tacrolimu
patient
receiv
hla
allelesmismatch
cord
unit
hla
fulli
match
match
match
median
nucleat
cell
cord
blood
kg
rang
kg
median
cell
kg
rang
kg
result
patient
engraft
median
time
neutrophil
engraft
day
rang
median
time
platelet
engraft
day
rang
median
followup
time
month
rang
month
patient
aliv
continu
complet
donor
engraft
achiev
complet
clinic
remiss
patient
develop
grade
iiiii
acut
graftversushost
diseas
gvhd
patient
develop
chronic
gvhd
skin
conclus
first
success
unrel
ubct
ladi
children
china
data
show
ucbt
provid
excel
outcom
patient
ladi
disclosur
noth
declar
excel
outcom
use
nktm
enrich
hematopoiet
stem
cell
transplant
patient
inborn
error
immun
result
major
patient
cohort
signific
infect
comorbid
time
hsct
patient
later
cohort
enter
hsct
earlier
patient
later
cohort
sicker
hsct
final
engraft
occur
except
patient
receiv
hla
mismatch
cord
blood
hsct
graft
failur
occur
patient
earlier
later
cohort
patient
receiv
unmanipul
hsct
hla
mismatch
unrel
donor
cb
bm
second
hsct
donor
differ
donor
patient
grade
ii
iv
acut
gvhd
extens
gvhd
occur
one
patient
cbt
die
infect
nonengraft
patient
later
cohort
compar
patient
earlier
cohort
aliv
engraft
cure
perform
statu
aliv
patient
patient
later
cohort
hla
mismatch
relat
hla
match
relat
donor
receiv
nktm
enrich
hsct
hla
mismatch
nktm
enrich
hsct
patient
receiv
high
nk
cell
dose
median
rang
rang
rang
kg
respect
invas
infect
occur
patient
immun
reconstitut
b
nk
compart
complet
year
hsct
month
year
hsct
background
viral
infect
contribut
signific
morbid
mortal
allogen
hematopoiet
cell
transplant
allohsct
increas
human
financi
cost
antivir
agent
often
ineffect
associ
toxic
method
view
tcell
antivir
immunotherapi
greec
evalu
actual
cost
convent
pharmacotherapi
cmv
ebv
bkv
reactiv
allohsct
calcul
cost
antivir
agent
ii
treatment
exclud
transfus
antivir
drug
primari
toxic
eg
graft
failur
cytopenia
renal
hepat
dysfunct
secondari
toxic
eg
leukopeniaassoci
bacteri
infect
iii
treatment
exclud
transfus
ie
bk
cystiti
infectionrel
complic
iv
transfus
due
treatmentrel
toxic
ie
cytopenia
infectionrel
complic
ie
bk
cystiti
v
inpati
outpati
daili
care
notwithstand
blood
product
common
natur
good
provid
free
countri
cost
relat
blood
platelet
collect
process
storag
laboratori
test
infus
includ
model
result
treatment
cost
cmv
ebv
bkv
reactivationsinfect
first
six
month
post
allohsct
evalu
patient
reactiv
virus
transplant
match
relat
match
unrel
mismatch
unrel
haploident
mismatch
relat
donor
detect
cmv
ebv
bkv
infectionsreactiv
patient
respect
mean
infect
per
patient
three
virus
note
patient
experienc
reactiv
one
viru
requir
repeat
treatment
antivir
agent
andor
rituximab
cost
antivir
agent
cmv
ebv
bkv
reactivationsinfect
respect
respect
treatment
cost
toxic
relat
antivir
drug
infectionrel
complic
exclud
transfus
includ
transfus
particular
cost
transfus
bkv
hemorrhag
cystiti
reach
repeat
andor
prolong
rang
hospit
need
total
day
inpati
hospit
shortterm
outpati
treatment
respect
hospit
increas
cost
inpati
outpati
posttranspl
care
respect
respect
onth
basi
rather
underestim
true
cost
fix
unifi
hospit
fee
conclus
overal
sixmonth
studi
period
treatment
cmv
ebv
bkv
infect
substanti
increas
cost
posttranspl
care
actual
cost
undoubtedli
higher
hospit
fee
transplant
recipi
larg
underestim
greec
consid
hematopoiet
also
solid
organ
transplant
recipi
financi
burden
antivir
treatment
nation
economi
enorm
given
antivir
pharmacotherapi
often
associ
suboptim
efficaci
toxic
develop
drug
resist
reactiv
recurr
repeat
hospit
expect
onetim
treatment
multivirusspecif
cell
abl
expand
vivo
provid
longlast
protect
without
signific
toxic
serv
power
costeffect
treatment
convent
pharmacotherapi
disclosur
noth
declar
method
singlecentr
retrospect
analysi
consecut
patient
underw
tcd
allohsct
myeloid
malign
januari
ebvdna
monitor
frequent
whole
blood
sampl
standardis
quantit
realtim
pcr
serum
protein
electrophoresi
routin
test
immunoglobulin
subclass
identifi
immunofix
electrophoresi
histolog
confirm
ptld
base
standard
diagnost
criteria
proven
without
biopsi
class
probabl
base
clinic
radiolog
criteria
defin
guidelin
result
major
patient
aml
md
median
age
year
rang
median
follow
survivor
month
rang
major
patient
develop
ebvr
median
time
day
inter
quartil
rang
iqr
day
higher
cumul
incid
atg
versu
alemtuzumab
p
show
schemat
represent
ebv
ptld
event
cumul
incid
month
significantli
higher
peak
ebv
dna
viral
load
evl
note
patient
ptld
p
develop
posthsct
mg
observ
roc
curv
identifi
peak
blood
evl
copiesml
significantli
correl
risk
develop
ptld
p
base
estim
subgroup
patient
ebvr
peak
evl
copi
ml
copiesml
categoris
group
along
patient
withwithout
mg
accordingli
group
patient
ebvr
significantli
better
os
os
vs
ebvr
logrank
p
surviv
benefit
mainli
driven
subgroup
patient
lower
evl
p
ptld
patient
trend
toward
inferior
os
vs
patient
mg
significantli
better
os
irrespect
degre
evl
group
p
report
sweet
spot
low
evl
presenc
mg
patient
clear
surviv
advantag
compar
ebvr
andor
mprotein
os
vs
p
overal
cumul
incid
relaps
cir
nonrelapsemort
nrm
year
multivari
analysi
mva
reveal
absenc
mprotein
high
evl
copiesml
ebvr
absenc
gvhd
signific
factor
high
cir
similarli
high
evl
ebvr
absenc
mprotein
itu
admiss
signific
predictor
high
nrm
conclus
studi
add
understand
role
ebv
viraemia
associ
mg
tcdhsct
highlight
signific
impact
risk
ptld
os
nrm
cir
low
ebv
burden
develop
mg
protect
significantli
better
surviv
outcom
recommend
preemptiv
approach
use
rituximab
ebvr
ptld
best
employ
higher
ebv
burden
eg
copiesml
dna
high
risk
patient
prospect
evalu
futur
studi
clinic
trial
registri
na
disclosur
noth
declar
impact
earli
candidemia
longterm
outcom
allogen
hematopoiet
stem
cell
transplant
non
leukem
patient
outcom
analysi
behalf
idwp
background
assess
incid
risk
factor
candida
infect
first
day
postallogen
hematopoiet
stem
cell
transplant
hsct
impact
longterm
surviv
method
outcom
analysi
patient
male
median
age
year
rang
diagnosi
hemoglobinopathi
bone
marrow
failur
lymphoma
myelodysplasticmyeloprolif
disesas
patient
underw
hsct
candidemia
day
without
candidemia
incid
candidemia
estim
use
cumul
incid
method
univari
multivari
risk
factor
analysi
candidemia
perform
causespecif
cox
regress
model
occurr
candidemia
analyz
timedepend
covari
overal
surviv
nonrelaps
mortal
day
assess
landmark
set
analysi
restrict
patient
surviv
day
post
transplant
imag
figur
result
incid
candidemia
day
ci
occur
median
day
posthsct
rang
consid
candidemia
within
hsct
time
depend
covari
higher
nonrelapsemort
nrm
hr
p
lower
overallsurviv
os
hr
ci
p
obtain
cox
model
patient
candidemia
factor
significantli
associ
candidemia
occurr
multivari
analysi
gender
femal
increas
age
hsct
bone
marrow
failur
lymphoma
myelodysplasticmyeloprolif
diagnosi
bone
marrow
cord
blood
stem
cell
sourc
tcell
deplet
less
recent
year
hsct
among
patient
aliv
day
nrm
os
without
candidemia
vs
p
vs
p
respect
median
followup
year
ci
figur
multivari
analysi
occurr
candidemia
episod
within
day
independ
risk
factor
higher
nrm
hr
lower
os
hr
conclus
despit
gener
improv
prophylaxi
treatment
occurr
earli
posthsct
candidemia
neg
impact
transplant
outcom
show
previous
leukem
patient
abstract
alreadi
publish
carbapenemresist
enterobacteriacea
colonizationimport
risk
cre
bacteremia
mortal
stem
cell
transplant
hsct
acut
leukemia
patient
marcia
garnica
marco
f
bellizz
priscila
g
de
jesu
rafaela
r
c
gome
filip
akamin
alan
j
luzinet
co
rangel
andreia
assi
marcia
rejan
valentim
angelo
maiolino
background
spread
infect
due
carbapenemresist
enterobacteriacea
cre
worldwid
phenomenon
associ
high
mortal
clinic
complic
gut
transloc
import
portal
entri
bacteria
neutropenia
cre
gut
colon
possibl
risk
factor
bacteremia
neutropenia
goal
present
studi
describ
frequenc
cre
colon
analyz
relationship
develop
cre
bacteremia
mortal
two
differ
scenario
stem
cell
transplant
patient
hsct
leukemia
patient
method
prospect
cohort
hsct
leukemia
patient
hsct
patient
analyz
condit
discharg
preengraph
phase
leukemia
patient
first
induct
chemotherapi
last
intensif
hsct
perform
leukemia
patient
patient
censor
leukemia
cohort
includ
hsct
cohort
patient
rectal
swab
perform
weekli
hospit
identif
cre
colon
patient
least
one
posit
swab
cre
colon
group
compar
patient
document
colon
control
outcom
analyz
bacteremia
due
cre
overal
mortal
result
hsct
perform
studi
autolog
allogen
multipl
myeloma
nonhodgkin
lymphoma
frequent
baselin
diseas
n
respect
cre
colon
document
frequent
among
allogen
hsct
leukemia
patient
p
cre
colon
patient
longer
hospit
vs
day
p
higher
frequenc
cre
bacteremia
vs
mortal
vs
p
compar
noncolon
hsct
neg
posit
predict
valu
cre
bacteremia
respect
thirtyon
patient
analyz
leukemia
cohort
account
hospit
median
hospit
per
patient
rang
median
age
year
aml
vs
cre
colon
document
eight
median
time
leukemia
diagnosi
colon
day
day
cre
bacteremia
document
colon
patient
vs
zero
eight
colon
patient
submit
cycl
chemotherapi
colon
one
cre
bacteremia
relaps
conclus
routin
surveil
cre
colon
show
colon
frequenc
hsct
leukemia
patient
respect
effect
stratifi
cre
bacteremia
risk
predict
neg
valu
colon
associ
cre
bacteremia
overal
mortal
effort
minim
risk
colon
mortal
necessari
inform
surveil
tool
improv
adequaci
empir
febril
neutropenia
therapi
hsct
leukemia
patient
disclosur
noth
declar
background
incid
hepat
b
viru
infect
high
asian
popul
attent
risk
hepat
b
viru
hbv
reactiv
hepat
b
core
antibodi
posit
patient
chemotherapi
monoclon
antibodi
hsct
intens
immunosuppress
drug
therapi
isdt
hepat
b
core
antibodi
associ
signific
risk
hbv
reactiv
patient
undergo
hsct
howev
remain
uncertain
effect
antihbsag
antibodi
hepat
b
viru
reactiv
among
hepat
b
core
antibodi
posit
patient
undergo
hsct
aim
investig
role
antihb
necess
anti
viru
hepat
b
surfac
antigen
hbsag
neg
hepat
b
core
antibodi
posit
patient
hsct
method
enrol
hematolog
malign
patient
receiv
hsct
center
classifi
hbsag
neg
undetect
hbv
dna
patient
group
antihbc
antihb
antihbc
antihb
antihbc
antihb
antihbc
antihb
result
hbv
reactiv
identifi
patient
hsct
signific
differ
hbv
reactiv
rate
antihbc
antihb
vs
antihbc
antihb
antihbc
antihb
vs
antihbc
antihb
antihbc
antihb
vs
antihbc
antihb
among
antihbc
antihb
antihbc
antihb
antihbc
antihb
wherea
differ
accord
donor
viral
profil
median
time
hbv
reactiv
hbsag
neg
patient
accept
hsct
day
hsct
patient
hbv
reactiv
control
nucleo
ide
analogu
drug
achiev
revers
seroconvers
detect
persist
antihbsag
antibodi
bodi
conclus
antihbsag
antibodi
neg
antihbc
posit
patient
highest
risk
hbv
reactiv
hsct
resolv
hbv
patient
antihbsag
antibodi
play
protect
role
resolv
hbv
patient
receiv
hsct
recommend
prophylact
anti
hepat
b
viru
hbsag
neg
antihbsag
antibodi
posit
patient
follow
hematopoiet
stem
cell
transplant
disclosur
noth
declar
method
allohsct
perform
acquir
bone
marrow
failur
hemoglobinopathi
stem
cell
sourc
includ
retrospect
registri
megafil
idwp
ebmt
studi
result
demograph
median
age
recipi
year
rang
children
recipi
donor
ebvseroposit
hsct
match
famili
donor
mismatch
famili
donor
unrel
donor
tcell
deplet
perform
vivo
ex
vivo
patient
condit
regimen
myeloabl
ric
median
followup
year
ci
transplant
outcom
ebvseroposit
recipi
comparison
ebvseroneg
recipi
lower
os
vs
higher
nrm
vs
signific
differ
found
ri
rf
acut
chronic
gvhd
respect
ebv
pretranspl
serostatu
donor
andor
recipi
multivari
analysi
ebv
serostatu
risk
factor
reach
signific
trend
toward
higher
risk
develop
cgvhd
ci
better
surviv
ci
allohsct
ebvseroposit
donor
allohsct
ebvseroposit
recipi
trend
toward
lower
risk
develop
cgvhd
ci
subgroup
rd
r
rd
rd
ebv
serolog
analyz
ebv
serostatu
signific
impact
os
rf
ri
trm
develop
acut
chronic
gvhd
conclus
allohsct
ebvseroposit
vs
ebvseroneg
donor
higher
risk
chronic
gvhd
patient
nonmalign
hematolog
disord
undergo
allohsct
howev
differ
nonsignific
multivari
analysi
disclosur
noth
declar
result
twentyeight
pt
male
femal
test
posit
group
subtyp
b
pt
male
femal
neg
group
vaccin
rate
group
significantli
lower
compar
group
median
time
transplant
vs
day
tcell
count
vs
bcell
count
vs
igglevel
vs
g
l
proport
immunosuppress
pt
vs
male
femal
ratio
significantli
differ
group
within
group
influenza
subtyp
similarli
distribut
vaccin
vaccin
pt
vs
b
vs
vs
pt
subtyp
b
infect
higher
level
vs
bcell
vs
longer
follow
sct
vs
day
compar
subtyp
infect
differ
signific
conclus
influenza
could
proven
one
third
test
pt
domin
b
subtyp
occurr
correspond
flu
epidem
dissemin
german
popul
import
protect
factor
outpati
sct
recipi
influenza
vaccin
disclosur
noth
declar
background
cmv
infect
one
frequent
complic
haplo
risk
factor
well
known
best
strategi
prophylact
preemptiv
treatment
mitig
complic
still
well
defin
primari
endpoint
studi
describ
incid
risk
factor
develop
cmv
infect
diseas
haplo
secondari
object
analyz
efficacytox
treatment
cmv
relat
mortal
method
analyz
patient
underw
haplo
center
may
may
receiv
ptci
tacrolimu
mycophenol
graft
versu
host
diseas
prophylaxi
preemptiv
therapi
base
viral
load
appli
treatment
start
uiml
cmv
detect
one
determin
uiml
two
consecut
determin
cmv
analys
made
plasma
use
coba
pcr
posit
viral
load
cutoff
point
uiml
cmv
viremia
determin
weekli
everi
two
week
immun
reconstitut
result
cmv
infect
diseas
incid
episod
episod
respect
cmv
diseas
digest
pulmonar
neurolog
dissemin
median
time
first
cmv
infect
day
thirtysix
patient
least
one
episod
cmv
infect
one
episod
two
episod
episod
respect
pretransplant
cmv
statu
significantli
associ
cmv
infect
p
risk
factor
shown
imag
median
viral
load
first
cmv
infect
diseas
uiml
uiml
respect
median
count
lymphocyt
cmv
infect
diseas
respect
preemptiv
therapi
first
episod
cmv
infect
valganciclovir
ganciclovir
foscarnet
reach
complet
viral
load
clearanc
median
time
respons
day
median
treatment
durat
day
grade
iiiiv
toxic
mainli
hematolog
observ
respect
three
patient
mutat
one
clinic
microbiolog
resist
mention
drug
three
patient
graft
failur
secondari
cmv
infect
five
patient
die
consequ
cmv
infect
secondari
cmv
diseas
pulmonar
dissemin
due
graft
failur
infecti
complic
median
follow
month
overal
surviv
month
patient
cmv
infect
compar
infect
conclus
high
incid
cmv
infect
haplo
ptci
shown
seri
contribut
mortal
patient
cmv
statu
dr
dr
significantli
associ
higher
risk
infect
identif
high
risk
patient
new
prophylact
treatment
strategi
may
improv
result
disclosur
noth
declar
method
consecut
patient
admit
sct
unit
review
first
admiss
analys
screen
consist
rectal
perin
swap
admiss
weekli
discharg
case
detect
mdro
patient
isol
infect
control
strategi
appli
result
patient
analys
median
age
year
male
median
durat
hospit
day
swab
perform
median
swapspati
patient
characterist
shown
tabl
patient
spike
fever
median
day
admiss
previou
document
mdro
colon
median
neutrophil
engraft
day
ci
patient
patient
posit
screen
patient
baselin
patient
detect
first
time
beyond
baselin
screen
cumul
incid
colon
day
ci
day
ci
day
figur
mdro
identifi
extendedspectrum
betalactamas
produc
e
coli
esblec
multidrugresist
pseudomona
aeruginosa
mrp
vancomycin
resist
enterococci
vre
patient
carbapenemaseproduc
cp
citrobact
freundii
colon
patient
develop
mdro
infect
patient
mrp
site
infect
urinari
tract
infect
uti
urethr
genit
ulcer
two
patient
treat
ceftolozan
tazobactam
meropenemamikacin
patient
esblec
uti
treat
meropenem
patient
cpcitrobact
freundii
uti
treat
ceftazidimeavibactam
patient
antibiot
treatment
febril
episod
guid
posit
screen
mdro
relat
icu
admiss
mortal
observ
patient
background
hepat
e
viru
hev
caus
chronic
infect
liver
cirrhosi
immunocompromis
individu
limit
data
hev
infect
patient
undergo
allogen
hematopoiet
stem
cell
transplant
hsct
aim
studi
investig
frequenc
clinic
import
hev
swedish
cohort
hsct
recipi
method
analyz
serum
sampl
hsct
patient
adult
children
collect
month
hsct
hev
igg
igm
detect
elisa
hev
rna
revers
transcriptas
pcr
quantif
hev
rna
perform
digit
pcr
patient
posit
hevrna
andor
serolog
month
also
sampl
collect
time
hsct
patient
donor
analyz
hev
rna
posit
patient
addit
sampl
analyz
determin
durat
viremia
three
hev
rna
neg
control
select
case
hev
infect
match
age
diagnosi
condit
regimen
donor
type
result
hev
rna
detect
patient
three
patient
hev
rna
posit
period
month
two
patient
infect
alreadi
time
hsct
five
patient
hevrna
posit
low
level
month
patient
detect
hev
igg
andor
igm
whereof
eight
patient
hev
rna
neg
patient
hev
infect
hev
rna
posit
alanin
aminotransferas
alt
upper
limit
normal
uln
patient
uln
patient
alt
normal
month
hsct
bilirubin
elev
uln
patient
uln
patient
month
hsct
two
patient
die
ongo
sign
hepat
hev
rna
detect
blood
one
develop
acut
liver
failur
time
interpret
drug
toxic
die
multiorgan
failur
patient
die
unrel
caus
remain
six
patient
clear
infect
median
month
hsct
activ
gvhd
present
month
hsct
patient
hev
infect
involv
liver
patient
corticosteroid
treatment
ongo
patient
mean
dose
preced
day
mgkg
patient
mg
kg
patient
mgkg
patient
hev
infect
correl
elev
alt
uln
uln
month
month
hsct
compar
hev
rna
neg
control
conclus
hev
infect
detect
patient
test
month
hsct
correl
abnorm
alt
spontan
clearanc
common
one
patient
die
acut
liver
failur
hev
may
contribut
hev
infect
differenti
diagnosi
patient
elev
alt
month
hsct
disclosur
noth
declar
monitor
tcell
respons
viralcod
antigen
pediatr
patient
receiv
haplohsct
follow
cell
administr
background
tcelldeplet
haplohsct
effect
option
children
hematolog
disord
need
allograft
howev
recoveri
adapt
immun
impair
patient
thu
order
acceler
immun
reconstitut
develop
novel
approach
base
posttranspl
infus
titrat
number
donor
cell
transduc
suicid
gene
cell
sponsor
bellicum
previous
report
immun
recoveri
children
transplant
institut
show
cell
infus
tcelldeplet
haplohsct
expand
invivo
persist
time
contribut
fasten
adapt
immun
recoveri
merli
report
result
lymphoprolifer
assay
viralencod
antigen
assess
tcell
function
patient
transplant
approach
method
evalu
children
male
femal
median
age
transplant
year
rang
patient
either
malign
children
nonmalign
disord
patient
given
posttranspl
graftversushost
diseas
prophylaxi
nine
children
enrol
phase
portion
trial
consist
cohort
receiv
escal
dose
cell
remain
patient
phase
ii
portion
receiv
recommend
dose
cellskg
identifi
phase
cell
infus
median
day
posthsct
rang
antigendriven
activ
peripher
mononuclear
cell
evalu
lymphoprolifer
assay
hthymidin
puls
harvest
stimuli
includ
pha
cmv
ebv
adv
whole
viral
lysat
result
given
stimul
index
si
cpm
stimul
samplecpm
unstimul
control
threshold
posit
respons
arbitrarili
set
si
viralencod
antigen
si
mitogen
stimul
pha
fraction
respond
indic
figur
result
patient
analyz
posthsct
pha
respond
increas
cmv
b
ebv
c
adv
respond
year
haplohsct
respons
ebv
adv
antigen
slightli
delay
improv
time
respons
pha
cmv
e
f
analyz
cmvreactiv
cmvnon
reactiv
group
cmvyescmvno
signific
differ
pha
respons
observ
moreov
increas
cmv
respons
observ
cmvreactiv
approxim
respond
oppos
cmvnon
reactiv
compris
respond
neither
primari
diseas
age
tbi
condit
regimen
influenc
prolif
capac
two
subgroup
shown
conclus
show
rapid
recoveri
time
tcell
function
tcelldeplet
haplohsct
follow
cell
administr
patient
group
accord
cmv
reactiv
previous
demonstr
strong
driver
immun
reconstitut
signific
differ
number
respond
among
patient
experienc
viral
reactiv
observ
use
cmv
lysat
immunodomin
protein
shown
suggest
viral
antigen
account
increas
tcell
respons
result
tcell
function
bpx
administr
complement
phenotyp
data
alreadi
report
clinic
trial
registri
disclosur
noth
declar
background
cytomegaloviru
cmv
associ
signific
morbid
mortal
allogen
hematopoiet
cell
transplant
allohct
patient
pt
cumul
incid
cmv
infect
highrisk
patient
haploident
hct
report
high
respect
letermovir
ltv
approv
prophylaxi
ppx
cmvseroposit
recipi
r
allohct
sinc
ltv
ppx
implement
center
primari
secondari
ppx
report
realworld
experi
method
adult
cmv
r
allohct
pt
initi
ltv
primari
andor
secondari
prophylaxi
identifi
cord
blood
transplant
exclud
primari
outcom
incid
clinic
signific
cmv
infect
cmv
viremia
requir
preemptiv
treatment
cmv
diseas
pt
follow
result
pt
initi
ltv
pt
high
risk
cmv
reactiv
diseas
primarili
ex
vivo
tcell
deplet
hct
n
haploident
treplet
hct
n
common
indic
hct
acut
myeloid
leukemia
n
major
patient
receiv
myeloabl
condit
n
pt
receiv
ltv
primari
ppx
hct
median
day
ltv
initi
rang
ltv
initi
pt
undetect
cmv
dna
cmv
iuml
clinic
signific
cmv
infect
requir
preemptiv
treatment
occur
pt
one
patient
treat
valganciclovir
vgv
persist
cmv
iuml
receiv
ltv
secondari
ppx
patient
develop
persist
detect
cmv
iu
ml
breakthrough
cmv
viremia
mutat
site
success
treat
vgv
median
durat
primari
ltv
ppx
day
primari
ppx
continu
beyond
week
post
hct
pt
median
addit
followup
patient
discontinu
ltv
day
without
clinic
signific
cmv
infect
date
addit
pt
overal
receiv
ltv
secondari
ppx
cmv
preemptiv
therapi
median
durat
secondari
ltv
ppx
day
reactiv
ltv
discontinu
due
toxic
intoler
patient
cmv
outcom
summar
figur
allcaus
mortal
pt
observ
period
conclus
primari
ltv
ppx
significantli
reduc
cmv
reactiv
highrisk
patient
may
benefit
extend
prophylaxi
patient
receiv
preemptiv
therapi
cmv
use
secondari
ppx
show
recurr
cmv
reactiv
ltv
well
toler
addit
studi
need
determin
optim
ppx
durat
clarifi
role
secondari
cmv
ppx
highrisk
allohct
futur
standard
care
like
includ
extend
primari
ppx
secondari
ppx
result
decreas
morbid
mortal
associ
cmv
disclosur
andrew
lin
noth
declar
molli
maloy
noth
declar
valkal
bhatt
noth
declar
lauren
derespiri
noth
declar
meagan
griffin
noth
declar
carmen
lau
noth
declar
anthoni
j
proli
noth
declar
juliet
barker
angiocrin
bioscienc
letermovir
primari
prophylaxi
pp
shown
reduc
clinic
signific
cmv
infect
favor
safeti
profil
letermovir
pp
improv
outcom
seroposit
patient
howev
patient
benefit
pp
experienc
cmv
episod
infect
diseas
hct
may
candid
secondari
prophylaxi
sp
inde
half
recurr
episod
preemptiv
treatment
pet
letermovir
avail
sinc
novemb
part
french
earli
access
program
pp
sp
report
outcom
patient
benefit
letermovir
sp
context
program
method
letermovir
grant
restrict
manner
french
drug
agenc
ansm
casebycas
basi
prophylaxi
cmv
episod
cmvseroposit
adult
allogen
hct
recipi
sp
patient
neg
baselin
cmv
pcr
alreadi
experienc
cmv
episod
context
potenti
harm
pet
accord
physician
plan
letermovir
daili
dose
mg
case
concomit
cyclosporin
mg
otherwis
patient
routin
screen
blood
plasma
cmv
pcr
result
novemb
patient
receiv
letermovir
earli
access
program
pp
sp
among
sp
patient
previou
cmv
diseas
gut
cn
mean
age
year
mf
ratio
sp
cohort
includ
one
cord
blood
haploident
hct
main
diagnos
acut
leukemia
myelodysplast
syndrom
condit
regimen
myeloabl
includ
atg
base
avail
data
miss
data
md
previou
gvhd
present
patient
activ
letermovir
initi
thirti
two
patient
plan
receiv
immunosuppress
donor
cmv
serolog
neg
md
baselin
cmv
pcr
detect
patient
letermovir
initi
median
day
iqr
transplant
mean
durat
day
one
patient
develop
cmv
breakthrough
median
followup
letermovir
initi
day
among
patient
expos
letermovir
prophylaxi
two
patient
perman
discontinu
letermovirrel
advers
event
acut
gvhd
nephropathi
one
loss
appetit
pruritu
diarrhoea
weight
loss
two
death
occur
causal
relationship
letermovir
data
consist
known
safeti
profil
letermovir
conclus
letermovir
soonli
avail
european
countri
cmv
prophylaxi
hct
recipi
pend
routin
use
letermovir
use
sp
well
toler
effect
patient
develop
breakthrough
infect
highrisk
popul
cmv
recurr
letermovir
may
provid
safe
bridg
pet
specif
immun
reconstitut
pend
taper
discontinu
immunosuppress
whether
sp
may
improv
surviv
deserv
studi
disclosur
thierri
allavoin
former
employe
msd
franc
nathali
benard
amir
guidoum
employe
msd
franc
marion
masur
employe
icta
pm
sophi
alain
catherin
cordonni
particip
advisori
board
member
speaker
bureau
msd
ibrahim
yacoubagha
receiv
honoraria
msd
author
noth
declar
realworld
data
letermovir
prophylaxi
cytomegaloviru
reactiv
allogen
hematopoiet
cell
transplant
singl
center
experi
patrick
derig
marialuisa
schubert
paul
schnitzler
carsten
peter
dreger
michael
schmitt
heidelberg
univers
hospit
heidelberg
germani
background
reactiv
cytomegaloviru
cmv
still
contribut
substanti
morbid
mortal
allogen
hematopoiet
cell
transplant
allohct
recent
letermovir
becam
avail
first
drug
approv
europ
prophylaxi
cmv
reactiv
seroposit
patient
undergon
allohct
letermovir
neither
myelonor
nephrotox
significantli
reduc
incid
cmv
reactiv
pivot
phase
iii
trial
nejm
therefor
adopt
letermovir
prophylaxi
accord
label
standard
polici
institut
seroposit
recipi
letermovir
initi
engraft
continu
day
cmv
reactiv
aim
present
studi
investig
favor
trial
result
could
reproduc
realworld
condit
method
studi
cohort
consist
first
seroposit
patient
receiv
letermovir
prophylaxi
institut
march
august
compar
control
cohort
transplant
august
march
advent
letermovir
studi
control
cohort
match
cmv
donorrecipi
serostatu
underli
diseas
donor
type
sourc
stem
cell
applic
atg
cmv
viremia
monitor
quantit
pcr
twice
week
inpati
period
weekli
thereaft
patient
reactiv
cmv
prior
engraft
consid
event
group
result
major
side
effect
letermovir
intak
observ
altogeth
reactiv
event
cumul
rate
cmv
reactiv
day
ci
letermovir
cohort
thu
significantli
lower
control
group
event
ci
hr
median
time
reactiv
day
control
group
reach
letermovir
group
cumul
number
day
valganciclovir
letermovir
patient
vs
control
patient
hospit
foscavir
administr
letermovir
group
compar
hospit
control
group
death
letermovir
group
one
pd
one
nrm
death
control
group
pd
conclus
observ
studi
confirm
safeti
efficaci
letermovir
prophylaxi
cmv
reactiv
seroposit
patient
allohct
realworld
set
result
good
concord
phase
iii
trial
although
letermovir
appear
reduc
need
therapeut
valganciclovir
foscavir
tremend
larger
sampl
longer
followup
need
assess
impact
letermovir
prophylaxi
nonrelaps
overal
mortal
well
resourc
consumpt
background
cmv
viremia
occur
cmv
r
hct
recipi
pet
use
reduc
risk
cmv
endorgan
diseas
eod
associ
mortal
howev
pet
use
may
lead
substanti
antivir
use
healthcar
resourc
util
limit
realworld
data
avail
outcom
pet
therefor
aim
examin
cmv
outcom
eod
resist
cmvrelat
mortal
day
healthcar
resourc
util
pet
nopet
group
among
cmv
r
recipi
undergo
first
hct
method
conduct
retrospect
cohort
studi
adult
cmv
r
recipi
first
peripher
blood
marrow
allograft
mskcc
identifi
march
decemb
data
extract
electron
medic
record
hct
databas
cmv
recipi
monitor
weekli
quantit
pcr
assay
start
post
hct
use
antivir
therapi
cmv
viremia
defin
pet
high
cmv
risk
hr
compris
tcell
deplet
tcd
hct
regardless
donor
hla
match
convent
hct
mismatch
haploident
donor
low
risk
lr
includ
convent
hct
match
relat
donor
cmv
eod
score
standard
criteria
cmv
resist
mutat
confirm
sequenc
viracoreurofin
length
stay
lo
hct
admiss
readmiss
identifi
stratifi
analys
perform
examin
outcom
pet
use
cmv
risk
background
phase
iii
random
doubleblind
placebocontrol
studi
cmvseroposit
posthsct
recipi
letermovir
prophylaxi
significantli
reduc
incid
clinic
signific
cmv
infect
week
object
research
assess
impact
cmv
prophylaxi
rate
rehospit
adult
cmv
seroposit
allogen
hsct
recipi
letermovir
phase
clinic
trial
method
rehospit
record
exploratori
endpoint
clinic
trial
end
treatment
time
primari
endpoint
extend
followup
period
cmvrelat
rehospit
assess
trial
prespecifi
analys
describ
observ
rate
rehospit
letermovir
placebo
group
specifi
time
finegray
cumul
incid
function
cif
regress
model
use
explor
rate
allcaus
cmvrelat
rehospit
account
compet
risk
mortal
multipl
linear
regress
model
use
describ
cumul
length
stay
lo
allcaus
rehospit
occur
exclud
time
initi
transplant
stay
result
observ
rate
allcaus
rehospit
lower
letermovir
group
compar
placebo
end
treatment
conclus
letermovir
shown
significantli
reduc
rate
clinic
signific
cmv
infect
placebocontrol
random
clinic
trial
analys
suggest
also
reduct
rate
cumul
day
rehospit
trial
suffici
power
detect
differ
exploratori
endpoint
nonetheless
data
provid
valuabl
insight
econom
burden
cmv
real
world
data
find
futur
clinic
trial
need
better
understand
natur
associ
cmv
rehospit
clinic
method
consecut
patient
hematolog
disord
receiv
hsct
center
januari
august
includ
among
evalu
patient
receiv
levofloxacin
antibacteri
prophylaxi
group
receiv
fq
prophylaxi
group
b
baselin
characterist
similar
two
group
except
number
patient
advanc
diseas
group
group
b
p
median
durat
neutropenia
day
rang
group
day
rang
group
b
posit
rectal
swab
carbapenemresist
enterobacteriacea
cre
detect
patient
group
patient
group
b
result
overal
bsi
detect
patient
group
group
b
median
onset
bsi
day
post
transplant
rang
without
signific
differ
two
group
univari
analysi
fq
prophylaxi
ic
bone
marrow
stem
cell
sourc
ic
signific
factor
associ
risk
bsi
gramneg
bacteria
account
bsi
group
n
group
b
gramposit
bacteria
n
bsi
group
versu
n
group
b
without
statist
signific
differ
p
polymicrob
bsi
group
group
b
mdrgram
neg
bsi
detect
patient
group
patient
group
b
overal
cre
esbl
produc
enterobacteriacea
mdrpseudomona
death
attribut
bsi
occur
patient
patient
receiv
fq
prophylaxi
pre
transplant
kpc
colon
activ
diseas
transplant
neither
antibacteri
prophylaxi
p
bsi
p
signific
impact
overal
surviv
os
conclus
preliminari
data
studi
show
fq
prophylaxi
associ
reduc
incid
bsi
particular
gramneg
infect
impact
os
limit
studi
may
differ
group
size
retrospect
nautur
studi
whether
antibacteri
prophylaxi
avoid
preengraft
period
still
matter
debat
need
evalu
larger
prospect
studi
disclosur
noth
disclos
gillen
oarbeascoa
niev
dorado
laura
solan
rebeca
bailen
pascual
balsalobr
carolina
martinezlaperch
ismael
javier
anguita
jose
lui
diezmartin
mi
kwon
hospit
gener
universitario
gregorio
hematolog
madrid
spain
instituto
de
sanitaria
gregorio
madrid
spain
universidad
complutens
de
madrid
madrid
spain
background
incid
outcom
invas
fungal
infect
ifi
well
character
set
peripher
blood
nonmanipul
haploident
stem
cell
transplant
postranspl
cyclophosphamid
haplosct
aim
studi
analyz
incid
risk
factor
ifi
patient
underw
haplosct
institut
method
consecut
patient
underw
peripher
blood
haplosct
postranspl
cyclophosphamid
centr
review
ifi
classifi
accord
eortc
definit
proven
probabl
ifi
includ
result
shown
tabl
primari
antifung
prophylaxi
perform
micafungin
day
oral
intak
follow
posaconazol
day
patient
steroid
treatment
gvhd
receiv
prophylaxi
micafungin
posaconazol
patient
obtain
neutrophil
engraft
twentytwo
episod
ifi
observ
patient
proven
probabl
cumul
incid
ifi
day
commonli
isol
organ
aspergillu
spp
follow
candida
spp
c
kruseii
c
parapsilosi
fusarium
spp
isol
case
inonotu
spp
mucor
spp
trichosporon
ashii
observ
pulmonari
involv
frequent
clinic
present
follow
fungemia
candidemia
trichosporon
ashii
skinpulmonari
involv
among
patient
lung
involv
show
probabl
ifi
elev
serum
galactomannan
posit
galactomannan
bronchoalveolar
lavag
bal
patient
without
galactomannan
one
posit
bal
cultur
penicillum
spp
aspergillu
spp
median
time
ifi
diagnosi
day
thirteen
case
diagnos
preengraft
period
engraft
case
day
among
patient
late
ifi
median
time
develop
day
associ
gvhd
grade
iiiiv
acut
gvhd
moderatesever
chronic
gvhd
ifi
outcom
favor
ifi
treatment
liposom
amphotericin
b
case
voriconazol
combin
treatment
amphotericin
b
azol
ifi
relat
death
cumul
incid
ifi
relat
death
prior
transplant
p
particularli
allohsct
associ
ifi
develop
p
patient
previou
allohsct
present
ifi
mainli
mold
aspergillu
fusarium
inonotu
trichosporon
mucor
also
candidemia
episod
factor
significantli
associ
ifi
occurr
conclus
experi
cumul
incid
ifi
set
haplosct
posttranspl
cyclophosphamid
similar
observ
previou
studi
allosct
receiv
previou
sct
especi
allosct
signific
factor
relat
ifi
develop
high
risk
popul
close
monitor
could
benefit
prophylaxi
azol
disclosur
noth
declar
method
rsv
infect
diagnos
nasal
wash
nw
bronchoalveolar
fluid
bal
dfa
millipor
usa
pcr
seeplex
seegen
kor
urti
lrti
defin
accord
guidelin
death
caus
assess
within
day
rsv
infect
attribut
rsv
patient
persist
progress
rsv
infect
respiratori
failur
time
death
neutropenia
lymphocytopenia
defin
absolut
neutrophil
count
anc
absolut
lymphocyt
count
alc
respect
result
median
number
confirm
rsv
infect
per
year
rang
outbreak
rsv
detect
possibl
due
lack
complianc
contact
precaut
unit
median
patient
age
year
time
rsv
infect
day
twentythre
patient
pt
receiv
autolog
transplant
allogen
hsct
recipi
median
time
engraft
day
rang
day
rsv
diagnosi
pt
present
urti
lrti
surprisingli
around
auto
hsct
recipi
rsv
pneumonia
diagnosi
variabl
significantli
associ
lrti
diagnosi
mud
hsct
ye
anc
alc
recent
preengraft
hsct
noy
among
pt
urti
diagnosi
progress
lrti
fortyfour
pt
die
mortal
rate
significantli
higher
pt
lrti
comparison
pt
urti
versu
death
attribut
rsv
pt
die
conclus
autolog
hsct
recipi
also
risk
lrti
caus
rsv
risk
rsv
lrti
higher
mud
hsct
infect
acquir
preengraft
earli
hsct
low
neutrophil
lymphocyt
count
continu
educ
necessari
sustain
complianc
contact
precaut
hsct
unit
disclosur
background
measl
lifethreaten
infect
allogen
hct
due
decreas
coverag
vaccin
mani
countri
diseas
reappear
increas
risk
outbreak
worldwid
allogen
hct
recipi
shown
seroposit
measl
roughli
case
year
transplant
howev
data
obtain
hct
popul
mainli
condit
myeloabl
regimen
aim
assess
measl
immun
consid
vaccin
cohort
hct
survivor
includ
patient
condit
reduc
intens
ric
nonma
regimen
method
allogen
hct
adult
recipi
vaccin
measl
sinc
hct
routin
screen
measl
immun
measl
igg
titer
determin
chemiluminesc
immunoassay
liaison
measl
igg
kit
liaison
xl
analys
diasorin
itali
patient
consid
seroposit
igg
titer
uaml
risk
factor
seroposit
analyz
qualit
variabl
describ
number
compar
use
test
fisher
exact
test
appropri
quantit
variabl
describ
median
mean
rang
compar
use
kruskallw
test
or
estim
separ
factor
yield
pvalu
univari
analysi
use
logist
regress
model
result
eightysix
patient
transplant
year
mean
year
ago
includ
mean
age
year
rang
sex
ratio
mf
underli
diseas
acut
leukemia
myelodysplast
syndrom
lymphoprolif
diseas
myeloprolif
neoplasm
nonmalign
diseas
hct
perform
hlaident
donor
unrel
donor
cordblood
condit
regimen
ric
nonma
patient
patient
experienc
measl
receiv
measl
vaccin
sinc
transplant
fiftyseven
patient
seroposit
measl
measl
seroposit
associ
condit
regimen
patient
age
transplant
patient
age
time
assess
donor
age
transplant
lymphocyt
count
gammaglobulin
level
type
transplant
hlaid
vs
other
measl
vaccin
transplant
previou
measl
transplant
paramet
significantli
associ
seroposit
absenc
previou
gvhd
type
sever
absenc
previou
extens
chronic
gvhd
conclus
sixtyseven
percent
allogen
hct
seroposit
measl
median
year
hct
vaccin
risk
factor
strongli
associ
seroneg
extens
chronic
gvhd
patient
background
cytomegaloviru
cmv
reactiv
frequent
complic
hematopoiet
stem
cell
transplant
hsct
extracellular
vesicl
ev
emerg
promis
new
categori
biolog
biomark
differ
scenario
includ
inflamm
tissu
damag
cancer
viral
infect
recent
report
potenti
use
serum
ev
biomark
agvhd
lia
g
et
al
leukemia
investig
potenti
correl
cmv
reactiv
plasma
ev
posttranspl
cyclophosphamid
ptci
haploidenticalhsct
haplohsct
method
plasma
sampl
collect
mononuclear
cell
separ
given
timepoint
pretranspl
day
haplohsct
ev
extract
protaminebas
precipit
method
concentr
dimens
character
nanotrack
particl
analysi
nanosight
extract
ev
analyz
flowcytometri
guava
easycyt
flow
cytomet
panel
antibodi
result
thirtytwo
patient
hematolog
malign
underw
haplohsct
cmv
reactiv
observ
occur
median
rang
day
transplant
preliminari
analysi
patient
show
fluoresc
plateletderiv
growth
factor
fluoresc
antigen
fluoresc
vecadherin
associ
increas
risk
cmv
reactiv
wherea
platelet
endotheli
cell
adhes
molecul
concentr
level
associ
decreas
risk
cmv
reactiv
biomark
show
signal
chang
cmv
reactiv
increas
reduct
figur
conclus
observ
potenti
associ
ev
membran
protein
cmv
reactiv
protein
crucial
endothelium
immun
cell
interact
cmv
infect
differ
cell
type
includ
endotheli
cell
bentz
gl
pna
moreov
shown
function
entri
receptor
cmv
express
ghglgo
complex
wu
et
al
plo
pathog
plan
implement
analysi
character
ev
content
mirna
appli
investig
viral
reactiv
eg
epstein
barr
viru
human
herp
viru
imag
method
explor
valu
cmv
dna
extract
gi
tissu
diagnosi
cmv
gastroenter
retrospect
evalu
patient
age
median
year
receiv
allohct
sibl
match
unrel
haploident
donor
receiv
myeloabl
reduc
intens
condit
underw
endoscopi
gastrointestin
symptom
cmv
dna
tissu
sampl
parallel
blood
sampl
measur
qpcr
posit
cmv
dna
tissu
consid
cmv
gi
infectioncmv
gi
diseas
proven
identif
cmv
inclus
bodi
posit
immunehistochem
stain
use
anticmv
antibodi
result
overal
endoscop
test
perform
colonoscopi
median
day
post
transplant
symptom
includ
nausea
vomit
diarrhea
abdomin
pain
weight
loss
cmv
dna
posit
tissu
sampl
median
copiesml
rang
half
patient
concurr
cmv
viremia
plasma
viral
load
cmv
gi
infect
correl
type
transplant
acut
chronic
gvhd
gi
cmv
diseas
document
biopsi
patient
cmv
dna
tissu
plasma
viral
load
predictor
biopsi
posit
ci
thirtysix
cmv
dna
posit
patient
receiv
specif
treatment
least
day
symptom
resolv
patient
gi
viral
load
signific
factor
predict
cure
gi
gvhd
diagnos
patient
among
cmv
dna
posit
median
os
day
ci
patient
cmv
infect
similar
without
median
os
ci
day
pn
studi
separ
endoscopi
upper
lower
gi
tract
signific
relationship
cmv
gastriti
proven
biopsi
cmv
dna
level
gastric
tissu
howev
viral
load
colon
predictor
cmv
enter
ci
auroc
qpcr
ci
sensit
specif
cutoff
valu
copiesml
dna
conclus
pathognomon
find
biopsi
remain
gold
standard
diagnosi
especi
upper
gi
tract
howev
lower
gi
tract
involv
quantif
cmv
viral
load
tissu
may
valuabl
tool
support
diagnosi
posit
cmv
dna
gi
tissu
linear
cmv
viremia
may
guid
preemptiv
treatment
prevent
cmv
diseas
disclosur
noth
declar
background
clostridium
difficil
infect
cdi
caus
cd
overgrowth
antibioticdisturb
intestin
microbiota
antibiot
target
unselect
benefici
tregulatori
cell
format
strain
clostridial
may
increas
proinflammatori
process
gut
promot
augment
develop
graft
vs
host
diseas
gvhd
efficaci
cdi
treatment
impact
persist
inflamm
might
influenc
alloreact
reaction
method
retrospect
prospect
analyz
data
transplant
center
concern
cdi
occurr
treatment
efficaci
gvhd
develop
studi
includ
patient
hematolog
malign
underw
allogen
hematopoiet
cell
transplant
allohct
result
median
time
cdi
day
postallohct
detect
toxin
b
case
disturb
intestin
microbiom
confirm
rate
colon
multidrugresist
bacteria
mdrb
cdi
symptom
resolv
neg
toxin
first
line
treatment
patient
median
time
remiss
therapi
durat
day
respect
fifteen
therapeut
failur
observ
treatment
metronidazol
vancomycin
combin
therapi
eleven
patient
respond
second
line
treatment
thirtyseven
patient
die
due
infect
relaps
gvhdinfect
note
recurr
cdi
case
eight
patient
die
activ
cdi
observ
occurr
exacerb
gvhd
patient
follow
cdi
includ
case
gut
involv
gigvhd
treatment
metronidazol
failur
first
line
therapi
increas
develop
escal
gigvhd
p
p
respect
durat
cdi
exceed
day
also
impact
gigvhd
incid
p
conclus
patient
colon
mdrb
high
risk
cdi
high
mortal
due
infect
andor
gvhd
patient
cdi
due
lower
efficaci
harm
immunomodulatori
impact
metronidazol
first
line
treatment
cdi
posthct
emphasi
must
put
fast
cdi
resolut
interrupt
viciou
circl
intestin
inflammatori
process
disclosur
noth
declar
establish
optim
preemptiv
cytomegaloviru
therapi
threshold
post
allogen
hct
patient
popul
high
preval
seroposit
statu
background
preemptiv
therapi
pet
cytomegaloviru
cmv
reactiv
post
allogen
hematopoiet
stem
cell
transplant
hct
shown
decreas
incid
cmv
diseas
howev
optim
pet
threshold
unknown
signific
toxic
associ
anticmv
therapi
institut
initi
pet
cmv
dna
titer
copiesml
iuml
aim
examin
efficaci
approach
includ
incid
spontan
clearanc
popul
high
preval
cmv
seroposit
statu
method
due
irb
approv
patient
underw
allogen
hct
identifi
record
retrospect
extractedcmv
reactiv
defin
first
detect
viral
titer
post
hct
plasma
sampl
wherea
clearanc
viremia
first
date
two
neg
pcr
valu
obtain
least
week
apart
cmv
monitor
initi
post
hct
perform
least
weekli
first
day
everi
week
thereaft
high
sensit
assay
abbott
realtim
cmv
use
detect
threshold
copiesml
iuml
analysi
comput
use
jmp
v
result
baselin
characterist
total
patient
identifi
includ
median
follow
month
median
age
year
male
indic
hct
malign
disord
case
major
match
relat
donor
cmv
igg
posit
donor
recipi
case
myeloabl
condit
given
receiv
tbi
vivo
tcell
deplet
given
atg
alemtuzumab
b
cmv
reactiv
pet
total
patient
posit
cmv
pcr
median
day
reactiv
post
hct
patient
peak
cmv
titer
copiesml
low
titer
wherea
remain
peak
titer
copiesml
high
titer
patient
high
titer
like
older
p
malign
diseas
p
haploident
unrel
donor
p
higher
incid
agvhd
grade
iiiv
p
shown
tabl
median
peak
titer
low
high
group
vs
respect
p
patient
low
titer
clear
spontan
median
time
clearanc
day
receiv
anti
cmv
therapi
remain
die
activ
viremia
rang
copi
ml
activ
diseas
one
patient
high
titer
group
develop
cmv
diseas
os
cinrm
vs
p
vs
p
low
high
titer
group
respect
conclus
cmv
reactiv
high
cohort
howev
low
titer
viremia
pet
threshold
copiesml
iuml
appear
desir
associ
spontan
clearanc
almost
patient
minim
treatment
relat
toxic
valid
observ
warrant
background
risk
pneumocysti
pneumonia
often
warrant
antifung
prophylaxi
recipi
blood
marrow
solid
organ
transplant
howev
complic
myelosuppress
nephrotox
intoler
exist
standard
trimethoprimsulfamethoxazol
tmpsmx
may
hinder
interrupt
prophylaxi
rezafungin
rzf
novel
echinocandin
develop
prevent
invas
fungal
diseas
caus
candida
aspergillu
pneumocysti
speci
blood
marrow
transplant
patient
rzf
favor
safeti
toler
profil
low
risk
drugdrug
interact
furthermor
stabil
pharmacokinet
rzf
allow
onceweekli
dose
broad
distribut
lung
target
organ
rzf
shown
prevent
vitro
pneumocysti
biofilm
format
reduc
viabil
matur
biofilm
previou
prophylact
studi
conduct
use
broader
rang
rzf
dose
current
studi
efficaci
rzf
evalu
better
understand
minimum
dose
necessari
prevent
pneumocysti
growth
mous
model
method
mice
immunosuppress
dexamethason
mgl
acidifi
drink
water
infect
intranas
p
murina
x
given
slow
growth
p
murina
test
agent
administ
time
mice
inocul
test
prophylact
efficaci
mice
receiv
intraperiton
inject
either
vehicl
controlsteroid
cs
tmp
smx
wk
caspofungin
mgkg
daili
rzf
mgkg
mgkg
daili
dose
period
mice
sacrif
lung
homogen
process
analysi
quantifi
nuclei
trophic
asci
cyst
form
pneumocysti
prophylaxi
efficaci
base
reduct
organ
burden
compar
cs
nuclei
asci
count
log
transform
analyz
anova
individu
group
compar
studentnewmankeul
test
surviv
rate
compar
use
graphpad
prism
result
mice
rzf
group
significantli
reduc
nuclei
asci
burden
compar
cs
group
lowest
dose
rzf
mgkg
work
well
tmpsmx
reduc
nuclei
level
similarli
rzf
group
except
mgkg
group
show
reduct
asci
level
compar
tmpsmx
surviv
rate
statist
differ
treatment
group
conclus
rzf
demonstr
potent
vivo
efficaci
prophylaxi
pneumocysti
vivo
mous
infect
model
dose
regimen
much
lower
human
equival
phase
regimen
data
support
develop
rzf
prevent
invas
fungal
infect
includ
pneumocysti
pneumonia
disclosur
melani
cushion
research
fund
cidara
therapeut
taylor
sandison
employe
stockhold
cidara
therapeut
alan
ashbaugh
noth
declar
yuhua
ru
zile
zhu
yang
xu
sune
chen
xiaowen
tang
background
immunocompromis
period
follow
allogen
hematopoiet
stem
cell
transplant
allohsct
may
allow
opportunist
pathogen
thrive
result
fatal
complic
epsteinbarr
viru
ebv
infect
chines
popul
reactiv
hsct
one
major
concern
due
increas
risk
ebv
diseas
posttranspl
lymphoprolif
diseas
develop
infect
prophylaxi
support
care
hsct
demograph
data
ebv
reactiv
posthsct
need
updat
method
retrospect
analyz
data
patient
receiv
allohsct
juli
juli
first
affili
hospit
soochow
univers
quantit
pcr
qpcr
use
monitor
ebvdna
load
peripher
blood
dynam
ganciclovir
prehsct
follow
acyclovir
given
viral
prophylaxi
treatment
protocol
ebv
reactiv
consist
taper
immunosuppress
agent
antivir
agent
includ
ganciclovir
sodium
phosphonatel
rituximab
persist
posit
patient
result
total
case
provinc
china
enrol
character
tabl
among
ebv
reactiv
develop
recipi
reactiv
event
occur
first
year
posthsct
peak
incid
rate
per
personyear
second
month
besid
episod
lateonset
reactiv
occur
patient
receiv
graft
haploidient
donor
figur
multivari
analys
reveal
major
impactor
ebv
reactiv
includ
atg
gvhd
prophylaxi
p
hlamismatch
donor
appear
chornic
gvhd
cumul
incid
ebv
reactiv
low
among
patient
major
risk
factor
increas
major
risk
factor
respect
figur
statist
differ
overal
surviv
peopl
without
ebv
reactiv
conclus
conclud
similar
ebv
reactiv
impactor
chines
popul
compar
literatur
includ
atg
use
hlamismatch
donor
appear
chronic
gvhd
addit
incid
ebv
reactiv
increas
significantli
accumul
risk
factor
howev
ebv
reactiv
impact
overal
surviv
current
viru
manag
protocol
disclosur
noth
declar
background
sever
studi
shown
loss
divers
gut
microbiom
associ
signific
gut
injuri
follow
hematopoiet
stem
cell
transplant
hsct
prolong
broad
spectrum
antibiot
use
promot
loss
microbiom
divers
increas
risk
intestin
colon
multidrugresist
mdr
bacteria
aim
studi
prospect
evalu
overal
chang
gut
microbiom
composit
hsct
differ
patient
colon
mdr
bacteria
treat
carbapenem
method
perform
prospect
observ
studi
evalu
gut
microbiota
hematolog
patient
undergo
hsct
admiss
day
fecal
microbiota
assess
ampliconbas
sequenc
clinic
microbiolog
data
well
fecal
sampl
collect
everi
th
day
admiss
result
onehundr
fecal
sampl
analyz
overal
found
progress
decreas
bacteri
rich
signific
reduct
blautia
ruminococcu
dorea
speci
strictli
associ
product
short
chain
fatti
acid
sca
moreov
patient
colon
esbl
bacteria
observ
signific
reduct
clostridium
spp
bifidobacterium
speci
antibiot
therapi
carbapenem
use
second
line
treatment
febril
neutropenia
case
usual
associ
aminoglycosid
patient
treat
meropenem
strong
declin
blautia
ruminococcu
speci
observ
find
suggest
correl
carbapenem
regimen
increas
proinflammatori
bacteri
strain
gut
conclus
data
support
hypothesi
loss
intestin
commens
produc
shortchain
fatti
acid
may
increas
dysbiosi
moreov
first
time
report
signific
progress
alter
composit
blautia
ruminococcu
bifidobacterium
speci
patient
treat
meropenem
colon
esbl
bacteria
respect
find
offer
potenti
modifi
target
reduc
risk
colon
mdr
bacteria
promot
carbapenemspar
approach
hsct
set
clinic
background
cmv
associ
signific
morbid
allogen
hematopoiet
stem
cell
transplant
strategi
prevent
cmvrelat
complic
includ
univers
prophylaxi
preemptiv
therapi
wide
spread
antivir
use
cmv
reactiv
cmvr
produc
major
toxic
cost
rate
character
cmvr
haploident
transplant
posttranspl
cyclophosphamid
haplo
ptci
scarc
goal
analyz
cmvr
rate
haplo
ptci
outcom
complic
associ
therapi
identifi
risk
factor
method
one
hundr
haplo
ptci
transplant
use
peripher
blood
stem
cell
sourc
perform
center
retrospect
review
gvhd
prophylaxi
consist
ptci
mg
kgday
day
mmf
csa
day
case
cmv
pcr
perform
biweekli
basi
admiss
transplant
treatment
weekli
thereaft
cmvr
consid
cmv
dna
level
pcr
assay
copiesml
prior
four
consecut
neg
weekli
pcr
need
consid
new
reactiv
episod
preemptiv
strategi
appli
case
data
collect
relat
cmvr
includ
cmv
serostatu
donorrecipi
dr
number
cmv
reactiv
length
reactiv
antivir
treatment
use
need
admiss
receiv
treatment
advers
event
relat
cmv
reactiv
andor
antivir
treatment
result
patient
characterist
summar
tabl
among
patient
posit
cmv
serolog
episod
cmvr
detect
seventysix
patient
least
one
cmvr
median
day
transplant
none
cmv
diseas
die
consequ
cmvr
median
durat
day
valganciclovir
ganciclovir
use
episod
foscarnet
use
episod
six
episod
occur
initi
discharg
requir
readmiss
treatment
median
length
hospit
day
cytopenia
requir
transfus
gcsf
support
occur
episod
treat
ganciclovir
valganciclovir
three
need
cell
booster
graft
rescu
mild
acut
renal
failur
genit
ulcer
found
event
treat
foscarnet
respect
case
sever
renal
failur
observ
serolog
statu
differ
negativeneg
nn
p
older
age
vs
year
p
significantli
associ
cmvr
relationship
observ
gender
diseas
donor
relationship
condit
gvhd
cell
infus
reactiv
frequent
among
patient
grade
iiiv
acut
gvhd
agvhd
moderatesever
chronic
gvhd
cgvhd
conclus
experi
rate
cmvr
unmanipul
haplo
ptci
use
pbsc
stem
cell
sourc
consider
high
signific
proport
patient
present
complic
associ
cmvr
treatment
cmv
serolog
statu
nn
older
age
associ
high
risk
cmvr
patient
grade
iiiv
agvhd
higher
risk
multipl
reactiv
popul
could
benefit
primari
prophylaxi
order
decreas
complic
readmiss
cost
disclosur
noth
declar
impact
infecti
event
occur
first
hundr
day
hsct
hematolog
malign
monocentr
retrospect
studi
fiveyear
period
mariepierr
ledoux
simand
karin
bilger
annegret
laplac
bruno
liour
background
patient
undergo
hematopoiet
stem
cell
transplant
hsct
hematolog
malign
often
present
infecti
event
earli
stage
procedur
document
impact
outcom
graft
instanc
cytomegaloviru
cmv
shown
author
protect
effect
relaps
whose
featur
remain
elucid
conduct
retrospect
monocentr
studi
regard
outcom
term
graft
versu
host
gvhd
relaps
surviv
consecut
patient
period
year
whether
present
infecti
event
day
among
follow
cmv
viremia
epsteinbarr
viru
ebv
viremia
human
herp
viru
viremia
bk
viru
bkv
viruria
bacteri
bloodstream
infect
bsi
invas
fungal
infect
result
high
proport
cmv
seroposit
recipi
underw
viral
reactiv
cmv
day
hsct
donor
seroneg
donor
seroposit
observ
cmv
nt
associ
lower
relaps
rate
cohort
data
nt
suffici
conclud
firmli
show
trend
toward
wors
acut
gvhd
hazard
ratio
hr
pvalu
signific
correl
found
ebv
viremia
occur
patient
mostli
earli
time
strongli
correl
wors
acut
gvhd
hr
pvalu
impact
surviv
signific
bkv
patient
bsi
patient
correl
poorer
outcom
term
overal
surviv
logrank
respect
although
significantli
associ
relaps
acut
gvhd
fungal
infect
rare
event
draw
conclus
conclus
thu
contrari
mani
studi
found
protect
relaps
induc
cmv
although
trend
wors
acut
gvhd
obviou
mechan
behind
discord
could
includ
earli
treatment
remain
studi
whether
caus
rather
consequ
acut
gvhd
treatment
debat
correl
strong
sequenc
event
suggest
might
act
trigger
gvhd
associ
bkv
viruria
higher
mortal
contrast
previou
observ
lack
associ
gvhd
relaps
could
suggest
bkv
surrog
poor
immun
recoveri
therefor
caus
nonrelaps
mortal
addit
direct
lethal
risk
bacteriemia
bsi
also
promot
late
nonrelaps
mortal
indirect
toxic
expans
immun
effector
promot
one
could
assum
infecti
event
play
role
gvhd
gvl
therefor
interfer
relaps
howev
associ
infecti
event
outcom
remain
clarifi
guid
prophylact
therapeut
choic
better
understand
bright
dark
side
infecti
event
disclosur
background
rezafungin
rzf
novel
echinocandin
phase
develop
treatment
candidaemia
invas
candidiasi
antifung
prophylaxi
invas
fungal
diseas
caus
candida
aspergillu
pneumocysti
blood
marrow
transplant
patient
rzf
differenti
stabl
prolong
pharmacokinet
pk
allow
onceweekli
dose
pkpharmacodynam
pd
profil
correl
efficaci
clinic
vivo
evalu
drug
interact
potenti
perform
proactiv
assess
risk
drugdrug
interact
ddi
respect
phase
dose
mg
weekli
known
pk
exposur
healthi
individu
method
openlabel
studi
healthi
inpati
assess
ddi
rzf
perpetr
drug
known
interact
cyp
enzym
transport
probe
drug
repaglinid
metformin
octmat
rosuvastatin
bcrpoatp
pitavastatin
oatp
caffein
efavirenz
midazolam
digoxin
pgp
well
tacrolimu
drug
like
coadminist
rzf
initi
dose
rzf
mg
administ
first
dose
day
approxim
steadi
state
plasma
concentr
multipl
onceweekli
dose
follow
onceweekli
dose
day
probe
drug
cocktail
contain
drug
administ
rzf
administr
schedul
design
allow
washout
dose
limit
interact
probe
test
drug
sampl
analys
determin
respect
drug
concentr
plasma
except
tacrolimu
whole
blood
character
pk
profil
analyt
area
curv
auc
maximum
concentr
c
max
calcul
plasmablood
concentrationtim
profil
noncompartment
analysi
lntransform
pk
paramet
statist
analys
use
analysi
varianc
model
ratio
geometr
least
squar
mean
substrat
drug
administ
without
rzf
correspond
confid
interv
ci
calcul
lntransform
c
max
auc
result
rzf
given
concomitantli
probe
drug
six
nine
substrat
metformin
pitavastatin
caffein
efavirenz
midazolam
digoxin
statist
demonstr
absenc
drugdrug
interact
ci
includ
within
default
noeffect
boundari
three
substrat
upper
repaglinid
rosuvastatin
lower
tacrolimu
bound
ci
fall
outsid
rang
figur
chang
consid
unlik
clinic
signific
conclus
meaning
pk
interact
observ
rzf
drug
known
ddi
andor
like
coadminist
rzf
find
provid
evid
dose
adjust
expect
rzf
coadminist
commonli
use
drug
stand
contrast
ddi
complic
wide
associ
azol
antifung
disclosur
voon
ong
employe
stockhold
cidara
therapeut
michael
boili
employe
altasci
hong
wong
employe
altasci
taylor
sandison
employe
stockhold
cidara
therapeut
shawn
flanagan
employe
stockhold
cidara
therapeut
abstract
withdrawn
background
cytomegaloviru
cmv
continu
caus
morbid
follow
allogen
hematopoiet
stem
cell
transplant
hsct
letermovir
newli
approv
drug
cmv
prophylaxi
cmvseroposit
allogen
hsct
recipi
howev
pauciti
data
efficaci
patient
receiv
invivo
tcell
deplet
tcd
weill
cornel
medic
center
perform
invivo
tcd
alemtuzumab
relat
hlaident
unrel
transplant
antithymocyt
globulin
umbil
cord
blood
transplant
support
third
parti
accessori
cell
haplocord
transplant
although
drug
reduc
frequenc
graftversushostdiseas
gvhd
significantli
delay
tcell
immun
reconstitut
post
hsct
may
caus
higher
rate
cmv
reactiv
histor
rate
cmv
reactiv
cmv
seroposit
recipi
receiv
high
dose
valacyclovir
prophylaxi
approxim
therefor
implement
letermovir
cmv
prophylaxi
februari
primari
aim
studi
determin
incid
cmv
infect
defin
cmv
viremia
warrant
treatment
develop
endorgan
diseas
tcd
cmv
seroposit
allogen
hsct
patient
receiv
letermovir
prophylaxi
method
singl
center
retrospect
cohort
studi
determin
incid
cmv
infect
adult
cmvseroposit
recipi
receiv
letermovir
prophylaxi
vivo
tcd
hsct
atg
alemtuzumab
gvhd
prophylaxi
includ
subject
least
day
posttranspl
result
allogen
hsct
transplant
recipi
met
inclus
criteria
median
age
year
iqr
male
eight
match
relat
donor
six
match
unrel
donor
haplocord
transplant
underli
malign
condit
regimen
summar
tabl
receiv
atg
receiv
alemtuzumab
gvhd
prophylaxi
median
follow
time
survivor
day
iqr
incid
cmv
infect
first
day
posttranspl
one
patient
reactiv
detect
cmv
viremia
patient
develop
cmv
pneumon
document
ul
resist
success
treat
ganciclovir
incid
cmv
infect
within
first
day
posttranspl
patient
six
patient
develop
acut
gvhd
first
day
one
relaps
malign
five
patient
die
within
day
posttranspl
none
death
cmv
relat
background
infecti
complic
caus
endogen
adenoviru
adv
common
associ
morbid
mortal
rate
patient
hematopoiet
stem
cell
transplant
hsct
adv
infect
occur
hsct
recipi
significantli
higher
rate
pediatr
patient
better
understand
adenoviralspecif
tcell
advt
respons
donor
serv
basi
develop
effect
strategi
antivir
therapi
method
frequenc
cytomegaloviru
cmv
advspecif
cell
determin
enzymelink
immunospot
elispot
assay
hexon
respect
health
donor
use
mononuclear
cell
mnc
per
well
elispot
assay
donor
divid
group
accord
number
spot
per
well
spw
follow
high
respond
hr
spot
low
respond
lr
spot
nonrespond
nr
spot
averag
spot
area
advand
cmvspecif
lymphocyt
calcul
multipl
tcell
gener
immunomagnet
neg
select
hla
type
class
ii
perform
sequenc
specif
oligonucleotid
technolog
statist
analysi
perform
use
graphpad
prism
softwar
level
signific
calcul
mannwhitney
ranksum
test
express
pvalu
p
result
median
frequenc
per
well
advt
hr
group
lr
group
nr
group
median
spw
cmvspecif
cell
donor
mnc
differ
group
antivir
activ
may
depend
amount
advt
also
abil
produc
averag
spot
area
advt
differ
hr
lr
nr
group
mm
respect
median
averag
spot
area
anticmv
tlymphocyt
equal
mm
thu
frequenc
advt
lower
cmvspecif
tcell
advt
abil
produc
per
cell
p
order
evalu
distribut
advt
naiv
memori
cell
compart
evalu
respons
adv
preselect
fraction
tcell
group
donor
median
frequenc
advt
unfraction
mnc
median
frequenc
advt
fraction
respect
amount
tcell
normal
amount
mnc
evalu
impact
hlaallel
antiadv
respons
tcell
differ
group
found
associ
hlaa
hr
group
ci
hlaa
lr
group
ci
conclus
studi
frequenc
donor
advt
correspond
report
frequenc
advseroposit
peopl
popul
russia
advt
exclus
cell
analysi
advt
potenti
hsct
donor
allow
determin
accur
amount
function
activ
specif
antivir
tlymphocyt
administ
patient
optim
antivir
therapi
disclosur
noth
declar
abstract
withdrawn
chemotaxi
exhaust
cell
allograft
associ
cmv
reactiv
hematopoiet
transplant
background
cytomegaloviru
cmv
reactiv
relat
diseas
remain
common
seriou
complic
patient
underwentallogen
hematopoiet
stem
cell
transplant
allohsct
previous
report
incid
total
refractori
cmv
reactiv
reach
approxim
haploident
hsct
major
studi
literatur
focus
adapt
cellsand
nk
cell
anticmv
immun
increas
evid
highlight
import
role
cell
context
progress
prolong
expans
cell
respons
cmv
reactiv
observ
allohsct
effect
cell
associ
cmv
clearanc
report
vitro
vivo
contrast
reconstitut
cell
post
transplant
whether
phenotyp
subset
allograft
correl
cmv
reactiv
hsct
recipi
document
method
proport
phenotyp
cell
detect
inallograft
unmanipul
gcsfmobil
bone
marrow
bm
peripher
blood
pb
harvest
donor
haplohsct
bm
graft
collect
aspir
fourth
day
gcsf
treatment
filgrastim
pb
graft
obtain
fifth
day
leukapheresi
immunophenotyp
tcell
subpopul
includ
express
hladr
perform
use
flow
cytometri
detect
intracellular
cytokin
bm
pb
graft
prestimul
cell
stimul
cocktail
ebiosci
cmv
dna
peripher
blood
recipi
routin
monitor
quantit
pcr
associ
tcell
content
allograft
cmv
reactiv
haplohsct
recipi
analyz
use
mannwhitney
u
test
spearman
test
calcul
perform
use
spss
statist
softwar
result
found
proport
total
cell
subset
bm
pb
graft
cmv
cmvrecipi
compar
neither
express
hladr
allograft
significantli
differ
correl
cmv
reactiv
hsct
product
intracellular
cytokin
subset
vari
bm
pb
graft
cmv
cmvrecipi
interestingli
proport
cell
bm
graft
cmv
recipi
significantli
higher
cmvrecipi
p
respect
meanwhil
pmastimul
cell
bm
graft
cmv
recipi
less
cmvrecipi
p
parallel
concentr
cell
pb
graft
cmv
recipi
significantli
higher
cmvrecipi
p
conclus
studi
first
connect
chemotaxi
exhaust
cell
graft
risk
cmv
infect
allogen
hsct
futur
studi
explor
express
chemokin
exhaust
marker
effector
cell
allograft
facilit
cmv
replic
andor
dissemin
set
hematopoiet
transplant
disclosur
author
conflict
interest
studi
support
nation
natur
scienc
foundat
china
grant
result
incid
ic
allohsct
autohsct
etiolog
c
parapsilosi
c
albican
c
krusei
candida
tropicali
candida
dubliniensi
frequent
underli
diseas
acut
leukemia
median
age
yo
month
year
median
day
onset
ic
allohsct
autohsct
febril
fever
main
clinic
symptom
septic
syndrom
develop
case
antifung
therapi
echinocandin
lipid
ampho
b
azol
fluconazol
voriconazol
without
therapi
earli
mortal
overal
surviv
os
day
diagnosi
invas
candidiasi
central
venou
cathet
cvc
remov
factor
significantli
improv
os
vs
conclus
incid
invas
candidiasi
children
hematopoiet
stem
cell
transplant
main
etiolog
agent
c
parapsilosi
invas
candidiasi
infect
often
affect
leukemia
patient
develop
later
allohsct
autohsct
overal
surviv
day
diagnosi
remov
cvc
improv
overal
surviv
children
invas
candida
infect
hsct
disclosur
noth
declar
background
graft
versu
host
diseas
gvhd
virusassoci
enteropathi
allogen
hematopoiet
stem
cell
transplant
allohsct
may
caus
sever
quantit
qualit
composit
chang
intestin
microbiota
lead
develop
small
intestin
bacteri
overgrowth
sibo
background
immunodefici
neg
impact
treatment
effect
gold
standard
diagnosi
main
criterion
sibo
detect
jejunum
aspir
ml
bacteria
andor
appear
colonlik
microbiota
small
intestin
also
accept
use
altern
noninvas
techniqu
hydrogen
breath
test
could
especi
import
patient
sever
mucos
grade
iiiiv
thrombocytopenia
grade
iv
sibo
diagnosi
set
gastrointestin
tract
damag
dysfunct
patient
treat
allohsct
insuffici
studi
method
studi
includ
patient
acut
myeloid
leukemia
acut
lymphoblast
leukemia
myelodysplast
syndrom
lymphoma
hurler
syndrom
underw
allohsct
unrel
haploident
donor
complic
enteropathi
develop
case
enteropathi
reason
combin
intestin
gvhd
viral
coliti
case
viral
coliti
patient
esophagogastroduodenoscopi
speci
aspir
descend
part
duodenum
fece
collect
bacteria
pcr
identif
hydrogen
breath
test
perform
also
patient
treat
oral
lactos
gkg
subsequ
hydrogen
assess
minut
studi
perform
period
day
allohsct
result
accord
fece
analysi
data
colon
microbiota
composit
significantli
differ
refer
valu
time
total
bacteri
mass
duodenum
less
comparison
colon
microbiota
respect
p
quantit
composit
duoden
microbiota
compar
colon
lactobacillu
spp
bifidobacterium
spp
escherichia
coli
bacteroid
fragili
group
faecalibacterium
prausnitzii
indic
presenc
sibo
case
hydrogen
breath
test
complet
uninform
basal
valu
ppm
hydrogen
concentr
minut
ppm
minut
ppm
less
healthi
volunt
conclus
quantit
composit
duoden
colon
microbiota
similar
case
intestin
gvhd
andor
virusassoci
enteropathi
allohsct
patient
may
diagnost
valu
sibo
confirm
hydrogen
breath
test
uninform
method
sibo
identif
patient
allohsct
disclosur
noth
declar
johann
schult
patrick
sebastian
voigt
background
adenoviru
adv
infect
reactiv
frequent
occur
pediatr
hematopoiet
stem
cell
transplant
sct
set
infect
contribut
increas
morbid
mortal
nucleotid
analog
cidofovir
might
effect
reduc
adv
load
howev
nephrotox
consider
side
effect
new
antivir
compound
brincidofovir
bcv
lipidconjug
nucleotid
analog
broadspectrum
antivir
activ
vitro
report
effect
case
cidofovir
treatment
unsuccess
method
data
eight
pediatr
patient
undergo
sct
malign
nonmalign
indic
analyz
patient
weekli
monitor
adv
viremia
pcr
case
two
consecut
posit
adv
pcr
result
indic
viral
copi
number
document
patient
receiv
weekli
dose
cidofovir
reduct
adv
load
seen
within
two
week
commenc
treatment
side
effect
demand
cidofovir
discontinu
bcv
obtain
emerg
expand
access
programm
result
eight
pediatr
patient
develop
adv
viremia
maximum
viral
load
rang
copiesml
six
patient
c
type
adv
two
patient
non
c
type
adv
infect
five
patient
viral
coinfect
two
addit
cmv
infect
one
epsteinbarr
viru
ebv
herp
simplex
viru
coinfect
one
patient
ebv
coinfect
one
patient
bk
viru
coinfect
eight
patient
initi
receiv
cidofovir
howev
substanti
decreas
adv
load
could
observ
patient
twoweek
administr
cours
except
one
patient
extens
intestin
graftversu
host
diseas
gvhd
adv
infect
clear
patient
within
three
week
begin
bcv
treatment
addit
coinfect
clear
nephrotox
side
effect
observ
conclus
bcv
effect
one
patient
oral
bcv
might
effect
advanc
upper
gut
gvhd
especi
appli
via
gastric
tube
yet
observ
one
patient
eventu
without
nephrotox
side
effect
bcv
could
use
altern
cidofovir
disclosur
noth
declar
background
use
posttranspl
highdos
cyclophosphamid
ptci
overcom
need
extens
deplet
lymphocyt
haploident
donor
graft
tradit
result
sever
prolong
immunosuppress
howev
reconstitut
cellular
immun
may
delay
even
cell
replet
haploident
stem
cell
transplant
haplosct
ptci
studi
incid
sever
viral
reactiv
therefor
relev
outcom
haplosct
ptci
method
studi
enrol
patient
womenmen
underw
cell
replet
haplosct
achiev
hematopoiet
engraft
median
age
transplant
year
rang
underli
diseas
aml
md
myelofibrosi
cml
cll
condit
regimen
myeloabl
reducedintens
nonmyeloabl
peripher
blood
graft
sourc
major
case
bone
marrow
remain
recipientdonor
cytomegaloviru
cmv
serostatu
n
combin
tacrolimu
mycophenol
mofetil
administ
addit
ptci
prevent
graftversushost
diseas
cmv
epsteinbarr
viru
ebv
human
reactiv
monitor
realtim
quantit
pcr
rqpcr
blood
twice
weekli
post
haplosct
bk
viru
bkv
reactiv
assess
rqpcr
urin
andor
blood
specimen
case
symptom
suggest
bkvassoci
hemorrhag
cystiti
hc
result
median
followup
time
month
rang
cumul
incid
cin
relaps
nonrelaps
mortal
nrm
ci
ci
year
respect
median
diseasefre
df
overal
surviv
os
ci
ci
year
respect
cin
cmv
reactivationinfect
copiesml
reach
ci
month
cmv
infect
develop
patient
risk
wherea
recurr
cmv
reactiv
observ
patient
median
number
episod
rang
per
patient
median
total
durat
antivir
therapi
cmv
infect
day
rang
cmv
diseas
pneumonia
document
patient
cin
ebv
reactiv
copiesml
ci
month
case
ebvrel
posttranspl
lymphoprolif
disord
observ
howev
preemptiv
therapi
rituximab
requir
patient
rapidli
increas
ebv
viral
load
reactiv
copiesml
observ
patient
cin
month
ci
none
requir
specif
therapi
bkvrelat
hc
occur
cin
ci
month
cystoscopi
bladder
hemostasi
requir
nephrostomi
patient
hc
conclus
despit
preserv
nonalloreact
memori
cell
haplosct
ptci
associ
substanti
rate
viral
reactiv
especi
cmv
bkv
result
need
prolong
antivir
therapi
consider
morbid
well
therefor
strategi
prevent
viral
reactiv
diseas
still
warrant
haploident
stem
cell
transplant
disclosur
noth
declar
background
adenoviru
adv
infect
wellrecognis
caus
morbid
mortal
children
adult
receiv
allogen
stem
cell
transplant
hsct
report
incid
adv
infect
higher
paediatr
hsct
adult
current
lack
accur
data
adv
infect
burden
among
adultscidofovir
extens
use
preemptiv
antiadenovir
therapi
current
standard
carew
present
singl
centr
experi
adv
incid
outcom
preemptiv
approach
adult
patient
receiv
tcell
deplet
tcd
hsct
myeloid
disord
method
singlecentr
retrospect
analysi
consecut
hsct
patient
myeloid
disord
includ
aml
md
mpn
aplast
anaemia
januari
use
atg
alemtuzumab
base
tcdadv
screen
perform
patient
standardis
real
time
quantit
pcr
weekli
basi
standard
risk
period
figur
result
baselin
characterist
patient
similar
across
cohort
without
adv
infect
overal
patient
posit
adv
dna
atleast
one
sanctuari
site
upper
respiratori
airway
blood
faec
urin
experienc
dissemin
infect
defin
adv
sanctuari
site
rise
adv
dna
copi
blood
develop
typic
adenovir
diseas
pulmonari
among
patient
dissemin
infect
major
adv
gastrointestin
genitourinari
sanctuari
site
infect
addit
blood
viraemia
case
cumul
incid
adv
infect
month
median
time
day
day
detect
advdna
post
hsctoveral
surviv
os
year
whole
cohort
median
statist
differ
patient
dissemin
adv
infect
vs
none
log
rank
overal
cumul
incid
nonrelaps
mortal
nrm
relaps
cir
year
statist
differ
note
patient
dissemin
adv
infect
none
nrm
cir
gray
test
preemptiv
therapi
cidofovir
weekli
iv
infus
week
fortnightli
thereaft
infect
free
requir
symptomat
adv
infect
patient
dissemin
infectionson
patient
requir
brincidofovir
therapi
refractori
diseas
one
patient
die
due
sever
sepsi
adv
specif
therapi
could
givenremain
patient
monitor
selfrecov
cessat
immunosuppressional
patient
treat
cidofovir
develop
renal
impair
defin
atleast
increas
baselin
creatinin
howev
major
recov
renal
function
near
baselin
conclus
adv
infect
remain
signific
caus
morbid
adult
hsct
patient
howev
preemptiv
manag
cidofovir
improv
os
nrm
despit
use
tcd
conditioningren
toxic
remain
common
cidofovir
use
intermedi
dose
major
recov
renal
function
clinic
trial
registri
na
disclosur
noth
declar
background
public
invas
fungal
diseas
ifd
lymphoma
patient
limit
especi
allohsct
data
outcom
allohsct
lymphoma
patient
prior
ifd
studi
focus
epidemiolog
ifd
allohsct
children
adult
hodgkin
lymphoma
hl
method
singl
center
prospect
studi
includ
patient
classic
rr
hl
receiv
allohsct
median
age
yo
children
yo
allohsct
mud
perform
mrd
mmud
haplo
ric
predominantli
ptcybas
gvhd
prophylaxi
primari
antifung
prophylaxi
fluconazol
secondari
voriconazol
eortcmsg
criteria
diagnosi
bronchoscopi
allohsct
pt
ctscan
lung
lesion
use
activ
ifd
mean
ifd
diagnos
hsct
median
followup
time
month
result
incid
ifd
allohsct
ifd
prior
hsct
invas
aspergillosi
ia
lung
involv
antifung
therapi
allohsct
use
pt
median
durat
month
complet
respons
antifung
therapi
pt
partial
respons
stabil
pt
activ
ifd
allohsct
pt
receiv
voriconazol
antifung
therapi
secondari
prophylaxi
cumul
incid
relaps
progress
ia
allohsct
median
day
hsct
success
treat
voriconazol
post
hsct
period
incid
ifd
allohsct
patient
etiolog
ifd
allohsct
ia
invas
candidiasi
ic
mucormycosi
combin
ifd
caus
aspergillu
fumigatu
rhizopu
stolonif
median
day
onset
ifd
allohsct
day
associ
posthsct
relaps
hl
main
site
infect
lung
main
clinic
symptom
febril
fever
antifung
therapi
use
patient
voriconazol
micafungin
posaconazol
lipid
amphotericin
b
combin
lipid
amphotericin
b
caspofungin
overal
surviv
os
week
diagnosi
ifd
allohsct
os
children
adult
hl
allohsct
develop
ifd
allohsct
decreas
os
rate
vs
impact
prior
ifd
os
allohsct
recipi
statist
signific
group
vs
separ
children
adult
conclus
incid
ifd
children
adult
hodgkin
lymphoma
allohsct
incid
ifd
allohsct
patient
hodgkin
lymphoma
major
etiolog
agent
allohsct
aspergillu
spp
ifd
late
complic
allohsct
associ
posthsct
relaps
despit
high
incid
ifd
allohsct
nt
influenc
outcom
children
adult
hodgkin
lymphoma
disclosur
noth
declar
commun
high
cmv
posit
serostatu
known
risk
cmv
infect
reactiv
conduct
studi
explor
incid
outcom
cmv
infect
among
posthsct
children
method
medic
record
pediatr
patient
age
year
undergo
singl
allogen
hsct
januari
decemb
king
faisal
specialist
hospit
research
centr
riyadh
saudi
arabia
review
patient
activ
cmv
infect
diseas
transplant
exclud
total
patient
includ
studi
femal
median
age
hsct
year
recipi
cmv
serostatu
posit
patient
hsct
donor
cmvposit
recipientdonor
rd
serolog
r
rd
rd
rd
indic
hsct
immun
disord
hemoglobinopathi
bone
marrow
failur
malign
disord
histiocyt
metabol
disord
sourc
stem
cell
bone
marrow
cord
blood
peripher
blood
stem
cell
case
donor
match
relat
among
unrel
matchedmismatch
haploident
relat
mismatch
total
bodi
irradi
tbi
base
condit
use
patient
atg
use
patient
result
total
patient
patient
develop
cmv
infect
posthsct
incid
femal
recipi
high
versu
pvalu
recipi
donor
cmv
serolog
posit
develop
cmv
infect
pvalu
howev
cmv
infect
recipi
donor
neg
group
rd
incid
cmv
infect
posthsct
high
patient
receiv
tbi
base
condit
pvalu
haploident
transplant
pvalu
sourc
stem
cell
myeloabl
versu
nonmyeloabl
condit
atg
use
condit
agvhd
exhibit
signific
associ
cmv
infect
multivari
set
adjust
primari
indic
transplant
donor
hla
type
tbi
base
condit
recipi
donor
cmv
serolog
transplant
haploident
donor
odd
ratio
pvalu
donorrecipi
cmv
seroposit
odd
ratio
pvalu
found
signific
risk
factor
cmv
infect
resolut
rate
median
followup
time
month
infus
fiveyear
overal
surviv
cmv
infect
group
lower
compar
noncmv
infect
pvalu
conclus
incid
cmv
infect
posthsct
center
compar
center
data
suggest
donorrecipi
cmv
posit
serostatu
haploident
donor
use
tbi
base
condit
necessit
close
attent
surveil
background
toxoplasmosi
rare
underestim
complic
follow
allogen
stem
cell
transplant
allosct
often
fatal
cours
part
due
limit
diagnost
reli
mainli
imag
detect
parasit
dna
pcr
present
eleven
case
toxoplasma
diseas
follow
allosct
method
retrospect
analyz
consecut
adult
patient
receiv
allosct
bone
marrow
transplant
unit
juli
juli
eleven
patient
diagnos
toxoplasma
diseas
main
characterist
patient
shown
tabl
patient
except
two
cord
blood
receiv
peripher
blood
stem
cell
fludarabinebas
condit
regim
use
patient
two
cord
blood
patient
receiv
thymoglobulin
condit
graftversushost
diseas
gvhd
prophylaxi
consist
tacrolimu
plu
mycophenol
mofetil
patient
posttranspl
cyclophosphamid
follow
tacrolimu
allosct
perform
iggigm
toxoplasma
serolog
recipi
donor
review
absolut
lymphocyt
count
alc
lymphocyt
count
within
four
week
prior
diagnosi
toxoplasmosi
patient
took
effect
primari
prophylaxi
parasit
toxoplasma
diseas
defin
presenc
toxoplasma
infect
plu
clinic
radiolog
patholog
evid
toxoplasma
diseas
consid
main
caus
death
major
lifethreaten
infect
potenti
fatal
complic
occur
immedi
death
result
median
rang
age
year
eleven
patient
diagnos
toxoplasma
diseas
pancytopenia
patient
receiv
trimethoprimsufmethoxazol
tmpsmz
pentamidin
pneumocysti
jiroveciipneumonia
pcp
prophylaxi
case
atovaquon
one
toxoplasma
serolog
pretranspl
posit
iggigm
ten
eleven
patient
donor
seroneg
iggigm
except
two
toxoplasmosi
diagnos
median
rang
day
post
allostc
clinic
present
cerebralenceph
chorioretin
pneumon
dissemin
toxoplasmosi
one
case
patient
donor
seroneg
pretranspl
present
primari
infect
form
chorioretin
three
patient
chorioretin
diagnos
day
allosct
time
toxoplasma
diseas
patient
alc
immunosuppress
therapi
corticosteroid
acut
chronic
gvhd
lymphocyt
count
four
patient
three
eight
eleven
patient
die
median
rang
day
sinc
diagnosi
toxoplasmosi
toxoplasma
diseas
main
caus
death
conclus
seri
incid
toxoplasma
diseas
allosct
low
relat
high
mortal
accord
report
group
posit
pretranspl
serolog
gvhd
treatment
factor
strongli
relat
toxoplasmosi
encourag
use
tmpsmz
instead
pentamidin
pcppneumonia
prophylaxi
patient
seroposit
toxoplasma
gondii
pretranspl
clinic
trial
registri
data
epidemiolog
children
scarc
retrospect
analyz
incid
sever
risk
factor
contribut
manifest
complic
pediatr
popul
method
period
januari
june
perform
center
allogen
transplant
malign
hematolog
diseas
nonmalign
major
patient
receiv
myeloabl
condit
regimen
diagnost
criteria
hemorrhag
cystiti
detect
viru
pcr
urin
sampl
andor
blood
sampl
combin
hematuria
lower
urinari
tract
symptom
dysuria
urinari
frequenc
urgenc
suprapub
pain
could
nt
attribut
reason
defin
hemorrhag
cystiti
sever
one
follow
factor
present
format
clot
continu
bladder
irrig
obstruct
uropathi
creatinin
elev
need
urolog
intervent
result
total
patient
median
age
year
studi
children
ci
manifest
bk
viru
associ
hemorrhag
cystiti
median
age
year
onset
cystiti
occur
median
time
day
day
day
transplant
children
cystiti
sever
median
durat
symptom
day
median
time
hospit
children
sever
cystiti
day
wherea
nt
manifest
cystiti
patient
examin
presenc
viru
urin
also
blood
sampl
test
posit
almost
half
manifest
sever
cystiti
risk
factor
examin
age
administr
antithymocyt
globulin
type
diseas
graft
sourc
type
donor
presenc
acut
graft
versu
host
diseas
agvhd
multivari
analysi
independ
risk
factor
manifest
hemorrhag
cystiti
age
year
old
hr
ci
p
transplant
malign
diseas
hr
ci
presenc
agvhd
hr
ci
p
overal
surviv
children
hemorrhag
cystiti
vs
nt
manifest
complic
multivari
analysi
surviv
cystiti
nt
statist
signific
risk
factor
conclus
accord
result
stem
cell
transplant
children
year
old
suffer
malign
diseas
presenc
agvhd
consist
independ
risk
factor
manifest
bk
viru
associ
hemorrhag
cystiti
identif
risk
factor
seriou
complic
contribut
better
manag
transplant
patient
research
prospect
trial
contribut
better
understand
pathophysiolog
hemorrhag
cystiti
establish
appropri
diagnost
therapeut
guidelin
disclosur
noth
declar
impact
natur
killer
cell
reconstitut
outcom
patient
earli
cytomegaloviru
reactiv
allogen
hematopoiet
stem
cell
transplant
background
cytomegaloviru
cmv
reactiv
influenc
surviv
allogen
hematopoiet
stem
cell
transplant
sct
induc
natur
killer
nk
cell
expans
evalu
nk
cell
reconstitut
clinic
outcom
follow
earli
cmv
reactiv
sct
method
lymphocyt
subset
measur
flow
cytometri
day
patient
hematolog
malign
undergo
sct
januari
decemb
kanagawa
cancer
center
exclud
patient
graft
failur
death
within
day
cmv
reactiv
defin
initi
preemptiv
cmv
therapi
follow
antigenemia
surveil
result
subject
male
femal
median
age
year
rang
year
median
followup
period
survivor
year
rang
year
patient
acut
myeloid
leukemia
acut
lymphoblast
leukemia
myelodysplast
syndrom
diseas
transplant
patient
standard
risk
high
risk
myeloabl
condit
reducedintens
condit
employ
patient
respect
bone
marrow
transplant
peripher
blood
stem
cell
transplant
cord
blood
transplant
perform
patient
respect
cmv
reactiv
occur
patient
median
day
rang
day
sct
grade
iiiv
acut
gvhd
chronic
gvhd
affect
patient
patient
respect
among
patient
overal
surviv
os
cumul
nonrelaps
mortal
nrm
cumul
relaps
cir
rate
respect
patient
without
cmv
reactiv
cmvr
versu
patient
cmv
reactiv
cmvr
os
nrm
cir
vs
p
vs
p
vs
p
respect
among
patient
median
level
cell
cell
day
rang
respect
nk
cell
subset
show
signific
differ
cmvrand
cmvr
patient
patient
divid
low
high
group
median
level
nk
cell
subset
cmvr
patient
high
cell
show
significantli
better
os
low
cell
vs
p
vs
p
vs
p
respect
high
cell
significantli
associ
lower
nrm
vs
p
high
significantli
associ
lower
cir
vs
p
multivari
analysi
confirm
nk
cell
subset
prognost
factor
cmvr
patient
conclus
nk
cell
reconstitut
may
contribut
improv
transplant
outcom
subgroup
cmvr
patient
disclosur
noth
declar
background
rezafungin
rzf
novel
echinocandin
develop
prevent
invas
fungal
infect
caus
candida
aspergillu
pneumocysti
spp
patient
high
risk
infect
rzf
demonstr
vivo
prophylaxi
efficaci
low
risk
drugdrug
interact
furthermor
stabil
pk
profil
rzf
allow
onceweekli
dose
rzf
also
develop
treatment
candidemia
invas
candidiasi
use
dose
regimen
rzf
mg
follow
mg
onceweekli
achiev
target
attain
candida
lower
dose
might
use
prevent
candida
pneumocysti
invas
aspergillosi
differ
challeng
evalu
rzf
dose
prophylaxi
aspergillu
fumigatu
blood
marrow
transplant
bmt
patient
use
pkpd
simul
treatment
dose
regimen
method
previou
popul
pk
model
refin
use
data
phase
phase
trial
iv
rzf
nonmem
ver
stepwis
forward
select
backward
elimin
use
assess
relationship
interindividu
pk
variabl
covari
age
sex
bsa
albumin
liver
renal
function
marker
infect
statu
final
model
valid
compar
modelbas
predict
observ
data
model
demograph
data
bmt
recipi
stanford
medic
center
use
mont
carlo
simul
expect
rzf
concentrationtim
profil
bmt
patient
receiv
iv
rzf
mg
week
follow
mg
weekli
x
patient
includ
demograph
dataset
femal
mean
valu
baselin
age
year
year
weight
kg
kg
median
rang
bsa
demograph
dataset
albumin
gdl
gdl
freedrug
concentrationtim
profil
evalu
human
proteinbind
rel
fumigatu
minim
effect
concentr
requir
inhibit
isol
test
mec
jmi
sentri
intern
surveil
data
result
popul
pk
model
linear
model
zero
order
iv
input
albumin
sex
infect
statu
bodi
surfac
area
statist
signific
predictor
interindividu
variabl
clinic
signific
factor
determin
model
provid
precis
unbias
fit
observ
data
r
observ
vs
individualpredict
concentr
rzf
plasma
freedrug
concentr
week
fumigatu
mec
mgl
entir
dose
interv
simul
patient
respect
week
base
mec
mgl
conclus
data
model
bmt
patient
support
rzf
dose
regimen
mg
iv
follow
mg
onceweekli
prophylaxi
fumigatu
current
antifung
prophylaxi
may
limit
toxic
ddi
patient
factor
mucos
pk
rzf
spectrum
safeti
toler
lack
ddi
may
address
current
unmet
need
ifi
prophylaxi
bmt
immunocompromis
patient
disclosur
janic
brown
research
fund
cidara
therapeut
elizabeth
lakota
research
fund
cidara
therapeut
shawn
flanagan
employ
cidara
therapeut
taylor
sandison
employ
cidara
therapeut
voon
ong
employ
cidara
therapeut
christoph
rubino
research
fund
cidara
therapeut
fungal
prophylaxi
necessari
non
myeloabl
peripher
blood
stem
cell
allogen
transplant
preengraf
period
julien
vaidi
jeanbaptist
woillard
girault
marielaur
arnaud
jaccard
daniel
ajzenberg
bernard
bouteil
pascal
turlur
background
non
myeloabl
peripher
blood
stem
cell
transplant
pbsc
limit
toxic
propos
elderli
patient
patient
comorbid
howev
fungal
infect
remain
key
issu
neg
impact
outcom
increas
durat
cost
hospit
systemat
fungal
prophylaxi
demonstr
benefit
outcom
context
myeloabl
condit
current
reduc
intens
condit
allograft
pbsc
fluconazol
prophylaxi
current
recommend
situat
ecil
method
primari
object
retrospect
studi
evalu
fungal
infect
incid
allograft
procedur
patient
receiv
non
myeloabl
allograft
pbsc
limog
univers
hospit
june
june
patient
receiv
fludarabin
allograft
busulfan
mgkgday
gvh
prophylaxi
consist
rabbit
antilymphocyt
serum
dose
mgkg
ciclosporin
begin
dose
per
os
twice
day
mycophenol
mofetil
ad
patient
hlamatch
mismatch
unrel
donor
patient
systemat
receiv
antifung
prophylaxi
neutropen
preengraft
period
patient
fever
hour
empir
fungal
treatment
caspofungin
ad
empir
antibiot
soon
neutropen
recov
case
apyrexia
without
microbiolog
document
antimicrobi
treatment
stop
case
microbiolog
document
treatment
adjust
germ
term
dose
time
administr
follow
recommend
howev
patient
receiv
antifung
azol
prophylaxi
neutropen
preengraft
period
case
histori
previou
invas
aspergillosi
ia
nasal
colon
aspergillu
postengraft
period
posaconasol
prophylaxi
administ
patient
system
corticotherapi
acut
graftversushost
diseas
result
patient
evalu
median
minmax
age
year
patient
receiv
hlaident
relat
donor
hlamatch
relat
donor
hlamismatch
unrel
donor
five
year
overal
surviv
surviv
without
relaps
gvhd
respect
ic
median
time
neutrophil
recoveri
day
patient
receiv
prophylaxi
patient
receiv
systemat
fungal
azol
prophylaxi
preengraft
period
two
patient
receiv
empir
treatment
caspofungin
ifi
document
neutropen
period
candida
krusei
blood
cultur
post
engraft
period
patient
acut
gvhd
treat
corticotherapi
receiv
antifung
prophylaxi
posaconazol
patient
probabl
ia
day
despit
prophylaxi
posaconasol
conclus
except
patient
previou
histori
ifi
result
provid
addit
argument
systemat
fungal
prophylaxi
reduc
intens
condit
pbsc
allogen
transplant
preengraft
period
low
incid
invas
fungal
infect
postengraf
period
posaconazol
prophylaxi
requir
patient
gvhd
treat
corticotherapi
disclosur
method
simpl
rapid
sensit
method
use
hplc
diodearray
detector
dad
develop
valid
quantif
letermovir
human
serum
use
sorafenib
intern
standard
pretreat
serum
sampl
liquidliquid
extract
tertbutyl
methyl
ether
separ
achiev
xterra
column
dimens
x
c
use
gradient
elut
mobil
phase
mm
ammonium
bicarbon
ph
mobil
phase
solventa
ammonium
bicarbon
ph
mobil
phase
solventb
sampl
elut
flow
rate
min
throughout
run
uv
wavelength
mode
use
detect
nm
result
calibr
curv
linear
r
concentr
rang
ng
ml
letermovir
hplc
assay
establish
letermovir
determin
show
high
rate
accuraci
precis
intraday
variabl
accuraci
precis
interday
variabl
accuraci
precis
respect
letermovir
serum
concentr
patient
male
femal
mean
age
year
determin
daili
clinic
practic
mean
concentr
ng
ml
median
ng
ml
standard
deviat
ng
ml
rang
ng
ml
conclus
newli
develop
hplc
method
use
determin
letermovir
concentr
patient
sampl
analyz
routin
clinic
set
demonstr
consider
interindividu
variabl
measur
concentr
letermovir
monitor
concentr
letermovir
could
help
prevent
overor
underexposur
especi
patient
polypharmaci
frequent
allogen
hematopoiet
stem
cell
transplant
recipi
disclosur
background
use
preemptiv
strategi
pet
lower
incid
cmv
diseas
allosct
nonetheless
use
strategi
impli
seroposit
patient
replic
cmv
sever
studi
shown
cmv
replic
detriment
patient
surviv
although
viral
load
relat
bad
outcom
variat
among
studi
object
analys
thel
impact
cmv
replic
overal
surviv
os
allohct
patient
method
analys
impact
cmv
replic
os
perform
unicentr
retrospect
studi
consecut
first
allohsct
patient
transplant
median
followup
day
patient
monitor
posthct
real
time
pcr
rtpcr
plasma
cutoff
incept
pet
iuml
cmv
mutat
studi
plasma
sampl
sanger
sequenc
median
cmv
viral
load
iuml
result
patient
womenmen
median
age
year
rang
ident
allogen
sct
haploident
sct
donor
relat
case
unrel
progenitor
sourc
peripher
blood
bone
marrow
cmv
statu
dr
dr
dr
dr
unknown
case
posit
pcr
detect
patient
one
episod
episod
episod
patient
fiftyf
patient
receiv
preemptiv
therapi
fourteen
episod
refractori
probabl
refractori
cmv
infect
accord
criteria
chemali
r
cid
resist
mutat
gene
detect
one
patient
refractori
infect
patient
develop
cmv
infect
inferior
nonsignific
os
year
vs
logrank
p
patient
receiv
pet
cmv
signific
inferior
os
compar
replic
cmv
nt
receiv
preemptiv
therapi
vs
log
rank
os
patient
receiv
pet
inferior
compar
without
pet
without
infect
vs
logrank
p
differ
surviv
found
patient
treat
preemptiv
refractori
vs
refractori
vs
logrank
p
conclus
patient
receiv
preemptiv
therapi
signific
inferior
overal
surviv
compar
replic
replic
cmv
nt
receiv
preemptiv
therapi
reinforc
relev
prophylact
strategi
cmv
drug
good
safeti
profil
like
letermovir
randomis
trial
prove
decreas
need
preemptiv
therapi
disclosur
rafael
de
la
camara
receiv
grant
astella
gilead
janssen
merck
novarti
pfizer
clinic
evalu
stenotrophomona
maltophilia
infect
allogen
hematopoiet
stem
cell
transplant
recipi
retrospect
singlecent
data
analysi
neg
bacillu
caus
sever
infect
associ
high
morbid
mortal
immunocompromis
patient
aim
studi
determin
incid
characterist
outcom
maltophilia
infect
patient
pt
underw
allogen
hematopoiet
stem
cell
transplant
allohsct
institut
hematolog
transfus
medicin
octob
novemb
method
retrospect
evalu
incid
clinic
featur
outcom
maltophilia
infect
consecut
patient
median
year
rang
underw
allohsct
unrel
donor
match
sibl
donor
haploident
donor
center
maltophilia
detect
culturebas
microbiolog
test
invas
infect
defin
isol
maltophilia
cultur
presenc
clinic
symptom
sign
infect
blood
stream
infect
bsi
pneumonia
without
pulmonari
haemorrhag
colon
statu
defin
maltophilia
cultureposit
sampl
absenc
infect
symptom
vitro
suscept
test
antibiot
perform
result
pt
median
year
rang
smaltophilia
cultur
posit
sampl
identifi
underw
allohsct
unrel
donor
match
sibl
donor
haploident
donor
among
bsi
develop
pt
pneumonia
pt
fulmin
fatal
pulmonari
hemorrhag
pt
patient
pneumonia
demonstr
bsi
posit
sputum
cultur
detect
pt
pt
hemoptysi
observ
rest
isol
strain
identifi
colon
throat
pt
stool
pt
patient
invas
maltophilia
infect
pathogen
identif
demonstr
persist
fever
despit
use
broadspectrum
antibiot
carbapenem
glycopeptid
aminoglycosid
colistin
prophylact
antifung
antivir
receiv
fluoroquinolon
ciprofloxacin
standard
antibacteri
prophylaxi
neutropen
fever
occur
patient
bsi
pneumonia
pulmonari
hemorrhag
die
engraft
anc
gl
hour
onset
posit
blood
cultur
maltophilia
creactiv
protein
crp
concentr
identif
maltophilia
invas
infect
upper
normal
limit
unl
suscept
antibiot
isol
strain
blood
sputum
respect
ceftazidim
trimethoprimsulfamethoxazol
levofloxacin
strain
resist
ciprofloxacin
over
surviv
os
os
group
respect
compar
group
without
maltophilia
infect
conclus
maltophilia
invas
infect
associ
high
morbid
mortal
allohsct
recipi
especi
period
condit
therapi
engraft
exposur
broadspectrum
antibiot
treatment
neutropen
fever
confirm
bacteremia
etiolog
one
risk
factor
breakthrough
maltophilia
infect
empir
therapi
maltophilia
select
patient
risk
infect
pathogen
identif
may
lifesav
procedur
disclosur
noth
declar
role
cmv
reactiv
follow
allogen
stem
cell
transplant
prevent
relaps
patient
acut
myeloid
leukemia
background
cytomegaloviru
cmv
reactiv
common
patient
undergo
allogen
stem
cell
transplant
shown
recent
cmv
reactiv
associ
reduc
risk
relaps
patient
undergo
allogen
stem
cell
transplant
aml
howev
analysi
cibmtr
data
show
effect
cmv
reactiv
relaps
background
conduct
analysi
patient
suffer
aml
undergo
allosct
long
term
diseas
free
surviv
respect
cmv
reactiv
method
obtain
permiss
hospit
medic
record
committe
retrospect
analys
data
electron
medic
record
patient
undergo
allosct
aml
center
januari
august
patient
underw
match
sibl
match
unrel
partial
match
allo
sct
includ
patient
underw
cmv
monitor
weekli
pcr
start
time
engraft
till
follow
allo
sct
valu
copiesmcl
consid
cut
initi
treatment
match
sibl
donor
transplant
unrel
donor
partial
match
donor
transplant
copiesmcl
use
cut
initi
pre
emptiv
therapi
result
total
patient
includ
studi
median
age
patient
underw
match
sibl
haplo
partial
match
mud
transplant
respect
median
follow
month
tabl
acut
gvhd
observ
patient
cmv
reactiv
occur
patient
overal
surviv
last
follow
patient
relaps
follow
relaps
free
surviv
last
follow
patient
cmv
reactiv
relaps
wherea
patient
cmv
reactiv
relaps
statist
strongli
signific
p
figur
similar
result
seen
recent
publish
paper
japanes
societi
hematopoiet
cell
transplant
jshct
transplantationrel
complic
work
group
conclus
cmv
reactiv
follow
allo
sct
benefici
effect
prevent
relaps
patient
aml
probabl
immun
activ
result
due
cmv
reactiv
may
result
better
graft
versu
leukemia
effect
prevent
subsequ
relaps
background
human
herpesviru
caus
lifethr
central
nervou
system
disord
enceph
allogen
hematopoiet
stem
cell
transplant
hsct
recent
studi
show
member
tumor
necrosi
factor
receptor
superfamili
implic
specif
receptor
express
level
cell
hsct
could
relat
reactiv
realtim
quantit
polymeras
chain
reaction
analysi
qpcr
commonli
use
method
detect
evalu
reactiv
hsct
sensit
detect
method
requir
recent
develop
new
monitor
method
reactiv
use
digit
pcr
dpcr
provid
high
sensit
detect
dna
clinic
sampl
prospect
studi
evalu
relationship
reactiv
monitor
dpcr
express
cell
allogen
hsct
method
thirtyfour
patient
underw
allogen
hsct
hematolog
diseas
keio
univers
hospit
tokyo
japan
januari
march
consecut
enrol
studi
peripher
blood
sampl
patient
obtain
condit
pre
day
transplant
day
weekli
first
month
transplant
day
viral
load
plasma
quantit
measur
dpcr
primer
probe
dpcr
select
immediateearli
protein
transactiv
region
evalu
relationship
reactiv
serial
express
rate
cell
ratio
measur
flow
cytometri
hsct
result
median
age
patient
year
onethird
patient
receiv
cord
blood
stem
cell
sourc
reactiv
detect
patient
dpcr
comparison
ratio
patient
without
reactiv
hsct
reveal
ratio
significantli
higher
patient
reactiv
without
condit
contrast
signific
differ
transplant
day
multivari
analysi
higher
ratio
condit
odd
ratio
confid
interv
ci
p
stem
cell
sourc
human
leukocyt
antigen
mismatch
donor
includ
cord
blood
transplant
case
ci
p
remain
significantli
associ
incid
reactiv
conclus
higher
express
rate
cell
hsct
associ
higher
risk
reactiv
could
promis
marker
predict
reactiv
allogen
hsct
care
observ
monitor
may
need
highli
express
patient
subject
research
clarifi
role
cell
reactiv
disclosur
noth
declar
method
criteria
administr
ici
vistid
grade
iiiiv
clinic
signific
hematuria
clot
bkrelat
hemorrhag
cystiti
allohct
show
improv
symptomat
therapi
hyperhydr
bladder
irrig
cidofovir
dilut
ml
normal
salin
instal
via
foley
cathet
block
hour
know
level
absorpt
drug
decid
give
probenecid
prophylaxi
patient
ici
repeat
weekli
accord
sever
symptom
urin
plasma
bkv
viral
load
quantifi
rqpcr
result
six
patient
median
year
receiv
ici
allohct
patient
haematolog
malign
aml
md
receiv
busilfexbas
myeloabl
condit
graft
pbsc
bm
hlamatch
haploident
donor
median
time
onset
bkvhc
allohct
day
rang
patient
standard
cyclosporin
prophylaxi
none
patient
sign
acut
gvhd
time
onset
hc
median
pcrbkv
viral
load
onset
bkvhc
urin
plasma
rang
rang
respect
median
maximum
pcrbkv
viral
load
urin
plasma
rang
rang
respect
five
patient
impair
renal
function
median
egfr
mlmin
rang
first
ici
probabl
multifactori
median
dose
intraves
cidofovir
mgkg
rang
mgkg
median
number
instil
rang
given
case
symptom
cystiti
improv
dramat
hematuria
resolv
virolog
respons
least
log
reduct
observ
case
two
patient
experienc
relaps
hemorrhag
cystiti
retreat
ici
result
resolut
symptom
hematuria
deterior
renal
function
system
advers
effect
observ
median
follow
day
transplant
rang
patient
aliv
without
cystiti
symptomatolog
die
due
relaps
due
trm
conclus
retrospect
studi
propos
local
therapi
bkvhc
ici
safe
high
clinic
virolog
respons
rate
administr
ici
allohct
control
prospect
random
trial
disclosur
noth
declar
background
sinc
cmvpreemptiv
therapi
approach
implement
cmv
diseas
frequenc
low
howev
cmv
reactiv
need
use
nephrotox
plusless
myelotox
drug
frequent
addit
toxic
medic
avoid
cmv
diseas
potenti
advers
effect
cmv
mention
medic
literatur
studi
want
estim
recipientdonor
serolog
statu
influenc
outcom
allohsct
recent
seri
patient
method
popul
analyz
report
patient
underw
allohsct
period
octob
septemb
unit
median
age
transplant
year
rang
one
hundr
thirti
male
femal
baselin
diseas
aml
lpd
md
mpd
mm
bmf
donor
unrel
transplant
famili
includ
haploident
condit
regimen
ric
procedur
intens
stem
cell
sourc
pb
bm
case
median
followup
month
rang
patient
donor
cmv
igg
posit
respect
recipientdonor
serolog
risk
group
risk
group
risk
group
risk
group
result
two
pt
underw
second
transplant
day
due
graft
failur
overal
mortal
om
day
rest
seri
pt
shown
tabl
highest
risk
group
recipi
cmv
donor
cmv
exhibit
doubl
om
day
four
time
om
day
compar
pt
lowest
risk
recipi
cmv
strike
differ
mainli
due
nrm
om
risk
group
ii
recipi
cmv
donor
cmv
intermedi
conclus
studi
popul
mainli
adult
patient
combin
cmvseroposit
patient
cmvseroneg
donor
clear
advers
impact
hsct
outcom
result
consid
elect
cmvposit
donor
cmvposit
patient
continu
strongli
advis
whenev
possibl
hand
letermovir
prove
effici
welltoler
licens
prophylaxi
cmv
high
risk
recipi
approach
appear
attract
tri
avoid
advers
impact
recipi
cmvseroposit
particularli
final
chosen
donor
cmv
neg
disclosur
noth
declar
activ
surveil
earli
individu
manag
critic
avoid
mortal
respiratori
viral
infect
allohsct
recipi
background
respiratori
viral
infect
rvi
frequent
among
gener
popul
transplant
recipi
rvi
known
caus
import
morbid
potenti
mortal
reason
sever
other
need
prevent
pt
contagi
avoid
misdiagnosi
infect
process
high
index
suspicion
vri
necessari
last
year
implement
activ
systemat
surveil
polici
orientedto
earli
detect
manag
rvi
hsct
recipi
method
popul
analyz
report
patient
underw
allohsct
januari
march
unit
median
age
transplant
year
rang
one
hundr
four
male
femal
baselin
diseas
aml
lpd
md
mpd
mm
bmf
donor
unrel
transplant
famili
includ
haploident
condit
regimen
reduc
procedur
intens
stem
cell
sourc
pb
bm
pt
median
followup
month
rang
close
analysi
major
seri
followup
superior
one
year
hsct
throat
swab
ts
taken
everi
patient
even
minor
respiratori
symptom
respiratorysampl
test
whith
complet
pcr
panel
human
respiratori
virus
rhinoviru
rv
influenza
b
viru
iva
ivb
parainfluenza
viru
piv
respiratori
syncyti
viru
rsv
metapneumoviru
mpv
coronaviru
cov
adenoviru
adv
bocaviru
bov
result
day
overal
mortal
seri
day
overal
mortal
nonrelaps
mortal
nrm
progressionrelaps
mortal
caus
nrm
reflect
tabl
patient
die
due
rvi
st
juli
th
june
period
ts
sampl
obtain
pt
median
number
samplespati
rang
total
rvi
episod
diagnos
pt
median
present
first
rvi
day
posthsct
viral
distribut
rv
iv
piv
rsv
mpv
cov
adv
bov
mix
two
virus
rvi
episod
temporari
distribut
vri
episod
shown
figur
conclus
symptomat
infect
due
respiratori
virus
frequent
among
allohsct
recipi
high
level
suspicion
well
earli
systemat
screen
manag
polici
critic
avoid
potenti
attribut
mortal
nosocomi
spread
rvi
among
transplant
recipi
seri
rhinoviru
parainfluenza
adenoviru
might
detect
moment
year
rest
virus
show
clear
season
pattern
novemb
april
imag
background
trimethoprimsulfamethoxazol
tmpsmx
suitabl
drug
prophylaxi
pneumocysti
pneumonia
infect
toxoplasma
allogen
haematopoiet
stem
cell
transplant
allohsct
allerg
reaction
hypersensit
mainli
exanthema
occur
patient
usual
result
use
altern
prophylact
drug
eg
pentamidin
atovaquon
hypothesis
allergi
might
cure
allohsct
method
conduct
retrospect
chart
review
patient
tmpsmx
reexposit
allohsct
decemb
septemb
followup
current
decemb
result
six
patient
fm
median
age
year
rang
year
histori
tmpsmx
hypersensit
prior
allohsct
reexpos
tmpsmx
engraft
match
relat
mrd
match
unrel
mud
donor
median
time
reexposit
rang
day
allohsct
one
oral
dose
tmpsmx
four
patient
tmpsmx
toler
without
sign
hypersensit
reaction
continu
median
day
rang
last
followup
one
patient
mud
reexposit
experienc
pruritu
erythema
hour
tablet
intak
anoth
patient
mud
reexposit
develop
exanthema
one
day
reexposit
later
diagnos
cutan
gvhd
conclus
reexposit
tmpsmx
patient
prior
hypersensit
feasibl
allohsct
success
reexposit
patient
treat
beststudi
drug
prophylaxi
infect
pneumocysti
toxoplasma
disclosur
noth
declar
brincidofovir
adenoviremia
paediatr
hsct
primari
immun
defici
background
reactiv
adenoviru
sever
complic
hsct
associ
signific
morbid
mortal
particularli
children
primari
immun
defici
pid
drug
current
licens
treat
adenoviru
infect
cidofovir
brincidofovir
lipidlink
deriv
cidofovir
shown
safe
effect
altern
treatment
cidofovir
limit
data
describ
use
brincidofovir
patient
undergo
hsct
primari
immun
defici
review
patient
receiv
brincidofovir
undergo
hsct
primari
immun
defici
great
north
children
hospit
newcastl
upon
tyne
uk
result
patient
transplant
pid
develop
signific
adenoviraemia
treat
cidofovir
initi
switch
brincidofovir
failur
respond
renal
toxic
resolv
adenoviraemia
within
day
commenc
treatment
figur
donor
sourc
tcr
deplet
haploident
tcr
deplet
mmud
mud
patient
condit
treosulphanfludarabinethiotepaatg
rituximab
treosulphanfludarabineatgrituximab
treosulphanfludarabinealemtuzumab
gcsfplerixafor
occurr
agvhd
treatment
agvhd
outlin
tabl
patient
die
day
posttranspl
multiorgan
failur
sever
thrombot
microangiopathi
sepsi
although
patient
initi
respond
brincidofovir
reactiv
occur
cessat
treatment
sever
diarrhoea
preclud
reintroduct
brincidofovir
adenoviraemia
persist
poor
immun
reconstitut
treatment
addback
cell
attempt
howev
patient
die
day
posttranspl
cerebr
haemorrhag
patient
longstand
chronic
diarrhoea
thought
sever
enough
warrant
cessat
brincidofovir
treatment
conclus
complet
resolut
adenoviraemia
patient
previous
fail
respond
prior
therapi
cidofovir
suggest
brincidofovir
may
effect
treatment
option
adenovir
reactiv
posthsct
pid
howev
resolut
adenoviraemia
influenc
mani
factor
includ
adequaci
immun
reconstitut
degre
induc
immun
suppress
presenc
comorbid
gvhd
due
small
sampl
size
difficult
assess
rel
import
factor
cohort
brincidofovir
well
toler
howev
effect
may
limit
poor
gastrointestin
function
one
patient
patient
could
use
viral
reactiv
anoth
reason
studi
use
brincidofovir
specif
cohort
need
clarifi
role
effect
treatment
background
high
preval
cmv
seroposit
algerian
popul
high
morbid
mortal
pt
underw
allo
sct
cmv
reactiv
effect
surveil
time
treatment
use
antivir
therapi
requir
risk
cmv
reactiv
depend
type
stem
cell
sourc
immunosuppress
serolog
statu
donor
recipi
pair
method
month
period
pt
underw
allohsct
malign
nonmalign
hematolog
diseas
pt
evalu
studi
cmv
reactiv
observ
pt
aml
pt
pt
cml
pt
multipl
myeloma
pt
nhl
skin
pt
primari
myelofibrosi
pt
aplast
anemia
pt
fanconi
anemia
pt
pt
median
age
year
sex
ratio
mf
allohsct
done
sibl
donor
pt
haploident
donor
pt
phenoident
donor
pt
pt
treat
chemotherapi
alon
condit
mac
pt
reduc
intens
ric
pt
pt
receiv
peripher
blood
stem
cell
averag
rate
cell
kg
addit
bone
marrow
graft
use
pt
receiv
haploident
graft
without
ptci
gvh
prophylaxi
associ
cyclosporin
csa
methotrex
sibl
phenoident
csamtxmmf
csamtxcyclophosphamid
haploident
transplant
donorrecipi
pair
high
risk
reactiv
pt
detect
cmv
reactiv
done
antigenaemia
quantit
pcr
weekli
first
month
treatment
acut
chronic
gvhd
preemptiv
therapi
initi
ganciclovir
soon
posit
antigenaemia
increas
viral
load
pcr
result
first
reactiv
occur
averag
day
pt
pt
corticotherapi
acut
gvhd
pt
thrombot
microangiopathi
pt
renal
failur
pt
due
reinforc
haploident
transplant
pt
one
pt
chronic
gvhd
present
late
reactiv
month
transplant
twenti
pt
present
nd
reactiv
averag
day
pt
rd
reactiv
averag
day
preemptiv
treatment
introduc
first
episod
viral
dna
polymeras
inhibitor
ganciclovir
pt
valganciclovir
pt
foscarnet
pt
neg
antigenaemia
observ
averag
day
treatment
second
line
treatment
requir
pt
due
resist
pt
sever
cytopenia
renal
failur
pt
onset
sever
cytopenia
impos
dose
reduct
pt
therapeut
stop
pt
day
two
pt
receiv
addit
mainten
treatment
negativ
delay
three
pt
die
cmv
infect
resist
antivir
treatment
pneumonia
coliti
conclus
cmv
infect
seriou
complic
allohsct
absenc
vaccin
systemat
monitor
cmv
reactiv
strongli
recommend
establish
rapid
effect
preemptiv
treatment
disclosur
noth
declar
abstract
withdrawn
result
transplant
group
episod
bkv
reactiv
occur
patient
case
urin
colon
c
found
hsct
group
patient
viru
transmit
urin
blood
b
dysuria
andor
hc
observ
patient
urin
serum
involv
case
bkv
replic
found
hsct
case
detect
urin
casesbothserum
urin
dysur
syndrom
andor
hc
found
case
patient
serum
urin
involv
urinari
tract
alway
first
locat
viru
case
isol
serum
reactiv
incid
bk
infect
higher
patient
older
yr
p
transplant
famili
donor
msd
p
mud
recipi
often
serum
urin
reactiv
p
isol
urin
involv
sex
day
neutrophil
recoveri
condit
regimen
use
total
bodi
irradi
signific
risk
factor
bkv
infect
hc
six
patient
treat
cidofovir
rang
dose
good
respons
death
due
evid
bkv
infect
conclus
bkv
reactiv
remain
one
frequent
infecti
complic
children
undergo
allogen
hsct
patient
experienc
mild
infect
age
year
posit
prognost
factor
influenc
incid
bkv
monitor
prompt
treatment
hc
result
excel
outcom
observ
surprisingli
high
rate
new
bkv
replic
hsct
disclosur
noth
declar
background
highdos
chemotherapi
hdct
auto
pbsct
standard
therapi
multipl
myeloma
mm
two
decad
despit
wide
rang
new
therapeut
option
recurrentrefractori
malign
lymphoma
recurrentmetastat
germ
cell
tumor
gct
also
benefit
intens
therapi
comparison
allogen
transplant
treatment
known
lower
complic
rate
eg
infect
howev
previou
studi
schown
treatment
relat
toxic
may
underestim
depend
condit
regimen
use
method
retrospect
analyz
patient
case
underw
hdct
plu
auto
pbsct
singlecent
studi
anlyz
incid
infect
depend
condit
regimen
form
follow
categori
base
agiho
infect
neutropen
fever
sepsi
sever
sepsi
result
median
age
analysi
year
male
frequent
diagnosi
mm
receiv
high
dose
melphalan
mel
follow
malign
lymphoma
receiv
beam
bcnu
etoposid
cytarabin
melphalan
relapsedmetastat
germ
cell
tumour
gct
receiv
high
dose
carboplatinetoposid
ce
patient
develop
sever
sepsi
patient
ventil
patient
die
sepsi
document
case
case
major
patient
case
develop
neutropen
fever
case
infect
complic
beam
condit
regimen
show
highest
tendenc
result
septic
cours
follow
ce
mel
commonli
document
pathogen
blood
cultur
epidermidi
follow
e
coli
miti
one
blood
cultur
detect
multiresist
pathogen
e
coli
p
aeruginosa
detect
blood
cultur
l
monocytogen
aureu
patient
develop
diarrhea
case
could
detect
c
difficil
condit
regimen
show
signific
effect
incid
c
difficil
mean
neutropen
period
day
malign
lymphoma
patient
follow
mm
patient
day
gct
patient
hospit
discharg
calcul
day
transplant
significantli
differ
malign
lymphoma
mean
day
mm
day
gct
day
conclus
data
correspond
former
publish
result
mani
group
beam
regimen
show
highest
infecti
complic
rate
follow
ce
mel
durat
neutropenia
hospit
stay
depend
condit
regimen
type
infecti
complic
nt
effect
progress
freeand
overal
surviv
analysi
disclosur
noth
declar
impact
donor
recipi
cytomegaloviru
serostatu
outcom
unrel
allogen
haematopoiet
stem
cell
transplant
background
cytomegaloviru
cmv
import
caus
morbid
mortal
allogen
haematopoiet
stem
cell
transplant
hsct
patient
aim
studi
evalu
outcom
cmv
seroposit
recipi
receiv
graft
seroposit
unrel
donor
dr
compar
graft
seroneg
unrel
donor
dr
method
retrospect
singl
center
studi
seri
cmv
seroposit
recipi
underw
hsct
unrel
donor
febuari
juli
total
patient
analyz
clinic
cours
laboratori
result
review
evid
cmv
reactiv
andor
cmv
diseas
defin
cmv
infect
detect
cmv
reactiv
primari
infect
antigenaemia
polymeras
chain
reaction
pcr
assay
accompani
sign
andor
symptom
suggest
system
diseas
cmv
diseas
occur
cmv
isol
site
associ
organspecif
sign
andor
symptom
monitor
cmv
infect
commenc
upon
engraft
approxim
day
peripher
blood
sampl
sent
twice
week
cmv
antigenaemia
cmv
quantit
pcr
durat
twice
weekli
monitor
least
day
longer
monitor
perform
patient
experienc
cmv
infect
hsct
result
patient
receiv
graftversushostdiseas
gvhd
prophylaxi
use
antithymocyt
globulin
atg
addit
cyclosporin
tacrolimu
among
entir
cohort
patient
cmv
infect
includ
patient
dr
group
patient
dr
group
patient
dr
group
patient
dr
group
cmv
reactiv
threshold
preemptiv
therapi
respect
patient
develop
cmv
diseas
dr
group
r
group
cmv
resist
foscarnet
ganciclovir
detect
patient
dr
group
none
dr
group
patient
die
due
cmv
diseas
dr
group
year
overal
surviv
os
versu
dr
group
dr
group
respect
median
surviv
reach
year
year
nonrelaps
mortal
nrm
dr
group
r
group
respect
conclus
incid
recurr
cmv
infect
higher
dr
group
compar
dr
group
statist
signific
differ
group
term
os
nrm
howev
trend
toward
higher
nrm
dr
group
compar
dr
group
find
suggest
match
unrel
hsct
may
still
import
select
seroposit
donor
seroposit
recipi
disclosur
none
background
known
patient
submit
allogen
stem
cell
transplant
asct
could
present
greater
suscept
infect
even
long
term
complet
remiss
potenti
cure
fact
relat
dynam
immunolog
recoveri
variabl
everi
singl
patient
depend
mani
factor
haematolog
diseas
condit
regimen
age
patient
donor
number
stem
cell
lymphocyt
infus
antigvhd
prophylaxi
use
antithimoglobulin
other
clinic
practis
observ
patient
potenti
cure
taper
stop
immunosuppress
treatment
month
year
ago
suddenli
grave
opportunist
infect
largest
part
infect
repres
varicellazost
viru
vzv
cutan
erupt
method
report
retrospect
analys
monocentr
cohort
patient
submit
asct
haematolog
malign
median
time
month
free
diseas
stop
immunosuppress
treatment
median
time
day
asct
rang
present
later
chronic
gvhd
need
treatment
neither
moder
sever
chronic
post
transplant
complic
diseas
prophylact
treatment
anti
viral
agent
acyclovir
valacyclovir
conduct
simultan
immunosuppress
treatment
period
rang
month
suspens
cohort
patient
consid
incid
vzv
erupt
occur
suspens
immunosuppress
treatment
analys
immunolog
recoveri
term
lymphocyt
subpopul
month
asct
result
patient
consid
develop
least
one
vzv
manifest
vzv
present
cutan
observ
neurolog
ophthalm
viscer
present
vzv
manifest
occur
patient
end
antivir
prophylaxi
median
time
present
day
asct
rang
remain
patient
present
vzv
manifest
kind
opportunist
infect
despit
absenc
antivir
prophylaxi
analysi
lymphocyt
subpopul
month
show
signific
differ
b
nk
lymphocyt
differ
post
transplant
period
conclus
vzv
reactiv
seem
correl
number
differ
lymphocyt
subpopul
post
transplant
period
actual
possibl
distinguish
patient
suitabl
vzv
reactiv
basi
lymphocyt
subpopul
analysi
antivir
prophylaxi
prolong
medium
period
suspens
immunosuppress
drug
absenc
anti
viral
prophylaxi
care
clinic
surveil
perform
order
treat
earli
eventu
vzv
manifest
disclosur
background
infect
diseas
cytomegaloviru
cmv
common
problem
patient
undergo
hematopoiet
stem
cell
transplant
hsct
cmv
infect
high
overal
seropreval
therefor
first
posthsct
import
prevent
reactiv
cmv
intern
clinic
recommend
use
ganciclovir
prophylaxi
hsct
patient
howev
cost
treatment
access
popul
respect
use
altern
valganciclovir
lower
cost
oral
administr
aim
assess
respons
safeti
valganciclovir
comparison
ganciclovir
prevent
viremia
cytomegaloviru
diseas
patient
undergo
allogen
hsct
method
retrospect
studi
perform
patient
receiv
hsctallo
januari
august
particip
enrol
two
group
accord
prophylaxi
treatment
ganciclovir
daili
b
valganciclovir
twice
daili
day
pretranspl
day
viremia
measur
pcr
demograph
clinic
inform
collect
medic
record
furthermor
analyz
spss
result
sixtyeight
patient
enrol
studi
male
median
age
year
follow
diagnos
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
granulocyt
chronic
leukemia
myelodysplast
syndrom
dendrit
cell
neoplasia
aplast
anemia
ninetyon
percet
patient
receiv
transplant
ident
hla
donor
receiv
haploident
transplant
thirtyfour
patient
receiv
ganciclovir
thirtyfour
valganciclovir
median
age
year
intermedi
risk
cmv
vs
associ
bacteri
infect
vs
fungal
infect
respect
reactiv
cmv
present
vs
respect
signific
differ
fever
bacteri
isol
dysfunct
graft
failur
presenc
degre
acut
chronic
gvhd
relaps
diseas
relev
characterist
complic
describ
tabl
within
whole
group
death
ganciclovir
group
valganciclovir
group
overal
surviv
vs
respect
group
associ
relaps
associ
transplant
conclus
ganciclovir
valganciclovir
effect
prevent
reactiv
cmv
statist
signific
differ
present
diseas
appear
earlier
valganciclovir
group
differ
toxic
group
identifi
disclosur
none
declar
background
invas
pulmonari
aspergillosi
ipa
sever
seriou
complic
occur
immedi
posttranspl
period
due
sever
neutropenia
late
usual
follow
prolong
corticosteroid
therapi
treatment
graftversushost
diseas
gvhd
object
studi
analyz
epidemiolog
diagnost
evolutionari
characterist
major
complic
period
year
method
januari
decemb
patient
pt
receiv
allogen
hematopoiet
stem
cell
transplant
allo
hsct
malign
nonmalign
haematolog
diseas
transplant
procedur
antiinfecti
prophylaxi
consist
pt
isol
digest
decontamin
fluconazol
aciclovir
secondari
prophylaxi
done
pt
prior
histori
aspergillosi
followup
standard
chest
xray
perform
systemat
control
case
clinic
sign
thorac
ct
scan
request
suspicion
diagnosi
ipa
made
accord
criteria
eortcmsg
base
predispos
criteria
host
clinicoradiolog
criteria
possibl
infect
galactomannan
antigen
histopatholog
criteria
common
practic
result
total
ipa
episod
identifi
pt
aml
aa
cml
mm
median
age
sex
ratio
transplant
famili
donor
genoident
haploident
condit
chemotherapi
alon
graft
csp
pt
peripher
stem
cellsbon
marrow
pt
pt
least
one
predispos
risk
factor
anteced
aspergillosi
pt
prolong
neutropenia
pt
acut
gvhd
pt
chronic
gvhd
pt
prolong
corticosteroid
therapi
mg
kgday
exceed
day
pt
diagnosi
api
possibl
averag
appear
clinic
sign
case
evoc
radiolog
case
case
standard
chest
xray
normal
time
thorac
ct
scan
pt
characterist
sign
halo
sign
pt
crescent
sign
pt
caviti
pt
minor
radiolog
sign
found
pt
empir
firstlin
antifung
therapi
start
monotherapi
pt
voriconazol
caspofungin
pt
combin
pt
secondlin
treatment
requir
pt
failur
averag
durat
day
three
pt
present
second
episod
averag
delay
month
favor
evolut
resumpt
thetreat
fourteen
pt
aliv
complet
resolut
median
treatment
time
month
twelv
pt
die
rapidli
averag
day
diagnosi
ipa
relaps
diseas
conclus
ipa
occur
allograft
allohsct
sever
complic
high
mortal
essenti
case
identifi
pt
risk
factor
perform
thorac
ctscan
send
serum
serolog
apergillu
galactomannan
antigenand
start
specif
treatment
soon
possibl
wait
abl
reinforc
diagnosi
direct
examin
sputum
brochoalveolar
lavag
aspir
disclosur
noth
declar
background
cmv
cytomegaloviru
preval
vari
pathogen
rel
low
gener
popul
usual
result
selflimit
viral
ill
immunosuppress
host
infect
lead
life
threaten
ill
dissemin
cmv
infect
manifest
number
organ
diagnos
use
intern
accept
criteria
post
solid
organ
stem
cell
transplant
sct
set
postul
viral
reactiv
rather
primari
reinfect
lead
cmv
viraemia
prevent
reactiv
requir
presenc
compet
immun
system
mediat
tcell
account
increas
incid
intens
tcell
deplet
sct
condit
regimen
despit
improv
outcom
follow
introduct
cmv
monitor
pcr
preemptiv
treatment
current
uk
guidanc
cmv
pneumon
still
carri
high
mortal
use
cmv
specif
immunoglobulin
cmvig
treatment
complic
gener
recommend
post
chemotherapi
sct
haematolog
cancer
due
lack
evid
howev
cmvig
wide
use
set
cmv
reactiv
post
solid
organ
transplant
report
use
cmvig
patient
suspect
cmv
pneumon
singl
uk
centr
aim
retrospect
studi
establish
safeti
review
efficaci
highli
immunocompromis
group
patient
method
data
collect
retrospect
use
cmvig
patient
haematolog
cancer
post
sct
chemotherapi
alon
manchest
royal
infirmari
uk
patient
includ
cmv
posit
pcr
blood
bronchoscopi
well
high
resolut
ct
imag
evid
cmv
infect
data
sourc
pharmaci
databas
crossreferenc
department
list
patient
identifi
case
note
prescript
sourc
data
collect
includ
patient
baselin
characterist
time
treatment
number
dose
cmvig
outcom
result
eight
patient
receiv
cmvig
suspect
cmv
pneumon
seven
patient
post
sct
one
patient
sever
immunosuppress
chemotherapi
alon
median
age
year
rang
cmvig
regimen
use
cytotect
day
follow
everi
four
day
resolut
symptom
infus
relat
reaction
observ
patient
receiv
median
dose
cmvig
four
patient
respond
treatment
show
full
recoveri
aliv
well
date
conclus
studi
show
use
cmvig
safe
postsct
set
acut
unwel
patient
multiorgan
failur
despit
limit
retrospect
studi
appear
benefit
use
cmvig
patient
popul
patient
show
full
recoveri
episod
allogen
sct
play
confound
role
outcom
patient
although
number
studi
small
clearli
need
better
treatment
cmv
pneumon
cmvig
promis
treatment
studi
need
identifi
optim
dose
regimen
provid
evid
efficaci
disclosur
biotesthonaria
abstract
withdrawn
background
risk
fungal
infect
relat
allogen
transplant
wellknown
caus
morbid
mortal
main
agent
implic
yeast
neutropen
period
filament
fungi
period
method
decid
evalu
effect
prophylact
regimen
contain
fluconazol
sinc
day
discharg
fluconazol
kept
day
switch
posaconazol
highrisk
patient
patient
gvhd
steroid
kept
prophylaxisth
group
high
risk
patient
defin
one
follow
variabl
relat
donor
campath
fludarabin
condit
gvhd
need
steroid
mgkg
analyz
patient
submit
allobmt
patient
first
admit
isol
room
hepa
filterspati
secondari
prophylaxi
exclud
breakthrough
fungal
infect
first
year
toxic
lead
discontinu
evalu
result
sixti
six
patient
includ
transplant
malefemal
ratio
age
rang
yo
median
malign
nonmalign
diagnosi
includ
donor
type
relat
haploident
nonrel
condit
regimen
includ
atg
campath
fludarabin
fourteen
patient
treat
discharg
fluconazol
posaconazol
three
patient
fluconazol
switch
micafungin
hepat
toxic
two
case
amphotericin
due
persist
fever
one
case
caspofungin
proven
fungal
infect
candida
parapsilosi
blood
stream
day
discharg
first
year
followup
singl
case
possibl
fungal
infect
diagnos
patient
gvhd
lung
nodul
conclus
neutropen
period
transplant
main
risk
fungal
infect
associ
candidiasi
greatest
risk
aspergillosi
occur
later
signific
relat
gvhd
except
candida
parapsilosi
main
sourc
yeast
gi
tract
main
sourc
aspergillu
aerosol
particl
retain
hepa
filter
patient
without
previou
episod
fungal
infect
main
risk
filament
fungi
occur
discharg
conclud
fluconazol
alon
follow
posaconazol
high
risk
patient
feasibl
effect
regimen
primari
prophylaxi
allogen
transplant
disclosur
background
bk
virusassoci
hemorrhag
cystiti
bkvhc
emerg
seriou
infect
hematopoiet
stem
cell
transplant
hsct
character
pain
hematuria
due
hemorrhag
inflamm
urinari
bladder
mucosa
caus
signific
morbid
prolong
hospit
care
extens
nurs
requir
increas
healthcar
cost
purpos
studi
determin
incid
risk
factor
durat
treatment
center
method
perform
retrospect
review
hsct
patient
lui
calvo
mackenna
hospit
santiago
chile
diagnos
bkvhc
januari
novemb
investig
incid
risk
factor
durat
treatment
bkvhc
paediatr
patient
undergo
hsct
month
period
bkvhc
defin
bk
viru
bkv
detect
urin
pcr
test
associ
clinic
symptom
hematuria
grade
higher
sixtyseven
patient
trasplant
period
result
eleven
patient
diagnos
bkvhc
institut
one
bk
viremia
cumul
incid
bkvhc
seri
treat
cidofovir
median
age
diagnosi
year
old
rang
yo
median
time
hsct
hemorrhag
cystiti
hc
day
rang
day
median
length
treatment
week
rang
patient
receiv
myeloabl
condit
regimen
use
cyclophosphamid
ten
unrel
cord
blood
transplant
recipi
nine
use
antithymocyt
globulin
concomit
viral
reactiv
demonstr
six
patient
patient
die
due
bkvhc
complic
follow
three
patient
die
one
relaps
two
post
complic
conclus
bkvhc
result
complex
interact
patient
characterist
donor
type
condit
regimen
intens
patient
experienc
signific
morbid
prolong
treatment
cohort
bkvhc
patient
one
transplant
unrel
umbil
cord
blood
unit
receiv
myeloabl
condit
regimen
cyclophosphamid
receiv
antithymocyt
globulin
also
observ
frequent
coexist
viral
infect
herp
famili
cmv
main
limit
work
retrospect
natur
singl
center
studi
necessari
better
understand
epidemiolog
risk
factor
associ
bkvhc
morbid
associ
treatment
disclosur
noth
declar
manag
reactiv
posttranspl
set
oscar
borsani
anna
amelia
colombo
daniela
caldera
paolo
bernasconi
univers
pavia
san
matteo
hospit
pavia
itali
background
enceph
lifethreaten
complic
posttranspl
set
develop
patient
receiv
tradit
hsct
sever
risk
factor
describ
differenti
diagnosi
enceph
neurolog
complic
extrem
import
often
noteasi
achiev
highli
heterogen
clinic
radiolog
featur
complex
interpret
especi
transplant
patient
describ
vignett
repres
highlight
distinct
problem
diagnosi
manag
transplant
patient
suspect
reactiv
method
collect
clinic
laboratori
radiolog
electroencephalogram
brain
mri
brain
ct
data
transplant
patient
develop
neurolog
syndrom
suspect
reactiv
detect
serum
csf
use
rtqpcr
result
patient
develop
diffus
erythema
subsequ
encephalit
syndrom
follow
hsct
brain
mri
reveal
clear
sign
limbic
encephalit
search
serum
csf
reveal
copiesml
copiesml
respect
antivir
therapi
start
clinic
benefit
achiev
patient
develop
typic
neurolog
syndrom
without
brain
mri
find
enceph
evid
skin
involv
lumbar
punctur
csf
analysi
show
total
dna
copiesml
antivir
therapi
ganciclovir
foscarnet
promptli
start
clinic
improv
drastic
reduct
dna
csf
serum
new
brain
mri
reveal
acut
limbic
enceph
slight
neurolog
syndrom
consist
confus
amnesia
develop
brain
mri
find
compat
wernick
syndrom
improv
neurolog
symptom
obtain
thiamin
supplement
csf
analysi
reveal
dna
detect
low
copi
number
serum
analysi
second
brain
mri
conclus
limbic
enceph
antivir
therapi
foscavir
start
radiolog
clinic
improv
note
patient
die
day
last
case
present
patient
develop
clinic
pictur
encephalopathi
ie
amnesia
ataxia
drowsi
weak
depress
rapid
progress
coma
seventyeight
day
hsct
brain
mri
show
slight
contrast
enhanc
parietaloccipit
region
recoveri
phase
conditioninginduc
cytopenia
increas
serum
dna
detect
search
dna
donor
follicl
show
chromosom
integr
cyclosporin
csa
interrupt
neurolog
improv
observ
follow
hour
diagnosi
pre
made
conclus
enceph
suspect
transplant
patient
clinic
syndrom
encephalopathi
pcr
detect
dna
csf
associ
either
typic
brain
mri
abnorm
clinic
diagnosi
nonspecif
encephalopathi
must
lead
urgent
initi
system
antivir
treatment
increas
serum
dna
wbc
detect
confirm
pre
import
differenti
diagnosi
transplant
patient
develop
encephalit
syndrom
disclosur
noth
declar
background
cytomegaloviru
cmv
infect
major
caus
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
caus
endorgan
diseas
multiorgan
dysfunct
syndrom
graft
failur
increas
suscept
infect
gvhd
greatest
risk
cmv
infect
seroposit
host
reactiv
latent
viru
method
prospect
descript
studi
perform
arm
forc
bone
marrow
transplant
centr
rawalpindi
pakistan
dec
sep
hundr
consecut
patient
underw
hsct
follow
weekli
cmv
dna
quantit
pcr
engraft
till
day
cmv
reactiv
patient
cmv
pcr
show
copiesml
treat
antivir
therapi
factor
associ
cmv
reactiv
outcom
antivir
therapi
effect
cmv
transplant
outcom
studi
result
case
hla
match
sibl
match
famili
donor
haploident
transplant
male
femal
mean
age
year
fourtytwo
transplant
done
thalassemia
aplasia
leukemia
hematolog
disord
immun
defici
ninetyeight
recipi
donor
cmv
seroposit
hsct
cmv
reactiv
seen
patient
cmv
viral
load
copiesml
patient
cmv
viral
load
less
copiesml
nineteen
patient
cmv
reactiv
mean
time
reactiv
sinc
transplant
day
valganciclovir
given
patient
due
eas
administr
six
patient
treat
ganciclovir
hospit
stay
one
patient
resist
diseas
mean
time
clear
viremia
day
patient
viral
load
less
copiesml
subsequ
clear
cmv
without
treatment
antivir
agent
ganciclovir
valganciclovir
equal
effect
treat
cmv
infect
efficaci
howev
advers
effect
seen
ganciclovir
myelosuppress
iiii
seen
patient
treat
valganciclovir
treat
valganciclovir
renal
impair
iii
seen
valganciclovir
ganciclovir
treat
patient
steroid
administr
strongli
associ
cmv
reactiv
p
statist
signific
associ
found
use
atg
gvhd
underli
diseas
abo
gender
mismatch
os
without
cmv
reactiv
df
without
cmv
reactiv
conclus
cmv
reactiv
seen
transplant
recipi
higher
compar
western
world
due
high
cmv
seroposit
region
steroid
administr
posttranspl
period
significantli
increas
risk
cmv
reactiv
preemptiv
therapi
valganciclovir
effect
treat
cmv
reactiv
accept
side
effect
viral
threshold
treatment
decid
consid
region
endem
cmv
advers
affect
transplant
outcom
term
df
os
disclosur
conflict
interest
acut
nephriti
requir
nephrectomi
caus
adenoviru
hadv
human
polyomaviru
bk
bkpyv
follow
allogen
hematopoiet
stemcel
transplant
patient
ph
background
adenoviru
infect
repres
import
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
allohsct
establish
therapi
although
differ
organ
may
affect
dissemin
hadv
infect
kidney
involv
rare
report
coinfect
hadv
bkpyv
common
complic
patient
undergo
allohsct
recent
studi
demonstr
bkpyv
may
facilit
replic
hadv
lead
elev
viremia
increas
virul
seriou
clinic
consequ
report
case
adult
patient
requir
monolater
nephrectomi
due
hadv
pyelonephr
earli
complic
allohsct
philadelphiaposit
acut
lymphoblast
leukemia
ph
method
septemb
ethiopian
gentleman
diagnos
ph
age
year
treat
polychemotherapi
associ
tyrosin
kinas
inhibitor
imatinib
mesyl
achiev
complet
remiss
cr
one
year
later
due
diseas
relaps
cn
involv
start
vincristin
dexamethason
plu
imatinib
treatment
april
refer
bmt
center
ethiopia
upon
confirm
ph
ball
diagnosi
therapi
scrabl
dual
inhibitor
dasatinib
associ
intrathec
chemotherapi
start
salvag
treatment
inotuzumab
ozogamicin
follow
allogen
hsct
hlaident
brother
plan
achiev
document
molecular
cr
diseas
statu
june
patient
underw
allohsct
follow
fludarabinemelphalan
reducedintens
condit
regimen
graftversushost
prophylaxi
includ
antithymocyt
globulin
cyclosporin
mycophenol
mofetil
result
day
posttransplant
patient
develop
macrohematuria
due
hemorrhag
cystiti
ct
scan
unveil
left
pyelonephr
mark
kidney
enlarg
kidney
microbi
investig
neg
time
hadv
viremia
high
copi
number
cpml
document
also
elev
bkpyv
cpml
viruria
viremia
cpml
genotyp
hadv
evidenc
serotyp
mainli
involv
infect
urinari
tract
treatment
cidofovir
immedi
start
nonetheless
due
rapid
clinic
worsen
despit
maxim
antibiot
therapi
day
left
nephrectomi
perform
led
subsequ
progress
resolut
clinic
symptom
negativ
hadv
bkpyv
viremia
viruria
pcr
real
time
perform
kidney
tissu
unveil
high
concentr
hadv
copi
number
conclus
acut
pyelonephr
due
dissemin
hadv
infect
may
repres
possibl
caus
sever
complic
follow
allohsct
monitor
hadv
copi
number
help
evalu
infect
sever
respons
treatment
coinfect
hadv
bkpyv
immunocompromis
patient
alway
consid
like
worsen
clinic
cours
outcom
disclosur
noth
declar
background
infect
major
caus
morbid
mortal
patient
pt
receiv
allohsct
sever
relat
primarili
depth
durat
neutropenia
febril
neutropenia
fn
defin
neutrophil
count
cellsmm
fever
singl
measur
time
one
hour
interv
object
studi
analyz
epidemiolog
clinic
biolog
characterist
febril
episod
fe
occur
pt
benefit
allocsh
period
year
method
januari
decemb
allohsct
perform
pt
includ
siblinghla
ident
haploident
phenoident
essenti
acut
leukemia
pt
acquir
congenit
aplasia
pt
median
age
year
sexratio
mf
prophylaxi
consist
isol
steril
room
laminar
flow
digest
decontamin
fluconazol
aciclovir
nine
pt
infect
time
hospit
cellul
pneumonia
bacteri
angina
veiniti
bronchial
pneumonia
furuncl
cutan
requir
treatment
antibiot
condit
regimen
myeloabl
pt
antithymocyt
globulin
use
pt
peripher
blood
stem
cell
pbsc
use
pt
averag
level
cell
kg
bone
marrow
bm
pt
mean
level
nucleat
cell
x
kg
associ
pbscbm
pt
haploident
fe
practic
chest
xray
procalcitonin
test
blood
cultur
microbiolog
studi
urin
stool
diarrhea
result
pt
show
aplasia
averag
durat
day
neutrophil
engraft
observ
day
one
hundr
twentynin
pt
present
fe
averag
per
pt
eleven
pt
fe
forti
nine
fe
clinic
document
digest
skin
pulmonari
urinari
otorhinolaryngolog
blood
cultur
made
fe
fe
microbiolog
document
gramposit
bacteremia
mainli
coagulas
neg
staphylococci
gramneg
bacilli
case
procalcitonin
test
perform
fe
normal
case
probabl
infect
case
probabl
sepsi
case
sever
sepsi
case
septic
shock
one
case
empir
doubl
antibiot
therapi
initi
pt
without
wait
result
microbiolog
studi
associ
suffici
pt
transit
second
line
need
pt
third
line
pt
antifung
ad
case
eight
pt
benefit
gcsf
evolut
favor
fe
apyrexia
obtain
averag
day
three
pt
die
sever
sepsi
durabl
aplasia
cellul
condit
conclus
fe
increas
morbid
mortal
allohsct
prophylact
measur
essenti
empir
antibiot
treatment
institut
quickli
absenc
document
disclosur
noth
declar
abstract
withdrawn
atsushi
satak
masaaki
hotta
ryo
saito
akiko
konishi
hideaki
yoshimura
takahisa
nakanishi
shinya
fujita
tomoki
ito
kazuyoshi
ishii
shosaku
nomura
kansai
medic
univers
osaka
japan
background
cytomegaloviru
cmv
infect
remain
common
complic
allogen
hematopoiet
stem
cell
transplant
ahsct
result
increas
morbid
mortal
letermovir
novel
anti
cmv
drug
inhibit
cmvterminas
complex
purpos
retrospect
studi
elucid
efficaci
safeti
cmv
prophylaxi
letermovir
earli
ahsct
clinic
practic
method
retrospect
analyz
incid
cmv
infect
cmv
diseas
preemptiv
therapi
advers
event
week
ahsct
rate
engraft
overal
surviv
patient
underw
ahsct
institut
hematopoiet
malign
may
nov
data
collect
studi
includ
patient
characterist
age
sex
diseas
statu
donor
sourc
cmv
diseas
risk
cmv
infect
evalu
cmv
antigenemia
studi
approv
research
ethic
committe
faculti
medicin
kansai
medic
univers
result
thirteen
patient
male
femal
underw
ahsct
receiv
cmv
prophylaxi
letermovir
median
age
year
rang
year
overal
patient
consid
high
risk
cmv
includ
patient
haploident
donor
mismatch
unrel
donor
patient
began
letermovir
day
ahsct
achiev
engraft
median
day
patient
develop
cmv
diseas
requir
preemptiv
therapi
one
patient
die
treatmentrel
mortal
patient
die
acut
gvhd
although
one
patient
discontinu
letermovir
day
ahsct
letermovir
suspect
caus
persist
nausea
sever
advers
event
observ
conclus
still
unknown
whether
cmv
prophylaxi
letermovir
improv
os
reduc
trm
howev
data
suggest
cmv
infect
consider
inhibit
administr
letermovir
earli
ahsct
clinic
trial
registri
applic
disclosur
author
declar
noconflict
interest
studi
background
cytomegaloviru
cmv
caus
increas
morbid
mortal
transplant
hematopoiet
cell
pathogenesi
cmv
diseas
infect
complex
multipl
interact
immun
system
mainli
acut
chronic
graftversushost
diseas
gvhd
aim
studi
analyz
risk
factor
reactiv
cmv
patient
undergo
allogen
hematopoiet
cell
transplant
hct
method
prospect
descript
studi
risk
factor
reactiv
cmv
describ
popul
univari
multivari
analysi
predispos
factor
perform
donor
graft
treatment
corticosteroid
use
antithymoglobin
serolog
statu
condit
regimen
presenc
gvhd
result
period
august
januari
patient
evalu
reactiv
cmv
averag
reactiv
day
post
transplant
recipi
donor
posit
cmv
igg
univari
analysi
reactiv
cmv
associ
haploident
transplant
p
use
corticosteroid
p
gvhd
p
multivari
analysi
haploident
transplant
maintain
statist
signific
comparison
relat
allogen
transplant
p
well
use
corticosteroid
p
patient
receiv
corticosteroid
treatment
grade
ii
iii
gvhd
serologicac
statu
myeloabl
condit
regimen
use
atg
show
statist
signific
associ
conclus
patient
undergo
allogen
transplant
found
risk
factor
reactiv
receiv
haploident
transplant
treatment
corticosteroid
anoth
risk
factor
show
greater
reactiv
presenc
gvhd
disclosur
noth
declar
method
yo
male
refer
allogen
transplant
follow
cycl
induct
therapi
aml
complex
karyotyp
mutat
achiev
complet
remiss
follow
first
cycl
chemotherapi
first
induct
cycl
complic
perian
myeloid
sarcoma
becam
infect
requir
surgic
drainag
format
defunct
colostomi
result
follow
allogen
transplant
first
complic
secondari
graft
failur
second
primari
graft
failur
present
two
skin
lesion
third
lesion
adjac
stoma
develop
shortli
admiss
lesion
erythemat
central
necrosi
progress
rapidli
size
hour
biopsi
skin
parastom
lesion
reveal
fungal
mycelia
cultur
subsequ
identifi
rhizopu
oryza
initi
treatment
liposom
amphotericin
b
follow
dose
escal
due
develop
new
skin
lesion
patient
take
posaconazol
tablet
prophylaxi
sinc
first
allogen
transplant
peripher
blood
drug
level
check
time
admiss
therapeut
confirm
breakthrough
fungal
infect
consequ
posaconazol
stop
isavuconazol
ad
treatment
regimen
surgic
assess
undertaken
surgeri
defer
basi
high
risk
due
extent
infect
profound
pancytopenia
organ
test
vitro
susceptibilitiy
found
resist
posaconazol
mic
borderlin
resist
isavuconazol
mic
sensit
amphotericin
b
mic
phe
mycolog
refer
laboratori
england
isavuconazol
therefor
stop
patient
manag
liposom
amphotericin
b
along
daili
granulocyt
infus
underw
third
allogen
transplant
use
differ
unrel
donor
stabl
engraft
achiev
post
transplant
initi
increas
size
parastom
lesion
new
skin
lesion
develop
follow
engraft
underw
resect
stomal
lesion
primari
closur
resit
stoma
amphotericin
b
replac
isavuconazol
prophylaxi
discharg
continu
make
excel
recoveri
conclus
whilst
aspergillu
speci
remain
common
caus
invas
fungal
infect
allogen
transplant
patient
speci
includ
mucoral
seen
gener
associ
poorer
outcom
whilst
standardis
methodolog
suscept
test
fungi
specif
cut
off
base
clinic
outcom
avail
limit
number
speci
antifung
agent
case
suscept
test
demonstr
resist
posaconazol
consist
clinic
present
invas
infect
despit
therapeut
level
posaconazol
also
worth
note
estim
r
oryza
isol
uk
resist
posaconazol
treatment
high
dose
amphotericin
b
result
improv
small
skin
lesion
stabilis
larger
stomal
lesion
count
recoveri
allow
surgic
resect
background
total
deplet
innat
adapt
immun
cell
popul
occur
intens
chemotherapi
hematopoiet
stem
cell
transplant
hsct
b
lymphocyt
pool
restor
slower
myelomonocyt
popul
hsct
patient
high
risk
bacteri
viral
infect
earli
term
day
posttranspl
reconstitut
immun
system
depend
time
requir
stem
cell
recruit
differenti
expans
matur
releas
bloodstream
restor
term
myeloid
cell
hsct
usual
defin
day
neutrophil
count
x
mean
recoveri
term
day
high
occurr
cytomegaloviru
cmv
hsct
patient
mostli
result
reactiv
latent
viru
acquir
earli
childhood
howev
delay
immun
reconstitut
subsequ
infect
cmv
adenoviru
adv
herp
diseas
unusu
still
constitut
major
caus
death
peru
method
peruvian
pediatr
patient
diagnos
aplast
anemia
md
aml
underw
haploident
hsct
perform
clinimac
devic
patient
treat
separ
two
group
group
patient
receiv
viral
prophylaxi
ganciclovir
compar
group
receiv
prophylaxi
treatment
viral
reactiv
confirm
pcr
test
twice
week
clinic
sign
within
day
hsct
result
group
receiv
prophylact
treatment
engraft
occur
close
day
post
haplohsct
none
patient
develop
gvhd
graft
versu
host
diseas
nevertheless
incid
cmv
bkv
infect
day
post
haplohsct
still
high
overal
surviv
os
ic
reach
end
first
year
hand
group
patient
receiv
prophylaxi
ganciclovir
develop
gvhd
reach
engraft
close
day
low
viremia
incid
first
month
post
haplohsct
viral
reactiv
caus
cmv
os
ic
end
first
year
previou
prophylaxi
donor
receptor
ganciclovir
everi
hour
condit
regimen
allow
better
control
viral
reactiv
conclus
attempt
improv
immun
function
reduc
nonrelaps
mortal
infecti
complic
without
increas
gvhd
focus
partial
cell
deplet
graft
cell
deplet
tcr
graft
retain
larg
number
effector
cell
tcr
natur
killer
cell
howev
delay
immun
reconstitut
subsequ
infect
big
issu
novel
partial
cell
deplet
strategi
deplet
cell
cell
could
enhanc
recoveri
immun
function
haplohsct
donor
pathogen
memori
cell
donor
retain
necessari
increas
studi
databas
set
scheme
previou
prophylaxi
recipi
contain
viral
reactiv
help
rapid
immun
reconstitut
disclosur
conflict
interest
declar
inform
recov
medic
record
result
thirtyfour
patient
includ
follow
diagnos
acut
leukemia
granulocyt
chronic
leukemia
dendrit
cell
neoplasia
aplast
anemia
patient
receiv
transplant
ident
hla
donor
receiv
haploident
transplant
mean
age
patient
year
prophylaxi
posaconazol
perform
patient
ident
hla
haploident
group
rest
patient
receiv
fluconazol
posaconazol
group
present
fever
mucos
giii
gastrointestin
toxic
giii
p
hepat
toxic
kidney
toxic
oral
candidiasi
period
none
patient
present
invas
fungal
infect
group
deceas
one
group
none
relat
fungal
infect
overal
surviv
versu
posaconazol
group
fluconazol
group
respect
conclus
prophylaxi
posaconazol
fluconazol
effect
prevent
invas
fungal
infect
first
day
toxic
similar
group
posaconazol
effect
prevent
haploident
type
necessari
continu
follow
patient
infect
risk
longterm
period
associ
chronic
gvhd
disclosur
none
declar
lymphoma
result
open
question
whether
allosct
still
offer
patient
method
aim
defin
role
allosct
refractori
relaps
two
line
de
novo
transform
dlbcl
patient
comparison
cart
cell
trial
neelapu
et
al
nejm
analys
longterm
allosct
result
de
novo
transform
dlbcl
allosct
perform
institut
octob
octob
result
patient
transplant
characterist
summar
tabl
complet
respons
cr
day
remain
cr
month
median
followup
month
progressionfre
surviv
pf
overal
surviv
os
transplantrel
mortal
refractori
time
transplant
associ
poorer
prognosi
refractori
patient
long
term
survivor
figur
similar
result
report
trial
best
respons
cr
retain
month
median
followup
month
pf
os
patient
characterist
differ
seri
except
patient
refractori
prior
therapi
tabl
conclus
although
patient
de
novo
transform
dlbcl
offer
allosct
allosct
cur
option
chemosensit
patient
matur
data
longer
followup
cart
therapi
reason
still
offer
poor
prognosi
patient
moreov
almost
patient
avail
donor
better
graftversushost
diseas
prophylaxi
decreas
trm
morbid
new
therapi
make
patient
sensit
diseas
allosct
therefor
allosct
cart
cell
strategi
discuss
everi
young
patient
avail
donor
disclosur
honoraria
advisor
speaker
gilead
method
consecut
patient
transplant
hgbl
exclud
burkitt
lymphoma
ebmt
databas
includ
data
collect
includ
age
sex
patholog
subtyp
hgbl
includ
subtyp
tfl
dhl
diseas
statu
sct
condit
vs
beam
cam
vs
flumelcamatg
engraft
day
outcom
trm
os
pf
elig
emea
licens
indic
cart
therapi
result
fifti
patient
median
age
diagnosi
sct
includ
subtyp
includ
hgbl
tfl
dhl
indic
sct
primari
refractori
relaps
month
primari
treatment
previou
autologoussct
dhl
median
line
therapi
rang
condit
use
cytbi
buci
etoptbi
flubuci
beamcam
fmct
n
patient
engraft
neutrophil
l
median
day
platelet
l
median
day
mortal
progress
diseas
nrm
year
os
mortal
due
progress
diseas
nrm
diseas
subtyp
influenc
outcom
os
primari
refractori
hgbl
relaps
hgbl
tfl
dhl
respect
patient
elig
licens
cart
product
conclus
outcom
high
risk
hgbl
patient
accept
os
relaps
diseas
commonest
caus
mortal
patient
dhl
particularli
good
outcom
seri
recent
evid
indic
patient
nonimmunoglobulin
gene
associ
myc
transloc
could
manag
conserv
ash
sehn
outcom
achiev
allogeneicsct
seri
provid
baselin
outcom
assess
cart
program
disclosur
noth
declar
background
immun
checkpoint
inhibitor
ici
allow
achiev
durabl
remiss
patient
resist
refractori
rr
classic
hodgkin
lymphoma
howev
inform
optim
durat
therapi
prognosi
patient
ici
cessat
limit
manson
blood
therefor
optim
role
hematopoiet
sct
hsct
patient
group
defin
aim
determin
remiss
durat
patient
discontinu
ici
monotherapi
achiev
complet
remiss
cr
method
analysi
includ
patient
femal
age
median
year
rr
classic
hodgkin
lymphoma
treat
nivolumab
mgkg
everi
day
achiev
cr
respons
assess
positronemiss
tomographycomput
tomographi
petct
use
lyric
criteria
everi
month
nivolumab
therapi
stop
patient
receiv
treatment
diseas
assess
everi
month
petct
median
followup
therapi
discontinu
month
result
moment
therapi
initi
patient
stage
diseas
patient
progress
diseas
pd
patient
stabl
diseas
patient
partial
remiss
complet
remiss
patient
bsymptom
ecog
score
median
number
previou
therapi
line
nivolumab
initi
high
dose
chemotherapi
autolog
sct
perform
patient
receiv
brentuximab
vedotin
median
number
nivolumab
cycl
cr
achiev
median
cycl
median
durat
therapi
achiev
cr
month
time
analysi
patient
aliv
patient
relaps
therapi
discontinu
median
progressionfre
surviv
pf
total
group
achiev
among
patient
relaps
median
time
pd
month
relaps
patient
retreat
nivolumab
monotherapi
chemotherapi
combin
one
patient
achiev
complet
remiss
partial
remiss
indetermin
respons
type
patient
continu
therapi
respons
yet
evalu
conclus
complet
respons
maintain
patient
median
follow
month
nivolumab
therapi
cessat
pf
plateau
reach
report
patient
relaps
nivolumab
discontinu
sustain
sensit
nivolumab
achiev
respons
retreat
nivolumab
monotherapi
chemotherapi
combin
patient
unsatisfactori
respons
nivolumab
retreat
hsct
option
consid
disclosur
noth
declar
high
dose
chemotherapi
autolog
stem
cell
transplant
primari
central
nervou
system
lymphoma
data
japan
societi
hematopoiet
cell
transplant
jshct
registri
center
hospit
tokyo
japan
nation
cancer
institut
bethesda
md
unit
state
okayama
univers
hospit
okayama
japan
kanazawa
medic
univers
uchinada
japan
kyoto
univers
kyoto
japan
aomori
prefectur
central
hospit
aomori
japan
yamagata
unvers
school
medicin
yamagata
japan
tenri
hospit
tenri
japan
hiroshima
univers
hiroshima
japan
japanes
data
center
hematopoiet
cell
transplant
nagoya
japan
nagoya
univers
graduat
school
medicin
nagoya
japan
shiman
univers
hospit
izumo
japan
background
highdos
chemotherapi
hdt
autolog
stem
cell
transplant
asct
shown
improv
prognosi
patient
central
nervou
system
cn
lymphoma
wherea
common
regimen
hdt
pcnsl
europ
us
thiotepabas
regimen
eg
bcnuthiotepa
tbc
thiotepabusulfancyclophosphamid
thiotepabas
regimen
avail
discontinu
thiotepa
japan
report
result
asct
pcnsl
japan
societi
hematopoiet
cell
transplant
jshct
registri
method
data
jshct
registri
retrospect
analyz
patient
pcnsl
receiv
first
hdtasct
evalu
distribut
differ
clinic
characterist
group
analyz
exact
mannwhitney
u
test
overal
surviv
os
progress
free
surviv
pf
calcul
use
kaplanmei
method
twogroup
analysi
cumul
incid
relaps
conduct
use
grey
test
factor
analyz
univari
analysi
factor
retain
multivari
model
p
valu
side
valu
regard
statist
signific
p
result
median
age
month
rang
patient
year
age
male
femal
ecogperform
statu
ps
diagnosi
better
patient
poor
patient
serum
lactat
dehydrogenas
ldh
level
diagnosi
elev
patient
karnofski
ps
cerebrospin
fluid
csf
protein
concentr
diagnosi
collect
registri
patient
complet
remiss
cr
patient
partial
respons
pr
patient
stabl
diseas
sd
progress
diseas
pd
time
hdtasct
hdtasct
addit
patient
achiev
cr
median
followup
period
month
os
pf
respect
signific
differ
os
pf
upfront
salvag
hdtasct
sinc
thiotepa
key
agent
hdtasct
pcnsl
unavail
discontinu
japan
hdt
regimen
use
uniform
thiotepacontain
hdt
receiv
patient
patient
thiotepacontain
hdt
show
improv
pf
lower
relaps
trend
toward
surviv
benefit
multivari
analysi
noncomplet
remiss
hdtasct
independ
predictor
os
thiotepacontain
hdt
remain
signific
pf
imag
os
pf
b
patient
cumul
incid
relaps
cr
patient
c
conclus
result
confirm
activ
thiotepacontain
regimen
hdtasct
pcnsl
patient
current
pharmaceut
compani
redevelop
thiotepa
new
approv
hdtasct
pediatr
solid
cancer
adult
lymphoma
japan
evalu
thiotepa
prospect
clinic
trial
warrant
disclosur
background
tcell
nonhodgkin
lymphoma
tnhl
rare
diseas
associ
wors
prognosi
compar
bcell
counterpart
allogen
stem
cell
transplant
allosct
may
cur
potenti
patient
due
graft
versu
lymphoma
effect
howev
data
limit
efficaci
allosct
diseas
method
identifi
patient
femal
median
age
tnhl
underw
allosct
univers
hospit
eppendorf
twentyon
patient
underw
allosct
match
sibl
donor
msd
match
unrel
donor
mud
sixteen
patient
ptcl
anaplast
largecel
lymphoma
alcl
angioimmunoblast
larg
cell
lymphoma
adult
tcell
leukemialymphoma
hepatosplen
gammadelta
tcell
lymphoma
enteropathi
associ
tcell
lymphoma
tcellprolymphocyt
leukemia
extranod
tnkcell
lymphoma
cutan
tcell
lymphoma
underli
diagnosi
median
ann
arbour
stage
diagnosi
rang
ten
patient
bone
marrow
involv
diagnosi
patient
heavili
pretreat
patient
relaps
post
autolog
stem
cell
transplant
apsct
one
patient
post
allosct
fifteen
patient
transplant
complet
remiss
cr
st
cr
nd
cr
partial
remiss
pr
advanc
diseas
patient
receiv
myeloabl
condit
thirtyeight
patient
receiv
total
bodi
irradi
base
regimen
receiv
chemotherapi
base
regimen
twenti
patient
receiv
antitlymphocyt
globulin
atlg
neovii
patient
receiv
gcsf
mobil
peripher
stem
cell
result
overal
patient
neutrophil
engraft
median
day
day
cumul
incid
grade
iiiv
grade
iiiiv
acut
gvhd
respect
median
follow
month
rang
cumul
incid
chronic
gvhd
distribut
evenli
limit
extens
twenti
nine
patient
achiev
cr
allosct
median
overal
surviv
os
diseas
free
pf
surviv
month
month
respect
year
os
pf
respect
fourteen
ci
death
due
non
relaps
mortal
nrm
patient
ci
die
due
diseas
progress
patient
male
donor
improv
os
compar
femal
donor
year
os
male
femal
patient
gender
diseas
subtyp
bone
marrow
involv
type
allosct
donor
patient
cmv
statu
abo
incompat
diseas
stage
diagnosi
previou
transplant
diseas
statu
transplant
condit
regimen
atg
stem
cell
sourc
effect
os
pf
nrm
post
transplant
complic
conclus
acknowledg
retrospect
natur
studi
show
allosct
induc
high
rate
complet
remiss
may
cur
potenti
even
diseas
relaps
post
asct
howev
find
need
confirm
larger
prospect
studi
disclosur
fund
conflict
interest
abstract
alreadi
publish
athom
autolog
stem
cell
transplant
lymphoma
patient
clinic
impact
nongcsf
administr
posttranspl
background
sever
neutropenia
remain
main
caus
morbid
mortal
autolog
stem
cell
transplant
asct
gcsf
administr
asct
common
practic
perform
reduc
durat
neutropenia
complic
previou
work
patient
multipl
myeloma
manag
home
asct
observ
deleteri
clinic
impact
patient
receiv
gcsf
posttranspl
martinezcibrian
n
et
al
bmt
despit
fact
lymphoma
patient
receiv
intens
condit
regimen
multipl
myeloma
patient
hypothes
use
gcsf
lymphoma
patient
manag
home
aplasia
phase
asct
provid
signific
clinic
benefit
method
lymphoma
patient
manag
athom
sinc
day
asct
februari
juli
patient
receiv
athom
gcsf
per
day
sinc
day
anc
reach
l
gcsf
group
sinc
august
patient
receiv
gcsf
nongcsf
group
patient
condit
beam
receiv
prophylaxi
quinolon
fluconazol
aerosol
pentamidin
lowdos
acyclovir
hv
case
ad
primari
prophylaxi
piperacillintazobactam
iv
use
portabl
intermitt
infus
pump
iip
absolut
neutrophil
count
anc
l
first
day
fever
attain
anc
l
firstlin
therapi
home
neutropen
fever
nf
refriger
meropenem
iv
use
portabl
iip
fever
indic
immedi
visit
hospit
patient
present
focal
infect
sign
sever
sepsi
admit
indic
readmiss
willing
patient
caregiv
uncontrol
nausea
vomit
diarrhea
mucos
requir
total
parenter
nutrit
iv
morphic
result
main
characterist
patient
shown
tabl
differ
group
respect
gender
diagnosi
stage
diseas
comorbid
index
hctci
sourc
stem
cell
peripher
blood
cell
dose
infus
median
rang
age
year
gcsf
group
nongcsf
group
durat
neutropenia
less
l
significantli
longer
nongcsf
group
median
day
rang
compar
rang
gcsf
group
p
sever
neutropenia
less
l
also
longer
nongcsf
group
day
vs
differ
observ
time
platelet
engraft
gcsf
posttranspl
avoid
influenc
incid
neutropen
fever
first
day
durat
fever
incid
sever
oral
mucos
bacteri
infect
document
number
readmiss
median
durat
whole
procedur
athom
day
shorter
gcsf
group
vs
day
conclus
polici
administ
gcsf
postasct
homebas
program
lymphoma
patient
includ
intens
bacteri
prophylaxi
deleteri
impact
main
result
review
suggest
elimin
use
achiev
disclosur
aim
studi
analyz
spanish
experi
patient
diagnos
nhl
receiv
haplosct
ptci
method
sixti
patient
receiv
haplosct
ptci
spanish
center
analyz
patient
followedup
gvhd
prophylaxi
consist
cyclophosphamid
mgkgd
day
mmf
calcineurin
inhibitor
day
result
patient
characterist
summar
tabl
median
age
patient
male
diagnos
cell
lymphoma
achiev
complet
respons
prior
transplant
activ
diseas
patient
receiv
previou
transplant
allogen
transplant
sourc
stem
cell
mainli
peripher
blood
reduc
intens
condit
prefer
regimen
donor
sibl
offspr
parent
median
neutrophil
platelet
engraft
day
respect
acut
gvhd
grade
iiiv
rate
patient
develop
grade
iiiiv
chronic
gvhd
rate
extens
median
followup
month
overal
surviv
event
free
surviv
respect
cumul
incid
relaps
cumul
incid
nrm
conclus
relapsedrefractori
nhl
aggress
entiti
fatal
cours
short
period
time
haplosct
ptci
permit
new
treatment
option
among
patient
accept
outcom
studi
need
larger
cohort
patient
longer
followup
confirm
result
disclosur
noth
disclos
higher
suv
pretranspl
day
posttranspl
pet
scan
independ
predict
inferior
surviv
patient
diffus
larg
b
cell
lymphoma
background
autolog
stem
cell
transplant
autohct
cure
patient
relaps
diffus
larg
bcell
lymphoma
dlbcl
relaps
occur
patient
center
other
util
routin
surveil
imag
posttranspl
util
set
unclear
imag
costli
expos
patient
radiat
novel
intervent
avail
patient
relaps
autohct
make
earli
diseas
recognit
crucial
interven
prior
clinic
progress
henc
studi
impact
postautohct
surveil
ffdgpet
ct
day
transplant
outcom
method
analyz
cohort
consecut
autohct
recipi
relapsedrefractori
dlbcl
underw
pretranspl
petct
surveil
pet
ct
day
interquartil
rang
iqr
day
posthct
univers
minnesota
medic
center
univari
analysi
perform
analyz
pet
paramet
includ
deauvil
score
standard
uptak
valu
suv
total
lesion
glycolysi
tlg
total
metabol
tumor
volum
tmtv
predictor
relaps
surviv
autohct
addit
assess
outcom
patient
clinic
versu
radiograph
detect
relaps
dlbcl
autohct
prehct
factor
analyz
includ
age
gender
condit
regimen
perform
statu
consolid
radiat
therapi
tmtv
suv
tlg
result
fiveyear
cumul
incid
relaps
autohct
ci
overal
surviv
os
ci
twelv
relaps
prior
day
dscore
patient
petct
median
surviv
year
respect
mean
suv
vari
suv
predict
relaps
os
risk
relaps
increas
doubl
suv
higher
suv
increas
hr
ci
p
mortal
increas
doubl
suv
prehct
increas
suv
associ
hr
ci
well
posthct
pet
hr
ci
irrespect
bulk
tumor
addit
risk
death
time
higher
patient
rel
hr
ci
patient
higher
tmtv
cm
compar
tmtv
cm
hazard
ratio
death
follow
relaps
higher
hr
ci
relaps
detect
clinic
versu
radiograph
median
followup
time
period
year
pretranspl
patient
diseas
characterist
significantli
influenc
outcom
conclus
patient
rr
dlbcl
undergo
autohct
surveil
petct
day
identifi
patient
poor
year
higher
suv
pretranspl
well
posthct
pet
predict
increas
mortal
patient
may
benefit
novel
treatment
concern
risk
nivolumab
treatment
allohsct
due
risk
heavi
gvhd
thu
place
immun
checkpoint
inhibitor
yet
defin
report
includ
analysi
center
experi
nivolumab
treatment
patient
rr
hl
allohsct
method
retrospect
evalu
result
allohsct
patient
rr
chl
undergon
transplant
analysi
includ
patient
receiv
flube
condit
ptci
gvhd
prophylaxi
group
patient
receiv
bridg
therapi
group
b
patient
receiv
bridg
therapi
brentuximab
vedotin
chemotherapybas
bridg
time
last
nivolumab
administr
allohsct
least
month
result
time
analysi
median
followup
month
group
month
group
b
differ
twoyear
os
significantli
better
ef
group
versu
group
b
vs
respect
relaps
incid
group
versu
group
b
cumul
incid
nonrelaps
mortal
year
group
group
b
respect
differ
grade
iiiv
vs
grade
iiiiv
vs
agvhd
well
extens
chronic
gvhd
vs
group
b
respect
ten
patient
relaps
allohsct
treat
differ
dose
mgkg
nivolumab
center
median
follow
mo
patient
remain
aliv
object
respons
therapi
assess
patient
note
patient
disregard
dose
nivolumab
cr
pr
respons
lost
four
patient
requir
nivolumab
retreat
none
patient
develop
gvhd
nivolumab
administr
analysi
also
correl
dose
nivolumab
incid
sever
advers
event
conclus
allohsct
combin
immun
checkpoint
inhibitor
good
option
patient
rr
chl
consider
immunemedi
toxic
potenti
increas
graftversushost
diseas
remain
import
earli
data
suggest
nivolumab
may
effici
therapi
patient
rr
chl
relaps
allohsct
research
need
disclosur
author
declar
conflict
interest
background
transform
diffus
larg
bcell
lymphoma
dlbcl
consid
one
unfavour
event
lymphoma
natur
histori
poorer
outcom
compar
de
novo
dlbcl
et
al
bjh
patient
suitabl
salvag
therapi
hematopoiet
stemcel
transplant
sct
could
option
although
role
well
stablish
analys
indic
outcom
transplant
transform
dlbcl
singl
refer
transplant
unit
method
total
transplant
perform
unit
autolog
dlbcl
transform
indol
nhl
receiv
autolog
sct
asct
allogen
sct
allosct
result
median
age
year
old
rang
rang
patient
receiv
asct
allosct
respect
asct
receiv
beam
condit
regimen
patient
allosct
group
receiv
fludarabinemelphalan
combin
gvhd
prophylaxi
consist
tacrolimussirolimu
combin
calcioneurin
plu
methotrex
regard
transplant
diseas
statu
asct
patient
transplant
complet
respons
cr
allosct
group
patient
receiv
three
treatment
line
transplant
patient
receiv
previou
asct
cr
partial
respons
pr
progress
diseas
transplant
relat
mortal
trm
asct
allosct
group
overal
surviv
os
progressionfreesurviv
pf
month
os
pf
patient
receiv
asct
os
pf
allosct
median
follow
month
patient
receiv
asct
remain
cr
allosct
group
median
follow
month
whole
group
month
aliv
patient
patient
aliv
diseas
free
die
due
trm
regard
progress
progress
autolog
transplant
allosct
conclus
indic
hematopoiet
sct
transform
dlbcl
stablish
patient
patient
transplant
unit
receiv
transplant
due
transform
lymphoma
correspond
autolog
activ
allogen
activ
accord
result
transplant
consid
cur
option
patient
transplant
cr
new
agent
tri
reach
best
respons
transplant
consid
imag
eva
konirova
antonin
vitek
marta
krejci
edgar
faber
katerina
steinerova
david
belada
jan
novak
juraj
dura
petr
sedlacek
veronika
valkova
andrea
janikova
ludek
raida
pavel
jindra
pavel
zak
toma
kozak
mari
trnkova
michal
kara
marek
trneni
manag
howev
differ
patient
characterist
well
frequenc
hsct
indic
differ
lymphoma
subtyp
observ
last
decad
aim
studi
retrospect
analysi
hsct
lymphoma
czech
republ
method
data
adult
patient
transplant
year
retrospect
analyz
use
ebmt
databas
result
autolog
hsct
asct
perform
patient
men
differ
lymphoma
subtyp
median
age
year
rang
patient
nonhodgkin
lymphoma
nhl
hodgkin
lymphoma
hl
nhl
group
compris
diffus
larg
bcell
lymphoma
dlbcl
follicular
lymphoma
fl
mantl
cell
lymphoma
mcl
tnhl
frequenc
asct
lymphoma
increas
constant
sinc
transplant
per
year
differ
frequenc
asct
observ
among
lymphoma
subtyp
decreas
number
dlbcl
fl
increas
number
tnhl
mcl
asct
part
induct
therapi
total
allogen
hsct
allosct
perform
patient
men
median
age
year
rang
patient
nhl
hl
common
nhl
subtyp
fl
mcl
tnhl
dlbcl
last
year
number
allosct
lymphoma
fluctuat
around
per
year
median
age
asct
significantli
higher
year
vs
vs
p
fig
increas
allosct
vs
reach
statist
signific
median
follow
allosct
probabl
os
patient
transplant
later
period
relaps
dlbcl
fl
hl
mcl
os
asct
part
first
line
therapi
period
mcl
tnhl
os
significantli
better
patient
underw
asct
year
vs
vs
p
trend
toward
better
os
patient
allosct
vs
fig
conclus
hsct
remain
import
treatment
modal
lymphoma
era
target
antibodi
molecular
therapi
transplant
older
patient
due
better
support
treatment
acknowledg
progress
uk
czech
ministri
educ
youth
sport
disclosur
noth
declar
background
diseas
chemosensit
salvag
treatment
proven
major
predict
factor
favor
outcom
autolog
stem
cell
transplant
asct
patient
refractori
lymphoma
therefor
import
effect
safe
salvageregimen
indisput
method
retrospect
compar
outcom
term
safeti
efficaci
patient
median
age
year
receiv
st
salvag
either
dicep
cyclophoshamid
mgm
etoposid
cisplatin
mg
day
wide
use
regimen
eshap
rituximab
addit
given
posit
lymphoma
patient
statist
analysi
base
independ
ttest
kaplan
meir
method
logrank
test
result
reason
salvag
treatment
primari
induct
failur
pif
earli
relaps
month
post
inductionremiss
therapi
late
relaps
diseas
specif
patient
dicepgroup
patient
eshapgroup
assess
pif
earli
relaps
diseas
howev
differ
statist
signific
regimen
well
toler
major
organ
toxic
notic
eleven
patient
dicepgroup
eshapgroup
develop
febril
infect
patient
success
manag
appropri
treatment
one
eshapgroup
requir
short
period
admiss
intens
care
unit
cycl
dicep
cycl
eshap
diseas
respons
reassess
petct
scan
overal
respons
rate
tumor
reduct
significantli
superior
dicepregimen
reach
patient
vs
patient
eshapregimen
eleven
patient
dicepgroup
eshapgroup
achiev
complet
metabol
remiss
accord
pet
ct
criteria
pn
median
hospit
period
day
dicepgroup
compar
day
eshapgroup
howev
eshapgroup
addit
median
hospit
day
requir
sinc
nonrespond
patient
receiv
nd
salvag
asct
mobil
stem
cell
collect
success
group
though
signific
higher
number
cell
collect
dicepgroup
kg
vs
kg
two
patient
due
refractori
diseas
underw
asct
notic
median
period
st
salvag
treatment
asct
significantli
shorter
dicepgroup
vs
day
appar
nonrespond
patient
eshapgroup
treat
nd
salvag
overal
progress
free
surviv
similar
dicepand
eshapgroup
vs
vs
respect
two
heavili
pretreat
patient
eshapgroup
develop
secondari
myelodysplast
syndrom
post
asct
conclus
seri
patient
regimen
prove
safe
interestingli
despit
fact
patient
dicepgroup
poor
risk
diseas
dicepregi
significantli
effect
result
thu
earlier
asct
less
exposur
chemotherapeut
agent
might
led
less
longterm
toxic
nevertheless
prospect
trial
larg
seri
patient
need
defin
role
dicep
salvag
treatment
set
disclosur
conflict
interest
background
although
autolog
hematopoiet
stem
cell
transplant
autohsct
one
best
cur
strategi
patient
chemosensit
tcell
lymphoma
major
limit
remain
tumor
contamin
graftrel
relaps
residu
diseas
chemotherapi
sever
purg
method
introduc
autohsct
limit
howev
studi
ex
vivo
purg
autograft
lymphoma
especi
tcell
lymphoma
therefor
retrospect
analyz
consecut
tcell
lymphoma
patient
receiv
autohsct
withwithout
ex
vivo
purg
method
among
patient
underw
autograft
manipul
ex
vivo
purg
cell
select
use
clinimac
devic
result
median
followup
durat
month
rang
month
overal
surviv
os
vs
progressionfre
surviv
pf
vs
purg
unpurg
group
respect
transplantrel
mortal
observ
group
patient
purg
group
patient
unpurg
group
neutrophil
vs
day
platelet
vs
day
recoveri
similar
group
engraft
failur
subgroup
analysi
accord
upfront
salvag
autohsct
surviv
outcom
improv
stem
cell
purg
upfront
autohsct
os
pf
differ
surviv
outcom
salvag
autohsct
unmanag
lateinfecti
complic
group
except
predominantli
cytomegaloviru
reactiv
purg
group
vs
patient
conclus
although
cohort
small
number
ex
vivo
graftpurg
method
feasibl
safe
tcell
lymphoma
purg
strategi
observ
favor
surviv
outcom
upfront
autohsct
salvag
set
therefor
random
studi
need
determin
firm
efficaci
purif
larg
number
patient
autohsct
celllymphoma
disclosur
noth
declar
nivolumabbas
regimen
relaps
refractori
non
hodgkin
lymphoma
role
hematopoiet
stem
cell
transplant
method
analyz
data
patient
rr
nhl
among
diffus
larg
bcell
lymphoma
dlbcl
primari
mediastin
bcell
lymphoma
pmbcl
gray
zone
lymphoma
gzl
gammadelta
peripher
tcell
lymphoma
ptcl
receiv
nivolumabbas
regimen
median
age
year
rang
year
patient
primari
chemoresist
diseas
rest
patient
relaps
median
line
prior
therapi
line
rang
line
sixteen
patient
dlbcl
pmbcl
receiv
cycl
nivolumab
combin
bendamustin
gemcitabin
rituximab
begern
patient
gzl
receiv
cycl
nivolumab
combin
brentuximab
vedotin
epoch
patient
ptcl
receiv
cycl
nivolumab
monotherapi
result
median
follow
month
object
respons
nivolumabbas
regimen
note
patient
complet
respons
cr
partial
respons
pr
patient
respect
cr
observ
patient
dlbcl
pmbcl
gzl
ptcl
pr
observ
patient
dlbcl
two
respond
patient
dlbcl
underw
autohsct
four
respond
patient
dlbcl
pmbcl
gzl
ptcl
receiv
allogen
hematopoiet
stem
cell
transplant
allohsct
median
durat
respons
patient
rang
month
among
patient
achiev
without
hsct
remain
cr
two
patient
receiv
autohsct
relaps
one
patient
dlbcl
improv
respons
allohsct
pr
cr
four
patient
allohsct
remain
cr
probabl
os
pf
rate
respect
conclus
nivolumabbas
regimen
lead
object
respons
patient
rr
nhl
howev
durabl
respons
therapi
long
nivolumabbas
regimen
use
bridg
allohsct
disclosur
conflict
interest
disclos
background
patient
aggress
nonhodgkin
lymphoma
nhl
relaps
autolog
stem
cell
transplant
dismal
outcom
could
benefit
radiotherapi
allogen
stem
cell
transplant
experiment
treatment
system
inflammatori
paramet
diagnosi
demonstr
use
predict
lymphoma
evolut
method
conduct
retrospect
review
patient
aggress
nhl
underw
autolog
stem
cell
transplant
astc
evalu
relationship
ldh
inflammatori
paramet
lymphocyt
alc
monocyt
count
amc
ferritin
creactiv
protein
imag
techniqu
day
postastc
progress
free
surviv
pf
well
role
residu
diseas
direct
radiotherapi
rt
result
one
hundr
sixti
patient
aggress
nhl
receiv
asct
consolid
treatment
center
common
diagnosi
diffus
larg
bcell
lymphoma
dlbcl
one
hundr
nine
patient
receiv
upfront
asct
high
risk
dlbcl
defin
ageadjust
ipi
receiv
two
line
obtain
first
complet
remiss
tcell
lymphoma
mantl
cell
lymphoma
rest
perform
relaps
lymphoma
fortyseven
patient
relaps
pf
month
pretranspl
respons
evalu
ct
scan
patient
partial
remiss
ctpr
patient
evalu
fdgpetct
pretranspl
posit
patient
maintain
posit
day
astc
pf
patient
ctpr
month
posit
one
month
posit
one
month
univari
analysi
show
posit
accur
predictor
relaps
hr
follow
amc
day
hr
albumin
day
hr
ldh
day
hr
p
pretranspl
alcamc
ratio
hr
multivari
analysi
demonstr
associ
posit
hr
p
ldh
day
hr
pf
five
ten
year
overal
surviv
neg
patient
vs
posit
one
p
eight
patient
posit
relaps
salvag
radiat
therapi
use
patient
posit
residu
mass
relaps
two
patient
relaps
one
patient
residu
mass
anoth
remot
affect
primari
site
could
consid
progress
day
conclus
post
asct
fdgpet
ct
superior
convent
ct
predict
outcom
aggress
lymphoma
astc
pre
post
asct
system
inflammatori
paramet
nt
help
improv
relaps
risk
predict
addit
consolid
rt
astc
demonstr
improv
pf
patient
pet
posit
would
neccesari
develop
random
trial
assess
role
rt
residu
diseas
advanc
aggress
nhl
insuffici
respons
system
treatment
pet
respons
evalu
disclosur
noth
declar
long
term
outcom
patient
lymphoid
malign
underw
high
dose
chemotherapi
follow
autolog
hematopoiet
cell
transplant
singl
institut
year
joanna
romejkojarosinska
ewa
paszkiewiczkozik
lukasz
targonski
lidia
jan
walewski
background
high
dose
chemotherapi
hdt
autolog
hematopoiet
cell
transplant
autohct
standard
care
relapsedrefractori
lymphoma
patient
pt
use
consolid
myeloma
high
risk
lymphoma
patient
first
line
treatment
retrospect
evalu
longterm
outcom
includ
late
effect
risk
factor
patient
lymphoid
malign
underw
autohct
method
collect
data
consecut
patient
hodgkin
lymphoma
hl
aggress
b
lymphoma
dlbcl
myeloma
indol
lymphoma
mantl
cell
lymphoma
peripher
cell
lymphoma
underw
autohct
institut
transplant
median
rang
age
year
clinic
stage
iiiiv
found
lymphoma
pt
complet
remiss
partial
remiss
stabl
progress
diseas
occur
pt
respect
beam
regimen
use
pt
pt
myeloabl
regimen
pt
result
respect
partial
remiss
stabl
diseas
transplant
clinic
stage
iii
iv
age
identifi
risk
factor
associ
inferior
os
pf
univari
multivari
analysi
histopatholog
diagnosi
risk
factor
os
pf
pn
outcom
patient
underw
autohct
inferior
outcom
patient
treat
year
os
p
year
pf
p
respect
record
case
second
primari
cancer
solid
tumor
hematolog
cancer
acut
cardiotox
occur
patient
year
transplant
requir
heart
transplant
patient
patient
die
main
caus
death
progress
diseas
pt
second
primari
malign
pt
treatment
relat
mortal
pt
mortal
within
day
imag
pf
os
patient
underw
hdt
autohct
conclus
patient
underw
hdt
autohct
long
term
surviv
without
progress
diseas
older
age
noncomplet
remiss
transplant
advanc
stage
associ
poor
outcom
patient
recent
transplant
better
outcom
patient
transplant
disclosur
noth
declar
outcom
haploident
match
relat
hsct
lymphoma
differ
significantli
singl
center
studi
nadira
durakov
zinaida
lana
desnica
ranka
serventiseiwerth
sandra
kinda
ivo
radmanlivaja
alen
ant
pavl
zorana
igor
aurer
radovan
vrhovac
univers
zagreb
school
medicin
intern
medicin
zagreb
croatia
uhc
zagreb
zagreb
croatia
background
allogen
hsct
still
offer
patient
relapsedrefractori
lymphoma
best
chanc
longterm
surviv
patient
time
hsct
crucial
therefor
relat
donor
prefer
analyz
acut
chronic
gvhd
incid
relaps
overal
surviv
also
time
immunosuppress
discontinu
hematopoiet
recoveri
compar
transplant
use
haploident
haplo
match
relat
donor
mrd
singl
center
indic
method
time
period
uhc
zagreb
croatia
mrd
haplo
transplant
lymphoma
done
hodgkin
nhl
patient
transplant
haploident
donor
receiv
ptci
data
comput
use
r
packag
probabl
gvhd
calcul
use
cumul
incid
method
subgroup
compar
use
gray
test
result
median
age
year
haplo
mrd
group
four
patient
pr
cr
haplo
group
mrd
group
patient
cr
pr
haplo
group
patient
receiv
bone
marrow
bm
peripher
blood
stem
cell
pbsc
mrd
group
patient
receiv
pbsc
patient
haplo
group
receiv
nma
baltimor
condit
ptci
mrd
group
patient
receiv
one
receiv
flutbi
condit
protocol
haplo
group
patient
previous
treat
autologu
transplant
mrd
group
signific
differ
time
discontinu
day
haplo
mrd
group
respect
patient
haplo
recov
slower
recov
anc
day
ci
ci
recov
platelet
day
ci
ci
p
haplo
mrd
group
median
follow
day
overal
surviv
ci
haplo
ci
mrd
group
trm
haplo
mrd
group
cumul
incid
agvhd
iiiv
ci
ci
haplo
mrd
group
respect
cumul
incid
cgvhd
requir
treatment
ci
mrd
ci
haplo
mrd
group
respect
case
cgvhd
develop
dli
cumul
incid
relaps
ci
ci
haplo
mrd
group
respect
conclus
found
signific
differ
overal
surviv
relaps
incid
agvhd
cgvhd
incid
two
group
hematopoiet
recoveri
slower
haploident
transplant
influenc
trm
higher
mrd
even
though
limit
number
data
contribut
grow
bodi
evid
use
haploident
donor
particularli
lymphoma
set
worthi
use
match
relat
donor
least
second
choic
donor
select
older
patient
older
donor
probabl
first
one
disclosur
noth
declar
adjuv
involv
field
radiotherapi
post
autolog
stem
cell
transplant
refractoryrelaps
lymphoma
result
favor
outcom
low
toxic
singl
center
experi
background
involv
field
radiotherapi
ifrt
previou
bulki
local
residu
diseas
wide
use
treatment
approach
minim
risk
relaps
post
autolog
stem
cell
transplant
asct
howev
proper
time
irradi
treatment
remain
controversi
adjuv
ifrt
adjifrt
preasct
period
could
caus
undesir
toxic
might
delay
even
cancel
asct
result
increas
risk
relaps
could
affect
marrow
environment
marrow
nich
result
thu
impair
engraft
hand
ajdiftr
earli
postasct
period
upon
marrow
recoveri
offer
potenti
advantag
deliv
irradi
suffici
diseas
respons
without
affect
engraft
retrospect
studi
evalu
safeti
efficaci
ifrt
adjuv
treatment
patient
previous
treat
asct
relaps
refractori
lymphoma
method
twentythre
patient
age
year
underw
asct
primari
refractori
relaps
diseas
patient
bulki
diseas
time
relaps
residu
mass
post
salvag
treatment
consid
candid
adjifrt
earli
within
month
document
autolog
stem
cell
engraft
patient
proceed
asct
chemosensit
diseas
median
line
salvag
therapi
time
asct
patient
residu
diseas
evalu
complet
remiss
prepar
regimen
singleag
melphalan
busulfanetoposidemelphalan
beam
bendamustinetoposidecytarabinemelphalan
filgrastim
given
till
neutrophil
recoveri
prophylaxi
bacteria
fungu
virus
pcp
administ
till
complet
adjifrt
result
patient
engraft
promptli
success
patient
experienc
sever
toxic
activ
infect
adjiftr
though
plan
proceed
adjifrt
within
month
post
asct
final
deliv
median
month
median
radiat
dose
gy
ten
patient
receiv
radiotherapi
mediastinum
abdomenpelvi
inguin
area
neck
left
leg
adjifrt
well
toler
patient
experienc
toxic
grade
none
requir
hospit
current
median
followup
year
patient
aliv
well
overal
progress
free
surviv
rate
respect
four
patient
die
due
relaps
diseas
heavili
pretreat
patient
due
secondari
myelodyspalst
syndrom
conclus
studi
adjifrt
earli
post
transplant
period
demonstr
safe
welltoler
profil
take
consider
poor
risk
statu
patient
residu
diseas
post
salvag
regimen
bulki
diseas
time
relaps
promis
overal
progress
free
surviv
rate
suggest
adjifrt
post
asct
also
effect
approach
well
design
trial
need
clarifi
role
appropri
time
radiotherapi
asct
set
disclosur
conflict
interest
advers
prognost
impact
pretranspl
neutrophil
lymphocyt
ratio
lymphoprolif
disord
background
brentuximabvedotin
bv
chimer
anti
antibodi
conjug
synthet
antitubulinmomomethylauristatin
bv
approv
treatment
classic
hodgkin
lymphoma
hl
relaps
either
autolog
stem
cell
transplant
asct
two
line
combin
chemotherapi
transplant
inelig
patient
aethera
trial
reveal
increas
pf
bv
use
mainten
therapi
cycl
high
risk
patient
asct
howev
schedul
associ
high
cost
signific
toxic
particularli
term
peripher
neuropathi
primari
object
assess
efficaci
cycl
brentuximab
consolid
therapi
asct
relapsedrefractori
rr
hl
secondari
object
includ
side
effect
progress
free
surviv
pf
overal
surviv
os
method
retrospect
singl
center
analysi
approv
irb
american
univers
beirut
medic
center
includ
studi
consecut
patient
rr
hl
underw
asct
receiv
bv
consolid
postasct
result
identifi
consecut
adult
patient
rr
hl
treat
bv
iv
everi
week
consolid
therapi
asct
indic
bv
consolid
primari
refractori
diseas
patient
earli
relaps
patient
median
time
month
rang
andextranodalinvolv
one
patient
median
number
line
therapi
preasct
rang
median
time
bv
initi
postasct
day
rang
patient
receiv
median
cycl
rang
bv
postasct
median
follow
month
rang
five
patient
relaps
asct
median
time
relaps
month
rang
median
pf
os
reach
observ
signific
toxic
therapi
conclus
cycl
bv
consolid
asct
seem
safe
effect
prevent
relaps
howev
find
need
confirm
larger
prospect
studi
chemotherapi
progress
autohsct
poor
despit
introduct
novel
agent
like
brentuximab
vedotin
bv
nivolumab
allohsct
appear
effect
treatment
option
cur
potenti
goal
studi
evalu
efficaci
allohsct
hl
includ
patient
pretreat
novel
agent
method
year
patient
includ
male
hl
treat
allohsct
msc
institut
oncolog
gliwic
poland
median
age
year
median
line
preced
chemotherapi
patient
pretreat
autohsct
radiotherapi
bv
nivolumab
diseas
statu
allohsct
follow
patient
treat
hsct
either
hlamatch
sibl
donor
msd
unrel
donor
urd
haploident
donor
condit
myeloabl
case
peripher
blood
use
sourc
stem
cell
result
one
patient
engraft
median
time
neutrophil
recoveri
day
incid
grade
grade
acut
gvhd
respect
incid
chronic
gvhd
probabl
os
pf
year
respect
incid
progress
transplantrel
mortal
respect
pf
rate
msd
urd
haploident
donor
univari
analysi
pf
affect
recipi
gender
femal
male
diseas
statu
allohsct
cr
pr
nr
multivari
model
diseas
statu
cr
factor
associ
increas
risk
treatment
failur
revers
pf
ci
neither
donor
type
condit
affect
longterm
outcom
conclus
result
allohsct
patient
relapsedrefractori
hl
determin
diseas
statu
transplant
effort
done
reduc
tumour
burden
transplant
optim
achiev
cr
disclosur
noth
declar
background
brentuximab
vedotin
bv
nivolumab
pembrolizumab
assign
chemorefractori
hodgkin
lymphoma
treatment
impact
agent
diseasefreesurviv
autolog
stem
cell
transplant
asct
remain
investig
aim
studi
compar
bvand
nivolumabtr
patient
control
group
method
clinic
characterist
outcom
chemo
refractori
hodgkin
lymphoma
patient
underw
asct
result
total
patient
men
women
median
age
year
old
treat
bv
pretranspl
posttranspl
preand
posttranspl
pretranspl
bv
patient
primari
refractori
diseas
earli
relaps
major
posttranspl
treatment
occur
context
relapsedrefractori
diseas
patient
allogen
stem
cell
transplant
among
addit
chemotherapi
nivolumab
gain
complet
metabol
respons
rest
patient
chang
treatment
due
eventu
bv
failur
occur
bv
administ
mainten
treatment
patient
six
bv
alreadi
administ
pretranspl
well
mainten
treatment
patient
relaps
subsequ
receiv
nivolumab
two
patient
die
due
prior
chemotherapi
complic
wherea
current
nivolumab
treatment
petbas
respons
avail
patient
complet
metabol
respons
cmr
partial
metabol
respons
stabl
diseas
achiev
ctbase
respons
rest
patient
major
toxic
observ
one
patient
present
grade
asymptomat
hypothyroid
one
grade
anemia
attribut
noninflammatori
upper
gastrointestin
blood
loss
total
patient
receiv
treatment
post
bv
failur
median
followup
month
overal
surviv
os
patient
treat
bv
compar
patient
treat
addit
treatment
figur
median
os
patient
treat
bv
month
wherea
median
os
reach
patient
receiv
treatment
conclus
bv
pre
posttranspl
treatment
posttranspl
bv
failur
outstand
result
chemo
refractori
lymphoma
patient
treatment
sequenc
allogen
transplant
elig
patient
remain
studi
disclosur
noth
declar
background
allogen
hematopoiet
cell
transplant
allohct
reducedintens
condit
ric
use
heavili
pretreat
lymphoma
patient
promis
decreas
treatmentrel
mortal
despit
improv
outcom
patient
lymphoid
neoplasm
sever
new
agent
emerg
potenti
therapi
therefor
aim
describ
longterm
experi
patient
hodgkin
hl
nonhodgkin
lymphoma
nhl
chronic
lymphocyt
leukemia
cll
post
allohct
method
retrospect
studi
enrol
consecut
patient
underw
allohct
lymphoid
neoplasm
institut
result
total
patient
male
age
year
underw
allohct
hl
nhl
cll
major
patient
diagnos
stage
iv
bone
marrow
involv
undergon
autolog
hct
patient
heavili
pretreat
median
rang
receiv
treatment
line
time
transplant
complet
respons
partial
respons
refractori
accord
diseaserisk
index
dri
patient
stratifi
low
intermedi
high
high
categori
among
patient
hodgkin
lymphoma
brentuximab
vedotin
administr
effect
bridg
allohct
patient
receiv
ric
mainli
fludarabin
cyclophosphamid
cll
nhl
thiotepa
fludarabin
mgm
cyclophosphamid
hl
match
sibl
match
mismatch
unrel
donor
graftversushost
diseas
gvhd
prophylaxi
consist
cyclosporin
tacrolimu
mycophenol
mofetil
shortterm
methotrex
addit
lowdos
antithymocyt
globulin
unrel
donor
peripher
blood
main
cell
sourc
median
number
cell
infus
kg
two
patient
succumb
advanc
underli
diseas
engraft
engraft
success
median
time
neutrophil
platelet
engraft
day
respect
eighteen
patient
develop
acut
gvhd
grade
iiiiv
steroid
sensit
relaps
oneyear
cumul
incid
ci
extens
chronic
gvhd
patient
requir
one
addit
line
immunosuppress
rang
ten
patient
present
cmv
reactiv
success
treat
antivir
medic
patient
die
enceph
median
follow
year
year
os
nonrelaps
mortal
ci
df
differ
surviv
accord
origin
diseas
os
multivari
analysi
reveal
high
high
dri
singl
predict
factor
os
hr
ci
assess
impact
diseas
dri
prior
treatment
line
gender
bone
marrow
infiltr
diagnosi
conclus
data
suggest
ric
allohct
provid
encourag
surviv
rate
potenti
offer
chanc
cure
accept
longterm
mortal
select
highrisk
patient
lymphoid
neoplasm
dri
mainli
associ
diseas
stage
transplant
independ
affect
surviv
therefor
continu
effort
necessari
clinic
applic
novel
agent
aim
lower
diseas
stage
pretranspl
disclosur
noth
declar
result
six
pt
identifi
median
age
year
diagnosi
five
hl
nodular
sclerosi
lymphocyt
deplet
median
number
therapeut
line
prior
allohsct
four
pt
previous
treat
brentuximaband
two
pt
submit
high
dose
chemotherapi
autolog
bone
marrow
support
time
allohsct
pt
progress
diseas
dp
partial
respons
complet
respons
cr
five
allohsct
perform
relat
donor
wich
haploident
parent
sibl
descend
unrel
donor
prophylaxi
gvhd
perform
tacrolimu
mycophenol
mofetil
posttranspl
cyclophosphamid
haploident
allohsct
day
evalu
pt
cr
patient
pt
dp
median
time
relaps
allohsct
month
time
initi
nivolumab
pt
steroid
therapi
diseas
control
without
immunosuppress
therapi
median
time
allohsct
begin
nivolumab
month
initi
dose
mg
kg
associ
corticosteroid
therapi
escal
mgkg
biweekli
accord
patient
toler
start
nivolumab
patient
previou
gvhd
manifest
present
worsen
cutan
gvhd
requir
escal
immunosuppress
therapi
toxic
pt
grade
pneumon
pt
grade
encephalitishypophys
pt
grade
pancreat
pt
headach
grade
pt
grade
cutan
reation
median
followup
month
sinc
nivolumab
treatment
overal
respons
rate
pt
obtain
cr
pt
partial
remiss
nevertheless
death
onset
nivolumab
pt
mont
dp
anoth
one
due
acut
myocardi
infarct
month
time
analysi
pt
maintain
respons
nivolumab
treatment
median
cycl
pt
therapi
suspend
toxic
conclus
result
demonstr
high
probabl
achiev
respons
nivolumab
treatment
patient
rrhl
relaps
allohsct
advers
event
grade
frequent
small
group
treatment
toxic
signific
disclosur
noth
declar
background
intravascular
larg
bcell
lymphoma
ivlbcl
rare
form
larg
bcell
lymphoma
patholog
find
intravascular
prolifer
andor
sinusoid
involv
lymphoma
cell
accord
geograph
distribut
ivlbcl
could
dichotom
asian
western
variant
compar
western
variant
skin
involv
common
asian
variant
report
involv
frequent
liver
spleen
bone
marrow
hemophagocyt
lymphohistiocytosi
common
asian
variant
diagnosi
ivlbl
still
difficult
lack
overt
lymphadenopathi
peripher
blood
involv
thu
time
diagnosi
immedi
treatment
remain
challeng
improv
outcom
patient
asian
variant
therefor
analyz
clinic
featur
treatment
outcom
patient
asian
variant
ivlbcl
method
analyz
patient
diagnos
ivlbcl
patient
treat
rituximab
cyclophosphamid
doxorubicin
vincristin
prednison
rchop
result
fortysix
patient
diagnos
ivlbcl
median
age
diagnosi
year
rang
year
male
patient
predomin
b
symptom
present
patient
hepatomegali
andor
splenomegali
observ
patient
wherea
lymphadenopathi
less
common
n
bone
marrow
liver
commonli
involv
extranod
organ
respect
common
site
biopsi
diagnosi
studi
patient
receiv
rchop
firstlin
treatment
diagnosi
median
number
six
cycl
rang
one
eight
end
treatment
patient
achiev
complet
respons
cr
wherea
eight
patient
show
progress
six
patient
die
first
second
cycl
rchop
caus
death
treatmentrel
advers
event
includ
cytopenia
infecti
complic
pulmonari
hemorrhag
upfront
asct
done
two
patient
includ
one
patient
cn
involv
diagnosi
patient
still
aliv
time
analysi
without
evid
relaps
hand
outcom
six
patient
undergo
salvag
asct
relaps
poor
thu
one
patient
aliv
likewis
patient
diseas
progress
end
treatment
rchop
show
dismal
prognos
even
salvag
chemotherapi
except
one
median
followup
month
confid
interv
ci
median
overal
surviv
month
ci
treatment
outcom
patient
asian
variant
ivlbcl
still
satisfactori
although
upfront
autolog
stem
cell
transplant
might
effect
select
patient
highrisk
relaps
role
still
clear
either
thu
studi
warrant
develop
effect
strategi
diagnosi
treatment
clinic
trial
registri
applic
disclosur
noth
disclar
background
peripher
tcell
lymphoma
ptcl
lymphoma
usual
aggress
clinic
cours
unfavor
prognosisgiven
heterogen
consensu
best
firstlin
treatment
role
autologousallogen
asctallosct
stem
cell
transplant
consolid
controversi
method
evalu
overal
surviv
os
progressionfre
surviv
pf
toxic
cohort
patient
ptcl
submit
asctallosct
intensif
institut
januari
juli
os
calcul
date
diagnosi
death
pf
measur
transplant
relaps
progress
diseas
last
followup
os
pf
rate
estim
use
kaplanmei
method
compar
logrank
test
result
twentysix
patient
identifi
femal
median
age
year
rang
ninetytwo
percent
patient
present
advancedstag
diseas
diagnosi
ann
arbor
stage
iii
iv
b
symptom
accord
classif
histolog
ptcl
subtyp
includ
angioimmunoblast
tcell
lymphoma
n
ptcl
otherwis
specifi
n
anaplast
larg
cell
lymphoma
alkneg
n
anaplast
larg
cell
lymphoma
alkposit
n
nodal
peripher
tcell
lymphoma
tfh
phenotyp
n
extranod
nktcell
lymphoma
nasal
type
primari
cutan
subtyp
exclud
ageadjust
ipi
aaipi
lowintermedi
low
patient
intermedi
highhigh
patient
twentyseven
transplant
perform
asct
allosct
consolid
respons
asct
allosct
complet
remiss
cr
partial
remiss
pr
nine
transplant
perform
consolid
nd
respons
asct
allosct
cr
pr
patient
allosct
perform
asct
due
earli
relaps
month
beam
regimen
use
asct
condit
flumel
allosct
patient
engraft
median
time
leukocyt
recoveri
day
rang
four
pt
submit
allosct
chronic
graft
versu
host
diseas
relev
complic
analysi
consid
whole
cohort
median
followup
month
rang
estim
os
pf
respect
seven
patient
relaps
earli
asct
relaps
allosct
howev
result
statist
signific
allosct
asct
group
os
rate
p
pf
rate
p
respect
patient
treatmentrel
mortal
trm
patient
die
progress
diseas
asct
hepat
toxic
allosct
conclus
result
retrospect
studi
take
account
advers
risk
profil
popul
suggest
autologousallogen
stem
cell
transplant
effect
safe
option
consolid
patient
ptcl
result
need
valid
prospect
studi
includ
larger
number
patient
disclosur
background
autolog
stem
cell
transplant
use
consolid
therapi
relaps
lymphoma
patient
howev
outcom
lymphoma
patient
relaps
autolog
stem
cell
transplant
poor
allogen
stem
cell
transplant
cur
use
transplant
elig
patient
set
besid
allogen
stem
cell
transplant
option
autolog
stem
cell
transplant
high
risk
patient
studi
aim
compar
surviv
rate
lymphoma
patient
older
year
age
patient
age
undergon
allogen
transplant
center
method
collect
data
lymphoma
patient
older
year
age
undergon
allogen
transplant
center
analyz
result
group
name
one
year
age
one
year
age
imag
figur
result
patient
age
undergon
allogen
stem
cell
trasplant
diagnosi
lmphoma
patient
year
age
patient
nonhodgkin
lymphoma
patient
hodgkin
lymphoma
characterist
patient
summar
tabl
patient
comorbid
index
calcul
augment
hctci
includ
patient
pretranspl
ferritin
thrombocyt
count
variabl
differ
could
found
group
regard
neutrophil
platelet
engraft
time
comorbid
index
howev
acut
graft
versu
rate
document
bacteri
infect
rate
hospit
period
higher
year
age
group
day
mortal
rate
nonrelaps
mortal
rate
differ
group
importantli
progress
free
surviv
pf
overal
surviv
os
patient
year
age
group
year
age
group
differ
figur
conclus
present
studi
although
number
patient
low
show
lymphoma
patient
year
age
similar
outcom
transplant
relat
toxic
patient
year
age
pf
os
close
studi
think
may
due
low
relaps
rate
patient
high
mortal
rate
relaps
patient
conclus
allogen
stem
cell
transplant
cur
potenti
may
employ
transplant
elig
elderli
lymphoma
patient
disclosur
noth
declar
background
follicular
lymphoma
fl
histolog
transform
consist
develop
aggress
lymphoma
usual
diffus
larg
b
cell
lymphoma
dlbcl
histolog
transform
consid
poor
prognosi
prerituximab
era
median
os
rang
year
howev
recent
seri
patient
treat
chemotherapi
plu
rituximab
outcom
transform
fl
improv
especi
receiv
autolog
stem
cell
transplant
asct
reach
os
seri
method
retrospect
studi
consecut
patient
undergo
asct
transform
fl
tertiari
center
basqu
countri
spain
patient
consid
transform
fl
diagnos
dlbcl
previou
histori
fl
histolog
evid
fl
anoth
locat
patient
compar
retrospect
cohort
dlbcl
patient
high
ipi
stage
receiv
asct
first
remiss
accord
institut
strategi
pf
os
calcul
time
asct
case
transform
fl
relaps
aggress
indol
lymphoma
consid
surviv
analysi
perform
kaplanmey
estim
result
total
transform
fl
dlbcl
patient
studi
median
follow
month
respect
patient
characterist
describ
tabl
pf
transform
fl
dlbcl
os
respect
pictur
signific
differ
pf
os
two
group
p
group
relaps
occur
first
three
year
asct
among
patient
transform
fl
relaps
observ
five
aggress
relaps
one
patient
present
relaps
indol
lymphoma
fl
histolog
grade
aggress
clinic
cours
imag
imag
transform
fl
dlbcl
pf
asct
conclus
experi
asct
transform
fl
offer
good
result
similar
dlbcl
fl
present
natur
cours
akin
dlbcl
relaps
occur
earli
surviv
reach
plateau
data
suggest
patient
transform
fl
cure
asct
disclosur
noth
declar
safeti
efficaci
intens
precondit
regimen
contain
cladribin
autolog
peripher
blood
stem
cell
transplant
refractori
relaps
young
highli
invas
lymphoma
background
autolog
peripher
blood
stem
cell
transplant
apbsct
one
main
treatment
patient
nonhodgkin
lymphoma
nhl
effect
safe
condit
regimen
improv
cure
rate
nhl
beam
common
pretreat
scheme
refractori
relaps
young
highli
invas
lymphoma
especi
dualexpress
dlbcl
pretreat
need
strengthen
studi
shown
cladribin
clad
gemcitabin
gem
busulfan
bu
combin
provid
synergist
cytotox
lymphoma
cell
linesw
evalu
safeti
shortterm
efficaci
intens
precondit
regimen
contain
cladribin
cladgembu
refractori
relaps
young
highli
invas
lymphoma
undergo
apbsct
method
ten
patient
nhl
receiv
apbsct
ca
ctx
arac
therapi
follow
gcsf
use
pbsc
mobil
sevenr
patient
receiv
condit
regimen
beam
beam
group
bcnu
arac
mel
three
patient
receiv
intens
precondit
regimen
contain
cladribin
clgb
group
clad
followup
date
expir
decemb
result
age
patient
clgb
group
year
respect
two
patient
diagnos
diffus
larg
bcell
lymphoma
doubl
express
one
diffus
larg
bcell
lymphoma
two
recurr
patient
beam
group
highrisk
relaps
refractori
nhlall
patient
success
engraft
infus
apbsc
averag
lowest
leukocyt
clgb
group
beam
group
l
vs
l
respect
averag
lowest
leukocyt
clgb
group
lower
beam
group
averag
time
anc
clgb
group
beam
group
vs
averag
time
l
clgb
group
beam
group
vs
averag
time
l
clgb
group
differ
beam
group
vs
averag
time
neutropenia
nt
significantli
differ
two
group
vs
advers
reaction
gastrointestin
tract
oral
mucosa
close
tow
groupsvod
hemorrhag
cystiti
pretreatmentrel
interstiti
pneumonia
liver
kidney
dysfunct
happen
tow
group
rate
infecti
fever
close
two
group
vs
median
followup
period
beam
group
month
beam
group
patient
die
day
transplant
diagnos
recurr
nkt
cell
lymphoma
intracrani
infect
caus
sever
sinu
infect
anoth
case
beam
group
diagnos
doubleexpress
dlbcl
relaps
month
transplant
remain
patient
ebmt
group
surviv
diseasefre
followup
time
patient
clgb
group
month
month
month
respect
patient
surviv
without
diseasehowev
followup
time
short
need
longterm
followup
conclus
treatment
intens
precondit
regimen
contain
cladribin
clgb
refractori
relaps
young
highli
invas
lymphoma
undergo
apbsct
safe
time
hematopoiet
reconstruct
short
advers
effect
toler
patient
refractori
relaps
young
highli
invas
lymphoma
current
shortterm
outcom
good
longterm
effect
need
longer
time
followup
disclosur
work
support
nation
natur
scienc
found
china
disclosur
conflict
interestth
author
name
xiangli
chen
yuzhu
zang
wenhui
zhang
yin
zhang
zhongwen
liu
pingchong
lei
jing
yang
yuqe
chen
kai
sun
background
small
part
children
hodgkin
diseas
hd
demonstr
initi
resist
standard
even
salvag
chemotherapi
need
innov
drug
treatment
method
girl
diagnos
classic
hd
nodular
sclerosi
correspond
stage
ii
e
b
fever
april
two
cycl
oepa
vincristin
etoposid
prednison
doxorubicin
next
two
cycl
copp
cyclophosphamid
vincristin
prednison
procarbazin
patient
progress
diseas
patient
achiev
partial
respons
pr
salvag
therapi
two
cycl
igev
ifosfamid
gemcitabin
vinorelbin
prednison
receiv
autosct
februari
patient
statu
autosct
pr
use
ccnucontain
condit
regimen
cem
lomustin
ccnu
mgm
etoposid
mgm
melphalan
mgm
day
autosct
patient
demonstr
progress
diseas
petctexamin
show
mediastin
tumor
mass
enlarg
increas
left
lung
nodul
simultan
short
metabol
activ
patient
observ
day
diseas
relaps
progress
examin
petct
demonstr
multifoc
progress
diseas
multipl
pulmonari
lesion
increas
metabol
comparison
previou
petct
scan
julyoctob
patient
salvag
chemotherapi
combin
brentuximab
vedotin
bv
bv
dhap
dexamethason
cytarabin
cisplatin
bv
without
chemotherapi
due
suspect
invas
mycosi
bv
dhap
howev
partial
petposit
remiss
achiev
mani
time
relaps
progress
diseas
pembrolizumab
therapi
start
octob
mg
kg
everi
three
week
four
cycl
total
toxic
effect
seriou
complic
therapi
pembrolizumab
observ
februari
pembrolizumab
patient
show
complet
metabol
remiss
diseas
control
petct
april
patient
receiv
haplosct
posttranspl
hdcyclophosphamid
use
condit
mode
reduc
toxic
fludarabin
treosulfan
high
dose
cy
mg
kg
day
tacrolimu
mycophenol
mofetil
start
day
mmf
termin
day
tacrolimu
day
patient
acut
chronic
gvhd
result
moment
patient
aliv
still
petneg
cr
durat
mo
conclus
pembrolizumab
demonstr
high
activ
resist
hd
even
postautosct
progress
good
toler
sick
child
disclosur
noth
declar
high
dose
chemotherapi
follow
autoloug
peripher
blood
stem
cell
transplant
asct
diffus
larg
b
cell
lymphoma
dlbcl
median
age
year
sex
ratio
mf
ann
arbor
stage
iiiiv
pt
hdt
induct
chemotherapi
chop
institut
associ
rituximab
pt
pt
receiv
treatment
line
pt
receiv
complementari
radiotherapi
transplant
diseas
statu
hdt
complet
remiss
cr
pt
partial
remiss
pt
rp
diseas
progress
pt
delay
diagnosi
hdt
month
hdt
protocol
use
tutshka
pt
pt
bam
busulfan
cytarabinemelphalan
pt
et
beam
pt
pt
receiv
thaw
mobil
pbsc
obtain
gcsf
mobil
day
alon
froze
liquid
nitrogen
median
rate
cell
infus
x
kg
median
followup
month
result
median
time
graft
pnc
x
l
day
ten
earli
death
observ
includ
infect
trm
diseas
progress
month
month
hdt
pt
assess
includ
pt
cr
pt
pr
relaps
observ
pt
earlier
relaps
period
month
pt
death
among
pt
persist
cr
achiev
pt
includ
mlcl
other
dlbcl
overal
surviv
os
event
free
surviv
ef
year
respect
os
ef
better
patient
receiv
rituximab
initi
therapi
os
vs
p
et
ef
vs
p
herein
present
one
patient
refractori
mcl
insensit
chemotherapi
experienc
dramat
improv
ibrutinib
monotherapi
later
develop
ibrutinib
resist
ultim
result
deterior
diseas
death
method
give
patient
sever
examin
includ
ultrasound
bone
marrow
biopsi
lymph
node
biopsi
exom
sequenc
sanger
sequenc
treatment
lymphoma
patient
receiv
chemotherapi
includ
cours
chop
cyclophosphamid
day
doxorubicin
day
vinorelbin
day
dexamethason
day
cours
rdhap
rituximab
cytarabin
day
cisplatin
day
dexamethason
day
successionbecaus
failur
control
diseas
progress
ibrutinib
qd
use
patient
die
result
man
initi
refer
hospit
complaint
abdomin
pain
distent
month
ultrasound
show
splenomegali
multipl
enlarg
retroperiton
lymph
nodesexcision
biopsi
conduct
right
neck
lymph
node
reveal
presenc
malign
cellsimmunohistochem
neoplast
cell
posit
fdc
cyclin
neg
fluoresc
situ
hybrid
fish
show
igh
thu
diagnosi
mcl
confirm
cours
therapeut
chemotherapi
appli
patient
respond
wellh
suffer
recurr
fever
thrombocytopenia
left
abdomin
pain
splenomegali
multipl
enlarg
lymph
node
receiv
ibrutinib
monotherapi
experienc
dramat
improv
bodi
temperatur
control
hemogram
becam
normal
spleen
lymph
node
taperedaft
month
respons
ibrutinib
diseas
deterior
rapidli
die
soon
exom
sequenc
patient
peripher
blood
time
detect
one
missens
mutat
exon
nucleotid
result
argnin
histidin
chang
amino
acid
sanger
sequenc
patient
bone
marrow
ffpe
sampl
time
origin
diagnosi
detect
mutat
conclus
thu
studi
report
mutat
mcl
patient
develop
ibrutinib
resist
progress
aggres
may
open
new
insight
futur
effort
altern
therapeut
strategi
ibrutinibrefractori
mcl
disclosur
noth
declar
minim
residu
diseas
toler
chimer
immun
reconstitut
peripher
blood
sampl
obtain
routin
analysi
sever
time
point
hsct
avail
blood
sampl
year
use
analysi
assess
chang
b
cell
count
time
account
correl
repeat
measur
patient
use
linear
mixedeffect
model
wilcoxon
rank
test
kruskalw
test
linear
regress
use
univari
analysi
result
one
year
hsct
univari
analysi
show
patient
transplant
cb
graft
compar
bm
pbsc
significantli
higher
absolut
number
b
cell
median
bm
median
median
memori
b
cell
median
bm
median
median
recipi
age
year
significantli
higher
absolut
number
b
memori
b
cell
year
increas
donor
age
associ
decreas
effect
b
cell
r
memori
b
cell
r
reconstitut
determin
regress
analysi
follow
univari
analysi
analys
factor
mix
effect
model
assess
relat
differ
b
cell
memori
b
cell
number
year
hsct
analysi
found
signific
decreas
b
cell
memori
b
cell
number
increas
donor
age
correct
recipi
age
sourc
p
increas
recipi
age
also
show
signific
decreas
b
cell
memori
b
cell
number
p
signific
influenc
donor
sourc
figur
conclus
b
cell
memori
b
cell
number
hsct
influenc
donor
recipi
age
donor
sourc
older
donor
recipi
show
decreas
b
cell
memori
b
cell
number
year
hsct
imag
figur
b
cell
develop
donor
age
green
show
cb
red
bm
blue
pbsc
mean
donor
age
copenhagen
univers
hospit
rigshospitalet
copenhagen
denmark
leiden
univers
medic
center
leiden
netherland
background
outcom
allogen
hsct
challeng
delay
longlast
imbalanc
tcell
reconstitut
increas
risk
acut
gvhd
infect
diseas
progress
although
role
differenti
function
distinct
tcell
subset
develop
complic
address
littl
known
factor
control
recoveri
studi
investig
impact
immuneregul
homeostat
cytokin
reconstitut
function
distinct
tcell
subset
associ
clinic
outcom
method
includ
children
undergo
allogen
hsct
aml
median
age
year
rang
donor
either
mrd
mud
mmud
bm
pb
use
stem
cell
sourc
condit
regimen
base
tbi
highdos
chemotherapi
alon
includ
atg
patient
thirti
agematch
healthi
children
includ
control
cytokin
scf
activ
atg
plasma
longitudin
measur
condit
month
hsct
along
extend
phenotyp
tcell
matur
differenti
flow
cytometri
result
homeostat
cytokin
increas
precondit
peak
week
posthsct
gradual
declin
thereaft
level
shortli
elev
scf
remain
rel
stabl
level
threshold
detect
time
point
earli
rise
strongli
associ
degre
tcell
deplet
atg
also
correl
marker
system
inflamm
level
significantli
higher
children
treat
atg
p
correl
longer
exposur
atg
p
increas
level
activ
atg
day
p
p
indic
high
level
cytokin
reflect
pronounc
tcell
deplet
lymphopenia
higher
circul
level
associ
slow
recoveri
tcell
count
day
posthsct
p
remain
cytokin
correl
immun
reconstitut
look
tcell
subpopul
increas
level
first
month
posttranspl
associ
lower
number
cell
correl
increas
proport
effector
memori
cell
figur
differenti
effect
cytokin
polar
cell
cell
treg
cell
found
atgtreat
patient
level
day
significantli
lower
patient
develop
acut
gvhd
grade
iiiv
respect
total
cohort
increas
level
associ
reactiv
ebv
conclus
find
suggest
quantif
indic
degre
tcell
deplet
first
week
hsct
predict
complic
overal
result
indic
lymphopeniainduc
elev
major
driver
initi
expans
donor
tcell
background
mathemat
kinet
model
adopt
studi
immun
cell
reconstitut
allogen
hematopoiet
stem
cell
transplant
allohsct
associ
acut
graftversushost
diseas
agvhd
relaps
immun
cell
reconstitut
kinet
model
explor
method
june
may
sixtyf
patient
hematolog
malign
allohsct
recruit
peripher
blood
collect
day
day
day
month
month
month
month
month
month
month
lymphocyt
subset
determin
flow
cytometri
includ
total
lymphocyt
helper
cell
cytotox
cell
ratio
natur
killer
nk
cell
nkt
cell
b
lymphocyt
naiv
cell
hladr
static
cell
hladr
regulatori
cell
high
mathemat
kinet
model
calcul
immun
cell
reconstitut
spss
result
allohsct
logarithm
curv
model
observ
cell
cubic
curv
model
observ
cell
high
cell
hladr
cell
nkt
cell
b
cell
cell
hladr
cell
nk
cell
show
type
curv
model
consid
cell
major
mediat
agvhd
graftversusleukemia
effect
allohsct
establish
immun
cell
kinet
model
found
differ
curv
model
observ
patient
without
agvhd
allohsct
although
kinet
model
almost
leukemiafre
relaps
patient
first
month
allohsct
significantli
differ
kinet
curv
could
observ
thereaft
conclus
immun
cell
reconstitut
show
differ
mathemat
curv
model
allohsct
kinet
reconstitut
model
certain
immun
cell
associ
agvhd
relaps
henc
mathemat
kinet
model
immun
cell
reconstitut
may
potenti
indictor
predict
agvhd
relaps
allohsct
disclosur
noth
declar
lineag
specif
chimer
analysi
pediatr
patient
follow
allogen
hematopoiet
cell
transplant
hct
background
outcom
allogen
hct
depend
sever
variabl
includ
patient
age
diseas
stage
cytoreduct
graft
graft
manipul
graft
versu
host
diseas
gvhd
prophylaxi
one
aspect
hct
remain
poorli
defin
studi
donor
host
dh
chimer
post
hct
sinc
follow
patient
dh
lineag
specif
chimer
post
hct
analys
perform
short
tandem
repeat
str
polymorph
analysi
american
red
cross
blood
servic
philadelphia
pa
studi
perform
blood
total
leukocyt
myeloidneutrophil
cell
tcell
bcell
nkcell
method
retrospect
studi
chart
consecut
patient
underw
allogen
hct
januari
june
pediatr
bone
marrow
transplant
servic
mskcc
retrospect
review
lineag
specif
donor
chimer
post
hct
studi
includ
dh
chimer
trend
factor
potenti
impact
chimer
includ
age
diseas
graft
sourc
tcell
deplet
tcd
preliminari
analyz
perform
cohort
includ
wilcoxon
rank
test
cox
proport
hazard
analys
result
patient
select
base
number
analys
median
age
year
patient
hematolog
malign
nonmalign
hematolog
diseas
immun
disord
cytoreduct
includ
tbi
chemotherapybas
regiment
patient
recipi
tcell
deplet
marrow
peripher
blood
graft
unmodifi
marrow
peripher
blood
graft
cord
blood
graft
full
donor
chimer
myeloid
cell
bcell
nkcell
tcell
occur
earli
posttranspl
differ
percentag
total
donor
leukocyt
month
vs
month
post
hsct
median
donor
tcell
chimer
month
month
post
hsct
p
figur
show
impact
differ
factor
includ
use
tbior
chemotherapybas
regimen
b
age
year
c
type
graft
tcell
deplet
vs
unmodifi
vs
cord
blood
donor
total
leukocyt
chimer
significantli
lower
month
compar
month
patient
year
age
graft
full
donor
chimer
tcell
occur
earli
tcell
deplet
transplant
took
one
year
complet
cord
blood
graft
associ
high
tcell
donor
chimer
throughout
posttranspl
period
signific
differ
donor
tcell
month
post
hct
compar
tcell
deplet
unmodifi
graft
conclus
preliminari
analysi
lineag
specif
chimer
posttranspl
show
donor
tcell
may
take
one
year
fulli
recov
posttranspl
mostli
follow
tcell
deplet
graft
without
intervent
cord
blood
graft
associ
high
donor
chimer
throughout
posttranspl
period
lastli
factor
associ
loss
donor
chimer
posttranspl
younger
age
nonmalign
disord
indepth
analys
perform
includ
relat
chimer
hct
outcom
disclosur
eileen
nicoletti
employe
rocket
pharmaceut
susan
prockop
investig
atara
biotherapeut
research
fund
susan
prockop
mesoblast
research
fund
nanci
kernan
gentium
support
jazz
pharmaceut
support
richard
atara
biotherapeut
royalti
consult
research
jaap
jan
boelen
bluebird
bio
consult
avrobio
consult
jaap
jan
boelen
chimerix
consult
magenta
consult
background
success
hematopoiet
stem
cell
transplant
hsct
lie
abil
engraft
immun
system
remov
residu
leukemia
cell
via
graftversusleukemia
effect
despit
relaps
remain
major
caus
mortal
among
patient
receiv
hsct
one
immun
evas
mechan
leukem
cell
escap
donor
cell
recognit
haplohsct
genom
loss
patient
specif
hla
describ
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
relaps
haplohsct
aim
studi
analyz
hla
loss
larg
cohort
patient
relaps
tcell
replet
haploident
transplant
posttranspl
cyclophosphamid
method
decemb
septemb
patient
hematolog
malign
receiv
haplohsct
recruit
among
patient
present
relaps
haplohsct
hla
type
perform
realtim
pcr
use
hlakmr
kit
gendx
netherland
nine
patient
exclud
analysi
kit
employ
includ
recipientspecif
hla
thu
total
relaps
case
analyz
analysi
chimer
carri
use
short
tandem
repeat
pcr
amplif
ampflstr
sgm
plu
thermo
fisher
usa
sensit
result
genom
loss
patient
hla
occur
patient
tabl
patient
present
differ
hematolog
neoplasm
interestingli
patient
present
lymphoid
neoplasm
acut
lymphoblast
leukemia
allt
dentrit
cell
leukemia
dcl
lymphoma
hl
hla
loss
relaps
occur
later
classic
relaps
day
regard
treatment
receiv
tabl
four
patient
studi
retrospect
three
treat
donor
lymphocyt
infus
dli
chemotherapi
drug
time
relaps
patient
receiv
treatment
end
patient
die
diseas
progress
prospect
detect
hla
loss
relaps
two
patient
moment
relaps
first
case
receiv
brentuximab
haplohsct
altern
donor
case
receiv
daratumumab
haplohsct
pend
patient
aliv
first
one
complet
remiss
cr
second
one
partial
remiss
pr
conclus
frequenc
hla
loss
relaps
similar
cohort
describ
literatur
hla
loss
identifi
patient
lymphoid
neoplasm
mechan
previous
describ
diseas
analysi
immun
evas
mechan
implement
routin
screen
patient
transplant
haploident
donor
order
design
effect
rescu
strategi
treatment
base
dli
second
transplant
donor
instead
altern
donor
use
background
adequ
immun
reconstitut
ir
crucial
reduc
transplant
toxic
relaps
rate
mortal
allogen
stem
cell
transplant
allohsct
aim
singl
center
retrospect
studi
investig
correl
recoveri
differ
lymphocyt
subpopul
main
transplant
outcom
includ
overal
surviv
os
diseas
free
surviv
df
nonrelaps
mortal
nrm
method
analyz
ir
adult
patient
aml
md
n
nhl
hd
cll
cml
mm
mpn
underw
allohsct
januari
march
median
age
transplant
year
rang
malefemal
ratio
donor
hlaident
sibl
famili
haploident
match
unrel
mismatch
unrel
cord
blood
unit
stem
cell
sourc
bone
marrow
bm
patient
cord
blood
gcsf
mobil
peripher
blood
condit
regimen
myeloabl
transplant
reduc
intens
immunosuppress
gvhd
prophylaxi
base
calcineurin
inhibitor
combin
methotrex
mofetil
mycophenol
antilymphocyt
immunoglobulin
use
patient
anti
thymocyt
globulin
atg
sanofigenzym
anti
tlymphocyt
globulin
atlg
neovii
biotech
peripher
blood
lymphocyt
subset
b
cell
nk
analyz
flow
cytometri
month
hsct
posttranspl
engraft
molecularli
determin
vntr
analysi
result
detail
tabl
proport
full
donor
chimer
analyz
peripher
blood
lymphocyt
improv
progress
transplant
pattern
observ
chimer
statu
measur
bone
marrow
mononuclear
cell
favor
achiev
full
donor
chimer
dli
perform
patient
start
median
day
transplant
median
followup
observ
month
rang
one
year
os
nrm
respect
month
allohsct
achiev
valu
higher
nk
cell
respect
significantli
associ
better
os
figur
df
p
lower
nrm
p
p
nk
better
lymphoid
reconstitut
observ
use
either
sibl
haplo
donor
match
unrel
cord
blood
donor
use
atg
significantli
associ
delay
recoveri
faster
nk
cell
reconstitut
conclus
six
month
allohsct
recoveri
nk
cell
predict
surviv
monitor
immun
recoveri
may
help
guid
pre
posttranspl
treatment
strategi
day
infect
diseas
control
sever
group
demonstr
independ
prognost
valu
differ
lymphocyt
subpopul
hsct
outcom
posttranspl
cyclophosphamid
ptci
effect
prevent
gvhd
hlahaploident
hematopoiet
stem
cell
transplant
haplo
use
ptci
hla
match
relat
mrd
unrel
mud
donor
hsct
although
less
explor
also
introduc
aim
studi
compar
earli
immun
reconstitut
allogen
hsct
haploident
hlamatch
donor
use
ptci
method
one
hundr
sixtyfour
hsct
perform
center
analyz
haplo
perform
hsct
hlaident
donor
consecut
mrd
sct
perform
ptci
mud
sct
ptci
ptci
administ
day
postranspl
follow
mmf
calcineurin
inhibitor
ciclosporina
tacrolimu
day
ahead
retrospect
compar
earli
immun
reconstitut
day
day
among
three
popul
earli
ir
assess
analysi
lymphocyt
subpopul
includ
total
lymphocyt
nk
cell
bright
immatur
subpopul
total
b
lymphocyt
lymphocyt
subpopul
determin
multiparametr
flow
cytometri
navio
beckman
result
patient
mud
haplo
receiv
pb
stem
cell
sourc
patient
receiv
prior
transplant
haplo
group
characterist
shown
tabl
patient
receiv
hsct
mrd
show
fastest
ir
statist
signific
differ
compar
haplo
almost
lymphocyt
popul
day
nk
cell
also
b
lymphocyt
day
comparison
haplo
mud
hsct
show
better
ir
among
haplo
demonstr
higher
count
nk
cell
count
day
differ
seen
day
figur
percentag
immatur
bright
nk
cell
higher
mud
hsct
differ
haplo
mrd
hsct
conclus
cohort
patient
ptci
base
gvhd
prophylaxi
regimen
receiv
hsct
mrd
show
earliest
immun
reconstitut
compar
haplo
mud
day
haplo
show
better
ir
compar
mud
day
nk
matur
day
littl
better
among
haplo
mrd
hsct
recipi
mud
hsct
patient
experi
use
mostli
pbsc
graft
sourc
type
donor
influenc
earli
ir
ptci
base
hsct
background
cellfre
dna
cfdna
isol
plasma
serum
receiv
increas
interest
diagnost
applic
howev
report
clinic
use
cfdna
patient
undergo
allogen
cell
transplant
hsct
scarc
method
chimer
statu
peripher
blood
cfdna
obtain
plasma
investig
patient
undergo
hsct
dna
rna
isol
plasma
within
four
hour
blood
draw
patient
evalu
chimer
day
posttranspl
panel
seven
microsatellit
amplifi
pcr
chimer
detect
pcr
product
analys
capillari
electrophoresi
cfdna
character
micro
rna
mirna
analys
use
digit
pcr
mutat
frequent
use
minim
residu
diseas
assess
also
investig
cfdna
result
mean
cfdna
concentr
transplant
patient
ngml
healthi
donor
use
control
group
ngml
mean
cfdna
concentr
differ
group
reach
statist
signific
p
analys
cfdna
transplant
patient
control
group
could
detect
dna
fragment
larger
bp
size
rang
analys
fragment
bp
patient
mixtur
donor
recipi
cfdna
mc
detect
except
three
patient
relaps
transplant
mc
detect
peripher
blood
plasma
rest
patient
mc
detect
plasma
mean
percentag
recipi
cfdna
plasma
sampl
rang
patient
acut
gvhd
agvhd
grade
iiv
show
mc
plasma
least
one
timepoint
test
signific
differ
found
mean
recipi
cfdna
percentag
patient
agvhd
grade
iii
compar
grade
iiiiv
meanwhil
group
patient
chronic
gvhd
mc
plasma
detect
patient
patient
clinic
improv
agvhd
decreas
percentag
recipi
cfdna
observ
treatment
patient
without
improv
even
agvhd
worsen
stabl
increas
recipi
cfdna
percentag
detect
sinc
recipi
cfdna
detect
patient
without
transplantrel
complic
analys
mirna
express
patient
recipi
cfdna
signific
differ
found
mirna
express
patient
agvhd
mean
mirna
mirna
copi
compar
patient
without
gvhd
mean
mirna
mirna
copi
patient
extramedullari
aml
relaps
frequent
mutat
detect
cfdna
fraction
conclus
longitudin
analysi
cfdna
repres
use
complementari
tool
particular
patient
clinic
complic
hsct
disclosur
noth
declar
comparison
impact
atgptcybas
tcr
gvhd
prophylaxi
regimen
recoveri
memori
tcell
compart
background
recent
year
haploident
hlamismatch
donor
increasingli
adopt
valid
donor
sourc
modern
graftversushost
diseas
gvhd
prophylaxi
regimen
drugbas
antithymocyt
globulin
atg
posttranspl
cyclophosphamid
ptci
graftmanipul
tcr
demonstr
effect
prevent
gvhd
report
data
influenc
differ
gvhd
prophylaxi
regimen
allohsct
pbsc
graft
sourc
memori
tcell
recoveri
method
studi
compris
leukemia
patient
underw
allohsct
pbsc
graft
sourc
nation
research
center
hematolog
moscow
russia
detail
patient
characterist
present
tabl
peripher
blood
sampl
collect
day
allohsct
flow
cytometri
analysi
perform
bd
fac
canto
ii
becton
dickinson
usa
defin
tmemori
subset
tnaiv
tstem
cell
memori
tnvtscm
tcentral
memori
tcm
ttransit
memori
ttm
teffector
memori
tem
ttermin
effector
tte
sysmex
use
calcul
absolut
count
differ
tmemori
cell
subset
mannwhitney
u
test
use
nonparametr
data
analysi
pvalu
less
consid
signific
result
result
mannwhitney
u
test
calcul
pvalu
compar
absolut
number
tmemori
cell
subset
term
differ
gvhd
prophylaxi
regimen
present
figur
followup
period
number
tnvscm
tcm
remain
significantli
reduc
atgptci
tcr
compar
atgbas
immunosuppress
regimen
day
observ
differ
number
tnvscm
tcm
cell
atgptci
tcr
termin
differenti
cell
ttm
tem
tte
count
significantli
lower
tcr
patient
group
comparison
atgptci
nevertheless
recoveri
tnvscm
tcm
ptci
faster
tcr
conclus
accord
data
mechan
ptci
seem
select
compar
tcr
due
transient
impact
tnvscm
tcm
without
affect
effector
pool
may
lead
delay
reconstitut
adapt
immun
tcr
compar
use
ptci
clinic
relev
quantit
characterist
immun
recoveri
context
differ
approach
gvhd
prevent
remain
establish
background
immun
effector
cell
belong
either
innat
acquir
immun
play
key
role
prevent
diseas
relaps
allogen
haematopoiet
stem
cell
transplant
hsct
known
immun
effector
tcell
natur
killer
lymphocyt
cell
act
modulatori
regulatori
cell
earli
posthsct
ratio
cellular
subset
may
indic
graft
vstumor
gvt
effect
method
retrospect
revis
immun
recoveri
allogen
hsct
perform
institut
analys
peripher
blood
multiparametr
flow
cytometri
lymphocyt
subpopul
panel
diagnosi
acut
leukemia
chronic
myeloprolif
neoplasm
lymphoma
myelodysplast
syndrom
multipl
myeloma
sever
aplast
anemia
establish
earli
timepoint
evalu
day
graft
infus
analys
differ
diseas
free
surviv
df
overal
surviv
os
patient
accord
x
ratio
result
median
ratio
day
time
point
patient
show
ratio
higher
median
better
df
median
df
time
reach
vs
month
p
figur
os
median
os
time
reach
vs
month
p
likewis
ratio
show
advantag
df
p
os
p
factor
possibl
affect
df
os
analys
univari
analysi
use
antithymocyt
globulin
atg
condit
regimen
intens
graft
sourc
hlamatch
diseas
statu
hsct
latter
variabl
significantli
detriment
impact
os
df
diseas
statu
confirm
independ
valriabl
associ
df
os
well
ratio
df
hazard
ratio
hr
p
os
hr
p
conclus
data
show
x
ratio
assess
independ
predictor
transplant
outcom
possibl
repres
row
indic
antileukem
immun
surveil
integr
index
known
outcom
predictor
may
help
improv
manag
posttranspl
phase
imag
figur
background
allogen
stem
cell
transplant
alohsct
cur
treatment
associ
lifethreaten
complic
death
due
relaps
graft
versu
host
diseas
gvhd
infect
pattern
qualiti
immun
reconstitut
ir
transplant
may
affect
outcom
howev
limit
data
associ
qualiti
ir
either
develop
gvhd
surviv
method
eightyf
patient
receiv
non
tcell
deplet
alohsct
center
prospect
studi
patient
receiv
hlaident
graft
total
cell
includ
central
memori
cell
lymphocyt
quantifi
flow
cytometri
data
collect
day
alohsct
associ
ir
gvhd
studi
anova
multivari
analysi
logist
regress
perform
includ
confus
clinic
variabl
signific
univari
analysi
studi
overal
surviv
os
versu
ir
perform
cox
regress
model
result
total
lymphocyt
reach
normal
number
within
first
two
month
median
count
cellsul
one
month
within
normal
rang
convers
took
nearli
one
year
get
normal
count
cell
cellsul
two
clinic
paramet
condit
wors
recoveri
cell
previou
alosensit
donor
sex
femal
donor
male
recipi
worst
combin
ir
paramet
influenc
qualiti
reconstitut
cell
note
age
hla
statu
influenc
qualiti
ir
patient
divid
gvhd
gvhd
found
differ
recoveri
either
proport
absolut
count
everi
cell
subpopul
includ
total
cell
well
memori
cell
final
multivari
analysi
confirm
absolut
count
cell
day
well
absolut
count
cell
day
associ
better
os
conclus
conclus
neither
develop
gvhd
relev
paramet
seem
play
determin
role
qualiti
ir
knowledg
first
studi
demonstr
clear
associ
recoveri
cell
measur
flow
cytometri
os
disclosur
noth
declar
abstract
alreadi
publish
azacitidin
aza
prophylaxi
preemptiv
therapi
myeloid
neoplasm
allogen
stem
cell
transplant
treat
prophylact
preemptiv
median
age
year
rang
patient
diagnosi
aml
highrisk
md
prophylact
treatment
consist
aza
mgm
day
cycl
day
preemptiv
set
patient
receiv
mgm
day
per
cycl
patient
mgm
day
per
cycl
median
cycl
rang
administ
prophylact
group
cycl
rang
preemptiv
group
ten
patient
also
receiv
least
one
dli
third
aza
cycl
patient
prophylact
group
patient
preemptiv
one
result
followup
patient
signific
delay
treatment
plan
due
transitori
mild
complic
howev
patient
present
infecti
complic
requir
hospitalis
patient
prophylaxi
group
preemptiv
group
present
form
gvhd
patient
develop
gvhd
discontinu
treatment
prophylaxi
group
also
patient
discontinu
treatment
due
diseas
progress
overal
dropout
rate
surviv
analys
initi
treatment
aza
median
followup
month
oneyear
ef
prophylaxi
group
one
patient
relaps
death
preemptiv
group
ef
median
ef
month
os
median
os
month
conclus
conclud
posttranspl
aza
treatment
welltoler
therapi
incid
side
effect
remain
discord
literatur
result
prophylaxi
group
excel
patient
posit
minim
residu
diseas
treat
preemptiv
lower
outcom
stabilis
diseas
randomis
prospect
trial
need
defin
patient
would
benefit
treatment
time
dosag
durat
treatment
disclosur
noth
declar
abstract
alreadi
publish
result
subject
experienc
hematopoiet
engraft
median
day
rang
demonstr
full
donor
myeloid
chimer
mmdsc
pmnmdsc
recoveri
peak
median
day
posttranspl
median
peak
absolut
mmdsc
count
cellml
rang
repres
rang
pbmc
pmnmdsc
peak
robust
median
absolut
peak
cellsml
rang
repres
median
pbmc
rang
note
one
patient
develop
sever
lifethreaten
gvhd
lowest
absolut
rel
pmnmdsc
recoveri
cellsml
total
pbmc
recoveri
mand
pmnmdsc
occur
similar
tempo
magnitud
two
recipi
standard
gvhd
prophylaxi
tacrolimusmethotrex
howev
mdsc
isol
ptci
recipi
exhibit
clear
tcell
suppress
capac
comparison
patient
see
figur
conclus
mdsc
recov
rapidli
robustli
allohct
use
ptci
gvhd
prophylaxi
may
play
role
mitig
gvhd
risk
mediat
tcell
suppress
may
mechan
ptci
result
donorrecipi
toler
background
high
dose
chemotherapi
follow
autolog
stem
cell
transplant
asct
offer
cure
upfront
relaps
set
hodgkin
hl
nonhodgkin
lymphoma
nhl
asct
also
remain
standard
care
previous
untreat
multipl
myeloma
mm
patient
induct
therapi
elig
avail
new
cellular
immun
therapi
use
asct
underscor
potenti
import
monitor
immun
reconstitut
asct
method
immun
reconstitut
panel
irp
evalu
retrospect
lymphoma
mm
patient
span
underw
asct
institut
patient
includ
preasct
measur
within
day
asct
two
irp
follow
timepoint
day
day
postasct
patient
lymphoma
cohort
irp
exclud
addit
treatment
within
first
year
postasct
mainten
rituximab
mononuclear
cell
peripher
blood
analyz
flow
cytometri
assess
lymphocyt
phenotyp
number
absolut
valu
compar
use
mannwhitney
u
test
result
data
patient
avail
analysi
mm
nhl
hl
lymphoma
patient
condit
beam
mm
patient
condit
standard
high
dose
melphalan
regimen
median
preasct
absolut
count
lymphoma
cohort
significantli
lower
mm
cohort
vs
respect
howev
mm
cohort
exhibit
greater
percent
reduct
cell
day
vs
respect
continu
day
vs
respect
led
nonsignific
chang
absolut
count
day
vs
respect
figur
median
absolut
count
preasct
mm
lymphoma
cohort
respect
similarli
greater
percent
reduct
cell
led
compar
absolut
count
day
vs
respect
failur
postasct
reconstitut
preasct
level
driven
lack
cell
recoveri
name
cell
median
mm
lymphoma
cohort
respect
day
figur
led
markedli
diminish
ratio
day
figur
imag
conclus
impair
tcell
reconstitut
lymphoma
mm
continu
postasct
shown
larger
percent
reduct
median
count
day
appreci
mm
compar
lymphoma
lead
nonsignific
differ
postasct
absolut
count
despit
significantli
higher
preasct
count
mm
cohort
impair
recoveri
tcell
may
increas
risk
opportunist
infect
decreas
respons
vaccin
lead
ineffect
antitumor
respons
prospect
larger
retrospect
studi
like
continu
modernera
may
help
predict
respons
intervent
requir
robust
tcell
repertoir
maxim
efficaci
cart
cell
bite
therapi
disclosur
noth
declar
peritranspl
detect
measur
residu
diseas
multicolor
flow
cytometri
highli
predict
relaps
acut
myeloid
leukemia
patient
background
presenc
measur
residu
diseas
mrd
prior
allosct
shown
predict
surviv
patient
hematolog
cr
aml
studi
analyz
impact
mrd
patient
measur
multiparamet
flow
cytometri
mfc
prior
day
posttranspl
method
bone
marrow
sampl
immedi
prior
allosct
day
posttranspl
retrospect
analyz
mrd
evalu
carri
antibodi
result
number
aml
patient
male
median
age
year
hematolog
cr
prior
allosct
enrol
studi
observ
lower
surviv
patient
mrd
mfc
pretranspl
os
vs
due
increas
relaps
incid
vs
multivari
analysi
mrd
po
prior
allosct
strong
signific
impact
os
hr
patient
sampl
day
transplant
avail
patient
patient
mrd
neg
prior
transplant
day
mrd
negneg
patient
mrd
posit
prior
transplant
neg
day
mrd
posneg
patient
mrd
posit
timepoint
mrd
pospo
df
os
three
group
follow
df
mrd
negneg
mrd
posneg
mrd
pospo
os
mrd
negneg
mrd
posneg
mrd
pospo
p
upon
multivari
analysi
mrd
statu
prior
transplant
day
show
strong
signific
impact
df
hr
os
observ
signific
impact
factor
includ
multivari
analysi
patient
age
patient
sex
recipi
donor
sex
constel
conclus
mrd
posit
prior
allotranspl
day
mfc
highli
predict
surviv
allosct
disclosur
noth
declair
background
immun
reconstitut
critic
factor
risk
assess
life
threaten
infect
longterm
surviv
patient
undergo
allogen
cell
transplant
hsct
method
immun
cell
subset
quantifi
flow
cytometri
trec
krec
quantifi
simultan
use
droplet
digit
pcr
dpcr
total
patient
evalu
mean
age
transplant
year
rang
year
sampl
obtain
hsct
day
hsct
result
absolut
number
cell
remain
pretranspl
level
day
increas
eventu
reach
pretranspl
level
one
year
hsct
absolut
count
remain
pretranspl
level
beyond
one
year
hsct
cell
character
fast
reconstitut
kinet
reach
pretranspl
level
alreadi
day
b
cell
correl
krec
level
timepoint
test
wherea
cell
correl
trec
level
one
year
transplant
compar
cell
subset
trec
krec
level
reconstitut
kinet
thereof
patient
reduc
intens
condit
full
condit
signific
differ
observ
patient
pretranspl
trec
level
mean
trec
copiesml
blood
show
higher
trec
level
faster
tcell
reconstitut
hsct
suggest
tcell
reconstitut
predict
analys
thymic
function
transplant
inde
patient
pretranspl
trec
trec
copiesml
blood
posit
predict
valu
effici
tcell
reconstitut
analys
recoveri
kinet
cell
subset
trec
krec
level
patient
without
transplantrel
complic
patient
either
acut
graftversushost
diseas
sever
infect
show
slower
trec
reconstitut
compar
patient
without
complic
conclus
data
suggest
analysi
immun
cell
subset
togeth
trec
krec
quantif
use
evalu
immun
reconstitut
process
hsct
pretranspl
trec
level
allow
tcell
reconstitut
effici
predict
hsct
disclosur
noth
declar
background
fall
donor
mix
chimer
allogen
haematopoet
stem
cell
transplant
sct
associ
increas
risk
relaps
potenti
graft
reject
donor
lymphocyt
infus
dli
often
administ
patient
mix
chimer
achiev
full
donor
chimer
littl
data
long
term
outcom
dli
given
persist
mix
chimer
method
retrospect
analysi
patient
administ
dli
mix
chimer
januari
perform
patient
transplant
univers
hospit
wale
within
south
wale
blood
marrow
transplant
swbmt
programm
patient
identifi
swbmt
databas
addit
outcom
data
gather
review
patient
medic
record
result
patient
treat
donor
lymphocyt
infus
januari
thirti
one
patient
treat
relaps
without
mix
chimer
exclud
patient
mismatch
donor
rest
match
twenti
six
patient
receiv
total
donor
lymphocyt
infus
mix
chimer
alon
median
age
year
rang
women
fourteen
patient
sibl
donor
transplant
twelv
match
unrel
donor
indic
transplant
aml
saml
myelofibrosi
md
hodgkin
lymphoma
nonhodgkin
lymphoma
escal
dose
donor
cell
administ
commenc
kg
kg
increas
half
log
increment
accord
chimer
result
full
donor
chimer
achiev
median
number
dose
administ
rang
median
interv
day
rang
median
dose
kg
rang
seventeen
patient
achiev
full
donor
chimer
remain
recent
follow
median
month
rang
one
patient
continu
receiv
dli
studi
period
later
revert
full
donor
two
patient
ongo
mix
chimer
evid
relaps
two
patient
relaps
one
later
achiev
remiss
six
case
gvhd
acut
gvhd
grade
ii
grade
iii
case
chronic
extens
gvhd
one
patient
gvhd
featur
consist
overlap
syndrom
total
five
patient
die
four
due
infect
one
patient
gvhd
one
due
cardiac
toxic
previou
treatment
confirm
postmortem
conclus
result
singl
centr
studi
help
reinforc
evid
dli
establish
full
donor
chimer
mix
chimer
detect
absenc
relaps
increment
dli
dose
effect
strategi
associ
low
relaps
rate
caution
still
given
risk
gvhd
follow
dli
howev
risk
appear
low
studi
larger
prospect
studi
ongo
address
optim
dose
strategi
dli
posttranspl
disclosur
noth
declar
hypomethyl
agent
treatment
relaps
acut
myeloid
leukemia
allogen
blood
stem
cell
transplant
singl
center
experi
mariarita
scium
giorgia
sapor
elena
tagliaferri
nicola
fracchiolla
federica
grifoni
giorgia
levati
luca
baldini
francesco
onida
posttranspl
period
wellbalanc
profil
good
efficaci
moder
toxic
retrospect
evalu
safeti
efficaci
hma
dli
reallif
cohort
aml
patient
relaps
allosct
method
data
patient
aml
underw
allosct
institut
last
year
subsequ
receiv
hma
salvag
treatment
diseas
recurr
preemptiv
loss
complet
donor
chimer
collect
result
eleven
patient
median
age
year
rang
identifi
median
time
allosct
time
hma
therapi
month
rang
accord
eln
genet
risk
stratif
patient
classifi
favor
group
intermediatei
intermediateii
advers
one
six
patient
treat
aza
wherea
remain
patient
dac
cycl
repeat
everi
day
ten
patient
start
hma
morpholog
aml
relaps
one
patient
receiv
aza
sequenti
treatment
dli
administ
loss
complet
donor
chimer
median
number
cycl
rang
treatment
strategi
includ
combin
dli
patient
dac
cohort
aza
cohort
one
case
aml
sorafenib
also
associ
dac
dli
grade
toxic
acut
gvhd
occur
clinic
signific
respons
observ
four
patient
receiv
least
cycl
hma
therapi
particular
complet
remiss
cr
achiev
patient
treat
morpholog
relaps
includ
one
receiv
dacdlisorafenib
combin
one
favor
eln
risk
receiv
aza
alon
elig
dli
due
concomit
lateonset
cutan
grade
gvhd
interest
latter
patient
also
display
resolut
cutan
gvhd
full
donor
chimer
recoveri
gvhd
observ
patient
receiv
aza
progress
donor
chimer
loss
respond
dli
alon
median
followup
month
rang
median
os
hma
treatment
respond
patient
month
rang
time
data
collect
respons
maintain
four
patient
seven
patient
die
six
aml
progress
one
sever
intestin
gvhd
occur
failur
dliaza
follow
salvag
induct
chemotherapi
treatment
conclus
although
aris
limit
number
patient
reallif
experi
treatment
hma
dli
aml
patient
relaps
allosct
show
gener
good
safeti
profil
promis
antileukem
activ
altogeth
suggest
facilit
graftversusleukemia
effect
gvl
associ
possibl
suppress
gvh
reaction
disclosur
noth
declar
conclus
studi
cell
count
igg
valu
recov
month
sct
institut
achiev
low
incid
infect
educ
medic
patient
recoveri
cell
count
igg
howev
found
higher
incid
infect
recoveri
cell
count
igg
month
sct
administr
prophylact
medic
sulfamethoxazoletrimethoprim
termin
social
comeback
return
school
work
achiev
patient
possibl
high
incid
communityacquir
infect
associ
comeback
thu
consid
addit
prevent
infect
patient
period
evalu
immunolog
marker
need
disclosur
potenti
conflict
interest
disclos
effect
minim
residu
diseas
transplant
outcom
haploident
hematopoiet
stem
cell
transplant
highrisk
acut
lymphoblast
leukemia
yehui
tan
sujun
gao
xiaoliang
liu
long
su
wei
han
yu
liu
yangzhi
zhao
background
analyz
effect
haploid
hematopoiet
stem
cell
transplant
hidhsct
highrisk
acut
lymphoblast
leukemia
explor
effect
minim
residu
diseas
mrd
transplant
prognosi
method
retrospect
analysi
made
high
risk
patient
accept
hidhsct
hospit
januari
januari
clinic
featur
stem
cell
implant
complic
surviv
recurr
compar
pretranspl
mrd
mrdpatient
result
patient
got
success
implant
overal
surviv
os
diseas
free
surviv
df
incid
acut
graft
versu
host
diseas
agvhd
includ
iiiv
degre
agvhd
iiiiv
degre
agvhd
signific
differ
stem
cell
implant
gvhd
cytomegaloviru
hemorrhag
cystiti
mrd
mrdpatient
df
os
mrd
patient
significantli
lower
mrd
patient
cumul
rr
rate
increas
significantli
signific
differ
cumul
trm
conclus
hidhsct
effect
method
treat
high
risk
mrd
patient
high
recurr
rate
poor
prognosi
strategi
adjust
consid
reduc
tumor
residu
transplant
strategi
optim
kind
high
risk
patient
improv
surviv
rate
disclosur
noth
declar
background
lymphocyt
respons
cellular
humor
immun
consequ
recoveri
allohsct
might
link
surviv
procedur
aim
studi
analyz
hypothesi
seri
patient
method
allohsct
perform
center
januari
juli
includ
analysi
median
age
year
rang
pt
male
femal
baselin
diseas
aml
lpd
md
mpd
mm
bmf
donor
unrel
famili
case
includ
haploident
stem
cell
sourc
pb
bm
pt
condit
regimen
reduc
procedur
intens
includ
one
nonmyeloabl
overal
mortal
day
latter
patient
followup
superior
year
respect
median
followup
month
rang
evolut
absolut
lymphocyt
count
alc
subpopul
prehsct
first
year
allohsct
analyz
result
shown
tabl
alc
lymphocyt
decreas
condit
therapi
recov
progress
posthsct
period
day
major
patient
alcmcl
clearli
improv
compar
admiss
valu
lymphocyt
day
still
low
day
around
half
seri
found
strong
link
alc
lymphocyt
lymphocyt
day
day
overal
surviv
day
seri
tabl
conclus
seri
immun
recoveri
late
event
major
patient
undergo
allohsct
addit
experi
precoc
qualiti
alc
cell
recoveri
clearli
link
longterm
surviv
background
reconstitut
natur
killer
nk
cell
hematopoiet
stem
cell
transplant
hsct
strongli
influenc
outcom
hsct
includ
viral
infect
graft
versushost
diseas
gvhd
purpos
studi
investig
clinic
efficaci
immun
reconstitut
includ
nk
cell
hsct
children
method
review
record
patient
undergo
allogen
hsct
depart
pediatr
pusan
nation
univers
children
hospit
januari
juli
count
lymphocyt
subset
nk
cell
monitor
peripher
blood
flow
cytometr
techniqu
month
posthsct
blood
sampl
cytomegaloviru
cmv
epsteinbarr
viru
ebv
monitor
test
realtim
pcr
assay
result
total
patient
mean
age
year
rang
year
patient
boy
girl
total
patient
without
prehsct
cmv
viremia
cmv
infect
recipi
experienc
cmv
infect
number
cell
month
posthsct
significantli
higher
patient
cmv
reactiv
compar
patient
without
median
vs
vs
recipi
present
acut
gvhd
number
cell
month
posthsct
significantli
lower
patient
acut
gvhd
compar
patient
without
median
vs
vs
number
nk
cell
month
posthsct
significantli
lower
patient
cmv
reactiv
acut
gvhd
compar
patient
without
vs
vs
respect
multivari
analysi
acut
gvhd
shown
decis
factor
influenc
total
cell
cmv
reactiv
independ
associ
cell
cell
count
associ
prior
hsct
histori
acut
gvhd
cell
count
also
significantli
associ
donor
type
conclus
overal
studi
document
immun
reconstitut
cell
nk
cell
strongli
associ
cmv
reactiv
acut
gvhd
addit
show
acut
gvhd
influenc
lack
suffici
number
nk
cell
well
cell
earli
sct
cell
hand
significantli
increas
cmvreactiv
like
play
import
role
reactiv
disclosur
noth
declar
background
cur
effect
allogen
hematopoiet
stem
cell
transplant
allohsct
depend
alloreact
tcell
immun
respons
toward
residu
malign
cell
graftversusleukemia
reaction
howev
alloreact
popul
phenotyp
defin
recent
studi
suggest
alloreact
cell
express
costimulatori
inhibitori
receptor
simultan
exhaust
caus
inhibitori
signal
dampen
tcell
function
could
lead
diseas
relaps
aim
investig
express
costimulatori
inhibitori
receptor
antigenexperienc
cell
transplant
isol
subpopul
specif
allohsct
patient
analyz
tcell
receptor
tcr
repertoir
method
express
coinhibitori
costimulatori
molecul
pbmc
patient
variou
time
point
allohsct
analyz
express
tigit
flow
cytometri
compar
healthi
donor
fraction
control
fraction
separ
fac
aria
ii
cell
sorter
doubl
barcod
cdna
librari
tcr
betachain
fraction
prepar
analyz
sequenc
illumina
platform
sequenc
result
process
migec
mixcr
vdjtool
softwar
enrich
clone
identifi
fisher
exact
test
p
result
find
signific
differ
patient
allohsct
healthi
donor
singl
marker
express
consid
coexpress
costimulatori
inhibitori
molecul
cell
found
subpopul
significantli
increas
allohsct
patient
moreov
increas
time
sinc
transplant
fig
popul
isol
cell
sort
alongsid
total
fraction
subject
tcr
betachain
repertoir
sequenc
popul
contain
clone
significantli
enrich
compar
fraction
repres
potenti
alloreact
cell
hypothesi
support
notion
level
express
costimulatori
molecul
lower
group
patient
subsequ
relaps
compar
patient
complet
remiss
express
inhibitori
receptor
high
group
conclus
accord
data
patient
allohsct
phenotyp
distinct
tcell
popul
character
simultan
express
costimulatori
inhibitori
marker
popul
contain
specif
enrich
clone
may
specif
alloantigen
function
assay
need
confirm
alloreact
potenti
subpopul
besid
low
express
costimulatori
molecul
combin
high
express
inhibitori
receptor
antigenexperienc
tcell
patient
allohsct
might
associ
diseas
relaps
fondazion
mbbm
monza
itali
ospedal
san
gerardo
laboratorio
stefano
verri
monza
itali
background
poor
graft
function
pgf
sever
complic
hsct
high
risk
morbid
mortal
mainli
due
infect
donor
scb
seem
offer
high
chanc
haematolog
recoveri
jeopard
gvhd
howev
pediatr
report
remain
scarc
method
patient
undergo
transplant
pediatr
unit
retrospect
evalu
least
line
persist
cytopenia
hb
plt
n
mmc
andor
transfusiondepend
beyond
month
hsct
presenc
full
donor
chimer
bone
marrow
cellular
evalu
biopsi
indic
pgf
donat
medic
decis
bone
marrow
cellular
patient
underw
scb
histolog
avail
case
treat
day
scb
patient
hematolog
respons
complet
partial
patient
patient
respons
infus
alway
well
toler
advers
event
worsen
gvhd
haematolog
recoveri
occur
spontan
day
bone
marrow
biopsi
significantli
lower
proport
patient
p
within
nonscb
group
two
case
platelet
engraft
significantli
delay
one
year
bone
marrow
biopsi
one
case
thrombocytopenia
persist
patient
still
receiv
thrombopoietin
agonist
red
blood
cell
transfus
month
bone
marrow
biopsi
conclus
stem
cell
boost
match
goal
yield
count
recoveri
cohort
viral
infect
gvhd
may
possibl
risk
factor
pgfbilinear
trilinear
cytopenia
transfus
depend
bom
cellular
full
donor
chimer
good
indic
scb
provid
significantli
earlier
hematolog
reconstitut
without
risk
gvhd
due
prove
earli
efficaci
safeti
stem
cell
infus
suggest
procedur
taken
consider
children
sever
bone
marrow
hypoplasia
persist
cytopenia
hsct
disclosur
background
allogen
hematopoiet
stem
cell
transplant
hsct
sometim
perform
despit
erythrocyt
antigen
incompat
mismatch
essenti
care
track
patient
genotyp
method
studi
use
erythrocyt
dna
patient
undergo
aboor
rhesusmismatch
hsct
donor
use
posttranspl
transfus
patient
period
accord
transplant
protocol
hemagglutin
method
plate
tube
use
monoclon
antibodi
abo
rhesu
antigen
hematolog
russia
extract
dna
dna
kit
bag
germani
conduct
pcrssp
kit
abotyp
rhtype
bag
germani
chimer
assess
strpcr
analysi
cordi
plu
multiplex
kit
amplif
polymorph
strmarker
amelogenin
loci
fragment
analysi
perform
genet
analyz
inform
loci
chosen
comparison
pretranspl
patient
donor
dna
percentag
donor
chimer
calcul
use
standard
formula
precis
rhce
abo
genotyp
determin
direct
sanger
sequenc
reveal
patient
unexpect
erythrocyt
abo
rhesu
phenotyp
genotyp
hsct
patient
day
patient
chimer
analys
str
show
aekh
glv
patient
donor
dna
less
recipi
one
bna
patient
relaps
chimer
analysi
reveal
recipi
dna
donor
one
use
serolog
method
pcrssp
reveal
genotyp
abo
rhd
rhce
ccee
patient
ekh
hsct
abo
rhd
rhce
ccee
donor
abo
rhd
rhce
ccee
hsct
genotyp
recipi
neither
donor
origin
direct
sequenc
prove
genotyp
reveal
donor
oneon
serolog
method
pcrssp
also
reveal
donor
genotyp
patient
patient
bna
genotyp
abo
rhd
rhce
c
w
cee
hsct
donor
abo
rhd
rhce
ccee
patient
relaps
rhesu
genotyp
detect
rhd
rhce
c
wcee
lack
e
gene
direct
sequenc
reveal
gene
rhce
ee
abo
genotyp
recipi
origin
patient
glv
use
serolog
pcrssp
method
determin
genotyp
abo
rhd
rhce
ccee
genotyp
hsct
abo
rhd
rhce
ccee
genotyp
hsc
donor
patient
unexpect
genotyp
abo
lack
antigen
rhce
ccee
lack
e
antigen
order
explain
unexpect
patient
genotyp
hsct
sequenc
rhce
abo
gene
found
donor
genotyp
ccee
agreement
result
str
analysi
resolv
discrep
serolog
pcrssp
sequenc
analysi
data
sequenc
patient
rhce
cdna
observ
ce
allel
present
time
molecular
basi
select
inactiv
one
two
rhce
allel
clear
patient
donor
genotyp
conclus
kind
mechan
led
discrep
result
obtain
differ
laboratori
method
still
clear
interest
case
express
one
rhce
allel
patient
glv
allow
us
suggest
involv
epigenet
mechan
like
dna
methyl
histon
modif
process
clinic
background
relaps
patient
acut
b
lymphoblast
leukemia
allb
achiev
complet
remiss
cr
reinduct
therapi
minim
residu
diseas
mrd
allb
cellsul
often
detect
accord
avail
data
condit
vari
even
case
assess
pcr
flow
cytometri
fc
presenc
mrd
import
risk
factor
recurr
abstract
describ
experi
bridg
therapi
use
blinatumomab
infus
reinduct
regimen
plan
allogen
stem
cell
transplant
allosct
procedur
perform
three
young
men
suffer
relaps
ph
allb
age
year
first
case
relaps
previou
mrd
account
occur
month
mrd
neg
next
patient
second
relaps
central
nervou
system
cn
involv
occur
month
allosct
perform
month
mrd
neg
third
patient
recurr
cn
testi
involv
occur
year
mrd
neg
patient
underw
chemotherapi
flam
hypercvad
dnrvcrpegaspdexa
regimen
respect
follow
one
cycl
blinatumomab
dose
day
follow
day
continu
infus
allosct
use
etocytbiatg
condit
regimen
ist
iiird
patient
iind
patient
use
match
unrel
donor
mud
ist
iiird
patient
match
relat
donor
iind
patient
mrd
statu
assess
cycl
blinatumomab
fc
result
patient
achiev
cr
mrd
po
reinduct
therapi
follow
clearanc
mrd
blinatumomab
cours
tab
second
patient
due
posit
mrd
month
allosct
receiv
donor
lymphocyt
infus
addit
administr
blinatumomab
advers
event
ae
observ
grade
one
patient
develop
cytokin
releas
syndrom
grade
progress
free
surviv
time
posit
mrd
follow
present
tab
conclus
use
blinatumomab
bridg
therapi
reinduct
regimen
allosct
patient
allb
mrd
po
appear
safe
lead
clearanc
mrd
may
crucial
os
pf
prolong
follow
allosct
futur
studi
larger
group
patient
necessari
confirm
thesi
background
haploident
hematopoiet
stem
cell
transplant
hsct
consid
altern
treatment
hematolog
malign
patient
hlaident
sibl
donor
sinc
infect
diseas
relaps
result
delay
immun
reconstitut
ir
common
caus
mortal
among
patient
undergo
haploidenticalhsct
time
ir
essenti
recoveri
surviv
patient
aim
studi
describ
evolut
ir
haploidenticalhsct
estim
surviv
rate
patient
delay
vs
adequ
reconstitut
singl
center
colombia
south
america
method
retrospect
cohort
studi
conduct
consecut
adult
haploidenticalhsct
recipi
tertiari
referr
center
immunoglobulin
level
monitor
hsct
first
month
everi
three
month
first
two
year
posttransplant
descript
statist
use
analyz
patient
clinic
characterist
kaplanmei
method
use
assess
overal
surviv
os
relapsefre
surviv
rf
rate
result
twentysix
patient
includ
male
median
age
year
rang
common
indic
haploident
hsct
acut
lymphoblast
leukemia
follow
nonhodgkin
lymphoma
myelodysplast
syndrom
patient
receiv
gvhd
prophylaxi
therapi
cyclophosphamid
tacrolimu
mycophenol
mofetil
fifteen
patient
present
cytomegaloviru
reactiv
risk
patient
epsteinbarr
viru
reactiv
patient
develop
adenoviru
infect
median
time
neutrophil
engraft
neutrophil
l
day
patient
recipi
peripher
blood
progenitor
cell
pbpc
day
three
remain
bone
marrow
recipi
platelet
engraft
defin
platelet
mm
background
daratumumab
human
monoclon
antibodi
direct
glycoprotein
overexpress
surfac
plasma
cell
multipl
myeloma
patient
approv
second
line
therapi
either
singl
agent
therapi
combin
lenalidomid
bortezomib
treatment
patient
relapsedrefractori
multipl
myeloma
despit
cur
potenti
allosct
high
relaps
rate
remain
clinic
problem
data
address
choic
optim
salvag
therapi
regim
heavili
pretreat
patient
miss
method
april
till
novemb
total
patient
male
median
age
year
receiv
daratumumab
salvag
therapi
relaps
multipl
myeloma
allosct
univers
hamburg
prior
allosct
one
patient
receiv
autograft
patient
even
autograft
patient
also
allograft
median
number
salvag
line
posttranspl
prior
first
daratumumab
infus
salvag
regimen
includ
cyclophosphamid
etoposid
bortezomib
lenalidomid
pomalidomid
carfilzomib
daratumumab
start
median
month
relaps
progress
initi
singl
agent
therapi
patient
concomitantli
patient
receiv
either
immunomodulatori
drug
lenalidomid
pomalidomid
proteasom
inhibitor
bortezomib
later
cours
daratumumab
infus
combin
therapi
initi
slow
rise
paraprotein
andor
free
light
chain
respons
monotherapi
observ
median
th
infus
result
median
number
infus
twenti
advers
reaction
observ
patient
dyspnea
bronchospasm
shiver
cough
musculoskelet
pain
acut
coronari
syndrom
skin
rush
facial
edema
pressur
eye
advers
reaction
appear
first
infus
mostli
mild
moder
ctc
toler
follow
infus
improv
none
case
therapi
stop
due
advers
event
three
patient
develop
late
onset
infect
pneumonia
urinari
tract
infect
follow
temporarili
therapi
interrupt
median
followup
month
first
administr
patient
remain
aliv
one
patient
die
due
progress
myeloma
anoth
die
due
sever
infectionsepsi
patient
respond
pr
vgpr
cr
therapi
daratumumab
respons
decreas
paraprotein
andor
free
light
chain
occur
median
day
first
administr
last
month
conclus
daratumumab
show
encourag
efficaci
accept
toxic
profil
patient
relapsedrefractori
myeloma
allosct
studi
need
investig
role
combin
therapi
immunomodulatori
drug
proteasom
inhibitor
set
disclosur
noth
declar
clonal
plasma
cell
detect
high
sensit
flow
cytometri
aphaeresi
product
poor
prognost
increas
use
plerixafor
alon
background
earlier
center
demonstr
residu
clonal
plasma
cell
cpc
decreas
overal
surviv
os
diseas
free
surviv
df
ash
plerixafor
select
antagonist
chemokin
receptor
abl
mobil
human
peripher
blood
stem
cell
pbsc
act
synergist
gcsfthe
purpos
studi
evalu
safeti
efficaci
plerixafor
myeloma
patient
proven
poor
mobil
specif
assess
flow
cytometr
measur
residu
clonal
plasma
cell
apheresi
product
method
patient
diagnosi
mm
underw
auto
hsct
center
januari
retrospect
analyzedout
patient
patient
receiv
plerixafor
mobil
regimen
due
poor
mobil
gcsfpbsc
graft
test
presenc
clonal
pc
cpc
number
normal
pc
npc
multiparamet
flow
cytometri
fcm
acquisit
cell
perform
use
navio
flow
cytomet
beckmancoult
upon
daili
check
instrument
cell
sampl
acquir
collect
data
analyz
use
kaluza
softwar
beckmancoult
usa
result
patient
demograph
shown
tabl
major
patient
male
median
age
year
plerixafor
groupth
median
interv
time
diagnosi
mobil
followup
mobil
month
month
plerixafor
group
respect
cpc
contamin
pbsc
graft
detect
patient
count
rang
gcsf
alon
gcsfplerixafor
group
respect
signific
differ
proport
patient
graft
contamin
subtyp
mm
group
one
hundr
gcsfplerixafor
patient
preasct
petct
imag
done
gcsfplerixafor
activ
lesion
time
mobil
statist
signific
associ
could
demonstr
diseas
cr
statu
mobil
number
apc
apheresi
product
group
p
twelv
patient
plerixafor
treatment
arm
proceed
transplant
within
median
monthsth
best
overal
respons
induct
treatment
shown
tabl
thirtyfour
patient
gcsf
alon
arm
patient
gcsfplerixafor
arm
die
followup
diseas
progress
seen
patient
gcsf
alon
group
patient
gcsfplerixafor
group
studi
estim
mean
os
better
among
patient
wo
apc
contamin
plerixafor
group
respect
vs
conclus
result
plerixafor
use
patient
show
clonal
plasma
cell
detect
multiparametr
flow
frequent
patient
poor
mobil
requir
plerixaforth
clonal
pc
contamin
attribut
myeloma
biolog
manifest
higher
number
line
induct
regimen
pet
posit
among
plerixaforrequir
patient
overal
diseas
surviv
impair
residu
clonal
pc
graft
plerixafor
per
se
neither
content
clonal
pc
differ
othersthu
share
hsc
myeloma
cell
caus
myeloma
mobil
clinic
trial
registri
disclosur
noth
declar
prognost
factor
overal
surviv
allogen
hematopoiet
cell
transplant
multipl
myeloma
patient
factor
signific
influenc
pt
surviv
includ
multivari
analysi
cox
regress
model
readmiss
first
day
demonstr
impact
os
hr
conclus
analyz
risk
factor
surviv
mm
pt
receiv
allohct
studi
identifi
diseaserel
risk
factor
like
iss
transplantationrel
factor
hctci
pam
hospit
readmiss
day
hospit
cmv
reactiv
associ
wors
longterm
surviv
seri
frequent
death
readmiss
caus
infect
focus
effort
reduct
infect
could
benefici
impact
improv
surviv
mm
undergo
allohct
imag
figur
disclosur
disclosur
novel
protocol
autolog
hsct
multipl
myeloma
ambulatori
chemomobil
transplant
fresh
hematopoiet
stem
cell
backup
storag
background
autolog
hematopoiet
stem
cell
transplant
ahsct
melphalan
condit
still
part
standard
treatment
multipl
myeloma
patient
tradit
transplant
frozen
stem
cell
pose
addit
risk
patient
connect
dmso
central
venou
cathet
transplant
fresh
cell
option
howev
mobil
protocol
either
loweffici
gcsf
expens
gcsf
plerixafor
toxic
standard
dose
chemomobil
directli
proceed
transplant
fragil
group
patient
describ
novel
combin
ambulatori
mobil
low
dose
arac
gcsf
connect
direct
ahsct
fresh
cell
method
prospect
collect
databas
patient
ahsct
search
patient
underw
ahsct
chemomobil
arac
transplant
fresh
cell
fc
compar
control
group
consecut
patient
transplant
standard
protocol
sp
transplant
frozen
cell
juli
octob
protocol
ambulatori
mobil
arac
day
gcsf
dose
day
escal
split
two
dose
apheresi
start
day
later
finish
least
x
posit
cell
collect
collect
cell
split
three
equal
use
fresh
transplant
frozen
possibl
nd
transplant
frozen
backup
result
transplant
fresh
cell
transplant
frozen
cell
compar
group
mobil
protocol
ambulatori
low
dose
arac
median
age
number
transplant
cell
similar
group
vs
vs
conclus
present
novel
approach
allow
direct
ahsct
chemo
mobil
patient
treat
melphalan
show
feasibl
ahsct
directli
chemomobil
also
result
may
favour
approach
compar
current
standard
disclosur
noth
declar
background
high
dose
chemotherapi
follow
autolog
hematopoiet
cell
transplant
hsct
consid
sinc
nineti
standard
care
patient
age
less
year
old
newli
diagnos
multipl
myeloma
mm
howev
optim
induct
treatment
prior
hsct
reduc
tumor
burden
chang
last
year
improv
regimen
shown
abl
increas
qualiti
prehsct
respons
might
subsequ
impact
posthsct
respons
prove
associ
longer
pf
recent
chang
induct
therapi
pt
candid
hsct
analysi
aim
check
newer
regimen
impact
pretranspl
respons
autohsct
chang
prehsct
statu
method
autohsct
mm
patient
perform
center
januari
august
includ
analysi
median
age
year
rang
pt
male
femal
duriesalmon
stage
distribut
follow
ii
iii
creatinin
mgdl
iss
type
monoclon
compon
igg
light
chain
iga
nonsecretori
benc
jone
proteinuria
condit
regimen
melphalan
mgm
melphalan
mgm
result
pretranspl
therapi
vcd
mostli
vtdvrdkrd
mostli
other
case
statu
diseas
transplant
crvgpr
pr
sd
distribut
pretranspl
respons
base
type
induct
shown
tabl
peritranspl
mortal
day
mortal
pt
due
progress
diseas
shown
tabl
patient
obtain
cr
prehsct
maintain
respons
day
posthsct
among
patient
vgpr
hsct
becam
cr
maintain
respons
cr
rate
posthsct
increas
compar
prehsct
versu
pt
altogeth
hsct
pt
improv
maintain
prehsct
respons
last
period
time
pt
start
posthsct
maintenanceconsolid
mainli
lenalidomid
conclus
new
chemotherapeut
scheme
patient
underw
hsct
cr
vgpr
major
pt
consolid
improv
prehsct
respons
cr
increas
substanti
time
transplant
optim
induct
regimen
along
autohsct
follow
recent
licens
use
mainten
therapi
lenalidomid
might
result
better
pf
patient
mm
background
autolog
stem
cell
transplant
asct
commonli
use
treatment
patient
year
multipl
myeloma
mm
howev
safeti
efficaci
procedur
debat
method
conduct
retrospect
review
mm
patient
underw
asct
institut
purpos
retrospect
studi
compar
mortal
time
engraft
incid
grade
toxic
elderli
mm
patient
younger
patient
take
account
comorbid
inform
secondari
end
point
measur
overal
surviv
os
progressionfre
surviv
pf
result
total
patient
analys
categor
age
young
patient
elderli
compar
group
differ
term
gender
ecog
hctspecif
comorbid
index
hctci
diseas
statu
asct
melphalan
dose
mgm
use
prepar
regimen
younger
patient
elderli
p
remain
patient
receiv
melphalan
lower
dose
rang
mgm
due
hctci
age
physician
discret
whole
studi
group
transplant
relat
death
within
first
day
asct
stratifi
age
statist
signific
differ
concern
febril
neutropenia
fn
incid
observ
younger
patient
elderli
contrast
fn
observ
frequent
patient
hctci
vs
grade
infect
frequent
older
patient
vs
p
differ
found
grade
infect
incid
rate
pneumonia
uroinfect
neutropen
enterocol
vs
grade
noninfecti
toxic
vs
vs
respect
median
time
granulocyt
engraft
day
rang
day
elderli
compar
younger
patient
time
platelet
recoveri
also
similar
median
followup
month
survivor
os
month
group
pf
moth
younger
patient
elderli
howev
associ
pf
dose
melphalan
use
condit
observ
pf
probabl
month
patient
condit
dose
mgm
mgm
mgm
respect
conclus
data
show
asct
transplant
elig
mm
patient
year
age
safe
provid
similar
outcom
seen
younger
patient
disclosur
noth
declar
mobil
chemotherapi
effect
respons
multipl
myeloma
background
high
dose
melphalan
therapi
autolog
stem
cell
support
standart
approach
symptomat
multipl
myeloma
patient
respons
rate
increas
novel
anti
myeloma
agent
use
chemotherapi
stem
cell
mobil
question
purpos
studi
determin
effect
cyclophosphamid
use
stem
cell
collect
diseas
respons
transplant
result
method
retrospect
collect
data
myeloma
patient
underw
autolog
stem
cell
transplant
asct
ankara
univers
medicin
faculti
blood
bone
marrow
transplant
unit
januari
novemb
patient
receiv
cyclophosphamid
protocol
stem
cell
mobil
includ
studi
diseas
respons
determin
accord
intern
myeloma
studi
group
imwg
criteria
cyclophosphamid
transplant
respons
effect
surviv
also
indic
result
diagnosi
mm
patient
male
femal
median
age
year
year
median
followup
month
month
underw
asct
mean
month
fortyon
patient
evalu
cyclophosphamid
tabl
patient
diseas
respons
alter
cyclophosphamid
therapi
patient
improv
respons
statu
posttranspl
respons
rate
patient
underw
stem
cell
mobil
cyclophosphamid
also
shown
mean
surviv
patient
month
patient
group
accord
chang
respons
statu
cyclophosphamid
statist
differ
mean
calcul
surviv
improv
respons
diseas
progress
stabl
diseas
month
month
month
respect
rate
overal
surviv
os
patient
respons
cyclophosphamid
treatment
follow
respect
thirteen
patient
follow
median
month
transplant
die
averag
month
death
caus
infect
transplant
conclus
studi
observ
use
cyclophosphamid
stem
cell
mobil
chang
diseas
respons
rate
posttranspl
surviv
rate
mm
patient
progress
diseas
cyclophosphamid
use
lower
howev
result
warrant
confirm
random
control
trial
clinic
trial
registri
disclosur
noth
declar
result
singl
center
experi
attempt
augment
condit
regimen
first
autolog
stem
cell
transplant
treatment
multipl
myeloma
mm
continu
evolv
era
novel
agent
addit
bortezomib
highdos
melphalan
borhdm
report
sever
group
outcom
toxic
profil
compar
high
dose
melphalan
hdm
alon
aim
retrospect
studi
evalu
outcom
borhdm
condit
regimen
overal
respons
patient
mm
undergo
first
singl
asct
institut
method
retrospect
singl
center
studi
review
consecut
myeloma
patient
receiv
first
asct
either
borhdm
mf
singl
agent
hdm
mf
condit
regimen
singl
agent
hdm
condit
regimen
melphalan
administ
intraven
total
dose
day
stem
cell
infus
day
borhdm
group
melphalan
administ
day
bortezomib
administ
intraven
dose
mgm
day
describ
phase
studi
intergroup
francophon
du
ifm
result
consecut
patient
underw
singl
asct
januari
march
use
borhdm
condit
hdm
evalu
condit
regimen
hdm
patient
borhdm
patient
median
age
significantli
lower
borhdm
condit
asct
compar
hdm
group
year
vs
year
signific
differ
mm
subtyp
iss
stage
diagnosi
prior
treatment
line
among
hdm
vs
borhdm
cohort
p
median
cycl
induct
chemotherapi
patient
borhd
exhibit
compar
hdm
group
p
p
preasct
immun
respons
report
patient
treat
hdm
higher
seen
borhdm
group
nine
patient
achiev
postasct
immun
respons
compar
hdm
group
time
analysi
ten
patient
borhdm
group
hdm
group
alreadi
die
respect
p
total
patient
borhdm
group
patient
hdm
group
alreadi
progress
p
estim
mean
os
pf
shorter
group
treat
borhdm
mo
mo
vs
mo
mo
respect
p
could
demonstr
impact
pre
post
transplant
immun
respons
surviv
diseas
free
surviv
engraft
failur
observ
either
treatment
group
worsen
peripher
neuropathi
develop
bortezomib
arm
conclus
singl
center
experi
small
patient
pool
abl
repeat
prospect
random
studi
result
ifm
studi
warrant
explor
regimen
especi
induct
treatment
novel
agent
employ
special
emphasi
highrisk
myeloma
patient
respons
rate
good
sustain
remain
issu
disclosur
noth
disclosur
efficaci
safeti
bortezomib
plu
busulfan
melphalan
condit
regimen
multipl
myeloma
undergo
autolog
stem
cell
transplant
phase
studi
background
bortezomib
power
antimyeloma
activ
regard
backbon
therapi
past
decad
safeti
efficaci
part
busulfan
melphalan
condit
regimen
autolog
stem
cell
transplant
yet
shown
method
phase
trial
explor
safeti
activ
bortezomib
day
ad
condit
regimen
busulfan
melphalan
bumel
mgkgday
busulfan
day
mg
day
melphalan
day
multipl
myeloma
mm
patient
receiv
autolog
stem
cell
transplant
follow
bortezomibbas
induct
chemotherapi
phase
escal
dose
mgm
bortezomib
bumel
administ
group
three
patient
determin
maximum
toler
dose
bortzomib
day
cohort
patient
analyz
phase
result
phase
dose
limit
toxic
observ
day
bortezomib
phase
overal
respons
month
shown
good
partial
respons
vgpr
better
complet
respons
cr
wherea
posttranspl
overal
best
respons
includ
vgpr
better
cr
respect
median
followup
durat
month
median
progressionfre
surviv
pf
month
probabl
yearspf
overal
surviv
os
estim
respect
especi
highrisk
cytogenet
associ
advers
surviv
outcom
compar
standardrisk
cytogenet
respect
pf
vs
month
os
vs
month
median
day
day
neutrophil
platelet
engraft
graft
failur
delay
engraft
observ
common
grade
sever
nonhematolog
advers
event
includ
neutropen
fever
stomat
except
three
case
transplantrel
mortal
due
sepsi
advers
event
manag
conclus
result
demonstr
bortezomib
safe
part
condit
regimen
combin
bumel
patient
transplantelig
multipl
myeloma
clinic
background
allogen
stemcel
transplant
allosct
one
treatment
option
patient
multipl
myeloma
mm
refractori
novel
agent
report
allosct
mm
limit
import
issu
argu
appropri
condit
regimen
stemcel
sourc
patient
popul
benefit
allosct
method
retrospect
analyz
consecut
patient
receiv
allosct
relaps
refractori
multipl
myeloma
rrmm
oct
juli
japanes
red
cross
medic
center
characterist
patient
progressionfre
surviv
pf
overal
surviv
os
analyz
result
median
age
allosct
rang
twelv
patient
male
femal
myeloma
type
iga
igd
bencejon
stemcel
sourc
peripher
blood
hlamatch
relat
donor
rpbsct
bone
mallow
hlamatch
unrel
donor
mud
bone
marrow
hlamismatch
donor
mmud
cord
blood
cb
twentythre
patient
receiv
flumelbas
one
patient
receiv
bumelbas
one
patient
receiv
etoposidecyclophosphamidebas
condit
regimen
twentytwo
patient
transplant
receiv
total
bodi
irradi
tbi
respons
allosct
cr
vgpr
pr
sd
fiveyear
pf
ci
os
ci
ten
patient
die
observ
period
caus
death
primari
diseas
treatmentrel
mortal
patient
vgpr
better
allosct
show
significantli
better
pf
os
compar
other
femal
recipi
show
significantli
better
pf
os
compar
male
recipi
recipi
mmud
show
significantli
better
pf
among
patient
surviv
patient
receiv
treatment
includ
mainten
therapi
conclus
reason
better
pf
os
femal
recipi
unknown
interest
recipi
mmud
show
better
pf
suggest
graftversusmyeloma
effect
allosct
effect
treatment
option
patient
stemcel
sourc
appropri
select
disclosur
author
declar
conflict
interest
second
autolog
hematopoiet
stem
cell
tranpslant
versu
chemoimmunotherapi
relaps
multipl
myeloma
first
transplant
singl
center
data
background
combin
therapi
mostli
tripl
follow
autolog
hematopoiet
stem
cell
transplant
autohct
wide
accept
firstlin
standard
therapi
multipl
myeloma
mm
despit
avail
agent
new
immunomodulatori
drug
imid
proteasom
inhibitor
pi
histonedeacetylas
inhibitor
antibodi
still
possibl
achiev
longer
deeper
respons
howev
multipl
myeloma
still
cure
relaps
inevit
avail
novel
agent
increas
question
determin
optim
treatment
patient
relaps
first
autohct
method
retrospect
analyz
patient
relaps
accord
intern
myeloma
work
group
imwg
criteria
autohct
first
group
salvag
chemotherapi
ct
treat
chemoimmunotherapi
earli
relaps
refractori
first
autosct
within
month
inelig
second
transplant
comorbid
unwilling
transplant
second
group
salvag
transplant
treat
second
autohct
salvag
therapi
consolid
long
term
mainten
treatment
use
group
result
differ
sex
age
salvag
ct
autosct
group
femalemal
vs
vs
best
respons
salvag
autosct
complet
remiss
cr
partial
remiss
pr
patient
cr
pr
patient
treat
salvag
ct
progress
free
surviv
pf
significantli
better
second
transplant
group
pf
first
year
second
year
transplant
vs
first
year
second
year
salvag
therapi
chemotherapi
patient
p
overal
surviv
os
salvag
autosct
group
longer
salvag
ct
although
reach
statist
signific
p
time
achiev
best
respons
salvag
autosct
salvag
ct
month
versu
month
grade
nonhematolog
toxic
similar
autosct
salvag
ct
group
conclus
salvag
autohct
may
provid
longer
progress
free
surviv
similar
toxic
profil
accord
chemoimmunotherapi
especi
patient
sensit
first
autosct
suggest
earlier
better
respons
longterm
progress
free
surviv
achiev
salvag
autosct
believ
statist
signific
os
pf
increas
number
patient
author
believ
larg
scale
random
clinic
trial
need
optim
treatment
relaps
multipl
myeloma
first
autosct
disclosur
noth
declar
background
one
condit
success
transplant
autolog
hematopoiet
stem
cell
autohsct
patient
multipl
myeloma
mm
time
recoveri
hematopoiesi
associ
quantit
qualit
characterist
graft
one
key
indic
content
cell
autograft
depend
mani
factor
due
previou
treatment
other
directli
relat
patient
age
stage
diseas
featur
hematopoiet
stem
cell
hsc
microenviron
aim
studi
assess
influenc
immun
respons
gene
autograft
cellular
patient
mm
method
retrospect
analysi
genotyp
result
perform
evalu
loci
gene
immun
respons
harvest
autolog
hsc
patient
mm
made
hematopoiet
stem
cell
mobil
regimen
includ
cyclophosphamid
gm
granulocyt
colonystimul
factor
genotyp
immun
respons
gene
polymorph
region
carri
polymeras
chain
reaction
allelespecif
primer
number
cell
count
fac
canto
ii
flow
cytomet
result
accord
result
autolog
transplant
harvest
two
group
patient
identifi
first
includ
patient
autograft
cellular
kg
bodi
weight
second
group
consist
patient
examin
number
cell
autograft
kg
patient
bodi
weight
compar
identifi
haplotyp
immun
respons
gene
cellular
transplant
materi
found
presenc
mutant
allel
homoand
heterozyg
haplotyp
gene
increas
chanc
harvest
cellular
materi
higher
content
cell
time
carriag
wild
type
allel
homoand
heterozyg
state
gene
time
current
shown
singl
nucleotid
amino
acid
substitut
gene
lead
chang
express
pattern
final
product
increas
secret
interleukin
chang
spatial
configur
function
receptor
thu
presenc
mutat
gene
enhanc
synthesi
influenc
fibroblast
immunocompet
endotheli
epitheli
cell
activ
hemopoiesi
turn
mutat
statu
locu
locat
within
tir
domain
receptor
cytosol
determin
spatial
configur
act
costimulatori
receptor
cell
ensur
engraft
graft
conclus
identifi
haplotyp
featur
gene
patient
mm
may
act
predictor
respons
effect
mobil
hsc
carrier
may
contribut
mobil
regimen
optim
contribut
harvest
optim
cellular
autolog
graft
clinic
trial
registri
none
disclosur
author
declar
conflict
interest
differenti
diffus
focal
pattern
comput
tomographi
ad
valu
radiom
approach
background
focal
pattern
multipl
myeloma
mm
seem
relat
poorer
surviv
differenti
diffus
focal
pattern
comput
tomographi
ct
interread
variabl
therefor
purpos
studi
assess
radiom
approach
could
help
radiologist
differenti
diffus
focal
pattern
method
retrospect
review
imag
data
patient
mm
januari
septemb
men
women
mean
age
ct
petct
mri
avail
bone
marrow
transplant
two
gener
radiologist
evalu
consensu
ct
imag
defin
focal
least
one
lytic
lesion
diamet
diffus
lesion
mm
osteoporosi
pattern
radiom
analysi
ct
thinslic
imag
appli
region
interest
roi
done
one
research
expert
medic
imag
mm
blindli
condit
patient
refer
standard
differenti
diffus
focal
pattern
done
radiolog
evalu
two
expert
musculosket
radiologist
blind
clinic
data
review
ct
mri
petct
imag
radiom
featur
extract
evalu
open
sourc
softwar
mannwhitney
u
test
unpair
data
bootstrap
sampl
use
compar
radiom
featur
diffus
focal
pattern
featur
reduct
done
avoid
overfit
receiv
oper
characterist
roc
analysi
area
curv
done
compar
radiologist
radiom
evalu
refer
standard
read
time
perform
radiom
analysi
also
estim
result
patholog
group
includ
diffus
focal
pattern
featur
reduct
featur
differ
p
diffus
focal
pattern
featur
shapebas
majoraxislength
spheric
gray
level
run
length
matrix
glrlm
number
eleven
patient
receiv
addit
immunosuppress
except
postci
result
median
follow
month
rang
patient
aliv
probabl
pf
os
cumul
incid
ci
relaps
nrm
year
respect
lower
serum
albumin
level
transplant
gdl
associ
increas
relaps
hr
nrm
hr
result
poorer
pf
os
mmud
haploident
donor
associ
poorer
nrm
hr
result
decreas
pf
highrisk
cytogenet
diagnosi
show
impact
surviv
ci
acut
grade
iiiv
day
chronic
gvhd
year
respect
absenc
immunosuppress
medic
besid
postci
associ
poorer
os
conclus
condit
bu
tt
postci
lead
favor
pf
os
due
low
incid
relaps
nrm
patient
multipl
myeloma
relaps
autograft
disclosur
noth
declar
method
januari
may
includ
patient
mm
underw
asct
receiv
bortezomiblenalidomidedexamethason
vrd
consolid
mainten
therapi
mainli
lenalidomid
r
day
everi
day
result
median
age
transplant
year
fortysix
patient
receiv
r
mainten
patient
receiv
vrd
mainten
higher
risk
featur
median
durat
r
mainten
month
r
dose
chang
toxic
grade
iii
patient
twentynin
patient
relaps
patient
shift
differ
treatment
protocol
treatment
chang
patient
kept
r
mainten
observ
group
patient
increas
lenalidomid
dose
dexamethason
r
group
patient
last
group
requir
chang
treatment
later
median
follow
month
median
tnt
month
year
estim
pf
os
respect
median
os
chang
therapi
month
patient
observ
group
versu
month
rd
group
month
treatment
chang
respect
statist
signific
differ
note
conclus
small
monocentr
studi
limit
retrospect
design
small
sampl
size
howev
suggest
increas
lenalidomid
dose
well
ad
dexamethason
select
patient
postpon
chang
differ
line
treatment
without
affect
surviv
disclosur
noth
declar
drug
use
autolog
hematopoiet
stem
cell
transplant
impact
cmv
reactiv
result
decreas
os
myeloma
patient
asct
intens
treatment
regimen
proteasom
inhibitor
pi
andor
immunomodulatori
imid
agent
perform
retrospect
singl
center
studi
evalu
incid
risk
factor
outcom
cmv
infect
patient
mm
underw
asct
highdos
melphalanbas
regimen
method
studi
involv
retrospect
review
patient
underw
asct
januari
novemb
stem
cell
transplant
center
total
consecut
adult
patient
diagnosi
mm
median
age
diagnosi
rang
underw
asct
follow
induct
treatment
novel
agent
pi
andor
imid
patient
receiv
antivir
prophylaxi
acyclovir
mgday
valaganciclovir
mgday
result
baselin
patient
characterist
accord
induct
treatment
summar
tabl
one
hundredf
patient
cmv
iggposit
asct
overal
cmvseroposit
patient
develop
least
one
episod
cmv
viremia
cmv
dna
copiesml
median
month
rang
mo
followup
persist
cmv
viremia
detect
cmv
dna
load
sequenti
plasma
specimen
occur
seroposit
asct
recipi
prevent
treat
ganciclovir
valganciclovir
time
stem
cell
infus
develop
cmv
viremia
rang
day
day
none
patient
untreat
viremia
develop
identifi
cmv
sequela
case
primari
infect
seroneg
patient
transplant
observ
ad
none
patient
develop
cmv
diseas
post
asct
analyz
subgroup
patient
accord
induct
therapi
pibas
imid
piimid
incid
postasct
cmv
reactiv
higher
statist
signific
patient
receiv
pi
vs
piimid
vs
univari
analysi
could
demonstr
import
induct
therapi
novel
agent
occurr
postasct
cmv
reactiv
requir
antivir
treatment
howev
statist
signific
associ
found
diseas
vgpr
statu
asct
cmv
reactiv
vs
median
followup
month
rang
month
signific
impact
pf
howev
signific
decreas
estim
mean
os
cmv
reactiv
compar
without
cmv
reactiv
vs
conclus
cmv
establish
lifelong
latenc
within
host
cell
set
impair
cellular
immun
cmv
may
reactiv
latenc
dissemin
directli
caus
lifethreaten
diseas
data
suggest
mm
patient
treat
pibas
induct
regimen
immunolog
respons
vgpr
time
asct
seem
higher
risk
develop
symptomat
cmv
reactiv
howev
studi
larg
number
patient
warrant
clarifi
find
clinic
background
highdos
therapi
follow
autolog
stem
cell
transplant
asct
shown
prolong
surviv
patient
multipl
myeloma
mm
random
trial
howev
trial
includ
patient
age
year
data
regard
safeti
outcom
patient
popul
lack
method
aim
studi
compar
safeti
profil
outcom
mm
patient
younger
older
yearsold
underw
asct
unit
juli
octob
patient
demograph
clinic
characterist
transplant
relat
variabl
probabl
admiss
intens
care
unit
icu
analyz
patient
age
yearsold
would
call
respect
sorror
index
use
estim
risk
mortal
two
cohort
result
hundr
eleven
patient
mm
underw
asct
studi
period
median
age
yearsold
rang
male
thirtythre
patient
year
probabl
high
risk
comorbid
index
similar
group
median
cell
obtain
apheresi
procedur
compar
differ
median
admiss
lenght
cohort
day
vs
day
median
day
neutrophil
recoveri
day
group
wider
rang
compar
differ
found
platelet
recoveri
day
vs
day
median
pack
red
blood
cell
platelet
transfus
respect
cohort
respect
incid
grade
mucos
respect
statist
signific
differ
term
use
morphin
pain
control
two
cohort
none
patient
requier
total
parenter
nutrit
tpn
group
one
group
incid
icu
admiss
time
higher
patient
age
patient
yearsold
differ
statist
signific
p
death
transplant
procedur
cohort
conclus
seri
highdos
therapi
follow
autolog
hematopoiet
cell
transplant
mm
patient
age
feasibl
transplant
procedur
older
patient
safe
patient
yearsold
differ
found
term
graft
transfus
support
transplant
relat
complic
length
admiss
age
limit
factor
consid
modal
asct
patient
popul
disclosur
noth
declar
correl
kinet
peripher
blood
count
respons
treatment
highdos
melphalan
stem
cell
support
multipl
myeloma
patient
background
longterm
surviv
mm
patient
dramat
increas
last
year
particularli
younger
patient
attribut
part
introduct
develop
high
dose
chemotherapi
melphalan
stem
cell
support
hdmasct
current
frontlin
asct
still
consid
standard
care
elig
patient
mani
prognost
factor
pre
post
transplant
identifi
eg
age
comorbid
cytogenitc
respons
treatment
diseas
statu
prior
post
transplant
knowledg
data
correl
kinet
count
respons
melphalan
prognosi
aim
assess
prognost
signific
neutrophil
platelet
decay
count
high
dose
melphalan
method
retrospect
analyz
cohort
multipl
myeloma
patient
underw
hdmasct
hadassah
medic
center
bone
marrow
transplant
depart
year
kinet
neutrophil
platelet
decay
first
two
week
melphalan
administr
fit
use
linear
exponenti
mathemat
model
method
retrospect
analyz
cohort
multipl
myeloma
patient
underw
hdmasct
hadassah
medic
center
bone
marrow
transplant
depart
year
kinet
neutrophil
platelet
decay
first
two
week
melphalan
administr
fit
use
linear
exponenti
mathemat
model
result
factor
associ
prolong
os
univari
analysi
iss
stage
line
treatment
prior
asct
p
favor
cytogenet
respons
treatment
pr
better
rapid
linear
neutrophil
decay
p
multivari
analysi
line
treatment
hdmasct
rapid
linear
neutrophil
count
decay
remain
statist
signific
os
prolong
predict
threshold
valu
neutrophil
decay
inclin
found
improv
pf
associ
line
treatment
prior
asct
respons
statu
hdmasct
addit
toxic
evalu
show
prolong
neutropenia
associ
inferior
os
hr
rapid
exponenti
decay
neutrophil
count
correl
higher
incid
mucos
p
fast
platelet
decay
associ
delay
platelet
engraft
p
conclus
shown
rapid
linear
decay
neutrophil
count
predict
better
os
without
signific
benefit
pf
mm
patient
undergo
hdmasct
discrep
might
reflect
problemat
estim
retrospect
analysi
pf
rapid
decreas
neutrophil
platelet
count
associ
toxic
higher
mucos
rate
delay
engraft
respect
therefor
rapid
decay
blood
count
hdmasct
appear
invivo
phamacodynam
marker
higher
efficaci
toxic
melphalan
disclosur
noth
declar
need
freez
hematopoiet
cell
autotranspl
patient
myeloma
condit
melphalan
daniel
garcia
belmont
beatriz
aguado
bueno
miguel
herrero
coderch
rafael
de
la
camara
background
multipl
myeloma
mm
frequent
indic
autohsct
repres
autohsct
passweg
jr
bmt
nearli
perform
peripher
blood
progenitor
cell
pbpc
melphalan
consid
gold
standard
condit
regimen
standard
procedur
consist
obtain
progenitor
cryopreserv
dimethyl
sulfoxid
dmso
store
subsequ
thaw
reinfus
patient
day
procedur
cryopreserv
expens
inher
toxic
dmso
loss
cell
procedur
sever
group
use
noncryopreserv
progenitor
show
benefit
compar
cryopreserv
transplant
mainli
faster
engraft
shorter
length
hospit
object
compar
noncryopreserv
vs
cryopreserv
autohsct
mm
method
perform
unicentr
retrospect
studi
consecut
first
autohsct
mm
patient
transplant
pbpc
condit
high
dose
melphalan
median
followup
day
rang
patient
receiv
noncryopreserv
cryopreserv
autohsct
patient
characterist
without
differ
noncryopreserv
vs
cryopreserv
womenmen
median
age
year
rang
major
autohsct
done
consolid
first
line
therapi
year
transplant
number
infus
cell
differ
median
kg
rang
noncryopreserv
patient
kg
rang
cryopreserv
patient
result
observ
signific
differ
day
engraft
noncryopreserv
vs
cryopreserv
although
alway
littl
bit
faster
noncryopreserv
group
tendenc
faster
platelet
engraft
median
day
vs
p
median
vs
day
p
median
vs
day
p
media
day
hospit
shorter
noncryopreserv
patient
vs
day
although
statist
signific
p
transplantrel
mortal
day
group
overal
surviv
year
differ
noncryopreserv
vs
cryopreserv
patient
kaplanmei
logrank
p
accumul
incid
relaps
median
follow
day
similar
noncryopreserv
vs
cryopreserv
patient
conclus
short
experi
autohsct
noncryopreserv
pbpc
myeloma
patient
condit
high
dose
melphalan
obtain
similar
result
perform
classic
cryopreserv
pbpc
might
faster
platelet
engraft
shorter
length
hospit
advantag
associ
cryopreserv
simplic
use
fresh
product
appeal
disclosur
noth
declar
abstract
withdrawn
result
earli
death
observ
one
pt
group
pt
group
median
delay
aplasia
day
day
respect
group
among
evalu
pt
cr
pt
pr
refractori
group
cr
pr
refractori
relaps
observ
group
group
frequenc
respect
first
month
month
group
group
dead
month
pt
pt
month
pt
pt
overal
surviv
os
group
group
pt
month
month
month
respect
without
signific
differ
event
free
surviv
ef
group
pt
month
month
month
respect
without
signific
differ
conclus
protocol
equival
toxic
allow
obtain
longterm
equival
result
respons
rate
earli
transplant
rate
relaps
overal
surviv
result
ident
fermand
disclosur
noth
declar
background
dimethylsulfoxid
dmso
major
intracellular
cryoprotect
use
cryopreserv
stem
cell
toxic
cell
patient
temperatur
c
reduct
effect
achiev
either
wash
cell
thaw
reduct
dmso
freez
storag
latter
requir
addit
extracellular
cryoprotect
freez
media
assess
effect
low
dmso
concentr
differ
hematocrit
frozen
cell
cell
viabil
hematolog
recoveri
patient
transplant
multipl
myeloma
method
cell
nonprogram
frozen
store
c
cryoprotect
solut
achiev
final
concentr
dmso
hydroxyethyl
starch
he
weight
averag
molecular
weight
da
human
serum
albumin
cell
concentr
frozen
product
first
patient
transplant
vari
cellsml
attempt
reduc
amount
dmso
infus
rest
patient
transplant
decreas
volum
freez
suspens
remov
entir
plasma
averag
age
transplant
patient
cell
bedsid
thaw
c
water
bath
averag
cell
dose
kg
kg
result
viabil
stem
cell
follow
thaw
assess
trypan
blue
exclus
hematocrit
frozen
cell
effect
cell
viabil
low
vs
high
major
complaint
stem
cell
infus
cough
increas
nausea
vomit
induc
prior
condit
averag
time
hematolog
recoveri
day
neutrophil
day
platelet
signific
differ
viabil
hematolog
recoveri
vs
patient
receiv
cell
frozen
low
high
hematocrit
conclus
dimethylsulfoxid
despit
cryoprotect
properti
toxic
stem
cell
temperatur
zero
c
induc
mani
side
effect
cardiac
neurolog
respiratori
etc
patient
reduc
side
effect
use
lower
dmso
concentr
high
hematocrit
result
lower
volum
frozen
cell
suspens
thu
reduc
final
quantiti
dmso
infus
patient
affect
cell
viabil
hematolog
recoveri
patient
transplant
easili
perform
method
unprogram
freez
stem
cell
final
dmso
concentr
c
safe
well
toler
provid
cryopreserv
allow
high
viabil
stabl
cell
engraft
reduc
undesir
side
effect
dmso
disclosur
noth
disclos
condit
regimen
consist
melphalan
patient
averag
age
time
transplant
year
patient
transplant
averag
cell
dose
kg
kg
first
transplant
kg
kg
second
one
everi
patient
receiv
cell
dose
first
averag
cell
viabil
littl
differ
first
second
transplant
result
averag
time
hematolog
recoveri
day
neutrophil
day
platelet
found
correl
cell
dose
hematolog
recoveri
differ
hematopoiet
recoveri
first
second
transplant
patient
underw
tandem
two
transplant
conclus
recoveri
time
consid
function
effect
stem
cell
number
find
correl
probabl
analyz
group
patient
except
four
receiv
dose
greater
kg
cell
accept
safe
dose
autolog
stem
cell
transplant
disclosur
noth
disclos
plerixaformobil
patient
high
risk
noninfecti
fever
engraft
autolog
peripher
blood
stem
cell
transplant
background
plerixafor
enabl
rapid
effici
mobil
hematopoiet
stem
cell
howev
impact
advers
clinic
event
autolog
peripher
blood
stem
cell
transplant
pbsct
fulli
understood
fever
one
major
complic
preengraft
phase
pbsct
research
focus
noninfecti
fever
around
time
bone
marrow
recoveri
investig
whether
plerixafor
mobil
therapi
play
role
engraft
fever
method
review
autolog
pbsct
treatment
multipl
myeloma
japanes
red
cross
medic
center
noninfecti
fever
defin
temperatur
onset
two
day
prior
two
day
engraft
without
clinic
microbiolog
document
infect
result
patient
mobil
cyclophosphamid
filgrastim
n
filgrastim
plerixafor
n
median
number
transfus
cell
kg
kg
respect
patient
transfus
plerixaformobil
graft
higher
risk
noninfecti
fever
vs
p
cell
number
cyclophosphamid
pretreat
relationship
noninfecti
fever
recoveri
lymphocyt
rapid
plerixaformobil
patient
howev
number
lymphocyt
associ
noninfecti
fever
conclus
combin
filgrastim
plerixafor
mobil
therapi
result
increas
risk
noninfecti
fever
engraft
compar
mobil
cyclophosphamid
filgrastim
mechan
remain
unclear
requir
studi
plerixaformobil
graft
may
result
unintend
increas
engraft
fever
clinician
awar
possibl
patient
transplant
graft
disclosur
ks
receiv
honorarium
outsid
submit
work
janssen
novarti
celgen
ono
pharmaceut
takeda
fujimoto
pharmaceut
srl
ti
receiv
honorarium
outsid
submit
work
janssen
celgen
ono
pharmaceut
takeda
assess
efficaci
new
condit
regimen
consist
decitabin
dec
busulfan
bu
cyclophosphamid
cy
fludarabin
flud
cytarabin
arac
allohsct
patient
md
md
mpn
fifti
patient
enrol
includ
md
cmml
patient
receiv
dec
mgm
day
day
combin
buci
flu
arac
modifi
prepar
regimen
result
median
followup
day
overal
surviv
os
diseasefre
surviv
df
relaps
incid
incid
sever
acut
grade
iiiiv
graftversushost
diseas
gvhd
predominantli
mild
chronic
gvhd
os
year
md
patient
high
risk
md
patient
high
risk
respect
surviv
delight
patient
poorrisk
mutat
three
gene
mutat
among
total
patient
poorrisk
mutat
research
one
patient
relaps
one
die
result
continu
observ
transplant
percentag
nk
cell
peripher
blood
patient
receiv
decflubucyarac
condit
increas
day
may
essenti
contribut
diseas
control
posttransplant
conclus
summari
addit
schedul
decitabin
flubucyarac
condit
regimen
proven
feasibl
low
level
toxic
promis
earli
diseas
control
especi
patient
high
risk
md
disclosur
conflict
interest
sfgmtc
md
score
day
associ
posttranspl
outcom
patient
myelodysplast
syndrom
underw
select
allogen
stem
cell
transplant
conclus
patient
md
undergo
tcdhct
sfgmtc
score
day
significantli
associ
surviv
lower
incid
acut
gvhd
recipi
transplant
use
myeloabl
condit
regimen
lower
relaps
may
explain
differ
origin
find
sfgmtc
predict
day
unmodifi
graft
disclosur
frequent
grade
toxic
thromobocytopenia
neutropenia
infect
develop
patient
neutropen
fever
five
patient
either
develop
experienc
exacerb
acut
graft
versu
host
diseas
gvhd
nonechron
gvhd
conclus
azacitidin
use
associ
modest
activ
patient
relaps
allohsct
howev
patient
respond
treatment
may
allow
durabl
diseas
control
disclosur
author
declar
compet
conflict
interest
background
somat
mutat
md
patient
close
relat
clinic
phenotyp
prognosi
md
patient
whether
mutat
prognost
outcom
allogen
hematopoiet
stemcel
transplant
allohsct
remain
elabor
method
target
mutat
analysi
perform
sampl
obtain
transplant
patient
underw
hsct
analyz
relationship
mutat
clinic
outcom
result
patient
carri
one
somat
mutat
frequent
pclo
srcap
mutat
associ
higher
ipssr
risk
complex
karyotyp
monosom
karyotyp
frequent
pediatr
patient
univari
analys
mutat
relat
decreas
diseasefre
surviv
mutat
relat
increas
diseasefre
surviv
df
multivari
analysi
includ
ipssr
stratif
gvhd
hctci
candid
gene
mutat
independ
associ
better
df
conclus
mutat
independ
associ
better
outcom
md
patient
treat
allohsct
may
predict
unfavor
outcom
account
somat
mutat
may
help
better
select
candid
allohsct
among
md
patient
disclosur
background
controversi
among
expert
patient
md
saml
receiv
cytoreduct
therapi
transplant
aim
reduc
diseas
burden
order
lower
risk
relaps
transplant
cytoreduct
therapi
associ
sever
drawback
besid
consider
risk
toxic
mortal
prevent
patient
proceed
transplant
cytoreduct
therapi
may
also
favour
select
resist
clone
may
difficult
treat
relaps
method
address
hypothesi
retrospect
analys
respons
surviv
follow
salvag
therapi
patient
md
saml
relaps
median
month
month
allosct
accord
pretranspl
strategi
upfront
transplant
induct
chemotherapi
ctx
hypomethyl
agent
hma
result
major
patient
receiv
salvag
therapi
hma
aza
dac
mostli
combin
dli
remain
receiv
salvag
treatment
intens
chemotherapi
dli
alon
nd
transplant
bsc
miscellan
miss
inform
focuss
patient
treat
hma
dli
becam
appar
significantli
higher
proport
patient
upfront
group
achiev
cr
salvag
therapi
comparison
pretreat
patient
cr
ctx
group
cr
hma
group
cr
accordingli
overal
surviv
os
calcul
time
relaps
significantli
longer
patient
upfront
group
group
pretreat
patient
os
vs
conclus
overal
find
impli
pretranspl
therapi
may
favour
iatrogen
select
resist
clone
poorli
respond
salvag
therapi
hma
dli
case
relaps
allosct
furthermor
result
support
concept
upfront
transplant
strategi
promis
altern
patient
md
saml
augment
salvag
therapi
hma
dli
disclosur
ts
gk
receiv
travel
support
lectur
fee
research
fund
celgen
gmbh
conclus
countri
procedur
shown
feasibl
hope
improv
better
infect
control
acquir
experi
relat
manag
patient
background
extramedullar
relaps
md
rare
complic
allogen
stem
cell
transplant
present
case
woman
admit
hospit
insecur
walk
paresi
leg
hypaesthesia
inner
thigh
increas
effort
urin
reduc
sphincter
tonu
central
paresi
right
arm
discreet
paresi
right
facial
nerv
document
neurolog
exam
mri
show
larg
tumour
dorsal
thorax
immur
adjac
rib
spine
affect
processu
transversu
invad
spinal
canal
patient
undergon
ric
allogen
stem
cell
transplant
five
year
ago
mdseb
complex
aberr
karyotyp
follow
unev
cours
sign
gvhd
immunosuppress
sinc
year
time
admiss
patient
slightli
lower
wbc
gptl
plt
gptl
clearli
increas
ldh
ul
method
histolog
ctbase
biopsi
paravertebr
tumour
show
infiltr
muscl
blastou
cell
tdt
question
posit
provison
diagnosi
therefor
lymphoblast
lymphoma
pox
test
neg
bone
marrow
hypocellular
increas
number
matur
lymphocyt
definit
sign
malign
cerebrospin
fluid
reveal
blast
immunotyp
hladr
posit
pox
lymphat
marker
neg
final
suspect
meningeosi
leucaemica
complet
diagnost
workup
genet
chimaer
test
compar
result
patient
md
allogen
stem
cell
transplant
imag
mri
scan
larg
thorac
tumour
result
cerebrospin
fluid
csf
cell
consist
recipi
cell
wherea
peripher
blood
cell
donor
high
risk
md
transplant
display
complex
caryotyp
includ
trisomi
tetrasomi
cell
csf
show
trisomi
tetrasomi
chimer
fish
solid
tumour
could
perform
coexpress
myeloid
marker
within
tumour
pend
conclus
conclus
patient
meningeosi
result
exclus
extramedullari
relaps
myeloid
blast
origin
initi
high
risk
md
blast
excess
complex
aberr
caryotyp
evolut
trisomi
clone
tetrasomi
clone
relaps
link
extramedullar
manifest
whether
solid
tumour
repres
myeloid
sarcoma
coexpress
lymphoid
marker
extramedullari
relaps
md
lymphoid
differenti
less
like
separ
lymphobast
lymphoma
yet
clear
disclosur
background
adopt
cell
therapi
genet
engin
cell
potent
innov
immunotherapeut
approach
cancer
treatment
unfortun
use
cell
redirect
tumor
antigen
sever
limit
difficulti
identifi
appropri
cell
surfac
antigen
could
target
car
cell
pauciti
tumorspecif
cell
receptor
tcr
share
oncogen
antigen
method
focus
tumorassoci
antigen
overexpress
acut
myeloid
leukemia
sever
solid
tumor
design
implement
innov
protocol
rapid
isol
cell
gener
character
librari
tcr
display
differ
human
leukocyt
antigen
hla
restrict
exploit
tcr
gene
transfer
tcr
gene
edit
aim
repetit
stimul
cell
autolog
antigenpres
cell
includ
immort
b
cell
puls
overlap
peptid
span
entir
protein
cell
recognit
assess
flow
cytometri
term
express
product
recogn
peptid
map
deconvolut
grid
cell
clonotyp
longitudin
track
sequenc
result
success
expand
tumorspecif
cell
consecut
healthi
donor
averag
round
vitro
stimul
abil
cell
recogn
natur
process
epitop
ontarget
specif
demonstr
upon
cocultur
antigenexpress
target
includ
primari
leukem
blast
track
repertoir
cultur
led
identif
clonotyp
recogn
sever
tumorassoci
peptid
restrict
hla
allel
includ
hlaa
tcr
express
via
genom
edit
briefli
simultan
edit
endogen
tcr
chain
gene
achiev
use
technolog
effici
follow
transduct
cell
lentivir
vector
encod
tcr
effici
cell
phenotyp
character
edit
lymphocyt
show
major
enrich
cell
harbor
stem
cell
memori
properti
function
valid
edit
cell
current
ongo
preliminari
result
hour
cocultur
experi
show
tcr
edit
cell
kill
fresh
leukem
blast
harvest
hlamatch
patient
effici
effector
target
ratio
kill
control
observ
conclus
set
protocol
enabl
consist
effici
hunt
tumorspecif
tcr
need
labor
intens
cell
clone
tcr
gene
easili
rapidli
use
redirect
cell
specif
cancer
cell
tcr
gene
edit
disclosur
chiara
bonini
research
fund
intellia
therapeut
car
cell
therapi
target
relaps
refractori
lymphoid
diseas
thirdgener
vector
marialuisa
schubert
anita
schmitt
leopold
sellner
brigitt
neuber
angela
kunz
alexand
lei
wang
gern
ulrik
birgit
michel
susann
hofmann
carsten
muellertidow
dreger
peter
michael
schmitt
background
cell
genet
engin
express
chimer
antigen
receptor
cart
direct
demonstr
signific
efficaci
patient
iymphoid
malign
includ
relaps
refractori
rr
blineag
acut
lymphoblast
leukemia
rr
bcell
nonhodgkin
lymphoma
nhl
access
cart
treatment
patient
europ
limit
far
given
vast
major
cart
trial
perform
unit
state
p
r
china
present
preliminari
result
first
investigatoriniti
trial
iit
cart
trial
germani
eudract
phase
iii
trial
inhous
cart
manufactur
initi
septemb
univers
hospit
heidelberg
method
adult
well
pediatr
patient
rr
patient
chronic
lymphocyt
leukemia
cll
nhl
includ
diffus
larg
bcell
lymphoma
dlbcl
follicular
lymphoma
fl
mantl
cell
lymphoma
mcl
treat
autolog
lymphocyt
transduc
thirdgener
car
retrovir
vector
target
main
purpos
evalu
safeti
feasibl
escal
thirdgener
car
cell
dose
transduc
cellsm
lymphodeplet
fludarabin
cyclophosphamid
patient
monitor
cytokin
releas
syndrom
cr
cartcel
relat
encephalopathi
syndrom
cre
andor
toxic
vivo
function
surviv
antitumor
efficaci
cart
assess
result
date
three
patient
cll
dlbcl
mcl
respect
enrol
subject
leukapheresi
high
number
transduc
cart
harvest
day
cultur
cart
transduct
effici
rang
cart
product
steril
free
mycoplasm
endotoxin
product
failur
occur
patient
receiv
cart
product
sign
cr
cre
grade
observ
assess
clinic
respons
pend
present
confer
along
updat
technic
result
conclus
gmpconform
leukapheresi
well
cart
manufactur
effect
administr
patient
monitor
followup
perform
inhous
provid
independ
transport
product
site
outsid
univers
hospit
heidelberg
altogeth
suggest
academ
cart
iit
feasibl
germani
clinic
background
prognosi
adult
patient
pt
relapsedrefractori
rr
precursor
bacut
lymphoblast
leukemia
dismal
includ
allogen
hematopoiet
stem
cell
transplant
allohsct
blinatumomab
bispecif
tcell
engag
inotuzumab
ozogamycin
io
antibodydrug
conjug
revolution
field
improv
outcom
chimer
antigen
receptor
cart
cell
therapi
led
progress
improv
outcom
jacobi
e
j
hematol
nowaday
patient
rr
ball
offer
therapi
limit
data
safeti
efficaci
cart
cell
therapi
post
antibodi
treatment
detail
singl
center
experi
regard
method
report
part
singl
center
phase
studi
therapi
bcell
malign
local
produc
cartcel
approach
use
autolog
cell
car
construct
compos
singlechain
fv
costimulatori
intracellular
domain
express
blast
document
prior
treatment
pt
flow
cytometri
pt
receiv
x
kg
cartcel
lymphodeplet
fludarabin
cyclophosphamid
result
six
pt
male
femal
rr
ball
enrol
includ
one
phposit
ball
median
age
year
median
number
prior
therapi
five
pt
prior
allohsct
four
pt
given
antibodi
last
therapi
prior
cart
cell
two
pt
receiv
blinatumomab
result
pr
one
two
addit
pt
receiv
io
fail
blinatumomab
achiev
mrdposit
cr
cytokin
releas
syndrom
occur
pt
sever
one
patient
requir
tocilizumab
treatment
patient
also
patient
experienc
neurotox
grade
treat
dexamethason
patient
eventu
die
day
post
infus
cart
cell
due
sever
pseudomembran
coliti
toxic
megacolon
sepsi
pt
prolong
neutropenia
median
day
infus
cart
cell
day
infus
cartcel
cr
entir
cohort
three
pt
mrdneg
one
mrdposit
respons
among
four
pt
receiv
antibodi
prior
cartcel
one
patient
mrdposit
two
pt
mrdneg
respons
patient
ph
posit
ball
progress
diseas
treatment
two
pt
refer
second
allohsct
donor
one
patient
mrdneg
respons
relaps
second
transplant
treat
salvag
therapi
second
patient
mrdneg
respons
demonstr
prolong
remiss
month
even
without
second
transplant
median
followup
month
median
progressionfre
overal
surviv
entir
cohort
month
respect
conclus
autolog
car
tcell
therapi
debulk
treatment
antibodi
includ
blinatumomab
andor
io
feasibl
result
high
respons
rate
pt
rr
ball
patient
may
respond
car
tcell
therapi
even
failur
last
salvag
therapi
blinatumomab
demonstr
similar
mechan
action
clinic
background
genet
engin
cell
express
chimer
antigen
receptor
cart
target
specif
antigen
present
acut
lymphoblast
leukemia
blast
gener
promis
result
children
adult
relaps
refractori
diseas
report
provid
insight
lineag
switch
occur
result
intens
immunolog
select
cart
cell
therapi
even
tumor
clone
potenti
switch
method
eight
year
old
caucasian
male
precursor
b
pb
cell
lymphocyt
leukemia
treat
cd
direct
cart
cell
therapi
third
remiss
relaps
previou
bone
marrow
transplant
bmt
diagnos
pb
cell
year
age
treat
bfm
protocol
relaps
month
complet
mainten
therapi
mmud
bone
marrow
transplant
etoposid
tbi
alemtuzumab
condit
therapi
cutan
acut
chronic
gvhd
month
posttranspl
relaps
pb
cell
cytogenet
immunophenotyp
diseas
characterist
treat
lymphodeplet
chemotherapi
fludarabin
cyclophosphamid
alemtuzumab
follow
infus
direct
car
cell
develop
cytokin
releas
syndrom
grade
sever
manifest
persist
fever
associ
car
cell
expans
blood
cart
infus
detect
b
cell
clone
marrow
pcr
cytogenet
neg
transloc
month
car
cell
therapi
found
mrd
posit
diseas
monitor
close
result
document
clonal
evolut
neg
mrd
posit
diseas
aml
ig
rearrang
clonal
diseas
complet
myeloid
phenotyp
mpo
posit
diseas
cytogenet
evolut
underli
clone
origin
retain
within
evolv
karyotyp
sadli
patient
develop
fludarabineneurotoxc
attempt
induc
aml
remiss
curativeint
chemotherapi
possibl
conclus
two
case
report
mll
rearrang
ball
acquir
clonal
relat
myeloid
phenotyp
associ
escap
direct
car
cell
therapi
far
first
post
cart
cell
therapi
transform
aml
mutat
recognis
lineageswitch
potenti
unlik
mll
transloc
pathogenesi
acut
myeloid
leukemia
report
literatur
theori
behind
transform
intens
immunolog
select
tumor
drive
myeloid
differenti
addit
clonal
cytogenet
event
disclosur
noth
declar
interim
analysi
phase
iii
clinic
studi
person
peptid
vaccin
base
patientindividu
tumorspecif
variant
relaps
pediatr
acut
lymphoblast
leukemia
armin
rabsteyn
christoph
mohr
olaf
witt
roland
meisel
cristian
chensantel
tobia
feuchting
christoph
schroeder
jakob
matth
background
acut
lymphoblast
leukemia
common
pediatr
malign
standard
chemotherapi
success
treatment
patient
develop
relaps
howev
patient
dismal
prognosi
prevent
relaps
firstlin
chemotherapi
stem
cell
transplant
sct
therefor
urgent
clinic
need
establish
platform
design
patientindividu
peptid
vaccin
cocktail
combin
whole
exom
sequenc
tumor
normal
tissu
silico
epitop
predict
algorithm
individu
patient
hla
type
start
clinic
translat
approach
start
phase
iii
clinic
trial
besid
feasibl
toxic
assess
aim
assess
capabl
peptid
vaccin
induc
neoantigenspecif
cell
respons
highrisk
patient
target
residu
tumor
cell
prevent
leukem
relaps
method
key
inclus
criteria
pediatr
patient
suffer
second
relaps
standard
therapi
first
relaps
sct
hematolog
remiss
reach
prior
vaccin
nonsynonym
mutat
identifi
whole
exom
transcriptom
sequenc
patient
leukem
blast
healthi
refer
tissu
hla
bind
peptid
harbor
alter
amino
acid
subsequ
predict
silico
algorithm
syfpeithi
netmhc
netmhcpan
patient
individu
hla
type
vaccin
cocktail
consist
individu
peptid
produc
formul
gmp
condit
vaccin
schedul
vaccin
week
use
gmcsf
imiquimod
adjuv
respons
vaccin
monitor
detect
cell
recogn
vaccin
peptid
occur
time
peripher
blood
patient
prestimul
intracellular
cytokin
stain
result
patient
recruit
whole
exom
sequenc
perform
identifi
allspecif
snv
use
compar
bioinformat
pipelin
found
averag
mutat
per
patient
dna
level
base
data
averag
hla
binder
deriv
neoantigen
could
predict
per
patient
averag
express
mutat
assess
rna
sequenc
case
valid
mutat
could
identifi
cocktail
design
feasibl
patient
receiv
vaccin
vaccin
gener
well
toler
mild
side
effect
observ
immun
monitor
perform
patient
first
patient
observ
transient
respons
one
vaccin
mhc
class
ii
ligand
sustain
respons
includ
wildtyp
control
peptid
deriv
antigen
survivin
second
patient
immun
monitor
perform
first
vaccin
timepoint
cell
respons
measur
timepoint
vaccin
conclus
whole
exom
sequenc
pediatr
patient
feasibl
yield
small
amount
express
tumorspecif
mutat
mutat
suffici
predict
hlabind
peptid
use
formul
individu
peptid
vaccin
cocktail
current
conduct
clinic
phase
iii
trial
small
cohort
highrisk
patient
assess
safeti
toxic
immunogen
clinic
background
chimer
antigen
receptor
cell
cart
consid
gene
therapi
medicin
product
gtmp
genet
modifi
organ
gmo
henc
cart
manufactur
clinic
applic
strictli
regul
appropri
method
assess
car
transgen
copi
number
cn
cart
product
definit
frequenc
cart
treat
cart
patient
mandatori
although
quantit
realtim
pcrbase
qpcr
analysi
use
purpos
standard
procedur
minim
systemat
error
enabl
compar
establish
yet
report
singl
copi
genebas
scg
duplex
dp
pcr
scgdppcr
determin
vector
copi
number
vcn
cart
product
well
patient
sampl
follow
cart
administr
scgdppcr
valid
compar
broadli
use
absolut
copi
number
qpcr
acn
approach
within
framework
clinic
trial
treat
patient
good
manufactur
practic
gmp
grade
cart
method
convent
acn
primer
probe
target
car
vector
design
standard
curv
establish
via
serial
dilut
sfgcar
plasmid
amplif
standard
curv
well
target
genom
dna
vcndetermin
perform
singleplex
sp
pcr
spcar
method
qpcr
plate
duplex
dp
qpcr
reaction
carri
addit
compon
compris
within
method
experiment
setup
contain
haploid
human
genom
well
primer
probe
target
ribonucleas
rnase
p
human
scg
amplif
sfgcar
plasmid
dpcar
rnasep
gene
dprnasep
perform
simultan
scgdppcr
method
b
scgdppcr
perform
standard
curv
target
sampl
targetsampl
dna
extract
cart
prepar
leukapheresi
product
three
healthi
donor
hd
result
method
valid
effici
linear
correl
coeffici
qpcr
reaction
method
spcar
method
b
dpcar
dprnasep
assess
linear
regress
pcr
signal
refer
standard
curv
overal
standard
curv
consid
valid
correl
coeffici
r
effici
achiev
vcn
appli
method
b
target
sampl
compar
spcar
pcr
reaction
display
effici
effici
achiev
dpcar
dprnase
pcr
reaction
respect
tabl
appli
scgdppcr
use
formula
rel
cn
assess
dpcar
dprnasep
hd
sampl
result
averag
increas
cn
compar
method
tabl
conclus
term
effici
linear
linear
regress
qpcr
reaction
compar
valid
scgdppcr
achiev
repres
exact
less
errorpron
method
fulfil
regulatori
safeti
releas
criteria
cart
product
besid
accur
assess
vcn
transduc
cell
scgdppcr
also
highli
robust
method
followup
cart
treat
patient
appli
approach
standard
curv
need
henc
significantli
econom
requir
materi
well
time
disclosur
noth
declar
background
tcell
antileukem
respons
amlpt
need
improv
dc
leu
effect
activ
tcell
leukem
blast
result
blastlysi
exvivo
factor
influenc
activ
known
method
gener
dcdc
leu
amlblastcontain
mononuclear
cell
use
standard
method
mncmethod
blastcontain
heparin
whole
blood
use
modulatori
kit
variou
combin
clinic
approv
responsemodifi
wbkit
patent
correl
statist
tutest
pearson
correl
mean
signific
proport
dctcellsubtypescytokineprofil
tcell
antileukem
cytotox
ctx
achiev
mix
lymphocyt
cultur
mlc
withwithout
mncmethod
dc
mnc
bla
mnc
wbkittreat
cultur
dc
wb
bla
wb
ctx
given
proport
case
achiev
improv
blastlysi
compar
control
frequenc
viabl
blast
bla
via
effectorcellinflu
pool
data
data
obtain
singl
method
differ
cohort
given
result
gener
dcdc
leu
mncmethod
dc
dc
leu
b
wbkit
dc
dc
leu
without
induct
blast
prolifer
tcellprolifer
increas
vs
uncultur
tcell
mlc
mncmethod
vs
b
wbkit
vs
antileukem
reactiv
teffectorcellcytotox
mlc
pool
data
mncmethod
dc
mnc
vs
bla
mnc
found
blastcytotox
case
bla
via
blastcytotox
improv
vs
control
decreas
bla
via
b
wbkit
dc
wb
vs
bla
wb
found
blastcytotox
case
bla
via
blastcytotox
improv
vs
control
case
decreas
bla
via
gener
result
could
confirm
singl
method
best
mncmethod
picibanil
mcmmimic
best
wbkit
kit
contain
gmcsfpicibanil
prostaglandin
correl
pool
data
case
improv
lysi
vs
improv
lysi
character
mncmethod
increas
proport
matur
dccell
vs
dc
leu
cell
vs
prolifer
tcell
vs
b
wbmethod
dccell
dc
leu
cell
dc
leu
bla
vs
dc
leu
dc
vs
tcell
vs
vs
pgml
conclus
blast
regularli
convert
dc
leu
presenc
mncmethod
wbkit
simul
vivo
microenviron
tcell
cocultur
dc
dc
leu
mlc
induc
improv
antileukem
tcell
activ
compar
control
blastcytotox
correl
proport
dcdc
leu
tcell
subtyp
releas
cytokin
data
support
role
antigen
present
leukem
cell
dc
leu
stimul
immun
respons
aml
vitro
possibl
vivo
disclosur
noth
declar
evalu
year
launch
motion
comic
immunot
explain
patient
caregiv
immunotherapi
strategi
work
background
one
year
ago
first
version
immunot
motion
comic
explain
patient
caregiv
immunotherapi
strategi
work
releas
peopl
inform
inspir
use
applic
inter
nation
meet
event
gener
public
meanwhil
motion
comic
refin
adapt
second
version
base
evalu
collect
first
version
adapt
includ
multilanguag
tool
current
languag
increas
user
friendli
new
support
music
score
also
websit
launch
second
version
could
download
tablet
smartphon
android
appl
new
onlin
evalu
form
could
fill
month
peopl
evalu
motion
comic
onlin
result
present
well
futur
plan
within
immunot
program
method
onlin
questionnair
particip
belgium
netherland
evalu
dutch
version
belgian
particip
evalu
french
version
motion
comic
result
total
group
consist
patient
famili
gener
public
student
health
care
profession
research
kindergarten
teacher
particip
age
rang
year
even
distribut
amongst
differ
gener
major
evalu
thought
motion
comic
good
way
explain
immunotherapi
patient
individu
felt
mainli
interest
watch
immunot
total
particip
felt
hope
motiv
focuss
patient
group
respond
think
immunot
motion
comic
good
tool
use
patientdoctor
consult
patient
felt
hope
andor
motiv
watch
whole
motion
comic
felt
comb
felt
grip
intrigu
new
music
score
particip
think
music
suitabl
app
evalu
think
new
music
fit
support
motion
comic
conclus
detail
evalu
allow
us
improv
immunot
aid
us
develop
motion
comic
plan
releas
cancert
motion
umbrella
current
version
immunot
singlecent
pilot
studi
set
test
efficaci
usabl
immunot
base
qualit
research
experi
tool
use
valid
questionnair
studi
want
evalu
impact
immunot
patient
empower
decis
make
process
studi
protocol
present
ebmt
disclosur
develop
immunot
partli
financi
support
celyad
calgen
novarti
roch
amgen
bm
compani
mean
influenc
content
develop
motion
comic
therapeut
strategi
trespass
blood
brain
barrier
adopt
nk
cell
therapi
glioblastoma
multiform
induc
rat
preclin
studi
background
glioblastoma
multiform
gbm
among
common
aggress
primari
brain
tumor
poor
prognosi
accord
central
brain
tumor
registri
unit
state
central
nervou
system
cn
tumor
pediatr
patient
age
year
old
second
common
malign
bloodborn
malign
first
amongst
solid
tumor
known
common
caus
cancerrel
death
although
hematopoiet
stem
cell
transplant
exploit
treat
mani
kind
malign
current
success
rate
gbm
limit
therefor
gbm
treatment
paradigm
need
shift
toward
effect
treatment
immun
cell
therapi
natur
killer
nk
cell
recogn
potenti
anticanc
effector
cell
recogn
target
tumor
cell
sinc
small
percentag
blood
cell
differenti
nk
cell
number
group
cell
hardli
enough
fight
tumor
multipl
activ
would
potenti
effect
cancer
treatment
method
preclin
studi
focus
set
optim
protocol
expans
activ
nk
cell
assess
efficaci
toward
induc
gbm
rat
model
exvivo
expand
heat
shock
treat
nk
cell
exploit
vitro
studi
confirm
efficaci
treat
cell
cytotox
assay
induc
gbm
male
wistar
rat
weight
gr
use
tumor
cell
inject
rat
brain
stereotact
surgeri
tumor
format
proven
mri
imag
follow
tumor
establish
analyz
effect
singl
inject
nk
cell
compar
singl
inject
nontreat
nk
cell
two
group
rat
result
system
intraven
deliveri
nk
cell
tail
vein
result
tumor
shrinkag
differ
time
interv
complet
remiss
first
group
gbminduc
rat
model
wherea
group
gbm
rat
receiv
untreat
nk
cell
tumor
progress
therapeut
efficaci
treat
nk
cell
ascertain
compar
nontreat
nk
cell
consid
tumor
shrinkag
observ
mri
surviv
rate
two
model
group
conclus
amelior
tumor
confirm
mri
prove
migrat
activ
nk
cell
blood
brain
barrier
home
cn
final
target
gbm
tumor
cell
data
suggest
nkcell
treat
may
promis
immun
cellbas
therapeut
approach
toward
treat
fatal
gbm
disclosur
noth
declar
abstract
withdrawn
long
term
sorafenib
respons
extramedullari
aml
relaps
allogen
stem
cell
transplant
sinc
june
sorafenib
dose
taper
mgday
due
mild
skin
gi
toxic
year
treatment
maintain
cr
medullari
extramedulari
level
evid
diseas
escap
mechan
action
chemo
hsct
dli
conclus
patient
treatment
sorafenib
provid
longterm
control
refractori
extramedullari
diseas
even
adjust
dose
studi
need
confirm
efficaci
inhibitor
control
relaps
allohsct
extramedullari
diseas
potenti
role
mainten
agent
disclosur
noth
declar
background
although
chemotherapeut
ct
agent
use
treatment
acut
lymphoblast
leukemia
increas
surviv
result
still
weak
longterm
surviv
ct
relaps
case
difficult
prognosi
weak
inotuzumab
ozogamicin
anticd
monoclon
antibodi
potenti
reduc
overal
toxic
intens
regimen
well
possibl
increas
number
patient
may
achiev
state
minim
residu
diseas
method
male
patient
diagnos
bcell
decemb
hoelzer
kt
protocol
start
mainten
treatment
continu
fifth
month
treatment
flag
ct
protocol
start
caus
recurr
seen
blast
detect
peripher
blood
smear
august
inotuzumab
ozogamicin
treatment
start
six
cure
complet
patient
remiss
septemb
gone
haploident
bone
marrow
transplant
sibl
donor
defibrotid
prophylaxi
venoocclus
diseas
vod
engraft
succes
chimerizm
day
transplant
day
transplant
remiss
result
bone
marrow
transplant
perform
sinc
complet
respons
achiev
patient
relaps
resist
ballin
patient
new
therapi
target
malign
lymphoblast
need
inotuzumab
ozogamicini
monoclon
antibodi
drug
conjug
target
antigen
malign
lymphoblastsin
mani
studi
shown
inotuzumab
ozogamycin
effect
reliabl
antitumor
activ
adult
recurr
resist
posit
howev
monoclon
antibodi
drug
conjug
shown
associ
vodsfor
purpos
use
defibrotid
protect
patient
vod
conclus
treatment
combin
ct
regimen
ball
suboptim
longterm
surviv
achiev
patientstarget
molecular
therapi
new
regimen
need
relaps
resist
patientsat
point
inotuzumab
ozogamycin
monoclon
antibodi
case
provid
remiss
recurr
resist
ball
patient
allow
patient
complet
treatment
allogen
transplant
fulli
compat
donor
disclosur
noth
declar
background
mesenchym
stem
cell
msc
attract
consider
therapeut
cure
mani
difficult
diseas
cellularlevel
due
trophic
effect
cytokin
chemokin
produc
msc
shown
multipl
benefici
properti
field
oncolog
studi
investig
effect
msc
deriv
human
bone
marrow
bm
adipos
tissu
umbil
cord
deriv
msc
ucmsc
ovarian
cancer
differenti
msc
perform
compar
analysi
variou
sourc
prolif
capac
surfac
antigen
express
differenti
abil
tumor
marker
paracrin
activ
influenc
ovarian
cancer
cell
prolifer
method
measur
ovarian
tumor
marker
protein
comput
elisa
prolif
effect
immunomodulatori
effect
apoptosi
msc
measur
cultur
count
coloni
format
flow
cytometri
fcm
use
measur
variat
immunophenotyp
cytokin
secret
cocultur
well
gene
express
result
cell
notic
prolifer
without
modif
immunophenotyp
third
subcultur
colonyform
unit
fibroblast
cfuf
test
show
prolifer
msc
along
healthi
cell
cancer
cell
line
chang
phenotyp
supernat
msc
show
increas
cellular
death
ovarian
cancer
cell
line
reduct
level
cocultur
declin
ldh
betahcg
observ
cocultur
cell
line
decreas
cancer
cell
line
cocultur
msc
supernat
show
reduct
cancer
tumorigen
aggress
rate
assert
stem
state
msc
supernat
decreas
cell
prolifer
mrna
express
increas
timp
suggest
msc
role
cell
death
inhibit
ovarian
cancer
cell
prolifer
increas
antiinflammatori
cytokin
decreas
growth
factor
gmcsf
along
proinflammatori
infa
tnfa
cytokin
also
note
conclus
gene
cytokin
activ
indic
potenti
therapeut
antiinflammatori
antiprolif
role
msc
ovarian
cancer
despit
sourc
reduct
ldh
betahcg
cocultur
along
decreas
amplifi
cellular
apoptosi
demonstr
benefici
effect
stem
cell
ovarian
cancer
cell
line
disclosur
background
hematopoiet
stem
cell
transplant
hsct
cure
sickl
cell
diseas
scd
far
risk
toxic
indic
franc
restrict
sever
patient
match
sibl
donor
studi
compar
incid
sever
acut
toxic
hsct
children
age
less
year
teenag
age
year
old
treat
scd
method
patient
suffer
scd
age
less
year
transplant
receiv
hsct
chu
robert
necker
includ
sever
acut
toxic
defin
onset
sever
acut
gvhd
organ
toxic
infect
compar
two
group
age
result
patient
children
teenag
includ
patient
receiv
myeloabl
condit
regimen
bone
marrow
sibl
donor
main
stem
cell
sourc
neither
death
reject
observ
median
followup
month
rang
incid
grade
iiiiv
acut
gvhd
similar
two
group
risk
factor
identifi
univari
analysi
teenag
frequent
acut
skin
toxic
vs
univari
analysi
patient
present
sever
organ
toxic
significantli
older
other
vs
year
old
teenag
frequent
treat
bacteri
vs
bk
viru
vs
infect
univari
analysi
patient
develop
infect
also
significantli
older
time
transplant
respect
vs
year
old
sever
sinusoid
obstruct
syndrom
observ
regard
longterm
toxic
patient
present
extens
chronic
gvhd
age
less
year
old
cutoff
age
could
defin
conclus
studi
confirm
excel
result
hsct
scd
eventfre
surviv
overal
surviv
older
age
transplant
seem
associ
frequent
sever
acut
toxic
result
consist
previou
studi
suggest
hsct
perform
soon
possibl
without
defin
best
age
prospect
studi
need
order
defin
place
therapeut
scd
aim
reduc
treatmentrel
toxic
develop
altern
strategi
patient
without
match
sibl
donor
disclosur
noth
declar
new
insight
risk
factor
transplantassoci
thrombot
microangiopathi
tatma
paediatr
hsct
associ
tatma
vs
vs
respect
presenc
comorbid
significantli
associ
increas
risk
tatma
absenc
comorbid
use
csatacbas
gvhd
prophylaxi
associ
less
tatma
incid
vs
agent
includ
univari
analysi
tatma
significantli
higher
among
patient
agvhd
grade
iiiv
vs
grade
pre
record
among
case
develop
tatma
two
patient
tatma
patholog
gene
mutat
complement
pathway
multivari
analysi
presenc
activ
comorbid
risk
factor
tatma
use
csatacbas
gvhd
prophylaxi
increas
risk
tatma
presenc
comorbid
use
defibrotid
prophylaxi
therapi
vod
associ
drop
incid
tatma
absenc
defibrotid
overal
surviv
significantli
lower
among
tatma
case
comparison
absenc
tatma
figur
conclus
activ
comorbid
signific
risk
factor
tatma
use
defibrotid
prophylaxi
patient
comorbid
time
hsct
might
offer
protect
tatma
surprisingli
use
csatac
base
gvhd
prophylaxi
risk
factor
tatma
probabl
limit
develop
high
grade
agvhd
associ
pre
tatma
suggest
common
pathway
endotheli
damag
background
gonad
impair
sever
late
effect
myeloabl
condit
regim
signific
impact
qualiti
life
cancer
survivor
aim
studi
analyz
gonad
function
busulfan
bu
treosulfan
treo
contain
regimen
regard
pubert
stage
method
retrospect
multicent
studi
involv
patient
treat
pediatr
ebmt
center
patient
receiv
myeloabl
dose
bu
treo
part
hsct
condit
elig
inclus
analysi
conduct
two
group
accord
pubert
statu
time
hsct
result
patient
pt
treat
pediatr
ebmt
bu
treo
allogen
hsct
median
age
transplant
year
rang
male
femal
f
pt
prepubert
hsct
f
post
pubert
patient
receiv
bu
prepubert
receiv
prepubert
figur
femal
receiv
treo
prepubert
stage
reach
often
spontan
puberti
vs
compar
prepubert
bu
group
occurr
menarch
higher
treo
group
p
hormon
replac
therapi
given
femal
transplant
prepubert
stage
transplant
postpubert
stage
male
pubert
last
followup
perform
sperm
analysi
unknown
three
pregnanc
report
popul
group
receiv
bu
regard
evalu
hormon
level
pubert
patient
time
hormon
dosag
median
yr
bu
treo
male
treat
treo
signific
lower
lh
level
p
compar
bu
group
femal
treat
treo
signific
lower
level
lh
fsh
p
p
respect
conclus
gonad
damag
relat
treo
significantli
lower
compar
bu
observ
femal
transplant
prepubert
period
spontan
puberti
frequent
treo
compar
bu
hypogonad
hypergonadotrop
frequent
bu
treo
result
must
confirm
larger
popul
background
viral
infect
significantli
contribut
morbid
mortal
patient
undergo
hematopoiet
stem
cell
transplant
tradit
antivir
therapi
associ
lack
efficaci
potenti
toxic
prolong
hospit
increas
patient
cost
viral
specif
cell
manufactur
donor
blood
treat
viral
infect
posttranspl
associ
increas
clinic
efficaci
low
toxic
postul
direct
cost
vst
therapi
lower
compar
tradit
antivir
medic
method
vst
manufactur
accord
local
protocol
fda
requir
total
drug
cost
per
institut
charg
per
drug
calcul
patient
requir
treatment
viral
infect
posthsct
manufactur
cost
vst
fix
per
fda
requir
patient
treat
investig
antivir
medic
includ
brincidofovir
exclud
analysi
patient
treat
vst
antivir
medic
year
period
compar
patient
treat
use
tradit
antivir
medic
includ
cidofovir
ganciclovir
valganciclovir
foscarnet
rituximab
result
demograph
shown
tabl
major
differ
two
group
treat
number
antivir
medic
use
vst
group
lower
compar
antivir
treatment
group
median
cost
vst
treatment
significantli
lower
compar
threat
tradit
antivir
therapi
vs
conclus
treatment
vst
posthsct
viral
infect
lower
cost
compar
antivir
medic
therapi
like
overal
cost
reduc
vst
due
reduc
inpati
hospit
time
less
monitor
lab
associ
antivir
medic
sideeffect
reduc
ancillari
cost
includ
nurs
pharmaci
studi
need
examin
indirect
cost
background
defici
autosom
recess
primari
immunodefici
pid
diseas
caus
lossoffunct
mutat
gene
patient
defici
present
multipl
abnorm
immun
system
includ
defect
cell
function
impair
product
antigenspecif
antibodi
lead
persist
viral
infect
skin
mucocutan
candidiasi
recurr
sinopulmonari
infect
atop
dermat
allerg
diseas
malign
sometim
autoimmun
hematopoiet
stem
cell
transplant
hsct
current
cur
treatment
option
avail
method
retrospect
evalu
patient
underw
allogen
hematopoiet
stem
cell
transplant
due
defici
ege
univers
pediatr
stem
cell
transplant
unit
result
identifi
patient
transplant
median
age
year
rang
year
patient
receiv
hsct
match
sibl
unrel
donor
patient
haploident
donor
use
busulfanbas
myeloabl
condit
regimen
patient
reduc
toxic
myeloabl
regimen
treosulfan
patient
nonmyeloabl
regimen
patient
eight
recipi
receiv
bone
marrow
patient
receiv
peripher
blood
stem
cell
recipi
receiv
cord
blood
stem
cell
sourc
fifteen
patient
achiev
engraft
median
followup
patient
month
grade
iiiiv
acut
graft
versu
host
diseas
gvhd
occur
patient
chronic
graft
versu
host
diseas
seen
patient
one
patient
receiv
cord
blood
unrel
donor
engraft
die
septic
shock
four
patient
die
transplant
relat
toxic
patient
surviv
patient
aliv
conclus
hsct
cur
treatment
option
defici
particular
patient
high
comorbid
score
high
risk
toxic
toxic
death
therefor
reduc
toxic
condit
regimen
use
patient
refer
background
eltrombopag
lowmolecularweight
synthet
nonpeptid
thrombopoietin
receptor
agonist
tpor
secondgener
tpo
oral
thrombopoietin
mimet
licens
chronic
immun
thrombocytopen
purpura
induc
platelet
matur
releas
bind
cmpl
receptor
megakaryocyt
recent
studi
patient
refractori
saa
eltrombopag
induc
respons
week
least
one
hematolog
lineag
patient
longer
requir
platelet
transfus
also
patient
becam
rbc
transfus
independ
neutrophil
respons
trilineag
respons
seen
patient
although
surpris
might
indic
stimul
cmpl
receptor
remain
stem
cell
delay
recoveri
thrombocytopenia
common
stem
cell
transplant
studi
includ
adult
patient
eltrombopag
use
enhanc
platelet
recoveri
posthsct
thrombocytopenia
well
toler
efficaci
offer
transfus
independ
method
retrospect
studi
eltrombopag
start
pediatr
patient
age
rang
year
median
age
year
posthematopoiet
stem
cell
transplant
hsct
thrombocytopenia
patient
fulfil
follow
criteria
undergon
hematopoiet
stem
cell
transplant
hsct
improv
total
leucocyt
count
leucocyt
engraft
prolong
thrombocytopenia
need
platelet
transfus
result
four
patient
receiv
ric
patient
condit
regimen
hsct
two
haploident
autolog
mud
msd
transplant
perform
et
start
patient
thrombocytopenia
despit
neutrophil
engraft
day
hsct
reduct
platelet
transfus
platelet
count
primari
endpoint
et
treatment
bone
marrow
biopsi
check
patient
patient
decreas
number
megacocyocyt
none
patient
activ
bleed
start
eltrombopag
high
risk
bleed
accord
platelet
monitor
patient
dose
increas
start
second
week
number
patient
need
platelet
transfus
end
first
month
end
month
patient
thrombocyt
count
third
month
patient
et
discontinu
month
dose
limit
toxic
observ
conclus
conclus
et
found
highli
effect
posthsct
thrombocytopenia
drug
relat
advers
effect
gradual
increas
platelet
count
none
patient
complic
due
thrombocytopenia
disclosur
background
isavuconazol
isa
new
triazol
approv
ifi
treatment
adult
popul
advantag
activ
mould
yeast
spp
excel
bioavail
oral
administr
without
relev
food
gastric
ph
effect
watersolubl
prodrug
develop
facilit
intraven
administr
without
nephrotox
excipi
potenti
poor
drugdrug
interact
isa
current
appear
requir
tdm
isa
safeti
efficaci
yet
establish
children
particular
data
avail
pediatr
hsct
set
method
italian
associ
pediatr
hematolog
oncolog
aieop
multicentr
analysi
cohort
allogen
hsct
pediatr
patient
receiv
isa
ifi
treatment
prophylaxi
due
lack
recommend
dose
pediatr
patient
clear
target
isa
plasma
troughlevel
rang
therapeut
monitor
tdm
isa
concentr
appli
valid
liquid
chromatographytandem
mass
spectrometri
hlpcm
ms
assay
techniqu
isa
trough
plasma
concentr
hour
drug
intak
measur
result
total
allohsct
recipi
includ
mf
median
age
year
rang
median
bodyweight
kg
rang
isa
use
ifi
treatment
case
prophylaxi
patient
donor
haploident
patient
matcheds
allogenicunrel
case
accord
eortc
criteria
ifi
proven
patient
penicilum
mucor
aspergillu
fumigatu
probabl
possibl
patient
lung
main
local
case
associ
cn
involv
case
paranas
sinus
patient
possibl
hepat
candidiasi
patient
one
receiv
isa
rescu
treatment
previou
therapeut
failur
ambisom
voriconazol
combin
therapi
posaconazol
seven
patient
receiv
iv
isa
receiv
oral
isa
wherea
patient
receiv
iv
oral
isa
patient
kg
bodi
weight
receiv
half
isa
dose
mg
tid
load
dose
day
mgdie
mantein
other
receiv
adult
schedul
patient
receiv
load
dose
isa
administ
median
day
rang
patient
isa
administ
combin
caspofungin
tdm
appli
patient
includ
patient
sever
vod
renal
failur
secondari
tatma
median
isa
concentr
mgl
mgl
respect
ifi
complet
remiss
achiev
case
partial
remiss
treatment
failur
experienc
patient
case
fungal
lesion
remain
stabl
ctae
grade
iiiii
toxic
observ
treatment
patient
increas
transaminas
andor
creatinin
level
resolv
temporari
isa
withdraw
drugdrug
interact
observ
patient
receiv
csa
gvhd
prophylaxi
modif
csa
daili
dose
need
conclus
isavuconazol
use
may
consid
pediatr
popul
even
hsct
set
safeti
efficaci
toler
drugdrug
interact
cours
data
deserv
evalu
disclosur
noth
declar
new
treosulfanbas
condit
regimen
includ
epigenet
agent
patient
highrisk
neuroblastoma
background
pt
age
mo
older
dissemin
nb
involv
bone
bone
marrow
constitut
group
pt
poor
prognosi
although
major
respons
intens
convent
chemotherapi
eventu
relaps
ef
year
begin
year
came
protocol
unfavor
group
includ
epigenet
therapi
phase
consolid
method
seven
pt
median
age
year
complet
protocol
receiv
hdct
autolog
sct
consolid
hdct
includ
two
differ
epigenet
agent
contain
regim
accord
tumor
respons
induct
therapi
assess
imibg
mri
ctscan
three
pt
reveal
larg
activ
residu
tumor
assess
imibg
scan
multipl
activ
bone
metastas
receiv
condit
regimen
regimen
includ
imibg
therapi
dose
mbekg
treosulfan
mgm
total
mgm
melphalan
mgm
total
mgm
mgm
total
mgm
four
pt
cr
vgpr
receiv
split
condit
regimen
regimen
b
includ
treosulfan
mgm
total
mgm
melphalan
mgm
total
mgm
mgm
total
mgm
median
number
infus
result
median
recoveri
time
wbc
l
unsupport
plt
l
day
respect
pt
experienc
grade
hematolog
well
infecti
toxic
assess
ncictc
score
episod
sever
organ
toxic
grade
occur
pt
case
observ
sever
mucos
case
gi
toxic
episod
erythema
multiform
occur
one
pt
reveal
lifethreaten
episod
hypotens
grade
transplantrel
death
occur
median
number
transfus
rbc
plt
dose
respect
pt
aliv
well
without
sign
diseas
progress
complet
hematolog
recoveri
limit
followup
mo
day
hdct
conclus
although
rather
earli
evalu
efficaci
epigenet
agent
inclus
induct
andor
consolid
phase
highrisk
nb
treatment
assum
first
hdct
combin
mibg
andor
high
dose
treosulfan
epigenet
agent
feasibl
accept
toxic
second
split
modal
treosulfan
use
condit
regimen
would
permit
increas
total
dose
alkyl
agent
inaccept
toxic
disclosur
noth
declar
preandpost
magnet
reson
imag
hip
knee
detect
osteonecrosi
children
undergo
hematopoiet
cell
transplant
necessari
ali
suliman
sue
c
kast
ying
li
dinesh
keerthi
guolian
kang
brandon
triplett
ashok
srinivasan
april
august
univers
medic
center
hamburgeppendorf
germani
includ
total
activ
ratg
plasma
level
analyz
elisa
flow
cytometri
respect
primari
endpoint
studi
exposur
ratg
secondari
endpoint
includ
transplantrel
mortal
incid
acut
chronic
gvhd
immun
reconstitut
chimer
reject
viral
infect
patient
monitor
least
day
post
transplant
statist
analys
perform
use
ibm
spss
statist
softwar
graphpad
prism
softwar
result
median
total
peak
plasma
level
respect
median
activ
peak
plasma
level
appl
respect
activ
plasma
level
show
highli
variabl
pharmacokinet
compar
neither
exposur
correl
lymphocyt
count
prior
transplant
cell
count
graft
wbc
mnc
cell
age
bodi
weight
bodi
surfac
area
bsa
indic
satur
effect
group
correl
high
low
ratg
exposur
clinic
outcom
paramet
built
two
group
within
patient
cohort
median
appl
incid
gvhd
depend
high
low
ratg
exposur
day
post
hsct
viral
infect
reactiv
ebv
cmv
adv
bkv
occur
patient
interestingli
adv
infect
affect
children
high
ratg
exposur
median
time
leukocyt
engraft
significantli
longer
high
ratg
group
compar
low
ratg
group
day
day
decreas
andor
delay
recoveri
cell
reconstitut
b
cell
nk
cell
high
exposur
group
compar
low
exposur
group
overal
surviv
statist
signific
group
without
influenc
ratg
exposur
conclus
high
low
exposur
result
signific
differ
outcom
paramet
incid
surviv
agvhd
cgvhd
reject
mix
chimer
limit
cohort
delay
decreas
immun
reconstitut
high
ratg
exposur
group
translat
differ
clinic
outcom
paramet
adv
infect
occur
high
ratg
exposur
group
show
distinct
pharmacolog
immunolog
differ
children
larger
cohort
need
detect
clinic
signific
differ
adjust
dose
regimen
individu
disclosur
noth
declar
background
optim
condit
regimen
allogen
hematopoiet
cell
transplant
allohct
children
myeloid
malign
remain
undefin
particularli
reducedintens
condit
ric
regimen
util
method
perform
retrospect
review
children
undergo
allohct
acut
myeloid
leukemia
aml
myelodysplasiarel
aml
mdraml
year
period
institut
compar
outcom
receiv
either
busulfan
bu
melphalanthiotepa
melthio
base
condit
regimen
result
total
patient
analyz
twentyon
receiv
fludarabinemelphalanthiotepa
receiv
myeloabl
busulfanbas
condit
either
combin
cyclophosphamid
fludarabin
atg
use
patient
depend
donor
recipi
melthio
select
ric
regimen
due
pretranspl
comorbid
cardiac
dysfunct
requir
peritranspl
milrinon
transplant
chemotherapyinduc
aplasia
underli
diagnosi
treatmentrel
aml
taml
signific
preallohct
chemotherapi
exposur
proport
patient
de
novo
aml
mel
thio
bu
mdraml
similar
group
howev
recipi
melthio
like
taml
vs
cytogenet
molecular
risk
factor
similar
group
major
patient
transplant
melthio
vs
bu
vs
recipi
bu
condit
vs
mrdneg
time
allohct
group
compar
proport
patient
marrow
donor
type
stem
cell
sourc
similar
group
except
unrel
umbil
cord
blood
common
bu
recipi
vs
graft
failur
melthio
recipi
compar
receiv
bubas
regimen
engraft
kinet
immun
reconstitut
similar
overal
acut
chronic
gvhd
incid
higher
recipi
mel
thio
compar
bu
vs
vs
respect
rate
grade
iiiiv
acut
extens
chronic
gvhd
compar
vod
requir
treatment
diagnos
recipi
bu
condit
melthio
recipi
median
durat
followup
month
rang
melthio
group
month
rang
bu
group
transplantrel
mortal
trm
similar
group
patient
occur
day
relaps
incid
compar
melthio
vs
bu
howev
relaps
occur
later
time
melthio
recipi
median
vs
overal
surviv
year
superior
melthio
recipi
vs
vs
respect
conclus
singl
institut
experi
use
melphalanthiotepabas
ric
regimen
associ
similar
outcom
compar
fullintens
bubas
condit
despit
higher
risk
patient
diseas
characterist
major
recipi
melthio
condit
signific
pretranspl
comorbid
translat
higher
trm
melthio
recipi
less
optim
leukemia
control
time
transplant
highrisk
leukemia
featur
eg
taml
relaps
similar
group
occur
later
mel
thio
recipi
may
contribut
better
overal
surviv
disclosur
noth
disclos
method
pubert
develop
biolog
gonad
paramet
assess
retrospect
monocentr
cohort
prepubert
patient
underw
hsct
myeloabl
condit
total
bodi
irradi
tbi
busulfan
result
seventyfour
patient
girl
boy
includ
spontan
pubert
develop
found
girl
boy
p
delay
puberti
spontan
pubert
develop
found
girl
boy
hormon
replac
therapi
use
girl
boy
p
univari
analysi
tbi
condit
femal
sex
p
acut
gvhd
extens
chronic
gvhd
steroid
treatment
month
malign
diseas
associ
spontan
pubert
develop
wherea
tbi
condit
extens
chronic
gvhd
associ
delay
puberti
multivari
analysi
factor
independ
associ
spontan
puberti
onset
femal
sex
age
year
factor
independ
associ
delay
puberti
extens
chronic
gvhd
age
year
tbi
independ
risk
factor
pubert
complic
conclus
studi
confirm
toxic
myeloabl
condit
pubert
develop
role
older
age
femal
sex
increas
pubert
issu
suggest
possibl
role
gvhd
delay
puberti
disclosur
noth
declar
abstract
alreadi
publish
neutrophil
elastas
activ
may
serv
marker
neutrophil
extracellular
trap
format
follow
stem
cell
transplant
ronit
elhasid
sivan
bergerachituv
hila
rosenfeldkeidar
szilvia
baron
tel
aviv
souraski
medic
center
tel
aviv
univers
tel
aviv
israel
background
posttranspl
infect
rise
dramat
patient
quantit
qualit
neutrophil
defect
constitut
major
sourc
morbid
mortal
follow
hematopoiet
stem
cell
transplant
hsct
neutrophil
protect
host
microorgan
via
multipl
process
includ
phagocytosi
format
neutrophil
extracellular
trap
net
although
reactiv
oxygen
speci
ro
product
seem
essenti
net
format
key
enzym
process
neutrophil
elastas
ne
myeloperoxidas
mpo
method
ne
mpo
activ
well
net
format
investig
follow
hsct
patient
week
neutrophil
engraft
neutrophil
isol
use
easysep
direct
human
neutrophil
isol
kit
stemcel
technolog
inc
immunomagnet
neg
select
enzymat
activ
ne
mpo
measur
use
colorimetr
assay
net
format
phorbol
pma
activ
neutrophil
investig
confoc
fluoresc
microscopi
result
compar
healthi
volunt
statist
signific
calcul
use
one
wayanova
bonferroni
post
hoc
test
result
patient
median
age
year
rang
year
investig
follow
allogen
hsct
acut
lymphoblast
leukemia
acut
myeloblast
leukemia
epidermolysi
bullosa
rhabdomyosarcoma
follow
autolog
hsct
ewe
sarcoma
desmoplast
small
round
cell
tumor
patient
experienc
fever
neutropenia
engraft
averag
ne
activ
significantli
decreas
compar
averag
valu
healthi
individu
ne
activ
improv
week
week
patient
reach
lower
refer
rang
week
follow
transplant
fig
continu
increas
enzymat
activ
mpo
compar
averag
valu
healthi
individu
fig
show
signific
differ
distinct
time
point
neutrophil
engraft
net
format
absent
compar
nonactiv
neutrophil
fig
although
net
format
increas
week
week
reach
averag
normal
control
monitor
time
period
also
linear
correl
ne
activ
net
format
r
demonstr
conclus
impair
ne
activ
follow
hsct
correspond
decreas
net
format
could
serv
marker
netosi
strategi
acceler
recoveri
ne
function
post
transplant
might
improv
net
format
therebi
induc
better
infect
control
averag
ne
activ
week
follow
hsct
refer
rang
measur
calcul
measur
healthi
volunt
use
b
averag
mpo
activ
week
follow
hsct
refer
rang
measur
calcul
measur
healthi
volunt
use
quartil
method
c
averag
netosi
activ
nm
pma
activ
background
better
understand
incid
treatment
outcom
risk
factor
immun
cytopenia
children
allogen
hsct
method
januari
septemb
pediatr
allogen
hsct
perform
patient
ghent
univers
hospit
ghent
belgium
autoimmun
hemolyt
anemia
defin
posit
direct
agglutinin
test
dat
dat
perform
moment
engraft
case
hemolysi
unexplain
anemia
platelet
antibodi
evalu
case
otherwis
explain
thrombocytopenia
result
cumul
incid
post
allo
sct
autoimmun
cytopenia
case
posit
antibodi
red
blood
cell
one
patient
antibodi
platelet
case
clinic
relev
need
treatment
median
observ
period
post
sct
whole
cohort
month
clinic
signific
immun
cytopenia
start
median
time
day
group
without
symptom
patient
present
autoimmun
thrombopenia
develop
antibodi
antigpiibiiia
resolv
day
treatment
consist
intraven
immunoglobulin
ivig
two
patient
autoimmun
hemolyt
anemia
igg
mediat
antibodi
complementmedi
dat
patient
treat
ivig
steroid
rapamun
rituximab
one
patient
still
dat
posit
month
clinic
stabl
two
also
dat
posit
hemolysi
follow
much
shorter
month
treosulfancontain
condit
regimen
frequent
use
patient
signific
immun
cytopenia
conclus
immun
cytopenia
infrequ
complic
allogen
hsct
howev
treatment
challeng
hemolysi
persist
year
associ
rapamun
rituximab
adequ
treat
problem
patient
background
approach
manag
refractori
relaps
classic
lymphoma
rr
chl
chang
becom
effect
role
target
immunochemotherapi
brentuximab
vedotin
bv
extens
investig
adult
rr
chl
elucid
children
studi
includ
children
adolesc
rr
chl
sucess
treat
bvbase
therapi
prior
hematopoet
stem
cell
transplant
hsct
median
age
patient
year
main
histolog
variant
nodular
sclerosi
advanc
stage
diagnosi
heavili
pretreat
median
number
previou
therapi
progress
autolog
hsct
document
refractori
diseas
diagnos
relaps
among
relaps
patient
multipl
episod
earli
late
relaps
treatment
regimen
consist
bv
monotherapi
mgkg
triweekli
combin
bv
mgkg
day
bendamustin
mg
day
cycl
combin
bv
mgkg
day
dhap
median
number
bv
infus
select
patient
achiev
complet
partial
remiss
prior
hsct
consolid
autolog
hsct
perform
allogen
hsct
primari
end
point
overal
os
progress
free
surviv
pf
respons
bv
assess
studi
respond
bvbase
treatment
includ
result
median
followup
day
os
pf
patient
respect
pf
autolog
hsct
allogen
hsct
respect
present
moment
patient
aliv
remiss
three
patient
die
diseas
progress
postranspl
idiopath
pneumonia
syndrom
posttranspl
pneumonia
bv
gener
well
toler
mild
polyneuropathi
patient
main
revers
document
advers
event
conclus
prognost
unfavour
heavili
pretreat
children
adolesc
rr
chl
achiev
respons
bvbase
therapi
prior
hsct
assosi
promis
rate
os
pf
disclosur
provid
treatment
restor
thymidin
phosphorylas
function
improv
diseas
manifest
report
outcom
affect
sibl
underw
transplant
use
unaffect
sibl
donor
highlight
import
experi
transplant
rare
condit
method
four
sibl
consanguin
pakistani
descent
age
year
underw
myeloabl
hsct
use
fulli
hlamatch
peripher
blood
stem
cell
harvest
singl
apheresi
unaffect
year
old
sibl
oldest
sibl
year
old
male
first
present
emigr
pakistan
histori
growth
failur
abnorm
movement
biochem
nerv
conduct
imag
studi
confirm
diagnosi
mngie
test
three
sibl
identifi
similar
biochem
abnorm
though
youngest
children
minim
clinic
manifest
diseas
base
progress
natur
diseas
avail
fulli
match
donor
decis
made
pursu
transplant
affect
sibl
result
due
sever
diseas
oldest
sibl
transplant
first
use
myeloabl
condit
regim
fludarabin
thiotepa
treosulfan
alemtuzumab
neutrophil
engraft
occur
day
donor
chimer
achiev
signific
transplant
relat
complic
posttranspl
cours
year
old
sibl
complic
major
strokelik
event
characteris
dramat
imag
chang
requir
ventil
though
caus
identifi
patient
neurolog
deficit
sinc
resolv
gastrointestin
symptom
persist
remain
tpn
depend
though
symptomat
shown
gradual
improv
follow
neurolog
complic
older
sibl
younger
sibl
condit
auctarget
busulfan
fludarabin
plu
alemtuzumab
neutrophil
engraft
occur
day
full
donor
chimer
achiev
progress
enter
feed
much
rapid
nutrit
fulli
enter
signific
transplant
relat
complic
conclus
stem
cell
transplant
repres
cur
option
mngie
due
rariti
rel
infanc
condit
littl
known
expect
cours
follow
transplant
best
approach
transplant
despit
previou
challeng
graft
failur
mngie
recipi
abl
gain
rapid
sustain
donor
engraft
use
differ
myeloabl
condit
regim
minim
transplantrel
morbid
mortal
keep
previou
report
resolut
establish
gastrointestin
symptom
slow
though
sibl
transplant
earlier
diseas
cours
shown
rapid
improv
support
role
earli
recognit
access
transplant
essenti
move
forward
specialis
transplant
centr
collabor
guid
clinician
manag
challeng
condit
disclosur
conflict
interest
disclos
congenit
neutropenia
biolog
inflammatori
coliti
associ
gcsf
use
diseas
respons
allogen
transplant
report
case
background
autosom
recess
diseas
catalyt
subunit
defici
rel
recent
identifi
caus
chronic
sever
neutropenia
spectrum
diseas
patient
may
also
present
nonhaematolog
featur
includ
promin
chest
vein
cardiac
endocrin
urogenit
abnorm
describ
patient
cohort
respons
gcsf
inflammatori
incapacit
biopsyproven
coliti
associ
gcsf
respons
transplant
children
coliti
describ
similar
coliti
intestin
failur
fourth
method
investig
biolog
neutropen
coliti
demonstr
necrosi
stimul
neutrophil
vitro
studi
demonstr
unstimul
neutrophil
patient
exhibit
significantli
increas
product
reactiv
oxygen
speci
ro
neutrophil
extracellular
trap
net
alongsid
significantli
higher
express
contrast
neutrophil
patient
produc
significantli
less
ro
neutrophil
elastas
net
upon
stimul
neutrophil
patient
also
exhibit
significantli
acceler
apoptosi
secondari
necrosi
exagger
upon
stimul
live
escherichia
coli
bacteria
could
partial
rescu
supplement
exogen
glucos
result
patient
undergon
hsct
neutropen
enterocol
unrel
donor
msd
fludarabin
treosulfan
thiotepa
condit
therapi
alemtuzumab
given
serotherapi
patient
aliv
well
immun
suppress
discotniun
gvhd
normal
organ
function
resolut
coliti
describ
th
patient
good
donor
continu
intestin
failur
gcsf
use
conclus
describ
aetiolog
intestin
inflamm
failur
extens
studi
neutrophil
biolog
metabol
neutropenia
describ
novel
indic
hsct
gcsfrespons
neutropenia
disclosur
noth
declar
bodi
mass
index
bmi
pose
risk
outcom
pediatr
noninfantil
patient
undergo
hematopoiet
cell
transplant
hsct
mona
alsaleh
khawar
siddiqui
amal
alseraihi
abdullah
aljefri
ali
alahmari
hawazen
alsaedi
awatif
alanazi
mouhab
aya
ibrahim
alghemla
evid
toxic
benefit
stoss
therapi
hsct
remain
unknown
safeti
yet
studi
extens
pediatr
popul
hypothes
stoss
therapi
effect
safe
method
reach
attain
suffici
level
vd
pediatr
patient
undergo
hsct
method
ongo
prospect
random
clinic
control
trial
phoenix
children
hospit
commenc
decemb
st
follow
consent
subject
random
intervent
stoss
control
arm
prior
hsct
stoss
therapi
consist
singl
oral
dose
vd
rang
given
base
baselin
oh
level
age
follow
standard
weekli
supplement
subject
enrol
control
arm
receiv
standard
care
base
endocrin
societi
guidelin
weekli
vd
supplement
data
collect
includ
demograph
oh
level
baselin
day
day
vd
toxic
hyperphosphatemia
hyperkalemia
renal
calculi
well
comorbid
collect
time
point
trial
arm
mean
oh
level
chang
baselin
comput
correspond
confid
interv
ci
indic
variabl
result
present
subject
complet
baselin
assess
day
day
followup
complet
respect
baselin
mean
ci
oh
ngdl
among
stoss
patient
ngdl
result
total
hrqol
score
transplant
patient
significantli
improv
compar
support
care
also
compar
healthi
sibl
p
respect
true
physic
p
respect
emot
function
p
respect
social
school
function
transplant
children
differ
healthi
sibl
p
respect
significantli
improv
compar
children
st
support
care
p
case
conclus
bmt
lowermiddl
incom
set
may
even
impact
compar
highincom
region
analysi
clearli
indic
normal
hrqol
major
area
children
transplant
st
possibl
resili
effect
note
physic
emot
score
improv
compar
healthi
sibl
control
could
howev
quantifi
effect
longerterm
issu
like
fertil
impair
bmt
may
eventu
advers
impact
hrqol
particularli
indian
cultur
disclosur
none
allogen
hematopoiet
stem
cell
transplant
ataxia
telangiectasia
patient
without
malign
background
ataxia
telangiectasia
primari
immunodefici
mutat
atmgen
besid
slowli
progress
neurodegen
cours
lead
increas
suscept
malign
affect
patient
year
high
mortal
mainli
due
tocompl
convent
radiochemotherapi
incid
cancer
correl
extent
immunodefici
patient
often
develop
sever
progress
granulomat
skin
diseas
evid
vaccinestrain
rubellaviru
lesion
prolong
surviv
neurolog
improv
malign
prevent
observ
atmdefici
mice
treatment
syngen
hsct
nevertheless
preemptiv
hsct
routin
perform
patient
due
concern
neurodegener
toxic
method
present
three
patient
sever
immunodefici
phenotyp
undergo
success
hsct
individu
treatment
strategi
intend
restor
immunodefici
longterm
malignancyprevent
treat
progress
skinjoint
granuloma
result
underw
reduc
intens
condit
ric
regimen
year
age
includ
fludarabin
mgm
cyclophosphamid
mgkg
atgfreseniu
mgkgd
toler
well
hematopoiet
engraft
occur
day
expans
memori
tcell
cell
initi
mix
donor
chimer
patient
pbmc
donor
observ
patient
tcell
reach
donor
origin
time
last
followup
year
well
without
sign
gvhd
organ
toxic
immunosuppress
normal
level
atmprotein
granuloma
resolv
yearold
male
transplant
hlaident
sibl
condit
fludarabin
cyclophosphamid
mgkg
atgfreseniu
mgkg
hematopoiet
engraft
observ
day
tcell
reconstitut
start
day
tcell
mix
chimer
rapidli
turn
donor
origin
donor
time
acut
toxic
howev
develop
lumbosacr
pain
episod
evid
urin
bkviru
spontan
remiss
intermitt
metapneumoviru
associ
pulmonari
hypertens
observ
pericardi
effus
treatment
includ
sildenafil
oxygen
last
followup
month
patient
well
without
immunosuppress
suffer
recurr
chest
infect
failur
thrive
progress
debilit
rubella
posit
progress
granuloma
skin
receiv
allohsct
hlaident
famili
donor
year
age
condit
includ
busulfan
mgkg
fludarabin
cyclophosphamid
mgkg
alemtuzumab
x
x
hsct
complic
intermitt
acut
renal
failur
cmv
reactiv
tma
hematopoiet
recoveri
observ
day
tcell
chimer
increas
rapidli
time
donor
last
followup
month
patient
well
immunosuppress
ivig
skin
granuloma
resolv
scar
residu
conclus
preemptiv
allohsct
feasibl
reduc
intens
condit
use
correct
immunodefici
might
treatment
option
patient
high
risk
hematolog
malign
sever
granulomat
skin
diseas
extent
restor
immun
system
increas
atmprotein
patient
could
prevent
develop
malign
need
evalu
disclosur
noth
disclos
abstract
withdrawn
hematopoiet
stem
cell
transplant
diamond
blackfan
anemia
brazilian
experi
background
diamondblackfan
anemia
dba
rare
inherit
red
cell
aplasia
caus
intrins
defect
erythropoiet
progenitor
main
therapeut
approach
base
repeat
red
blood
cell
transfus
andor
corticosteroid
therapi
hematopoiet
stem
cell
transplant
hsct
potenti
cur
treatment
dba
indic
patient
respond
firstlin
therapi
method
aim
retrospect
studi
report
outcom
brazilian
dba
patient
transplant
bmt
center
median
age
patient
ys
rang
male
seventeen
patient
transplant
match
relat
donor
mrd
thirteen
match
mismatch
unrel
donor
mudmmud
mrd
group
patient
receiv
bone
marrow
hsc
sourc
mudmmud
eight
patient
receiv
bone
marrow
five
receiv
cord
blood
patient
incompat
mismatch
ucb
nineteen
recipi
condit
busulfan
plu
cyclophosphamid
remain
receiv
fludarabin
busulfan
prefer
regimen
brazil
recent
year
transplant
mrd
mud
recipi
receiv
cyclosporin
short
cours
methotrex
graft
versu
host
diseas
gvhd
prophylaxi
result
twentytwo
patient
aliv
diseasefre
median
followup
month
rang
month
overal
surviv
os
ci
fig
similar
result
demonstr
studi
europ
unit
state
analyz
accord
donor
type
os
ci
ci
mrd
mudmmud
respect
fig
three
patient
transplant
ucb
die
result
agreement
previous
publish
data
show
wors
result
unrel
ucb
transplant
twentynin
patient
engraft
success
evalu
patient
median
time
neutrophil
engraft
day
rang
one
patient
experienc
earli
death
hemorrhag
shock
day
neutrophil
recoveri
anoth
two
patient
experienc
primari
graft
failur
posttranspl
chimer
avail
patient
sixteen
complet
chimera
chimer
patient
present
mix
chimer
acut
gvhd
observ
patient
classifi
grade
iv
five
patient
develop
chronic
gvhd
consid
sever
three
eight
patient
die
mean
day
rang
day
hsct
main
caus
death
infect
hemorrhag
disord
conclus
hsct
potenti
cur
treatment
option
dba
present
studi
report
outcom
patient
dba
transplant
brazil
os
better
result
mrd
compar
mud
expect
despit
small
number
observ
lower
surviv
mudmmud
ucb
transplant
sinc
dba
rare
diseas
intern
collabor
studi
essenti
better
understand
benefit
hsct
treatment
patient
disclosur
noth
declar
treatment
obliter
bronchiol
pediatr
allogen
recipi
two
period
compar
result
group
therapi
administ
bo
includ
prolong
treatment
steroid
patient
antitnf
azatioprin
group
patient
receiv
ima
montelukast
azitromicin
receiv
iv
mpd
median
durat
imatinib
therapi
year
year
median
followup
year
rang
yr
patient
group
die
bo
progress
transplantrel
caus
group
die
presenc
worsen
bo
estim
os
year
hsct
ci
group
ci
group
figur
os
year
decreas
ci
group
remain
stabl
group
conclus
experi
show
relev
improv
prognosi
children
bo
use
protocol
includ
ima
sinc
signific
improv
surviv
obtain
confirm
report
adult
popul
disclosur
result
present
patient
pre
age
rang
month
year
averag
year
ten
patient
thalassemia
major
two
patient
acut
lymphoblast
leukemia
three
patient
sickl
cell
diseas
one
patient
myelodysplast
syndrom
one
patient
immun
defici
two
patient
acut
miyeloid
leukemia
one
patient
aplast
anemia
ten
patient
male
ten
femal
patient
treat
csa
tacrolimu
metilprednisolon
prophylasix
gvhd
pre
occur
median
day
rang
clinic
find
onset
leukoencephalopathi
hypertens
headach
seizur
visual
disturb
alter
mental
function
eighteen
patient
aliv
normal
neurolog
statu
mri
show
abnorm
patient
includ
patchi
bilater
cortic
subcort
lesion
especi
parietooccipit
lobe
conclus
bmt
associ
sever
neurolog
complic
may
underli
diseas
bmt
procedur
sever
immunosupress
pre
uncommon
seriou
complic
bmt
report
case
pre
receiv
allogen
bmt
thalassemia
major
emphas
import
earli
recognit
institut
appropri
manag
pre
bmt
disclosur
noth
declar
continu
complet
molecular
remiss
use
three
differ
monoclon
antibodi
follow
allogen
bone
marrow
transplant
infant
chemotherapyrefractori
acut
lymphoblast
leukemia
bernd
gruhn
susan
wittig
thoma
ernst
jana
ernst
univers
jena
jena
germani
background
infant
diagnos
immatur
acut
lymphoblast
leukemia
myeloid
marker
foreign
univers
hospit
end
induct
therapi
accord
current
lalshop
protocol
leukem
cell
detect
bone
marrow
treatment
chang
fludarabin
cytarabin
granulocyt
colonystimul
factor
flag
combin
liposom
doxorubicin
reinduct
still
leukem
cell
detect
bone
marrow
bispecif
tcell
engag
antibodi
blinatumomab
given
due
increas
portion
leukem
cell
continu
infus
antibodi
therapi
stop
cycl
clofarabin
cyclophosphamid
etoposid
administ
unfortun
still
leukem
cell
detect
afterward
chemotherapyrefractori
leukemia
palli
oral
treatment
mercaptopurin
start
howev
parent
accept
palli
situat
search
altern
therapeut
option
univers
hospit
europ
plenti
refus
infant
admit
hospit
five
month
diagnosi
method
molecular
character
genom
dna
isol
leukem
cell
rearrang
consequ
transloc
detect
use
marker
minim
residu
diseas
molecular
character
target
deep
nextgener
sequenc
perform
panel
leukemiaassoci
gene
interestingli
mutat
found
allow
precis
immunophenotyp
leukem
cell
treatment
mercaptopurin
stop
result
first
immunophenotyp
antigen
found
administ
monoclon
antibodi
gemtuzumab
ozogamicin
twice
within
two
week
detect
leukem
cell
infus
gemtuzumab
ozogamicin
antibodi
daratumumab
given
altern
twice
within
two
week
unfortun
afterward
leukem
cell
reappear
neg
und
posit
therefor
administ
third
antibodi
monoclon
antibodi
inotuzumab
ozogamicin
whereupon
patient
develop
tumor
lysi
syndrom
sever
bone
marrow
aplasia
shortli
allogen
bone
marrow
transplant
unrel
donor
use
special
condit
regimen
consist
thymoglobulin
busulfan
fludarabin
clofarabin
conduct
clofarabin
ad
addit
antileukem
effect
especi
infant
mll
rearrang
describ
transplant
patient
suffer
sever
hepat
sinusoid
obstruct
syndrom
massiv
ascit
renal
pulmonari
dysfunct
final
patient
recov
complet
first
bone
marrow
examin
day
transplant
reveal
donor
chimer
complet
molecular
remiss
use
rearrang
marker
minim
residu
diseas
followup
bone
marrow
sampl
observ
complet
donor
chimer
complet
molecular
remiss
current
eight
month
transplant
patient
good
physic
condit
normal
develop
accord
age
background
paediatr
chronic
graft
versu
host
diseas
cgvhd
debilit
condit
associ
substanti
morbid
mortal
date
approv
therapi
paediatr
patient
cgvhd
current
treatment
often
lack
suffici
efficaci
lead
severelifethreaten
toxic
limit
effect
ibrutinib
firstinclass
oncedaili
inhibitor
bruton
tyrosin
kinas
btk
approv
us
treatment
adult
patient
cgvhd
failur
line
system
therapi
phase
studi
evalu
use
ibrutinib
paediatr
patient
moder
sever
cgvhd
method
openlabel
multicent
intern
phase
studi
includ
patient
moder
sever
cgvhd
defin
nih
consensu
develop
project
criteria
divid
two
part
part
determin
recommend
paediatr
equival
dose
rped
ibrutinib
patient
age
year
part
b
aim
evalu
safeti
efficaci
ibrutinib
patient
age
year
part
patient
cgvhd
age
year
fail
line
system
therapi
receiv
daili
oral
ibrutinib
start
dose
mgm
escal
mgm
day
grade
toxic
occur
rped
determin
part
b
patient
age
year
cgvhd
fail
line
system
therapi
newli
diagnos
cgvhd
receiv
daili
ibrutinib
mg
one
follow
criteria
met
treatment
longer
requir
new
system
treatment
cgvhd
initi
progress
cgvhd
recurr
underli
diseas
unaccept
toxic
patient
newli
diagnos
cgvhd
receiv
ibrutinib
addit
daili
corticosteroid
mgkg
prednison
patient
year
age
may
enrol
part
b
treat
rped
determin
part
key
exclus
criteria
includ
uncontrol
activ
system
infect
activ
infect
requir
system
treatment
progress
underli
malign
diseas
posttranspl
lymphoprolif
diseas
activ
hepat
chepat
b
viru
patient
must
adequ
renal
hepat
hematolog
function
enrol
primari
endpoint
part
rped
ibrutinib
base
pharmacokinet
pk
data
secondari
endpoint
includ
safeti
pharmacodynam
btk
occup
primari
endpoint
part
b
pk
safeti
ibrutinib
paediatr
patient
cgvhd
secondari
endpoint
part
b
includ
respons
rate
week
defin
nih
consensu
develop
project
criteria
durat
respons
overal
surviv
late
effect
growth
develop
immun
reconstitut
result
global
studi
current
enrol
conclus
phase
studi
explor
use
ibrutinib
paediatr
patient
cgvhd
potenti
meet
high
unmet
need
proven
effect
therapi
popul
disclosur
enzym
replac
therapi
ert
treatment
choic
nonneuropath
hunter
syndrom
recombin
enzym
cross
blood
brain
barrier
neuropath
hunter
syndrom
left
untreat
hematopoiet
stem
cell
transplant
hsct
standard
care
patient
sever
mucopolysaccharidosi
mp
type
mpsih
hurler
syndrom
earli
transplant
halt
cognit
declin
patient
significantli
improv
surviv
case
studi
publish
potenti
benefit
hsct
mp
ii
mostli
use
busulfanbas
condit
regimen
one
compar
nonrandomis
multicent
studi
hsct
might
superior
compar
ert
present
experi
hsct
three
children
hunter
syndrom
use
treosulfanbas
condit
regimen
method
retrospect
chart
review
carri
patient
underw
hsct
hunter
syndrom
condit
chemotherapi
regimen
includ
fludarabin
treosulfan
thiotepa
atg
patient
receiv
bone
marrow
either
relat
match
unrel
donor
gvhd
prophylaxi
perform
csa
methotrexat
result
three
patient
hunter
syndrom
transplant
depart
age
six
month
two
year
four
year
respect
bone
marrow
donor
relat
one
patient
match
unrel
two
patient
condit
therapi
gener
well
toler
major
complic
fever
unknown
origin
need
antibiot
therapi
mucos
one
patient
develop
cmv
reactiv
patient
engraft
success
recov
well
hsct
case
acut
chronic
gvhd
three
patient
aliv
donor
chimer
complet
one
patient
two
patient
mix
donor
chimer
applic
donor
lymphocyt
infus
one
patient
donor
chimer
stabl
low
level
donor
chimer
patient
still
slowli
declin
current
stem
cell
transplant
two
patient
show
progress
diseas
even
achiev
psychomotor
improv
interestingli
one
patient
one
low
donor
chimer
one
patient
suffer
progress
underli
diseas
psychomotor
agit
aggress
behavior
loss
speech
occur
within
first
year
follow
hsct
neurocognit
stabil
thereaft
conclus
found
benefici
effect
hsct
neuropsycholog
outcom
least
stabil
neurocognit
function
patient
followup
eight
year
despit
low
toxic
condit
regimen
increas
donor
chimer
may
improv
neurolog
outcom
disclosur
noth
declar
tandem
sct
pediatr
solid
tumor
brain
tumor
advantag
term
ef
singl
proceduresingl
center
experi
germcel
tumour
gct
ewe
sarcoma
es
nefroblastoma
patient
divid
group
accord
number
procedur
groupsingl
sct
procedur
groupmultipl
procedur
regimen
use
stem
cell
mobilis
topoci
nbl
epitax
gct
follow
condit
regimen
bumel
thiotepaci
pt
nbl
thiotax
ice
pt
gct
patient
receiv
antibiot
antivir
antifung
prophylaxi
parenter
nutrit
support
treatment
patient
receiv
consolid
treatment
follow
monthli
first
year
yearli
patient
evalu
residu
diseas
imag
test
parent
sign
inform
consent
form
result
perform
sct
procedur
patient
nbl
es
gct
nefroblastoma
studi
patient
nbl
gct
consid
group
pt
group
patient
diagnos
stage
treat
accord
intern
protocol
sex
ratio
age
distribut
pt
pt
pt
peripher
stem
cell
pbsc
mobilis
difficult
patient
multipl
cours
found
differ
period
engraft
follow
procedur
hospit
support
measur
increas
procedur
day
patient
multipl
cours
chemotherapi
multipl
hospit
increas
infecti
risk
procedur
develop
variou
infecti
complicationsincid
sever
oral
mucos
first
hsct
tandem
hsct
nbl
patient
patient
aliv
ef
receiv
anti
treatment
patientsal
patientsnot
reach
timepoint
mibg
scan
patientsmibg
neg
first
relaps
mo
patient
deceas
due
pulmonari
toxic
gct
patient
patient
aliv
ef
high
valu
afp
level
receiv
metronom
therapi
patient
deceas
due
progress
diseas
sct
patient
one
procedur
die
due
progress
diseas
conclus
studi
tandem
hsct
children
solid
tumour
lead
increas
surviv
rate
least
first
month
sct
patient
progress
relapsedrefractori
diseas
refer
depart
multipl
procedur
requir
higher
number
cell
hard
achiev
patient
multipl
cours
radiotherapi
new
approach
consid
diseas
especi
high
risk
group
disclosur
noth
declar
background
antimicrobi
prophylaxi
prolong
neutropenia
occur
preengraft
period
common
practic
allogen
hsct
recipi
data
effect
gener
case
seri
random
clinic
trial
especi
children
method
clinic
record
allohsct
perform
januari
st
novemb
th
hsctunit
istituto
ggaslini
genoaitali
retrospect
review
collect
data
underli
diseas
type
donor
antibiot
prophylaxi
administr
type
develop
fever
pathogen
isol
blood
cultur
preengraft
neutropenia
antibiot
prophylaxi
usual
start
togeth
condit
regimen
categor
standard
amoxicillinclavulan
ampicillinsulbactam
tailor
base
previou
bacteri
isol
colon
result
allohsct
perform
pediatr
patient
male
median
age
hsct
year
iqr
rang
hsct
perform
altern
donor
ad
patient
rel
donor
rd
haploident
donor
tabl
show
preengraft
febril
neutropenia
episod
accord
type
antibiot
prophylaxi
hsct
receiv
standard
prophylaxi
tailor
one
receiv
prophylaxi
fever
occur
episod
patient
receiv
standard
prophylaxi
treat
tailor
prophylaxi
group
without
prophylaxi
patient
receiv
prophylaxi
develop
feverin
patient
febril
episod
diagnos
bloodstream
infect
staphylococcu
aureu
con
enterococcu
spp
enterobacteriacea
pseudomona
aeruginosa
nonfer
gram
neg
fungi
conclus
occurr
fever
patient
receiv
antibiot
prophylaxi
suggest
could
effect
prevent
fever
relat
neutropenia
allohsct
person
prophylaxi
could
possibl
path
follow
patient
disclosur
method
total
patient
leukemia
neuroblastoma
includ
studi
patient
mother
sign
inform
consent
particip
studi
six
studi
particip
boy
girl
age
year
control
group
consist
healthi
preschool
children
group
children
age
year
boy
girl
result
game
role
doctor
play
child
one
child
declin
imperson
patient
doctor
younger
children
mostli
agre
patient
toy
propos
psychologist
one
child
child
mother
medic
psychologist
game
last
minut
patient
prefer
use
real
medic
consum
instrument
syring
adhes
tape
wing
infus
set
rare
pill
often
syring
adhes
tape
chosen
known
mother
among
medic
manipul
unpleas
children
inject
chang
implant
cathet
dress
also
healthi
preschool
children
prefer
use
real
medic
instrument
toy
one
group
often
use
syring
wing
infus
set
adhes
tape
gauz
pill
group
often
chose
syring
gauz
among
medic
instrument
group
often
chose
phonendoscop
thermometeron
patient
refus
caus
pain
toy
patient
children
sympath
toy
patient
stroke
inject
dress
locat
site
use
sooth
term
wait
littl
go
right
wish
prompt
recoveri
hug
patient
one
child
angri
patient
wish
get
hurt
first
preschool
group
children
mostli
scold
toy
patient
guilti
get
sick
second
group
children
mostli
compassion
encourag
toy
patient
tell
procedur
need
get
healthi
children
schoolmast
know
first
group
children
receiv
vaccin
week
test
children
second
group
inject
overal
attitud
toward
toy
patient
mild
second
group
conclus
play
children
mostli
use
medic
devic
caus
discomfort
andor
pain
manipul
item
children
illustr
impress
medic
procedur
unpleas
children
may
express
neg
emot
direct
toward
medic
manipul
via
play
action
neg
reaction
may
suppress
differ
way
parent
medic
staff
intens
child
traumat
experi
attitud
nearbi
adult
may
influenc
child
attitud
toward
patient
mother
wish
child
toler
medic
procedur
eas
exce
real
capabl
small
child
disclosur
noth
declar
allogen
stem
cell
transplant
patient
mucopolysaccharidosi
type
iiia
sanfilippo
case
seri
method
allogen
sct
perform
age
year
respect
three
patient
receiv
intrathec
enzym
replac
therapi
within
clinic
trial
set
prior
hsct
condit
regimen
consist
treosulfan
fludarabin
thiotepa
thymoglobulin
gvhdprophylaxi
carri
csa
mtx
two
patient
csa
mmf
one
patient
stem
cell
sourc
bone
marrow
two
patient
peripher
blood
stem
cell
one
patient
result
condit
regimen
well
toler
three
patient
success
engraft
two
three
patient
uncompl
cours
without
occurr
acut
chronic
graftversushostdiseas
gvhd
last
followup
month
hsct
patient
good
condit
show
constant
progress
psychomotor
develop
third
patient
experienc
sever
steroid
refractori
acut
gvhd
intestin
stage
skin
stage
resolv
intens
immunosuppress
cyclosporin
mycophenol
ruxolitinib
around
day
hsct
patient
show
clinic
biochem
sign
transplantassoci
microangiopathi
tma
cerebr
seizur
acut
renal
failur
cerebr
mri
show
progress
cerebr
atrophi
leukoencephalopathi
also
consist
progress
mp
iiia
last
followup
month
hsct
patient
recov
tma
stabl
clinic
condit
conclus
consider
small
case
number
short
followup
period
cohort
allogen
hsct
might
consid
salvag
therapi
patient
mp
iiia
therapeut
option
unavail
children
otherwis
unfavour
prognosi
howev
earli
psychoneurolog
cours
transplant
seem
promis
compar
literatur
hsct
could
becom
treatment
option
rare
diseas
disclosur
noth
declar
method
identif
underli
molecular
mechan
lead
increas
sensibl
rm
cell
activ
statu
differ
nfkb
signal
pathway
analyz
use
western
blot
analysi
quantit
real
time
pcr
qpcr
flow
cytometri
use
analyz
surfac
express
death
receptor
either
sm
treat
untreat
rm
cell
overal
effect
cell
death
induct
measur
pihoechst
stain
use
fluoresc
microscop
result
treatment
sm
led
suspect
degrad
iap
follow
activ
canon
signal
pathway
indic
phosphoryl
noncanon
signal
pathway
indic
accumul
nik
degrad
determin
select
target
gene
transcript
reveal
upregul
inhibitor
nik
later
time
point
death
receptor
analysi
gene
transcript
also
led
find
neither
upnor
downregul
evalu
involv
sm
induc
sensit
toward
nk
cellmedi
kill
surfac
express
death
receptor
analyz
treatment
sm
led
induc
transcript
also
increas
surfac
present
subsequ
ligat
either
wttrail
specif
agonist
antibodi
result
signific
increas
cell
death
induct
aforement
analysi
gene
transcript
hint
toward
bimod
feedback
mechan
regul
canon
noncanon
signal
pathway
one
side
canon
pathway
neg
regul
induc
transcript
inhibitor
side
induc
transcript
nik
relb
point
toward
posit
feedback
loop
noncanon
pathway
one
mechan
increas
rm
cell
sensit
might
induc
transcript
surfac
present
death
receptor
involv
trail
receptor
valid
cytotox
data
illustr
sm
mediat
sensit
toward
trail
induc
cell
death
induct
mode
cell
death
fit
previou
research
trail
transcript
could
induc
nk
cell
sm
treatment
graphic
abstract
show
transcript
upregul
target
gene
lead
put
bimod
nfkb
regul
increas
surfac
present
treatment
smac
mimet
aim
investig
outcom
ucb
transplant
pediatr
patient
malign
non
malign
diseas
method
data
patient
underw
first
allogen
bone
marrow
transplant
ucb
retrospect
analyz
eighteen
malign
diseas
md
complet
hematolog
respons
non
malign
diseas
nmd
scid
chronic
granulomat
diseas
sever
aplast
anemia
skostmann
osteopetrosi
amegakaryocyt
thrombocytopenia
major
patient
male
md
nmd
well
respect
median
age
year
rang
year
year
rang
year
respect
result
patient
one
receiv
ucb
unit
hla
compat
antigenallel
level
least
patient
md
condit
regimen
myeloabl
tbi
gy
given
gvhd
prophylaxi
consist
cyclosporin
atg
given
patient
pretransplant
median
valu
nucleat
cell
md
kg
rang
kg
nmd
kg
rang
kg
neutrophil
platelet
engraft
achiev
patient
md
respect
median
time
day
rang
day
rang
patient
nmd
neutrophil
platelet
engraft
achiev
median
day
engraft
day
rang
day
rang
respect
acut
gvhd
grade
present
patient
md
nmd
although
none
cgvhd
incid
viral
infect
case
patient
md
case
patient
nmd
diseas
relaps
occur
patient
md
median
time
year
follow
overal
surviv
os
event
free
surviv
ef
children
md
respect
nmd
os
ef
treatment
relat
mortal
md
nmd
among
patient
md
still
aliv
rest
die
relaps
n
viral
infect
n
septicemia
n
agvhd
n
among
patient
nmd
aliv
rest
die
viral
infect
n
septicemia
multipl
organ
failur
median
time
hospit
patient
md
day
rang
whilst
nmd
day
rang
conclus
transplant
unrel
ucb
unit
combin
high
trm
children
nmd
higher
probabl
relaps
md
disclosur
noth
declar
serum
level
cysteinyldopa
associ
stem
cell
transplant
relat
complic
yukayo
terashita
mamoru
honda
minako
sugiyama
yuko
cho
akihiro
iguchi
hokkaido
univers
hospit
pediatr
sapporo
japan
background
diffus
hyperpigment
common
patient
receiv
chemotherapi
stem
cell
transplant
sct
howev
report
relationship
skin
reaction
pigment
complic
pigment
skin
thought
result
melanin
stagnat
dermic
layer
due
increas
synthesi
melanin
destruct
basement
membran
due
inflamm
induc
chemoradiotherapi
melanin
pigment
classifi
two
type
brown
black
eumelanin
yellow
reddishbrown
pheomelanin
cysteinyldopa
precursor
pheomelanin
serum
level
use
specif
biochem
marker
malign
melanoma
examin
serial
cours
sct
determin
associ
sct
relat
complic
visual
evalu
skin
color
difficult
report
sct
relat
biomark
method
prospect
analyz
male
femal
patient
receiv
sct
may
march
hokkaido
univers
hospit
median
age
transplant
patient
year
rang
indic
sct
acut
myelogen
leukemia
patient
acut
lymphoblast
leukemia
patient
diseas
patient
juvenil
myelomonocyt
leukemia
malign
solid
tumor
immunodefici
anaplast
anemia
diamond
blackfan
anemia
patient
receiv
allogen
sct
receiv
autolog
sct
myeloabl
condit
mac
use
patient
reduc
intens
condit
ric
use
patient
sera
obtain
patient
condit
therapi
day
blood
sampl
centrifug
rpm
min
store
use
also
examin
sct
relat
complic
graftversushost
diseas
gvhd
viral
infect
preengraft
syndrom
pe
statist
analys
complet
use
mannwhitney
u
test
unpair
sampl
kruskalw
test
three
sampl
test
perform
level
signific
result
averag
valu
reach
two
peak
nmoll
nmoll
regardless
stem
cell
sourc
intens
condit
patient
found
level
associ
viral
reactiv
associ
pe
associ
malign
diseas
similarli
patient
receiv
allogen
sct
level
associ
viral
reactiv
associ
pe
day
associ
malign
diseas
addit
level
associ
gvhd
skin
peak
level
associ
acut
gvhd
conclus
found
biomark
sctrelat
complic
aut
gvhd
presum
product
pheomelanin
could
induc
inflammatori
procedur
sct
disclosur
noth
declar
hsct
children
bone
marrow
failur
outcom
singl
singapor
centr
prasad
iyer
michaela
seng
vijayakumari
k
ah
moy
tan
mei
yoke
chan
rajat
bhattacharyya
kk
women
children
hospit
paediatr
haematologyoncolog
singapor
singapor
background
children
present
pancytopenia
often
present
challeng
paediatr
haematologist
underli
diagnosi
hard
establish
mani
inherit
bone
marrow
failur
syndrom
ibmf
present
protean
manifest
larg
major
patient
bone
marrow
failur
often
diagnos
idiopath
sever
aplast
anaemia
saa
despit
extens
test
report
experi
hsct
patient
treat
primari
acquir
bone
marrow
failur
method
review
case
note
children
underw
hsct
bone
marrow
failur
centr
result
total
fifteen
patient
underw
eighteen
stem
cell
transplant
centr
three
patient
diagnos
fanconi
anaemia
one
hoyeraalhreidarsson
syndrom
one
paroxysm
nocturn
haemoglobinuria
remain
ten
children
idiopath
saa
eight
children
match
sibl
donor
transplant
match
relat
donor
match
unrel
donor
umbil
cord
blood
transplant
remaind
haploident
transplant
four
haploident
transplant
tcell
deplet
one
tcell
replet
one
child
fanconi
anaemia
primari
graft
reject
cord
blood
transplant
success
rescu
haploident
transplant
one
child
saa
primari
graft
reject
twice
tcell
deplet
graft
rescu
altern
haploident
donor
tcell
replet
graft
two
patient
die
one
fatal
fungal
infect
ten
month
transplant
die
due
sever
influenza
pneumon
three
half
year
bmt
conclus
haematopoiet
stem
cell
transplant
outcom
centr
compar
lead
centr
world
understand
underli
condit
present
bone
marrow
failur
improv
approach
way
treat
bone
marrow
failur
syndrom
clinic
trial
registri
applic
disclosur
noth
declar
method
retrospect
studi
perform
children
treat
hsct
receiv
po
flu
earli
neutropen
period
engraft
januari
decemb
siriraj
hospit
thailand
efficaci
safeti
toler
po
compar
flu
result
hsct
recipi
allohsct
autohsct
mean
age
year
patient
thalassemia
follow
hematolog
malign
solid
tumor
seventeen
case
receiv
po
flu
respect
patient
po
group
allohsct
wherea
flu
group
allohsct
po
group
case
diagnos
suspect
ifi
case
probabl
ifi
total
case
flu
group
case
diagnos
suspect
ifi
case
probabl
ifi
total
case
compar
group
statist
signific
possibl
proven
ifi
group
flu
group
patient
receiv
empir
antifung
treatment
po
group
statist
signific
group
similar
rate
elev
liver
function
test
earli
discontinu
antifung
prophylaxi
intoler
found
group
patient
achiev
po
target
trough
level
mgl
day
treatment
start
dose
mgkg
three
time
day
conclus
po
flu
compar
effect
safeti
toler
ifi
prophylaxi
neutropen
children
treat
hsct
defin
dose
recommend
po
set
requir
larger
studi
disclosur
background
sever
congenit
neutropenia
scn
typic
character
anc
matur
arrest
bone
marrow
myeloid
precursor
promyelocytemyelocyt
stage
suscept
lethal
pyogen
bacteri
fungal
infect
scn
rare
group
disord
result
intrins
defect
myeloid
cell
prolifer
matur
caus
mutat
sever
gene
elan
among
common
one
almost
patient
refractori
gcsf
definit
cur
approach
patient
allogen
hsct
current
absolut
indic
hsct
failur
respond
gcsf
treatment
develop
mdsleukemia
patient
scn
present
result
children
scn
receiv
allogen
hsct
method
retrospect
assess
allogen
hsct
children
sever
congenit
neutropenia
patient
receiv
busulphan
bu
base
myeloabl
condit
regimen
busulphan
use
accord
weight
adjust
dose
addit
patient
receiv
fludarabin
five
day
cyclophosphamid
mgkg
day
atg
mgkg
day
cyclosporina
mtx
use
graft
versu
host
diseas
gvhd
prophylaxi
donor
chimer
evalu
either
bone
marrow
peripher
blood
day
result
median
transplant
age
patient
month
rang
month
six
male
two
donor
match
sibl
unrel
two
ag
ag
mismatch
stem
cell
sourc
bone
marrow
patient
peripher
blood
cord
blood
patient
patient
engraft
median
time
neutrophil
platelet
engrat
day
day
respect
graft
reject
experienc
patient
one
receiv
unrel
cord
blood
patient
aliv
eight
full
donor
chimer
without
complic
infect
gvhd
median
month
rang
month
follow
probabl
diseas
free
overal
surviv
found
respect
conclus
conclud
hsct
use
treatment
scn
patient
especi
unrespons
gcsf
treatment
high
risk
leukem
transform
howev
larger
number
scn
patient
longer
followup
necessari
identifi
appropri
condit
regimen
longterm
prognosi
disclosur
noth
declar
background
prolong
thrombocytopenia
pt
secondari
failur
platelet
recoveri
sfpr
lifethreaten
complic
occur
respect
patient
follow
allogen
hematopoiet
stem
cell
transplant
allohsct
manag
strategi
includ
use
growth
factor
stem
cell
boost
mesenchym
stem
cell
msc
transfus
second
allohsct
effect
possibl
patient
eltrombopag
oral
nonpeptid
thrombopoietin
receptor
agonist
lead
signal
transduct
result
promot
prolifer
differenti
megakaryocyt
recent
studi
show
also
promot
haematopoiesi
along
three
lineag
method
describ
experi
paediatr
patient
poor
graft
function
secondari
failur
platelet
recoveri
allogen
stem
cell
transplant
treat
eltrombopag
result
patient
characterist
detail
tabl
patient
receiv
allohst
median
dose
cell
infus
neutrophil
engraft
occur
day
platelet
day
patient
hypoplast
bone
marrow
complet
chimer
median
durat
transplant
spcf
diagnosi
month
one
patient
receiv
stem
cell
boost
prior
eltrombopag
without
respons
time
onset
spgfsfpr
diagnosi
initi
eltrombopag
day
eltrombopag
start
dose
requir
increas
dose
case
median
dose
mgd
overal
respons
rate
two
patient
achiev
complet
respons
cr
defin
platelet
patient
alreadi
got
neutrophil
without
gcsf
time
eltrombopag
initi
achiev
cr
day
treatment
given
median
day
discontinu
day
respect
two
respond
patient
patient
maintain
stabl
blood
count
discontinu
treatment
nonrespond
patient
stop
treatment
reason
relat
eltrombopag
patient
rescu
cell
boost
good
respons
two
patient
treatment
voriconazol
fungal
infect
develop
hyperbilirubinemia
grade
toxic
relat
eltrombopag
conclus
experi
accord
recent
publish
studi
eltrombopag
safe
efficaci
drug
treatment
secondari
failur
platelet
recoveri
posthsct
may
use
success
children
sometim
higher
dose
may
consid
respons
achiev
prospect
trial
need
increas
level
evid
identifi
predictor
respons
disclosur
noth
declar
slow
clearanc
busulfan
child
infant
leukemia
background
busulfan
drug
high
interindividu
variabl
dose
exposit
therefor
recommend
perform
therapeut
drug
monitor
tdm
context
myeloabl
condit
especi
children
method
report
old
boy
kg
cm
caucasian
decent
born
nonconsanguin
parent
mllrearrang
problymphoblast
leukemia
diagnosi
establish
one
month
birth
peripher
blood
csf
tap
show
cn
involv
primari
chemotherapi
commenc
accord
protocol
howev
mrd
remain
posit
two
month
treatment
lead
indic
allogen
stem
cell
transplant
protocol
opt
condit
regimen
compris
fludarabin
mgkg
day
busulfan
thiotepa
mgkg
institut
busulfan
appli
daili
target
auc
h
mgl
high
risk
situat
accord
bodi
weight
busulfan
given
mg
kg
threehour
infus
first
day
busulfan
concentr
plasma
measur
ga
chromatographymass
spectrometri
gcm
auc
calcul
use
bayesian
curv
fit
result
exact
busulfan
quantif
possibl
first
dose
due
technic
reason
level
estim
high
decid
reduc
second
dose
busulfan
result
high
auc
h
mgl
second
dose
busulfan
discontinu
two
day
calcul
patient
alreadi
receiv
busulfan
cumul
auc
h
mgml
trough
level
first
second
dose
respect
patient
show
slow
clearanc
lhsqm
volum
distribut
usual
rang
lkg
bilirubin
liver
transaminas
normal
rang
time
condit
albumin
quick
decreas
day
transplant
patient
develop
clinic
und
biochem
sign
venoocclus
diseas
vod
vod
symptom
complet
resolv
therapi
defibrotid
leukocyt
engraft
establish
day
unfortun
patient
suffer
earli
relaps
leukemia
day
attempt
induc
second
remiss
blinatumomab
fail
patient
current
palli
chemotherapi
conclus
busulfan
tdm
import
especi
infant
receiv
myeloabl
dose
busulfan
prevent
underor
overexposur
evid
high
busulfan
trough
level
contribut
develop
vod
antileukem
activ
busulfan
cn
permeabl
make
valuabl
drug
high
risk
patient
childhood
leukemia
larger
patient
cohort
need
assess
exposur
depend
risk
toxic
versu
relaps
infant
toddler
disclosur
noth
declar
blood
ucb
obtain
deliveri
three
children
receiv
diagnosi
cerebr
palsi
method
immunophenotyp
ucb
leukocyt
fraction
perform
use
multicolor
flow
cytometri
procedur
perform
accord
protocol
shatorj
colleagu
briefli
ucb
sampl
label
specif
antibodi
incub
dark
minut
afterward
sampl
treat
bd
fac
lyse
solut
minut
preserv
leukocyt
fraction
cell
wash
use
pb
roch
centrifug
twice
rpm
minut
result
analyz
use
facsdiva
softwar
becton
dickinson
result
found
increas
white
blood
cell
wbc
count
lymphocyt
count
ratio
ucb
sampl
one
patient
low
nk
cell
count
percentag
anoth
low
bcell
count
percentag
one
sampl
display
high
th
cell
count
percentag
within
limit
refer
valu
conclus
detect
elev
wbc
lymphocyt
count
ucb
sampl
despit
lack
intrauterin
infect
symptom
mani
author
describ
pathogenesi
hypoxicischem
encephalopathi
briefli
acut
hypoxiaischemia
insult
activ
rest
microglia
show
macrophagelik
activ
lead
breakdown
bloodbrain
barrier
infiltr
peripher
leukocyt
brain
exposur
exacerb
inflamm
role
system
inflamm
evalu
anim
model
known
system
inflamm
play
role
traumat
brain
injuri
tbi
independ
risk
factor
poor
outcom
isol
tbi
patient
hand
microglia
inhibit
inflamm
protect
neuron
secondari
damag
death
howev
antiinflammatori
mechan
neonat
immatur
expos
extrem
intens
inflamm
therefor
antiinflammatori
agent
includ
stem
cell
may
benefici
patient
disclosur
three
four
author
employe
polish
stem
cell
bank
warsaw
poland
refer
background
hypothesi
earli
natur
killer
cell
infus
nki
follow
haploident
stem
cell
transplant
haplosct
reduc
relaps
earli
posttranspl
period
conduct
pilot
studi
evalu
safeti
feasibl
nki
follow
haplosct
children
recurr
neuroblastoma
fail
previou
tandem
highdos
chemotherapi
autolog
sct
method
use
highdos
imetaiodo
benzylguanidin
cyclophosphamidefludarabineantithymocyt
globulin
regimen
condit
infus
kg
exvivo
expand
nk
cell
deriv
haploident
parent
donor
day
posttranspl
result
seven
children
receiv
total
nki
nkirel
acut
toxic
fever
n
follow
chill
n
hypertens
n
toxic
toler
grade
acut
gvhd
chronic
gvhd
develop
two
five
patient
respect
higher
amount
nk
cell
popul
detect
peripher
blood
day
posttranspl
compar
refer
cohort
cytomegaloviru
bk
viru
reactiv
occur
patient
epsteinbarr
viru
six
patient
six
patient
die
relapseprogress
n
treatmentrel
mortal
n
one
patient
remain
aliv
conclus
nki
follow
haplosct
rel
safe
feasibl
patient
recurr
neuroblastoma
studi
enhanc
graftversustumor
effect
without
increas
gvhd
need
disclosur
noth
declar
regen
medicin
repeat
administr
gcsf
use
stem
cell
mobil
protocol
could
induc
improv
cognit
function
children
cerebr
palsi
phase
ii
random
placebocontrol
studi
background
perform
phase
ii
random
placebocontrol
clinic
studi
reveal
safeti
feasibl
repeat
granulocyt
colonystimul
factor
gcsf
administr
improv
cognit
function
children
cerebr
palsi
method
fortyfour
children
nonsever
type
cerebr
palsi
enrol
age
year
old
gcsf
administ
day
subcutan
everi
month
compar
cognit
function
magnet
reson
imag
mri
find
follow
tool
month
treatment
zoo
locat
pictur
memori
work
memori
index
wmi
wechsler
preschool
primari
scale
intellig
wpssi
recept
express
vocabulari
test
revt
visual
motor
integr
vmi
visual
percept
vp
test
mobil
stem
cell
count
cytokin
level
measur
gcsf
administr
day
everi
month
result
signific
find
demographi
notic
gcsf
g
placebo
p
group
seriou
advers
event
observ
whole
studi
period
nonsever
advers
event
urticaria
itch
sens
bone
pain
headach
fever
stomat
toler
parent
felt
clinic
improv
cognit
case
ggroup
case
pgroup
languag
case
ggroup
case
pgroup
zoo
locat
test
find
signific
score
express
age
equival
differ
gand
pgroup
howev
pictur
memori
test
signific
improv
age
equival
month
month
studi
period
ggroup
compar
month
pgroup
revt
signific
improv
month
age
equival
express
test
ggroup
compar
month
pgroup
signific
find
note
recept
test
vmi
test
show
increas
tendenc
month
age
equival
ggroup
compar
pgroup
increment
cell
count
peripher
blood
signific
ggroup
compar
pgroup
chang
level
interleukin
il
vascular
endotheli
growth
factor
vegf
well
gcsf
note
ggroup
also
observ
correl
cognit
function
test
white
matter
connectom
sever
network
use
functionallydefin
white
matter
atlas
conclus
repeat
administr
gcsf
use
stem
cell
mobil
protocol
safe
feasibl
improv
languag
cognit
function
children
cerebr
palsi
studi
cellular
paracrin
effect
gcsf
andor
mobil
peripher
blood
stem
cell
would
need
background
highdos
chemotherapi
hdct
autolog
hematopoiet
stem
cell
transplant
autohsct
integr
part
multimod
therapi
highrisk
neuroblastoma
hr
nb
still
subgroup
result
extrem
poor
patient
allograft
allohsct
may
offer
hope
method
summar
experi
consecut
hr
nb
patient
receiv
therapi
pediatr
transplant
depart
median
age
year
month
year
total
autohsct
allohsct
perform
autohsct
recipi
character
one
sever
highrisk
featur
age
month
diseas
onset
primari
dissemin
diseas
unfavor
biolog
variant
poor
st
line
therapi
respons
system
relaps
patient
receiv
bumel
hdct
younger
patient
oral
busulfan
replac
busilvex
primari
resist
case
regimen
use
total
patient
chemosensit
relaps
resist
relaps
poor
mobil
local
advanc
resist
tumor
receiv
allohsct
haploident
donor
fludarabinebas
ric
case
transplant
modifi
via
immunomagnet
posit
neg
select
patient
receiv
posttranspl
cyclophosphamid
postci
base
gvhd
prophylaxi
gvhd
prophylaxi
also
consist
calceneurin
inhibitor
sirolimu
thirteen
allohsct
recipi
receiv
posttranspl
immunoadopt
target
therapi
result
os
ef
autohsct
recipi
accordingli
one
patient
engraft
median
time
day
bumel
regimen
character
accept
toxic
common
toxic
oral
mucos
infecti
complic
vodso
incid
four
patient
die
due
infect
cn
hemorrhag
secondari
leukemia
accord
multivari
analysi
import
prognost
factor
respons
st
line
therapi
post
autohsct
mibg
scan
result
prognosi
initi
resist
patient
good
respons
nd
rd
line
therapi
still
poor
patient
relaps
median
ef
month
patient
receiv
second
autohsct
relaps
die
due
diseas
progress
median
follow
month
allohsct
recipi
aliv
sign
diseas
progress
longterm
respond
receiv
posttranspl
therapi
one
patient
die
due
transplant
complic
death
caus
diseas
progress
obviou
differ
outcom
postci
base
transplant
modificationbas
transplant
agvhd
often
develop
modifi
transplant
recipi
patient
vs
postci
group
case
gr
iiiiv
patient
postci
group
grade
iiiiv
hemorrhag
cystiti
median
time
engraft
longer
ptcm
group
compar
transplant
modif
group
vs
accordingli
conclus
singl
hsct
autohsct
golden
standard
hr
nb
patient
relaps
rate
still
high
prognosi
relapsedrefractori
patient
dismal
allograft
limit
effect
case
posttranspl
therapi
potenti
improv
disclosur
noth
declar
abstract
alreadi
publish
venoocclus
liver
diseas
vod
frequent
well
treatabl
earli
defibrotid
administr
children
neuroblastoma
receiv
highdos
busulfan
melphalan
background
use
highdos
intraven
busulfan
melphalan
bumel
prior
autolog
stem
cell
transplant
sct
children
highrisk
neuroblastoma
seem
decreas
toxic
myeloabl
regimen
except
vod
multicent
retrospect
studi
aim
assess
outcom
bumelassoci
vod
earli
defibrotid
treatment
intervent
method
retrospect
analyz
children
highrisk
neuroblastoma
underw
autolog
sct
iv
bumel
regimen
slovakia
pragu
czech
republ
period
busulfan
administ
hour
schedul
therapeut
drug
level
monitor
patient
vod
patient
except
one
treat
defibrotid
start
standard
dose
mgkgday
given
dose
per
day
patient
treat
support
therapi
ursodeoxychol
acid
use
prophylaxi
patient
vod
establish
use
modifi
seattl
clinic
criteria
corbacioglu
lancet
result
incid
vod
patient
treat
intraven
busulfan
melphalan
signific
differ
busulfan
total
dosekg
patient
mgkg
without
mgkg
vod
manifest
vod
develop
median
day
sct
rang
day
anicter
form
vod
document
although
patient
vod
present
increas
bilirubin
patient
vod
develop
ascit
patient
requir
ascit
drainag
vod
patient
receiv
renal
replac
therapi
one
need
mechan
ventil
importantli
success
treat
vod
patient
relaps
progress
neuroblastoma
caus
death
vod
patient
die
conclus
despit
target
busulfan
level
decreas
toxic
regimen
vod
common
observ
vod
incid
exactli
rang
siopen
hr
multicent
studi
ladenstein
earli
recognit
earli
treatment
defibrotid
seem
effect
vod
associ
bumel
regimen
none
patient
die
due
vod
disclosur
noth
declar
result
highdos
chemotherapi
hdct
autolog
hematopoiet
stem
cell
transplant
autohsct
treatment
ewe
sarcoma
famili
tumor
esft
background
current
doseintens
treatment
protocol
allow
achiev
surviv
local
esft
patient
longterm
surviv
highrisk
case
still
unsatisfactori
although
consider
bodi
data
highdos
consolid
real
effect
optim
indic
option
still
complet
clarifi
therefor
larg
prospect
cohort
analysi
may
still
yield
use
data
method
whole
cohort
includ
consecut
highrisk
esft
patient
median
age
rang
year
receiv
hdct
autohsct
obtain
st
nd
cr
pr
stabl
diseas
highrisk
featur
includ
lung
bone
bone
marrow
involv
inadequ
local
control
primari
axial
tumor
larg
lesion
volum
poor
treatment
respons
chemosensit
relaps
patient
sever
risk
factor
dissemin
diseas
patient
also
evalu
accord
prognost
score
rladenstein
et
al
highdos
busulfanmelphalan
follow
autolog
stemcel
transplant
hdtsct
use
result
median
observ
time
rang
month
overal
os
eventfre
ef
surviv
accordingli
import
outcom
predictor
inadequ
local
control
chemoresist
case
primari
tumor
volum
ml
one
bone
metastat
site
bone
marrow
involv
addit
lung
metastas
accord
prognost
risk
score
dissemin
diseas
esft
patient
identifi
three
group
os
rate
score
patient
score
patient
score
patient
p
conclus
bumel
hdct
autohsct
may
still
feasibl
option
accept
toxic
chemosensit
patient
inadequ
local
control
primarili
dissemin
case
ineffect
primari
resist
highrisk
metastat
patient
disclosur
noth
declar
efficaci
tandem
highdos
chemotherapi
autolog
hematopoiet
stem
cell
transplant
treatment
infant
embryon
brain
tumor
day
rang
second
autohsct
day
rang
twoyear
overal
surviv
os
diseas
free
surviv
df
df
significantli
better
among
patient
mb
pnet
compar
children
etmr
pb
atrt
df
patient
receiv
tandem
autohsct
compar
infant
receiv
one
autohsct
complic
grade
accord
common
toxic
criteria
observ
case
conclus
employ
tandem
hdct
autohsct
primari
infant
embryon
brain
tumor
may
feasibl
option
patient
induct
treatment
condit
regimen
accept
toxic
patient
tandem
hdct
autohsct
better
os
compar
singl
hdct
patient
mb
pnet
better
prognosi
os
respect
compar
embryon
tumor
disclosur
noth
declar
background
metastat
extra
ocular
retinoblastoma
carri
poor
prognosi
therapeut
intensif
highdos
marrowabl
chemotherapi
autolog
hsct
explor
role
yet
clear
studi
aim
evalu
surviv
outcom
patient
extraocular
retinoblastoma
post
autolog
stem
cell
transplant
treat
singl
center
method
retrospect
studi
includ
patient
metastat
extraocular
retinoblastoma
stage
underw
autolog
hsct
children
cancer
hospit
egypt
cche
novemb
juli
treatment
protocol
adopt
cog
protocol
patient
receiv
cycl
induct
chemotherapi
follow
consolid
myloabl
condit
cem
melphalan
carboplatin
stem
cell
rescu
patient
data
includ
initi
diseas
characterist
transplant
data
surviv
outcom
collect
analyz
result
total
case
includ
median
age
year
male
femal
ratio
nine
patient
initi
present
extra
ocular
diseas
patient
present
intra
ocular
diseas
progress
metastat
diseas
accord
cog
stage
extra
ocular
diseas
patient
stage
stage
trilater
diseas
induct
therapi
show
complet
respons
partial
respons
averag
count
kg
median
time
anc
platelet
engraft
day
day
respect
transplant
relat
mortal
posttranspl
radiotherapi
given
patient
median
durat
follow
month
overal
event
free
surviv
rate
whole
patient
respect
conclus
high
dose
chemotherapi
stem
cell
transplant
promis
potenti
cur
option
patient
metastat
extra
ocular
two
primari
gf
occur
without
dsa
patient
develop
primari
pgf
os
pf
nrm
analyz
accord
presenc
dsa
comparison
neg
popul
statist
differ
found
impact
presenc
dsa
risk
develop
gf
pgf
reveal
major
outcom
transplant
analyz
separ
patient
pgf
good
graft
function
ggf
os
pf
ggf
primari
pgf
popul
vs
p
vs
p
vs
respect
conclus
presenc
low
level
dsa
absenc
desensit
nt
correl
risk
develop
gf
pgf
patient
experienc
pgf
wors
outcom
comparison
patient
ggf
disclosur
noth
declar
impact
mismatch
tcell
replet
unrel
donor
allogen
stem
cell
transplant
background
high
resolut
match
donorrecipi
hla
improv
outcom
allogen
stem
cell
transplant
match
hlaa
b
c
dq
mandatori
transplant
centr
identifi
match
unrel
donor
high
resolut
match
ad
last
year
howev
role
match
yet
clearli
defin
method
studi
retrospect
analyz
impact
match
outcom
tcell
replet
allogen
hematopoiet
stem
cell
transplant
cyamtxand
without
atg
gvhd
prophylaxi
patient
hematolog
malign
oslo
univers
hospit
patient
unrel
donor
fulli
match
hlaa
b
c
loci
includ
patientrecipi
pair
also
fulli
match
permiss
nonpermiss
mimatch
one
two
allel
three
group
compar
respect
diagnosi
gender
age
cytomegaloviru
serostatu
condit
regimen
result
cumul
incid
relaps
year
significantli
higher
match
pair
compar
permiss
nonpermiss
mimatch
one
vs
p
respect
relpas
free
surviv
overal
surviv
superior
nonpermiss
permiss
mismatch
group
vs
fulli
match
vs
vs
respect
differ
frequenc
acut
gvhd
grade
iiiv
three
group
found
dp
match
permiss
mismatch
nonpermiss
mismatch
neither
differ
seen
gvhd
grade
iiiiv
vs
vs
respect
final
similar
outcom
three
group
regard
chronic
gvhd
trm
correct
multivari
analysi
dp
match
signific
influenc
mortal
surviv
conclus
result
show
favor
relaps
free
overal
surviv
follow
mud
allotranspl
permiss
nonpermiss
mismatch
donor
compar
fulli
match
like
due
increas
gvleffect
mismatch
group
without
counterbal
increas
acut
gvhd
trm
disclosur
noth
declar
haploident
may
better
choic
femal
genoident
donor
transplant
patient
high
risk
acut
myelogen
leukemia
first
remiss
norbert
gorin
myriam
labopin
didier
blais
goda
choi
gerard
soci
jean
henri
bourhi
fabio
ciceri
emmanuel
polg
arnon
nagler
mohamad
mohti
china
first
affili
hospit
soochow
univers
hematolog
suzhou
china
background
despit
incid
leukemia
increas
age
current
geriatr
popul
poorli
repres
standard
care
concern
older
adult
undergo
hematopoiet
cell
transplant
hct
may
experi
higher
transplantrel
mortal
trm
previou
studi
demonstr
donor
age
vital
older
patient
affect
trm
surviv
accordingli
relev
question
whether
outcom
improv
younger
hlahaploident
offspr
donor
rather
older
hlamatch
sibl
msd
previou
multicent
report
atggcsf
base
protocol
haplo
hct
offspr
donor
correl
lower
trm
higher
leukemia
free
surviv
lf
compar
older
msd
subgroup
analysi
recipi
although
reach
statist
signific
contrari
recent
report
ebmt
cibmtr
ptci
modal
haplo
hct
among
patient
age
year
despit
lower
chronic
graftversushostdiseas
gvhd
graft
failur
trm
overal
mortal
higher
transplant
offspr
compar
msd
although
differ
transplant
platform
group
method
extend
multicent
dataset
match
pair
analysi
perform
outcom
acut
leukemia
patient
year
transplant
receiv
hct
offspr
msd
jan
june
present
multicent
databas
analyz
patient
popul
small
ratio
match
pair
analysi
implement
follow
match
factor
underli
diseas
acut
myeloid
leukemia
acut
lymphoblast
leukemia
diseas
statu
age
sex
patient
year
transplant
blood
group
incompat
sex
donor
result
abl
match
offspr
msd
patient
two
match
group
compar
baselin
characterist
except
donor
age
due
famili
relationship
patient
achiev
myeloid
recoveri
median
time
msd
cohort
offspr
group
platelet
recoveri
rate
group
cumul
incid
grade
iiiv
acut
gvhd
msd
cohort
significantli
lower
offspr
group
vs
incid
chronic
gvhd
msd
cohort
significantli
higher
offspr
group
vs
trm
vs
significantli
lower
offspringhct
compar
msdhct
relaps
incid
compar
vs
result
overal
surviv
vs
lf
vs
figur
significantli
higher
offspringhct
compar
msdhct
multivari
analysi
msdhct
remain
signific
factor
decreas
overal
surviv
hr
increas
trm
p
comparison
offspringhct
conclus
data
favor
young
offspr
older
msd
patient
year
current
analys
confirm
nonhla
donor
characterist
rather
hla
dispar
predominantli
influenc
surviv
older
acut
leukemia
patient
valid
find
requir
prospect
trial
wherein
transplant
platform
close
match
imag
lf
offspringhct
compar
msdhct
vs
disclosur
noth
declar
impact
sibl
donorrecipi
sex
combin
reject
hlamatch
bone
marrow
transplant
sever
thalassemia
foundat
florenc
itali
sankalp
india
foundat
bangalor
india
peopl
tree
hospit
bangalor
india
south
east
asia
institut
thalassemia
jaipur
india
pakistan
institut
medic
scienc
islamabad
pakistan
central
asiri
hospit
colombo
sri
lanka
nawaloka
hospit
colombo
sri
lanka
kokilaben
dhirubhani
ambani
hospit
mumbai
india
background
sever
thalassemia
st
ie
thalassemia
syndrom
inabl
keep
spontan
hemoglobin
gdl
common
indic
bone
marrow
transplant
bmt
children
middl
east
south
east
asia
sex
mismatch
associ
increas
risk
solid
organ
reject
gener
consid
import
transplantassoci
risk
factor
context
fulli
match
sibl
bmt
st
method
total
consecut
sibl
bone
marrow
transplant
carri
januari
april
condit
busulfan
mgkg
oral
adjust
serum
level
cyclophosphamid
mgkg
patient
addit
either
thiotepa
mgkg
patient
antithymocyt
globulin
genzym
mg
kg
freseniu
mgkg
day
patient
fludarabin
mgm
patient
analys
case
receiv
cyclosporin
methotrex
mycophenol
mofetil
gvhdreject
prophylaxi
thiotepa
group
methylprednisolon
mgkgday
also
use
first
day
bmt
lucarelli
protocol
bone
marrow
sourc
hematopoiet
stem
cell
case
atg
group
gcsfprime
twice
daili
day
prior
harvest
patient
consid
low
risk
base
liver
size
cm
costal
margin
age
less
year
median
year
rang
sibl
pair
hlacompat
result
imag
sibl
donorrecipi
sex
combin
lowest
reject
rate
observ
sister
sister
group
case
follow
brother
brother
group
case
sister
brother
group
case
reject
rate
brother
sister
group
case
univari
analysi
signific
differ
p
level
log
rank
test
vs
group
reject
proport
respect
interestingli
patient
reject
persist
pancytopenia
femal
recipi
male
graft
conclus
even
though
sever
prepar
regimen
employ
period
data
suggest
sex
mismatch
among
compat
sibl
consid
relev
variabl
relat
bmt
decisionmak
also
recommend
consid
autolog
back
hematopoiet
stem
cell
collect
storag
sibl
sex
mismatch
transplant
particularli
brother
sister
bmt
samesex
fulli
match
relat
bmt
sever
thalassemia
might
best
scenario
reducedintens
prepar
strategi
aim
maxim
fertil
preserv
might
explor
disclosur
noth
declar
outcom
tcell
replet
hematopoiet
cell
transplant
mismatch
relat
unrel
donor
use
high
dose
posttranspl
cyclophosphamid
base
gvhd
prophylaxi
background
high
dose
posttranspl
cyclophosphamid
ptci
base
gvhd
prophylaxi
overcom
immunolog
barrier
hla
mismatch
donor
transplant
ptci
adopt
mani
center
de
facto
standard
hct
haploident
donor
haplo
hct
use
mismatch
unrel
donor
transplant
mmud
hct
less
well
establish
method
analyz
retrospect
outcom
contemporari
cohort
patient
underw
haplo
hct
mmud
hct
use
ptci
cyclosporin
csa
mycophenol
mofetil
mmf
center
compar
outcom
outcom
cohort
patient
underw
hct
match
unrel
donor
mud
use
atg
base
gvhd
prophylaxi
match
sibl
donor
msd
csa
mmf
patient
donor
consid
match
background
hlaalloantibodi
major
risk
factor
engraft
failur
allogen
hematopoiet
stem
cell
transplant
hsct
particularli
complement
fix
donor
specif
antibodi
shown
associ
earli
engraft
failur
prospect
antibodyscreen
although
current
requir
donor
search
could
permit
earli
identif
high
risk
patient
posit
crossmatch
aim
studi
set
basi
futur
applic
antibodyscreeningbas
definit
accept
mismatch
donor
select
creat
larg
prospect
antibodyscreen
databas
patient
due
receiv
hlamismatch
allogen
hsct
method
patient
diagnos
mdsmp
nhl
mm
cll
cml
anaemia
aplast
anemia
hemoglobinopathi
pnh
hl
prospect
screen
hlaantibodi
whenev
initi
donor
search
indic
complet
match
donor
would
avail
screen
perform
elisa
class
ii
screen
assay
posit
screen
case
test
antigenspecif
antibodi
identif
luminex
sab
accept
mismatch
defin
result
subsequ
consid
donor
search
select
report
frequenc
alloimmun
observ
patient
result
highest
rate
alloimmun
observ
patient
anaemia
diseas
group
overal
follow
mdsmpn
group
overal
lowest
immun
rate
observ
cll
overal
hl
patient
alloimmun
rate
hlaclass
antigen
p
significantli
higher
compar
hlaclass
ii
antigen
overal
hlaclass
immun
rate
rang
hlaclass
ii
immun
rate
rang
tabl
conclus
find
suggest
patient
high
transfus
burden
like
anaemia
mdsmpn
patient
highest
risk
hlaalloimmun
antihla
preval
rate
respect
analysi
followup
data
enabl
us
confirm
whether
prospect
definit
consider
accept
mismatch
donor
select
may
lead
similar
engraft
failur
rate
immun
nonimmun
patient
undergo
hlamismatch
hsct
background
mother
display
persist
fetal
microchimer
fm
prove
suitabl
donor
celldeplet
haploident
stem
cell
transplant
hhsct
children
presum
fetal
cell
leav
imprint
mother
immun
system
posit
affect
recognit
elimin
malign
cell
child
matern
effector
cell
distinct
killer
cell
immunoglobulinlik
receptor
kir
hla
constel
associ
reduc
relaps
rate
hsct
children
also
supposedli
influenc
establish
fm
method
approv
local
irb
obtain
inform
consent
initi
protocol
elucid
factor
influenc
establish
persist
effect
fm
establish
digit
droplet
pcr
ddpcr
protocol
determin
fetal
microchimer
differenti
matern
fetal
cell
biallel
short
insertiondelet
polymorph
use
kir
hlac
genotyp
perform
ssppcr
parent
nk
cell
alloreact
respect
leukem
blast
kir
phenotyp
analyz
flow
cytometri
result
analyz
parent
whose
children
treat
hematolog
diseas
univers
medic
center
hamburgeppendorf
fetal
microchimer
detect
mother
amount
fetal
cell
vari
individu
observ
posit
correl
persist
fm
homoand
heterozyg
mother
along
matern
cen
ab
cen
bb
genotyp
addit
fm
posit
mother
show
higher
surfac
express
respect
receptor
percentag
alloreact
matern
nk
cell
fetal
cell
higher
compar
patern
nk
cell
alloreact
fm
posit
matern
nk
cell
similar
nk
cell
fm
neg
mother
conclus
persist
fm
frequent
mother
carri
least
one
allel
centromer
bx
motif
phenotyp
fm
posit
mother
higher
express
indic
role
receptor
persist
fm
vitro
matern
nk
cell
show
higher
alloreact
compar
patern
nk
cell
differ
alloreact
whether
mother
fm
posit
neg
suggest
mechan
respons
superior
outcom
transplant
fm
posit
mother
disclosur
noth
declar
background
although
signific
improv
convent
therapi
beta
thalassemia
major
hematopoiet
stem
cell
transplant
cur
therapi
relat
donor
prefer
diminish
transplant
risk
lack
ident
relat
donor
ident
unrel
donor
second
best
choic
studi
thalassemia
major
patient
transplant
unrel
donor
mud
compar
thalassem
patient
transplant
rel
donor
mrd
retrospect
method
patient
transplant
june
decemb
medic
park
hospit
pediatr
bone
marrow
transplant
unit
evalu
retrospect
patient
classifi
accord
pesaro
risk
classif
thirti
four
receiv
busulfan
fludarabin
cyclophosphamid
thioteopa
condit
receiv
myeloabl
prepar
regimen
treosulfan
fludarabin
thiotepa
cyclophosphamid
patient
given
atg
cyclosporin
methoterax
gvhd
prophylaxi
patient
compar
term
acut
complic
first
day
engraft
chimer
acut
chronic
gvhd
transplant
result
evalu
ibm
spss
statist
ibm
spss
program
result
total
patient
male
femal
age
year
median
year
evalu
patient
evalu
two
group
mud
n
mrd
n
group
differ
group
given
stem
cell
mud
kg
mrd
kg
neither
signific
differ
differ
pesaro
risk
group
term
develop
acut
chronic
gvhd
decreas
chimer
detect
neutrophil
engraft
time
day
mrd
group
significantli
longer
mud
group
day
p
differ
platelet
engraft
observ
gvhd
ratio
mud
donor
group
mrd
group
statist
signific
differ
found
p
incid
engraft
loss
mud
group
mrd
group
statist
signific
differ
p
rate
decreas
chimer
found
significantli
higher
mrd
group
mud
group
p
surviv
rate
mud
group
mrd
group
diseasefre
surviv
rate
mud
group
mrd
group
diseasefre
surviv
mud
group
significantli
higher
mrd
group
conclus
studi
transplant
relat
complic
success
transplant
mud
mrd
found
similar
promis
mud
transplant
found
lower
decreas
chimer
similar
os
dfss
base
result
conclud
hsct
nonfamili
donor
especi
patient
incompat
chelat
therapi
organ
damag
transplant
unrel
ident
donor
good
choic
although
result
studi
seem
promis
larger
patient
group
prospect
clinic
trial
requir
disclosur
noth
declar
background
use
gcsf
stimul
bone
marrow
bm
donor
benefici
mani
aspect
enhanc
tnc
yield
also
immunomodulatori
effect
donor
cell
function
particularli
invari
natur
killer
inkt
cell
expans
well
apc
analyz
outcom
consecut
patient
receiv
bone
marrow
hlahaploident
donor
stimul
gcsf
prior
harvest
method
time
period
patient
receiv
bone
marrow
donor
stimul
ugkg
bw
gcsf
day
day
bm
collect
four
patient
receiv
myeloabl
buci
condit
one
receiv
tec
ric
condit
receiv
nma
baltimor
condit
patient
receiv
posttransplant
cyclophosphamid
ptci
day
tacrolimu
mmf
start
day
patient
donor
father
mother
sibl
children
result
median
age
year
femal
male
patient
twelv
patient
aml
hodgkin
lymphoma
md
nhl
cml
median
number
infus
tnc
graft
kg
bw
cell
kg
bw
median
follow
day
rang
overal
surviv
median
surviv
month
engraft
establish
patient
primari
reject
patient
die
sepsi
prior
engraft
patient
engraft
patient
secondari
reject
two
transplant
haploident
donor
use
pbsc
sourc
graft
median
time
neutrophil
recoveri
anc
day
median
time
platelet
recoveri
plt
l
day
evalu
patient
cumul
incid
agvhd
iiiv
ci
note
patient
develop
agvhd
one
grade
iii
remain
patient
grade
ii
cumul
incid
cgvhd
requir
treatment
ci
cumul
incid
relaps
ci
trm
ci
conclus
use
gcsf
mobil
bm
graft
hlahaploident
set
ptci
proven
use
us
term
tnc
yield
satisfactori
contribut
adequ
hematolog
recoveri
also
excel
control
acut
chronic
gvhd
patient
develop
agvhd
grade
ii
one
grade
iii
actual
develop
dli
given
decreas
chimer
compar
studi
cours
warrant
prove
benefit
data
contribut
grow
bodi
evid
inde
donor
stem
cell
stimul
gcsf
potenti
power
immunomodulatori
effect
disclosur
noth
disclos
otherrel
donor
reliabl
bank
allogen
hsct
countri
cultur
accept
cousincousin
marriag
twoyear
report
pediatr
center
iran
background
although
optim
donor
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
fullymatch
sibl
cousincousin
consanguin
marriag
countri
extend
chanc
find
match
donor
hsctrecipi
studi
outcom
analysi
transplant
patient
receiv
stem
cell
rel
sibl
otherrel
nonsibl
donor
provid
method
retrospect
crosssect
studi
twoyear
report
patient
receiv
allohsct
otherrel
donor
septemb
septemb
depart
stem
cell
transplant
children
medic
center
tehran
iran
present
patient
follow
st
decemb
result
time
period
patient
underw
hsct
autolog
allogen
center
case
receiv
allohsct
allohsct
recipi
donor
stem
cell
case
otherrel
median
rang
age
hsct
year
major
patient
boy
accord
diseas
class
patient
commonli
involv
nonmalign
hematolog
diseas
patient
figur
sourc
hsc
patient
case
peripher
blood
patient
sourc
bone
marrow
donor
patient
fulli
match
one
patient
receiv
hsc
onelocu
mismatch
donor
hsct
success
patient
achiev
full
chimer
patient
follow
develop
mix
chimer
patient
one
patient
experienc
graft
failur
posthsct
complic
includ
cmv
infect
patient
infect
hemorrhag
cystiti
pre
acut
gvhd
occur
patient
chronic
gvhd
death
occur
case
transplantrel
due
diseas
relaps
due
graft
failur
median
overal
surviv
day
conclus
likelihood
receiv
hsc
hlamatch
otherrel
donor
onethird
children
undergo
allohsct
compar
outcom
sibl
unrel
donor
evidenc
studi
compar
studi
introduc
famili
bank
reliabl
sourc
pediatr
allohsct
countri
cultur
accept
cousincousin
marriag
henc
transplant
physician
parent
consanguin
would
indic
extend
search
potenti
match
donor
among
patient
famili
imag
distribut
patient
accord
diseas
diseas
class
disclosur
noth
declar
abstract
alreadi
publish
updat
hla
frequenc
distribut
portugues
bone
marrow
donor
registri
eduardo
espada
ligeiro
trindad
forjaz
de
lacerda
frequenc
distribut
vari
throughout
countri
allow
analys
molecular
varianc
gener
rel
geograph
accur
graphic
represent
genet
distanc
region
district
conclus
recent
hla
analysi
portugues
bone
marrow
donor
registri
abl
extrapol
highresolut
haplotyp
frequenc
common
lowresolut
haplotyp
correspond
estim
haplotyp
level
lead
optim
use
hope
limit
time
donor
search
allogen
hematopoiet
stem
cell
transplant
disclosur
noth
declar
abstract
alreadi
publish
abstract
alreadi
publish
unmanipul
haploident
donor
transplant
compar
ident
sibl
donor
better
antileukemia
effect
refractoryrelaps
acut
myeloid
leukemia
remiss
statu
background
patient
diagnos
saa
sibl
donor
refractori
immunosupress
candid
hematopoiet
stem
cell
transplant
use
altern
donor
haploident
donor
transplant
report
use
cyclophosphamid
cy
post
stem
cell
infus
immunephrophylaxi
present
studi
object
evalu
overal
surviv
engraft
rate
haploident
stem
cell
transplant
saa
refer
center
method
saa
adult
patient
yo
receiv
hsct
haploident
donor
de
median
age
donor
father
six
mother
five
brother
four
case
stem
cell
sourc
marrow
case
condit
patient
receiv
cy
fludarabin
e
tbi
remain
receiv
drug
radiotherapi
dose
vari
receiv
immunephrophylaxi
post
transplant
cy
cyclosporin
mmf
median
infus
cell
tcn
kg
result
eight
patient
engraft
among
seven
graft
failur
four
receiv
second
haploident
transplant
one
receiv
unrel
donor
transplant
salvag
regimen
two
patient
success
rescu
second
haplo
other
die
infecti
complic
three
year
overal
surviv
death
caus
includ
five
infect
two
lung
hemorrhag
median
surviv
day
patient
acut
graftversushostdiseas
gvhd
one
patient
mild
cgvhd
conclus
haploident
transplant
feasibl
therapi
saa
refractori
immunessupress
overal
surviv
cohort
graft
failur
howev
still
problem
address
set
disclosur
disclosur
stem
cell
mobil
collect
engin
abstract
alreadi
publish
key
perform
qualiti
indic
success
bone
marrow
collect
marco
sampaio
ana
salsela
amado
filipa
bordalo
lope
catarina
pinho
susana
roncon
one
ecc
staphylococcu
spp
present
posit
microbiolog
result
conclus
bm
collect
challeng
strategi
onetim
procedur
manual
operatordepend
techniqu
simultan
difficult
control
final
cellular
content
bm
risk
donor
volum
deplet
bm
collect
feasibl
even
donor
recipi
weight
differ
poorer
perform
may
found
higher
tnc
request
respond
efficaci
request
tnc
fail
accomplish
higher
tnc
valu
must
emphasis
icc
tnc
demand
gener
lower
ecc
decid
appropri
tnc
patient
remain
dare
art
disclosur
noth
declar
impact
ad
plerixafor
mobil
protocol
immun
reconstitut
cell
autolog
hematopoiet
stem
cell
transplant
efrat
luttwak
yael
chava
cohen
odelia
amit
irit
avivi
svetlana
trestman
esti
rom
rinat
eshel
ram
ron
tel
aviv
medic
center
tel
aviv
israel
sackler
faculti
medicin
tel
aviv
univers
tel
aviv
israel
background
multipl
myeloma
remain
incur
diseas
even
era
novel
therapi
front
line
treatment
typic
compris
induct
chemotherapi
cycl
bortezomibbas
regimen
stem
cell
mobil
harvest
peripher
blood
stem
cell
pbsc
apharesi
follow
high
dose
melphalan
hct
brotezomibbas
induct
regimen
demonstr
advers
impact
hematopoiet
cell
harvest
number
qualiti
studi
analyz
impact
time
last
brotezomib
dose
prior
collect
studi
aim
determin
effect
time
last
dose
brotezomib
hematopoiet
cell
collect
collect
yield
method
singl
center
histor
prospect
studi
includ
sequenti
newli
diagnos
patient
myeloma
given
bortezomibbas
induct
therapi
cycl
follow
pbsc
collect
exclud
patient
either
receiv
st
line
vtdpace
lenalidomidecontain
regimen
peripher
blood
cell
measur
day
collect
patient
level
cell
microlit
start
collect
day
lower
level
given
plerixafor
perform
regress
analys
analyz
impact
varieti
precollect
factor
includ
day
last
bortezomib
therapi
collect
yield
result
identifi
patient
fulfil
inclus
criteria
tabl
median
time
last
dose
brotezomib
first
leukapheresi
rang
day
statist
signific
correl
found
day
last
dose
brotezomib
first
collect
cellskg
p
total
collect
cellskg
figur
optim
cutoff
point
indic
roc
curv
day
accord
collect
success
sensit
specif
index
multivari
analysi
includ
factor
affect
collect
yield
age
gender
statu
diseas
collect
prior
radiat
time
last
dose
brotizomib
remain
significantli
associ
total
collect
cellskg
increas
age
femal
gender
prior
radiat
associ
lower
collect
yield
respect
base
develop
model
predict
total
collect
cell
time
day
last
dose
brotezomib
age
femal
prior
radat
conclus
time
last
dose
brotezomib
import
factor
predict
success
collect
washout
period
day
associ
better
collect
yield
result
valid
prospect
studi
age
median
rang
gender
male
prior
radiat
treatment
diseas
statu
collect
disclosur
noth
declar
mobil
plerixafor
poor
mobil
relat
unrel
donor
hpca
case
fail
mobil
gcsf
background
allogen
hpc
transplant
relat
unrel
donor
commonli
use
sourc
peripher
blood
mobil
gcsf
howev
known
donor
poor
mobil
rescu
strategi
third
apheret
collect
bone
marrow
donat
method
itali
procedur
adopt
case
fail
mobil
peripher
blood
stem
cell
defin
share
ibmdr
cnt
transplant
nation
center
cn
blood
nation
center
scientif
societi
simti
sidem
gitmo
use
plerixafor
select
revers
antagonist
receptor
binder
stromal
deriv
factor
combin
standard
gcsf
dose
moreov
sinc
accord
protocol
compet
author
aifa
extend
registr
plerixafor
law
also
mobil
poor
mobil
healthi
donor
final
protocol
extend
poor
mobil
famili
donor
make
manag
equival
relat
unrel
donor
time
inform
consent
donat
hpc
hypothesi
lack
mobil
inadequ
collect
illustr
possibl
action
propos
backup
donat
anticip
fail
mobil
cse
defin
presenc
one
two
criteria
number
circul
peripher
blood
lower
day
stimul
collect
weight
recipi
first
apheresi
case
singl
dose
plerixafor
administ
subcutan
health
profession
medic
supervis
bodi
weight
hour
start
apheresi
case
use
plerixafor
due
fail
mobil
hpca
collect
inappropri
number
notif
made
collect
center
ibmdr
famili
nonfamili
donor
recipi
transplant
center
donor
recipi
express
consent
final
collect
complet
collect
center
inform
ibmdr
turn
notifi
cntcnssimtisidemgitmo
advers
reactionsev
notifi
real
time
base
sop
specif
current
regul
result
sinc
introduct
nation
protocol
donor
unrel
donor
relat
donor
treat
present
least
one
two
inclus
criteria
first
collect
use
plerixafor
donor
requir
dose
obtain
ensur
success
transplant
suffici
increas
cell
side
effect
advers
reaction
relat
administr
plerixafor
occur
conclus
case
fail
mobil
relat
unrel
donor
use
plerixafor
accord
method
describ
share
protocol
ibmdr
cn
cnt
simti
sidem
gitmo
prove
safe
effect
protocol
emphas
great
valu
share
procedur
regist
institut
scientif
societi
ensur
supervis
process
protect
donor
recipi
disclosur
noth
declar
background
autolog
stem
cell
transplant
asct
effect
treatment
option
young
patient
multipl
myeloma
mm
minor
patient
may
still
experi
untoward
toxic
due
delay
engraft
thu
current
polici
mani
center
aim
increas
target
dose
collect
cell
optim
level
kg
per
procedur
therefor
ideal
mobil
aim
collect
cellskg
one
apheresi
achiev
number
circul
cell
good
mobil
plerixafor
may
help
maxim
collect
use
limit
high
cost
carri
retrospect
analysi
aim
predict
qualiti
mobil
develop
algorithm
optim
time
collect
use
plerixafor
method
retrospect
collect
data
mobil
procedur
perform
center
mm
receiv
mobil
protocol
cyclophosphamid
rang
grsqm
gcsf
cell
count
start
white
blood
cell
wbc
count
exceed
l
patient
exclud
analysi
show
count
target
achiev
first
day
count
andor
count
second
day
miss
andor
plerixafor
administ
first
day
accord
previou
polici
sixtyeight
patient
evalu
studi
univari
multivari
logist
regress
analysi
studi
kinet
assess
predictor
impact
mobil
carri
ratio
wbc
first
day
count
gender
diseas
categori
time
mobil
chemotherapi
also
includ
result
among
patient
includ
analysi
threshold
cell
second
day
reach
patient
groupa
whilst
remain
fail
target
groupb
median
rang
wbc
l
mcl
count
group
b
respect
statist
signific
differ
among
group
mannwhitney
p
respect
wbc
ratio
mcl
first
day
count
impact
kinet
optim
mobil
logist
regress
model
highlight
ci
first
count
independ
predictor
second
day
optim
mobil
auc
roc
analysi
two
threshold
calcul
ppv
npv
identifi
poor
mobil
ppv
exclud
probabl
fail
second
day
count
ratio
ci
predictor
optim
mobil
auc
cutoff
valu
sensibl
specif
conclus
assess
circul
wbc
ratio
wbc
recoveri
chemobas
mobil
valid
tool
manag
collect
strategi
ondemand
use
plerixafor
develop
algorithm
aim
use
plerixafor
rescu
poor
mobil
boost
count
intermedi
mobil
background
success
autolog
stem
cell
transplant
asct
requir
infus
suffici
number
hematopoiet
stem
cell
hsc
peripher
blood
pb
commonli
use
sourc
hsc
therefor
import
optim
method
use
mobil
hsc
clinic
use
chemotherapeut
agent
effect
mobil
cyclophosphamid
etoposid
recent
publish
studi
suggest
etoposid
better
mobil
effect
cyclophosphamid
even
lower
dose
clear
differ
occur
studi
tri
determin
whether
differ
mechan
mobil
cyclophosphamid
etoposid
method
first
order
confirm
clinic
data
efficaci
toxic
mobil
retrospect
analyz
data
patient
diagnos
lymphoma
perform
mobil
use
cyclophosphamid
etoposid
januari
decemb
second
mesenchym
stem
cell
msc
primarili
cultur
healthi
control
treat
cyclophosphamid
etoposid
concentr
inhibit
cell
growth
cytokin
analysi
perform
identifi
cytokin
known
associ
mobil
third
mobil
mous
model
use
cyclophosphamid
etoposid
gener
total
blood
collect
time
hsc
collect
cytokin
network
analysi
use
ingenu
pathway
analysi
perform
result
mobil
yield
cyclophosphamid
etoposid
analyz
etoposid
mibliz
significantli
higher
median
number
cyclophosphamid
rate
success
adequ
mobil
also
significanctli
higher
etoposid
univari
multivari
analysi
tabl
analysi
toxic
mobil
incid
neutropen
fever
higher
cyclophosphamid
group
p
mobil
cyclophosphamid
maintain
lower
wbc
count
etoposid
show
larg
increas
wbc
count
start
collect
figur
cumul
dose
cyclophosphamid
etoposid
patient
underw
autolog
stem
cell
transplant
affect
leukocyt
anc
platelet
plt
engraft
msc
treat
etoposid
concentr
inhibit
cell
growth
cytokin
promot
hematopoiet
stem
cell
mobil
shown
statist
signific
increas
figur
mous
model
mobil
figur
level
kc
one
homologu
mice
significantli
increas
etoposidetr
group
compar
level
cyclophosphamidetr
group
level
homologu
lix
also
show
increas
etoposidetr
group
compar
cyclophosphamidetr
group
differ
howev
statist
signific
figur
network
analysi
base
vivo
cytokin
result
identifi
etoposid
could
promot
mobil
associ
matrix
metalloproteinas
compar
cyclophosphamid
figur
conclus
etoposid
higher
mobil
efficaci
compar
cyclophosphamid
could
due
differ
mechan
mobil
elev
activ
matrix
metalloproteinas
associ
therewith
background
highdos
chemotherapi
follow
autolog
blood
stem
cell
transplant
asct
standard
therapi
wide
rang
hematolog
solid
malign
although
variou
method
introduc
improv
peripher
blood
stem
cell
pbsc
mobil
autolog
stem
cell
collect
ascc
success
everi
patient
furthermor
even
ascc
complet
lead
asct
evalu
result
ascc
actual
use
pbsc
graft
current
practic
set
method
retrospect
review
consecut
ascc
procedur
perform
depart
oncolog
asan
medic
center
seoul
korea
januari
octob
target
number
background
fanconi
anemia
fa
rare
inherit
genet
bone
marrow
bm
failur
syndrom
abnorm
bm
cell
product
occur
earli
life
usual
age
diagnosi
year
old
gene
therapi
gt
might
altern
hematopoiet
stem
cell
hsc
transplant
harvest
larg
number
autolog
hsc
remain
challeng
start
mobil
assay
fancomob
evalu
safeti
efficaci
fa
patient
mobil
granulocytecoloni
stimul
factor
gcsf
plerixafor
studi
part
fa
european
gt
project
eurofancolen
method
four
patient
fanca
mutat
follow
inclus
criteria
select
pancytopenia
note
diagnos
clinic
manifest
famili
screen
receiv
subcutan
inject
gcsf
twice
day
plerixafor
mgkgday
collect
protocol
target
cell
base
predict
futur
weight
year
cell
white
blood
cell
wbc
blood
count
monitor
tightli
along
mobil
patient
cluster
aspect
detect
flow
cytometri
plerixafor
inject
underw
apheresi
cell
immunoselect
collect
clinimac
purif
system
miltenyi
cryopreserv
gt
manipul
result
mobil
target
achiev
first
two
includ
patient
year
old
year
old
minimum
valu
requir
nt
obtain
flow
cytometri
aspect
cluster
cell
mobil
quickli
transit
plerixafor
inject
last
two
patient
year
old
respect
patient
underw
apheresi
procedur
cell
rebound
observ
apheresi
stoppedcollect
target
achiev
four
day
collect
obtain
first
day
figur
backup
hsc
transplant
could
cryopreserv
limit
number
cell
collect
patient
shortterm
advers
event
observ
follow
immunoselect
cell
puriti
recoveri
poor
normal
rang
describ
literatur
fanconi
patient
tabl
one
month
collect
hemogram
unchang
conclus
clinic
studi
offer
new
data
show
mobil
fa
patient
gcsf
plerixafor
safe
effici
younger
patient
especi
clinic
manifest
bm
failur
effort
requir
establish
effect
technic
purifi
cell
harvest
basal
cell
platelet
count
strong
predictor
mobil
peripher
blood
stem
cell
day
gcsf
treatment
donor
cryopreserv
pbsc
associ
consider
effort
patient
caus
addit
treatment
cost
one
hand
therapeut
option
autolog
transplant
futur
may
repres
clinic
relev
advantag
howev
huge
number
stem
cell
product
kept
storag
mani
year
without
ever
use
transplant
studi
provid
caus
care
reevalu
current
clinic
practic
may
help
focu
precis
patient
actual
benefit
cryostor
autolog
stem
cell
graft
imag
fig
absolut
number
rel
distribut
stem
cell
graft
disclosur
author
confirm
potenti
conflict
interest
disclos
except
follow
katharina
kriegsmann
research
fund
bm
celgen
sanofi
patrick
wuchter
membership
advisori
board
sanofiaventi
reduct
dimethylsulfoxid
dmso
concentr
criopreserv
stem
cell
influenc
kinet
engraft
toler
infus
patricia
lopezpereira
beatriz
aguado
elena
sola
carmen
isabel
lorena
vega
adrian
alegr
hospit
universitario
de
la
princesa
madrid
spain
background
dmso
cryoprotect
use
cryopreserv
stem
cell
associ
advers
effect
infus
product
toxic
proport
volum
infus
common
concentr
use
although
recent
public
report
reduc
lead
lower
rate
side
effect
without
impact
product
graft
retrospect
analyz
patient
recipi
autolog
peripher
blood
stem
cell
transplant
hct
hospit
januari
septemb
divid
two
group
accord
concentr
dmso
use
freez
septemb
sinc
octob
baselin
characterist
patient
infus
product
graft
shown
tabl
count
perform
flow
cytometri
freez
perform
biolog
freezer
program
control
rate
cryopreserv
store
ultrafreez
result
popul
group
homogen
ttest
use
statist
analysi
regard
variabl
statist
signific
differ
observ
p
neither
variabl
leukocyt
recoveri
platelet
recoveri
p
p
respect
differ
variabl
viabil
unit
statist
signific
p
favor
dmso
regard
advers
effect
n
seriou
advers
reaction
occur
dmso
group
hypotens
seizur
mild
moder
one
similar
group
mild
nausea
vomit
flush
overal
statist
signific
differ
observ
due
low
rate
advers
effect
found
patient
start
octob
total
patient
attempt
collect
autolog
pbsc
poor
mobil
reciev
plerixafor
first
mobil
cycl
total
patient
requir
repeat
mobil
cycl
plerixafor
group
total
patient
reciev
pleriksafor
femal
male
median
age
follow
diagnos
nhl
mh
multipl
myeloma
neuroblastoma
nephroblastoma
sarcoma
ewe
seminoma
repeat
mobil
plerixafor
patient
still
fail
collect
adequ
transplant
period
altogeth
unsuccess
mobil
repeat
cycl
total
group
patient
consist
male
femal
patient
median
age
diagnosi
nhl
failur
collect
leukapheresi
procedur
median
number
leukapheresi
need
adequ
collect
preemtiv
plerixafor
use
repeat
mobil
conclus
expiri
show
preemtiv
use
plerixafor
poor
mobil
effici
enhach
success
pbsc
collect
due
drug
high
cost
institut
need
develop
algorythm
manag
poor
mobil
factor
contribut
plerixafor
mobil
failur
still
need
elucid
disclosur
noth
declar
platelet
recov
mobil
leukapheresi
unit
obtain
hlahaploident
donor
fulfil
criteria
convent
hemocompon
use
transfus
background
central
venou
cathet
cvc
relat
complic
may
lead
high
morbid
mortal
unlik
cvc
peripher
cannul
offer
quick
inexpens
method
safe
nontraumat
vascular
access
va
thu
util
strongli
recommend
whenev
possibl
ultrasound
us
guidanc
acquir
peripher
va
use
tool
reduct
elimin
need
use
cvc
stem
cell
collect
made
attempt
introduc
us
method
apheresi
unit
previou
experi
us
devic
aim
studi
measur
decreas
cvc
insert
introduc
us
evalu
qualiti
va
compar
averag
flow
rate
confirm
desir
blood
volum
could
process
method
theoret
educ
involv
free
elearn
cours
peripher
ultrasoundguid
va
pugva
usabcd
aarhu
denmark
subsequ
personnel
implement
knowledg
practic
train
gelatin
silicon
phantom
healthi
volunt
practic
activ
also
includ
fiveday
cours
apheresi
centr
usguid
cannul
experi
detail
concern
va
record
includ
va
site
cannula
size
averag
inlet
flow
rate
number
inlet
pressur
alarm
report
apheresi
devic
procedur
detail
tradit
approach
appli
ie
palpabl
cannul
cvc
collect
similarli
necessari
data
procedur
vein
assess
ultrasound
prior
apheresi
record
result
introduc
ultrasonographi
stem
cell
collect
perform
patient
procedur
accomplish
cvc
peripher
va
median
cubit
vein
vessel
choic
peripher
va
procedur
problemat
inlet
pressur
alarm
everi
procedur
train
stage
collect
procedur
perform
patient
introduc
us
observ
signific
reduct
number
cvc
insert
requir
success
apheresi
chisquar
test
fisher
exact
thirti
one
procedur
complet
peripher
va
ultrasound
devic
enabl
cannul
superfici
vein
also
deeper
vein
cannul
site
includ
upper
arm
cephal
vein
median
cubit
vein
upper
arm
basil
vein
median
antebrachi
vein
collect
consid
problemat
differ
averag
flow
rate
observ
procedur
perform
peripher
without
ultrasound
usag
u
mannwhitney
test
conclus
despit
previou
experi
us
guidanc
success
manag
introduc
new
method
apheresi
unit
within
month
reduc
cvc
usag
threefold
personnel
gain
experi
suppos
cvc
usag
may
reduc
episod
case
despit
slightli
higher
number
pressur
alarm
procedur
ultrasound
guidanc
complet
plan
ultrasound
guidanc
import
tool
signific
increas
peripher
va
usag
may
becom
option
patient
difficult
va
disclosur
noth
declar
abstract
alreadi
publish
donor
blood
manag
healthi
bone
marrow
donor
retrospect
singl
institut
analysi
background
last
two
decad
mobil
peripher
blood
stem
cell
pbsc
establish
main
sourc
stem
cell
improv
engraft
necess
hospit
donor
nevertheless
due
introduct
promis
new
transplant
regimen
especi
haploident
transplant
set
bone
marrow
bm
donat
regain
import
although
donat
method
sever
side
effect
rare
describ
bm
collect
associ
consider
blood
loss
henc
symptom
acut
blood
loss
commonli
observ
therefor
autolog
blood
collect
routin
institut
donat
sinc
collect
bone
marrow
amount
depend
target
dose
wbc
yield
product
influenc
requir
bone
marrow
volum
therefor
sought
investig
relationship
collect
volum
rbc
volum
remov
drop
hb
indic
blood
transfus
furthermor
assess
wbc
relationship
variou
donor
paramet
product
volum
order
find
predict
tool
collect
volum
method
allogen
bone
marrow
harvest
adult
donor
perform
institut
retrospect
analyz
complet
blood
count
serum
iron
ferritin
assess
workup
week
donat
bone
marrow
product
qualiti
includ
wbc
hematocrit
hct
cell
assess
automat
hemocytometri
singleplatform
flow
cytometri
ishag
gate
result
besid
local
pain
side
effect
relat
blood
loss
none
donor
receiv
blood
transfus
mean
reduct
hemoglobin
level
gdl
minimum
hemoglobin
level
persist
anemia
accord
criteria
week
patholog
low
ferritin
level
donor
present
symptom
indic
blood
transfus
median
wbc
concentr
bm
product
nl
concentr
percentil
linear
regress
analysi
leukocyt
count
donor
donat
correl
significantli
wbc
concentr
product
thu
order
collect
certainti
mio
wbc
typic
perkg
dose
allogen
recipi
ml
bone
marrow
must
collect
collect
volum
systemat
affect
wbc
cell
concentr
conclus
achiev
high
wbc
yield
bone
marrow
product
allow
collect
rel
modest
bm
volum
thu
protect
donor
excess
blood
loss
acut
advers
event
accept
optim
periop
manag
healthi
bone
marrow
donor
may
achiev
good
collect
techniqu
reevalu
wbc
yield
institut
calcul
requir
bone
marrow
amount
collect
autolog
blood
indic
furthermor
stringent
preand
postop
hemoglobin
manag
predict
limit
advers
effect
disclosur
noth
declar
donorrecipi
weight
ratio
predict
success
stem
cell
mobil
day
four
gcsf
mobil
result
group
median
age
donor
year
rang
year
group
median
age
donor
year
tabl
tabl
elabor
paramet
analyz
two
group
one
patient
group
develop
grade
ii
acut
gvhd
wherea
patient
group
develop
acut
gvhd
grade
iiiv
last
follow
patient
group
symptom
chronic
gvhd
wherea
patient
group
featur
chronic
gvhd
one
extens
one
limit
conclus
observ
suggest
upfront
use
plerixafor
combin
gcsf
modifi
graft
favor
decreas
risk
graft
failur
graft
versu
host
diseas
acut
chronic
also
help
donor
decreas
total
volum
process
amount
acd
exposur
durat
harvest
disclosur
none
impact
vitamin
level
peripher
stem
cell
mobil
autolog
hematopoiet
stem
cell
transplant
recipi
ferda
zeynep
arzu
yegin
zubeyd
nur
ozkurt
orhun
akdogan
lale
kaynar
total
product
cell
count
vs
significantli
higher
patient
receiv
chemotherapygcsf
gcsf
studi
group
divid
two
group
base
peripher
cutoff
level
kg
well
product
level
cutoff
level
kg
vitamin
level
found
similar
among
group
p
total
product
cell
count
found
rel
lower
patient
vitamin
level
vs
figur
conclus
base
effect
stem
cell
vitro
studi
may
consid
vitamin
may
favour
impact
stem
cell
mobil
statist
insignific
rel
lower
total
product
cell
count
patient
lower
vitamin
level
may
indic
role
vitamin
stem
cell
mobil
need
confirm
larger
studi
consid
high
preval
vitamin
defici
gener
popul
possibl
role
vitamin
hematopoiet
stem
cell
mobil
deserv
consider
disclosur
noth
declar
background
one
factor
affect
effici
autolog
hematopoiet
stem
cell
transplant
autohsct
hodgkin
lymphoma
hl
patient
earli
recoveri
graft
depend
cd
cell
count
condit
cell
product
cryopreserv
storag
well
known
dimethylsulfoxid
dmso
use
cryopreserv
cardiotox
caus
divers
gastrointestin
pulmonari
kidney
liver
side
effect
acut
hemolysi
lethal
anim
dose
mgkg
lead
life
threaten
arrhythmia
respiratori
arrest
order
improv
dmso
toxic
differ
way
altern
cryoconserv
mode
studi
lower
dmso
concentr
vs
temperatur
instead
ultralow
wash
cell
product
aim
studi
evalu
influenc
dmso
wash
hematopoiet
recoveri
autohsct
method
retrospect
analysi
hematopoiet
recoveri
relapserefractori
hl
patient
autohsct
perform
mobil
regimen
includ
second
line
chemotherapi
hl
dhap
begev
igev
ice
consecut
gcsf
administr
cd
cell
assess
use
flow
cytomet
fac
canto
ii
cell
collect
thaw
wash
cell
dmso
store
wash
case
transplant
human
albumindextran
reopolyglukin
centrifug
statist
data
process
perform
method
pearson
criterion
p
level
signific
differ
result
patient
group
differ
age
diseas
stage
gender
time
treatment
start
autohsct
cell
count
p
time
wbc
recoveri
median
day
vs
median
day
time
platelet
recoveri
median
day
vs
median
day
group
without
cell
wash
respect
differ
blood
compon
consumpt
observ
patient
cell
reinfus
without
wash
nausea
vomit
arteri
hypertens
observ
reaction
detect
cell
wash
p
conclus
wash
autolog
mononuclear
cell
cryopreserv
dmso
lead
low
hematopoiet
recoveri
rate
autohsct
avoid
toxic
thu
make
autohsct
safe
disclosur
author
declar
conflict
interest
qualiti
asses
hematopoiet
stem
cell
autograft
cryostorag
harvest
use
plerixafor
background
introduct
highdos
chemotherapi
follow
transplant
autolog
hemopoiet
stem
cell
hsc
treatment
program
multipl
myeloma
mm
significantli
increas
frequenc
achiev
complet
remiss
overal
surviv
patient
obtain
suffici
amount
hsc
hematopoiesi
stimul
granulocytemacrophag
factor
gmcsf
mono
mode
administr
cytostat
follow
cytapheresi
session
alon
cytostat
follow
cytapheresi
session
cryopreserv
protocol
use
preserv
cell
viabl
state
follow
longterm
storag
transplant
liquid
nitrogen
howev
patient
possibl
obtain
necessari
amount
hsc
inclus
plerixafor
standard
mobil
scheme
allow
prepar
suffici
quantiti
hsc
patient
mm
method
studi
includ
sampl
autograft
patient
mm
median
hsc
mobil
perform
background
unstabl
blood
format
high
dose
cyclophosphamid
gm
subsequ
administr
gcsf
dose
kg
sampl
patient
addit
plerixaphor
dose
kg
sampl
patient
immunophenotyp
viabil
hsc
autotranspl
cryopreserv
determin
flow
cytometri
use
ishag
protocol
flow
cytomet
fac
cantoii
becton
dickinson
express
surfac
marker
antibodi
stain
colonyform
activ
hsc
cfucfumix
cfugm
cfug
cfum
evalu
methylcellulos
methocult
stemcel
technolog
canada
transplant
cell
day
result
viabil
hsc
autograft
cryopreserv
group
group
sampl
use
plerixaphor
higher
content
primit
hemopoiesi
precursor
primit
cell
detect
compar
control
group
respect
cfu
count
cfucfumix
cfugm
cfug
cfum
plerixafor
group
per
explant
cell
control
group
figur
conclus
use
plerixafor
background
standard
protocol
mobil
hsc
allow
obtain
highqual
graft
higher
content
primit
cell
prolif
activ
disclosur
conflict
interest
noth
declar
comparison
effect
plerixafor
plu
gcsf
poor
poormovil
efficaci
combin
plerixafor
gcsf
poormovil
background
healthi
donor
ocassion
show
poor
respons
mobil
agent
plerixaforgcsf
salvag
strategi
poor
mobil
seri
describ
use
plerixafor
collect
greater
dose
cell
hematopoiet
stem
cell
transplant
hsct
tcell
deplet
plerixafor
use
mobil
protocol
could
help
collect
higher
dose
indirect
tcell
deplet
select
exvivo
manipul
haploident
transplant
less
number
apheresi
rapid
engraft
method
data
fourteen
healthi
peripheralblood
donor
retrospect
collect
receiv
day
mcgkgday
gcsf
mgkgday
plerixafor
day
mobil
treatment
fourteen
pediatr
patient
median
age
year
rang
diagnos
malign
malign
hematolog
diseas
receiv
haploident
hsct
select
deplet
februari
juli
result
one
leukoapheresi
procedur
perform
case
median
process
volum
liter
rang
median
cell
obtain
kg
rang
posit
select
kg
cell
infus
case
figur
neutrophil
engraft
achiev
median
day
rang
donor
present
plerixafor
mild
secondari
effect
conclus
experi
show
mobil
protocol
use
gcsf
standard
dose
plerixafor
compas
use
safe
strategi
allow
collect
great
dose
one
apheresi
procedur
could
use
haploident
transplant
exvivo
deplet
especi
weight
disproport
donor
patient
background
mesenchym
stem
cell
msc
selfrenew
multipot
progenitor
cell
wide
differenti
potenti
eas
isol
expans
vitro
well
uniqu
regen
therapeut
properti
suggest
use
msc
approach
treat
sever
disord
extraembryon
tissu
placenta
propos
potenti
sourc
msc
due
absenc
ethic
problem
neither
risk
patient
furthermor
protocol
use
fresh
placent
tissu
describ
far
protocol
isol
msc
delayedmanipul
tissu
design
test
order
optim
use
placent
msc
mscsp
advanc
therapi
context
method
full
term
placenta
obtain
healthi
mother
hospit
universitario
central
de
asturia
spain
inform
consent
obtain
mother
prior
deliveri
dissect
gr
decidu
tissu
wash
salin
b
braun
germani
cut
small
piec
biopsi
conserv
hour
dmem
media
antibiot
solut
gibco
usausa
process
day
tissu
mechan
minc
enzimat
digest
combin
dnase
sigma
aldrich
usa
tripsinedta
solut
wv
biochrom
germani
hour
mixtur
filter
cell
strainer
bd
bioscienc
usa
centrifug
minut
final
cell
resuspend
dmem
media
suplement
fb
antibiot
seed
flask
incub
forma
stericult
co
incub
thermo
fisher
scientif
usa
co
cultureexpand
msc
cell
phenotip
character
flow
cytometri
fac
aria
iiu
bd
antibodi
hladr
use
mesenchym
cell
kit
immunostep
spain
afterward
cell
differenti
adipogen
osteogen
chondrogen
lineag
use
stemmac
adipodiff
media
stemmac
osteodiff
media
nh
chondrodiff
medium
miltenyi
biotec
germani
respect
three
week
differenti
cell
fix
paraformaldehid
merck
usa
analyz
adipogen
osteogen
chondrogen
differenti
visual
stain
oil
red
alkalin
phosphatas
hematoxilineosin
sigmaaldrich
usa
result
mscsp
isol
cell
character
accord
isct
criteria
mesenchym
stem
cell
posit
neg
hladr
indic
typic
msc
phenotyp
figur
marker
show
high
percentag
express
mean
msc
popul
obtain
design
method
homogen
similarli
stain
three
studi
lineag
posit
figur
conclus
describ
protocol
allow
us
obtain
msc
decidu
placent
tissu
store
process
hour
biopsi
extract
use
uniqu
enzymat
digest
circumst
permit
take
advantag
placenta
discard
deliveri
give
us
option
obtain
mesenchym
cell
could
use
clinic
trial
disclosur
noth
declar
outcom
umbil
cord
transplant
high
risk
relaps
refractori
acut
myeloid
leukaemia
background
highrisk
relapsedrefractori
acut
myeloid
leukaemia
aml
fatal
diseas
allogen
haematopoiet
stem
cell
transplant
repres
chanc
cure
transplant
reli
graftversusleukaemia
gvl
effect
differ
donor
exert
differ
gvl
effect
choos
right
donor
assum
great
import
manchest
larg
bmt
centr
north
england
practic
aml
choos
unrel
cord
blood
ucbt
without
serotherapi
condit
therapi
prefer
donor
cell
sourc
method
report
result
unrel
ucbt
patient
five
boy
ten
girl
highrisk
aml
defin
relaps
refractori
diseas
thirteen
patient
receiv
st
transplant
two
patient
receiv
nd
transplant
relaps
aml
post
match
unrel
donor
transplant
one
receiv
ucbt
twice
nine
patient
mismatch
ucbt
rest
fulli
match
classi
hlaa
b
andc
classii
condit
given
treosulfan
fludarabin
thiotepa
half
patient
n
treosulfanbas
regimen
use
two
patient
busulfanbas
regimen
use
six
patient
serotherapi
given
result
median
age
transplant
year
rang
neutrophil
platelet
engraft
achiev
patient
median
day
respect
patient
engraft
syndrom
engraft
patient
achiev
donor
chimer
except
one
patient
mix
lymphoid
chimer
initi
correct
spontan
three
month
transplant
acut
gvhd
grade
iii
develop
six
patient
grade
iiiiv
develop
three
patient
case
resolv
except
two
patient
acut
gvhd
evolv
chronic
gvhd
one
grade
skin
gvhd
fulli
resolv
one
grade
iii
gvhd
gut
coliti
parenter
nutrit
depend
till
death
two
patient
develop
chronic
grade
skin
gvhd
resolv
chronic
gvhd
develop
total
three
patient
develop
venoocclus
diseas
vod
complet
resolv
defibrotid
treatment
necessit
ascit
drainag
one
viral
reactiv
occur
five
patient
success
treat
median
followup
month
rang
seven
month
four
year
eight
patient
die
median
rang
day
transplantrel
mortal
relapserel
mortal
five
patient
relaps
postucbt
four
die
one
success
second
ucbt
eventfre
surviv
immun
reconstitut
aliv
patient
achiev
median
eight
month
conclus
highrisk
patient
treat
ucbt
good
overal
surviv
eventfre
surviv
similar
aml
treatment
rate
lowrisk
diseas
disclosur
noth
declar
haploident
transplant
incid
acut
chronic
gvhd
strictli
relat
stem
cell
sourc
result
odd
ratio
confid
interv
conclus
risk
infect
uc
relat
microbiolog
statu
ucb
possibl
explan
presenc
antibiot
medium
use
uc
ucb
transport
mean
cryopreserv
uc
contamin
cord
blood
obtain
justifi
comparison
turkish
stem
cell
coordin
center
turkok
istanbul
univers
bone
marrow
bank
tri
singl
center
experi
match
unrel
donor
aziz
mergen
selim
aksoy
yunu
emr
dikm
funda
ceyhun
bozkurt
older
patient
increasingli
transplant
thank
improv
allogen
hematopoiet
stem
cell
transplant
allohsct
techniqu
increas
donor
age
associ
greater
risk
mortal
graftversushost
diseas
gvhd
sinc
sibl
donor
similar
age
recipi
hypothes
older
patient
young
match
unrel
donor
mud
would
compar
hlamatch
sibl
donor
msd
method
retrospect
compar
outcom
allohsct
msd
hla
mud
patient
age
year
hematolog
malign
transplant
patient
receiv
reducedintens
condit
graft
sourc
peripher
blood
primari
outcom
overal
surviv
msd
serv
refer
categori
compar
mud
split
three
age
group
year
use
univari
analys
multivari
cox
regress
model
adjust
patient
diseas
transplant
featur
result
median
age
hsct
recipi
year
similar
across
group
median
donor
age
msd
year
mud
age
group
year
acut
leukemia
lead
transplant
indic
follow
myelodysplast
syndrom
myeloprolif
neoplasm
indol
nonhodgkin
lymphoma
diseas
risk
distribut
similar
across
donor
group
low
intermedi
high
complet
popul
time
diagnosi
hsct
longer
mud
compar
msd
increas
older
age
mud
univari
analysi
overal
surviv
msd
mud
correspond
nonrelaps
mortal
nrm
cumul
incid
p
figur
gvhdrelapsefre
grf
multivari
cox
model
young
mud
similar
risk
mortal
compar
msd
hr
monoton
increas
risk
observ
older
donor
age
mud
hr
hr
tabl
find
confirm
propens
score
analysi
match
key
covari
nrm
grade
acut
gvhd
consist
higher
mud
greatest
risk
associ
older
mud
hazard
grf
higher
mud
age
higher
compar
msd
risk
higher
younger
mud
conclus
older
patient
receiv
reduc
intens
condit
msd
remain
optim
choic
howev
avail
young
mud
provid
compar
result
disclosur
noth
declar
background
grow
evid
commun
acquir
respiratori
viru
carv
increas
risk
pulmonari
invas
fungal
diseas
ifd
recipi
allogen
hematopoiet
stem
cell
transplant
allohsct
date
lack
knowledg
regard
rate
ifd
risk
factor
rf
well
critic
period
develop
later
ifd
carv
infect
allohsct
recipi
method
prospect
observ
studi
retrospect
analyz
effect
carv
develop
later
ifd
consecut
cohort
allohsct
adult
recipi
develop
carv
infecti
episod
decemb
decemb
respiratori
viru
upper
andor
lower
respiratori
tract
specimen
test
use
multiplex
pcr
panel
assay
result
overal
allohsct
recipi
develop
ifd
within
month
carv
episod
median
day
rang
day
day
carv
detect
ifd
involv
lung
case
diagnost
ia
accomplish
criteria
probabl
n
proven
note
ifd
occur
within
first
year
transplant
overal
rate
ifd
carv
episod
wherea
rate
higher
recipi
develop
carv
first
year
transplant
ifd
diagnos
carv
lower
respiratori
tract
diseas
lrtd
episod
compar
carv
upper
respiratori
tract
diseas
urtd
p
twentythre
carv
episod
involv
lrtd
first
year
transplant
develop
ifd
found
differ
ifd
rate
accord
type
carv
identifi
multivari
analysi
identifi
rf
ifd
use
atg
part
condit
odd
ratio
confid
interv
ci
p
carv
lrtd
ci
p
carv
infect
first
year
transplant
natur
killer
cell
alloreact
haploident
stem
cell
transplant
multipl
myeloma
patient
catharina
elssen
lott
wieten
peter
von
dem
born
ellen
meijer
gerard
bo
maastricht
univers
medic
center
maastricht
netherland
leiden
univers
medic
center
leiden
netherland
amsterdam
univers
medic
center
locat
vumc
cancer
center
amsterdam
netherland
background
past
year
mani
new
drug
multipl
myeloma
mm
develop
respons
increas
surviv
notwithstand
progress
mm
remain
incur
result
allogen
stem
cell
transplant
sct
includ
haploident
transplant
mm
shown
clinic
result
howev
respons
observ
minor
patient
hypothes
observ
might
due
differ
natur
killer
nk
cell
alloreacitv
sinc
shown
vivo
vitro
model
mismatch
alloreact
nk
cell
hold
capac
kill
mm
cell
aim
prospect
phase
studi
evalu
kirligand
mismatch
haploindent
bone
marrow
transplant
bmt
posttranspl
cyclophosphamid
improv
progress
free
surviv
pf
poor
risk
mm
patient
method
poor
risk
mm
patient
age
year
enrol
respons
last
line
therapi
poor
risk
defin
highrisk
cytogenet
relaps
within
year
autolog
sct
treat
three
previou
line
therapi
prerequisit
enrol
possibl
nk
cell
mismatch
avail
mismatch
famili
donor
patient
exclud
donorspecif
hlaantibodi
present
patient
receiv
haploident
bmt
nonmyeloabl
condit
regimen
posttranspl
cyclophosphamid
primari
endpoint
pf
year
secondari
endpoint
engraft
bone
marrow
reconstitut
nk
cell
reconstitut
repertoir
graft
versu
host
diseas
gvhd
infect
nonrelaps
mortal
nrm
year
result
total
poor
risk
patient
includ
studi
could
evalu
primari
end
point
graft
failur
diseas
progress
transplant
render
remain
two
patient
evalu
interim
analysi
patient
alreadi
reach
year
follow
relaps
within
year
die
due
treatment
relat
infect
without
show
progress
diseas
nrm
averag
time
progress
day
day
two
remain
patient
follow
still
show
respons
diseas
day
en
averag
time
neutrophil
reconstitut
day
day
evalu
patient
show
nk
cell
reconstitut
matur
phenotyp
bone
marrow
peripher
blood
day
three
patient
develop
acut
gvhd
grade
iii
agvhd
patient
show
grade
iv
agvhd
treatment
relat
mortal
case
due
infecti
diseas
conclus
interim
analysi
mismatch
haploident
bmt
mm
show
treatment
feasibl
form
possibl
platform
immunotherapeut
strategi
major
patient
show
earli
diseas
progress
predefin
pf
year
would
qualifi
treatment
option
success
two
patient
still
remiss
goal
achiev
hypothes
late
nk
cell
reconstitut
day
respons
lack
respons
clinic
background
msc
known
immun
modulatori
capac
may
effect
treatment
patient
acut
gvhd
howev
clinic
studi
yield
inconclus
result
part
due
great
heterogen
msc
use
offtheshelf
msc
prepar
mscffm
gener
proprietari
pool
process
select
plasticadher
expans
aggreg
four
week
follow
cryopreserv
use
avail
germani
nation
market
author
mscffm
indic
steroidrefractori
agvhd
dose
kg
bw
iv
four
dose
one
week
apart
method
report
seven
consecut
pediatr
patient
median
age
receiv
mscffm
unrel
hla
dispar
donor
decemb
novemb
institut
gave
msc
infus
patient
steroidrefractori
grade
iiiiv
agvhd
one
patient
therapyrefractori
background
regulatori
cell
treg
known
immunosuppress
function
proven
success
graftversushost
diseas
gvhd
prophylaxi
allogen
bone
marrow
transplant
number
preclin
well
first
clinic
studi
without
compromis
graftversu
leukemia
gvl
effect
murin
model
acut
gvhd
lymph
node
home
capac
via
lselectin
prove
essenti
diseas
prevent
yet
treg
recruit
lymph
node
peripher
site
ongo
gvhd
also
seem
necessari
achiev
maximum
protect
well
therapeut
effect
chemokin
receptor
direct
activ
cell
site
inflamm
thu
high
express
facilit
treg
home
affect
gvhd
target
organ
project
lay
foundat
futur
vivo
studi
treg
therapi
gvhd
upregul
express
method
perform
systemat
ex
vivo
analysi
express
murin
naiv
memori
convent
tconv
regulatori
cell
isol
spleen
blood
bone
marrow
lymph
node
liver
lung
cell
stain
characterist
surfac
intracellular
marker
character
multiparametr
flowcytometr
analysi
express
kinet
follow
stimul
analys
tconv
treg
isol
murin
splenocyt
fac
polyclon
activ
bead
presenc
exogen
express
monitor
daili
flow
cytometr
analysi
overexpress
induc
transduct
expand
treg
mrna
via
electropor
express
kinet
monitor
fac
receptor
function
test
transwel
migrat
assay
use
ligand
result
systemat
analys
show
higher
express
memori
treg
naiv
counterpart
examin
organ
bone
marrow
sampl
display
greatest
dispar
memori
treg
show
higher
express
memori
tconv
analys
organ
except
lymph
node
memori
popul
reveal
equal
express
level
stimul
vitro
expand
treg
tconv
lead
strong
increas
express
maximum
level
respect
wherea
restimul
result
relev
express
treg
perform
systemat
optim
stimul
mrnaelectropor
condit
reliabl
achiev
highlevel
shortterm
express
transduct
treg
vitro
expans
result
strong
express
maximum
level
electropor
strong
express
detect
least
transwel
migrat
assay
show
enhanc
migrat
properti
mrnaelectropor
treg
toward
ligand
analys
perform
electropor
show
persist
migrat
even
though
measur
surfac
express
alreadi
declin
significantli
conclus
show
high
express
detect
memori
treg
analys
organ
sinc
vitro
stimul
murin
treg
reliabl
induc
express
establish
protocol
mrnaelectropor
electropor
cell
show
stabl
shortterm
express
enhanc
migrat
properti
toward
ligand
vitro
futur
studi
show
whether
induct
shortterm
express
facilit
vivo
home
adopt
transfer
treg
site
ongo
gvhd
thu
mediat
longterm
inflamm
suppress
disclosur
author
conflict
disclos
surviv
immun
reconstitut
syngen
haploident
allogen
hematopoiet
stem
cell
transplant
atmdefici
mice
ruth
pia
duecker
patrick
c
baer
stefan
zielen
ralf
schubert
allohsct
necessari
chemotherapi
transplant
patient
bone
marrow
blast
cell
time
diagnosi
imag
figur
hcict
patient
transplant
occur
grade
iiiiv
agvhd
overal
surviv
background
allogen
haematopoiet
stem
cell
transplant
sct
offer
chanc
cure
patient
transfusiondepend
thalassemia
tdt
base
nonneoplast
natur
condit
sct
approach
urgent
requir
prove
efficaci
safe
method
report
children
adolesc
young
adult
median
age
year
rang
year
tdt
receiv
sct
hlamatch
donor
mud
msd
mfd
center
patient
receiv
treosulfanbas
condit
regimen
treosulfan
fludarabin
thiotepa
gvhd
prophylaxi
base
mud
mfd
donor
csa
taper
day
well
mtx
day
mmf
patient
mtx
toxic
respect
stem
cell
sourc
bone
marrow
peripher
blood
stem
cell
cord
blood
patient
prior
transplant
children
receiv
cytoreduct
treatment
azathioprin
hydroxycarbamid
intensifi
erythrocyt
transfus
iron
elimin
therapi
carri
children
deferasirox
among
patient
avail
analysi
patient
show
substanti
liver
iron
overload
liver
iron
despit
intens
chelat
prior
sct
result
patient
achiev
leukocyt
engraft
median
day
rang
howev
two
patient
requir
pbsc
boost
day
day
base
delay
platelet
andor
erythrocyt
engraft
nine
patient
exhibit
full
donor
chimer
bm
day
show
mix
chimer
autolog
cell
day
peripher
blood
chimer
complet
patient
remain
patient
exhibit
stabl
split
chimer
donorderiv
erythrocyt
autolog
myeloid
cell
acut
gvhd
observ
three
patient
grade
grade
howev
patient
respond
immunosuppress
therapi
steroid
ecp
reiniti
cni
one
patient
suffer
background
patient
relaps
refractori
acut
myeloid
leukaemia
aml
poor
prognosi
allogen
hematopoiet
stem
cell
transplant
cur
option
howev
allogen
transplant
activ
leukemia
fail
improv
significantli
longterm
outcom
improv
outcom
allohsct
highrisk
refractori
patient
sequenti
schedul
cytoreduct
therapi
follow
nonmyeloabl
condit
develop
method
evalu
outcom
sequenti
intensifi
condit
regimen
follow
allogen
hematopoiet
stem
cell
transplant
allohsct
refractori
acut
myeloid
leukemia
aml
result
total
patient
primari
secondari
refractori
aml
transplant
june
juli
includ
refractori
defin
primari
induct
failur
relaps
within
month
induct
consolid
chemotherapi
second
relaps
median
age
year
salvag
chemotherapi
administ
flagida
two
patient
receiv
intens
chemotherapi
recoveri
induct
chemotherapi
seven
day
end
flagida
reduc
intens
condit
consist
thiotepa
busulfan
mgkg
iv
haploident
donor
fludarabin
plu
busulfan
hla
ident
sibl
unrel
donor
administ
graftversushost
diseas
gvhd
prophylaxi
consist
tacrolimu
mycophenol
mofetil
mycophenol
withdrawn
day
posttransplant
tacrolimu
day
donor
lymphocyt
dli
infus
patient
without
agvhd
day
posttransplant
seventeen
patient
achiev
complet
donor
chimer
patient
progress
earli
patient
die
engraft
one
patient
recoveri
persist
leukemia
reach
donor
chimer
immunosupress
discontinu
ten
patient
aliv
complet
remiss
median
followup
survivor
month
rang
five
patient
die
leukem
progress
result
gvhd
suffer
intracrani
hemorrhag
five
patient
receiv
prophylact
dli
incid
acut
moderatesever
gvhd
moderatesever
chronic
gvhd
respect
nonrelaps
mortal
mainli
due
acut
gvhd
cumul
incid
relaps
posttransplant
probabl
relaps
os
df
conclus
strategi
sequenti
chemotherapi
follow
allohsct
prophylact
dli
accept
toxic
profil
improv
relaps
rate
surviv
refractori
aml
patient
disclosur
noth
declar
background
concept
immunolog
intervent
prevent
relaps
hematopoiet
stem
cell
transplant
associ
assess
chimer
statu
distinguish
patient
donor
hematopoiesi
usual
perform
strpcr
power
method
develop
forens
purpos
howev
method
show
restrict
respect
detect
limit
precis
possibl
autom
read
digit
pcr
could
circumv
limit
method
recent
valid
biorad
droplet
digit
platform
biotyp
mentyp
digitalqu
assay
releas
assay
use
indel
polymorph
chromosom
dna
distinguish
patient
donor
hematopoiesi
fret
hydrolysi
assay
basi
taqman
assay
thu
assay
principl
applic
chamber
base
digit
pcr
system
thermo
fisher
due
differ
reaction
chemistri
physic
properti
thermal
transfer
digit
pcr
platform
protocol
reason
fulli
compat
would
lead
lower
fluoresc
intens
poor
signal
resolut
solid
chip
base
thermo
fisher
platform
adjust
pcr
protocol
establish
optim
use
repres
marker
follow
determin
toler
optim
amount
input
dna
specif
sensit
reproduc
test
artifici
mix
sampl
preced
extens
verif
compar
measur
clinic
sampl
ringtrial
sampl
sourc
allogen
bm
pbsc
ucb
unit
immedi
avail
transplant
frozen
bank
defin
hla
type
advantag
patient
need
urgent
transplant
addit
higher
degre
hla
mismatch
appear
accept
compar
lower
risk
acut
chronic
gvhd
meanwhil
higher
incid
engraft
failur
delay
neutrophil
platelet
recoveri
posttranspl
immun
disord
includ
preengraft
immun
reaction
pir
major
problem
unrel
ucbt
method
institut
gvhd
prophylaxi
ucbt
chang
march
januari
march
thirtytwo
patient
receiv
tacrolimu
plu
methylprednisolon
tacmpsl
april
januari
thirtyon
patient
receiv
tac
plu
methotrex
tacmtx
gvhd
prophylaxi
investig
better
gvhd
prophylaxi
ucbt
compar
transplant
outcom
ucbt
use
gvhd
prophylaxi
tacmpsl
tacmtx
singlepediatr
transplant
center
result
cumul
incid
neutrophil
engraft
day
tacmpsl
group
tacmtx
group
median
time
neutrophil
engraft
day
earlier
tacmtx
group
day
tacmpsl
group
day
accord
pir
acut
gvhd
tacmtx
group
show
superior
outcom
incid
pir
cumul
incid
acut
gvhd
day
vs
p
grade
iiiv
vs
grade
iiiiv
significantli
lower
tacmtx
group
tacmpsl
howev
incid
relaps
cytomegaloviru
viremia
estim
overal
surviv
eventfre
surviv
compar
two
group
conclus
result
indic
gvhd
prophylaxi
tacmtx
favor
effect
reduc
incid
rip
acut
gvhd
ucbt
without
neg
influenc
disclosur
noth
declar
transfer
donor
regulatori
tcell
atg
recondit
cure
sever
refractori
gvhd
lead
long
term
persist
regulatori
tcell
recipi
cell
plu
devic
miltenyi
biotec
cell
product
contain
tcell
patient
receiv
kg
reg
day
subsequ
intestin
gvhd
decreas
final
resolv
three
month
first
reg
transfer
patient
got
second
reg
transfer
kg
day
due
decreas
reg
level
thereaft
reg
persist
recurr
gvhd
patient
well
low
dose
sirolimu
prednison
immunosuppress
particularli
recov
intestin
function
conclus
case
illustr
unusu
sever
acut
gvhd
match
sibl
sct
transfer
donorderiv
reg
abl
cure
sever
refractori
gvhd
tcell
ablat
atg
transfer
reg
persist
recipi
long
period
lead
advers
event
disclosur
disclosur
declaim
allogen
hsct
patient
transfus
depend
anemia
match
mismatch
donor
julia
fekadu
andrea
jarisch
jan
emilia
salzmann
eva
retting
willasch
shahrzad
bakhtiar
thoma
klingebiel
peter
bader
first
asct
mean
harvest
patient
receiv
dhap
cellskg
cellskg
cy
cellskg
igev
cellskg
ice
cellskg
choep
patient
mobil
vtdpace
achiev
cellskg
apheresi
patient
achiev
target
number
kg
cell
apheresi
two
three
apheresi
median
time
apheresi
day
without
signific
differ
regimen
mean
wbc
count
time
apheresi
l
dhap
l
cy
l
igev
l
ice
l
choep
correl
wbc
harvest
cell
grate
thrombocytopenia
found
patient
dhap
ice
vtdpace
grate
anemia
regist
patient
dhap
vtdpace
correl
found
cd
harvest
age
number
previou
line
chemotherapi
respons
mobil
type
lymphoma
clinic
stage
conclus
result
demonstr
chemogcsf
protocol
compar
effect
accep
background
cytomegaloviru
cmv
may
caus
sever
complic
recipi
allogen
haematolog
stem
cell
transplant
allohsct
letermovir
ltv
daili
withoutwith
coadministr
cyclosporin
recent
licenc
cmv
prophylaxi
adult
allohsctrecipi
paediatr
data
well
data
cmv
therapi
miss
far
method
administ
letermovir
oral
daili
coadministr
cyclosporin
paediatr
patient
allohsct
edtaplasma
occasion
obtain
differ
time
point
frozen
determin
letermovir
level
use
liquid
chromatographymass
spectrometri
lcmsm
result
detail
patient
treatment
cmv
load
see
tabl
short
period
letermovir
administr
cmv
blood
level
becam
neg
patient
consid
lack
safeti
data
paediatr
patient
stop
letermovir
treatment
patient
liver
paramet
increas
patient
hepatopathi
turn
repres
histolog
proven
graft
versu
host
diseas
gvhd
patient
liver
paramet
increas
despit
withdraw
anoth
week
howev
hepatopathi
mild
selflimit
patient
addit
receiv
possibl
hepatotox
substanc
mycophenol
mofetil
trimethoprim
sulfamethoxazol
letermovir
plasma
level
median
ml
ngml
administr
conclus
short
letermovir
treatment
observ
fast
resolut
cmv
viraemia
well
rise
liver
paramet
patient
elev
liver
paramet
repres
gvhd
patient
causal
relationship
letermovir
might
consid
patient
letermovir
peak
level
administr
within
rang
report
adult
administr
trough
level
higher
indic
differ
pharmacokinet
term
delay
clearanc
inguin
lymphadenomegali
failur
respond
seven
convent
treatment
line
methotrex
cop
cyclophosphamid
vincristin
prednison
gemcitabin
puva
interferon
acitretin
extracorpor
photopheresi
allogen
hsct
ident
hla
male
donor
indic
nonmyeloabl
condit
consist
fludarabin
cyclophosphamid
kg
total
bodi
irradi
tbi
prophylaxi
graft
versu
host
diseas
gvhd
perform
cyclosporin
kg
mycophenol
mofetil
condit
improv
pruritu
involut
skin
bone
marrow
infus
occur
present
recurr
skin
lesion
fmf
donor
lymphocyt
infus
dli
perform
x
cell
kg
recipi
present
oral
lichen
diarrhea
respect
manifest
gvhd
infecti
intercurr
hemorrhag
cystiti
occur
bk
viru
month
first
dli
receiv
conserv
treatment
remain
without
system
immunosuppress
nine
month
hsct
second
dli
x
cell
kg
receptor
perform
time
patient
without
clinic
manifest
fmf
gvhd
conclus
clinic
respons
present
case
confirm
report
literatur
ctcl
appear
particularli
suscept
gvl
effect
make
hsct
potenti
cure
advanc
ctcl
elig
patient
time
perform
hsct
clinic
cours
diseas
remain
matter
settl
clinic
trial
registri
applic
disclosur
conflict
interest
abstract
alreadi
publish
